data_1ghk_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1ghk _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 5.4 mp . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' A' ' 4' ' ' ILE . 39.6 t0 -88.98 132.82 34.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.239 -0.913 . . . . 0.0 109.452 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.481 ' N ' ' OD1' ' A' ' 3' ' ' ASP . 82.2 mt -99.99 124.24 53.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.424 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.41 ' HA ' ' O ' ' A' ' 70' ' ' GLU . 2.6 mttt -122.75 175.59 6.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.209 -0.932 . . . . 0.0 109.448 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.422 ' HB2' ' HD2' ' A' ' 7' ' ' PRO . . . -79.68 161.38 66.9 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.883 . . . . 0.0 109.49 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' A' ' 6' ' ' ALA . 35.6 Cg_endo -78.06 173.8 13.42 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.638 2.225 . . . . 0.0 110.389 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.5 m -92.07 134.68 34.61 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.478 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -100.14 155.82 35.98 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 109.438 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.426 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -77.99 -159.93 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.589 2.193 . . . . 0.0 110.473 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' A' ' 12' ' ' SER . 2.5 mt-10 -78.64 -58.69 3.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 109.497 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 11' ' ' GLU . 31.1 t -42.83 -45.09 4.75 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.295 -0.878 . . . . 0.0 109.628 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.426 ' HB ' ' HD2' ' A' ' 10' ' ' PRO . 33.7 mm -104.43 136.92 35.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.297 -0.877 . . . . 0.0 109.472 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.407 ' C ' ' OD1' ' A' ' 15' ' ' ASP . . . -119.03 16.81 13.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.233 -0.917 . . . . 0.0 109.451 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -169.18 -170.73 1.16 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 0.0 109.438 -179.982 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.68 -170.08 16.11 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.512 ' O ' ' CB ' ' A' ' 39' ' ' GLU . 1.4 m -150.0 128.57 12.3 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.221 -1.164 . . . . 0.0 109.499 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.1 t -56.42 153.82 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.226 -0.921 . . . . 0.0 109.406 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.47 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -96.86 -72.98 0.62 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.256 -0.903 . . . . 0.0 109.546 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.7 m -160.05 132.61 6.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.22 -0.925 . . . . 0.0 109.558 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.634 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.9 83.0 6.12 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.257 -0.902 . . . . 0.0 109.528 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.572 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 2.0 m80 -42.85 -64.84 0.55 Allowed 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.38 -0.825 . . . . 0.0 109.441 -179.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.17 -179.25 4.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.557 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -125.84 168.48 13.84 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.249 -0.907 . . . . 0.0 109.487 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.479 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 34.9 Cg_endo -76.66 123.26 6.84 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.626 2.218 . . . . 0.0 110.398 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.3 12.64 9.61 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -118.22 -172.44 2.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.205 -1.173 . . . . 0.0 109.457 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -98.68 153.56 18.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.242 -0.911 . . . . 0.0 109.462 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.489 ' CG2' HD13 ' A' ' 35' ' ' ILE . 2.8 p -138.36 162.3 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 109.48 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.457 ' N ' ' CG2' ' A' ' 29' ' ' VAL . 0.0 OUTLIER -134.59 126.13 28.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.256 -0.903 . . . . 0.0 109.517 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.506 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 16.8 ttp180 -42.72 146.82 0.34 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.323 -0.861 . . . . 0.0 109.664 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.506 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 2.9 t70 75.18 33.95 0.68 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.447 ' HB2' ' O ' ' A' ' 30' ' ' LYS . 3.4 tt0 -138.83 123.6 18.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -0.912 . . . . 0.0 109.444 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.572 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 50.6 tp -42.98 156.97 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.273 -0.892 . . . . 0.0 109.531 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.489 HD13 ' CG2' ' A' ' 29' ' ' VAL . 35.8 mm -139.11 -38.17 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.2 -0.937 . . . . 0.0 109.651 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.433 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.5 p -166.66 139.1 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.175 -0.953 . . . . 0.0 109.527 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.47 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 1.1 m-20 -98.61 158.5 15.56 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.447 HD13 ' CG2' ' A' ' 47' ' ' VAL . 36.1 mt -125.01 153.63 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.532 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.512 ' CB ' ' O ' ' A' ' 17' ' ' THR . 15.0 tt0 -109.88 123.61 49.89 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.236 -0.915 . . . . 0.0 109.454 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.435 ' O ' ' C ' ' A' ' 41' ' ' ASP . 3.9 p -107.54 -162.44 0.84 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.256 -0.903 . . . . 0.0 109.475 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.435 ' C ' ' O ' ' A' ' 40' ' ' THR . 16.7 t0 -42.72 -66.7 0.34 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.33 -0.856 . . . . 0.0 109.65 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 13.3 mtpt -142.79 26.16 1.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.31 -0.869 . . . . 0.0 109.476 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 42.1 t -136.48 136.5 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.28 -0.888 . . . . 0.0 109.504 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 56.4 t -95.65 119.26 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.292 -0.88 . . . . 0.0 109.458 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 4.2 mtt -93.71 179.7 5.28 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.242 -0.911 . . . . 0.0 109.503 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -131.96 148.9 52.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.514 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.447 ' CG2' HD13 ' A' ' 38' ' ' ILE . 21.2 t -121.91 107.95 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.256 -0.903 . . . . 0.0 109.441 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.428 ' HG ' ' C ' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -98.16 153.11 18.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 109.494 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.448 ' HB3' HG13 ' A' ' 35' ' ' ILE . . . -76.87 143.65 39.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.26 -0.9 . . . . 0.0 109.416 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.459 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 0.1 OUTLIER -96.25 15.42 21.08 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.469 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 166.9 148.28 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.468 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.496 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -69.96 170.96 10.22 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.348 179.978 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.496 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 157.27 -146.61 13.92 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.6 t -135.39 124.6 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.25 -1.147 . . . . 0.0 109.506 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 12.1 mm -70.03 158.88 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.275 -0.891 . . . . 0.0 109.496 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.45 ' HB1' ' O ' ' A' ' 74' ' ' LYS . . . -95.13 -64.43 1.07 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.199 -0.938 . . . . 0.0 109.457 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.479 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 11.7 pt-20 -179.17 146.32 0.29 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.461 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.634 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 30.6 mm -99.07 127.42 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.245 -0.909 . . . . 0.0 109.475 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.3 t -90.08 -29.92 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.497 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 0.2 OUTLIER -90.78 148.1 22.77 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.234 -0.916 . . . . 0.0 109.481 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 4.5 m-80 -110.45 156.31 21.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.503 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -60.6 139.19 57.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.269 -0.894 . . . . 0.0 109.526 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 90.11 4.97 71.01 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -105.76 170.7 7.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -1.186 . . . . 0.0 109.355 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 7.3 t -102.21 154.26 19.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.528 -0.732 . . . . 0.0 109.564 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.497 HG13 ' CD2' ' A' ' 72' ' ' LEU . 30.3 m -130.66 133.81 62.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.47 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -92.43 169.86 10.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.465 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -59.51 143.21 50.74 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.248 -0.908 . . . . 0.0 109.451 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 67.7 12.02 61.18 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.41 ' O ' ' HA ' ' A' ' 5' ' ' LYS . 5.3 tp10 -70.33 120.58 16.21 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.287 -1.125 . . . . 0.0 109.467 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.434 HD23 ' HD2' ' A' ' 74' ' ' LYS . 10.0 tt -77.97 111.92 14.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.301 -0.874 . . . . 0.0 109.459 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.497 ' CD2' HG13 ' A' ' 66' ' ' VAL . 1.9 mt -88.3 -21.12 24.59 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.267 -0.895 . . . . 0.0 109.462 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.417 ' N ' HD22 ' A' ' 71' ' ' LEU . . . 172.5 -177.17 45.23 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.459 ' NZ ' ' OE2' ' A' ' 57' ' ' GLU . 0.0 OUTLIER -139.63 153.81 47.41 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.195 -1.18 . . . . 0.0 109.52 179.963 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -94.69 155.61 16.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.267 -0.896 . . . . 0.0 109.435 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.4 m . . . . . 0 N--CA 1.49 1.554 0 O-C-N 121.204 -0.935 . . . . 0.0 109.456 179.972 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.415 HG13 ' HB3' ' A' ' 75' ' ' LEU . 2.0 pt . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.41 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 20.9 t0 -120.59 136.86 54.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.281 -0.887 . . . . 0.0 109.461 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 65.8 mt -110.46 118.85 58.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.189 -0.944 . . . . 0.0 109.481 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.86 156.77 48.34 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.289 -0.882 . . . . 0.0 109.418 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -58.7 163.54 5.11 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.202 -0.936 . . . . 0.0 109.46 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.06 178.16 7.92 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.618 2.212 . . . . 0.0 110.41 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.43 ' O ' ' CD1' ' A' ' 9' ' ' PHE . 0.2 OUTLIER -76.56 176.42 8.35 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.896 . . . . 0.0 109.509 -179.966 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.452 ' CE1' HG22 ' A' ' 40' ' ' THR . 23.7 m-85 -138.7 71.78 43.11 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.453 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.93 -0.14 10.38 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.636 2.224 . . . . 0.0 110.432 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.515 ' O ' ' CD1' ' A' ' 13' ' ' ILE . 5.9 mm-40 -85.33 46.46 1.29 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.394 -0.816 . . . . 0.0 109.438 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 12' ' ' SER . 6.6 t 39.25 39.21 0.41 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.528 -0.733 . . . . 0.0 110.034 179.707 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.515 ' CD1' ' O ' ' A' ' 11' ' ' GLU . 15.0 mm -98.82 156.35 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.891 . . . . 0.0 109.374 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.496 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -93.83 -1.88 54.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.19 -0.944 . . . . 0.0 109.727 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.496 ' CB ' ' O ' ' A' ' 14' ' ' ALA . 1.1 p30 163.74 -169.63 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.227 -0.921 . . . . 0.0 109.442 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.0 -169.33 11.63 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 93.6 m -150.02 123.26 8.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.204 -1.174 . . . . 0.0 109.534 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.516 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 24.2 t -51.09 169.49 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.22 -0.925 . . . . 0.0 109.482 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.462 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -112.73 -73.14 0.68 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.179 -0.951 . . . . 0.0 109.609 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.448 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 16.4 m -159.98 137.13 9.44 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.53 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.558 ' CZ2' HG21 ' A' ' 58' ' ' ILE . 32.7 m95 -89.98 83.85 6.14 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.259 -0.901 . . . . 0.0 109.501 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.572 ' CD2' HD22 ' A' ' 34' ' ' LEU . 2.2 m80 -42.86 -69.82 0.13 Allowed 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.39 -0.819 . . . . 0.0 109.487 -179.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.05 -171.58 2.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 109.674 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.467 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 1.8 mttt -128.8 170.76 9.93 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.227 -0.92 . . . . 0.0 109.435 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.523 ' CG ' ' HA ' ' A' ' 57' ' ' GLU . 34.8 Cg_endo -75.61 129.52 11.88 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.657 2.238 . . . . 0.0 110.39 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 120.98 -11.88 9.95 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -95.84 166.48 11.78 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.254 -1.145 . . . . 0.0 109.472 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.29 133.39 35.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -0.907 . . . . 0.0 109.411 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.444 ' O ' HG21 ' A' ' 29' ' ' VAL . 25.1 m -136.31 135.84 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.162 -0.961 . . . . 0.0 109.528 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 31' ' ' ARG . 9.6 pttp -117.35 146.23 43.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.88 . . . . 0.0 109.389 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.464 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 4.0 ttt180 -42.9 156.23 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.244 -0.91 . . . . 0.0 109.623 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.464 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 18.8 t70 73.34 29.21 1.69 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -0.881 . . . . 0.0 109.453 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.521 ' N ' ' CD2' ' A' ' 48' ' ' LEU . 30.5 tt0 -137.71 111.63 8.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.285 -0.884 . . . . 0.0 109.446 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.572 HD22 ' CD2' ' A' ' 22' ' ' HIS . 43.4 tp -42.9 153.56 0.08 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.36 -0.837 . . . . 0.0 109.595 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.441 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 11.1 mm -139.08 -38.51 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.15 -0.969 . . . . 0.0 109.55 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.514 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 10.8 p -160.21 131.53 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.263 -0.898 . . . . 0.0 109.466 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.462 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 32.4 m-20 -92.15 157.09 16.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.918 . . . . 0.0 109.482 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.513 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 20.6 tt -127.91 162.98 32.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.325 -0.859 . . . . 0.0 109.447 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -148.76 110.65 4.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.24 -0.912 . . . . 0.0 109.434 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.452 HG22 ' CE1' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -80.73 -160.65 0.32 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.29 -0.881 . . . . 0.0 109.503 179.94 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.404 ' HB2' HD13 ' A' ' 13' ' ' ILE . 50.0 t0 -42.83 -67.64 0.26 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.293 -0.88 . . . . 0.0 109.631 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -132.02 23.22 4.55 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -0.934 . . . . 0.0 109.491 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.423 ' C ' HG21 ' A' ' 44' ' ' VAL . 1.9 t -117.97 162.13 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.226 -0.921 . . . . 0.0 109.437 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.423 HG21 ' C ' ' A' ' 43' ' ' VAL . 6.9 t -137.35 126.7 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.284 -0.885 . . . . 0.0 109.51 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' MET . . . . . 0.513 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 1.7 mtt -123.63 -171.01 2.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.256 -0.903 . . . . 0.0 109.434 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.3 152.4 48.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.417 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.514 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 35.0 t -122.52 111.18 29.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.319 -0.863 . . . . 0.0 109.47 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.521 ' CD2' ' N ' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -102.02 165.78 10.98 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.281 -0.887 . . . . 0.0 109.464 -179.978 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -76.35 144.97 39.81 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.333 -0.855 . . . . 0.0 109.472 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -108.49 7.44 26.86 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.143 -0.973 . . . . 0.0 109.536 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -175.45 122.32 0.21 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.178 -0.951 . . . . 0.0 109.531 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.499 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -55.14 170.93 0.17 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.3 -0.875 . . . . 0.0 109.32 179.999 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.499 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 140.82 -139.34 9.57 Favored Glycine 0 N--CA 1.49 2.233 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 45.0 t -139.15 123.55 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -1.184 . . . . 0.0 109.429 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.462 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 13.9 mm -65.06 167.75 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.249 -0.907 . . . . 0.0 109.537 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.411 ' N ' HG23 ' A' ' 55' ' ' ILE . . . -101.72 -65.42 0.98 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.181 -0.95 . . . . 0.0 109.472 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.523 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -171.68 159.09 5.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.502 179.992 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.558 HG21 ' CZ2' ' A' ' 21' ' ' TRP . 74.2 mt -89.97 130.56 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.318 -0.864 . . . . 0.0 109.403 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.458 ' HB ' ' O ' ' A' ' 71' ' ' LEU . 50.0 t -89.99 -37.77 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.2 -0.938 . . . . 0.0 109.417 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.437 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -113.89 137.63 51.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.229 -0.92 . . . . 0.0 109.4 -179.989 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -79.96 156.37 27.25 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.213 -0.929 . . . . 0.0 109.443 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.516 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -70.3 142.76 52.21 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 93.99 -15.62 62.74 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.506 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -84.24 170.88 13.28 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.181 -1.188 . . . . 0.0 109.365 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.506 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 88.5 m -96.78 133.49 41.29 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.518 -0.739 . . . . 0.0 109.477 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.401 HG11 ' HG2' ' A' ' 60' ' ' LYS . 6.3 m -116.68 -154.66 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.26 -0.9 . . . . 0.0 109.429 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mp -149.65 176.64 10.48 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.262 -0.899 . . . . 0.0 109.495 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.2 t -69.41 109.21 4.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.251 -0.905 . . . . 0.0 109.449 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.55 21.47 26.57 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -74.0 121.05 20.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -1.133 . . . . 0.0 109.428 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.458 ' O ' ' HB ' ' A' ' 59' ' ' VAL . 25.5 tp -64.9 111.62 2.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.255 -0.903 . . . . 0.0 109.492 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 8.4 mt -95.18 -10.91 29.13 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -0.887 . . . . 0.0 109.48 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.34 163.39 21.13 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 26.4 mttt -125.41 144.71 50.39 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -1.139 . . . . 0.0 109.456 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.471 ' HG ' ' N ' ' A' ' 76' ' ' THR . 12.4 tp -90.0 153.51 20.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.445 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.471 ' N ' ' HG ' ' A' ' 75' ' ' LEU . 14.6 m . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.903 . . . . 0.0 109.489 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.444 HG13 ' HB3' ' A' ' 75' ' ' LEU . 1.8 pp . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.453 ' OD2' HD11 ' A' ' 71' ' ' LEU . 8.3 t0 -89.72 129.28 36.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.313 -0.867 . . . . 0.0 109.483 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 87.4 mt -97.08 75.97 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.238 -0.914 . . . . 0.0 109.517 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.33 161.6 13.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.227 -0.92 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.51 163.11 70.54 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.216 -0.927 . . . . 0.0 109.437 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.08 -179.85 5.83 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.632 2.222 . . . . 0.0 110.386 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 m -93.82 106.99 18.93 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.297 -0.877 . . . . 0.0 109.443 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.407 ' HB3' ' HD2' ' A' ' 10' ' ' PRO . 80.9 m-85 -61.5 157.81 43.82 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.233 -0.917 . . . . 0.0 109.452 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.45 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.1 -163.08 0.2 Allowed 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.585 2.19 . . . . 0.0 110.415 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.6 OUTLIER -80.82 -59.06 2.82 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.265 -0.897 . . . . 0.0 109.436 -179.972 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 11' ' ' GLU . 35.3 t -42.82 -31.24 0.47 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.365 -0.835 . . . . 0.0 109.618 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.45 ' HB ' ' HD2' ' A' ' 10' ' ' PRO . 24.4 mt -113.81 141.41 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.227 -0.921 . . . . 0.0 109.445 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -126.96 31.25 5.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.5 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 174.8 -171.47 0.06 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.8 -164.71 13.82 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.462 ' HA ' ' O ' ' A' ' 64' ' ' ASP . 84.6 m -150.12 120.99 7.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.214 -1.168 . . . . 0.0 109.44 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.515 HG13 ' N ' ' A' ' 19' ' ' ALA . 60.0 t -43.79 162.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.302 -0.874 . . . . 0.0 109.487 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.515 ' N ' HG13 ' A' ' 18' ' ' VAL . . . -108.11 -75.17 0.64 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.278 -0.889 . . . . 0.0 109.562 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.9 m -160.17 131.61 5.92 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.167 -0.958 . . . . 0.0 109.619 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.55 ' CE2' HG22 ' A' ' 58' ' ' ILE . 33.3 m95 -89.82 85.88 6.51 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.255 -0.903 . . . . 0.0 109.448 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.571 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 2.5 m80 -42.34 -69.88 0.12 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.356 -0.84 . . . . 0.0 109.654 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.69 -174.09 2.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.217 -0.927 . . . . 0.0 109.78 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.461 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -116.87 165.67 14.75 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.377 -0.827 . . . . 0.0 109.262 179.975 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.519 ' CG ' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -77.18 145.43 24.38 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.552 2.168 . . . . 0.0 110.426 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.44 -8.89 60.58 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.462 ' OE1' ' O ' ' A' ' 28' ' ' ALA . 0.4 OUTLIER -94.1 176.74 6.21 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.202 -1.175 . . . . 0.0 109.453 -179.972 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.462 ' O ' ' OE1' ' A' ' 27' ' ' GLU . . . -91.37 158.4 16.55 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.291 -0.881 . . . . 0.0 109.486 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.7 m -138.87 -167.53 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.257 -0.902 . . . . 0.0 109.506 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 31' ' ' ARG . 5.1 tptm -142.18 140.85 32.51 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.221 -0.925 . . . . 0.0 109.463 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.1 OUTLIER -42.84 123.48 2.74 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.311 -0.868 . . . . 0.0 109.649 -179.874 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.516 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 6.1 t70 75.9 57.06 0.05 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.276 -0.89 . . . . 0.0 109.491 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.496 ' N ' HD22 ' A' ' 48' ' ' LEU . 0.9 OUTLIER -131.76 121.3 23.95 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.203 -0.936 . . . . 0.0 109.402 -179.934 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.571 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 51.3 tp -42.94 162.25 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.329 -0.857 . . . . 0.0 109.499 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.489 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 91.6 mt -141.52 -49.49 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.933 . . . . 0.0 109.48 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.523 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.9 p -152.25 151.93 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.915 . . . . 0.0 109.417 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.457 ' N ' HG21 ' A' ' 36' ' ' VAL . 49.8 m-20 -117.6 151.38 37.3 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.257 -0.902 . . . . 0.0 109.554 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.446 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 3.6 mm -108.17 156.36 8.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.248 -0.907 . . . . 0.0 109.383 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -135.28 117.48 15.52 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.262 -0.899 . . . . 0.0 109.489 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.431 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -115.8 -167.48 1.27 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.229 -0.919 . . . . 0.0 109.495 -179.991 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.431 ' C ' ' O ' ' A' ' 40' ' ' THR . 53.8 t0 -42.7 -67.74 0.25 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.359 -0.838 . . . . 0.0 109.626 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 1.7 mtpp -139.16 34.25 2.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.205 -0.934 . . . . 0.0 109.468 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.4 t -135.73 107.35 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.952 . . . . 0.0 109.504 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.2 t -89.98 115.85 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' MET . . . . . 0.446 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 4.6 mtp -99.23 178.31 4.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.302 -0.874 . . . . 0.0 109.488 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.417 ' HA ' ' OD1' ' A' ' 37' ' ' ASP . 41.0 mt-10 -138.48 169.64 17.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.205 -0.935 . . . . 0.0 109.438 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.523 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 97.1 t -141.92 103.09 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.224 -0.923 . . . . 0.0 109.478 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.51 ' CD2' ' HA ' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -104.38 155.31 18.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.218 -0.927 . . . . 0.0 109.506 -179.982 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.461 ' N ' HD13 ' A' ' 35' ' ' ILE . . . -84.19 165.22 18.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.515 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.501 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 0.8 OUTLIER -103.44 13.15 34.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.501 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 164.7 164.2 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.455 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.503 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -58.18 170.95 0.61 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.26 -0.9 . . . . 0.0 109.336 179.979 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.503 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 150.07 -174.64 29.45 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 69.6 t -124.86 131.18 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -1.132 . . . . 0.0 109.418 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.484 ' CD1' ' N ' ' A' ' 55' ' ' ILE . 1.4 mm -71.24 -176.64 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.271 -0.893 . . . . 0.0 109.486 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.463 ' HB2' ' HG2' ' A' ' 74' ' ' LYS . . . -114.01 -59.57 2.0 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.235 -0.916 . . . . 0.0 109.409 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.519 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 17.5 pt-20 -178.88 157.47 0.89 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.26 -0.9 . . . . 0.0 109.548 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.55 HG22 ' CE2' ' A' ' 21' ' ' TRP . 1.7 mp -89.96 140.88 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 109.446 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.45 ' HB ' ' O ' ' A' ' 71' ' ' LEU . 11.1 t -100.67 -15.17 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.261 -0.899 . . . . 0.0 109.366 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.464 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -126.37 -172.58 2.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.31 -0.869 . . . . 0.0 109.403 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.464 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 17.3 m-80 -132.45 164.26 26.96 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.169 -0.957 . . . . 0.0 109.509 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.01 133.41 48.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.306 -0.871 . . . . 0.0 109.408 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.05 -6.78 82.67 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -79.72 170.76 16.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.219 -1.165 . . . . 0.0 109.428 179.902 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.516 ' N ' ' OD1' ' A' ' 64' ' ' ASP . 32.3 m -98.77 138.84 35.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.547 -0.721 . . . . 0.0 109.498 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 6.2 m -122.29 170.67 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.268 -0.895 . . . . 0.0 109.455 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.457 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.1 OUTLIER -132.94 177.6 7.53 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.474 -179.98 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.1 t -62.85 146.61 52.35 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.914 . . . . 0.0 109.468 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 57.85 28.59 60.71 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.457 ' HB2' ' O ' ' A' ' 67' ' ' LEU . 8.0 tp10 -84.06 115.28 22.28 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.174 -1.192 . . . . 0.0 109.419 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.453 HD11 ' OD2' ' A' ' 3' ' ' ASP . 16.0 tp -72.91 106.09 4.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.262 -0.898 . . . . 0.0 109.49 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 15.7 mt -89.36 -10.91 44.87 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.224 -0.922 . . . . 0.0 109.455 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.36 164.29 22.75 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.463 ' HG2' ' HB2' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -136.12 142.9 44.29 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -1.173 . . . . 0.0 109.451 179.985 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.444 ' HB3' HG13 ' A' ' 2' ' ' ILE . 2.7 tt -97.44 167.99 10.66 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.239 -0.913 . . . . 0.0 109.479 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.0 m . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.448 -179.956 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 30.3 mm . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -66.35 127.99 34.39 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.1 mt -102.54 97.97 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.319 -0.863 . . . . 0.0 109.495 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.447 ' HG3' ' HA ' ' A' ' 71' ' ' LEU . 0.0 OUTLIER -118.76 146.9 44.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.211 -0.931 . . . . 0.0 109.461 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -61.26 157.51 43.58 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.197 -0.939 . . . . 0.0 109.494 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.422 ' O ' ' C ' ' A' ' 8' ' ' THR . 35.6 Cg_endo -78.07 122.85 5.92 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 C-N-CA 122.581 2.188 . . . . 0.0 110.379 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.456 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 17.5 m -44.17 108.02 0.1 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.244 -0.91 . . . . 0.0 109.454 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -71.03 147.95 94.1 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.245 -0.909 . . . . 0.0 109.501 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.449 ' HD2' HD11 ' A' ' 13' ' ' ILE . 35.5 Cg_endo -78.18 -159.44 0.1 Allowed 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.599 2.199 . . . . 0.0 110.324 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.433 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.4 OUTLIER -75.98 -52.65 9.8 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -0.899 . . . . 0.0 109.47 -179.956 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.8 t -42.82 -56.14 3.36 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.252 -0.905 . . . . 0.0 109.628 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.518 ' CG2' ' O ' ' A' ' 15' ' ' ASP . 2.5 mp -89.95 111.14 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.226 -0.921 . . . . 0.0 109.452 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.466 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -88.77 10.45 20.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.204 -0.935 . . . . 0.0 109.502 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.518 ' O ' ' CG2' ' A' ' 13' ' ' ILE . 0.8 OUTLIER 166.6 -172.39 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 -179.921 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.08 -167.87 16.81 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.454 HG22 ' O ' ' A' ' 64' ' ' ASP . 90.3 m -148.21 131.94 16.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.265 -1.138 . . . . 0.0 109.463 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.1 t -52.56 163.93 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.218 -0.926 . . . . 0.0 109.435 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.515 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -108.96 -76.41 0.61 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.175 -0.953 . . . . 0.0 109.442 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.4 m -160.03 131.9 6.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.248 -0.908 . . . . 0.0 109.46 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.636 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 31.9 m95 -89.87 85.43 6.38 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.26 -0.9 . . . . 0.0 109.56 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.571 ' CD2' HD22 ' A' ' 34' ' ' LEU . 2.0 m80 -42.77 -58.25 2.43 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.355 -0.841 . . . . 0.0 109.38 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -101.43 -175.04 2.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.57 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.41 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -125.65 167.82 15.57 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.344 -0.847 . . . . 0.0 109.446 179.985 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.463 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.91 118.04 4.66 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.588 2.192 . . . . 0.0 110.418 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 124.56 7.52 6.21 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -113.26 -172.25 2.03 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.223 -1.163 . . . . 0.0 109.55 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -105.02 158.02 16.83 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.169 -0.957 . . . . 0.0 109.448 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -142.49 -174.35 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 0.0 109.436 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 3.7 mttp -147.67 137.54 22.77 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.491 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.434 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.1 OUTLIER -42.78 137.21 2.35 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.344 -0.847 . . . . 0.0 109.63 -179.914 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.42 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 8.2 t0 70.06 51.23 0.41 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.314 -0.866 . . . . 0.0 109.521 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.453 ' O ' HG13 ' A' ' 35' ' ' ILE . 1.8 tm-20 -140.8 120.65 13.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.185 -0.947 . . . . 0.0 109.493 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.571 HD22 ' CD2' ' A' ' 22' ' ' HIS . 35.3 tp -42.93 142.82 0.83 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.301 -0.874 . . . . 0.0 109.57 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.453 HG13 ' O ' ' A' ' 33' ' ' GLU . 12.8 mt -134.97 -43.07 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.232 -0.917 . . . . 0.0 109.598 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.462 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.4 p -158.66 142.52 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.223 -0.923 . . . . 0.0 109.508 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.515 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 55.9 m-20 -105.46 152.44 23.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.214 -0.929 . . . . 0.0 109.404 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 10.9 mt -128.81 153.84 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.211 -0.93 . . . . 0.0 109.537 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -121.74 150.94 41.1 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.233 -0.917 . . . . 0.0 109.443 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.439 ' OG1' ' O ' ' A' ' 43' ' ' VAL . 28.1 p -133.62 -168.37 2.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.241 -0.912 . . . . 0.0 109.491 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.411 ' C ' ' O ' ' A' ' 40' ' ' THR . 27.2 t70 -42.68 -69.25 0.14 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.348 -0.845 . . . . 0.0 109.686 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.9 mtmt -136.64 27.15 3.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.227 -0.92 . . . . 0.0 109.425 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.439 ' O ' ' OG1' ' A' ' 40' ' ' THR . 1.9 t -135.86 162.1 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.259 -0.901 . . . . 0.0 109.507 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.3 p -122.53 138.81 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.352 -0.843 . . . . 0.0 109.479 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' MET . . . . . 0.427 ' SD ' HG22 ' A' ' 40' ' ' THR . 1.9 mpp? -127.05 101.94 6.76 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.254 -0.904 . . . . 0.0 109.453 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.456 ' HG2' ' OD1' ' A' ' 37' ' ' ASP . 15.0 mt-10 -73.9 163.81 27.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.277 -0.889 . . . . 0.0 109.475 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.462 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 71.6 t -131.04 107.69 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.281 -0.887 . . . . 0.0 109.44 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.482 ' CD1' ' HA ' ' A' ' 34' ' ' LEU . 1.3 mp -91.91 170.2 10.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.906 . . . . 0.0 109.536 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -71.91 124.7 25.43 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.257 -0.902 . . . . 0.0 109.458 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.526 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -82.68 6.85 16.57 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.9 . . . . 0.0 109.5 -179.947 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.526 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 163.94 141.46 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.516 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -49.01 170.97 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 109.338 -179.974 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 135.8 -155.84 22.51 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' A' ' 55' ' ' ILE . 48.5 t -138.71 125.04 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.318 -1.107 . . . . 0.0 109.477 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.46 ' O ' ' O ' ' A' ' 54' ' ' VAL . 4.6 mm -46.45 172.25 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.255 -0.903 . . . . 0.0 109.464 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 74' ' ' LYS . . . -110.91 -65.09 1.2 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.266 -0.896 . . . . 0.0 109.478 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.463 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -170.27 138.78 1.65 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.469 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.636 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 21.5 mm -101.38 128.53 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.245 -0.91 . . . . 0.0 109.49 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.2 t -98.06 -30.97 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.262 -0.898 . . . . 0.0 109.481 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.464 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -91.23 117.65 29.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.32 -0.862 . . . . 0.0 109.454 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 57.6 m-80 -84.06 157.23 21.85 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.311 -0.868 . . . . 0.0 109.451 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -57.19 142.44 42.78 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.26 -0.9 . . . . 0.0 109.463 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.76 11.29 68.42 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -104.69 170.92 7.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -1.125 . . . . 0.0 109.292 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 52.0 m -107.52 146.95 31.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.45 -0.781 . . . . 0.0 109.465 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.46 ' N ' HG21 ' A' ' 65' ' ' THR . 7.1 m -124.59 139.82 49.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.237 -0.914 . . . . 0.0 109.49 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -101.06 -175.55 2.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.316 -0.865 . . . . 0.0 109.436 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.456 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 1.5 t -64.47 122.22 16.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.266 -0.897 . . . . 0.0 109.496 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.51 31.28 41.69 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -83.84 104.56 14.03 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.187 -1.184 . . . . 0.0 109.484 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.447 ' HA ' ' HG3' ' A' ' 5' ' ' LYS . 1.0 OUTLIER -66.4 120.28 13.06 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -0.912 . . . . 0.0 109.487 179.966 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.447 HD22 HG12 ' A' ' 66' ' ' VAL . 1.0 OUTLIER -95.81 -18.92 20.02 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.283 -0.886 . . . . 0.0 109.495 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.77 -179.64 41.0 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' A' ' 56' ' ' ALA . 2.1 mtmt -140.58 152.44 45.48 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.295 -1.12 . . . . 0.0 109.484 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -92.61 151.34 20.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.425 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 8.6 m . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.899 . . . . 0.0 109.434 -179.999 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.8 pt . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.453 ' OD2' ' HB3' ' A' ' 5' ' ' LYS . 29.5 t70 -117.47 135.92 53.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.23 -0.919 . . . . 0.0 109.432 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 91.3 mt -99.47 73.08 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.216 -0.928 . . . . 0.0 109.517 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.453 ' HB3' ' OD2' ' A' ' 3' ' ' ASP . 0.9 OUTLIER -104.77 159.31 15.88 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.228 -0.92 . . . . 0.0 109.445 179.963 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.46 147.69 75.86 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.21 -0.931 . . . . 0.0 109.436 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.21 160.82 29.47 Favored 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.608 2.206 . . . . 0.0 110.379 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 9' ' ' PHE . 27.2 m -71.6 89.38 0.98 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.327 -0.858 . . . . 0.0 109.48 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.463 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 31.4 m-85 -44.07 147.98 0.86 Allowed Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.298 -0.876 . . . . 0.0 109.444 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.4 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.8 Cg_endo -78.06 -159.96 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.691 2.261 . . . . 0.0 110.415 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 12' ' ' SER . 46.7 tt0 -77.38 -58.41 3.29 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.215 -0.928 . . . . 0.0 109.401 -179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.8 t -42.8 -55.71 3.53 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.273 -0.892 . . . . 0.0 109.693 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.4 ' HB ' ' HD2' ' A' ' 10' ' ' PRO . 3.5 mt -91.45 134.08 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.251 -0.905 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.18 11.3 16.25 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.242 -0.911 . . . . 0.0 109.486 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.463 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 0.5 OUTLIER 171.31 -171.15 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.182 -0.949 . . . . 0.0 109.477 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.76 -167.3 17.77 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.46 HG21 ' O ' ' A' ' 64' ' ' ASP . 94.6 m -150.0 125.83 10.46 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -1.156 . . . . 0.0 109.483 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.41 ' C ' ' O ' ' A' ' 17' ' ' THR . 47.0 t -45.26 160.07 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 109.454 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.464 ' HB2' ' O ' ' A' ' 37' ' ' ASP . . . -106.16 -73.06 0.69 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.186 -0.946 . . . . 0.0 109.51 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.1 m -160.08 131.89 6.12 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.237 -0.914 . . . . 0.0 109.521 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.635 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.4 m95 -89.87 85.57 6.42 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 121.279 -0.888 . . . . 0.0 109.545 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.571 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 2.0 m80 -43.26 -62.21 1.12 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.32 -0.863 . . . . 0.0 109.392 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -100.58 176.66 5.25 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.929 . . . . 0.0 109.506 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.16 167.46 11.33 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.427 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.495 ' HA ' ' CG2' ' A' ' 55' ' ' ILE . 35.2 Cg_endo -76.92 108.94 2.75 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.689 2.259 . . . . 0.0 110.422 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 139.01 -10.22 3.33 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -97.48 -172.22 2.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.29 -1.123 . . . . 0.0 109.541 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -106.76 154.66 20.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.299 -0.875 . . . . 0.0 109.498 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.4 p -139.58 148.94 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.499 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -114.58 137.69 51.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.151 -0.968 . . . . 0.0 109.504 -179.972 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.461 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 29.5 ttt85 -42.73 150.03 0.17 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.331 -0.855 . . . . 0.0 109.663 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.461 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 8.5 t70 72.3 41.14 0.63 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.48 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.439 ' O ' ' O ' ' A' ' 34' ' ' LEU . 2.4 tp10 -141.94 124.23 15.61 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.147 -0.97 . . . . 0.0 109.448 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.571 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 45.7 tp -43.16 164.69 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.346 -0.846 . . . . 0.0 109.482 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.508 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 27.4 mm -139.52 -46.07 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.109 -0.994 . . . . 0.0 109.579 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.454 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.6 p -166.3 137.25 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.262 -0.899 . . . . 0.0 109.473 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.464 ' O ' ' HB2' ' A' ' 19' ' ' ALA . 16.9 m-20 -97.96 152.67 19.01 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.253 -0.904 . . . . 0.0 109.44 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 6.0 mm -119.52 156.15 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.461 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.453 ' HB2' ' O ' ' A' ' 17' ' ' THR . 1.1 mm-40 -118.23 128.91 55.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.425 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.1 OUTLIER -109.87 -161.23 0.75 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.266 -0.896 . . . . 0.0 109.429 179.992 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.425 ' C ' ' O ' ' A' ' 40' ' ' THR . 13.6 t0 -42.8 -71.01 0.09 Allowed 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.342 -0.849 . . . . 0.0 109.681 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.5 mmtm -137.29 28.24 2.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.274 -0.891 . . . . 0.0 109.475 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 24.6 t -128.43 169.32 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.24 -0.913 . . . . 0.0 109.51 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.461 ' O ' HG12 ' A' ' 44' ' ' VAL . 7.5 p -129.66 122.43 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.302 -0.874 . . . . 0.0 109.457 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 87.2 mmm -103.89 176.51 5.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 0.0 109.476 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -136.21 153.15 51.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.215 -0.928 . . . . 0.0 109.543 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.454 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 45.8 t -125.09 102.58 10.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.336 -0.853 . . . . 0.0 109.454 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.41 150.21 20.85 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.214 -0.929 . . . . 0.0 109.44 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.8 137.71 37.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.469 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -101.33 19.96 16.75 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.332 -0.855 . . . . 0.0 109.496 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -176.57 134.61 0.23 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.244 -0.91 . . . . 0.0 109.5 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.5 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -62.75 170.94 2.31 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.263 -0.898 . . . . 0.0 109.377 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.5 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 146.71 -151.74 23.97 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.435 ' O ' ' OG1' ' A' ' 76' ' ' THR . 71.4 t -134.28 130.63 54.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -1.149 . . . . 0.0 109.425 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.495 ' CG2' ' HA ' ' A' ' 25' ' ' PRO . 5.1 mt -52.15 160.5 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.338 -0.851 . . . . 0.0 109.524 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.447 ' N ' ' CG2' ' A' ' 55' ' ' ILE . . . -97.69 -68.79 0.78 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.142 -0.974 . . . . 0.0 109.444 -179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.439 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 1.5 mt-10 -176.02 133.08 0.25 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.293 -0.879 . . . . 0.0 109.495 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.635 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 20.1 mm -95.33 125.22 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.309 -0.869 . . . . 0.0 109.47 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 44.3 t -89.91 -29.75 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.912 . . . . 0.0 109.425 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.521 ' CG ' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -90.0 162.72 15.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -0.912 . . . . 0.0 109.424 -179.986 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.464 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 13.7 m-80 -117.08 157.57 25.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.212 -0.93 . . . . 0.0 109.5 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -61.14 134.61 57.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.21 -0.931 . . . . 0.0 109.443 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 94.15 -7.05 72.65 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.521 ' OD2' ' CG ' ' A' ' 60' ' ' LYS . 0.2 OUTLIER -86.06 170.71 11.99 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -1.145 . . . . 0.0 109.301 -179.996 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.502 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 9.6 t -99.58 163.09 12.65 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.536 -0.728 . . . . 0.0 109.521 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 5.7 m -127.02 144.32 37.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.199 -0.938 . . . . 0.0 109.468 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -107.1 167.81 9.65 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.216 -0.928 . . . . 0.0 109.54 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.6 t -67.44 101.83 1.03 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.311 -0.868 . . . . 0.0 109.458 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 107.47 13.2 21.36 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.401 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 46.9 tp10 -81.13 123.84 28.75 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.261 -1.14 . . . . 0.0 109.522 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 5.8 tt -81.88 114.22 20.34 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.184 -0.947 . . . . 0.0 109.517 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.442 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 22.3 mt -89.32 -20.02 24.56 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.17 -0.956 . . . . 0.0 109.495 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 161.29 179.96 36.34 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.442 ' HG2' ' HB2' ' A' ' 56' ' ' ALA . 0.6 OUTLIER -149.74 153.04 36.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -1.175 . . . . 0.0 109.458 -179.968 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.461 ' HG ' ' N ' ' A' ' 76' ' ' THR . 17.0 tp -90.26 153.17 20.67 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.315 -0.866 . . . . 0.0 109.47 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.461 ' N ' ' HG ' ' A' ' 75' ' ' LEU . 5.6 m . . . . . 0 N--CA 1.49 1.567 0 O-C-N 121.311 -0.868 . . . . 0.0 109.46 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.3 mp . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -60.81 130.77 48.15 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.272 -0.893 . . . . 0.0 109.502 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.424 HD11 ' C ' ' A' ' 73' ' ' GLY . 2.7 mp -100.29 110.61 27.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.195 -0.941 . . . . 0.0 109.472 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.7 pttp -120.17 166.82 12.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.198 -0.939 . . . . 0.0 109.478 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.99 164.46 41.59 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.265 -0.897 . . . . 0.0 109.487 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.02 153.54 28.84 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.625 2.217 . . . . 0.0 110.455 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.459 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 41.2 m -75.75 110.49 10.22 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.933 . . . . 0.0 109.455 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -69.92 153.31 95.56 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.205 -0.934 . . . . 0.0 109.482 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.11 176.74 9.61 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 C-N-CA 122.656 2.237 . . . . 0.0 110.453 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.513 ' HG3' ' N ' ' A' ' 12' ' ' SER . 22.5 pt-20 -65.24 -45.44 84.59 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.287 -0.883 . . . . 0.0 109.469 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.513 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 1.5 t -42.61 -40.12 2.59 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.379 -0.826 . . . . 0.0 109.699 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.459 HG23 ' O ' ' A' ' 15' ' ' ASP . 30.0 mm -108.11 154.05 9.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.259 -0.901 . . . . 0.0 109.453 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -118.18 0.16 11.7 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.235 -0.916 . . . . 0.0 109.611 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.459 ' O ' HG23 ' A' ' 13' ' ' ILE . 0.7 OUTLIER 179.23 -174.45 0.21 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.189 -0.945 . . . . 0.0 109.506 -179.995 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -150.92 -160.56 9.47 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.416 ' O ' ' C ' ' A' ' 18' ' ' VAL . 16.8 m -150.02 129.04 12.62 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.236 -1.155 . . . . 0.0 109.418 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.419 HG13 ' N ' ' A' ' 19' ' ' ALA . 60.8 t -44.45 161.26 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.398 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.504 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -106.65 -75.13 0.64 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.247 -0.908 . . . . 0.0 109.515 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.6 m -160.13 131.42 5.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.234 -0.917 . . . . 0.0 109.558 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.637 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.82 85.88 6.51 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.337 -0.852 . . . . 0.0 109.53 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.625 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.7 m80 -42.12 -69.02 0.15 Allowed 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.355 -0.841 . . . . 0.0 109.483 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -96.93 -177.24 3.81 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.215 -0.928 . . . . 0.0 109.628 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.422 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 4.5 mttp -122.76 169.4 9.9 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.292 -0.88 . . . . 0.0 109.453 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.459 ' HG3' HG12 ' A' ' 58' ' ' ILE . 35.1 Cg_endo -76.23 136.43 17.97 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.626 2.217 . . . . 0.0 110.416 179.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.73 14.07 35.69 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -112.5 -172.3 2.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -1.119 . . . . 0.0 109.508 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.75 138.93 31.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.346 -0.846 . . . . 0.0 109.456 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.484 HG11 ' N ' ' A' ' 30' ' ' LYS . 55.9 t -118.5 141.76 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.406 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.484 ' N ' HG11 ' A' ' 29' ' ' VAL . 8.8 ttpt -131.86 127.03 35.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.296 -0.878 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.528 ' CG ' ' HA ' ' A' ' 51' ' ' ALA . 0.2 OUTLIER -42.75 147.24 0.31 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.374 -0.829 . . . . 0.0 109.63 -179.889 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.484 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 11.8 t0 73.4 26.41 2.02 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -0.888 . . . . 0.0 109.463 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.427 ' O ' ' O ' ' A' ' 34' ' ' LEU . 12.5 tm-20 -126.8 110.24 12.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.363 -0.836 . . . . 0.0 109.474 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.625 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 47.4 tp -42.98 164.23 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.321 -0.862 . . . . 0.0 109.597 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.513 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 27.4 mt -138.18 -47.72 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.27 -0.894 . . . . 0.0 109.606 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.553 HG22 ' CE2' ' A' ' 21' ' ' TRP . 12.6 p -150.61 152.78 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.236 -0.915 . . . . 0.0 109.51 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.504 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 23.3 m-20 -113.99 150.63 33.56 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.27 -0.894 . . . . 0.0 109.461 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 3.3 mt -115.27 145.09 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.263 -0.898 . . . . 0.0 109.489 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -118.59 143.91 46.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.209 -0.932 . . . . 0.0 109.423 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.456 ' HB ' ' O ' ' A' ' 43' ' ' VAL . 55.7 m -134.96 165.35 25.54 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.199 -0.938 . . . . 0.0 109.422 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.425 ' HB3' HD13 ' A' ' 13' ' ' ILE . 45.0 t0 -42.79 -36.14 1.37 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.869 . . . . 0.0 109.639 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.456 ' O ' HG21 ' A' ' 43' ' ' VAL . 20.3 mttp -158.48 28.91 0.24 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.277 -0.89 . . . . 0.0 109.503 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.456 ' O ' ' HB ' ' A' ' 40' ' ' THR . 7.6 t -142.05 117.79 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.501 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -107.04 124.86 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.251 -0.906 . . . . 0.0 109.461 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 4.0 mtp -117.2 -174.59 2.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.236 -0.915 . . . . 0.0 109.478 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.464 ' HB2' HD12 ' A' ' 34' ' ' LEU . 0.8 OUTLIER -140.89 168.86 18.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.232 -0.918 . . . . 0.0 109.502 -179.949 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.527 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 53.0 t -142.03 102.98 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.242 -0.912 . . . . 0.0 109.521 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.565 ' CD2' ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.46 166.49 10.51 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.192 -0.943 . . . . 0.0 109.418 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.509 ' CB ' HD13 ' A' ' 35' ' ' ILE . . . -83.52 157.57 22.32 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.918 . . . . 0.0 109.48 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -104.07 7.17 36.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.571 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.528 ' HA ' ' CG ' ' A' ' 31' ' ' ARG . . . 173.18 161.76 0.13 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.959 . . . . 0.0 109.51 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.514 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -59.99 171.0 1.04 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.218 -0.926 . . . . 0.0 109.322 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.514 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.19 -163.9 28.93 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' A' ' 55' ' ' ILE . 40.5 t -133.8 119.6 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.257 -1.143 . . . . 0.0 109.527 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.466 ' O ' ' O ' ' A' ' 54' ' ' VAL . 2.3 mp -47.02 174.45 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.384 -0.823 . . . . 0.0 109.755 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.523 ' CB ' ' O ' ' A' ' 74' ' ' LYS . . . -111.99 -60.86 1.8 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.159 -0.963 . . . . 0.0 109.458 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 177.45 138.0 0.07 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.499 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.637 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.1 mm -95.14 128.48 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.337 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 83.7 t -90.04 -33.52 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.196 -0.94 . . . . 0.0 109.518 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.499 ' HE2' ' CG ' ' A' ' 70' ' ' GLU . 1.0 OUTLIER -97.83 145.96 25.89 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.2 -0.937 . . . . 0.0 109.497 -179.928 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 -109.72 169.44 8.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.293 -0.879 . . . . 0.0 109.435 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -64.26 150.62 45.59 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.193 -0.942 . . . . 0.0 109.56 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.68 5.59 86.43 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.507 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -105.17 170.85 7.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.115 -1.226 . . . . 0.0 109.26 -179.991 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.507 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 9.8 t -99.35 153.77 18.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.607 -0.683 . . . . 0.0 109.467 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 28.5 m -124.75 136.82 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.233 -0.917 . . . . 0.0 109.472 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.441 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.1 OUTLIER -92.84 163.2 13.8 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.263 -0.898 . . . . 0.0 109.412 179.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.459 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 33.1 t -55.7 123.02 12.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 109.469 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 67.46 35.83 87.64 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.499 ' CG ' ' HE2' ' A' ' 60' ' ' LYS . 8.4 tp10 -79.91 136.91 36.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.259 -1.142 . . . . 0.0 109.442 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.424 HD22 ' N ' ' A' ' 73' ' ' GLY . 9.0 tt -77.88 117.72 19.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.279 -0.888 . . . . 0.0 109.432 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.459 HD22 ' NZ ' ' A' ' 60' ' ' LYS . 0.4 OUTLIER -99.41 -14.89 18.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.871 . . . . 0.0 109.397 179.972 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.424 ' C ' HD11 ' A' ' 4' ' ' ILE . . . 160.14 -169.49 36.03 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.523 ' O ' ' CB ' ' A' ' 56' ' ' ALA . 4.7 ptmt -150.1 152.82 35.38 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -1.154 . . . . 0.0 109.466 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.403 HD21 ' O ' ' A' ' 76' ' ' THR . 0.5 OUTLIER -104.15 156.51 17.82 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.466 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.403 ' O ' HD21 ' A' ' 75' ' ' LEU . 5.9 m . . . . . 0 N--CA 1.49 1.563 0 O-C-N 121.321 -0.862 . . . . 0.0 109.49 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 4.7 mm . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.401 ' OD2' ' HD2' ' A' ' 5' ' ' LYS . 27.2 t0 -114.87 137.9 51.42 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.249 -0.907 . . . . 0.0 109.536 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.9 mt -105.78 72.67 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.434 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.401 ' HD2' ' OD2' ' A' ' 3' ' ' ASP . 1.3 ptmt -102.85 149.8 24.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.27 -0.894 . . . . 0.0 109.421 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -61.63 158.55 39.86 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.292 -0.88 . . . . 0.0 109.534 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.0 -178.96 5.0 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.676 2.251 . . . . 0.0 110.405 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 60.6 m -92.74 129.3 38.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.453 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -81.1 148.96 65.34 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.192 -0.943 . . . . 0.0 109.453 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.02 -165.99 0.37 Allowed 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.659 2.239 . . . . 0.0 110.393 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.418 ' CG ' ' N ' ' A' ' 12' ' ' SER . 12.7 pt-20 -73.69 -41.67 62.31 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.267 -0.896 . . . . 0.0 109.525 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.418 ' N ' ' CG ' ' A' ' 11' ' ' GLU . 38.4 t -42.89 -72.95 0.05 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.367 -0.833 . . . . 0.0 109.634 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.42 HG22 ' HB2' ' A' ' 41' ' ' ASP . 1.8 mp -90.71 150.57 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.522 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -121.29 31.48 6.32 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.212 -0.93 . . . . 0.0 109.514 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -177.33 -171.84 0.35 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.925 . . . . 0.0 109.439 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.63 175.59 32.69 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.518 ' O ' ' CG ' ' A' ' 39' ' ' GLU . 98.1 m -150.07 114.97 5.33 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.144 -1.21 . . . . 0.0 109.527 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.516 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 40.2 t -46.0 168.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.313 -0.867 . . . . 0.0 109.477 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.52 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -113.22 -71.08 0.77 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.254 -0.904 . . . . 0.0 109.58 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.482 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 20.7 m -160.03 134.75 7.73 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.197 -0.939 . . . . 0.0 109.572 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.626 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.5 m95 -89.89 84.01 6.2 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.26 -0.9 . . . . 0.0 109.505 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.629 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -42.72 -70.12 0.12 Allowed 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.39 -0.819 . . . . 0.0 109.469 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 7.6 mmtt -89.5 -172.2 3.5 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.61 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.46 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 8.2 mttp -136.66 165.24 36.75 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.27 -0.894 . . . . 0.0 109.247 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.525 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -77.21 114.44 3.77 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.553 2.169 . . . . 0.0 110.383 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 135.23 -9.9 4.42 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -100.21 -172.36 2.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.235 -1.156 . . . . 0.0 109.487 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.453 ' O ' HG21 ' A' ' 29' ' ' VAL . . . -86.83 170.47 11.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.293 -0.879 . . . . 0.0 109.484 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.453 HG21 ' O ' ' A' ' 28' ' ' ALA . 52.2 t -142.08 148.27 20.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.212 -0.93 . . . . 0.0 109.482 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.2 OUTLIER -135.38 136.01 41.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.259 -0.901 . . . . 0.0 109.479 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.458 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 15.7 ttp180 -42.87 145.38 0.47 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.29 -0.881 . . . . 0.0 109.733 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.458 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 54.9 t0 67.45 48.11 1.17 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.285 -0.884 . . . . 0.0 109.477 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' A' ' 34' ' ' LEU . 1.2 tp10 -137.57 105.95 5.79 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.216 -0.927 . . . . 0.0 109.508 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.629 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 42.7 tp -43.13 164.89 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.302 -0.874 . . . . 0.0 109.537 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.5 HD13 ' CB ' ' A' ' 49' ' ' ALA . 49.3 mt -142.56 -47.64 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.245 -0.909 . . . . 0.0 109.615 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.522 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.9 p -151.47 134.98 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.168 -0.957 . . . . 0.0 109.552 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.52 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 6.4 m-20 -95.59 163.86 13.03 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.31 -0.868 . . . . 0.0 109.427 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.424 HD12 ' CG2' ' A' ' 47' ' ' VAL . 21.6 mt -134.0 152.8 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.185 -0.947 . . . . 0.0 109.399 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 17' ' ' THR . 10.9 pt-20 -146.43 144.56 29.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.204 -0.935 . . . . 0.0 109.557 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.418 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -140.28 -172.04 3.33 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.281 -0.887 . . . . 0.0 109.481 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.42 ' HB2' HG22 ' A' ' 13' ' ' ILE . 3.0 t70 -42.89 -64.15 0.67 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.354 -0.841 . . . . 0.0 109.66 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.65 44.13 1.96 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.428 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 2.8 t -148.22 104.28 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.26 -0.9 . . . . 0.0 109.497 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.434 ' O ' ' HG2' ' A' ' 45' ' ' MET . 62.1 t -98.04 143.43 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.242 -0.911 . . . . 0.0 109.535 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' MET . . . . . 0.434 ' HG2' ' O ' ' A' ' 44' ' ' VAL . 2.7 mmt -143.52 -178.89 6.11 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.227 -0.921 . . . . 0.0 109.489 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -141.33 165.68 26.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.176 -0.953 . . . . 0.0 109.512 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.522 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 18.1 t -137.35 98.36 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.232 -0.918 . . . . 0.0 109.467 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.561 ' CD2' ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -103.18 160.58 14.53 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 121.227 -0.92 . . . . 0.0 109.371 179.943 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.5 ' CB ' HD13 ' A' ' 35' ' ' ILE . . . -77.9 132.63 38.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.459 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -86.28 12.4 10.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.221 -0.924 . . . . 0.0 109.489 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . 178.86 155.12 0.43 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.295 -0.878 . . . . 0.0 109.446 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.499 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -65.97 170.94 4.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.178 -0.952 . . . . 0.0 109.392 179.94 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.499 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 149.9 -153.99 25.43 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.6 t -135.19 126.27 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -1.129 . . . . 0.0 109.45 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.519 ' CG2' ' N ' ' A' ' 56' ' ' ALA . 5.1 mt -56.21 164.39 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.193 -0.942 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.519 ' N ' ' CG2' ' A' ' 55' ' ' ILE . . . -105.08 -63.69 1.2 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.531 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.525 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 1.1 pt-20 -179.24 144.09 0.22 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.248 -0.907 . . . . 0.0 109.465 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.626 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 24.5 mm -105.3 123.91 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.279 -0.888 . . . . 0.0 109.503 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.0 t -89.91 -19.88 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.251 -0.905 . . . . 0.0 109.546 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.464 ' HG3' ' OD1' ' A' ' 64' ' ' ASP . 3.9 tptt -115.97 129.9 56.59 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.239 -0.913 . . . . 0.0 109.51 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.445 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 14.9 m-80 -87.62 157.03 19.22 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 0.0 109.454 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.516 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -60.66 151.81 28.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.31 -10.49 68.86 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.514 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -88.63 171.02 10.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -1.164 . . . . 0.0 109.321 -179.97 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.514 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 97.9 m -91.51 147.18 23.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.518 -0.739 . . . . 0.0 109.482 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.405 ' N ' HG21 ' A' ' 65' ' ' THR . 17.1 m -120.04 178.73 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.281 -0.887 . . . . 0.0 109.405 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -130.33 162.69 28.48 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.915 . . . . 0.0 109.466 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -65.16 97.22 0.24 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.225 -0.922 . . . . 0.0 109.441 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.77 27.74 7.78 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.504 -1.439 . . . . 0.0 109.504 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -84.08 132.06 34.74 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.201 -1.176 . . . . 0.0 109.49 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 8.4 tt -78.9 114.98 18.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -0.924 . . . . 0.0 109.464 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 5.1 mt -91.24 -22.15 20.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.322 -0.861 . . . . 0.0 109.466 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 170.85 177.03 40.52 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.409 ' O ' ' CB ' ' A' ' 56' ' ' ALA . 12.5 mttt -124.94 138.36 54.24 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.3 -1.117 . . . . 0.0 109.492 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -94.71 144.16 25.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.499 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 10.8 m . . . . . 0 N--CA 1.489 1.519 0 O-C-N 121.207 -0.933 . . . . 0.0 109.464 179.987 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.3 mt . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.402 ' OD2' ' HE3' ' A' ' 74' ' ' LYS . 46.2 t0 -72.71 127.7 33.34 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.296 -0.877 . . . . 0.0 109.513 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 60.7 mt -95.63 80.28 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.33 -0.857 . . . . 0.0 109.504 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.42 ' O ' ' HG3' ' A' ' 5' ' ' LYS . 0.2 OUTLIER -100.14 145.94 27.4 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.537 179.971 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -52.15 162.9 0.77 Allowed Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.227 -0.921 . . . . 0.0 109.451 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -77.95 162.81 28.99 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.642 2.228 . . . . 0.0 110.484 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.444 HG21 ' O ' ' A' ' 8' ' ' THR . 2.5 t -82.95 105.74 14.2 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.186 -0.947 . . . . 0.0 109.436 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -72.4 150.72 91.76 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.187 -0.946 . . . . 0.0 109.492 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.07 176.34 10.09 Favored 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.6 2.2 . . . . 0.0 110.42 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.436 ' O ' ' C ' ' A' ' 12' ' ' SER . 2.1 mt-10 -56.64 -50.98 70.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.309 -0.869 . . . . 0.0 109.441 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 11' ' ' GLU . 7.3 t -42.93 -46.65 5.46 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.37 -0.831 . . . . 0.0 109.58 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.409 HG12 ' HB2' ' A' ' 41' ' ' ASP . 64.5 mt -92.76 150.34 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.212 -0.93 . . . . 0.0 109.477 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -127.0 17.07 7.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.942 . . . . 0.0 109.471 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 178.75 -169.08 0.09 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.196 -0.94 . . . . 0.0 109.499 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.91 -176.17 21.23 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 69.4 m -149.91 115.27 5.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.254 -1.145 . . . . 0.0 109.495 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.524 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 27.5 t -49.41 169.28 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.264 -0.898 . . . . 0.0 109.391 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.521 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -114.69 -73.97 0.63 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.191 -0.943 . . . . 0.0 109.53 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.0 m -160.07 133.72 7.09 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.198 -0.939 . . . . 0.0 109.523 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.631 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.5 m95 -89.87 92.9 9.21 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 121.155 -0.965 . . . . 0.0 109.556 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.574 ' CD2' HD22 ' A' ' 34' ' ' LEU . 1.6 m80 -54.98 -72.24 0.07 Allowed 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.324 -0.86 . . . . 0.0 109.421 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -84.18 -172.77 4.35 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.238 -0.914 . . . . 0.0 109.609 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -136.35 166.97 23.78 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.388 -0.82 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.488 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.6 Cg_endo -77.03 138.82 18.67 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.683 2.256 . . . . 0.0 110.493 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 106.79 -9.82 40.75 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -102.2 -174.37 2.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.315 -1.109 . . . . 0.0 109.417 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.82 147.77 27.36 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.302 -0.873 . . . . 0.0 109.466 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m -129.95 -169.53 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.212 -0.93 . . . . 0.0 109.467 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.448 ' O ' ' CB ' ' A' ' 33' ' ' GLU . 9.9 tptm -157.06 139.61 14.92 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.224 -0.923 . . . . 0.0 109.479 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.426 ' C ' ' O ' ' A' ' 30' ' ' LYS . 2.3 ttp180 -42.78 154.83 0.06 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.289 -0.882 . . . . 0.0 109.622 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.0 t70 60.24 33.44 20.97 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.244 -0.91 . . . . 0.0 109.47 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.448 ' CB ' ' O ' ' A' ' 30' ' ' LYS . 28.9 tt0 -126.45 113.92 17.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.223 -0.923 . . . . 0.0 109.508 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.574 HD22 ' CD2' ' A' ' 22' ' ' HIS . 56.8 tp -42.86 160.23 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.357 -0.839 . . . . 0.0 109.623 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.481 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 4.3 mt -142.77 -43.95 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.229 -0.919 . . . . 0.0 109.56 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.518 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 13.6 p -160.87 138.65 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.282 -0.886 . . . . 0.0 109.439 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.521 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 28.3 m-20 -97.76 149.5 22.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.139 -0.976 . . . . 0.0 109.39 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.518 HD13 ' CG2' ' A' ' 47' ' ' VAL . 31.5 mt -122.46 156.3 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.196 -0.94 . . . . 0.0 109.42 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.401 ' OE2' ' O ' ' A' ' 40' ' ' THR . 2.4 tm-20 -135.62 153.17 51.74 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.433 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.414 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -140.23 -178.98 5.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.195 -0.94 . . . . 0.0 109.509 -179.993 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.414 ' C ' ' O ' ' A' ' 40' ' ' THR . 6.7 t0 -42.78 -70.02 0.12 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.344 -0.848 . . . . 0.0 109.593 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.449 ' O ' HG21 ' A' ' 43' ' ' VAL . 7.2 mttt -129.38 35.05 4.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.255 -0.903 . . . . 0.0 109.392 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.449 HG21 ' O ' ' A' ' 42' ' ' LYS . 9.7 t -144.09 152.71 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 109.447 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.4 t -130.5 153.88 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.184 -0.948 . . . . 0.0 109.487 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' MET . . . . . 0.418 ' C ' ' HG3' ' A' ' 46' ' ' GLU . 4.4 mmt -143.25 167.38 22.28 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.188 -0.945 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.418 ' HG3' ' C ' ' A' ' 45' ' ' MET . 0.7 OUTLIER -128.98 156.22 44.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.285 -0.884 . . . . 0.0 109.478 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.518 ' CG2' HD13 ' A' ' 38' ' ' ILE . 20.9 t -126.88 99.95 6.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.895 . . . . 0.0 109.502 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.558 ' CD2' ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.93 164.96 11.31 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.295 -0.878 . . . . 0.0 109.396 -179.992 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.408 ' CB ' HD12 ' A' ' 35' ' ' ILE . . . -83.34 129.41 34.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.291 -0.881 . . . . 0.0 109.522 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -91.35 10.84 25.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.197 -0.939 . . . . 0.0 109.443 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.408 ' O ' ' O ' ' A' ' 52' ' ' ASP . . . 171.58 132.33 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.316 -0.865 . . . . 0.0 109.454 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.506 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -47.42 170.93 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.253 -0.904 . . . . 0.0 109.294 179.973 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.506 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 153.88 -160.95 29.67 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 46.5 t -124.56 123.91 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.272 -1.134 . . . . 0.0 109.494 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.507 ' CG2' ' N ' ' A' ' 56' ' ' ALA . 4.9 mt -61.52 163.7 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.338 -0.852 . . . . 0.0 109.615 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.507 ' N ' ' CG2' ' A' ' 55' ' ' ILE . . . -103.22 -65.51 1.0 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -0.922 . . . . 0.0 109.485 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.488 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER 172.66 141.35 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.239 -0.913 . . . . 0.0 109.427 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.631 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 9.9 mm -89.97 140.38 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.279 -0.888 . . . . 0.0 109.398 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 98.8 t -89.99 -53.13 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.184 -0.947 . . . . 0.0 109.438 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.514 ' CE ' ' HA ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -94.87 167.17 11.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.251 -0.906 . . . . 0.0 109.391 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 49.3 m-80 -104.65 156.06 18.31 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.422 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.524 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -64.97 155.54 34.15 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.417 -179.933 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.08 2.54 89.4 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -105.28 170.96 7.58 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.196 -1.179 . . . . 0.0 109.313 -179.984 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.51 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 95.4 m -98.93 122.91 42.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.553 -0.717 . . . . 0.0 109.489 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.433 ' HB ' ' HG2' ' A' ' 70' ' ' GLU . 5.5 m -104.41 -172.37 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.273 -0.892 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -133.45 176.3 8.65 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.501 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.9 t -63.8 143.54 57.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.414 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 60.17 26.01 63.07 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.433 ' HG2' ' HB ' ' A' ' 66' ' ' VAL . 35.2 tp10 -82.92 110.43 17.9 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.455 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.452 ' CD1' ' HD2' ' A' ' 74' ' ' LYS . 9.6 tt -69.24 109.97 4.36 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.264 -0.897 . . . . 0.0 109.486 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 35.9 mt -94.33 -11.8 29.29 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.521 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.431 ' O ' ' HG2' ' A' ' 74' ' ' LYS . . . 173.04 177.92 42.66 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.452 ' HD2' ' CD1' ' A' ' 71' ' ' LEU . 20.3 mtpt -147.7 129.2 14.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -1.127 . . . . 0.0 109.466 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.457 HD22 ' O ' ' A' ' 76' ' ' THR . 1.1 tt -96.02 147.66 23.47 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.238 -0.914 . . . . 0.0 109.539 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.457 ' O ' HD22 ' A' ' 75' ' ' LEU . 5.8 m . . . . . 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.513 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 36.8 pt . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.518 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 14.4 t0 -113.97 133.57 55.4 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.233 -0.917 . . . . 0.0 109.479 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.8 mt -105.57 98.08 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.193 -0.942 . . . . 0.0 109.48 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.02 168.69 14.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.17 -0.956 . . . . 0.0 109.5 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.2 153.73 92.33 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.307 -0.87 . . . . 0.0 109.47 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.99 140.64 18.23 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.565 2.177 . . . . 0.0 110.418 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.429 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 8.9 t -62.32 129.59 41.41 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -0.962 . . . . 0.0 109.451 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.491 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 23.4 m-85 -96.93 151.88 38.03 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.887 . . . . 0.0 109.472 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.448 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -78.08 171.31 17.33 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.671 2.247 . . . . 0.0 110.376 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.424 ' O ' ' C ' ' A' ' 12' ' ' SER . 4.5 mt-10 -45.67 -54.52 7.66 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.144 -0.973 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.424 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.95 -62.46 1.01 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.282 -0.886 . . . . 0.0 109.601 -179.917 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.521 ' CG2' ' O ' ' A' ' 15' ' ' ASP . 29.8 mm -92.85 119.13 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.181 -0.949 . . . . 0.0 109.482 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.438 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -96.18 13.21 28.13 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.262 -0.899 . . . . 0.0 109.484 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.521 ' O ' ' CG2' ' A' ' 13' ' ' ILE . 0.8 OUTLIER 167.42 -171.82 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.884 . . . . 0.0 109.431 -179.957 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.34 -159.28 8.39 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 52.1 m -149.57 123.29 9.23 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.243 -1.151 . . . . 0.0 109.502 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.512 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 39.6 t -47.98 168.64 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.302 -0.874 . . . . 0.0 109.426 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.523 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -113.13 -75.0 0.61 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.413 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.5 m -160.08 134.7 7.66 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.336 -0.853 . . . . 0.0 109.451 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.639 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.1 m95 -89.78 84.9 6.3 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.231 -0.918 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.551 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.8 m80 -42.34 -60.46 1.48 Allowed 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.371 -0.831 . . . . 0.0 109.497 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 4.1 mmtt -99.66 -172.11 2.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.593 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -130.12 168.59 16.12 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.288 -0.882 . . . . 0.0 109.496 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.517 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.51 115.58 4.11 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 122.664 2.243 . . . . 0.0 110.39 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.83 -11.92 5.38 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.431 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 1.2 pp20? -95.6 -172.89 2.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.352 -1.087 . . . . 0.0 109.467 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.431 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -101.04 151.2 22.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.1 m -114.9 166.63 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.358 -0.839 . . . . 0.0 109.429 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.436 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.3 mttt -121.3 134.5 55.15 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.262 -0.899 . . . . 0.0 109.506 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.51 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.81 113.42 0.47 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.352 -0.843 . . . . 0.0 109.684 -179.898 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.51 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 14.5 t0 75.99 56.37 0.05 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.293 -0.879 . . . . 0.0 109.495 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.462 ' O ' HG13 ' A' ' 35' ' ' ILE . 15.9 tt0 -131.24 124.15 29.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.319 -0.863 . . . . 0.0 109.437 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.551 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 51.1 tp -42.8 151.63 0.12 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.377 -0.827 . . . . 0.0 109.596 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.476 HD13 ' N ' ' A' ' 49' ' ' ALA . 96.9 mt -137.84 -41.21 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.319 -0.863 . . . . 0.0 109.476 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.52 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 13.6 p -158.24 135.0 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.277 -0.89 . . . . 0.0 109.451 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.523 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 10.7 m-20 -93.28 153.83 18.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.287 -0.883 . . . . 0.0 109.438 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.413 HG23 HD11 ' A' ' 38' ' ' ILE . 2.8 mt -121.44 155.81 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.271 -0.893 . . . . 0.0 109.507 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.0 145.06 50.85 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.295 -0.878 . . . . 0.0 109.439 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.43 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -130.6 -176.98 4.15 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -0.932 . . . . 0.0 109.479 179.962 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' A' ' 40' ' ' THR . 63.5 t0 -42.78 -55.08 3.8 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.286 -0.883 . . . . 0.0 109.686 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 18.3 mttm -147.45 25.45 1.08 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.246 -0.908 . . . . 0.0 109.396 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 2.1 t -134.05 130.87 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.231 -0.918 . . . . 0.0 109.457 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.0 t -108.57 139.78 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.218 -0.926 . . . . 0.0 109.512 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 18.7 mtp -131.62 175.28 9.31 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.212 -0.93 . . . . 0.0 109.467 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -124.59 159.91 29.62 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.508 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.52 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 5.4 t -130.14 89.5 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.286 -0.884 . . . . 0.0 109.45 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.557 ' CD2' ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.92 156.72 17.47 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.239 -0.913 . . . . 0.0 109.372 179.974 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.476 ' N ' HD13 ' A' ' 35' ' ' ILE . . . -77.84 149.13 34.4 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.196 -0.94 . . . . 0.0 109.538 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.456 ' O ' ' HB1' ' A' ' 51' ' ' ALA . 1.3 mt-10 -92.27 12.02 23.84 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.229 -0.92 . . . . 0.0 109.449 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.456 ' HB1' ' O ' ' A' ' 50' ' ' GLU . . . 179.13 150.07 0.28 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.243 -0.911 . . . . 0.0 109.493 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -55.35 170.93 0.2 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.216 -0.928 . . . . 0.0 109.32 -179.97 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.509 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 154.74 -153.88 25.12 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 52.4 t -138.75 127.0 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.247 -1.149 . . . . 0.0 109.442 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.413 HD11 ' CD1' ' A' ' 75' ' ' LEU . 14.9 mm -62.25 158.15 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.213 -0.929 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -97.37 -69.56 0.75 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.238 -0.914 . . . . 0.0 109.468 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.517 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 2.9 pt-20 -174.76 142.44 0.7 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.255 -0.903 . . . . 0.0 109.453 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.639 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 15.7 mm -93.86 138.05 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.208 -0.933 . . . . 0.0 109.498 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.7 t -90.56 -57.71 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.275 -0.891 . . . . 0.0 109.532 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.517 ' CE ' ' HA ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -89.93 163.22 15.06 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.17 -0.956 . . . . 0.0 109.439 -179.964 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 -102.56 156.49 17.58 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 109.53 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.512 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.2 OUTLIER -66.49 160.1 25.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.245 -0.909 . . . . 0.0 109.432 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 81.75 -7.35 62.55 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.515 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -100.81 171.02 7.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -1.165 . . . . 0.0 109.333 179.997 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.9 t -92.4 153.77 18.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.546 -0.722 . . . . 0.0 109.441 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.449 ' HA ' ' OE1' ' A' ' 70' ' ' GLU . 18.0 m -129.0 -174.66 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.233 -0.917 . . . . 0.0 109.55 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -128.98 170.88 12.91 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.283 -0.886 . . . . 0.0 109.432 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.429 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 3.9 t -72.22 99.7 2.42 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.872 . . . . 0.0 109.474 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 109.51 14.86 13.28 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.449 ' OE1' ' HA ' ' A' ' 66' ' ' VAL . 3.9 tt0 -75.45 119.29 19.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -1.127 . . . . 0.0 109.448 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.518 ' CD1' ' OD1' ' A' ' 3' ' ' ASP . 68.4 tp -69.72 108.73 4.03 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.266 -0.896 . . . . 0.0 109.47 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.441 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 16.6 mt -88.39 -13.92 39.35 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.24 -0.913 . . . . 0.0 109.514 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 161.45 178.46 35.41 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 5.1 mtpt -137.91 144.17 41.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.22 -1.164 . . . . 0.0 109.444 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.413 ' CD1' HD11 ' A' ' 55' ' ' ILE . 17.1 tp -93.32 140.51 29.47 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.2 -0.937 . . . . 0.0 109.506 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 14.8 m . . . . . 0 N--CA 1.49 1.546 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.957 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.0 mm . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 121.263 0.554 . . . . 0.0 109.517 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 62.8 t0 -80.71 132.12 35.52 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.214 -0.929 . . . . 0.0 109.495 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 40.9 mt -104.23 99.1 7.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.327 -0.858 . . . . 0.0 109.481 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.412 ' HA ' ' HA ' ' A' ' 71' ' ' LEU . 4.2 mttp -106.66 177.03 4.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.244 -0.91 . . . . 0.0 109.508 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.98 165.8 48.06 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.264 -0.897 . . . . 0.0 109.493 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.528 ' HG2' ' CZ ' ' A' ' 9' ' ' PHE . 35.3 Cg_endo -77.6 157.11 32.17 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.615 2.21 . . . . 0.0 110.44 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.3 t -62.77 146.63 52.02 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.848 . . . . 0.0 109.495 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.528 ' CZ ' ' HG2' ' A' ' 7' ' ' PRO . 24.0 m-85 -129.99 91.37 39.77 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.224 -0.922 . . . . 0.0 109.477 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.5 Cg_endo -78.03 -162.94 0.19 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.63 2.22 . . . . 0.0 110.445 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.429 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.0 OUTLIER -51.81 -54.83 24.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.293 -0.879 . . . . 0.0 109.446 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.429 ' C ' ' O ' ' A' ' 11' ' ' GLU . 34.4 t -42.94 -60.23 1.69 Allowed 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.324 -0.86 . . . . 0.0 109.626 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.463 ' O ' ' O ' ' A' ' 10' ' ' PRO . 27.0 mt -102.47 119.03 50.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.215 -0.928 . . . . 0.0 109.56 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -96.88 -0.25 48.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.922 . . . . 0.0 109.549 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.463 ' O ' HG23 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -173.53 -173.59 0.9 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.244 -0.91 . . . . 0.0 109.401 -179.976 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.479 ' O ' ' CG2' ' A' ' 65' ' ' THR . . . -154.6 170.79 32.99 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.518 ' O ' ' CG ' ' A' ' 39' ' ' GLU . 21.8 m -150.04 118.59 6.51 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.312 -1.111 . . . . 0.0 109.414 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.482 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 42.8 t -45.25 168.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.204 -0.935 . . . . 0.0 109.506 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.406 ' O ' ' OE1' ' A' ' 62' ' ' GLU . . . -113.65 -70.68 0.79 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.185 -0.947 . . . . 0.0 109.574 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.421 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 17.1 m -158.56 134.77 9.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.171 -0.955 . . . . 0.0 109.608 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.497 ' CZ2' HG21 ' A' ' 58' ' ' ILE . 31.4 m95 -89.86 84.77 6.26 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.269 -0.894 . . . . 0.0 109.559 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.636 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.7 m80 -42.69 -70.41 0.11 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.37 -0.831 . . . . 0.0 109.48 -179.763 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -101.11 -172.11 2.11 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.223 -0.923 . . . . 0.0 109.534 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.409 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 4.0 mttt -125.92 167.41 16.92 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.264 -0.897 . . . . 0.0 109.441 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.519 ' CG ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.93 131.22 11.95 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.608 2.205 . . . . 0.0 110.49 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.45 -12.48 18.8 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -89.8 -174.33 4.24 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.3 -1.118 . . . . 0.0 109.398 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.7 140.31 42.42 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.288 -0.883 . . . . 0.0 109.456 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.495 HG23 ' CD1' ' A' ' 55' ' ' ILE . 47.3 t -128.21 161.68 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.431 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 31' ' ' ARG . 3.7 tptt -153.28 137.5 16.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.207 -0.933 . . . . 0.0 109.491 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 30' ' ' LYS . 8.3 tmm_? -42.8 139.61 1.59 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.296 -0.877 . . . . 0.0 109.593 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 20.0 t70 68.05 49.0 0.9 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.349 -0.844 . . . . 0.0 109.469 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.424 ' O ' ' C ' ' A' ' 34' ' ' LEU . 1.6 tt0 -133.95 103.88 6.02 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.921 . . . . 0.0 109.426 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.636 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 38.4 tp -42.58 151.54 0.12 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.357 -0.839 . . . . 0.0 109.632 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.51 HD13 ' N ' ' A' ' 49' ' ' ALA . 5.1 mt -142.04 -40.18 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.166 -0.959 . . . . 0.0 109.542 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.505 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 12.2 p -151.92 128.2 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.407 ' OD1' ' HG2' ' A' ' 46' ' ' GLU . 12.9 m-20 -89.89 164.24 14.67 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.403 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 80.8 mt -136.69 151.97 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.223 -0.923 . . . . 0.0 109.522 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 17' ' ' THR . 4.6 pt-20 -140.68 135.11 31.3 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.265 -0.897 . . . . 0.0 109.425 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.461 HG21 ' O ' ' A' ' 43' ' ' VAL . 5.3 t -128.31 -162.33 1.17 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.336 -0.853 . . . . 0.0 109.35 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.452 ' N ' HG22 ' A' ' 40' ' ' THR . 11.8 t70 -42.43 -61.85 1.11 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.325 -0.859 . . . . 0.0 109.697 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.449 ' O ' HG21 ' A' ' 43' ' ' VAL . 5.9 mtpm? -149.47 45.09 0.96 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.225 -0.922 . . . . 0.0 109.515 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.461 ' O ' HG21 ' A' ' 40' ' ' THR . 54.5 t -154.69 108.25 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.195 -0.94 . . . . 0.0 109.489 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.471 HG21 ' N ' ' A' ' 45' ' ' MET . 3.8 p -96.43 140.01 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.343 -0.848 . . . . 0.0 109.396 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' MET . . . . . 0.471 ' N ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER -131.77 134.23 45.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.261 -0.9 . . . . 0.0 109.499 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.525 ' HB3' ' CD1' ' A' ' 34' ' ' LEU . 25.2 mt-10 -89.64 151.49 21.86 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.296 -0.878 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.505 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 91.8 t -123.0 103.62 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.173 -0.954 . . . . 0.0 109.507 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.43 ' HA ' HG13 ' A' ' 35' ' ' ILE . 0.2 OUTLIER -102.78 171.2 7.55 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.276 -0.89 . . . . 0.0 109.37 179.966 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.51 ' N ' HD13 ' A' ' 35' ' ' ILE . . . -84.98 134.81 34.22 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.255 -0.903 . . . . 0.0 109.464 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.431 ' O ' ' HB3' ' A' ' 51' ' ' ALA . 0.9 OUTLIER -84.81 10.95 10.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.156 -0.965 . . . . 0.0 109.426 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.431 ' HB3' ' O ' ' A' ' 50' ' ' GLU . . . 173.38 154.39 0.1 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 109.42 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.513 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -69.07 171.03 8.83 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.277 -179.939 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.513 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.22 -146.02 15.15 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.421 ' HB ' HG23 ' A' ' 76' ' ' THR . 49.9 t -138.68 126.9 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -1.158 . . . . 0.0 109.492 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.563 ' CD1' ' N ' ' A' ' 55' ' ' ILE . 1.1 mm -74.6 171.91 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.203 -0.936 . . . . 0.0 109.422 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.459 ' HB1' ' HG3' ' A' ' 74' ' ' LYS . . . -104.33 -63.85 1.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.227 -0.921 . . . . 0.0 109.509 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.519 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -179.29 158.39 0.87 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.246 -0.909 . . . . 0.0 109.5 180.0 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.514 HD13 ' CG ' ' A' ' 25' ' ' PRO . 1.5 mp -93.52 146.2 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.211 -0.93 . . . . 0.0 109.468 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.514 ' CG2' ' O ' ' A' ' 72' ' ' LEU . 49.5 t -89.9 -52.46 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.226 -0.921 . . . . 0.0 109.479 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.449 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 2.1 tptp -108.29 157.37 18.42 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.274 -0.891 . . . . 0.0 109.397 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 50.2 m-80 -88.82 156.18 19.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.482 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.482 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 2.4 pp20? -61.09 145.91 49.22 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.257 -0.902 . . . . 0.0 109.384 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 94.96 -12.15 68.79 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.504 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -89.04 170.9 10.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.273 -1.133 . . . . 0.0 109.325 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 62.7 m -111.96 146.92 36.96 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.489 -0.757 . . . . 0.0 109.467 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.487 ' N ' HG21 ' A' ' 65' ' ' THR . 27.3 m -129.62 -176.21 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.8 mp -116.63 173.9 6.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.177 -0.952 . . . . 0.0 109.469 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -63.85 125.74 25.35 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.897 . . . . 0.0 109.384 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 86.85 19.6 55.73 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.485 ' CB ' ' HB ' ' A' ' 66' ' ' VAL . 4.6 tp10 -82.18 112.82 19.56 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -1.134 . . . . 0.0 109.465 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.471 ' CD2' ' C ' ' A' ' 71' ' ' LEU . 7.5 tt -78.26 128.42 33.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.307 -0.87 . . . . 0.0 109.491 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.514 ' O ' ' CG2' ' A' ' 59' ' ' VAL . 13.3 mt -97.05 -70.51 0.72 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.421 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -128.14 163.64 21.67 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.459 ' HG3' ' HB1' ' A' ' 56' ' ' ALA . 2.2 ptmt -126.33 147.97 49.64 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.27 -1.135 . . . . 0.0 109.493 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.458 HD21 ' O ' ' A' ' 76' ' ' THR . 6.0 tt -90.56 166.45 13.2 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.278 -0.889 . . . . 0.0 109.488 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.458 ' O ' HD21 ' A' ' 75' ' ' LEU . 3.0 t . . . . . 0 N--CA 1.489 1.513 0 O-C-N 121.268 -0.895 . . . . 0.0 109.735 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.457 ' O ' HD12 ' A' ' 4' ' ' ILE . 15.4 mt . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.418 ' OD2' HD13 ' A' ' 71' ' ' LEU . 9.8 t70 -67.64 125.9 27.65 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.461 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.457 HD12 ' O ' ' A' ' 2' ' ' ILE . 4.9 mm -104.61 120.64 55.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.262 -0.899 . . . . 0.0 109.424 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.454 ' HA ' HD13 ' A' ' 72' ' ' LEU . 0.6 OUTLIER -136.83 176.23 8.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.169 -0.957 . . . . 0.0 109.469 179.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -80.44 157.78 72.26 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.282 -0.886 . . . . 0.0 109.439 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.01 156.32 30.33 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.661 2.241 . . . . 0.0 110.48 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 77.0 m -68.53 119.36 12.86 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.301 -0.874 . . . . 0.0 109.478 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -73.85 154.58 89.06 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.294 -0.878 . . . . 0.0 109.539 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.432 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.09 -173.93 2.03 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.677 2.252 . . . . 0.0 110.433 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.7 mp0 -73.15 -49.34 28.76 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.461 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.2 OUTLIER -42.82 -29.05 0.29 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.371 -0.831 . . . . 0.0 109.589 -179.87 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.435 ' CG2' ' O ' ' A' ' 15' ' ' ASP . 4.1 mt -121.17 146.04 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -0.895 . . . . 0.0 109.496 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -114.31 1.76 14.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.247 -0.908 . . . . 0.0 109.611 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.435 ' O ' ' CG2' ' A' ' 13' ' ' ILE . 0.2 OUTLIER -178.35 -171.41 0.26 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.18 -0.95 . . . . 0.0 109.457 -179.984 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.38 -167.44 17.69 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.515 ' O ' ' CB ' ' A' ' 39' ' ' GLU . 29.4 m -148.13 130.88 16.01 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -1.122 . . . . 0.0 109.468 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.478 HG13 ' N ' ' A' ' 19' ' ' ALA . 46.6 t -44.56 165.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.248 -0.907 . . . . 0.0 109.49 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.478 ' N ' HG13 ' A' ' 18' ' ' VAL . . . -114.06 -73.12 0.67 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.301 -0.874 . . . . 0.0 109.53 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 38.5 m -160.01 132.19 6.32 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.205 -0.934 . . . . 0.0 109.518 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.625 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 36.0 m95 -89.84 81.78 6.3 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.259 -0.901 . . . . 0.0 109.517 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.568 ' CD2' HD22 ' A' ' 34' ' ' LEU . 2.1 m80 -42.87 -61.54 1.25 Allowed 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.305 -0.872 . . . . 0.0 109.42 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.462 ' O ' ' HE3' ' A' ' 24' ' ' LYS . 1.2 mtpt -96.89 -177.36 3.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.918 . . . . 0.0 109.584 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.462 ' HE3' ' O ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -120.95 167.72 12.44 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.248 -0.908 . . . . 0.0 109.516 179.989 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.509 ' HA ' ' CG2' ' A' ' 55' ' ' ILE . 35.1 Cg_endo -76.96 90.21 1.25 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.694 2.263 . . . . 0.0 110.395 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 138.59 45.03 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.46 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 2.2 pp20? -139.35 -173.37 3.58 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.317 -1.108 . . . . 0.0 109.462 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.46 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -90.68 128.78 36.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.206 -0.934 . . . . 0.0 109.474 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.503 HG21 ' N ' ' A' ' 30' ' ' LYS . 12.4 p -127.11 155.15 38.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.215 -0.928 . . . . 0.0 109.528 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.503 ' N ' HG21 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -134.63 133.72 40.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -0.949 . . . . 0.0 109.502 -179.989 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.506 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.78 143.26 0.73 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.288 -0.883 . . . . 0.0 109.658 -179.969 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.506 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 8.2 t70 75.51 41.59 0.26 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.262 -0.898 . . . . 0.0 109.452 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.445 ' O ' HG12 ' A' ' 35' ' ' ILE . 3.5 tt0 -141.83 121.75 13.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.229 -0.919 . . . . 0.0 109.477 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.568 HD22 ' CD2' ' A' ' 22' ' ' HIS . 59.6 tp -42.84 156.1 0.05 OUTLIER 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.328 -0.858 . . . . 0.0 109.644 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.512 ' CD1' ' O ' ' A' ' 34' ' ' LEU . 15.7 mm -146.12 -39.12 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.276 -0.89 . . . . 0.0 109.505 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.509 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -159.79 141.95 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -0.891 . . . . 0.0 109.369 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.444 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 1.2 m-20 -104.93 146.37 29.12 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.251 -0.906 . . . . 0.0 109.465 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.445 HG21 ' N ' ' A' ' 39' ' ' GLU . 57.2 mt -107.13 142.46 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.175 -0.953 . . . . 0.0 109.514 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.515 ' CB ' ' O ' ' A' ' 17' ' ' THR . 1.4 tt0 -105.35 129.21 53.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.209 -0.932 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.454 ' OG1' ' O ' ' A' ' 43' ' ' VAL . 0.2 OUTLIER -115.73 171.61 7.65 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.238 -0.914 . . . . 0.0 109.49 -179.948 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 40' ' ' THR . 12.7 t0 -42.87 -51.37 5.53 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.321 -0.862 . . . . 0.0 109.618 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.422 ' HG2' ' O ' ' A' ' 41' ' ' ASP . 7.8 mmtt -148.37 30.66 0.84 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.271 -0.893 . . . . 0.0 109.443 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.454 ' O ' ' OG1' ' A' ' 40' ' ' THR . 2.0 t -139.6 134.49 38.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.939 . . . . 0.0 109.436 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.412 ' O ' HG11 ' A' ' 44' ' ' VAL . 8.1 p -98.76 136.86 28.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.255 -0.903 . . . . 0.0 109.474 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' MET . . . . . 0.424 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 0.9 OUTLIER -125.17 165.83 17.54 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.15 -0.969 . . . . 0.0 109.473 -179.983 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -129.26 161.91 29.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.501 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.509 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 78.7 t -140.73 108.89 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.214 -0.929 . . . . 0.0 109.501 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.443 HD11 ' O ' ' A' ' 48' ' ' LEU . 0.2 OUTLIER -103.14 155.74 18.19 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.339 -0.851 . . . . 0.0 109.362 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -70.58 144.78 51.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.898 . . . . 0.0 109.521 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.402 ' C ' ' HG3' ' A' ' 31' ' ' ARG . 0.6 OUTLIER -101.87 11.23 38.97 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.276 -0.89 . . . . 0.0 109.475 179.988 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -178.57 138.2 0.17 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.305 -0.872 . . . . 0.0 109.428 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.504 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.2 OUTLIER -58.5 170.95 0.67 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.245 -0.91 . . . . 0.0 109.343 -179.977 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.504 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 145.65 -162.39 28.26 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.42 ' HB ' HG23 ' A' ' 76' ' ' THR . 48.1 t -128.94 124.97 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.328 -1.101 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.532 ' CG2' ' N ' ' A' ' 56' ' ' ALA . 5.0 mt -59.41 165.23 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.278 -0.889 . . . . 0.0 109.568 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.532 ' N ' ' CG2' ' A' ' 55' ' ' ILE . . . -103.43 -66.08 0.97 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.188 -0.945 . . . . 0.0 109.518 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.444 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -167.75 139.11 2.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.206 -0.934 . . . . 0.0 109.55 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.625 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.9 mm -95.09 121.69 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.326 -0.859 . . . . 0.0 109.508 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.4 t -89.94 -27.99 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.19 -0.944 . . . . 0.0 109.428 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.489 ' HG2' ' CG1' ' A' ' 66' ' ' VAL . 0.0 OUTLIER -91.08 134.21 34.7 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.288 -0.882 . . . . 0.0 109.466 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 13.7 m120 -98.71 165.76 11.64 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.286 -0.884 . . . . 0.0 109.519 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -68.85 141.12 55.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 80.52 14.92 79.26 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -101.73 170.88 7.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -1.141 . . . . 0.0 109.277 -179.972 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 23.3 m -97.3 141.76 30.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.493 -0.754 . . . . 0.0 109.416 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.489 ' CG1' ' HG2' ' A' ' 60' ' ' LYS . 2.3 m -126.98 139.04 53.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.469 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.04 167.53 10.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.261 -0.899 . . . . 0.0 109.486 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 36.2 t -57.17 128.82 38.9 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 73.56 23.31 77.22 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -79.19 119.25 22.01 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.247 -1.149 . . . . 0.0 109.491 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.418 HD13 ' OD2' ' A' ' 3' ' ' ASP . 10.2 tt -67.37 138.31 56.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.288 -0.882 . . . . 0.0 109.543 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.46 HD22 HG13 ' A' ' 66' ' ' VAL . 0.5 OUTLIER -118.85 -24.86 6.47 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.293 -0.879 . . . . 0.0 109.428 -179.985 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.64 159.67 26.6 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 8.3 mtpt -122.31 133.39 54.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.204 -1.174 . . . . 0.0 109.446 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -92.1 147.57 22.84 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -0.948 . . . . 0.0 109.512 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.42 HG23 ' HB ' ' A' ' 54' ' ' VAL . 3.0 t . . . . . 0 N--CA 1.489 1.503 0 O-C-N 121.272 -0.893 . . . . 0.0 109.724 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 61.7 mt . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.473 -0.565 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.414 ' HA ' ' HA ' ' A' ' 74' ' ' LYS . 15.9 t70 -76.15 162.73 27.75 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.228 -0.92 . . . . 0.0 109.441 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.401 HG13 ' C ' ' A' ' 3' ' ' ASP . 2.7 mt -135.39 125.03 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.269 -0.894 . . . . 0.0 109.452 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.0 pttm -133.04 172.98 11.91 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.243 -0.911 . . . . 0.0 109.462 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.46 147.72 60.63 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.144 -0.972 . . . . 0.0 109.447 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.03 155.11 29.79 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.649 2.233 . . . . 0.0 110.455 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.416 ' HA ' ' HB2' ' A' ' 68' ' ' SER . 1.3 m -71.11 132.49 45.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.414 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 63.0 m-85 -99.34 153.6 37.7 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.426 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.99 -159.65 0.1 Allowed 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.632 2.221 . . . . 0.0 110.454 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.0 OUTLIER -77.18 -55.6 5.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.464 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 11' ' ' GLU . 18.6 t -42.72 -50.3 5.55 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.278 -0.889 . . . . 0.0 109.617 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 14.8 mt -90.11 143.45 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.418 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.517 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -115.1 -1.76 12.94 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.517 ' CB ' ' O ' ' A' ' 14' ' ' ALA . 0.5 OUTLIER 163.89 -169.09 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.212 -0.93 . . . . 0.0 109.464 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.438 ' O ' ' CG2' ' A' ' 65' ' ' THR . . . -142.97 -163.13 9.6 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.46 ' O ' ' HB2' ' A' ' 39' ' ' GLU . 17.0 m -150.0 133.07 16.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -1.114 . . . . 0.0 109.426 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.459 ' O ' ' HG3' ' A' ' 39' ' ' GLU . 39.4 t -49.08 159.73 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.216 -0.928 . . . . 0.0 109.419 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.523 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -104.35 -77.0 0.58 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.218 -0.926 . . . . 0.0 109.517 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 17.8 m -159.97 130.48 5.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.555 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.637 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.6 m95 -89.95 85.54 6.38 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.207 -0.933 . . . . 0.0 109.509 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.575 ' CD2' HD22 ' A' ' 34' ' ' LEU . 2.1 m80 -43.18 -67.28 0.29 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.346 -0.846 . . . . 0.0 109.419 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -93.81 -172.33 2.84 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.216 -0.927 . . . . 0.0 109.468 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.442 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -125.23 168.23 14.14 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.287 -0.883 . . . . 0.0 109.392 -179.894 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.465 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.3 Cg_endo -76.59 127.75 9.81 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.733 2.288 . . . . 0.0 110.373 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.65 18.99 9.01 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 13.8 mm-40 -119.69 -176.98 3.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.306 -1.114 . . . . 0.0 109.486 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -92.85 145.93 24.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.267 -0.896 . . . . 0.0 109.444 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 69.0 t -139.37 151.33 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -0.896 . . . . 0.0 109.532 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 11.0 mptt -126.64 140.11 52.66 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.228 -0.92 . . . . 0.0 109.463 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.434 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.7 OUTLIER -42.71 153.1 0.08 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.383 -0.823 . . . . 0.0 109.704 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 25.2 t0 63.19 41.8 7.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.927 . . . . 0.0 109.468 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 34' ' ' LEU . 0.8 OUTLIER -135.98 116.05 13.33 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.291 -0.88 . . . . 0.0 109.51 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.575 HD22 ' CD2' ' A' ' 22' ' ' HIS . 37.5 tp -43.1 142.9 0.88 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.275 -0.891 . . . . 0.0 109.556 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.514 HD13 ' CB ' ' A' ' 49' ' ' ALA . 10.9 mt -125.92 -46.08 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.272 -0.893 . . . . 0.0 109.585 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.497 HG22 ' CE2' ' A' ' 21' ' ' TRP . 7.3 p -162.8 147.5 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.277 -0.889 . . . . 0.0 109.528 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.523 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 1.2 m-20 -105.32 160.25 15.26 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.347 -0.845 . . . . 0.0 109.428 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.514 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 1.8 tt -129.31 148.54 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -0.933 . . . . 0.0 109.449 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.46 ' HB2' ' O ' ' A' ' 17' ' ' THR . 4.8 mm-40 -106.96 150.33 26.58 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.305 -0.872 . . . . 0.0 109.481 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.404 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -135.47 -175.38 3.92 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 40' ' ' THR . 7.8 t0 -42.78 -68.9 0.16 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.307 -0.871 . . . . 0.0 109.643 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.7 mtmm -135.39 36.73 2.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.172 -0.955 . . . . 0.0 109.493 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 67.9 t -152.0 153.44 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.34 -0.85 . . . . 0.0 109.472 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 11.7 p -124.2 131.04 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' MET . . . . . 0.514 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 0.0 OUTLIER -107.89 177.2 4.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.181 -0.949 . . . . 0.0 109.502 179.98 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -130.28 151.3 50.94 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.223 -0.923 . . . . 0.0 109.452 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.4 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 44.3 t -122.75 98.11 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.45 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.519 ' CD1' ' HA ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -90.99 168.72 11.45 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.195 -0.941 . . . . 0.0 109.487 -179.998 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.514 ' CB ' HD13 ' A' ' 35' ' ' ILE . . . -85.1 136.91 33.35 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.223 -0.923 . . . . 0.0 109.402 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.454 ' O ' ' HB3' ' A' ' 51' ' ' ALA . 2.2 mm-40 -98.53 14.64 27.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.545 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.454 ' HB3' ' O ' ' A' ' 50' ' ' GLU . . . 173.54 134.78 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.268 -0.895 . . . . 0.0 109.469 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.502 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.25 171.02 0.12 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -0.894 . . . . 0.0 109.3 179.999 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.502 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 142.77 -154.04 25.02 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 66.2 t -136.65 134.63 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.274 -1.133 . . . . 0.0 109.412 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 15.3 mm -61.85 168.84 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.218 -0.926 . . . . 0.0 109.516 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -101.42 -62.83 1.2 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.914 . . . . 0.0 109.53 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.465 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.7 OUTLIER -177.89 131.47 0.15 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.259 -0.9 . . . . 0.0 109.462 179.95 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.637 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 21.5 mm -90.09 125.63 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.435 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 42.2 t -89.93 -33.13 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.291 -0.88 . . . . 0.0 109.471 -179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.492 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 1.5 mptt -94.38 143.66 26.22 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.282 -0.886 . . . . 0.0 109.488 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.445 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 65.3 m-80 -111.0 164.74 12.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.248 -0.908 . . . . 0.0 109.526 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -59.06 146.43 38.47 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.493 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 86.75 7.74 77.82 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.506 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -105.35 170.71 7.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.221 -1.164 . . . . 0.0 109.411 -179.98 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.506 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 11.9 m -107.77 145.69 33.2 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.536 -0.728 . . . . 0.0 109.458 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 4.9 m -114.98 137.37 48.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.471 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -106.08 174.53 5.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.192 -0.943 . . . . 0.0 109.522 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.416 ' HB2' ' HA ' ' A' ' 8' ' ' THR . 1.5 t -62.03 129.13 39.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.234 -0.917 . . . . 0.0 109.497 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.98 21.63 73.53 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -79.82 104.34 10.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.255 -1.144 . . . . 0.0 109.52 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 9.1 tt -78.1 121.9 24.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.243 -0.911 . . . . 0.0 109.458 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.5 mp -92.69 -69.05 0.76 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.352 -0.843 . . . . 0.0 109.38 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -140.74 -175.82 14.87 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.414 ' HA ' ' HA ' ' A' ' 3' ' ' ASP . 0.3 OUTLIER -143.69 142.0 30.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.297 -1.119 . . . . 0.0 109.485 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -90.51 144.52 25.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.886 . . . . 0.0 109.436 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.0 t . . . . . 0 N--CA 1.489 1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.74 -179.981 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.512 HD12 ' CD2' ' A' ' 75' ' ' LEU . 3.2 mp . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.468 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 22.9 t70 -82.28 154.12 25.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.204 -0.935 . . . . 0.0 109.496 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.2 mt -130.86 122.34 51.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.883 . . . . 0.0 109.432 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.456 ' HD2' ' OD2' ' A' ' 3' ' ' ASP . 0.0 OUTLIER -144.89 164.85 29.82 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.234 -0.916 . . . . 0.0 109.464 179.958 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -67.34 148.13 98.77 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.291 -0.881 . . . . 0.0 109.495 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.02 -172.2 1.42 Allowed 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.628 2.219 . . . . 0.0 110.417 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -97.86 96.52 8.26 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.235 -0.915 . . . . 0.0 109.449 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.534 ' CE2' ' C ' ' A' ' 15' ' ' ASP . 19.5 m-85 -59.81 149.34 72.98 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.245 -0.909 . . . . 0.0 109.493 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.04 -166.25 0.39 Allowed 'Trans proline' 0 C--N 1.308 -1.556 0 C-N-CA 122.61 2.207 . . . . 0.0 110.494 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' A' ' 12' ' ' SER . 4.8 tt0 -72.78 -42.43 63.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.231 -0.918 . . . . 0.0 109.484 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 11' ' ' GLU . 2.5 t -42.88 -64.54 0.61 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.298 -0.876 . . . . 0.0 109.554 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.444 HG13 ' HA ' ' A' ' 41' ' ' ASP . 15.1 mm -104.95 145.86 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.216 -0.928 . . . . 0.0 109.445 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -114.36 21.77 14.33 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.294 -0.879 . . . . 0.0 109.485 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.534 ' C ' ' CE2' ' A' ' 9' ' ' PHE . 0.3 OUTLIER -161.74 -173.11 3.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.135 -0.978 . . . . 0.0 109.572 -179.997 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.533 ' HA3' ' CZ ' ' A' ' 9' ' ' PHE . . . -150.56 -176.56 23.65 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.436 ' O ' ' O ' ' A' ' 18' ' ' VAL . 25.8 m -150.06 122.09 8.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.176 -1.19 . . . . 0.0 109.5 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.526 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 41.4 t -45.83 168.72 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.251 -0.906 . . . . 0.0 109.353 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.526 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -111.13 -74.34 0.65 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.117 -0.989 . . . . 0.0 109.589 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.2 m -160.05 127.78 4.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.254 -0.904 . . . . 0.0 109.605 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.637 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 36.7 m95 -89.91 83.4 6.15 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.26 -0.9 . . . . 0.0 109.461 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.604 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -42.95 -70.18 0.11 Allowed 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.322 -0.861 . . . . 0.0 109.424 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -93.67 177.98 5.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.25 -0.906 . . . . 0.0 109.678 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.443 ' HD3' ' HD2' ' A' ' 25' ' ' PRO . 5.4 mttp -121.39 169.48 9.06 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.283 -0.886 . . . . 0.0 109.445 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.521 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.3 Cg_endo -76.15 119.7 5.42 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.657 2.238 . . . . 0.0 110.463 179.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 122.68 10.13 6.04 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.444 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 1.1 pp20? -112.4 173.88 6.15 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -1.129 . . . . 0.0 109.507 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.444 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -82.5 144.28 30.53 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.922 . . . . 0.0 109.511 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.8 t -112.31 156.85 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.287 -0.883 . . . . 0.0 109.47 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.1 OUTLIER -142.96 135.88 27.96 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.274 -0.892 . . . . 0.0 109.493 179.957 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.474 ' HG2' ' N ' ' A' ' 32' ' ' ASP . 2.7 ttm180 -42.8 141.13 1.14 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.337 -0.852 . . . . 0.0 109.651 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.474 ' N ' ' HG2' ' A' ' 31' ' ' ARG . 20.8 t70 69.71 49.66 0.53 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.289 -0.882 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' A' ' 34' ' ' LEU . 3.0 tt0 -138.5 106.89 5.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 0.0 109.429 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 40.1 tp -43.46 165.14 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.291 -0.88 . . . . 0.0 109.472 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.491 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 91.3 mt -134.26 -47.13 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.15 -0.969 . . . . 0.0 109.637 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.569 ' HB ' ' CE3' ' A' ' 21' ' ' TRP . 2.6 p -171.99 144.01 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.158 -0.964 . . . . 0.0 109.52 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.526 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 1.3 m-20 -100.19 167.03 10.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.247 -0.908 . . . . 0.0 109.458 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.449 HG23 ' O ' ' A' ' 45' ' ' MET . 1.2 tt -142.63 156.33 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.253 -0.904 . . . . 0.0 109.539 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.58 122.14 38.99 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.268 -0.895 . . . . 0.0 109.47 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.418 ' O ' ' C ' ' A' ' 41' ' ' ASP . 44.4 p -101.92 -151.91 0.43 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 109.475 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.444 ' HA ' HG13 ' A' ' 13' ' ' ILE . 43.1 t0 -42.71 -62.82 0.9 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.277 -0.89 . . . . 0.0 109.613 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.7 mttt -149.48 17.78 0.92 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.212 -0.93 . . . . 0.0 109.474 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 1.9 t -119.34 172.21 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.895 . . . . 0.0 109.503 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.408 ' O ' ' CG1' ' A' ' 44' ' ' VAL . 9.6 p -129.62 126.7 63.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.3 -0.875 . . . . 0.0 109.431 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' MET . . . . . 0.449 ' O ' HG23 ' A' ' 38' ' ' ILE . 1.3 mtt -113.83 124.43 52.21 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.186 -0.946 . . . . 0.0 109.484 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.6 147.32 26.46 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.334 -0.854 . . . . 0.0 109.443 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.449 ' O ' ' HB ' ' A' ' 35' ' ' ILE . 55.9 t -116.06 103.87 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.184 -0.947 . . . . 0.0 109.504 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -105.03 163.85 12.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.915 . . . . 0.0 109.396 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.458 ' CB ' HD12 ' A' ' 35' ' ' ILE . . . -84.88 164.83 18.16 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.159 -0.963 . . . . 0.0 109.456 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.526 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -105.82 3.67 28.97 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.542 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.526 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 163.94 167.54 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.184 -0.948 . . . . 0.0 109.455 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.502 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -49.96 170.98 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.291 -0.881 . . . . 0.0 109.313 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.502 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.93 -164.01 30.67 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.411 ' HB ' HG23 ' A' ' 76' ' ' THR . 48.7 t -136.85 125.35 34.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -1.142 . . . . 0.0 109.427 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.452 ' HA ' HD11 ' A' ' 75' ' ' LEU . 15.3 mm -61.68 160.08 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.294 -0.879 . . . . 0.0 109.448 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -100.51 -66.31 0.92 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.306 -0.871 . . . . 0.0 109.492 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.521 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 33.4 tt0 177.34 141.68 0.08 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.294 -0.879 . . . . 0.0 109.46 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.637 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 15.3 mm -91.42 158.28 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.273 -0.892 . . . . 0.0 109.449 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.405 HG22 ' O ' ' A' ' 71' ' ' LEU . 52.8 t -90.03 -67.52 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.261 -0.899 . . . . 0.0 109.342 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.459 ' HD3' ' CB ' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -101.1 174.99 5.75 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.254 -0.904 . . . . 0.0 109.399 179.926 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -95.87 155.43 16.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.931 . . . . 0.0 109.469 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.526 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -60.1 149.94 31.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.3 -0.875 . . . . 0.0 109.387 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 92.39 -12.62 69.25 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.499 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -87.3 170.94 10.99 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.295 -1.12 . . . . 0.0 109.286 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.499 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 99.0 m -100.73 135.41 42.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.519 -0.738 . . . . 0.0 109.461 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.416 ' C ' HD22 ' A' ' 67' ' ' LEU . 5.2 m -118.58 -176.8 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.448 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.416 HD22 ' C ' ' A' ' 66' ' ' VAL . 13.2 mt -121.45 162.38 20.56 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.248 -0.907 . . . . 0.0 109.441 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 t -64.25 122.54 16.88 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.238 -0.914 . . . . 0.0 109.494 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 91.31 10.16 62.53 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -84.98 112.56 20.7 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.191 -1.182 . . . . 0.0 109.447 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.468 ' CD1' ' OD1' ' A' ' 3' ' ' ASP . 1.2 tp -72.49 127.11 31.55 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.319 -0.863 . . . . 0.0 109.496 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 77.0 mt -93.92 -68.05 0.82 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.302 -0.874 . . . . 0.0 109.435 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -136.39 178.8 18.52 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.457 ' HD3' HD23 ' A' ' 71' ' ' LEU . 1.5 mtmp? -145.94 151.74 38.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -1.162 . . . . 0.0 109.472 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.512 ' CD2' HD12 ' A' ' 2' ' ' ILE . 13.2 tp -99.05 152.37 19.92 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.224 -0.923 . . . . 0.0 109.474 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.411 HG23 ' HB ' ' A' ' 54' ' ' VAL . 3.0 t . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.286 -0.884 . . . . 0.0 109.677 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.41 ' HA ' HD11 ' A' ' 2' ' ' ILE . 24.3 mm . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 121.296 0.57 . . . . 0.0 109.483 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.519 ' OD2' ' CD1' ' A' ' 71' ' ' LEU . 43.7 t0 -71.84 142.28 49.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.16 -0.963 . . . . 0.0 109.463 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.9 mm -112.19 103.83 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.225 -0.922 . . . . 0.0 109.415 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.63 166.02 10.67 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.225 -0.922 . . . . 0.0 109.468 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.446 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . . . -72.72 159.69 84.72 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.27 -0.894 . . . . 0.0 109.435 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.446 ' HD2' ' HB3' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.18 165.29 26.03 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.57 2.18 . . . . 0.0 110.368 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -90.28 108.8 19.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.472 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -60.86 149.24 81.23 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.442 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.08 -160.6 0.12 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.626 2.218 . . . . 0.0 110.369 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.3 OUTLIER -77.4 -58.88 3.03 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.247 -0.908 . . . . 0.0 109.497 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.2 t -42.93 -55.97 3.49 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.359 -0.838 . . . . 0.0 109.594 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.458 ' CD1' ' HB2' ' A' ' 41' ' ' ASP . 12.0 mm -95.1 136.55 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.275 -0.891 . . . . 0.0 109.444 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.78 14.48 10.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.216 -0.927 . . . . 0.0 109.436 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -156.53 -171.34 3.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.244 -0.91 . . . . 0.0 109.419 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.5 178.82 39.59 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.465 HG21 ' O ' ' A' ' 64' ' ' ASP . 17.8 m -150.03 119.25 6.79 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.23 -1.159 . . . . 0.0 109.367 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.471 HG13 ' N ' ' A' ' 19' ' ' ALA . 46.4 t -44.25 162.99 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.438 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.516 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -106.2 -75.47 0.63 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -0.906 . . . . 0.0 109.58 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.456 ' HA ' ' HB3' ' A' ' 62' ' ' GLU . 17.3 m -160.01 136.23 8.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.238 -0.914 . . . . 0.0 109.531 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.633 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.1 m95 -89.85 84.11 6.22 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.244 -0.91 . . . . 0.0 109.512 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.575 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.3 m80 -42.59 -55.64 3.44 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.44 -0.788 . . . . 0.0 109.531 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -109.82 158.71 17.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.098 -1.001 . . . . 0.0 109.612 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.447 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 4.9 mttt -97.22 167.99 10.99 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.275 -0.891 . . . . 0.0 109.428 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.462 ' HG3' HG12 ' A' ' 58' ' ' ILE . 35.2 Cg_endo -76.68 101.84 1.55 Allowed 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.625 2.216 . . . . 0.0 110.446 179.869 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.5 -5.08 4.48 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.477 ' N ' ' CD ' ' A' ' 27' ' ' GLU . 1.3 mp0 -90.36 -172.66 3.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.18 -1.188 . . . . 0.0 109.458 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -97.3 149.83 21.63 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.301 -0.874 . . . . 0.0 109.438 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.6 m -135.5 161.55 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.214 -0.929 . . . . 0.0 109.514 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.8 tttt -129.29 135.29 48.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.24 -0.912 . . . . 0.0 109.52 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.433 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 9.2 ttt180 -42.86 140.34 1.39 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.325 -0.86 . . . . 0.0 109.613 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 18.0 t0 70.82 47.0 0.47 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.23 -0.919 . . . . 0.0 109.516 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.434 ' O ' ' O ' ' A' ' 34' ' ' LEU . 29.4 tt0 -140.12 121.99 15.51 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.279 -0.888 . . . . 0.0 109.558 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.575 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 47.4 tp -43.14 164.56 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.278 -0.889 . . . . 0.0 109.587 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.51 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 25.4 mm -145.27 -42.56 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.185 -0.947 . . . . 0.0 109.535 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.524 HG22 ' CE2' ' A' ' 21' ' ' TRP . 12.7 p -154.7 134.18 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.234 -0.916 . . . . 0.0 109.551 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.516 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 22.1 m-20 -100.39 159.45 15.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.267 -0.896 . . . . 0.0 109.463 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.518 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 7.3 tt -128.87 156.9 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.463 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.404 ' N ' HG12 ' A' ' 38' ' ' ILE . 1.3 tt0 -129.65 142.78 50.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.208 -0.933 . . . . 0.0 109.423 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.464 HG21 ' O ' ' A' ' 43' ' ' VAL . 5.5 t -132.01 -163.45 1.34 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.256 -0.903 . . . . 0.0 109.362 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.458 ' HB2' ' CD1' ' A' ' 13' ' ' ILE . 2.2 t0 -42.34 -68.0 0.22 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.317 -0.864 . . . . 0.0 109.782 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.512 ' O ' ' CG2' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -142.97 48.76 1.49 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.136 -0.978 . . . . 0.0 109.541 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.512 ' CG2' ' O ' ' A' ' 42' ' ' LYS . 90.0 t -159.04 118.04 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.251 -0.906 . . . . 0.0 109.499 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.6 t -100.57 126.63 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.487 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' MET . . . . . 0.518 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 31.4 mtt -106.44 -179.65 4.0 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.448 ' HA ' ' OD1' ' A' ' 37' ' ' ASP . 3.7 mt-10 -133.52 146.96 51.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.249 -0.907 . . . . 0.0 109.44 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.499 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 36.2 t -117.76 106.68 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.492 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.429 HD11 ' HA ' ' A' ' 34' ' ' LEU . 0.6 OUTLIER -89.99 161.35 15.92 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.294 -0.879 . . . . 0.0 109.377 -179.964 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.03 160.91 24.42 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.44 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.508 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 0.5 OUTLIER -99.02 2.12 45.99 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.178 -0.951 . . . . 0.0 109.608 179.958 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.508 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 164.18 155.34 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.212 -0.93 . . . . 0.0 109.478 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.503 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -65.12 170.86 4.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.33 -0.856 . . . . 0.0 109.321 -179.995 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.503 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.45 -137.59 6.09 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.47 ' O ' ' CB ' ' A' ' 76' ' ' THR . 44.8 t -139.87 135.25 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.338 -1.095 . . . . 0.0 109.448 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 9.5 mm -75.74 153.9 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.332 -0.855 . . . . 0.0 109.457 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -87.94 -65.99 0.96 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.208 -0.933 . . . . 0.0 109.397 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.449 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -178.88 139.21 0.16 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -0.907 . . . . 0.0 109.399 179.949 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.633 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.1 mm -94.84 138.69 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.233 -0.917 . . . . 0.0 109.515 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 96.1 t -110.04 -14.52 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.309 -0.869 . . . . 0.0 109.425 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.522 ' CD ' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -91.04 -172.4 3.32 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.286 -0.884 . . . . 0.0 109.39 179.995 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.454 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 46.2 m-80 -137.05 155.95 49.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.328 -0.858 . . . . 0.0 109.576 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.456 ' HB3' ' HA ' ' A' ' 20' ' ' THR . 0.5 OUTLIER -72.18 144.14 48.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.265 -0.897 . . . . 0.0 109.518 -179.939 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 57.54 19.56 34.84 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.522 ' OD2' ' CD ' ' A' ' 60' ' ' LYS . 0.2 OUTLIER -99.4 170.95 8.27 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.262 -1.14 . . . . 0.0 109.352 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 11.5 t -88.17 154.25 20.6 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.525 -0.734 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.463 HG11 ' HD2' ' A' ' 60' ' ' LYS . 1.5 m -141.67 173.94 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.233 -0.917 . . . . 0.0 109.42 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.448 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.3 OUTLIER -127.99 162.56 26.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.301 -0.875 . . . . 0.0 109.433 -179.956 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 6.6 t -56.53 143.71 34.34 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.19 -0.944 . . . . 0.0 109.478 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 58.99 24.61 58.49 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.448 ' HB2' ' O ' ' A' ' 67' ' ' LEU . 13.9 tp10 -79.21 105.23 10.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -1.184 . . . . 0.0 109.491 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.519 ' CD1' ' OD2' ' A' ' 3' ' ' ASP . 0.4 OUTLIER -61.99 130.39 45.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.275 -0.89 . . . . 0.0 109.392 -179.915 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 7.9 mt -100.84 -71.12 0.72 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.27 -0.894 . . . . 0.0 109.45 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -144.39 -176.9 18.82 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 10.0 mtmt -128.26 151.67 49.01 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.313 -1.11 . . . . 0.0 109.462 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.406 HD22 ' O ' ' A' ' 76' ' ' THR . 0.5 OUTLIER -103.63 152.09 22.17 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.174 -0.954 . . . . 0.0 109.512 -179.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.47 ' CB ' ' O ' ' A' ' 54' ' ' VAL . 13.0 m . . . . . 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 109.427 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 62.9 mt . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.506 ' OD2' ' CG ' ' A' ' 5' ' ' LYS . 24.9 t0 -61.04 154.54 22.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.2 -0.937 . . . . 0.0 109.496 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 16.4 mt -123.58 98.59 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.286 -0.884 . . . . 0.0 109.429 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.506 ' CG ' ' OD2' ' A' ' 3' ' ' ASP . 3.8 mtmt -122.39 154.76 37.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.914 . . . . 0.0 109.465 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -78.93 162.5 64.56 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.252 -0.905 . . . . 0.0 109.52 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.04 159.57 30.44 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.555 2.17 . . . . 0.0 110.485 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.1 m -73.74 142.36 46.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.348 -0.845 . . . . 0.0 109.436 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.568 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 25.6 m-85 -89.88 156.95 46.72 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.27 -0.894 . . . . 0.0 109.512 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -77.97 -167.12 0.45 Allowed 'Trans proline' 0 C--N 1.309 -1.516 0 C-N-CA 122.655 2.237 . . . . 0.0 110.48 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.438 ' O ' ' C ' ' A' ' 12' ' ' SER . 39.0 tt0 -75.24 -56.38 4.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.176 -0.953 . . . . 0.0 109.456 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 11' ' ' GLU . 4.9 t -42.72 -52.8 4.8 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.3 -0.875 . . . . 0.0 109.619 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 25.2 mt -94.1 147.42 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.236 -0.915 . . . . 0.0 109.494 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -124.33 6.54 8.4 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.183 -0.948 . . . . 0.0 109.615 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.568 ' HA ' ' CD2' ' A' ' 9' ' ' PHE . 0.7 OUTLIER 178.91 -172.53 0.15 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.236 -0.915 . . . . 0.0 109.488 -179.974 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.78 -157.41 8.18 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.461 ' O ' ' HB3' ' A' ' 39' ' ' GLU . 36.4 m -150.02 135.4 18.15 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -1.135 . . . . 0.0 109.529 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.5 t -55.88 158.78 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 109.461 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.506 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -101.94 -76.81 0.56 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.154 -0.967 . . . . 0.0 109.485 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 19.6 m -160.04 136.61 9.0 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.602 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.573 ' CZ2' HG21 ' A' ' 58' ' ' ILE . 32.4 m95 -89.99 83.15 6.09 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.259 -0.9 . . . . 0.0 109.491 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.578 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 1.7 m80 -43.02 -68.34 0.2 Allowed 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.313 -0.867 . . . . 0.0 109.395 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.11 -172.0 3.17 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.259 -0.9 . . . . 0.0 109.561 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.4 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 7.8 mttp -141.09 168.29 14.66 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.31 -0.869 . . . . 0.0 109.4 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.523 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.55 125.96 8.65 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.569 2.179 . . . . 0.0 110.467 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 117.19 10.96 9.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 45.6 mm-40 -128.4 -172.3 2.67 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.207 -1.172 . . . . 0.0 109.472 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -100.91 179.39 4.4 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.266 -0.896 . . . . 0.0 109.468 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.51 ' CG1' ' N ' ' A' ' 30' ' ' LYS . 64.6 t -147.04 165.95 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.293 -0.879 . . . . 0.0 109.451 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.51 ' N ' ' CG1' ' A' ' 29' ' ' VAL . 0.0 OUTLIER -112.34 132.38 55.02 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.565 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.477 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -43.01 121.01 1.96 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.291 -0.88 . . . . 0.0 109.604 -179.931 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.477 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 3.0 t70 73.94 55.21 0.1 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.26 -0.9 . . . . 0.0 109.484 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 34' ' ' LEU . 2.3 tp10 -131.74 126.51 34.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.278 -0.888 . . . . 0.0 109.475 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.578 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 48.6 tp -42.89 161.68 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.288 -0.882 . . . . 0.0 109.586 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.469 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 29.8 mm -144.72 -42.56 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.209 -0.932 . . . . 0.0 109.586 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.571 HG22 ' CE2' ' A' ' 21' ' ' TRP . 9.4 p -152.3 137.18 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.224 -0.923 . . . . 0.0 109.514 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.506 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 25.1 m-20 -100.71 163.14 12.47 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -0.871 . . . . 0.0 109.411 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.6 mt -129.86 154.34 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.232 -0.918 . . . . 0.0 109.517 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.461 ' HB3' ' O ' ' A' ' 17' ' ' THR . 27.8 tt0 -116.57 149.66 39.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.46 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.415 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -133.94 174.57 10.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -0.895 . . . . 0.0 109.487 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 40' ' ' THR . 5.6 t0 -42.9 -64.68 0.58 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.334 -0.853 . . . . 0.0 109.624 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.429 ' O ' ' CG2' ' A' ' 43' ' ' VAL . 11.6 mttp -134.06 39.76 3.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.217 -0.927 . . . . 0.0 109.479 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.429 ' CG2' ' O ' ' A' ' 42' ' ' LYS . 38.5 t -155.23 143.63 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.222 -0.924 . . . . 0.0 109.474 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 81.9 t -115.76 136.28 53.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.871 . . . . 0.0 109.487 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 84.4 mtp -121.36 178.27 4.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.213 -0.929 . . . . 0.0 109.456 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -137.27 160.03 40.22 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.218 -0.926 . . . . 0.0 109.467 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.522 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 21.3 t -127.2 104.78 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.94 . . . . 0.0 109.559 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.507 ' HG ' ' N ' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -95.58 158.16 15.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.347 -0.845 . . . . 0.0 109.491 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.56 161.94 22.12 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.271 -0.893 . . . . 0.0 109.45 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.524 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -89.3 -0.49 57.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.229 -0.919 . . . . 0.0 109.618 179.994 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.524 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 164.12 162.75 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.48 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.507 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -53.64 171.05 0.1 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.257 -0.902 . . . . 0.0 109.367 179.955 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.507 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 154.54 -150.88 22.57 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.8 t -136.2 123.11 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -1.172 . . . . 0.0 109.493 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.446 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 15.5 mm -61.66 166.29 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -0.915 . . . . 0.0 109.512 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.44 ' HB1' ' O ' ' A' ' 74' ' ' LYS . . . -105.46 -67.21 0.93 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.252 -0.905 . . . . 0.0 109.464 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.523 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 2.9 tm-20 -174.6 150.13 1.33 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.139 -0.976 . . . . 0.0 109.577 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.573 HG21 ' CZ2' ' A' ' 21' ' ' TRP . 8.1 mt -89.98 151.72 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.279 -0.888 . . . . 0.0 109.514 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 71' ' ' LEU . 56.0 t -97.16 -67.01 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.267 -0.896 . . . . 0.0 109.453 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.42 ' HD2' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -92.62 -170.71 2.54 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.232 -0.917 . . . . 0.0 109.451 179.988 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 12.6 m-80 -125.24 168.52 13.36 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.209 -0.932 . . . . 0.0 109.512 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -65.99 149.8 49.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.196 -0.94 . . . . 0.0 109.542 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 82.07 4.94 90.09 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -99.93 170.89 8.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.16 -1.2 . . . . 0.0 109.319 179.969 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 28.3 m -95.46 126.29 40.65 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.522 -0.737 . . . . 0.0 109.504 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 18.8 m -89.97 176.38 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.33 -0.856 . . . . 0.0 109.427 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -142.51 164.09 31.06 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.141 -0.974 . . . . 0.0 109.443 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.1 t -58.14 133.17 55.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 109.453 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 62.75 24.58 66.58 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 30.1 tp10 -73.47 119.55 17.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.255 -1.144 . . . . 0.0 109.431 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.459 ' O ' HG22 ' A' ' 59' ' ' VAL . 6.8 tt -75.93 109.08 9.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.199 -0.938 . . . . 0.0 109.444 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -88.81 -10.44 48.12 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.177 -0.952 . . . . 0.0 109.477 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 157.59 -175.4 34.94 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.44 ' O ' ' HB1' ' A' ' 56' ' ' ALA . 1.3 mtmm -138.84 149.08 44.52 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.193 -1.18 . . . . 0.0 109.498 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -100.3 146.95 26.32 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.264 -0.898 . . . . 0.0 109.448 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 14.9 m . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.246 -0.909 . . . . 0.0 109.483 -179.959 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.7 mt . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -71.13 150.91 44.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.318 -0.864 . . . . 0.0 109.486 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.3 mt -127.2 72.6 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.232 -0.918 . . . . 0.0 109.426 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.406 ' HA ' ' HG ' ' A' ' 72' ' ' LEU . 5.0 pttp -101.34 167.99 9.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.194 -0.941 . . . . 0.0 109.472 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -66.34 158.02 79.52 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.344 -0.848 . . . . 0.0 109.438 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -78.05 169.26 20.71 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.586 2.191 . . . . 0.0 110.422 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.7 141.35 40.94 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.464 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.52 ' CD2' ' HB2' ' A' ' 68' ' ' SER . 18.6 m-85 -107.91 153.07 41.86 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.23 -0.919 . . . . 0.0 109.462 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.441 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -78.06 167.41 23.49 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.593 2.195 . . . . 0.0 110.373 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.1 mt-10 -49.45 -53.52 22.53 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.2 -0.938 . . . . 0.0 109.54 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 11' ' ' GLU . 19.1 t -42.75 -48.88 5.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.385 -0.822 . . . . 0.0 109.631 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.472 ' CG2' HG23 ' A' ' 40' ' ' THR . 22.5 mt -96.18 122.05 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.223 -0.923 . . . . 0.0 109.402 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -101.13 11.46 39.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.214 -0.929 . . . . 0.0 109.439 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.438 ' O ' HG23 ' A' ' 13' ' ' ILE . 0.9 OUTLIER -176.67 -170.13 0.31 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.247 -0.908 . . . . 0.0 109.403 179.982 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.453 ' O ' HG22 ' A' ' 65' ' ' THR . . . -151.58 -173.33 21.28 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.464 HG21 ' O ' ' A' ' 64' ' ' ASP . 4.2 m -150.04 127.93 11.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -1.147 . . . . 0.0 109.411 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.521 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 47.9 t -54.31 164.05 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.218 -0.926 . . . . 0.0 109.45 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.442 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -109.7 -73.86 0.67 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.26 -0.9 . . . . 0.0 109.518 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.526 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 18.3 m -158.46 134.67 9.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.211 -0.931 . . . . 0.0 109.489 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.638 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.1 m95 -89.7 84.7 6.32 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.231 -0.918 . . . . 0.0 109.567 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.566 ' CD2' HD22 ' A' ' 34' ' ' LEU . 2.2 m80 -42.76 -60.31 1.62 Allowed 'General case' 0 N--CA 1.499 2.004 0 O-C-N 121.401 -0.812 . . . . 0.0 109.483 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.402 ' HA ' ' HD2' ' A' ' 23' ' ' LYS . 1.1 mmmt -100.28 -171.99 2.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -0.873 . . . . 0.0 109.562 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.426 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -124.54 169.17 11.31 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.254 -0.904 . . . . 0.0 109.483 -179.934 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.466 ' HG3' HG12 ' A' ' 58' ' ' ILE . 35.2 Cg_endo -76.48 94.24 1.04 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.67 2.247 . . . . 0.0 110.409 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 151.04 -17.45 0.92 Allowed Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -84.75 170.68 13.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -1.134 . . . . 0.0 109.541 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.11 127.94 42.57 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.886 . . . . 0.0 109.389 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.3 m -96.63 -172.04 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.464 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.426 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -148.4 136.97 21.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.47 -179.959 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.454 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 10.3 tmm_? -42.79 128.28 4.14 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.319 -0.863 . . . . 0.0 109.624 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 7.7 t70 72.81 54.36 0.14 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.276 -0.89 . . . . 0.0 109.453 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.496 ' N ' HD22 ' A' ' 48' ' ' LEU . 1.4 tp10 -141.91 120.78 12.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.296 -0.877 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.566 HD22 ' CD2' ' A' ' 22' ' ' HIS . 47.9 tp -42.87 142.31 0.92 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.309 -0.87 . . . . 0.0 109.581 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.441 HD12 ' O ' ' A' ' 33' ' ' GLU . 22.7 mm -129.75 -42.15 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.889 . . . . 0.0 109.443 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.525 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -157.53 144.43 9.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.296 -0.878 . . . . 0.0 109.466 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 46' ' ' GLU . 19.6 m-20 -102.68 150.3 23.58 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.452 HG13 ' CG2' ' A' ' 47' ' ' VAL . 21.8 mt -110.47 150.72 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.186 -0.946 . . . . 0.0 109.464 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -141.7 98.73 3.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.486 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.472 HG23 ' CG2' ' A' ' 13' ' ' ILE . 0.7 OUTLIER -90.19 -174.37 4.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.202 -0.936 . . . . 0.0 109.488 -179.996 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.446 ' O ' ' HG3' ' A' ' 42' ' ' LYS . 0.6 OUTLIER -42.87 -45.18 4.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.274 -0.891 . . . . 0.0 109.647 -179.866 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.446 ' HG3' ' O ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -156.28 27.33 0.35 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.199 -0.938 . . . . 0.0 109.446 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 3.5 t -128.36 106.66 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.327 -0.858 . . . . 0.0 109.42 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.5 t -90.31 130.48 39.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.242 -0.911 . . . . 0.0 109.484 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 10.2 mmt -141.86 108.45 5.34 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.181 -0.95 . . . . 0.0 109.476 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 5.4 mt-10 -63.0 172.08 1.92 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.278 -0.889 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.525 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 15.7 t -135.25 102.32 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.236 -0.915 . . . . 0.0 109.504 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.496 HD22 ' N ' ' A' ' 33' ' ' GLU . 0.0 OUTLIER -94.5 154.85 17.21 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.479 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.94 143.15 29.16 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.227 -0.921 . . . . 0.0 109.525 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.31 13.93 31.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.325 -0.859 . . . . 0.0 109.45 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -179.7 140.83 0.14 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.322 -0.862 . . . . 0.0 109.454 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -59.83 170.89 1.02 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.248 -0.908 . . . . 0.0 109.309 179.999 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 154.32 175.84 25.97 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.411 ' HB ' HG23 ' A' ' 76' ' ' THR . 49.2 t -112.93 124.83 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.206 -1.173 . . . . 0.0 109.498 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.448 HD12 ' CD1' ' A' ' 75' ' ' LEU . 15.6 mm -61.25 164.82 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.488 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -106.39 -63.7 1.24 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.314 -0.867 . . . . 0.0 109.462 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.457 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -170.41 136.43 1.33 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.16 -0.962 . . . . 0.0 109.528 -179.915 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.638 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 26.6 mm -89.94 141.37 14.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.343 -0.848 . . . . 0.0 109.452 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 89.1 t -90.18 -62.46 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -0.912 . . . . 0.0 109.55 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.451 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -89.95 155.1 19.35 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 109.44 -179.917 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -102.54 158.47 16.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.247 -0.908 . . . . 0.0 109.433 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.526 ' CB ' ' HA ' ' A' ' 20' ' ' THR . 2.1 pp20? -60.81 143.35 54.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.206 -0.934 . . . . 0.0 109.451 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 98.48 -10.32 62.99 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.513 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -100.16 170.9 8.15 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.239 -1.153 . . . . 0.0 109.274 -179.971 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.513 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 47.5 m -101.54 146.91 27.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.492 -0.755 . . . . 0.0 109.484 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.41 160.94 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.226 -0.921 . . . . 0.0 109.497 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 15.0 mt -90.42 145.28 25.05 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.246 -0.909 . . . . 0.0 109.476 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.52 ' HB2' ' CD2' ' A' ' 9' ' ' PHE . 1.9 t -49.33 114.32 1.0 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.295 -0.878 . . . . 0.0 109.515 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.45 22.43 24.34 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 38.9 tp10 -84.0 131.9 34.79 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.293 -1.122 . . . . 0.0 109.483 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 4.9 tt -66.09 114.25 5.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.261 -0.899 . . . . 0.0 109.501 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.406 ' HG ' ' HA ' ' A' ' 5' ' ' LYS . 6.1 mt -96.59 -22.17 17.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.266 -0.896 . . . . 0.0 109.456 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.38 159.83 23.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -124.32 133.98 53.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.265 -1.138 . . . . 0.0 109.483 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.448 ' CD1' HD12 ' A' ' 55' ' ' ILE . 4.5 tp -92.35 152.09 19.94 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.92 . . . . 0.0 109.503 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.411 HG23 ' HB ' ' A' ' 54' ' ' VAL . 2.9 t . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.313 -0.867 . . . . 0.0 109.727 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 25.1 mt . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.427 ' OD1' HD13 ' A' ' 71' ' ' LEU . 39.9 t0 -77.67 124.03 27.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.244 -0.91 . . . . 0.0 109.459 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.6 mm -100.32 108.28 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.235 -0.916 . . . . 0.0 109.472 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.5 mtmt -125.15 165.72 17.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.59 163.41 67.53 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.207 -0.933 . . . . 0.0 109.528 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.479 ' O ' ' CE1' ' A' ' 9' ' ' PHE . 35.5 Cg_endo -78.09 134.69 13.23 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.637 2.225 . . . . 0.0 110.436 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.1 m -57.64 134.74 56.44 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.194 -0.941 . . . . 0.0 109.503 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.479 ' CE1' ' O ' ' A' ' 7' ' ' PRO . 4.2 m-85 -94.97 149.17 35.88 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.201 -0.937 . . . . 0.0 109.415 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.409 ' HD2' HD11 ' A' ' 13' ' ' ILE . 35.8 Cg_endo -78.09 -165.22 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.621 2.214 . . . . 0.0 110.456 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.1 OUTLIER -72.41 -49.19 35.53 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.414 179.995 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 11' ' ' GLU . 30.9 t -42.78 -52.12 5.12 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.308 -0.87 . . . . 0.0 109.635 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.409 HD11 ' HD2' ' A' ' 10' ' ' PRO . 3.2 mt -92.95 150.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.206 -0.934 . . . . 0.0 109.439 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.419 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -122.28 12.77 10.25 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.327 -0.858 . . . . 0.0 109.494 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.419 ' CB ' ' O ' ' A' ' 14' ' ' ALA . 0.3 OUTLIER 170.75 -170.76 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.256 -0.902 . . . . 0.0 109.499 -179.987 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.09 -169.92 18.09 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.461 ' O ' ' HB2' ' A' ' 39' ' ' GLU . 17.1 m -149.94 128.78 12.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -1.126 . . . . 0.0 109.469 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.42 HG13 ' N ' ' A' ' 19' ' ' ALA . 25.5 t -52.35 160.65 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.336 -0.852 . . . . 0.0 109.489 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.521 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -100.52 -75.63 0.58 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.473 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.7 m -160.11 136.11 8.57 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.564 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.573 ' CE2' HG22 ' A' ' 36' ' ' VAL . 33.4 m95 -89.76 82.46 6.26 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.256 -0.902 . . . . 0.0 109.64 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.552 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -43.57 -71.46 0.08 Allowed 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.284 -0.885 . . . . 0.0 109.362 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.0 mtmt -100.09 -171.93 2.13 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.245 -0.909 . . . . 0.0 109.571 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.62 167.39 19.41 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.328 -0.858 . . . . 0.0 109.465 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.524 ' CG ' ' HA ' ' A' ' 57' ' ' GLU . 35.5 Cg_endo -76.92 153.18 32.69 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.66 2.24 . . . . 0.0 110.412 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.11 9.49 67.48 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 41.5 mm-40 -113.38 -173.33 2.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.172 -1.193 . . . . 0.0 109.418 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -83.58 132.5 34.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.457 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.6 t -123.28 138.26 53.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.458 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.1 mttt -119.01 132.95 56.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.437 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -42.9 143.39 0.74 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.258 -0.901 . . . . 0.0 109.595 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.425 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 17.6 t0 69.56 46.76 0.7 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.224 -0.923 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.438 ' O ' HG12 ' A' ' 35' ' ' ILE . 1.8 tp10 -140.41 110.19 6.41 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.229 -0.92 . . . . 0.0 109.49 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.552 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 55.7 tp -42.97 161.51 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.27 -0.894 . . . . 0.0 109.604 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.516 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 22.2 mm -149.9 -40.25 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.213 -0.929 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.573 HG22 ' CE2' ' A' ' 21' ' ' TRP . 13.5 p -151.03 131.01 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.257 -0.902 . . . . 0.0 109.541 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.521 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 12.9 m-20 -97.96 171.94 7.95 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.247 -0.908 . . . . 0.0 109.485 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.514 ' N ' ' HB1' ' A' ' 19' ' ' ALA . 2.5 mt -138.74 164.49 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.288 -0.882 . . . . 0.0 109.44 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 17' ' ' THR . 37.4 mt-10 -132.95 141.6 48.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.238 -0.913 . . . . 0.0 109.419 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -126.35 -160.48 0.99 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 -179.992 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 40' ' ' THR . 3.8 t70 -42.87 -63.1 0.85 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.277 -0.889 . . . . 0.0 109.563 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.6 mttt -145.65 22.3 1.46 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 109.443 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 1.9 t -127.42 139.22 52.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.226 -0.921 . . . . 0.0 109.437 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.1 p -105.98 134.26 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.403 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' MET . . . . . 0.419 ' C ' ' HG3' ' A' ' 46' ' ' GLU . 8.8 mtm -113.55 -176.81 2.98 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.264 -0.897 . . . . 0.0 109.463 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.419 ' HG3' ' C ' ' A' ' 45' ' ' MET . 29.1 mt-10 -143.97 161.65 38.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.307 -0.87 . . . . 0.0 109.402 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.514 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 63.5 t -136.72 108.25 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.563 ' CD2' ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.89 148.9 25.07 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.286 -0.883 . . . . 0.0 109.381 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -63.55 147.62 50.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.442 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.518 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 1.1 mt-10 -93.05 10.49 31.28 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.239 -0.913 . . . . 0.0 109.473 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.518 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 164.34 157.23 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.257 -0.902 . . . . 0.0 109.479 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.508 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -65.55 170.96 4.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.336 -0.852 . . . . 0.0 109.348 -179.977 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.508 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.31 -143.79 10.94 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.8 t -138.21 124.46 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.249 -1.147 . . . . 0.0 109.489 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 9.6 mm -75.13 171.76 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.3 -0.875 . . . . 0.0 109.523 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -102.88 -62.45 1.27 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.203 -0.935 . . . . 0.0 109.514 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.524 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 5.3 pt-20 173.27 161.05 0.14 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 109.533 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.523 HD13 ' CG ' ' A' ' 25' ' ' PRO . 1.6 mp -90.43 143.84 10.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.255 -0.903 . . . . 0.0 109.44 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.445 HG22 HD22 ' A' ' 71' ' ' LEU . 53.5 t -99.42 -21.09 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.214 -0.929 . . . . 0.0 109.47 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.518 ' CG ' ' OD2' ' A' ' 64' ' ' ASP . 9.8 tptt -120.65 -171.87 2.27 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.248 -0.907 . . . . 0.0 109.559 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 17.1 m120 -123.25 167.9 13.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.896 . . . . 0.0 109.49 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -71.52 143.03 50.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.272 -0.893 . . . . 0.0 109.533 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 72.86 17.06 78.18 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.716 -1.353 . . . . 0.0 109.716 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.518 ' OD2' ' CG ' ' A' ' 60' ' ' LYS . 0.2 OUTLIER -100.65 170.83 8.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.232 -1.157 . . . . 0.0 109.331 179.966 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.513 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.8 t -90.94 153.78 19.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.481 -0.762 . . . . 0.0 109.53 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 16.1 m -133.39 144.49 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.227 -0.921 . . . . 0.0 109.517 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -92.67 160.73 14.86 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.3 -0.875 . . . . 0.0 109.387 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.2 t -52.89 119.3 4.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.129 -0.982 . . . . 0.0 109.493 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 74.53 33.36 56.24 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -76.8 137.73 39.43 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.277 -1.131 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.445 HD22 HG22 ' A' ' 59' ' ' VAL . 0.6 OUTLIER -78.19 128.32 33.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.456 -179.961 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 7.5 mt -105.76 -23.17 12.78 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.313 -0.867 . . . . 0.0 109.459 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 171.87 171.16 36.63 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 4.4 mtmt -127.78 136.81 52.0 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.27 -1.135 . . . . 0.0 109.509 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 2.7 tt -97.75 151.27 20.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.235 -0.916 . . . . 0.0 109.508 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 15.1 m . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.262 -0.899 . . . . 0.0 109.464 179.958 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.1 pp . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -80.41 133.42 35.88 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.178 -0.951 . . . . 0.0 109.449 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 12.2 mt -96.45 107.76 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.1 mttt -121.28 173.36 7.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.909 . . . . 0.0 109.449 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.96 149.19 82.52 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.292 -0.88 . . . . 0.0 109.468 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.02 135.87 14.28 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.661 2.24 . . . . 0.0 110.372 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 t -56.73 112.33 1.27 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.202 -0.936 . . . . 0.0 109.474 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -67.24 157.45 85.19 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.867 . . . . 0.0 109.431 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.455 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.07 -159.61 0.1 Allowed 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.557 2.171 . . . . 0.0 110.423 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.416 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.1 tt0 -80.07 -61.94 1.83 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.25 -0.906 . . . . 0.0 109.521 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.416 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.9 t -42.81 -47.51 5.53 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.296 -0.877 . . . . 0.0 109.633 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.455 ' HB ' ' HD2' ' A' ' 10' ' ' PRO . 16.6 mt -99.81 130.16 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.234 -0.916 . . . . 0.0 109.418 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -118.79 28.15 8.47 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.274 -0.891 . . . . 0.0 109.383 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 176.42 -170.44 0.07 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.314 -0.866 . . . . 0.0 109.429 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.85 -173.53 33.58 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.452 HG21 ' O ' ' A' ' 64' ' ' ASP . 16.7 m -149.91 122.75 8.71 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.154 -1.204 . . . . 0.0 109.422 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.426 ' C ' ' O ' ' A' ' 17' ' ' THR . 47.1 t -44.24 156.96 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -0.905 . . . . 0.0 109.41 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -106.12 -74.9 0.64 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -0.906 . . . . 0.0 109.475 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.8 m -158.85 134.81 8.93 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.258 -0.901 . . . . 0.0 109.413 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.632 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 33.1 m95 -89.85 84.4 6.24 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.232 -0.917 . . . . 0.0 109.565 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.574 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 2.1 m80 -42.93 -63.25 0.83 Allowed 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.364 -0.835 . . . . 0.0 109.372 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -92.39 -172.07 2.98 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.187 -0.946 . . . . 0.0 109.509 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.467 ' HB2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.47 164.39 43.06 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.272 -0.893 . . . . 0.0 109.452 -179.95 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.468 ' HG3' HG12 ' A' ' 58' ' ' ILE . 35.2 Cg_endo -77.59 90.38 1.26 Allowed 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 122.688 2.259 . . . . 0.0 110.36 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 160.56 -23.28 0.25 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 49.6 mm-40 -94.38 -172.43 2.78 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.35 -1.088 . . . . 0.0 109.472 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -105.0 149.1 26.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.241 -0.912 . . . . 0.0 109.483 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.0 m -120.55 175.66 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.269 -0.894 . . . . 0.0 109.431 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.09 130.6 50.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.425 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 14.1 ttt180 -42.91 141.65 1.07 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.287 -0.883 . . . . 0.0 109.625 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.7 t70 65.55 45.56 2.71 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.434 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 34' ' ' LEU . 4.9 tt0 -136.52 124.83 23.25 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.334 -0.854 . . . . 0.0 109.502 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.574 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 49.8 tp -42.81 150.93 0.14 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.372 -0.83 . . . . 0.0 109.603 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.401 HD12 ' HB1' ' A' ' 49' ' ' ALA . 11.8 mt -139.49 -38.73 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.321 -0.862 . . . . 0.0 109.509 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.509 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 9.7 p -154.51 131.12 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.208 -0.933 . . . . 0.0 109.497 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.45 ' OD1' ' HA ' ' A' ' 46' ' ' GLU . 39.3 m-20 -97.0 152.18 18.98 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.176 -0.952 . . . . 0.0 109.443 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.461 ' O ' ' HA ' ' A' ' 44' ' ' VAL . 5.5 mt -115.91 146.69 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.275 -0.89 . . . . 0.0 109.482 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.68 111.54 21.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.315 -0.866 . . . . 0.0 109.495 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.511 HG22 ' N ' ' A' ' 41' ' ' ASP . 4.8 t -106.64 -153.73 0.5 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.191 -0.943 . . . . 0.0 109.385 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.511 ' N ' HG22 ' A' ' 40' ' ' THR . 0.3 OUTLIER -43.09 -71.53 0.08 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.898 . . . . 0.0 109.627 -179.882 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.456 ' O ' HG21 ' A' ' 43' ' ' VAL . 17.8 mtmm -143.88 36.9 1.29 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.519 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.456 HG21 ' O ' ' A' ' 42' ' ' LYS . 2.1 t -146.82 145.6 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.296 -0.877 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' A' ' 38' ' ' ILE . 10.6 p -109.8 133.51 54.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 0.0 109.438 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 2.7 mtt -105.35 126.95 52.68 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.454 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.45 ' HA ' ' OD1' ' A' ' 37' ' ' ASP . 6.7 mt-10 -81.4 131.25 35.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.179 -0.951 . . . . 0.0 109.466 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.509 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 92.8 t -116.4 102.03 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.247 -0.908 . . . . 0.0 109.509 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.434 HD11 ' O ' ' A' ' 48' ' ' LEU . 0.2 OUTLIER -102.91 163.24 12.32 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.211 -0.931 . . . . 0.0 109.406 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.401 ' HB1' HD12 ' A' ' 35' ' ' ILE . . . -79.45 142.35 35.96 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.207 -0.933 . . . . 0.0 109.48 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -82.5 8.21 12.28 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.281 -0.887 . . . . 0.0 109.535 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -177.08 141.73 0.34 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.889 . . . . 0.0 109.534 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.2 OUTLIER -57.93 170.93 0.56 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.223 -0.923 . . . . 0.0 109.312 -179.953 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.99 -145.09 12.25 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.4 t -138.4 125.21 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.3 -1.118 . . . . 0.0 109.433 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.478 HG23 ' N ' ' A' ' 56' ' ' ALA . 5.0 mt -58.17 161.75 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.316 -0.865 . . . . 0.0 109.529 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.515 ' CB ' ' HG3' ' A' ' 74' ' ' LYS . . . -97.66 -66.84 0.88 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.275 -0.891 . . . . 0.0 109.522 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.446 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 8.2 tt0 -175.05 138.75 0.45 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.207 -0.933 . . . . 0.0 109.456 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.632 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.9 mm -101.94 119.92 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.246 -0.909 . . . . 0.0 109.387 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.4 t -90.0 -19.11 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -0.929 . . . . 0.0 109.402 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.416 ' HG3' ' CG ' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -97.81 131.87 43.93 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.466 179.977 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.453 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 47.9 m-80 -97.55 156.35 16.55 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -0.867 . . . . 0.0 109.471 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -51.24 148.79 4.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.257 -0.902 . . . . 0.0 109.524 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 75.87 19.7 78.61 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.5 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -100.5 170.91 8.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.267 -1.137 . . . . 0.0 109.274 -179.978 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.5 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 65.1 m -106.67 133.6 51.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.539 -0.725 . . . . 0.0 109.475 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 25.0 m -100.79 163.73 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -0.884 . . . . 0.0 109.451 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -145.68 167.39 23.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.272 -0.893 . . . . 0.0 109.476 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.5 t -62.29 115.4 4.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.227 -0.921 . . . . 0.0 109.508 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 89.84 18.4 51.25 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 27.2 tp10 -83.19 121.75 27.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.229 -1.159 . . . . 0.0 109.485 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -83.98 119.2 24.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.211 -0.931 . . . . 0.0 109.422 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.438 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 12.0 mt -99.82 -19.09 16.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.268 -0.895 . . . . 0.0 109.44 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 159.5 168.12 21.07 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.515 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -127.21 158.51 36.92 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.16 -1.2 . . . . 0.0 109.487 179.982 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 8.8 tp -96.48 152.84 18.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.436 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.1 m . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.873 . . . . 0.0 109.523 179.952 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.43 ' O ' HG21 ' A' ' 2' ' ' ILE . 3.5 mp . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 121.311 0.577 . . . . 0.0 109.459 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.463 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 63.2 t0 -57.85 123.26 15.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.531 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 53.0 mt -98.69 121.3 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.228 -0.92 . . . . 0.0 109.39 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.7 ptpp? -147.1 168.5 21.45 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.242 -0.911 . . . . 0.0 109.53 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.42 150.89 91.78 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.02 127.83 8.75 Favored 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.579 2.186 . . . . 0.0 110.423 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -45.84 143.46 2.12 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.27 -0.894 . . . . 0.0 109.451 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.517 ' CE2' ' C ' ' A' ' 15' ' ' ASP . 22.1 m-85 -102.84 154.5 37.47 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.923 . . . . 0.0 109.443 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -78.0 163.75 28.0 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.671 2.247 . . . . 0.0 110.415 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.0 OUTLIER -45.84 -49.77 14.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.141 -0.974 . . . . 0.0 109.505 179.985 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -43.17 -59.96 1.85 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.293 -0.879 . . . . 0.0 109.68 -179.936 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.497 HG22 ' CG2' ' A' ' 40' ' ' THR . 2.5 mp -90.28 132.94 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.267 -0.895 . . . . 0.0 109.48 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.76 25.98 11.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.906 . . . . 0.0 109.486 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.517 ' C ' ' CE2' ' A' ' 9' ' ' PHE . 0.2 OUTLIER 177.09 -171.09 0.09 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.24 -0.913 . . . . 0.0 109.487 -179.94 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.407 ' HA3' ' CZ ' ' A' ' 9' ' ' PHE . . . -159.14 -175.09 29.69 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.492 ' CG2' ' O ' ' A' ' 64' ' ' ASP . 85.2 m -150.02 122.59 8.55 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.292 -1.122 . . . . 0.0 109.45 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.518 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 38.2 t -48.14 168.97 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.297 -0.877 . . . . 0.0 109.453 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.484 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -111.1 -73.9 0.66 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.266 -0.897 . . . . 0.0 109.58 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.465 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 23.9 m -160.08 135.46 8.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.117 -0.989 . . . . 0.0 109.674 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.572 ' CZ2' HG21 ' A' ' 58' ' ' ILE . 34.2 m95 -89.94 83.38 6.13 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 121.161 -0.962 . . . . 0.0 109.494 179.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.576 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 1.5 m80 -43.16 -70.8 0.09 Allowed 'General case' 0 N--CA 1.501 2.109 0 O-C-N 121.315 -0.866 . . . . 0.0 109.425 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.85 -171.75 2.23 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.219 -0.926 . . . . 0.0 109.62 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.437 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.28 169.86 12.72 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.329 -0.857 . . . . 0.0 109.428 -179.903 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.528 ' HD3' ' CD1' ' A' ' 58' ' ' ILE . 34.9 Cg_endo -76.05 135.98 17.82 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 122.642 2.228 . . . . 0.0 110.377 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.13 10.61 27.59 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.421 ' CD ' ' O ' ' A' ' 28' ' ' ALA . 1.2 pp20? -115.51 173.16 6.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.225 -1.162 . . . . 0.0 109.471 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.421 ' O ' ' CD ' ' A' ' 27' ' ' GLU . . . -78.7 144.96 34.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.288 -0.883 . . . . 0.0 109.481 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.2 t -127.92 163.95 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.902 . . . . 0.0 109.472 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.422 ' O ' ' C ' ' A' ' 31' ' ' ARG . 4.3 tttp -156.8 141.85 17.17 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.275 -0.891 . . . . 0.0 109.474 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.465 ' HG2' ' N ' ' A' ' 32' ' ' ASP . 1.5 tmm_? -42.78 144.8 0.52 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.337 -0.852 . . . . 0.0 109.718 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.465 ' N ' ' HG2' ' A' ' 31' ' ' ARG . 16.4 t0 72.18 46.91 0.31 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.269 -0.894 . . . . 0.0 109.498 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 34' ' ' LEU . 3.6 tp10 -142.22 100.99 3.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.281 -0.887 . . . . 0.0 109.561 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.576 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 39.9 tp -43.36 146.9 0.43 Allowed 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.299 -0.875 . . . . 0.0 109.519 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 44.5 mt -121.86 -44.66 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.889 . . . . 0.0 109.652 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.515 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.9 p -160.09 139.24 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.2 -0.937 . . . . 0.0 109.566 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.484 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 11.5 m-20 -99.18 168.39 10.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.896 . . . . 0.0 109.478 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.438 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 12.8 mt -136.02 161.75 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.284 -0.885 . . . . 0.0 109.46 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -143.1 167.35 22.29 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.236 -0.915 . . . . 0.0 109.489 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.497 ' CG2' HG22 ' A' ' 13' ' ' ILE . 8.5 m -159.18 170.91 20.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.273 -0.892 . . . . 0.0 109.455 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 40' ' ' THR . 8.9 t0 -42.83 -40.61 2.95 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.252 -0.905 . . . . 0.0 109.631 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.434 ' O ' HG21 ' A' ' 43' ' ' VAL . 3.5 mtpm? -156.29 26.0 0.35 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.434 HG21 ' O ' ' A' ' 42' ' ' LYS . 78.6 t -140.64 105.09 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.33 -0.856 . . . . 0.0 109.46 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.458 HG21 ' N ' ' A' ' 45' ' ' MET . 3.7 p -95.48 139.32 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.186 -0.946 . . . . 0.0 109.531 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' MET . . . . . 0.458 ' N ' HG21 ' A' ' 44' ' ' VAL . 13.2 mmt -128.05 -167.88 1.82 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.275 -0.89 . . . . 0.0 109.477 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.5 pt-20 -158.39 167.06 30.7 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.169 -0.957 . . . . 0.0 109.486 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.515 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 71.3 t -138.31 104.02 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.381 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.446 ' HG ' ' HA ' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -95.98 171.02 8.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 -179.994 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.05 139.64 31.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 0.0 109.44 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.466 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 2.9 mm-40 -100.38 8.09 43.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -0.913 . . . . 0.0 109.548 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.466 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 166.57 142.99 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.958 . . . . 0.0 109.491 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.504 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.84 170.98 0.15 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.198 -0.939 . . . . 0.0 109.225 -179.926 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.504 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.95 -146.3 14.88 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.4 t -135.89 124.45 37.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.302 -1.117 . . . . 0.0 109.505 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.517 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 5.0 mt -61.17 158.65 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 109.567 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.498 ' N ' HG21 ' A' ' 55' ' ' ILE . . . -95.56 -69.41 0.76 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.249 -0.907 . . . . 0.0 109.549 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.521 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -178.97 152.9 0.6 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.241 -0.912 . . . . 0.0 109.471 179.992 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.572 HG21 ' CZ2' ' A' ' 21' ' ' TRP . 24.9 mt -89.91 141.28 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.219 -0.926 . . . . 0.0 109.412 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.448 HG22 ' O ' ' A' ' 71' ' ' LEU . 61.8 t -90.53 -66.77 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.172 -0.955 . . . . 0.0 109.411 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.459 ' O ' HG23 ' A' ' 58' ' ' ILE . 0.0 OUTLIER -92.79 -173.67 3.39 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.25 -0.906 . . . . 0.0 109.448 -179.983 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.449 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 70.7 m-80 -110.6 155.57 22.16 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.296 -0.878 . . . . 0.0 109.44 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.518 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -69.52 153.43 43.51 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.244 -0.91 . . . . 0.0 109.451 -179.984 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 77.49 7.45 87.09 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.502 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -105.29 170.95 7.59 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.238 -1.154 . . . . 0.0 109.32 -179.966 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.502 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 48.6 m -99.14 128.55 45.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.457 -0.777 . . . . 0.0 109.494 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.427 HG11 ' CD ' ' A' ' 60' ' ' LYS . 6.6 m -121.52 -169.7 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.329 -0.857 . . . . 0.0 109.455 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.2 tp -127.15 165.95 18.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -0.903 . . . . 0.0 109.445 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 t -61.7 138.76 58.34 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.279 -0.888 . . . . 0.0 109.505 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.02 15.4 81.4 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -79.05 116.63 19.47 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.243 -1.151 . . . . 0.0 109.51 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.463 ' CD1' ' OD1' ' A' ' 3' ' ' ASP . 10.9 tp -66.57 115.92 6.96 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.203 -0.935 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 15.4 mt -98.36 -12.35 21.55 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.245 -0.909 . . . . 0.0 109.404 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 164.1 169.96 28.36 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.461 ' O ' ' HB1' ' A' ' 56' ' ' ALA . 26.5 mtmt -132.25 139.09 48.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.188 -1.184 . . . . 0.0 109.504 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 12.8 tp -98.41 136.86 37.95 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.207 -0.933 . . . . 0.0 109.543 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 12.7 m . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.225 -0.922 . . . . 0.0 109.501 179.995 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.1 pp . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.464 ' OD2' ' CD1' ' A' ' 71' ' ' LEU . 26.1 t70 -74.53 166.4 23.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.3 -0.875 . . . . 0.0 109.521 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 61.1 mt -129.96 118.45 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.475 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 ptpp? -137.25 165.0 27.18 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.272 -0.893 . . . . 0.0 109.425 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.45 150.58 91.59 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.485 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.11 166.4 24.78 Favored 'Trans proline' 0 C--N 1.309 -1.524 0 C-N-CA 122.612 2.208 . . . . 0.0 110.409 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.09 94.96 2.98 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.173 -0.954 . . . . 0.0 109.445 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.526 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 21.5 m-85 -50.1 151.0 3.77 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.298 -0.877 . . . . 0.0 109.457 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.426 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.2 Cg_endo -78.14 177.31 8.93 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.559 2.173 . . . . 0.0 110.383 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 12' ' ' SER . 43.2 tt0 -66.0 -54.05 31.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.501 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.425 ' C ' ' O ' ' A' ' 11' ' ' GLU . 21.6 t -42.95 -46.41 5.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.34 -0.85 . . . . 0.0 109.628 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' A' ' 10' ' ' PRO . 11.6 mm -94.5 151.69 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.415 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -121.36 2.64 10.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.618 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.526 ' HA ' ' CD2' ' A' ' 9' ' ' PHE . 0.5 OUTLIER 167.96 -169.25 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.109 -0.995 . . . . 0.0 109.502 -179.992 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.67 -159.46 9.94 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.524 ' CG2' ' O ' ' A' ' 64' ' ' ASP . 0.2 OUTLIER -149.06 170.68 17.85 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.277 -1.131 . . . . 0.0 109.048 179.987 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.66 171.53 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.051 -1.031 . . . . 0.0 109.409 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.431 ' HB1' ' O ' ' A' ' 37' ' ' ASP . . . -118.91 -74.19 0.62 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.462 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.44 ' HA ' ' HG2' ' A' ' 62' ' ' GLU . 65.2 m -160.21 132.3 6.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.144 -0.972 . . . . 0.0 109.622 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.632 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.0 m95 -89.85 82.23 6.24 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.256 -0.902 . . . . 0.0 109.397 179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.625 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.4 m80 -42.67 -57.12 2.85 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.401 -0.812 . . . . 0.0 109.484 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.3 163.58 12.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.245 -0.909 . . . . 0.0 109.66 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.463 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 23.6 mttt -114.46 165.8 13.01 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.346 -0.846 . . . . 0.0 109.152 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.525 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.76 102.5 1.62 Allowed 'Trans proline' 0 C--N 1.308 -1.582 0 C-N-CA 122.544 2.163 . . . . 0.0 110.419 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 145.01 -13.43 1.91 Allowed Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.8 mm-40 -96.61 -172.13 2.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.234 -1.156 . . . . 0.0 109.512 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.68 161.99 13.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.533 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.462 ' O ' ' OD2' ' A' ' 52' ' ' ASP . 35.5 t -138.36 153.42 26.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.239 -0.913 . . . . 0.0 109.479 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.437 ' N ' HG11 ' A' ' 29' ' ' VAL . 0.6 OUTLIER -126.71 137.6 53.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.929 . . . . 0.0 109.5 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.515 ' HG2' ' N ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -42.98 146.04 0.43 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.302 -0.874 . . . . 0.0 109.639 -179.939 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.515 ' N ' ' HG2' ' A' ' 31' ' ' ARG . 3.1 t70 67.66 38.82 2.9 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.486 ' C ' ' CD1' ' A' ' 48' ' ' LEU . 8.6 tp10 -127.84 115.94 19.39 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.194 -0.941 . . . . 0.0 109.455 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.625 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 41.4 tp -43.25 162.37 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.283 -0.886 . . . . 0.0 109.463 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.451 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 29.6 mm -135.49 -48.05 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 109.63 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.494 HG11 ' CG2' ' A' ' 47' ' ' VAL . 14.3 p -160.18 131.55 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.158 -0.964 . . . . 0.0 109.539 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.431 ' O ' ' HB1' ' A' ' 19' ' ' ALA . 3.4 m-20 -90.32 150.82 21.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.5 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 60.9 mt -119.54 155.48 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -0.913 . . . . 0.0 109.501 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.452 ' CG ' ' HB ' ' A' ' 17' ' ' THR . 12.1 pt-20 -128.58 154.51 46.12 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.257 -0.902 . . . . 0.0 109.539 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -141.58 175.5 9.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.258 -0.902 . . . . 0.0 109.425 -179.93 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 4.2 t0 -42.83 -60.67 1.51 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.334 -0.853 . . . . 0.0 109.636 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 15.7 mttt -138.5 36.44 2.25 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.29 -0.881 . . . . 0.0 109.464 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 90.6 t -147.65 127.35 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.28 -0.887 . . . . 0.0 109.436 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.6 t -102.3 152.0 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.277 -0.889 . . . . 0.0 109.463 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.9 176.33 9.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 109.468 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -141.54 149.63 41.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 109.495 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.494 ' CG2' HG11 ' A' ' 36' ' ' VAL . 30.5 t -115.59 96.9 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.285 -0.885 . . . . 0.0 109.431 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.486 ' CD1' ' C ' ' A' ' 33' ' ' GLU . 29.8 tp -96.04 153.16 17.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.35 -0.843 . . . . 0.0 109.52 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.467 ' N ' ' HG ' ' A' ' 48' ' ' LEU . . . -83.41 148.07 27.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.192 -0.942 . . . . 0.0 109.446 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -99.77 17.98 19.34 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.936 . . . . 0.0 109.485 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . 171.87 154.01 0.07 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.288 -0.883 . . . . 0.0 109.483 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.501 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -66.09 170.94 5.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.308 -0.87 . . . . 0.0 109.289 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.501 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.26 -159.81 28.39 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.0 t -135.62 125.11 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -1.159 . . . . 0.0 109.51 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.527 ' CG2' ' N ' ' A' ' 56' ' ' ALA . 4.9 mt -59.11 165.5 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.938 . . . . 0.0 109.528 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.527 ' N ' ' CG2' ' A' ' 55' ' ' ILE . . . -104.45 -67.19 0.91 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.46 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.525 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -169.25 140.63 2.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.227 -0.921 . . . . 0.0 109.565 -179.991 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.632 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.3 mm -93.77 138.97 19.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.233 -0.917 . . . . 0.0 109.393 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 18.0 t -89.94 -39.42 12.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.237 -0.914 . . . . 0.0 109.435 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.464 ' HD3' ' O ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -102.39 158.06 16.47 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.222 -0.924 . . . . 0.0 109.411 179.974 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -117.27 163.32 16.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.303 -0.873 . . . . 0.0 109.432 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.44 ' HG2' ' HA ' ' A' ' 20' ' ' THR . 2.3 mp0 -55.28 134.41 49.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.22 -0.925 . . . . 0.0 109.447 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 100.68 -8.29 58.12 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.524 ' O ' ' CG2' ' A' ' 17' ' ' THR . 0.2 OUTLIER -92.06 170.44 9.84 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.244 -1.151 . . . . 0.0 109.362 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.498 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.6 t -100.36 164.15 12.06 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.565 -0.71 . . . . 0.0 109.511 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.42 ' O ' HG22 ' A' ' 66' ' ' VAL . 22.6 m -130.83 131.08 64.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -0.905 . . . . 0.0 109.44 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -101.59 162.04 13.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -0.885 . . . . 0.0 109.541 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.1 t -59.82 110.03 1.07 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.514 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.79 20.6 16.25 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -83.71 133.91 34.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.264 -1.139 . . . . 0.0 109.499 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.464 ' CD1' ' OD2' ' A' ' 3' ' ' ASP . 9.5 tp -83.26 125.38 31.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.504 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 4.5 mt -100.0 -22.17 15.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.264 -0.897 . . . . 0.0 109.477 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.67 173.49 27.14 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.439 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 39.7 pttt -129.46 153.01 48.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -1.122 . . . . 0.0 109.493 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 22.9 tp -96.22 153.02 18.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -0.898 . . . . 0.0 109.464 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 8.3 m . . . . . 0 N--CA 1.491 1.601 0 O-C-N 121.289 -0.882 . . . . 0.0 109.45 179.984 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 8.5 mt . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' A' ' 4' ' ' ILE . 10.6 t0 -68.37 152.57 45.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.527 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.502 ' N ' ' OD1' ' A' ' 3' ' ' ASP . 8.2 mm -123.74 136.35 60.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.902 . . . . 0.0 109.524 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.34 172.5 12.67 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.281 -0.887 . . . . 0.0 109.447 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.413 ' HB2' ' HD2' ' A' ' 7' ' ' PRO . . . -69.06 158.82 85.47 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.413 ' HD2' ' HB2' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.04 114.86 3.66 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.707 2.271 . . . . 0.0 110.381 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 29.7 m -46.52 126.12 7.81 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.265 -0.897 . . . . 0.0 109.464 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.562 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 1.3 p90 -107.89 151.86 41.4 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.333 -0.854 . . . . 0.0 109.445 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.04 -169.64 0.8 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.68 2.253 . . . . 0.0 110.385 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.438 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.4 OUTLIER -66.61 -45.15 80.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.273 -0.892 . . . . 0.0 109.476 -179.984 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.6 OUTLIER -42.75 -36.85 1.57 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.373 -0.83 . . . . 0.0 109.578 -179.838 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.525 ' CG2' ' O ' ' A' ' 15' ' ' ASP . 18.5 mm -114.58 108.92 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.249 -0.907 . . . . 0.0 109.411 179.954 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.46 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -74.67 -1.48 21.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.217 -0.927 . . . . 0.0 109.667 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.562 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 0.8 OUTLIER 166.92 -174.12 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.917 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.63 -165.96 11.32 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.944 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.523 ' CG2' ' O ' ' A' ' 64' ' ' ASP . 0.4 OUTLIER -149.99 128.27 12.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.293 -1.122 . . . . 0.0 109.397 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.431 ' C ' ' O ' ' A' ' 17' ' ' THR . 61.3 t -43.83 159.49 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.217 -0.927 . . . . 0.0 109.529 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.455 ' HB3' ' OE2' ' A' ' 39' ' ' GLU . . . -111.99 -71.02 0.78 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.253 -0.904 . . . . 0.0 109.574 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.6 m -159.28 133.12 7.43 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.264 -0.897 . . . . 0.0 109.594 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.633 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.2 m95 -89.92 85.65 6.41 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.3 -0.875 . . . . 0.0 109.486 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.556 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.4 m80 -42.86 -60.09 1.73 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.325 -0.859 . . . . 0.0 109.352 -179.864 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -105.37 155.0 19.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.231 -0.918 . . . . 0.0 109.495 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.6 mttt -95.01 167.26 13.29 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.361 -0.837 . . . . 0.0 109.519 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.463 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.5 Cg_endo -76.75 104.56 1.93 Allowed 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.682 2.255 . . . . 0.0 110.494 179.892 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 140.45 -9.72 2.93 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -90.63 -172.17 3.3 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -1.151 . . . . 0.0 109.514 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -101.85 149.19 24.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -0.892 . . . . 0.0 109.421 -179.951 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -130.49 162.65 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.295 -0.878 . . . . 0.0 109.444 179.895 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 6.7 tttp -133.22 142.56 48.63 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.224 -0.923 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.46 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 10.5 ttp-105 -42.92 137.45 2.35 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.285 -0.884 . . . . 0.0 109.588 -179.863 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.463 ' HA ' ' CD2' ' A' ' 48' ' ' LEU . 23.9 t0 72.27 52.04 0.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.256 -0.902 . . . . 0.0 109.524 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.487 ' N ' HD13 ' A' ' 48' ' ' LEU . 0.5 OUTLIER -141.44 114.58 8.67 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.274 -0.891 . . . . 0.0 109.425 -179.978 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.556 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 54.3 tp -42.74 162.31 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.323 -0.861 . . . . 0.0 109.6 -179.937 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.501 HD13 ' N ' ' A' ' 49' ' ' ALA . 4.2 mt -140.84 -42.03 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.214 -0.929 . . . . 0.0 109.536 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.517 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.2 p -158.75 139.88 4.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.319 -0.863 . . . . 0.0 109.502 179.925 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -98.62 149.97 22.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.938 . . . . 0.0 109.544 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.428 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 32.8 mm -104.46 140.79 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.288 -0.883 . . . . 0.0 109.424 -179.993 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.455 ' OE2' ' HB3' ' A' ' 19' ' ' ALA . 0.7 OUTLIER -126.36 92.51 3.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.503 -179.975 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.434 ' OG1' ' HB ' ' A' ' 43' ' ' VAL . 3.0 p -87.81 -173.49 4.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.296 -0.878 . . . . 0.0 109.515 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 40' ' ' THR . 9.7 t0 -42.8 -61.56 1.23 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.367 -0.833 . . . . 0.0 109.626 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -141.62 33.25 1.63 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.477 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.434 ' HB ' ' OG1' ' A' ' 40' ' ' THR . 9.8 t -132.24 109.86 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.166 -0.959 . . . . 0.0 109.447 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.3 t -93.11 126.45 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.319 -0.863 . . . . 0.0 109.524 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' MET . . . . . 0.428 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 0.3 OUTLIER -123.95 -178.27 4.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.321 -0.862 . . . . 0.0 109.477 -180.0 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.414 ' HG3' ' C ' ' A' ' 45' ' ' MET . 0.7 OUTLIER -133.77 155.17 50.27 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.256 -0.902 . . . . 0.0 109.544 179.959 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.517 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 35.0 t -126.84 98.19 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.332 -0.855 . . . . 0.0 109.459 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.512 ' CD1' ' N ' ' A' ' 34' ' ' LEU . 2.6 tt -107.67 151.44 25.65 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.888 . . . . 0.0 109.426 -179.955 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.501 ' N ' HD13 ' A' ' 35' ' ' ILE . . . -83.76 161.12 21.09 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.205 -0.935 . . . . 0.0 109.485 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.86 17.83 23.27 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.194 -0.941 . . . . 0.0 109.396 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -178.58 173.75 1.29 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.298 -0.876 . . . . 0.0 109.494 -179.954 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -77.55 170.92 15.73 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.213 -0.929 . . . . 0.0 109.306 179.953 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.72 175.01 23.77 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.946 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.1 t -121.64 124.9 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.326 -1.102 . . . . 0.0 109.447 179.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.44 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 16.5 mm -58.22 162.36 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.256 -0.902 . . . . 0.0 109.509 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -101.67 -67.42 0.87 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.193 -0.942 . . . . 0.0 109.41 -179.965 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.463 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 2.2 mt-10 -162.46 135.09 5.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.445 -179.983 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.633 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 27.3 mm -93.17 122.23 44.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.224 -0.922 . . . . 0.0 109.409 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.5 t -89.95 -15.7 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.508 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.51 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 1.5 mptt -110.46 125.47 53.32 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.434 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 -92.99 173.59 7.66 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.905 . . . . 0.0 109.496 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -69.49 147.96 50.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 109.564 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.67 -8.76 76.42 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.523 ' O ' ' CG2' ' A' ' 17' ' ' THR . 0.1 OUTLIER -84.49 170.83 13.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.206 -1.173 . . . . 0.0 109.313 -179.92 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.51 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.8 t -99.9 159.29 15.18 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.511 -0.743 . . . . 0.0 109.48 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 29.9 m -122.54 160.51 24.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.222 -0.924 . . . . 0.0 109.452 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -125.36 174.54 8.09 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.179 -0.95 . . . . 0.0 109.492 179.983 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 35.9 t -72.92 85.97 1.28 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.495 -179.932 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 108.85 22.51 6.92 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -78.45 118.03 20.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -1.109 . . . . 0.0 109.459 -179.946 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 7.6 tt -65.77 131.68 46.88 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.281 -0.887 . . . . 0.0 109.448 179.995 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.477 HD21 ' CB ' ' A' ' 60' ' ' LYS . 4.4 mt -115.86 -13.47 11.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.281 -0.887 . . . . 0.0 109.491 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.77 163.69 22.12 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.98 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 7.2 mttt -124.54 145.95 49.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.24 -1.153 . . . . 0.0 109.483 179.939 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.416 HD22 ' O ' ' A' ' 76' ' ' THR . 0.6 OUTLIER -91.65 147.85 22.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.289 -0.882 . . . . 0.0 109.463 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.416 ' O ' HD22 ' A' ' 75' ' ' LEU . 2.9 t . . . . . 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.911 . . . . 0.0 109.787 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 20.8 mm . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -60.5 136.42 58.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.24 -0.912 . . . . 0.0 109.472 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 80.5 mt -114.47 121.3 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.181 -0.949 . . . . 0.0 109.438 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 17.3 mtpt -123.25 178.15 5.25 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.213 -0.93 . . . . 0.0 109.508 179.966 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.18 164.58 42.99 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.255 -0.903 . . . . 0.0 109.505 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -77.99 117.76 4.25 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.644 2.229 . . . . 0.0 110.451 179.928 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -53.97 136.47 41.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.241 -0.912 . . . . 0.0 109.474 179.953 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.555 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 21.8 m-85 -95.33 155.34 38.9 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.469 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.416 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.1 Cg_endo -77.99 -178.53 4.68 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.71 2.273 . . . . 0.0 110.369 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.481 ' HG3' ' N ' ' A' ' 12' ' ' SER . 16.9 pt-20 -61.64 -43.85 98.08 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.481 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.82 -72.93 0.05 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.32 -0.863 . . . . 0.0 109.631 -179.88 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.416 ' O ' ' O ' ' A' ' 10' ' ' PRO . 1.8 mp -91.16 167.52 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.243 -0.911 . . . . 0.0 109.446 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.441 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -142.09 44.83 1.67 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.448 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.555 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 0.3 OUTLIER 168.74 -169.91 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.3 -0.875 . . . . 0.0 109.456 179.938 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -168.21 -170.04 32.43 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.996 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 29.9 m -150.07 126.69 10.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -1.146 . . . . 0.0 109.514 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.519 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 21.8 t -51.89 169.92 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.523 ' HB1' ' CB ' ' A' ' 37' ' ' ASP . . . -113.85 -75.34 0.6 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.229 -0.919 . . . . 0.0 109.534 -179.936 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.515 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 23.2 m -158.38 133.54 8.58 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.221 -0.924 . . . . 0.0 109.529 -179.918 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.623 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.85 84.77 6.26 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.232 -0.917 . . . . 0.0 109.524 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.628 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.9 m80 -43.07 -67.42 0.28 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.298 -0.876 . . . . 0.0 109.35 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -89.26 -171.92 3.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.42 179.911 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.472 ' HB2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.7 164.76 40.53 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.282 -0.886 . . . . 0.0 109.445 179.974 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.472 ' HD2' ' HB2' ' A' ' 24' ' ' LYS . 34.9 Cg_endo -77.18 101.21 1.48 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.559 2.173 . . . . 0.0 110.4 179.938 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 149.75 -16.8 1.09 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.896 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -93.0 -179.03 4.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -1.152 . . . . 0.0 109.437 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.52 159.62 18.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.21 -0.931 . . . . 0.0 109.519 179.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 80.5 t -143.57 156.33 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.393 -179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 31' ' ' ARG . 49.1 tttt -140.79 141.92 34.74 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 30' ' ' LYS . 5.7 ttm180 -42.82 151.34 0.13 Allowed 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.356 -0.84 . . . . 0.0 109.634 -179.848 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.9 t70 68.14 40.56 2.15 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.221 -0.924 . . . . 0.0 109.465 -179.982 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 34' ' ' LEU . 1.6 tt0 -140.14 111.05 6.9 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 0.0 109.467 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.628 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 51.2 tp -42.76 163.44 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.381 -0.825 . . . . 0.0 109.611 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.498 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 39.5 mt -147.18 -43.51 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.227 -0.921 . . . . 0.0 109.612 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.506 HG22 ' CE2' ' A' ' 21' ' ' TRP . 11.4 p -159.81 136.87 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.305 -0.872 . . . . 0.0 109.531 -179.925 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.523 ' CB ' ' HB1' ' A' ' 19' ' ' ALA . 3.5 m-20 -94.85 163.17 13.45 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.307 -0.871 . . . . 0.0 109.422 179.84 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.3 mt -129.33 156.87 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.119 -0.988 . . . . 0.0 109.527 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.17 134.45 50.16 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.288 -0.882 . . . . 0.0 109.503 179.938 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.462 HG21 ' O ' ' A' ' 43' ' ' VAL . 5.6 t -124.24 -163.94 1.2 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.183 -0.948 . . . . 0.0 109.392 180.0 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.438 ' C ' ' O ' ' A' ' 40' ' ' THR . 42.3 t0 -42.3 -68.87 0.16 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.247 -0.908 . . . . 0.0 109.741 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.419 ' O ' ' CG2' ' A' ' 43' ' ' VAL . 1.4 mttp -141.84 48.34 1.61 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.192 -0.942 . . . . 0.0 109.513 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.462 ' O ' HG21 ' A' ' 40' ' ' THR . 76.4 t -156.04 119.92 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.229 -0.92 . . . . 0.0 109.428 -179.956 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.0 t -89.95 118.11 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.216 -0.928 . . . . 0.0 109.523 -179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 1.6 mtp -96.79 -170.8 2.12 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.276 -0.89 . . . . 0.0 109.437 179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.46 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 5.2 pt-20 -149.15 159.6 44.1 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.287 -0.883 . . . . 0.0 109.448 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.43 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 68.0 t -130.74 108.28 15.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.263 -0.898 . . . . 0.0 109.459 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.497 ' HG ' ' N ' ' A' ' 34' ' ' LEU . 0.1 OUTLIER -93.85 172.59 8.15 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.294 -0.879 . . . . 0.0 109.537 179.962 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.413 ' HB1' HD13 ' A' ' 35' ' ' ILE . . . -76.16 136.01 39.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.278 -0.888 . . . . 0.0 109.419 -179.979 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.47 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -95.67 10.12 37.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.531 179.975 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.47 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 165.54 140.8 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.272 -0.892 . . . . 0.0 109.451 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.508 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.31 170.92 0.13 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 109.35 -179.982 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.508 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 140.29 -155.07 24.41 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 55.6 t -134.79 128.62 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.304 -1.116 . . . . 0.0 109.464 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 17.0 mm -56.35 159.36 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.28 -0.888 . . . . 0.0 109.511 179.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -99.66 -65.55 0.96 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.341 -0.849 . . . . 0.0 109.535 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.457 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 6.4 tt0 -173.1 132.77 0.51 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.158 -0.963 . . . . 0.0 109.528 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.623 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 28.4 mm -91.64 125.51 44.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.886 . . . . 0.0 109.391 179.953 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 23.2 t -90.08 -39.37 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.219 -0.926 . . . . 0.0 109.449 179.974 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.03 128.29 41.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.485 179.951 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 71.2 m-80 -87.91 155.98 19.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.303 -0.873 . . . . 0.0 109.446 -179.95 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.519 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -65.02 143.57 57.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.303 -0.873 . . . . 0.0 109.5 -179.937 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 97.11 -13.75 64.48 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.988 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.501 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -92.41 170.89 9.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.284 -1.127 . . . . 0.0 109.303 179.955 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.501 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 21.8 m -98.12 139.54 33.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.486 -0.759 . . . . 0.0 109.516 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.436 ' N ' HG21 ' A' ' 65' ' ' THR . 6.0 m -114.78 -161.95 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.289 -0.882 . . . . 0.0 109.391 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -146.62 170.84 16.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.278 -0.889 . . . . 0.0 109.49 -179.932 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 5.6 t -69.01 104.81 2.21 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.48 179.988 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 102.56 10.71 37.54 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.984 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 31.2 tp10 -72.3 125.53 27.58 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -1.132 . . . . 0.0 109.404 -179.967 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -74.58 121.42 21.56 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -0.917 . . . . 0.0 109.439 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.439 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 9.1 mt -95.85 -22.53 17.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.222 -0.923 . . . . 0.0 109.489 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 168.38 174.63 37.31 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -127.33 135.82 51.06 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.23 -1.159 . . . . 0.0 109.51 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -90.05 138.23 31.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.392 -179.92 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.2 m . . . . . 0 N--CA 1.489 1.522 0 O-C-N 121.268 -0.895 . . . . 0.0 109.481 179.96 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 49.9 mt . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -75.61 118.47 18.49 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.202 -0.936 . . . . 0.0 109.43 -179.933 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.8 mt -96.04 98.73 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.275 -0.89 . . . . 0.0 109.508 179.935 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.46 ' HG3' ' HA ' ' A' ' 71' ' ' LEU . 7.5 ttpt -118.78 163.93 16.15 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -0.884 . . . . 0.0 109.487 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.452 ' N ' HD13 ' A' ' 72' ' ' LEU . . . -65.5 160.78 57.08 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.897 . . . . 0.0 109.464 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -78.1 129.76 9.86 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.613 2.209 . . . . 0.0 110.396 -179.924 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.9 t -56.36 111.92 1.11 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.91 . . . . 0.0 109.445 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -74.24 126.6 88.91 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.329 -0.857 . . . . 0.0 109.345 -179.969 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.42 -159.44 0.1 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.398 2.065 . . . . 0.0 110.388 179.963 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.9 mm-40 -73.36 -55.0 6.98 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.161 -0.962 . . . . 0.0 109.398 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.435 ' C ' ' O ' ' A' ' 11' ' ' GLU . 17.0 t -42.87 -45.42 4.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.358 -0.839 . . . . 0.0 109.585 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 16.9 mt -91.3 163.61 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.293 -0.879 . . . . 0.0 109.491 -179.96 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -143.89 13.37 1.68 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.306 -0.871 . . . . 0.0 109.436 -179.965 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 172.23 -172.27 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.454 -179.968 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.42 172.45 40.19 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.445 ' O ' ' HB2' ' A' ' 39' ' ' GLU . 68.3 m -149.25 125.66 10.9 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.254 -1.145 . . . . 0.0 109.425 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.497 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 24.9 t -50.01 169.41 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.203 -0.935 . . . . 0.0 109.515 179.946 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.431 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -112.76 -73.27 0.67 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.158 -0.964 . . . . 0.0 109.502 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.462 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 52.4 m -159.62 131.21 6.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.483 -179.891 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.633 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.4 m95 -89.91 84.16 6.2 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 121.261 -0.899 . . . . 0.0 109.441 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.579 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 1.5 m80 -42.56 -64.89 0.54 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.373 -0.829 . . . . 0.0 109.454 -179.709 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 5.7 mptt -95.15 -172.19 2.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.244 -0.91 . . . . 0.0 109.532 -179.922 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.425 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.67 168.37 17.77 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.312 -0.868 . . . . 0.0 109.452 -179.965 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.471 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.64 133.09 13.86 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 C-N-CA 122.648 2.232 . . . . 0.0 110.409 179.878 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.8 -11.47 20.82 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.917 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 53.3 mm-40 -97.13 -174.91 3.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.241 -1.152 . . . . 0.0 109.502 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.03 172.65 8.42 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.222 -0.924 . . . . 0.0 109.51 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 t -141.91 155.08 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.974 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -131.65 128.26 38.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.228 -0.92 . . . . 0.0 109.496 179.969 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 3.2 ttt-85 -42.83 137.27 2.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.394 -0.817 . . . . 0.0 109.601 -179.822 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.497 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 10.7 t0 74.97 33.27 0.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.259 -0.901 . . . . 0.0 109.427 179.955 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.488 ' C ' ' CD1' ' A' ' 48' ' ' LEU . 1.2 tt0 -124.29 115.68 21.42 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.258 -0.902 . . . . 0.0 109.503 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.579 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 45.0 tp -43.11 150.94 0.16 Allowed 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.231 -0.918 . . . . 0.0 109.525 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.444 HD13 ' HB3' ' A' ' 49' ' ' ALA . 13.4 mt -129.69 -46.43 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.223 -0.923 . . . . 0.0 109.588 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.508 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.7 p -162.83 142.72 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.233 -0.917 . . . . 0.0 109.461 -179.908 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 46' ' ' GLU . 33.5 m-20 -100.73 163.03 12.51 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.284 -0.885 . . . . 0.0 109.437 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.473 ' CG2' ' N ' ' A' ' 39' ' ' GLU . 9.6 mt -129.33 162.86 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.174 -0.954 . . . . 0.0 109.483 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.473 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 6.1 mm-40 -133.87 151.65 51.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 -179.978 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -140.25 -177.53 5.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.256 -0.903 . . . . 0.0 109.486 179.971 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 40' ' ' THR . 5.4 t70 -42.95 -66.47 0.37 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.326 -0.859 . . . . 0.0 109.629 -179.907 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.2 mttp -135.85 40.69 2.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.286 -0.884 . . . . 0.0 109.461 -179.974 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.426 ' O ' ' OG1' ' A' ' 40' ' ' THR . 52.5 t -151.49 128.18 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.273 -0.892 . . . . 0.0 109.463 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.0 p -98.58 134.41 37.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 0.0 109.442 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' MET . . . . . 0.42 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 1.3 mtt -114.59 -172.45 2.11 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.46 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 6.1 pt-20 -154.73 164.56 38.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.254 -0.904 . . . . 0.0 109.461 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.508 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 58.2 t -134.69 103.55 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 109.442 -179.927 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.488 ' CD1' ' C ' ' A' ' 33' ' ' GLU . 0.4 OUTLIER -93.96 167.04 11.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.2 -0.937 . . . . 0.0 109.52 179.984 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.444 ' HB3' HD13 ' A' ' 35' ' ' ILE . . . -84.54 136.1 33.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.405 -179.929 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.46 ' O ' ' HB1' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -95.87 9.9 39.03 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.162 -0.961 . . . . 0.0 109.466 -179.977 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.46 ' HB1' ' O ' ' A' ' 50' ' ' GLU . . . 167.06 142.93 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.233 -0.917 . . . . 0.0 109.478 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.505 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -58.63 170.96 0.69 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.317 -0.864 . . . . 0.0 109.375 179.96 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.505 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.78 -157.43 27.27 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.928 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.7 t -128.64 127.11 66.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.25 -1.147 . . . . 0.0 109.572 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.415 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 14.4 mm -64.0 156.79 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.27 -0.894 . . . . 0.0 109.437 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -95.55 -69.57 0.75 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.21 -0.931 . . . . 0.0 109.416 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.471 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 1.2 pt-20 -172.27 142.48 1.35 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.252 -0.905 . . . . 0.0 109.449 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.633 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 24.5 mm -94.8 129.54 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.23 -0.919 . . . . 0.0 109.48 -179.977 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.1 t -90.15 -28.99 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.29 -0.881 . . . . 0.0 109.442 179.987 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.443 ' HD3' ' HG2' ' A' ' 70' ' ' GLU . 0.0 OUTLIER -109.16 131.99 54.54 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.182 -0.949 . . . . 0.0 109.529 179.926 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -85.47 155.93 21.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.165 -0.96 . . . . 0.0 109.461 179.992 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.497 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -68.29 141.51 55.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.914 . . . . 0.0 109.476 179.958 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 96.12 -11.3 67.58 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.505 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -95.95 170.9 8.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.262 -1.14 . . . . 0.0 109.327 -179.986 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.505 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 13.0 t -89.02 157.95 18.18 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.492 -0.755 . . . . 0.0 109.516 -179.992 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 1.9 m -127.21 -174.82 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.245 -0.909 . . . . 0.0 109.464 -179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -140.96 177.81 7.79 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.336 -0.853 . . . . 0.0 109.481 -179.957 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.4 t -69.46 124.17 23.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.489 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 75.24 21.89 77.09 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 179.951 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.443 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 42.6 tp10 -74.58 103.65 4.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.191 -1.182 . . . . 0.0 109.472 179.966 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.46 ' HA ' ' HG3' ' A' ' 5' ' ' LYS . 0.7 OUTLIER -60.93 105.47 0.47 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.213 -0.929 . . . . 0.0 109.438 180.0 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 1.4 mt -84.22 -11.46 56.45 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.249 -0.907 . . . . 0.0 109.503 179.94 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.77 165.39 15.82 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.536 -1.425 . . . . 0.0 109.536 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.432 ' HE2' HD12 ' A' ' 71' ' ' LEU . 29.7 mtmt -125.83 151.85 46.27 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.23 -1.159 . . . . 0.0 109.484 179.967 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.9 tt -98.1 152.54 19.21 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.276 -0.89 . . . . 0.0 109.496 179.976 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 14.2 m . . . . . 0 N--CA 1.491 1.585 0 O-C-N 121.243 -0.911 . . . . 0.0 109.438 -179.974 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 25.4 mm . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.458 ' OD2' HD13 ' A' ' 71' ' ' LEU . 11.7 t70 -89.3 129.93 35.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.192 -0.942 . . . . 0.0 109.562 179.9 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mp -104.81 128.84 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.265 -0.897 . . . . 0.0 109.469 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 48.3 mtpt -130.43 176.25 8.29 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.317 -0.864 . . . . 0.0 109.468 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.94 156.55 60.78 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.479 -179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.97 134.53 13.27 Favored 'Trans proline' 0 C--N 1.308 -1.554 0 C-N-CA 122.664 2.242 . . . . 0.0 110.404 179.959 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.432 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -45.49 115.04 0.85 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.223 -0.923 . . . . 0.0 109.502 179.995 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -64.34 149.27 94.96 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.487 179.969 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.406 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -78.02 174.81 11.95 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.598 2.198 . . . . 0.0 110.402 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 12' ' ' SER . 30.5 tt0 -66.75 -55.31 15.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.313 -0.867 . . . . 0.0 109.463 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 11' ' ' GLU . 35.1 t -42.81 -40.86 3.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.361 -0.837 . . . . 0.0 109.581 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.406 ' HB ' ' HD2' ' A' ' 10' ' ' PRO . 12.3 mm -94.35 152.4 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.266 -0.896 . . . . 0.0 109.452 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -126.43 9.29 7.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.26 -0.9 . . . . 0.0 109.497 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 173.64 -172.03 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.206 -0.934 . . . . 0.0 109.414 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.16 -176.09 27.88 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.988 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.515 ' CG2' ' O ' ' A' ' 64' ' ' ASP . 0.3 OUTLIER -150.03 128.94 12.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -1.121 . . . . 0.0 109.431 -179.961 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' A' ' 17' ' ' THR . 53.0 t -43.96 165.74 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.238 -0.914 . . . . 0.0 109.537 -179.943 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.456 ' HB2' ' O ' ' A' ' 37' ' ' ASP . . . -117.52 -72.8 0.67 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.266 -0.896 . . . . 0.0 109.422 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 34.5 m -160.05 127.48 4.57 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.261 -0.899 . . . . 0.0 109.579 -179.977 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.629 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 33.1 m95 -89.85 87.37 6.93 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 121.207 -0.933 . . . . 0.0 109.519 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.613 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.8 m80 -42.46 -57.91 2.45 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.416 -0.803 . . . . 0.0 109.522 -179.76 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 9.3 mttp -106.19 178.94 4.41 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.218 -0.927 . . . . 0.0 109.604 -179.953 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -118.31 167.51 11.32 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.271 -0.893 . . . . 0.0 109.497 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.459 ' HG3' HG12 ' A' ' 58' ' ' ILE . 35.3 Cg_endo -76.94 136.31 16.46 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.617 2.211 . . . . 0.0 110.413 179.96 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.34 -8.77 35.51 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -93.5 -175.39 3.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.227 -1.16 . . . . 0.0 109.477 179.997 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.461 ' O ' HG11 ' A' ' 29' ' ' VAL . . . -104.61 147.77 27.26 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.93 . . . . 0.0 109.462 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.461 HG11 ' O ' ' A' ' 28' ' ' ALA . 2.6 m -147.56 169.48 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.236 -0.915 . . . . 0.0 109.421 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.427 ' O ' ' C ' ' A' ' 31' ' ' ARG . 16.5 tttp -133.06 143.39 49.32 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.252 -0.905 . . . . 0.0 109.442 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.452 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.82 152.32 0.11 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.231 -0.918 . . . . 0.0 109.624 -179.89 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.452 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 26.0 t70 69.04 41.78 1.37 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -0.907 . . . . 0.0 109.418 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' A' ' 34' ' ' LEU . 10.8 tt0 -140.97 117.42 10.8 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.325 -0.859 . . . . 0.0 109.456 179.995 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.613 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 48.8 tp -42.96 163.34 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.241 -0.912 . . . . 0.0 109.562 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.498 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 59.5 mt -149.5 -43.27 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.156 -0.965 . . . . 0.0 109.522 -179.948 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.522 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 9.3 p -157.75 143.32 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.273 -0.892 . . . . 0.0 109.51 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.473 ' OD2' ' NE2' ' A' ' 22' ' ' HIS . 3.7 m-20 -108.54 147.49 31.67 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 109.458 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.461 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 46.7 mt -103.97 150.54 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.316 -0.865 . . . . 0.0 109.434 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -131.79 99.46 4.77 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.942 . . . . 0.0 109.468 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.525 ' CG2' ' HB ' ' A' ' 43' ' ' VAL . 6.6 t -93.62 -170.14 2.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.915 . . . . 0.0 109.476 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 2.6 t0 -42.5 -56.33 3.1 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.294 -0.879 . . . . 0.0 109.767 -179.923 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.473 ' C ' ' CG2' ' A' ' 43' ' ' VAL . 4.1 mtmp? -148.22 49.56 1.04 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -0.884 . . . . 0.0 109.561 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.525 ' HB ' ' CG2' ' A' ' 40' ' ' THR . 1.9 t -154.34 106.44 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.254 -0.904 . . . . 0.0 109.566 179.896 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 94.0 t -89.95 106.63 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.412 179.985 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' MET . . . . . 0.461 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 27.2 mtp -90.05 177.12 6.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 0.0 109.494 179.941 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -132.76 151.58 51.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.921 . . . . 0.0 109.425 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.522 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 85.7 t -127.11 107.55 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.246 -0.909 . . . . 0.0 109.456 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.463 ' CD1' ' HA ' ' A' ' 34' ' ' LEU . 1.1 mp -92.27 176.75 6.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.463 -179.96 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.439 ' CB ' HD12 ' A' ' 35' ' ' ILE . . . -81.9 123.78 29.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.174 -0.954 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.433 ' O ' ' HB1' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -92.92 14.5 17.38 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.174 -0.954 . . . . 0.0 109.419 -179.922 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.433 ' HB1' ' O ' ' A' ' 50' ' ' GLU . . . 174.49 124.96 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.287 -0.883 . . . . 0.0 109.411 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -59.43 170.91 0.9 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.206 -0.934 . . . . 0.0 109.298 -179.969 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.51 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 132.48 -140.56 11.93 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.968 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.462 ' O ' ' HB ' ' A' ' 76' ' ' THR . 46.4 t -139.12 132.12 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.16 -1.2 . . . . 0.0 109.433 179.979 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.458 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 14.7 mm -63.69 169.57 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.271 -0.893 . . . . 0.0 109.506 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -108.52 -65.86 1.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.235 -0.916 . . . . 0.0 109.481 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.456 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -165.47 141.53 5.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.212 -0.93 . . . . 0.0 109.474 179.994 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.629 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 22.7 mm -95.04 125.59 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.192 -0.943 . . . . 0.0 109.425 179.96 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.486 HG22 ' CD2' ' A' ' 71' ' ' LEU . 23.7 t -89.95 -15.26 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.529 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.517 ' CD ' ' HG2' ' A' ' 70' ' ' GLU . 0.0 OUTLIER -110.64 130.04 55.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.27 -0.894 . . . . 0.0 109.453 -179.991 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 57.9 m-80 -105.23 165.37 11.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.227 -0.921 . . . . 0.0 109.44 -179.931 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -67.2 136.6 55.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.538 179.931 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 95.08 2.74 62.21 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.515 ' O ' ' CG2' ' A' ' 17' ' ' THR . 0.1 OUTLIER -104.92 170.83 7.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.105 -1.233 . . . . 0.0 109.377 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.505 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.8 t -98.27 159.59 14.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.497 -0.752 . . . . 0.0 109.51 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 11.9 m -132.7 130.6 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.206 -0.934 . . . . 0.0 109.435 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -94.1 168.64 10.8 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.903 . . . . 0.0 109.509 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.432 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 44.5 t -60.75 130.25 45.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.521 179.989 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 72.74 27.44 69.12 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.999 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.517 ' HG2' ' CD ' ' A' ' 60' ' ' LYS . 0.4 OUTLIER -80.81 132.02 35.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.287 -1.125 . . . . 0.0 109.463 -179.989 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.504 HD22 ' N ' ' A' ' 73' ' ' GLY . 10.4 tt -78.31 122.09 25.28 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.294 -0.879 . . . . 0.0 109.46 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 5.7 mt -96.9 -25.53 15.4 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.352 -0.843 . . . . 0.0 109.469 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.504 ' N ' HD22 ' A' ' 71' ' ' LEU . . . 175.07 157.2 15.86 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.449 ' HG2' ' HA ' ' A' ' 3' ' ' ASP . 0.0 OUTLIER -113.82 159.14 20.13 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.319 -1.106 . . . . 0.0 109.481 179.982 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 19.7 tp -100.83 159.89 14.82 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.225 -0.922 . . . . 0.0 109.429 -179.986 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.462 ' HB ' ' O ' ' A' ' 54' ' ' VAL . 2.9 t . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.278 -0.889 . . . . 0.0 109.703 179.971 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.443 HD13 HD21 ' A' ' 75' ' ' LEU . 8.1 mt . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 . . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 3' ' ' ASP . . . . . 0.469 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 11.4 t70 -75.91 127.08 32.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.46 -179.983 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 18.7 mt -103.38 126.18 57.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.271 -0.893 . . . . 0.0 109.432 -179.991 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -132.96 159.23 40.57 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.303 -0.873 . . . . 0.0 109.481 179.972 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.94 164.45 61.33 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.426 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.08 179.78 6.18 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.676 2.25 . . . . 0.0 110.382 179.979 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.87 126.55 36.07 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.206 -0.933 . . . . 0.0 109.471 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -81.61 156.08 70.8 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.257 -0.902 . . . . 0.0 109.458 -179.969 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.05 173.31 14.15 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.682 2.254 . . . . 0.0 110.363 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 12' ' ' SER . 7.8 pt-20 -65.9 -47.9 73.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.266 -0.896 . . . . 0.0 109.46 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.428 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.74 -49.37 5.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.312 -0.868 . . . . 0.0 109.617 -179.935 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.451 HG23 ' O ' ' A' ' 15' ' ' ASP . 8.7 mt -91.22 166.52 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.284 -0.885 . . . . 0.0 109.475 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.425 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -131.9 11.61 4.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.249 -0.907 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.451 ' O ' HG23 ' A' ' 13' ' ' ILE . 0.9 OUTLIER 169.96 -171.45 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.244 -0.91 . . . . 0.0 109.4 -179.966 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.23 -163.71 9.91 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.994 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.452 ' O ' ' CB ' ' A' ' 39' ' ' GLU . 26.5 m -149.95 128.21 12.08 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -1.123 . . . . 0.0 109.424 -179.962 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.464 HG11 ' N ' ' A' ' 19' ' ' ALA . 39.5 t -50.74 154.2 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.285 -0.885 . . . . 0.0 109.445 179.934 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.523 ' HB1' ' CB ' ' A' ' 37' ' ' ASP . . . -99.84 -76.84 0.54 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.161 -0.962 . . . . 0.0 109.511 179.972 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.2 m -159.89 130.16 5.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.541 -179.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.628 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.1 m95 -89.8 84.94 6.29 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.225 -0.922 . . . . 0.0 109.559 -179.893 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' HIS . . . . . 0.566 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -43.26 -61.59 1.29 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.313 -0.867 . . . . 0.0 109.335 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -94.67 -172.1 2.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.345 -0.847 . . . . 0.0 109.493 179.986 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.521 ' HD2' ' CD ' ' A' ' 25' ' ' PRO . 2.9 mmmt -130.81 163.87 45.77 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.24 -0.913 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.521 ' CD ' ' HD2' ' A' ' 24' ' ' LYS . 35.5 Cg_endo -77.48 106.43 2.21 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.562 2.175 . . . . 0.0 110.429 179.921 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 137.72 -10.28 3.7 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.939 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.1 -172.33 2.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.249 -1.148 . . . . 0.0 109.416 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -105.7 150.03 25.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.28 -0.888 . . . . 0.0 109.477 179.974 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.3 m -131.93 -170.93 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.244 -0.91 . . . . 0.0 109.459 -179.963 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.439 ' HA ' ' HB2' ' A' ' 52' ' ' ASP . 12.5 mttm -149.91 130.91 14.34 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.217 -0.927 . . . . 0.0 109.52 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.474 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 4.3 ttm105 -42.82 143.61 0.69 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.318 -0.864 . . . . 0.0 109.669 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.474 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 6.7 t70 73.84 38.28 0.6 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.316 -0.865 . . . . 0.0 109.476 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.434 ' O ' ' C ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -138.98 122.73 17.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.909 . . . . 0.0 109.436 179.96 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.566 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 36.0 tp -43.0 149.14 0.21 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.201 -0.937 . . . . 0.0 109.548 -179.939 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 35.4 mm -132.62 -42.86 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -0.915 . . . . 0.0 109.554 -179.921 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.447 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 4.4 p -162.1 147.48 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.244 -0.91 . . . . 0.0 109.546 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.523 ' CB ' ' HB1' ' A' ' 19' ' ' ALA . 1.3 m-20 -107.33 154.79 20.77 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.896 . . . . 0.0 109.396 179.966 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.414 ' O ' ' HA ' ' A' ' 44' ' ' VAL . 26.8 mm -122.73 148.09 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.218 -0.926 . . . . 0.0 109.489 -179.937 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.452 ' CB ' ' O ' ' A' ' 17' ' ' THR . 0.3 OUTLIER -107.14 109.69 21.59 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.535 179.941 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 41' ' ' ASP . 35.4 p -97.27 -150.35 0.34 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.202 -0.936 . . . . 0.0 109.434 -179.949 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 3.0 t0 -42.8 -70.05 0.12 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.318 -0.863 . . . . 0.0 109.668 -179.886 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -145.1 25.19 1.42 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.222 -0.924 . . . . 0.0 109.458 179.963 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.9 t -136.53 130.66 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -0.961 . . . . 0.0 109.466 179.947 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 38' ' ' ILE . 2.1 t -90.96 109.48 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.223 -0.923 . . . . 0.0 109.512 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -79.99 163.79 23.96 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.299 -0.875 . . . . 0.0 109.507 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -108.07 145.17 34.41 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.247 -0.908 . . . . 0.0 109.43 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.447 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 10.1 t -118.75 100.85 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.312 -0.868 . . . . 0.0 109.426 179.958 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.421 ' HG ' ' C ' ' A' ' 33' ' ' GLU . 0.4 OUTLIER -91.91 153.83 19.25 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.193 -0.942 . . . . 0.0 109.49 179.991 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.17 138.85 44.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.9 . . . . 0.0 109.49 179.983 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -88.51 13.52 11.8 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.294 -0.879 . . . . 0.0 109.505 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . 170.49 150.37 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.252 -0.905 . . . . 0.0 109.45 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -78.6 170.99 15.78 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.317 179.994 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.51 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 149.91 -137.69 6.34 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 50.9 t -136.07 125.6 39.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -1.129 . . . . 0.0 109.465 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 14.1 mm -64.58 161.78 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.925 . . . . 0.0 109.531 180.0 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -103.51 -67.02 0.91 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.256 -0.903 . . . . 0.0 109.466 -179.948 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.459 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 2.5 tt0 -169.83 140.59 2.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.286 -0.884 . . . . 0.0 109.463 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.628 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 22.5 mm -93.86 131.63 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.171 -0.956 . . . . 0.0 109.527 -179.965 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 72.0 t -89.96 -38.41 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.274 -0.892 . . . . 0.0 109.497 179.957 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.458 ' HA ' ' HE2' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -94.77 125.21 39.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.343 -0.848 . . . . 0.0 109.424 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 28.8 m-80 -89.64 176.24 6.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.253 -0.904 . . . . 0.0 109.482 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -74.9 153.33 38.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.246 -0.909 . . . . 0.0 109.502 179.957 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.94 15.12 62.13 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.515 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -104.58 170.88 7.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.177 -1.19 . . . . 0.0 109.312 179.993 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.1 m -100.45 138.31 37.69 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.445 -0.784 . . . . 0.0 109.5 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.453 HG11 ' HG2' ' A' ' 60' ' ' LYS . 4.9 m -115.8 172.75 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.207 -0.933 . . . . 0.0 109.461 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -136.06 -173.95 3.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.255 -0.903 . . . . 0.0 109.472 179.936 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.97 149.3 48.98 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.175 -0.953 . . . . 0.0 109.464 -179.965 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 49.69 29.95 13.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.986 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.436 ' OE2' ' HD3' ' A' ' 60' ' ' LYS . 49.6 tp10 -80.55 114.27 19.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.271 -1.135 . . . . 0.0 109.495 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.469 ' CD1' ' OD1' ' A' ' 3' ' ' ASP . 0.5 OUTLIER -66.31 118.69 10.35 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.191 -0.943 . . . . 0.0 109.47 179.95 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 8.7 mt -87.96 -28.27 21.58 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.483 179.968 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 176.96 170.59 39.6 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.429 ' HE3' HD23 ' A' ' 71' ' ' LEU . 10.0 mttt -128.44 134.45 48.76 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -1.158 . . . . 0.0 109.445 180.0 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.455 HD22 ' O ' ' A' ' 76' ' ' THR . 0.5 OUTLIER -91.56 147.2 23.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -0.88 . . . . 0.0 109.414 -179.974 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.455 ' O ' HD22 ' A' ' 75' ' ' LEU . 7.3 m . . . . . 0 N--CA 1.49 1.543 0 O-C-N 121.282 -0.886 . . . . 0.0 109.514 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 5.4 mp -134.2 115.67 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -0.908 . . . . 0.0 109.454 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' A' ' 4' ' ' ILE . 39.6 t0 -88.98 132.82 34.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.239 -0.913 . . . . 0.0 109.452 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.481 ' N ' ' OD1' ' A' ' 3' ' ' ASP . 82.2 mt -99.99 124.24 53.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.424 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.41 ' HA ' ' O ' ' A' ' 70' ' ' GLU . 2.6 mttt -122.75 175.59 6.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.209 -0.932 . . . . 0.0 109.448 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.422 ' HB2' ' HD2' ' A' ' 7' ' ' PRO . . . -79.68 161.38 66.9 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.883 . . . . 0.0 109.49 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' A' ' 6' ' ' ALA . 35.6 Cg_endo -78.06 173.8 13.42 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.638 2.225 . . . . 0.0 110.389 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.5 m -92.07 134.68 34.61 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.478 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -100.14 155.82 35.98 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 109.438 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.426 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -77.99 -159.93 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.589 2.193 . . . . 0.0 110.473 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' A' ' 12' ' ' SER . 2.5 mt-10 -78.64 -58.69 3.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 109.497 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 11' ' ' GLU . 31.1 t -42.83 -45.09 4.75 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.295 -0.878 . . . . 0.0 109.628 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.426 ' HB ' ' HD2' ' A' ' 10' ' ' PRO . 33.7 mm -104.43 136.92 35.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.297 -0.877 . . . . 0.0 109.472 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.407 ' C ' ' OD1' ' A' ' 15' ' ' ASP . . . -119.03 16.81 13.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.233 -0.917 . . . . 0.0 109.451 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -169.18 -170.73 1.16 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 0.0 109.438 -179.982 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.68 -170.08 16.11 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.512 ' O ' ' CB ' ' A' ' 39' ' ' GLU . 1.4 m -150.0 128.57 12.3 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.221 -1.164 . . . . 0.0 109.499 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.1 t -56.42 153.82 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.226 -0.921 . . . . 0.0 109.406 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.47 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -96.86 -72.98 0.62 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.256 -0.903 . . . . 0.0 109.546 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.7 m -160.05 132.61 6.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.22 -0.925 . . . . 0.0 109.558 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.634 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.9 83.0 6.12 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.257 -0.902 . . . . 0.0 109.528 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.572 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 2.0 m80 -42.85 -64.84 0.55 Allowed 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.38 -0.825 . . . . 0.0 109.441 -179.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.17 -179.25 4.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.557 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -125.84 168.48 13.84 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.249 -0.907 . . . . 0.0 109.487 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.479 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 34.9 Cg_endo -76.66 123.26 6.84 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.626 2.218 . . . . 0.0 110.398 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.3 12.64 9.61 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -118.22 -172.44 2.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.205 -1.173 . . . . 0.0 109.457 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -98.68 153.56 18.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.242 -0.911 . . . . 0.0 109.462 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.489 ' CG2' HD13 ' A' ' 35' ' ' ILE . 2.8 p -138.36 162.3 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 109.48 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.457 ' N ' ' CG2' ' A' ' 29' ' ' VAL . 0.0 OUTLIER -134.59 126.13 28.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.256 -0.903 . . . . 0.0 109.517 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.506 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 16.8 ttp180 -42.72 146.82 0.34 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.323 -0.861 . . . . 0.0 109.664 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.506 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 2.9 t70 75.18 33.95 0.68 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.447 ' HB2' ' O ' ' A' ' 30' ' ' LYS . 3.4 tt0 -138.83 123.6 18.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -0.912 . . . . 0.0 109.444 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.572 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 50.6 tp -42.98 156.97 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.273 -0.892 . . . . 0.0 109.531 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.489 HD13 ' CG2' ' A' ' 29' ' ' VAL . 35.8 mm -139.11 -38.17 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.2 -0.937 . . . . 0.0 109.651 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.433 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.5 p -166.66 139.1 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.175 -0.953 . . . . 0.0 109.527 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.47 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 1.1 m-20 -98.61 158.5 15.56 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.447 HD13 ' CG2' ' A' ' 47' ' ' VAL . 36.1 mt -125.01 153.63 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.532 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.512 ' CB ' ' O ' ' A' ' 17' ' ' THR . 15.0 tt0 -109.88 123.61 49.89 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.236 -0.915 . . . . 0.0 109.454 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.435 ' O ' ' C ' ' A' ' 41' ' ' ASP . 3.9 p -107.54 -162.44 0.84 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.256 -0.903 . . . . 0.0 109.475 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.435 ' C ' ' O ' ' A' ' 40' ' ' THR . 16.7 t0 -42.72 -66.7 0.34 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.33 -0.856 . . . . 0.0 109.65 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 13.3 mtpt -142.79 26.16 1.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.31 -0.869 . . . . 0.0 109.476 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 42.1 t -136.48 136.5 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.28 -0.888 . . . . 0.0 109.504 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 56.4 t -95.65 119.26 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.292 -0.88 . . . . 0.0 109.458 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 4.2 mtt -93.71 179.7 5.28 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.242 -0.911 . . . . 0.0 109.503 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -131.96 148.9 52.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.514 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.447 ' CG2' HD13 ' A' ' 38' ' ' ILE . 21.2 t -121.91 107.95 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.256 -0.903 . . . . 0.0 109.441 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.428 ' HG ' ' C ' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -98.16 153.11 18.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 109.494 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.448 ' HB3' HG13 ' A' ' 35' ' ' ILE . . . -76.87 143.65 39.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.26 -0.9 . . . . 0.0 109.416 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.459 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 0.1 OUTLIER -96.25 15.42 21.08 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.469 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 166.9 148.28 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.468 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.496 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -69.96 170.96 10.22 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.348 179.978 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.496 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 157.27 -146.61 13.92 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.6 t -135.39 124.6 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.25 -1.147 . . . . 0.0 109.506 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 12.1 mm -70.03 158.88 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.275 -0.891 . . . . 0.0 109.496 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.45 ' HB1' ' O ' ' A' ' 74' ' ' LYS . . . -95.13 -64.43 1.07 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.199 -0.938 . . . . 0.0 109.457 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.479 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 11.7 pt-20 -179.17 146.32 0.29 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.461 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.634 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 30.6 mm -99.07 127.42 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.245 -0.909 . . . . 0.0 109.475 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.3 t -90.08 -29.92 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.497 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 0.2 OUTLIER -90.78 148.1 22.77 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.234 -0.916 . . . . 0.0 109.481 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 4.5 m-80 -110.45 156.31 21.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.503 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -60.6 139.19 57.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.269 -0.894 . . . . 0.0 109.526 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 90.11 4.97 71.01 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -105.76 170.7 7.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -1.186 . . . . 0.0 109.355 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 7.3 t -102.21 154.26 19.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.528 -0.732 . . . . 0.0 109.564 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.497 HG13 ' CD2' ' A' ' 72' ' ' LEU . 30.3 m -130.66 133.81 62.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.47 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -92.43 169.86 10.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.465 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -59.51 143.21 50.74 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.248 -0.908 . . . . 0.0 109.451 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 67.7 12.02 61.18 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.41 ' O ' ' HA ' ' A' ' 5' ' ' LYS . 5.3 tp10 -70.33 120.58 16.21 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.287 -1.125 . . . . 0.0 109.467 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.434 HD23 ' HD2' ' A' ' 74' ' ' LYS . 10.0 tt -77.97 111.92 14.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.301 -0.874 . . . . 0.0 109.459 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.497 ' CD2' HG13 ' A' ' 66' ' ' VAL . 1.9 mt -88.3 -21.12 24.59 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.267 -0.895 . . . . 0.0 109.462 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.417 ' N ' HD22 ' A' ' 71' ' ' LEU . . . 172.5 -177.17 45.23 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.459 ' NZ ' ' OE2' ' A' ' 57' ' ' GLU . 0.0 OUTLIER -139.63 153.81 47.41 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.195 -1.18 . . . . 0.0 109.52 179.963 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -94.69 155.61 16.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.267 -0.896 . . . . 0.0 109.435 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.4 m -106.23 171.48 7.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.204 -0.935 . . . . 0.0 109.456 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -78.77 143.77 35.8 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.241 -0.912 . . . . 0.0 109.452 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -102.57 -178.11 27.14 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.31 0 CA-C-O 117.992 -1.449 . . . . 0.0 109.533 179.999 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.415 HG13 ' HB3' ' A' ' 75' ' ' LEU . 2.0 pt -137.81 173.3 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.197 -0.939 . . . . 0.0 109.526 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.41 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 20.9 t0 -120.59 136.86 54.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.281 -0.887 . . . . 0.0 109.461 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 65.8 mt -110.46 118.85 58.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.189 -0.944 . . . . 0.0 109.481 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.86 156.77 48.34 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.289 -0.882 . . . . 0.0 109.418 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -58.7 163.54 5.11 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.202 -0.936 . . . . 0.0 109.46 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.06 178.16 7.92 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.618 2.212 . . . . 0.0 110.41 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.43 ' O ' ' CD1' ' A' ' 9' ' ' PHE . 0.2 OUTLIER -76.56 176.42 8.35 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.896 . . . . 0.0 109.509 -179.966 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.452 ' CE1' HG22 ' A' ' 40' ' ' THR . 23.7 m-85 -138.7 71.78 43.11 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.453 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.93 -0.14 10.38 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.636 2.224 . . . . 0.0 110.432 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.515 ' O ' ' CD1' ' A' ' 13' ' ' ILE . 5.9 mm-40 -85.33 46.46 1.29 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.394 -0.816 . . . . 0.0 109.438 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 12' ' ' SER . 6.6 t 39.25 39.21 0.41 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.528 -0.733 . . . . 0.0 110.034 179.707 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.515 ' CD1' ' O ' ' A' ' 11' ' ' GLU . 15.0 mm -98.82 156.35 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.891 . . . . 0.0 109.374 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.496 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -93.83 -1.88 54.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.19 -0.944 . . . . 0.0 109.727 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.496 ' CB ' ' O ' ' A' ' 14' ' ' ALA . 1.1 p30 163.74 -169.63 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.227 -0.921 . . . . 0.0 109.442 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.0 -169.33 11.63 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 93.6 m -150.02 123.26 8.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.204 -1.174 . . . . 0.0 109.534 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.516 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 24.2 t -51.09 169.49 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.22 -0.925 . . . . 0.0 109.482 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.462 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -112.73 -73.14 0.68 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.179 -0.951 . . . . 0.0 109.609 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.448 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 16.4 m -159.98 137.13 9.44 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.53 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.558 ' CZ2' HG21 ' A' ' 58' ' ' ILE . 32.7 m95 -89.98 83.85 6.14 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.259 -0.901 . . . . 0.0 109.501 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.572 ' CD2' HD22 ' A' ' 34' ' ' LEU . 2.2 m80 -42.86 -69.82 0.13 Allowed 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.39 -0.819 . . . . 0.0 109.487 -179.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.05 -171.58 2.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 109.674 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.467 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 1.8 mttt -128.8 170.76 9.93 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.227 -0.92 . . . . 0.0 109.435 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.523 ' CG ' ' HA ' ' A' ' 57' ' ' GLU . 34.8 Cg_endo -75.61 129.52 11.88 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.657 2.238 . . . . 0.0 110.39 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 120.98 -11.88 9.95 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -95.84 166.48 11.78 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.254 -1.145 . . . . 0.0 109.472 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.29 133.39 35.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -0.907 . . . . 0.0 109.411 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.444 ' O ' HG21 ' A' ' 29' ' ' VAL . 25.1 m -136.31 135.84 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.162 -0.961 . . . . 0.0 109.528 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 31' ' ' ARG . 9.6 pttp -117.35 146.23 43.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.88 . . . . 0.0 109.389 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.464 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 4.0 ttt180 -42.9 156.23 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.244 -0.91 . . . . 0.0 109.623 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.464 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 18.8 t70 73.34 29.21 1.69 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -0.881 . . . . 0.0 109.453 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.521 ' N ' ' CD2' ' A' ' 48' ' ' LEU . 30.5 tt0 -137.71 111.63 8.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.285 -0.884 . . . . 0.0 109.446 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.572 HD22 ' CD2' ' A' ' 22' ' ' HIS . 43.4 tp -42.9 153.56 0.08 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.36 -0.837 . . . . 0.0 109.595 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.441 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 11.1 mm -139.08 -38.51 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.15 -0.969 . . . . 0.0 109.55 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.514 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 10.8 p -160.21 131.53 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.263 -0.898 . . . . 0.0 109.466 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.462 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 32.4 m-20 -92.15 157.09 16.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.918 . . . . 0.0 109.482 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.513 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 20.6 tt -127.91 162.98 32.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.325 -0.859 . . . . 0.0 109.447 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -148.76 110.65 4.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.24 -0.912 . . . . 0.0 109.434 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.452 HG22 ' CE1' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -80.73 -160.65 0.32 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.29 -0.881 . . . . 0.0 109.503 179.94 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.404 ' HB2' HD13 ' A' ' 13' ' ' ILE . 50.0 t0 -42.83 -67.64 0.26 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.293 -0.88 . . . . 0.0 109.631 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -132.02 23.22 4.55 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -0.934 . . . . 0.0 109.491 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.423 ' C ' HG21 ' A' ' 44' ' ' VAL . 1.9 t -117.97 162.13 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.226 -0.921 . . . . 0.0 109.437 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.423 HG21 ' C ' ' A' ' 43' ' ' VAL . 6.9 t -137.35 126.7 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.284 -0.885 . . . . 0.0 109.51 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' MET . . . . . 0.513 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 1.7 mtt -123.63 -171.01 2.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.256 -0.903 . . . . 0.0 109.434 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.3 152.4 48.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.417 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.514 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 35.0 t -122.52 111.18 29.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.319 -0.863 . . . . 0.0 109.47 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.521 ' CD2' ' N ' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -102.02 165.78 10.98 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.281 -0.887 . . . . 0.0 109.464 -179.978 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -76.35 144.97 39.81 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.333 -0.855 . . . . 0.0 109.472 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -108.49 7.44 26.86 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.143 -0.973 . . . . 0.0 109.536 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -175.45 122.32 0.21 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.178 -0.951 . . . . 0.0 109.531 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.499 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -55.14 170.93 0.17 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.3 -0.875 . . . . 0.0 109.32 179.999 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.499 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 140.82 -139.34 9.57 Favored Glycine 0 N--CA 1.49 2.233 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 45.0 t -139.15 123.55 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -1.184 . . . . 0.0 109.429 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.462 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 13.9 mm -65.06 167.75 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.249 -0.907 . . . . 0.0 109.537 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.411 ' N ' HG23 ' A' ' 55' ' ' ILE . . . -101.72 -65.42 0.98 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.181 -0.95 . . . . 0.0 109.472 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.523 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -171.68 159.09 5.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.502 179.992 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.558 HG21 ' CZ2' ' A' ' 21' ' ' TRP . 74.2 mt -89.97 130.56 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.318 -0.864 . . . . 0.0 109.403 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.458 ' HB ' ' O ' ' A' ' 71' ' ' LEU . 50.0 t -89.99 -37.77 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.2 -0.938 . . . . 0.0 109.417 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.437 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -113.89 137.63 51.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.229 -0.92 . . . . 0.0 109.4 -179.989 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -79.96 156.37 27.25 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.213 -0.929 . . . . 0.0 109.443 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.516 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -70.3 142.76 52.21 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 93.99 -15.62 62.74 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.506 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -84.24 170.88 13.28 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.181 -1.188 . . . . 0.0 109.365 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.506 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 88.5 m -96.78 133.49 41.29 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.518 -0.739 . . . . 0.0 109.477 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.401 HG11 ' HG2' ' A' ' 60' ' ' LYS . 6.3 m -116.68 -154.66 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.26 -0.9 . . . . 0.0 109.429 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mp -149.65 176.64 10.48 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.262 -0.899 . . . . 0.0 109.495 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.2 t -69.41 109.21 4.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.251 -0.905 . . . . 0.0 109.449 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.55 21.47 26.57 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -74.0 121.05 20.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -1.133 . . . . 0.0 109.428 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.458 ' O ' ' HB ' ' A' ' 59' ' ' VAL . 25.5 tp -64.9 111.62 2.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.255 -0.903 . . . . 0.0 109.492 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 8.4 mt -95.18 -10.91 29.13 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -0.887 . . . . 0.0 109.48 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.34 163.39 21.13 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 26.4 mttt -125.41 144.71 50.39 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -1.139 . . . . 0.0 109.456 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.471 ' HG ' ' N ' ' A' ' 76' ' ' THR . 12.4 tp -90.0 153.51 20.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.445 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.471 ' N ' ' HG ' ' A' ' 75' ' ' LEU . 14.6 m -113.49 171.99 7.23 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.903 . . . . 0.0 109.489 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -82.1 149.3 28.09 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.229 -0.919 . . . . 0.0 109.478 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -114.13 120.52 5.11 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.95 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.408 ' C ' HG21 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.444 HG13 ' HB3' ' A' ' 75' ' ' LEU . 1.8 pp -146.76 126.1 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.294 -0.879 . . . . 0.0 109.509 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.453 ' OD2' HD11 ' A' ' 71' ' ' LEU . 8.3 t0 -89.72 129.28 36.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.313 -0.867 . . . . 0.0 109.483 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 87.4 mt -97.08 75.97 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.238 -0.914 . . . . 0.0 109.517 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.33 161.6 13.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.227 -0.92 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.51 163.11 70.54 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.216 -0.927 . . . . 0.0 109.437 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.08 -179.85 5.83 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.632 2.222 . . . . 0.0 110.386 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 m -93.82 106.99 18.93 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.297 -0.877 . . . . 0.0 109.443 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.407 ' HB3' ' HD2' ' A' ' 10' ' ' PRO . 80.9 m-85 -61.5 157.81 43.82 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.233 -0.917 . . . . 0.0 109.452 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.45 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.1 -163.08 0.2 Allowed 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.585 2.19 . . . . 0.0 110.415 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.6 OUTLIER -80.82 -59.06 2.82 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.265 -0.897 . . . . 0.0 109.436 -179.972 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 11' ' ' GLU . 35.3 t -42.82 -31.24 0.47 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.365 -0.835 . . . . 0.0 109.618 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.45 ' HB ' ' HD2' ' A' ' 10' ' ' PRO . 24.4 mt -113.81 141.41 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.227 -0.921 . . . . 0.0 109.445 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -126.96 31.25 5.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.5 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 174.8 -171.47 0.06 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.8 -164.71 13.82 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.462 ' HA ' ' O ' ' A' ' 64' ' ' ASP . 84.6 m -150.12 120.99 7.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.214 -1.168 . . . . 0.0 109.44 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.515 HG13 ' N ' ' A' ' 19' ' ' ALA . 60.0 t -43.79 162.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.302 -0.874 . . . . 0.0 109.487 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.515 ' N ' HG13 ' A' ' 18' ' ' VAL . . . -108.11 -75.17 0.64 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.278 -0.889 . . . . 0.0 109.562 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.9 m -160.17 131.61 5.92 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.167 -0.958 . . . . 0.0 109.619 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.55 ' CE2' HG22 ' A' ' 58' ' ' ILE . 33.3 m95 -89.82 85.88 6.51 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.255 -0.903 . . . . 0.0 109.448 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.571 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 2.5 m80 -42.34 -69.88 0.12 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.356 -0.84 . . . . 0.0 109.654 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.69 -174.09 2.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.217 -0.927 . . . . 0.0 109.78 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.461 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -116.87 165.67 14.75 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.377 -0.827 . . . . 0.0 109.262 179.975 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.519 ' CG ' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -77.18 145.43 24.38 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.552 2.168 . . . . 0.0 110.426 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.44 -8.89 60.58 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.462 ' OE1' ' O ' ' A' ' 28' ' ' ALA . 0.4 OUTLIER -94.1 176.74 6.21 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.202 -1.175 . . . . 0.0 109.453 -179.972 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.462 ' O ' ' OE1' ' A' ' 27' ' ' GLU . . . -91.37 158.4 16.55 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.291 -0.881 . . . . 0.0 109.486 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.7 m -138.87 -167.53 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.257 -0.902 . . . . 0.0 109.506 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 31' ' ' ARG . 5.1 tptm -142.18 140.85 32.51 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.221 -0.925 . . . . 0.0 109.463 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.1 OUTLIER -42.84 123.48 2.74 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.311 -0.868 . . . . 0.0 109.649 -179.874 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.516 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 6.1 t70 75.9 57.06 0.05 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.276 -0.89 . . . . 0.0 109.491 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.496 ' N ' HD22 ' A' ' 48' ' ' LEU . 0.9 OUTLIER -131.76 121.3 23.95 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.203 -0.936 . . . . 0.0 109.402 -179.934 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.571 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 51.3 tp -42.94 162.25 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.329 -0.857 . . . . 0.0 109.499 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.489 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 91.6 mt -141.52 -49.49 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.933 . . . . 0.0 109.48 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.523 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.9 p -152.25 151.93 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.915 . . . . 0.0 109.417 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.457 ' N ' HG21 ' A' ' 36' ' ' VAL . 49.8 m-20 -117.6 151.38 37.3 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.257 -0.902 . . . . 0.0 109.554 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.446 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 3.6 mm -108.17 156.36 8.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.248 -0.907 . . . . 0.0 109.383 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -135.28 117.48 15.52 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.262 -0.899 . . . . 0.0 109.489 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.431 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -115.8 -167.48 1.27 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.229 -0.919 . . . . 0.0 109.495 -179.991 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.431 ' C ' ' O ' ' A' ' 40' ' ' THR . 53.8 t0 -42.7 -67.74 0.25 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.359 -0.838 . . . . 0.0 109.626 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 1.7 mtpp -139.16 34.25 2.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.205 -0.934 . . . . 0.0 109.468 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.4 t -135.73 107.35 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.952 . . . . 0.0 109.504 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.2 t -89.98 115.85 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' MET . . . . . 0.446 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 4.6 mtp -99.23 178.31 4.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.302 -0.874 . . . . 0.0 109.488 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.417 ' HA ' ' OD1' ' A' ' 37' ' ' ASP . 41.0 mt-10 -138.48 169.64 17.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.205 -0.935 . . . . 0.0 109.438 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.523 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 97.1 t -141.92 103.09 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.224 -0.923 . . . . 0.0 109.478 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.51 ' CD2' ' HA ' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -104.38 155.31 18.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.218 -0.927 . . . . 0.0 109.506 -179.982 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.461 ' N ' HD13 ' A' ' 35' ' ' ILE . . . -84.19 165.22 18.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.515 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.501 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 0.8 OUTLIER -103.44 13.15 34.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.501 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 164.7 164.2 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.455 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.503 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -58.18 170.95 0.61 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.26 -0.9 . . . . 0.0 109.336 179.979 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.503 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 150.07 -174.64 29.45 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 69.6 t -124.86 131.18 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -1.132 . . . . 0.0 109.418 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.484 ' CD1' ' N ' ' A' ' 55' ' ' ILE . 1.4 mm -71.24 -176.64 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.271 -0.893 . . . . 0.0 109.486 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.463 ' HB2' ' HG2' ' A' ' 74' ' ' LYS . . . -114.01 -59.57 2.0 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.235 -0.916 . . . . 0.0 109.409 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.519 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 17.5 pt-20 -178.88 157.47 0.89 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.26 -0.9 . . . . 0.0 109.548 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.55 HG22 ' CE2' ' A' ' 21' ' ' TRP . 1.7 mp -89.96 140.88 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 109.446 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.45 ' HB ' ' O ' ' A' ' 71' ' ' LEU . 11.1 t -100.67 -15.17 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.261 -0.899 . . . . 0.0 109.366 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.464 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -126.37 -172.58 2.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.31 -0.869 . . . . 0.0 109.403 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.464 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 17.3 m-80 -132.45 164.26 26.96 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.169 -0.957 . . . . 0.0 109.509 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.01 133.41 48.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.306 -0.871 . . . . 0.0 109.408 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.05 -6.78 82.67 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -79.72 170.76 16.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.219 -1.165 . . . . 0.0 109.428 179.902 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.516 ' N ' ' OD1' ' A' ' 64' ' ' ASP . 32.3 m -98.77 138.84 35.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.547 -0.721 . . . . 0.0 109.498 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 6.2 m -122.29 170.67 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.268 -0.895 . . . . 0.0 109.455 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.457 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.1 OUTLIER -132.94 177.6 7.53 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.474 -179.98 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.1 t -62.85 146.61 52.35 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.914 . . . . 0.0 109.468 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 57.85 28.59 60.71 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.457 ' HB2' ' O ' ' A' ' 67' ' ' LEU . 8.0 tp10 -84.06 115.28 22.28 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.174 -1.192 . . . . 0.0 109.419 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.453 HD11 ' OD2' ' A' ' 3' ' ' ASP . 16.0 tp -72.91 106.09 4.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.262 -0.898 . . . . 0.0 109.49 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 15.7 mt -89.36 -10.91 44.87 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.224 -0.922 . . . . 0.0 109.455 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.36 164.29 22.75 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.463 ' HG2' ' HB2' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -136.12 142.9 44.29 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -1.173 . . . . 0.0 109.451 179.985 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.444 ' HB3' HG13 ' A' ' 2' ' ' ILE . 2.7 tt -97.44 167.99 10.66 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.239 -0.913 . . . . 0.0 109.479 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.0 m -87.71 169.22 12.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.448 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 76.8 mt-10 -55.15 -54.49 42.63 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.282 -0.887 . . . . 0.0 109.487 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -148.43 -88.03 0.07 OUTLIER Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 CA-C-O 118.027 -1.429 . . . . 0.0 109.562 -179.938 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 30.3 mm -111.65 94.76 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.926 . . . . 0.0 109.486 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -66.35 127.99 34.39 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.1 mt -102.54 97.97 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.319 -0.863 . . . . 0.0 109.495 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.447 ' HG3' ' HA ' ' A' ' 71' ' ' LEU . 0.0 OUTLIER -118.76 146.9 44.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.211 -0.931 . . . . 0.0 109.461 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -61.26 157.51 43.58 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.197 -0.939 . . . . 0.0 109.494 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.422 ' O ' ' C ' ' A' ' 8' ' ' THR . 35.6 Cg_endo -78.07 122.85 5.92 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 C-N-CA 122.581 2.188 . . . . 0.0 110.379 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.456 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 17.5 m -44.17 108.02 0.1 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.244 -0.91 . . . . 0.0 109.454 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -71.03 147.95 94.1 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.245 -0.909 . . . . 0.0 109.501 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.449 ' HD2' HD11 ' A' ' 13' ' ' ILE . 35.5 Cg_endo -78.18 -159.44 0.1 Allowed 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.599 2.199 . . . . 0.0 110.324 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.433 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.4 OUTLIER -75.98 -52.65 9.8 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -0.899 . . . . 0.0 109.47 -179.956 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.8 t -42.82 -56.14 3.36 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.252 -0.905 . . . . 0.0 109.628 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.518 ' CG2' ' O ' ' A' ' 15' ' ' ASP . 2.5 mp -89.95 111.14 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.226 -0.921 . . . . 0.0 109.452 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.466 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -88.77 10.45 20.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.204 -0.935 . . . . 0.0 109.502 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.518 ' O ' ' CG2' ' A' ' 13' ' ' ILE . 0.8 OUTLIER 166.6 -172.39 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 -179.921 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.08 -167.87 16.81 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.454 HG22 ' O ' ' A' ' 64' ' ' ASP . 90.3 m -148.21 131.94 16.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.265 -1.138 . . . . 0.0 109.463 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 27.1 t -52.56 163.93 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.218 -0.926 . . . . 0.0 109.435 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.515 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -108.96 -76.41 0.61 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.175 -0.953 . . . . 0.0 109.442 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.4 m -160.03 131.9 6.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.248 -0.908 . . . . 0.0 109.46 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.636 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 31.9 m95 -89.87 85.43 6.38 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.26 -0.9 . . . . 0.0 109.56 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.571 ' CD2' HD22 ' A' ' 34' ' ' LEU . 2.0 m80 -42.77 -58.25 2.43 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.355 -0.841 . . . . 0.0 109.38 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -101.43 -175.04 2.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.57 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.41 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -125.65 167.82 15.57 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.344 -0.847 . . . . 0.0 109.446 179.985 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.463 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.91 118.04 4.66 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.588 2.192 . . . . 0.0 110.418 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 124.56 7.52 6.21 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -113.26 -172.25 2.03 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.223 -1.163 . . . . 0.0 109.55 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -105.02 158.02 16.83 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.169 -0.957 . . . . 0.0 109.448 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -142.49 -174.35 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 0.0 109.436 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 3.7 mttp -147.67 137.54 22.77 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.491 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.434 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.1 OUTLIER -42.78 137.21 2.35 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.344 -0.847 . . . . 0.0 109.63 -179.914 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.42 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 8.2 t0 70.06 51.23 0.41 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.314 -0.866 . . . . 0.0 109.521 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.453 ' O ' HG13 ' A' ' 35' ' ' ILE . 1.8 tm-20 -140.8 120.65 13.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.185 -0.947 . . . . 0.0 109.493 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.571 HD22 ' CD2' ' A' ' 22' ' ' HIS . 35.3 tp -42.93 142.82 0.83 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.301 -0.874 . . . . 0.0 109.57 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.453 HG13 ' O ' ' A' ' 33' ' ' GLU . 12.8 mt -134.97 -43.07 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.232 -0.917 . . . . 0.0 109.598 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.462 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.4 p -158.66 142.52 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.223 -0.923 . . . . 0.0 109.508 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.515 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 55.9 m-20 -105.46 152.44 23.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.214 -0.929 . . . . 0.0 109.404 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 10.9 mt -128.81 153.84 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.211 -0.93 . . . . 0.0 109.537 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -121.74 150.94 41.1 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.233 -0.917 . . . . 0.0 109.443 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.439 ' OG1' ' O ' ' A' ' 43' ' ' VAL . 28.1 p -133.62 -168.37 2.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.241 -0.912 . . . . 0.0 109.491 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.411 ' C ' ' O ' ' A' ' 40' ' ' THR . 27.2 t70 -42.68 -69.25 0.14 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.348 -0.845 . . . . 0.0 109.686 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.9 mtmt -136.64 27.15 3.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.227 -0.92 . . . . 0.0 109.425 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.439 ' O ' ' OG1' ' A' ' 40' ' ' THR . 1.9 t -135.86 162.1 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.259 -0.901 . . . . 0.0 109.507 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.3 p -122.53 138.81 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.352 -0.843 . . . . 0.0 109.479 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' MET . . . . . 0.427 ' SD ' HG22 ' A' ' 40' ' ' THR . 1.9 mpp? -127.05 101.94 6.76 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.254 -0.904 . . . . 0.0 109.453 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.456 ' HG2' ' OD1' ' A' ' 37' ' ' ASP . 15.0 mt-10 -73.9 163.81 27.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.277 -0.889 . . . . 0.0 109.475 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.462 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 71.6 t -131.04 107.69 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.281 -0.887 . . . . 0.0 109.44 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.482 ' CD1' ' HA ' ' A' ' 34' ' ' LEU . 1.3 mp -91.91 170.2 10.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.906 . . . . 0.0 109.536 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -71.91 124.7 25.43 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.257 -0.902 . . . . 0.0 109.458 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.526 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -82.68 6.85 16.57 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.9 . . . . 0.0 109.5 -179.947 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.526 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 163.94 141.46 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.516 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -49.01 170.97 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 109.338 -179.974 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 135.8 -155.84 22.51 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' A' ' 55' ' ' ILE . 48.5 t -138.71 125.04 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.318 -1.107 . . . . 0.0 109.477 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.46 ' O ' ' O ' ' A' ' 54' ' ' VAL . 4.6 mm -46.45 172.25 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.255 -0.903 . . . . 0.0 109.464 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 74' ' ' LYS . . . -110.91 -65.09 1.2 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.266 -0.896 . . . . 0.0 109.478 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.463 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -170.27 138.78 1.65 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.469 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.636 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 21.5 mm -101.38 128.53 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.245 -0.91 . . . . 0.0 109.49 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.2 t -98.06 -30.97 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.262 -0.898 . . . . 0.0 109.481 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.464 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -91.23 117.65 29.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.32 -0.862 . . . . 0.0 109.454 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 57.6 m-80 -84.06 157.23 21.85 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.311 -0.868 . . . . 0.0 109.451 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -57.19 142.44 42.78 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.26 -0.9 . . . . 0.0 109.463 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.76 11.29 68.42 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -104.69 170.92 7.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -1.125 . . . . 0.0 109.292 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 52.0 m -107.52 146.95 31.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.45 -0.781 . . . . 0.0 109.465 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.46 ' N ' HG21 ' A' ' 65' ' ' THR . 7.1 m -124.59 139.82 49.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.237 -0.914 . . . . 0.0 109.49 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -101.06 -175.55 2.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.316 -0.865 . . . . 0.0 109.436 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.456 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 1.5 t -64.47 122.22 16.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.266 -0.897 . . . . 0.0 109.496 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.51 31.28 41.69 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -83.84 104.56 14.03 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.187 -1.184 . . . . 0.0 109.484 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.447 ' HA ' ' HG3' ' A' ' 5' ' ' LYS . 1.0 OUTLIER -66.4 120.28 13.06 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -0.912 . . . . 0.0 109.487 179.966 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.447 HD22 HG12 ' A' ' 66' ' ' VAL . 1.0 OUTLIER -95.81 -18.92 20.02 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.283 -0.886 . . . . 0.0 109.495 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.77 -179.64 41.0 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' A' ' 56' ' ' ALA . 2.1 mtmt -140.58 152.44 45.48 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.295 -1.12 . . . . 0.0 109.484 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -92.61 151.34 20.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.425 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 8.6 m -98.77 172.21 7.6 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.899 . . . . 0.0 109.434 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -74.49 -169.42 0.83 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.236 -0.915 . . . . 0.0 109.511 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 144.29 89.75 0.11 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.242 0 CA-C-O 118.025 -1.431 . . . . 0.0 109.55 -179.983 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.8 pt -131.99 176.59 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.235 -0.916 . . . . 0.0 109.482 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.453 ' OD2' ' HB3' ' A' ' 5' ' ' LYS . 29.5 t70 -117.47 135.92 53.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.23 -0.919 . . . . 0.0 109.432 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 91.3 mt -99.47 73.08 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.216 -0.928 . . . . 0.0 109.517 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.453 ' HB3' ' OD2' ' A' ' 3' ' ' ASP . 0.9 OUTLIER -104.77 159.31 15.88 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.228 -0.92 . . . . 0.0 109.445 179.963 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.46 147.69 75.86 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.21 -0.931 . . . . 0.0 109.436 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.21 160.82 29.47 Favored 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.608 2.206 . . . . 0.0 110.379 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 9' ' ' PHE . 27.2 m -71.6 89.38 0.98 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.327 -0.858 . . . . 0.0 109.48 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.463 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 31.4 m-85 -44.07 147.98 0.86 Allowed Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.298 -0.876 . . . . 0.0 109.444 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.4 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.8 Cg_endo -78.06 -159.96 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.691 2.261 . . . . 0.0 110.415 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 12' ' ' SER . 46.7 tt0 -77.38 -58.41 3.29 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.215 -0.928 . . . . 0.0 109.401 -179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.8 t -42.8 -55.71 3.53 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.273 -0.892 . . . . 0.0 109.693 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.4 ' HB ' ' HD2' ' A' ' 10' ' ' PRO . 3.5 mt -91.45 134.08 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.251 -0.905 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.18 11.3 16.25 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.242 -0.911 . . . . 0.0 109.486 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.463 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 0.5 OUTLIER 171.31 -171.15 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.182 -0.949 . . . . 0.0 109.477 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.76 -167.3 17.77 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.46 HG21 ' O ' ' A' ' 64' ' ' ASP . 94.6 m -150.0 125.83 10.46 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -1.156 . . . . 0.0 109.483 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.41 ' C ' ' O ' ' A' ' 17' ' ' THR . 47.0 t -45.26 160.07 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 109.454 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.464 ' HB2' ' O ' ' A' ' 37' ' ' ASP . . . -106.16 -73.06 0.69 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.186 -0.946 . . . . 0.0 109.51 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.1 m -160.08 131.89 6.12 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.237 -0.914 . . . . 0.0 109.521 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.635 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.4 m95 -89.87 85.57 6.42 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 121.279 -0.888 . . . . 0.0 109.545 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.571 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 2.0 m80 -43.26 -62.21 1.12 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.32 -0.863 . . . . 0.0 109.392 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -100.58 176.66 5.25 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.929 . . . . 0.0 109.506 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.16 167.46 11.33 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.427 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.495 ' HA ' ' CG2' ' A' ' 55' ' ' ILE . 35.2 Cg_endo -76.92 108.94 2.75 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.689 2.259 . . . . 0.0 110.422 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 139.01 -10.22 3.33 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -97.48 -172.22 2.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.29 -1.123 . . . . 0.0 109.541 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -106.76 154.66 20.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.299 -0.875 . . . . 0.0 109.498 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.4 p -139.58 148.94 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.499 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -114.58 137.69 51.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.151 -0.968 . . . . 0.0 109.504 -179.972 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.461 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 29.5 ttt85 -42.73 150.03 0.17 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.331 -0.855 . . . . 0.0 109.663 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.461 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 8.5 t70 72.3 41.14 0.63 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.48 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.439 ' O ' ' O ' ' A' ' 34' ' ' LEU . 2.4 tp10 -141.94 124.23 15.61 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.147 -0.97 . . . . 0.0 109.448 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.571 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 45.7 tp -43.16 164.69 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.346 -0.846 . . . . 0.0 109.482 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.508 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 27.4 mm -139.52 -46.07 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.109 -0.994 . . . . 0.0 109.579 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.454 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.6 p -166.3 137.25 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.262 -0.899 . . . . 0.0 109.473 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.464 ' O ' ' HB2' ' A' ' 19' ' ' ALA . 16.9 m-20 -97.96 152.67 19.01 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.253 -0.904 . . . . 0.0 109.44 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 6.0 mm -119.52 156.15 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.461 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.453 ' HB2' ' O ' ' A' ' 17' ' ' THR . 1.1 mm-40 -118.23 128.91 55.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.425 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.1 OUTLIER -109.87 -161.23 0.75 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.266 -0.896 . . . . 0.0 109.429 179.992 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.425 ' C ' ' O ' ' A' ' 40' ' ' THR . 13.6 t0 -42.8 -71.01 0.09 Allowed 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.342 -0.849 . . . . 0.0 109.681 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.5 mmtm -137.29 28.24 2.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.274 -0.891 . . . . 0.0 109.475 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 24.6 t -128.43 169.32 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.24 -0.913 . . . . 0.0 109.51 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.461 ' O ' HG12 ' A' ' 44' ' ' VAL . 7.5 p -129.66 122.43 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.302 -0.874 . . . . 0.0 109.457 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 87.2 mmm -103.89 176.51 5.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 0.0 109.476 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -136.21 153.15 51.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.215 -0.928 . . . . 0.0 109.543 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.454 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 45.8 t -125.09 102.58 10.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.336 -0.853 . . . . 0.0 109.454 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.41 150.21 20.85 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.214 -0.929 . . . . 0.0 109.44 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.8 137.71 37.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.469 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -101.33 19.96 16.75 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.332 -0.855 . . . . 0.0 109.496 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -176.57 134.61 0.23 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.244 -0.91 . . . . 0.0 109.5 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.5 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -62.75 170.94 2.31 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.263 -0.898 . . . . 0.0 109.377 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.5 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 146.71 -151.74 23.97 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.435 ' O ' ' OG1' ' A' ' 76' ' ' THR . 71.4 t -134.28 130.63 54.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -1.149 . . . . 0.0 109.425 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.495 ' CG2' ' HA ' ' A' ' 25' ' ' PRO . 5.1 mt -52.15 160.5 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.338 -0.851 . . . . 0.0 109.524 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.447 ' N ' ' CG2' ' A' ' 55' ' ' ILE . . . -97.69 -68.79 0.78 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.142 -0.974 . . . . 0.0 109.444 -179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.439 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 1.5 mt-10 -176.02 133.08 0.25 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.293 -0.879 . . . . 0.0 109.495 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.635 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 20.1 mm -95.33 125.22 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.309 -0.869 . . . . 0.0 109.47 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 44.3 t -89.91 -29.75 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.912 . . . . 0.0 109.425 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.521 ' CG ' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -90.0 162.72 15.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -0.912 . . . . 0.0 109.424 -179.986 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.464 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 13.7 m-80 -117.08 157.57 25.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.212 -0.93 . . . . 0.0 109.5 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -61.14 134.61 57.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.21 -0.931 . . . . 0.0 109.443 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 94.15 -7.05 72.65 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.521 ' OD2' ' CG ' ' A' ' 60' ' ' LYS . 0.2 OUTLIER -86.06 170.71 11.99 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -1.145 . . . . 0.0 109.301 -179.996 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.502 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 9.6 t -99.58 163.09 12.65 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.536 -0.728 . . . . 0.0 109.521 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 5.7 m -127.02 144.32 37.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.199 -0.938 . . . . 0.0 109.468 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -107.1 167.81 9.65 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.216 -0.928 . . . . 0.0 109.54 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.6 t -67.44 101.83 1.03 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.311 -0.868 . . . . 0.0 109.458 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 107.47 13.2 21.36 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.401 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 46.9 tp10 -81.13 123.84 28.75 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.261 -1.14 . . . . 0.0 109.522 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 5.8 tt -81.88 114.22 20.34 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.184 -0.947 . . . . 0.0 109.517 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.442 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 22.3 mt -89.32 -20.02 24.56 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.17 -0.956 . . . . 0.0 109.495 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 161.29 179.96 36.34 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.442 ' HG2' ' HB2' ' A' ' 56' ' ' ALA . 0.6 OUTLIER -149.74 153.04 36.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -1.175 . . . . 0.0 109.458 -179.968 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.461 ' HG ' ' N ' ' A' ' 76' ' ' THR . 17.0 tp -90.26 153.17 20.67 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.315 -0.866 . . . . 0.0 109.47 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.461 ' N ' ' HG ' ' A' ' 75' ' ' LEU . 5.6 m -91.52 170.66 9.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.311 -0.868 . . . . 0.0 109.46 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -69.27 178.82 2.2 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.294 -0.879 . . . . 0.0 109.453 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.36 -44.99 0.85 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.3 0 CA-C-O 117.979 -1.456 . . . . 0.0 109.544 -179.973 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.3 mp -125.68 91.96 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.157 -0.965 . . . . 0.0 109.45 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -60.81 130.77 48.15 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.272 -0.893 . . . . 0.0 109.502 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.424 HD11 ' C ' ' A' ' 73' ' ' GLY . 2.7 mp -100.29 110.61 27.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.195 -0.941 . . . . 0.0 109.472 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.7 pttp -120.17 166.82 12.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.198 -0.939 . . . . 0.0 109.478 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.99 164.46 41.59 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.265 -0.897 . . . . 0.0 109.487 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.02 153.54 28.84 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.625 2.217 . . . . 0.0 110.455 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.459 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 41.2 m -75.75 110.49 10.22 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.933 . . . . 0.0 109.455 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -69.92 153.31 95.56 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.205 -0.934 . . . . 0.0 109.482 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.11 176.74 9.61 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 C-N-CA 122.656 2.237 . . . . 0.0 110.453 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.513 ' HG3' ' N ' ' A' ' 12' ' ' SER . 22.5 pt-20 -65.24 -45.44 84.59 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.287 -0.883 . . . . 0.0 109.469 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.513 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 1.5 t -42.61 -40.12 2.59 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.379 -0.826 . . . . 0.0 109.699 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.459 HG23 ' O ' ' A' ' 15' ' ' ASP . 30.0 mm -108.11 154.05 9.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.259 -0.901 . . . . 0.0 109.453 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -118.18 0.16 11.7 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.235 -0.916 . . . . 0.0 109.611 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.459 ' O ' HG23 ' A' ' 13' ' ' ILE . 0.7 OUTLIER 179.23 -174.45 0.21 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.189 -0.945 . . . . 0.0 109.506 -179.995 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -150.92 -160.56 9.47 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.416 ' O ' ' C ' ' A' ' 18' ' ' VAL . 16.8 m -150.02 129.04 12.62 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.236 -1.155 . . . . 0.0 109.418 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.419 HG13 ' N ' ' A' ' 19' ' ' ALA . 60.8 t -44.45 161.26 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.398 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.504 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -106.65 -75.13 0.64 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.247 -0.908 . . . . 0.0 109.515 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.6 m -160.13 131.42 5.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.234 -0.917 . . . . 0.0 109.558 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.637 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.82 85.88 6.51 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.337 -0.852 . . . . 0.0 109.53 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.625 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.7 m80 -42.12 -69.02 0.15 Allowed 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.355 -0.841 . . . . 0.0 109.483 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -96.93 -177.24 3.81 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.215 -0.928 . . . . 0.0 109.628 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.422 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 4.5 mttp -122.76 169.4 9.9 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.292 -0.88 . . . . 0.0 109.453 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.459 ' HG3' HG12 ' A' ' 58' ' ' ILE . 35.1 Cg_endo -76.23 136.43 17.97 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.626 2.217 . . . . 0.0 110.416 179.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.73 14.07 35.69 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -112.5 -172.3 2.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -1.119 . . . . 0.0 109.508 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.75 138.93 31.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.346 -0.846 . . . . 0.0 109.456 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.484 HG11 ' N ' ' A' ' 30' ' ' LYS . 55.9 t -118.5 141.76 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.406 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.484 ' N ' HG11 ' A' ' 29' ' ' VAL . 8.8 ttpt -131.86 127.03 35.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.296 -0.878 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.528 ' CG ' ' HA ' ' A' ' 51' ' ' ALA . 0.2 OUTLIER -42.75 147.24 0.31 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.374 -0.829 . . . . 0.0 109.63 -179.889 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.484 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 11.8 t0 73.4 26.41 2.02 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -0.888 . . . . 0.0 109.463 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.427 ' O ' ' O ' ' A' ' 34' ' ' LEU . 12.5 tm-20 -126.8 110.24 12.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.363 -0.836 . . . . 0.0 109.474 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.625 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 47.4 tp -42.98 164.23 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.321 -0.862 . . . . 0.0 109.597 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.513 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 27.4 mt -138.18 -47.72 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.27 -0.894 . . . . 0.0 109.606 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.553 HG22 ' CE2' ' A' ' 21' ' ' TRP . 12.6 p -150.61 152.78 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.236 -0.915 . . . . 0.0 109.51 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.504 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 23.3 m-20 -113.99 150.63 33.56 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.27 -0.894 . . . . 0.0 109.461 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 3.3 mt -115.27 145.09 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.263 -0.898 . . . . 0.0 109.489 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -118.59 143.91 46.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.209 -0.932 . . . . 0.0 109.423 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.456 ' HB ' ' O ' ' A' ' 43' ' ' VAL . 55.7 m -134.96 165.35 25.54 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.199 -0.938 . . . . 0.0 109.422 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.425 ' HB3' HD13 ' A' ' 13' ' ' ILE . 45.0 t0 -42.79 -36.14 1.37 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.869 . . . . 0.0 109.639 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.456 ' O ' HG21 ' A' ' 43' ' ' VAL . 20.3 mttp -158.48 28.91 0.24 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.277 -0.89 . . . . 0.0 109.503 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.456 ' O ' ' HB ' ' A' ' 40' ' ' THR . 7.6 t -142.05 117.79 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.501 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -107.04 124.86 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.251 -0.906 . . . . 0.0 109.461 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 4.0 mtp -117.2 -174.59 2.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.236 -0.915 . . . . 0.0 109.478 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.464 ' HB2' HD12 ' A' ' 34' ' ' LEU . 0.8 OUTLIER -140.89 168.86 18.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.232 -0.918 . . . . 0.0 109.502 -179.949 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.527 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 53.0 t -142.03 102.98 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.242 -0.912 . . . . 0.0 109.521 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.565 ' CD2' ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.46 166.49 10.51 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.192 -0.943 . . . . 0.0 109.418 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.509 ' CB ' HD13 ' A' ' 35' ' ' ILE . . . -83.52 157.57 22.32 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.918 . . . . 0.0 109.48 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -104.07 7.17 36.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.571 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.528 ' HA ' ' CG ' ' A' ' 31' ' ' ARG . . . 173.18 161.76 0.13 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.959 . . . . 0.0 109.51 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.514 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -59.99 171.0 1.04 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.218 -0.926 . . . . 0.0 109.322 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.514 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.19 -163.9 28.93 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' A' ' 55' ' ' ILE . 40.5 t -133.8 119.6 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.257 -1.143 . . . . 0.0 109.527 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.466 ' O ' ' O ' ' A' ' 54' ' ' VAL . 2.3 mp -47.02 174.45 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.384 -0.823 . . . . 0.0 109.755 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.523 ' CB ' ' O ' ' A' ' 74' ' ' LYS . . . -111.99 -60.86 1.8 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.159 -0.963 . . . . 0.0 109.458 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 177.45 138.0 0.07 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.499 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.637 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.1 mm -95.14 128.48 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.337 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 83.7 t -90.04 -33.52 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.196 -0.94 . . . . 0.0 109.518 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.499 ' HE2' ' CG ' ' A' ' 70' ' ' GLU . 1.0 OUTLIER -97.83 145.96 25.89 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.2 -0.937 . . . . 0.0 109.497 -179.928 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 -109.72 169.44 8.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.293 -0.879 . . . . 0.0 109.435 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -64.26 150.62 45.59 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.193 -0.942 . . . . 0.0 109.56 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.68 5.59 86.43 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.507 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -105.17 170.85 7.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.115 -1.226 . . . . 0.0 109.26 -179.991 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.507 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 9.8 t -99.35 153.77 18.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.607 -0.683 . . . . 0.0 109.467 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 28.5 m -124.75 136.82 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.233 -0.917 . . . . 0.0 109.472 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.441 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.1 OUTLIER -92.84 163.2 13.8 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.263 -0.898 . . . . 0.0 109.412 179.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.459 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 33.1 t -55.7 123.02 12.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 109.469 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 67.46 35.83 87.64 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.499 ' CG ' ' HE2' ' A' ' 60' ' ' LYS . 8.4 tp10 -79.91 136.91 36.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.259 -1.142 . . . . 0.0 109.442 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.424 HD22 ' N ' ' A' ' 73' ' ' GLY . 9.0 tt -77.88 117.72 19.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.279 -0.888 . . . . 0.0 109.432 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.459 HD22 ' NZ ' ' A' ' 60' ' ' LYS . 0.4 OUTLIER -99.41 -14.89 18.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.871 . . . . 0.0 109.397 179.972 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.424 ' C ' HD11 ' A' ' 4' ' ' ILE . . . 160.14 -169.49 36.03 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.523 ' O ' ' CB ' ' A' ' 56' ' ' ALA . 4.7 ptmt -150.1 152.82 35.38 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -1.154 . . . . 0.0 109.466 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.403 HD21 ' O ' ' A' ' 76' ' ' THR . 0.5 OUTLIER -104.15 156.51 17.82 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.466 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.403 ' O ' HD21 ' A' ' 75' ' ' LEU . 5.9 m -93.75 169.52 10.25 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.321 -0.862 . . . . 0.0 109.49 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -54.69 134.49 47.31 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.244 -0.91 . . . . 0.0 109.457 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -83.07 131.91 10.71 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.453 ' O ' ' OD1' ' A' ' 52' ' ' ASP . . . . . . . . 0 N--CA 1.491 2.305 0 CA-C-O 118.0 -1.444 . . . . 0.0 109.561 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 4.7 mm -128.99 170.13 19.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.149 -0.969 . . . . 0.0 109.462 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.401 ' OD2' ' HD2' ' A' ' 5' ' ' LYS . 27.2 t0 -114.87 137.9 51.42 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.249 -0.907 . . . . 0.0 109.536 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.9 mt -105.78 72.67 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.434 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.401 ' HD2' ' OD2' ' A' ' 3' ' ' ASP . 1.3 ptmt -102.85 149.8 24.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.27 -0.894 . . . . 0.0 109.421 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -61.63 158.55 39.86 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.292 -0.88 . . . . 0.0 109.534 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.0 -178.96 5.0 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.676 2.251 . . . . 0.0 110.405 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 60.6 m -92.74 129.3 38.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.453 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -81.1 148.96 65.34 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.192 -0.943 . . . . 0.0 109.453 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.02 -165.99 0.37 Allowed 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.659 2.239 . . . . 0.0 110.393 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.418 ' CG ' ' N ' ' A' ' 12' ' ' SER . 12.7 pt-20 -73.69 -41.67 62.31 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.267 -0.896 . . . . 0.0 109.525 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.418 ' N ' ' CG ' ' A' ' 11' ' ' GLU . 38.4 t -42.89 -72.95 0.05 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.367 -0.833 . . . . 0.0 109.634 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.42 HG22 ' HB2' ' A' ' 41' ' ' ASP . 1.8 mp -90.71 150.57 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.522 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -121.29 31.48 6.32 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.212 -0.93 . . . . 0.0 109.514 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -177.33 -171.84 0.35 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.925 . . . . 0.0 109.439 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.63 175.59 32.69 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.518 ' O ' ' CG ' ' A' ' 39' ' ' GLU . 98.1 m -150.07 114.97 5.33 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.144 -1.21 . . . . 0.0 109.527 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.516 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 40.2 t -46.0 168.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.313 -0.867 . . . . 0.0 109.477 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.52 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -113.22 -71.08 0.77 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.254 -0.904 . . . . 0.0 109.58 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.482 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 20.7 m -160.03 134.75 7.73 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.197 -0.939 . . . . 0.0 109.572 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.626 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.5 m95 -89.89 84.01 6.2 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.26 -0.9 . . . . 0.0 109.505 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.629 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -42.72 -70.12 0.12 Allowed 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.39 -0.819 . . . . 0.0 109.469 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 7.6 mmtt -89.5 -172.2 3.5 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.61 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.46 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 8.2 mttp -136.66 165.24 36.75 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.27 -0.894 . . . . 0.0 109.247 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.525 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -77.21 114.44 3.77 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.553 2.169 . . . . 0.0 110.383 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 135.23 -9.9 4.42 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -100.21 -172.36 2.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.235 -1.156 . . . . 0.0 109.487 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.453 ' O ' HG21 ' A' ' 29' ' ' VAL . . . -86.83 170.47 11.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.293 -0.879 . . . . 0.0 109.484 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.453 HG21 ' O ' ' A' ' 28' ' ' ALA . 52.2 t -142.08 148.27 20.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.212 -0.93 . . . . 0.0 109.482 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.2 OUTLIER -135.38 136.01 41.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.259 -0.901 . . . . 0.0 109.479 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.458 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 15.7 ttp180 -42.87 145.38 0.47 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.29 -0.881 . . . . 0.0 109.733 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.458 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 54.9 t0 67.45 48.11 1.17 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.285 -0.884 . . . . 0.0 109.477 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' A' ' 34' ' ' LEU . 1.2 tp10 -137.57 105.95 5.79 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.216 -0.927 . . . . 0.0 109.508 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.629 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 42.7 tp -43.13 164.89 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.302 -0.874 . . . . 0.0 109.537 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.5 HD13 ' CB ' ' A' ' 49' ' ' ALA . 49.3 mt -142.56 -47.64 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.245 -0.909 . . . . 0.0 109.615 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.522 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.9 p -151.47 134.98 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.168 -0.957 . . . . 0.0 109.552 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.52 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 6.4 m-20 -95.59 163.86 13.03 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.31 -0.868 . . . . 0.0 109.427 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.424 HD12 ' CG2' ' A' ' 47' ' ' VAL . 21.6 mt -134.0 152.8 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.185 -0.947 . . . . 0.0 109.399 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 17' ' ' THR . 10.9 pt-20 -146.43 144.56 29.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.204 -0.935 . . . . 0.0 109.557 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.418 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -140.28 -172.04 3.33 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.281 -0.887 . . . . 0.0 109.481 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.42 ' HB2' HG22 ' A' ' 13' ' ' ILE . 3.0 t70 -42.89 -64.15 0.67 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.354 -0.841 . . . . 0.0 109.66 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.65 44.13 1.96 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.428 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 2.8 t -148.22 104.28 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.26 -0.9 . . . . 0.0 109.497 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.434 ' O ' ' HG2' ' A' ' 45' ' ' MET . 62.1 t -98.04 143.43 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.242 -0.911 . . . . 0.0 109.535 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' MET . . . . . 0.434 ' HG2' ' O ' ' A' ' 44' ' ' VAL . 2.7 mmt -143.52 -178.89 6.11 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.227 -0.921 . . . . 0.0 109.489 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -141.33 165.68 26.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.176 -0.953 . . . . 0.0 109.512 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.522 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 18.1 t -137.35 98.36 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.232 -0.918 . . . . 0.0 109.467 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.561 ' CD2' ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -103.18 160.58 14.53 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 121.227 -0.92 . . . . 0.0 109.371 179.943 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.5 ' CB ' HD13 ' A' ' 35' ' ' ILE . . . -77.9 132.63 38.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.459 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -86.28 12.4 10.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.221 -0.924 . . . . 0.0 109.489 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . 178.86 155.12 0.43 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.295 -0.878 . . . . 0.0 109.446 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.499 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -65.97 170.94 4.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.178 -0.952 . . . . 0.0 109.392 179.94 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.499 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 149.9 -153.99 25.43 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.6 t -135.19 126.27 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -1.129 . . . . 0.0 109.45 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.519 ' CG2' ' N ' ' A' ' 56' ' ' ALA . 5.1 mt -56.21 164.39 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.193 -0.942 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.519 ' N ' ' CG2' ' A' ' 55' ' ' ILE . . . -105.08 -63.69 1.2 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.531 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.525 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 1.1 pt-20 -179.24 144.09 0.22 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.248 -0.907 . . . . 0.0 109.465 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.626 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 24.5 mm -105.3 123.91 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.279 -0.888 . . . . 0.0 109.503 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.0 t -89.91 -19.88 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.251 -0.905 . . . . 0.0 109.546 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.464 ' HG3' ' OD1' ' A' ' 64' ' ' ASP . 3.9 tptt -115.97 129.9 56.59 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.239 -0.913 . . . . 0.0 109.51 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.445 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 14.9 m-80 -87.62 157.03 19.22 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 0.0 109.454 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.516 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -60.66 151.81 28.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.31 -10.49 68.86 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.514 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -88.63 171.02 10.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -1.164 . . . . 0.0 109.321 -179.97 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.514 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 97.9 m -91.51 147.18 23.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.518 -0.739 . . . . 0.0 109.482 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.405 ' N ' HG21 ' A' ' 65' ' ' THR . 17.1 m -120.04 178.73 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.281 -0.887 . . . . 0.0 109.405 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -130.33 162.69 28.48 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.915 . . . . 0.0 109.466 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -65.16 97.22 0.24 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.225 -0.922 . . . . 0.0 109.441 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.77 27.74 7.78 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.504 -1.439 . . . . 0.0 109.504 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -84.08 132.06 34.74 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.201 -1.176 . . . . 0.0 109.49 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 8.4 tt -78.9 114.98 18.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -0.924 . . . . 0.0 109.464 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 5.1 mt -91.24 -22.15 20.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.322 -0.861 . . . . 0.0 109.466 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 170.85 177.03 40.52 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.409 ' O ' ' CB ' ' A' ' 56' ' ' ALA . 12.5 mttt -124.94 138.36 54.24 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.3 -1.117 . . . . 0.0 109.492 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -94.71 144.16 25.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.499 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 10.8 m -107.59 171.75 7.21 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.207 -0.933 . . . . 0.0 109.464 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -84.72 -168.67 2.29 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.223 -0.923 . . . . 0.0 109.4 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.42 ' HA3' ' HA2' ' A' ' 53' ' ' GLY . . . -160.58 75.29 0.19 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 CA-C-O 118.0 -1.444 . . . . 0.0 109.513 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.3 mt -122.69 101.9 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 109.493 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.402 ' OD2' ' HE3' ' A' ' 74' ' ' LYS . 46.2 t0 -72.71 127.7 33.34 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.296 -0.877 . . . . 0.0 109.513 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 60.7 mt -95.63 80.28 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.33 -0.857 . . . . 0.0 109.504 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.42 ' O ' ' HG3' ' A' ' 5' ' ' LYS . 0.2 OUTLIER -100.14 145.94 27.4 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.537 179.971 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -52.15 162.9 0.77 Allowed Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.227 -0.921 . . . . 0.0 109.451 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -77.95 162.81 28.99 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.642 2.228 . . . . 0.0 110.484 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.444 HG21 ' O ' ' A' ' 8' ' ' THR . 2.5 t -82.95 105.74 14.2 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.186 -0.947 . . . . 0.0 109.436 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -72.4 150.72 91.76 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.187 -0.946 . . . . 0.0 109.492 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.07 176.34 10.09 Favored 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.6 2.2 . . . . 0.0 110.42 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.436 ' O ' ' C ' ' A' ' 12' ' ' SER . 2.1 mt-10 -56.64 -50.98 70.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.309 -0.869 . . . . 0.0 109.441 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 11' ' ' GLU . 7.3 t -42.93 -46.65 5.46 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.37 -0.831 . . . . 0.0 109.58 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.409 HG12 ' HB2' ' A' ' 41' ' ' ASP . 64.5 mt -92.76 150.34 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.212 -0.93 . . . . 0.0 109.477 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -127.0 17.07 7.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.942 . . . . 0.0 109.471 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 178.75 -169.08 0.09 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.196 -0.94 . . . . 0.0 109.499 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.91 -176.17 21.23 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 69.4 m -149.91 115.27 5.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.254 -1.145 . . . . 0.0 109.495 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.524 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 27.5 t -49.41 169.28 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.264 -0.898 . . . . 0.0 109.391 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.521 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -114.69 -73.97 0.63 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.191 -0.943 . . . . 0.0 109.53 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.0 m -160.07 133.72 7.09 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.198 -0.939 . . . . 0.0 109.523 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.631 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.5 m95 -89.87 92.9 9.21 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 121.155 -0.965 . . . . 0.0 109.556 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.574 ' CD2' HD22 ' A' ' 34' ' ' LEU . 1.6 m80 -54.98 -72.24 0.07 Allowed 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.324 -0.86 . . . . 0.0 109.421 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -84.18 -172.77 4.35 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.238 -0.914 . . . . 0.0 109.609 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -136.35 166.97 23.78 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.388 -0.82 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.488 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.6 Cg_endo -77.03 138.82 18.67 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.683 2.256 . . . . 0.0 110.493 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 106.79 -9.82 40.75 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -102.2 -174.37 2.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.315 -1.109 . . . . 0.0 109.417 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.82 147.77 27.36 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.302 -0.873 . . . . 0.0 109.466 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m -129.95 -169.53 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.212 -0.93 . . . . 0.0 109.467 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.448 ' O ' ' CB ' ' A' ' 33' ' ' GLU . 9.9 tptm -157.06 139.61 14.92 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.224 -0.923 . . . . 0.0 109.479 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.426 ' C ' ' O ' ' A' ' 30' ' ' LYS . 2.3 ttp180 -42.78 154.83 0.06 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.289 -0.882 . . . . 0.0 109.622 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.0 t70 60.24 33.44 20.97 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.244 -0.91 . . . . 0.0 109.47 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.448 ' CB ' ' O ' ' A' ' 30' ' ' LYS . 28.9 tt0 -126.45 113.92 17.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.223 -0.923 . . . . 0.0 109.508 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.574 HD22 ' CD2' ' A' ' 22' ' ' HIS . 56.8 tp -42.86 160.23 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.357 -0.839 . . . . 0.0 109.623 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.481 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 4.3 mt -142.77 -43.95 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.229 -0.919 . . . . 0.0 109.56 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.518 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 13.6 p -160.87 138.65 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.282 -0.886 . . . . 0.0 109.439 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.521 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 28.3 m-20 -97.76 149.5 22.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.139 -0.976 . . . . 0.0 109.39 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.518 HD13 ' CG2' ' A' ' 47' ' ' VAL . 31.5 mt -122.46 156.3 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.196 -0.94 . . . . 0.0 109.42 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.401 ' OE2' ' O ' ' A' ' 40' ' ' THR . 2.4 tm-20 -135.62 153.17 51.74 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.433 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.414 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -140.23 -178.98 5.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.195 -0.94 . . . . 0.0 109.509 -179.993 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.414 ' C ' ' O ' ' A' ' 40' ' ' THR . 6.7 t0 -42.78 -70.02 0.12 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.344 -0.848 . . . . 0.0 109.593 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.449 ' O ' HG21 ' A' ' 43' ' ' VAL . 7.2 mttt -129.38 35.05 4.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.255 -0.903 . . . . 0.0 109.392 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.449 HG21 ' O ' ' A' ' 42' ' ' LYS . 9.7 t -144.09 152.71 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 109.447 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.4 t -130.5 153.88 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.184 -0.948 . . . . 0.0 109.487 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' MET . . . . . 0.418 ' C ' ' HG3' ' A' ' 46' ' ' GLU . 4.4 mmt -143.25 167.38 22.28 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.188 -0.945 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.418 ' HG3' ' C ' ' A' ' 45' ' ' MET . 0.7 OUTLIER -128.98 156.22 44.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.285 -0.884 . . . . 0.0 109.478 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.518 ' CG2' HD13 ' A' ' 38' ' ' ILE . 20.9 t -126.88 99.95 6.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.895 . . . . 0.0 109.502 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.558 ' CD2' ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.93 164.96 11.31 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.295 -0.878 . . . . 0.0 109.396 -179.992 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.408 ' CB ' HD12 ' A' ' 35' ' ' ILE . . . -83.34 129.41 34.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.291 -0.881 . . . . 0.0 109.522 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -91.35 10.84 25.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.197 -0.939 . . . . 0.0 109.443 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.408 ' O ' ' O ' ' A' ' 52' ' ' ASP . . . 171.58 132.33 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.316 -0.865 . . . . 0.0 109.454 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.506 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -47.42 170.93 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.253 -0.904 . . . . 0.0 109.294 179.973 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.506 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 153.88 -160.95 29.67 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 46.5 t -124.56 123.91 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.272 -1.134 . . . . 0.0 109.494 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.507 ' CG2' ' N ' ' A' ' 56' ' ' ALA . 4.9 mt -61.52 163.7 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.338 -0.852 . . . . 0.0 109.615 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.507 ' N ' ' CG2' ' A' ' 55' ' ' ILE . . . -103.22 -65.51 1.0 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -0.922 . . . . 0.0 109.485 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.488 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER 172.66 141.35 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.239 -0.913 . . . . 0.0 109.427 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.631 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 9.9 mm -89.97 140.38 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.279 -0.888 . . . . 0.0 109.398 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 98.8 t -89.99 -53.13 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.184 -0.947 . . . . 0.0 109.438 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.514 ' CE ' ' HA ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -94.87 167.17 11.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.251 -0.906 . . . . 0.0 109.391 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 49.3 m-80 -104.65 156.06 18.31 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.422 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.524 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -64.97 155.54 34.15 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.417 -179.933 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.08 2.54 89.4 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -105.28 170.96 7.58 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.196 -1.179 . . . . 0.0 109.313 -179.984 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.51 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 95.4 m -98.93 122.91 42.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.553 -0.717 . . . . 0.0 109.489 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.433 ' HB ' ' HG2' ' A' ' 70' ' ' GLU . 5.5 m -104.41 -172.37 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.273 -0.892 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -133.45 176.3 8.65 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.501 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.9 t -63.8 143.54 57.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.414 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 60.17 26.01 63.07 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.433 ' HG2' ' HB ' ' A' ' 66' ' ' VAL . 35.2 tp10 -82.92 110.43 17.9 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.455 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.452 ' CD1' ' HD2' ' A' ' 74' ' ' LYS . 9.6 tt -69.24 109.97 4.36 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.264 -0.897 . . . . 0.0 109.486 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 35.9 mt -94.33 -11.8 29.29 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.521 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.431 ' O ' ' HG2' ' A' ' 74' ' ' LYS . . . 173.04 177.92 42.66 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.452 ' HD2' ' CD1' ' A' ' 71' ' ' LEU . 20.3 mtpt -147.7 129.2 14.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -1.127 . . . . 0.0 109.466 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.457 HD22 ' O ' ' A' ' 76' ' ' THR . 1.1 tt -96.02 147.66 23.47 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.238 -0.914 . . . . 0.0 109.539 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.457 ' O ' HD22 ' A' ' 75' ' ' LEU . 5.8 m -91.86 169.67 10.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.513 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -57.7 -65.51 0.62 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.205 -0.934 . . . . 0.0 109.466 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 114.33 73.7 0.59 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 CA-C-O 117.924 -1.487 . . . . 0.0 109.523 -179.99 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 36.8 pt -139.6 178.13 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.292 -0.88 . . . . 0.0 109.451 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.518 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 14.4 t0 -113.97 133.57 55.4 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.233 -0.917 . . . . 0.0 109.479 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.8 mt -105.57 98.08 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.193 -0.942 . . . . 0.0 109.48 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.02 168.69 14.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.17 -0.956 . . . . 0.0 109.5 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.2 153.73 92.33 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.307 -0.87 . . . . 0.0 109.47 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.99 140.64 18.23 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.565 2.177 . . . . 0.0 110.418 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.429 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 8.9 t -62.32 129.59 41.41 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -0.962 . . . . 0.0 109.451 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.491 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 23.4 m-85 -96.93 151.88 38.03 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.887 . . . . 0.0 109.472 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.448 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -78.08 171.31 17.33 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.671 2.247 . . . . 0.0 110.376 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.424 ' O ' ' C ' ' A' ' 12' ' ' SER . 4.5 mt-10 -45.67 -54.52 7.66 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.144 -0.973 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.424 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.95 -62.46 1.01 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.282 -0.886 . . . . 0.0 109.601 -179.917 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.521 ' CG2' ' O ' ' A' ' 15' ' ' ASP . 29.8 mm -92.85 119.13 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.181 -0.949 . . . . 0.0 109.482 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.438 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -96.18 13.21 28.13 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.262 -0.899 . . . . 0.0 109.484 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.521 ' O ' ' CG2' ' A' ' 13' ' ' ILE . 0.8 OUTLIER 167.42 -171.82 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.884 . . . . 0.0 109.431 -179.957 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.34 -159.28 8.39 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 52.1 m -149.57 123.29 9.23 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.243 -1.151 . . . . 0.0 109.502 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.512 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 39.6 t -47.98 168.64 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.302 -0.874 . . . . 0.0 109.426 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.523 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -113.13 -75.0 0.61 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.413 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.5 m -160.08 134.7 7.66 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.336 -0.853 . . . . 0.0 109.451 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.639 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.1 m95 -89.78 84.9 6.3 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.231 -0.918 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.551 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.8 m80 -42.34 -60.46 1.48 Allowed 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.371 -0.831 . . . . 0.0 109.497 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 4.1 mmtt -99.66 -172.11 2.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.593 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -130.12 168.59 16.12 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.288 -0.882 . . . . 0.0 109.496 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.517 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.51 115.58 4.11 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 122.664 2.243 . . . . 0.0 110.39 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.83 -11.92 5.38 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.431 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 1.2 pp20? -95.6 -172.89 2.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.352 -1.087 . . . . 0.0 109.467 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.431 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -101.04 151.2 22.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.1 m -114.9 166.63 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.358 -0.839 . . . . 0.0 109.429 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.436 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.3 mttt -121.3 134.5 55.15 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.262 -0.899 . . . . 0.0 109.506 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.51 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.81 113.42 0.47 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.352 -0.843 . . . . 0.0 109.684 -179.898 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.51 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 14.5 t0 75.99 56.37 0.05 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.293 -0.879 . . . . 0.0 109.495 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.462 ' O ' HG13 ' A' ' 35' ' ' ILE . 15.9 tt0 -131.24 124.15 29.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.319 -0.863 . . . . 0.0 109.437 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.551 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 51.1 tp -42.8 151.63 0.12 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.377 -0.827 . . . . 0.0 109.596 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.476 HD13 ' N ' ' A' ' 49' ' ' ALA . 96.9 mt -137.84 -41.21 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.319 -0.863 . . . . 0.0 109.476 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.52 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 13.6 p -158.24 135.0 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.277 -0.89 . . . . 0.0 109.451 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.523 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 10.7 m-20 -93.28 153.83 18.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.287 -0.883 . . . . 0.0 109.438 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.413 HG23 HD11 ' A' ' 38' ' ' ILE . 2.8 mt -121.44 155.81 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.271 -0.893 . . . . 0.0 109.507 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.0 145.06 50.85 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.295 -0.878 . . . . 0.0 109.439 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.43 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -130.6 -176.98 4.15 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -0.932 . . . . 0.0 109.479 179.962 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' A' ' 40' ' ' THR . 63.5 t0 -42.78 -55.08 3.8 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.286 -0.883 . . . . 0.0 109.686 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 18.3 mttm -147.45 25.45 1.08 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.246 -0.908 . . . . 0.0 109.396 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 2.1 t -134.05 130.87 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.231 -0.918 . . . . 0.0 109.457 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.0 t -108.57 139.78 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.218 -0.926 . . . . 0.0 109.512 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 18.7 mtp -131.62 175.28 9.31 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.212 -0.93 . . . . 0.0 109.467 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -124.59 159.91 29.62 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.508 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.52 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 5.4 t -130.14 89.5 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.286 -0.884 . . . . 0.0 109.45 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.557 ' CD2' ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.92 156.72 17.47 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.239 -0.913 . . . . 0.0 109.372 179.974 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.476 ' N ' HD13 ' A' ' 35' ' ' ILE . . . -77.84 149.13 34.4 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.196 -0.94 . . . . 0.0 109.538 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.456 ' O ' ' HB1' ' A' ' 51' ' ' ALA . 1.3 mt-10 -92.27 12.02 23.84 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.229 -0.92 . . . . 0.0 109.449 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.456 ' HB1' ' O ' ' A' ' 50' ' ' GLU . . . 179.13 150.07 0.28 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.243 -0.911 . . . . 0.0 109.493 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -55.35 170.93 0.2 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.216 -0.928 . . . . 0.0 109.32 -179.97 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.509 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 154.74 -153.88 25.12 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 52.4 t -138.75 127.0 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.247 -1.149 . . . . 0.0 109.442 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.413 HD11 ' CD1' ' A' ' 75' ' ' LEU . 14.9 mm -62.25 158.15 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.213 -0.929 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -97.37 -69.56 0.75 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.238 -0.914 . . . . 0.0 109.468 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.517 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 2.9 pt-20 -174.76 142.44 0.7 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.255 -0.903 . . . . 0.0 109.453 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.639 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 15.7 mm -93.86 138.05 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.208 -0.933 . . . . 0.0 109.498 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.7 t -90.56 -57.71 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.275 -0.891 . . . . 0.0 109.532 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.517 ' CE ' ' HA ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -89.93 163.22 15.06 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.17 -0.956 . . . . 0.0 109.439 -179.964 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 -102.56 156.49 17.58 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 109.53 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.512 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.2 OUTLIER -66.49 160.1 25.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.245 -0.909 . . . . 0.0 109.432 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 81.75 -7.35 62.55 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.515 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -100.81 171.02 7.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -1.165 . . . . 0.0 109.333 179.997 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.9 t -92.4 153.77 18.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.546 -0.722 . . . . 0.0 109.441 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.449 ' HA ' ' OE1' ' A' ' 70' ' ' GLU . 18.0 m -129.0 -174.66 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.233 -0.917 . . . . 0.0 109.55 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -128.98 170.88 12.91 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.283 -0.886 . . . . 0.0 109.432 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.429 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 3.9 t -72.22 99.7 2.42 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.872 . . . . 0.0 109.474 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 109.51 14.86 13.28 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.449 ' OE1' ' HA ' ' A' ' 66' ' ' VAL . 3.9 tt0 -75.45 119.29 19.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -1.127 . . . . 0.0 109.448 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.518 ' CD1' ' OD1' ' A' ' 3' ' ' ASP . 68.4 tp -69.72 108.73 4.03 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.266 -0.896 . . . . 0.0 109.47 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.441 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 16.6 mt -88.39 -13.92 39.35 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.24 -0.913 . . . . 0.0 109.514 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 161.45 178.46 35.41 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 5.1 mtpt -137.91 144.17 41.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.22 -1.164 . . . . 0.0 109.444 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.413 ' CD1' HD11 ' A' ' 55' ' ' ILE . 17.1 tp -93.32 140.51 29.47 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.2 -0.937 . . . . 0.0 109.506 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 14.8 m -112.85 171.94 7.23 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -74.23 -72.33 0.28 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.901 . . . . 0.0 109.425 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -139.44 -152.89 5.96 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.939 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.0 mm -145.9 99.11 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.29 -0.882 . . . . 0.0 109.517 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 62.8 t0 -80.71 132.12 35.52 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.214 -0.929 . . . . 0.0 109.495 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 40.9 mt -104.23 99.1 7.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.327 -0.858 . . . . 0.0 109.481 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.412 ' HA ' ' HA ' ' A' ' 71' ' ' LEU . 4.2 mttp -106.66 177.03 4.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.244 -0.91 . . . . 0.0 109.508 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.98 165.8 48.06 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.264 -0.897 . . . . 0.0 109.493 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.528 ' HG2' ' CZ ' ' A' ' 9' ' ' PHE . 35.3 Cg_endo -77.6 157.11 32.17 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.615 2.21 . . . . 0.0 110.44 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.3 t -62.77 146.63 52.02 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.848 . . . . 0.0 109.495 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.528 ' CZ ' ' HG2' ' A' ' 7' ' ' PRO . 24.0 m-85 -129.99 91.37 39.77 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.224 -0.922 . . . . 0.0 109.477 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.5 Cg_endo -78.03 -162.94 0.19 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.63 2.22 . . . . 0.0 110.445 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.429 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.0 OUTLIER -51.81 -54.83 24.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.293 -0.879 . . . . 0.0 109.446 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.429 ' C ' ' O ' ' A' ' 11' ' ' GLU . 34.4 t -42.94 -60.23 1.69 Allowed 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.324 -0.86 . . . . 0.0 109.626 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.463 ' O ' ' O ' ' A' ' 10' ' ' PRO . 27.0 mt -102.47 119.03 50.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.215 -0.928 . . . . 0.0 109.56 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -96.88 -0.25 48.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.922 . . . . 0.0 109.549 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.463 ' O ' HG23 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -173.53 -173.59 0.9 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.244 -0.91 . . . . 0.0 109.401 -179.976 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.479 ' O ' ' CG2' ' A' ' 65' ' ' THR . . . -154.6 170.79 32.99 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.518 ' O ' ' CG ' ' A' ' 39' ' ' GLU . 21.8 m -150.04 118.59 6.51 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.312 -1.111 . . . . 0.0 109.414 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.482 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 42.8 t -45.25 168.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.204 -0.935 . . . . 0.0 109.506 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.406 ' O ' ' OE1' ' A' ' 62' ' ' GLU . . . -113.65 -70.68 0.79 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.185 -0.947 . . . . 0.0 109.574 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.421 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 17.1 m -158.56 134.77 9.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.171 -0.955 . . . . 0.0 109.608 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.497 ' CZ2' HG21 ' A' ' 58' ' ' ILE . 31.4 m95 -89.86 84.77 6.26 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.269 -0.894 . . . . 0.0 109.559 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.636 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.7 m80 -42.69 -70.41 0.11 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.37 -0.831 . . . . 0.0 109.48 -179.763 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -101.11 -172.11 2.11 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.223 -0.923 . . . . 0.0 109.534 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.409 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 4.0 mttt -125.92 167.41 16.92 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.264 -0.897 . . . . 0.0 109.441 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.519 ' CG ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.93 131.22 11.95 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.608 2.205 . . . . 0.0 110.49 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.45 -12.48 18.8 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -89.8 -174.33 4.24 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.3 -1.118 . . . . 0.0 109.398 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.7 140.31 42.42 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.288 -0.883 . . . . 0.0 109.456 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.495 HG23 ' CD1' ' A' ' 55' ' ' ILE . 47.3 t -128.21 161.68 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.431 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 31' ' ' ARG . 3.7 tptt -153.28 137.5 16.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.207 -0.933 . . . . 0.0 109.491 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 30' ' ' LYS . 8.3 tmm_? -42.8 139.61 1.59 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.296 -0.877 . . . . 0.0 109.593 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 20.0 t70 68.05 49.0 0.9 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.349 -0.844 . . . . 0.0 109.469 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.424 ' O ' ' C ' ' A' ' 34' ' ' LEU . 1.6 tt0 -133.95 103.88 6.02 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.921 . . . . 0.0 109.426 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.636 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 38.4 tp -42.58 151.54 0.12 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.357 -0.839 . . . . 0.0 109.632 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.51 HD13 ' N ' ' A' ' 49' ' ' ALA . 5.1 mt -142.04 -40.18 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.166 -0.959 . . . . 0.0 109.542 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.505 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 12.2 p -151.92 128.2 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.407 ' OD1' ' HG2' ' A' ' 46' ' ' GLU . 12.9 m-20 -89.89 164.24 14.67 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.403 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 80.8 mt -136.69 151.97 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.223 -0.923 . . . . 0.0 109.522 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 17' ' ' THR . 4.6 pt-20 -140.68 135.11 31.3 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.265 -0.897 . . . . 0.0 109.425 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.461 HG21 ' O ' ' A' ' 43' ' ' VAL . 5.3 t -128.31 -162.33 1.17 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.336 -0.853 . . . . 0.0 109.35 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.452 ' N ' HG22 ' A' ' 40' ' ' THR . 11.8 t70 -42.43 -61.85 1.11 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.325 -0.859 . . . . 0.0 109.697 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.449 ' O ' HG21 ' A' ' 43' ' ' VAL . 5.9 mtpm? -149.47 45.09 0.96 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.225 -0.922 . . . . 0.0 109.515 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.461 ' O ' HG21 ' A' ' 40' ' ' THR . 54.5 t -154.69 108.25 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.195 -0.94 . . . . 0.0 109.489 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.471 HG21 ' N ' ' A' ' 45' ' ' MET . 3.8 p -96.43 140.01 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.343 -0.848 . . . . 0.0 109.396 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' MET . . . . . 0.471 ' N ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER -131.77 134.23 45.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.261 -0.9 . . . . 0.0 109.499 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.525 ' HB3' ' CD1' ' A' ' 34' ' ' LEU . 25.2 mt-10 -89.64 151.49 21.86 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.296 -0.878 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.505 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 91.8 t -123.0 103.62 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.173 -0.954 . . . . 0.0 109.507 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.43 ' HA ' HG13 ' A' ' 35' ' ' ILE . 0.2 OUTLIER -102.78 171.2 7.55 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.276 -0.89 . . . . 0.0 109.37 179.966 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.51 ' N ' HD13 ' A' ' 35' ' ' ILE . . . -84.98 134.81 34.22 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.255 -0.903 . . . . 0.0 109.464 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.431 ' O ' ' HB3' ' A' ' 51' ' ' ALA . 0.9 OUTLIER -84.81 10.95 10.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.156 -0.965 . . . . 0.0 109.426 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.431 ' HB3' ' O ' ' A' ' 50' ' ' GLU . . . 173.38 154.39 0.1 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 109.42 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.513 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -69.07 171.03 8.83 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.277 -179.939 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.513 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.22 -146.02 15.15 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.421 ' HB ' HG23 ' A' ' 76' ' ' THR . 49.9 t -138.68 126.9 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -1.158 . . . . 0.0 109.492 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.563 ' CD1' ' N ' ' A' ' 55' ' ' ILE . 1.1 mm -74.6 171.91 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.203 -0.936 . . . . 0.0 109.422 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.459 ' HB1' ' HG3' ' A' ' 74' ' ' LYS . . . -104.33 -63.85 1.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.227 -0.921 . . . . 0.0 109.509 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.519 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -179.29 158.39 0.87 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.246 -0.909 . . . . 0.0 109.5 180.0 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.514 HD13 ' CG ' ' A' ' 25' ' ' PRO . 1.5 mp -93.52 146.2 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.211 -0.93 . . . . 0.0 109.468 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.514 ' CG2' ' O ' ' A' ' 72' ' ' LEU . 49.5 t -89.9 -52.46 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.226 -0.921 . . . . 0.0 109.479 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.449 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 2.1 tptp -108.29 157.37 18.42 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.274 -0.891 . . . . 0.0 109.397 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 50.2 m-80 -88.82 156.18 19.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.482 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.482 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 2.4 pp20? -61.09 145.91 49.22 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.257 -0.902 . . . . 0.0 109.384 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 94.96 -12.15 68.79 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.504 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -89.04 170.9 10.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.273 -1.133 . . . . 0.0 109.325 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 62.7 m -111.96 146.92 36.96 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.489 -0.757 . . . . 0.0 109.467 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.487 ' N ' HG21 ' A' ' 65' ' ' THR . 27.3 m -129.62 -176.21 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.8 mp -116.63 173.9 6.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.177 -0.952 . . . . 0.0 109.469 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -63.85 125.74 25.35 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.897 . . . . 0.0 109.384 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 86.85 19.6 55.73 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.485 ' CB ' ' HB ' ' A' ' 66' ' ' VAL . 4.6 tp10 -82.18 112.82 19.56 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -1.134 . . . . 0.0 109.465 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.471 ' CD2' ' C ' ' A' ' 71' ' ' LEU . 7.5 tt -78.26 128.42 33.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.307 -0.87 . . . . 0.0 109.491 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.514 ' O ' ' CG2' ' A' ' 59' ' ' VAL . 13.3 mt -97.05 -70.51 0.72 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.421 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -128.14 163.64 21.67 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.459 ' HG3' ' HB1' ' A' ' 56' ' ' ALA . 2.2 ptmt -126.33 147.97 49.64 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.27 -1.135 . . . . 0.0 109.493 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.458 HD21 ' O ' ' A' ' 76' ' ' THR . 6.0 tt -90.56 166.45 13.2 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.278 -0.889 . . . . 0.0 109.488 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.458 ' O ' HD21 ' A' ' 75' ' ' LEU . 3.0 t -89.35 -157.74 0.47 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.268 -0.895 . . . . 0.0 109.735 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.451 ' N ' ' CG2' ' A' ' 76' ' ' THR . 4.4 mm-40 -79.61 163.17 24.82 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 121.804 -0.56 . . . . 0.0 109.544 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -136.62 -110.27 1.01 Allowed Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 CA-C-O 117.967 -1.463 . . . . 0.0 109.523 179.93 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.457 ' O ' HD12 ' A' ' 4' ' ' ILE . 15.4 mt -141.98 104.8 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.187 -0.946 . . . . 0.0 109.482 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.418 ' OD2' HD13 ' A' ' 71' ' ' LEU . 9.8 t70 -67.64 125.9 27.65 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.461 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.457 HD12 ' O ' ' A' ' 2' ' ' ILE . 4.9 mm -104.61 120.64 55.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.262 -0.899 . . . . 0.0 109.424 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.454 ' HA ' HD13 ' A' ' 72' ' ' LEU . 0.6 OUTLIER -136.83 176.23 8.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.169 -0.957 . . . . 0.0 109.469 179.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -80.44 157.78 72.26 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.282 -0.886 . . . . 0.0 109.439 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.01 156.32 30.33 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.661 2.241 . . . . 0.0 110.48 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 77.0 m -68.53 119.36 12.86 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.301 -0.874 . . . . 0.0 109.478 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -73.85 154.58 89.06 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.294 -0.878 . . . . 0.0 109.539 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.432 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.09 -173.93 2.03 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.677 2.252 . . . . 0.0 110.433 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.7 mp0 -73.15 -49.34 28.76 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.461 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.2 OUTLIER -42.82 -29.05 0.29 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.371 -0.831 . . . . 0.0 109.589 -179.87 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.435 ' CG2' ' O ' ' A' ' 15' ' ' ASP . 4.1 mt -121.17 146.04 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -0.895 . . . . 0.0 109.496 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -114.31 1.76 14.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.247 -0.908 . . . . 0.0 109.611 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.435 ' O ' ' CG2' ' A' ' 13' ' ' ILE . 0.2 OUTLIER -178.35 -171.41 0.26 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.18 -0.95 . . . . 0.0 109.457 -179.984 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.38 -167.44 17.69 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.515 ' O ' ' CB ' ' A' ' 39' ' ' GLU . 29.4 m -148.13 130.88 16.01 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -1.122 . . . . 0.0 109.468 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.478 HG13 ' N ' ' A' ' 19' ' ' ALA . 46.6 t -44.56 165.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.248 -0.907 . . . . 0.0 109.49 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.478 ' N ' HG13 ' A' ' 18' ' ' VAL . . . -114.06 -73.12 0.67 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.301 -0.874 . . . . 0.0 109.53 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 38.5 m -160.01 132.19 6.32 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.205 -0.934 . . . . 0.0 109.518 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.625 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 36.0 m95 -89.84 81.78 6.3 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.259 -0.901 . . . . 0.0 109.517 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.568 ' CD2' HD22 ' A' ' 34' ' ' LEU . 2.1 m80 -42.87 -61.54 1.25 Allowed 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.305 -0.872 . . . . 0.0 109.42 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.462 ' O ' ' HE3' ' A' ' 24' ' ' LYS . 1.2 mtpt -96.89 -177.36 3.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.918 . . . . 0.0 109.584 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.462 ' HE3' ' O ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -120.95 167.72 12.44 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.248 -0.908 . . . . 0.0 109.516 179.989 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.509 ' HA ' ' CG2' ' A' ' 55' ' ' ILE . 35.1 Cg_endo -76.96 90.21 1.25 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.694 2.263 . . . . 0.0 110.395 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 138.59 45.03 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.46 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 2.2 pp20? -139.35 -173.37 3.58 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.317 -1.108 . . . . 0.0 109.462 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.46 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -90.68 128.78 36.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.206 -0.934 . . . . 0.0 109.474 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.503 HG21 ' N ' ' A' ' 30' ' ' LYS . 12.4 p -127.11 155.15 38.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.215 -0.928 . . . . 0.0 109.528 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.503 ' N ' HG21 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -134.63 133.72 40.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -0.949 . . . . 0.0 109.502 -179.989 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.506 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.78 143.26 0.73 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.288 -0.883 . . . . 0.0 109.658 -179.969 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.506 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 8.2 t70 75.51 41.59 0.26 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.262 -0.898 . . . . 0.0 109.452 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.445 ' O ' HG12 ' A' ' 35' ' ' ILE . 3.5 tt0 -141.83 121.75 13.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.229 -0.919 . . . . 0.0 109.477 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.568 HD22 ' CD2' ' A' ' 22' ' ' HIS . 59.6 tp -42.84 156.1 0.05 OUTLIER 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.328 -0.858 . . . . 0.0 109.644 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.512 ' CD1' ' O ' ' A' ' 34' ' ' LEU . 15.7 mm -146.12 -39.12 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.276 -0.89 . . . . 0.0 109.505 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.509 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -159.79 141.95 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -0.891 . . . . 0.0 109.369 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.444 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 1.2 m-20 -104.93 146.37 29.12 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.251 -0.906 . . . . 0.0 109.465 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.445 HG21 ' N ' ' A' ' 39' ' ' GLU . 57.2 mt -107.13 142.46 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.175 -0.953 . . . . 0.0 109.514 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.515 ' CB ' ' O ' ' A' ' 17' ' ' THR . 1.4 tt0 -105.35 129.21 53.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.209 -0.932 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.454 ' OG1' ' O ' ' A' ' 43' ' ' VAL . 0.2 OUTLIER -115.73 171.61 7.65 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.238 -0.914 . . . . 0.0 109.49 -179.948 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 40' ' ' THR . 12.7 t0 -42.87 -51.37 5.53 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.321 -0.862 . . . . 0.0 109.618 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.422 ' HG2' ' O ' ' A' ' 41' ' ' ASP . 7.8 mmtt -148.37 30.66 0.84 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.271 -0.893 . . . . 0.0 109.443 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.454 ' O ' ' OG1' ' A' ' 40' ' ' THR . 2.0 t -139.6 134.49 38.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.939 . . . . 0.0 109.436 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.412 ' O ' HG11 ' A' ' 44' ' ' VAL . 8.1 p -98.76 136.86 28.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.255 -0.903 . . . . 0.0 109.474 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' MET . . . . . 0.424 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 0.9 OUTLIER -125.17 165.83 17.54 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.15 -0.969 . . . . 0.0 109.473 -179.983 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -129.26 161.91 29.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.501 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.509 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 78.7 t -140.73 108.89 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.214 -0.929 . . . . 0.0 109.501 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.443 HD11 ' O ' ' A' ' 48' ' ' LEU . 0.2 OUTLIER -103.14 155.74 18.19 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.339 -0.851 . . . . 0.0 109.362 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -70.58 144.78 51.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.898 . . . . 0.0 109.521 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.402 ' C ' ' HG3' ' A' ' 31' ' ' ARG . 0.6 OUTLIER -101.87 11.23 38.97 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.276 -0.89 . . . . 0.0 109.475 179.988 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -178.57 138.2 0.17 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.305 -0.872 . . . . 0.0 109.428 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.504 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.2 OUTLIER -58.5 170.95 0.67 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.245 -0.91 . . . . 0.0 109.343 -179.977 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.504 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 145.65 -162.39 28.26 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.42 ' HB ' HG23 ' A' ' 76' ' ' THR . 48.1 t -128.94 124.97 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.328 -1.101 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.532 ' CG2' ' N ' ' A' ' 56' ' ' ALA . 5.0 mt -59.41 165.23 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.278 -0.889 . . . . 0.0 109.568 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.532 ' N ' ' CG2' ' A' ' 55' ' ' ILE . . . -103.43 -66.08 0.97 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.188 -0.945 . . . . 0.0 109.518 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.444 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -167.75 139.11 2.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.206 -0.934 . . . . 0.0 109.55 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.625 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.9 mm -95.09 121.69 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.326 -0.859 . . . . 0.0 109.508 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.4 t -89.94 -27.99 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.19 -0.944 . . . . 0.0 109.428 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.489 ' HG2' ' CG1' ' A' ' 66' ' ' VAL . 0.0 OUTLIER -91.08 134.21 34.7 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.288 -0.882 . . . . 0.0 109.466 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 13.7 m120 -98.71 165.76 11.64 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.286 -0.884 . . . . 0.0 109.519 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -68.85 141.12 55.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 80.52 14.92 79.26 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -101.73 170.88 7.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -1.141 . . . . 0.0 109.277 -179.972 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 23.3 m -97.3 141.76 30.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.493 -0.754 . . . . 0.0 109.416 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.489 ' CG1' ' HG2' ' A' ' 60' ' ' LYS . 2.3 m -126.98 139.04 53.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.469 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.04 167.53 10.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.261 -0.899 . . . . 0.0 109.486 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 36.2 t -57.17 128.82 38.9 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 73.56 23.31 77.22 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -79.19 119.25 22.01 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.247 -1.149 . . . . 0.0 109.491 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.418 HD13 ' OD2' ' A' ' 3' ' ' ASP . 10.2 tt -67.37 138.31 56.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.288 -0.882 . . . . 0.0 109.543 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.46 HD22 HG13 ' A' ' 66' ' ' VAL . 0.5 OUTLIER -118.85 -24.86 6.47 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.293 -0.879 . . . . 0.0 109.428 -179.985 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.64 159.67 26.6 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 8.3 mtpt -122.31 133.39 54.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.204 -1.174 . . . . 0.0 109.446 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -92.1 147.57 22.84 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -0.948 . . . . 0.0 109.512 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.457 ' CG2' ' N ' ' A' ' 77' ' ' GLU . 3.0 t -97.72 -157.77 0.62 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.272 -0.893 . . . . 0.0 109.724 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.457 ' N ' ' CG2' ' A' ' 76' ' ' THR . 64.7 mm-40 -81.57 177.18 9.09 Favored 'General case' 0 C--N 1.295 -1.774 0 O-C-N 121.728 -0.608 . . . . 0.0 109.508 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -78.61 -51.25 5.64 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.223 0 CA-C-O 117.997 -1.446 . . . . 0.0 109.602 -179.931 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 61.7 mt -133.92 93.2 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.32 -0.863 . . . . 0.0 109.473 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.414 ' HA ' ' HA ' ' A' ' 74' ' ' LYS . 15.9 t70 -76.15 162.73 27.75 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.228 -0.92 . . . . 0.0 109.441 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.401 HG13 ' C ' ' A' ' 3' ' ' ASP . 2.7 mt -135.39 125.03 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.269 -0.894 . . . . 0.0 109.452 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.0 pttm -133.04 172.98 11.91 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.243 -0.911 . . . . 0.0 109.462 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.46 147.72 60.63 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.144 -0.972 . . . . 0.0 109.447 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.03 155.11 29.79 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.649 2.233 . . . . 0.0 110.455 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.416 ' HA ' ' HB2' ' A' ' 68' ' ' SER . 1.3 m -71.11 132.49 45.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.414 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 63.0 m-85 -99.34 153.6 37.7 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.426 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.99 -159.65 0.1 Allowed 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.632 2.221 . . . . 0.0 110.454 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.0 OUTLIER -77.18 -55.6 5.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.464 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 11' ' ' GLU . 18.6 t -42.72 -50.3 5.55 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.278 -0.889 . . . . 0.0 109.617 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 14.8 mt -90.11 143.45 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.418 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.517 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -115.1 -1.76 12.94 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.517 ' CB ' ' O ' ' A' ' 14' ' ' ALA . 0.5 OUTLIER 163.89 -169.09 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.212 -0.93 . . . . 0.0 109.464 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.438 ' O ' ' CG2' ' A' ' 65' ' ' THR . . . -142.97 -163.13 9.6 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.46 ' O ' ' HB2' ' A' ' 39' ' ' GLU . 17.0 m -150.0 133.07 16.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -1.114 . . . . 0.0 109.426 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.459 ' O ' ' HG3' ' A' ' 39' ' ' GLU . 39.4 t -49.08 159.73 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.216 -0.928 . . . . 0.0 109.419 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.523 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -104.35 -77.0 0.58 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.218 -0.926 . . . . 0.0 109.517 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 17.8 m -159.97 130.48 5.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.555 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.637 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.6 m95 -89.95 85.54 6.38 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.207 -0.933 . . . . 0.0 109.509 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.575 ' CD2' HD22 ' A' ' 34' ' ' LEU . 2.1 m80 -43.18 -67.28 0.29 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.346 -0.846 . . . . 0.0 109.419 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -93.81 -172.33 2.84 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.216 -0.927 . . . . 0.0 109.468 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.442 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -125.23 168.23 14.14 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.287 -0.883 . . . . 0.0 109.392 -179.894 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.465 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.3 Cg_endo -76.59 127.75 9.81 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.733 2.288 . . . . 0.0 110.373 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.65 18.99 9.01 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 13.8 mm-40 -119.69 -176.98 3.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.306 -1.114 . . . . 0.0 109.486 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -92.85 145.93 24.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.267 -0.896 . . . . 0.0 109.444 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 69.0 t -139.37 151.33 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -0.896 . . . . 0.0 109.532 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 11.0 mptt -126.64 140.11 52.66 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.228 -0.92 . . . . 0.0 109.463 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.434 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.7 OUTLIER -42.71 153.1 0.08 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.383 -0.823 . . . . 0.0 109.704 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 25.2 t0 63.19 41.8 7.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.927 . . . . 0.0 109.468 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 34' ' ' LEU . 0.8 OUTLIER -135.98 116.05 13.33 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.291 -0.88 . . . . 0.0 109.51 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.575 HD22 ' CD2' ' A' ' 22' ' ' HIS . 37.5 tp -43.1 142.9 0.88 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.275 -0.891 . . . . 0.0 109.556 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.514 HD13 ' CB ' ' A' ' 49' ' ' ALA . 10.9 mt -125.92 -46.08 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.272 -0.893 . . . . 0.0 109.585 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.497 HG22 ' CE2' ' A' ' 21' ' ' TRP . 7.3 p -162.8 147.5 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.277 -0.889 . . . . 0.0 109.528 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.523 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 1.2 m-20 -105.32 160.25 15.26 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.347 -0.845 . . . . 0.0 109.428 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.514 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 1.8 tt -129.31 148.54 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -0.933 . . . . 0.0 109.449 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.46 ' HB2' ' O ' ' A' ' 17' ' ' THR . 4.8 mm-40 -106.96 150.33 26.58 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.305 -0.872 . . . . 0.0 109.481 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.404 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -135.47 -175.38 3.92 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 40' ' ' THR . 7.8 t0 -42.78 -68.9 0.16 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.307 -0.871 . . . . 0.0 109.643 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.7 mtmm -135.39 36.73 2.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.172 -0.955 . . . . 0.0 109.493 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 67.9 t -152.0 153.44 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.34 -0.85 . . . . 0.0 109.472 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 11.7 p -124.2 131.04 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' MET . . . . . 0.514 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 0.0 OUTLIER -107.89 177.2 4.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.181 -0.949 . . . . 0.0 109.502 179.98 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -130.28 151.3 50.94 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.223 -0.923 . . . . 0.0 109.452 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.4 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 44.3 t -122.75 98.11 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.45 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.519 ' CD1' ' HA ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -90.99 168.72 11.45 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.195 -0.941 . . . . 0.0 109.487 -179.998 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.514 ' CB ' HD13 ' A' ' 35' ' ' ILE . . . -85.1 136.91 33.35 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.223 -0.923 . . . . 0.0 109.402 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.454 ' O ' ' HB3' ' A' ' 51' ' ' ALA . 2.2 mm-40 -98.53 14.64 27.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.545 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.454 ' HB3' ' O ' ' A' ' 50' ' ' GLU . . . 173.54 134.78 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.268 -0.895 . . . . 0.0 109.469 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.502 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.25 171.02 0.12 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -0.894 . . . . 0.0 109.3 179.999 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.502 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 142.77 -154.04 25.02 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 66.2 t -136.65 134.63 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.274 -1.133 . . . . 0.0 109.412 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 15.3 mm -61.85 168.84 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.218 -0.926 . . . . 0.0 109.516 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -101.42 -62.83 1.2 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.914 . . . . 0.0 109.53 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.465 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.7 OUTLIER -177.89 131.47 0.15 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.259 -0.9 . . . . 0.0 109.462 179.95 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.637 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 21.5 mm -90.09 125.63 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.435 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 42.2 t -89.93 -33.13 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.291 -0.88 . . . . 0.0 109.471 -179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.492 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 1.5 mptt -94.38 143.66 26.22 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.282 -0.886 . . . . 0.0 109.488 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.445 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 65.3 m-80 -111.0 164.74 12.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.248 -0.908 . . . . 0.0 109.526 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -59.06 146.43 38.47 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.493 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 86.75 7.74 77.82 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.506 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -105.35 170.71 7.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.221 -1.164 . . . . 0.0 109.411 -179.98 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.506 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 11.9 m -107.77 145.69 33.2 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.536 -0.728 . . . . 0.0 109.458 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 4.9 m -114.98 137.37 48.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.471 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -106.08 174.53 5.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.192 -0.943 . . . . 0.0 109.522 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.416 ' HB2' ' HA ' ' A' ' 8' ' ' THR . 1.5 t -62.03 129.13 39.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.234 -0.917 . . . . 0.0 109.497 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.98 21.63 73.53 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -79.82 104.34 10.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.255 -1.144 . . . . 0.0 109.52 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 9.1 tt -78.1 121.9 24.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.243 -0.911 . . . . 0.0 109.458 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.5 mp -92.69 -69.05 0.76 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.352 -0.843 . . . . 0.0 109.38 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -140.74 -175.82 14.87 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.414 ' HA ' ' HA ' ' A' ' 3' ' ' ASP . 0.3 OUTLIER -143.69 142.0 30.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.297 -1.119 . . . . 0.0 109.485 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -90.51 144.52 25.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.886 . . . . 0.0 109.436 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.44 ' CG2' ' N ' ' A' ' 77' ' ' GLU . 3.0 t -81.78 -157.83 0.21 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.74 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.44 ' N ' ' CG2' ' A' ' 76' ' ' THR . 79.7 mm-40 -57.94 174.09 0.28 Allowed 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -173.78 -62.82 0.05 OUTLIER Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.282 0 CA-C-O 118.02 -1.434 . . . . 0.0 109.565 179.966 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.512 HD12 ' CD2' ' A' ' 75' ' ' LEU . 3.2 mp -148.13 88.05 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.326 -0.859 . . . . 0.0 109.476 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.468 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 22.9 t70 -82.28 154.12 25.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.204 -0.935 . . . . 0.0 109.496 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.2 mt -130.86 122.34 51.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.883 . . . . 0.0 109.432 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.456 ' HD2' ' OD2' ' A' ' 3' ' ' ASP . 0.0 OUTLIER -144.89 164.85 29.82 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.234 -0.916 . . . . 0.0 109.464 179.958 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -67.34 148.13 98.77 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.291 -0.881 . . . . 0.0 109.495 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.02 -172.2 1.42 Allowed 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.628 2.219 . . . . 0.0 110.417 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -97.86 96.52 8.26 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.235 -0.915 . . . . 0.0 109.449 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.534 ' CE2' ' C ' ' A' ' 15' ' ' ASP . 19.5 m-85 -59.81 149.34 72.98 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.245 -0.909 . . . . 0.0 109.493 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.04 -166.25 0.39 Allowed 'Trans proline' 0 C--N 1.308 -1.556 0 C-N-CA 122.61 2.207 . . . . 0.0 110.494 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' A' ' 12' ' ' SER . 4.8 tt0 -72.78 -42.43 63.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.231 -0.918 . . . . 0.0 109.484 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 11' ' ' GLU . 2.5 t -42.88 -64.54 0.61 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.298 -0.876 . . . . 0.0 109.554 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.444 HG13 ' HA ' ' A' ' 41' ' ' ASP . 15.1 mm -104.95 145.86 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.216 -0.928 . . . . 0.0 109.445 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -114.36 21.77 14.33 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.294 -0.879 . . . . 0.0 109.485 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.534 ' C ' ' CE2' ' A' ' 9' ' ' PHE . 0.3 OUTLIER -161.74 -173.11 3.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.135 -0.978 . . . . 0.0 109.572 -179.997 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.533 ' HA3' ' CZ ' ' A' ' 9' ' ' PHE . . . -150.56 -176.56 23.65 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.436 ' O ' ' O ' ' A' ' 18' ' ' VAL . 25.8 m -150.06 122.09 8.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.176 -1.19 . . . . 0.0 109.5 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.526 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 41.4 t -45.83 168.72 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.251 -0.906 . . . . 0.0 109.353 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.526 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -111.13 -74.34 0.65 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.117 -0.989 . . . . 0.0 109.589 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.2 m -160.05 127.78 4.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.254 -0.904 . . . . 0.0 109.605 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.637 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 36.7 m95 -89.91 83.4 6.15 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.26 -0.9 . . . . 0.0 109.461 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.604 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -42.95 -70.18 0.11 Allowed 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.322 -0.861 . . . . 0.0 109.424 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -93.67 177.98 5.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.25 -0.906 . . . . 0.0 109.678 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.443 ' HD3' ' HD2' ' A' ' 25' ' ' PRO . 5.4 mttp -121.39 169.48 9.06 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.283 -0.886 . . . . 0.0 109.445 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.521 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.3 Cg_endo -76.15 119.7 5.42 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.657 2.238 . . . . 0.0 110.463 179.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 122.68 10.13 6.04 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.444 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 1.1 pp20? -112.4 173.88 6.15 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -1.129 . . . . 0.0 109.507 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.444 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -82.5 144.28 30.53 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.922 . . . . 0.0 109.511 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.8 t -112.31 156.85 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.287 -0.883 . . . . 0.0 109.47 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.1 OUTLIER -142.96 135.88 27.96 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.274 -0.892 . . . . 0.0 109.493 179.957 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.474 ' HG2' ' N ' ' A' ' 32' ' ' ASP . 2.7 ttm180 -42.8 141.13 1.14 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.337 -0.852 . . . . 0.0 109.651 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.474 ' N ' ' HG2' ' A' ' 31' ' ' ARG . 20.8 t70 69.71 49.66 0.53 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.289 -0.882 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' A' ' 34' ' ' LEU . 3.0 tt0 -138.5 106.89 5.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 0.0 109.429 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 40.1 tp -43.46 165.14 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.291 -0.88 . . . . 0.0 109.472 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.491 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 91.3 mt -134.26 -47.13 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.15 -0.969 . . . . 0.0 109.637 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.569 ' HB ' ' CE3' ' A' ' 21' ' ' TRP . 2.6 p -171.99 144.01 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.158 -0.964 . . . . 0.0 109.52 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.526 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 1.3 m-20 -100.19 167.03 10.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.247 -0.908 . . . . 0.0 109.458 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.449 HG23 ' O ' ' A' ' 45' ' ' MET . 1.2 tt -142.63 156.33 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.253 -0.904 . . . . 0.0 109.539 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.58 122.14 38.99 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.268 -0.895 . . . . 0.0 109.47 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.418 ' O ' ' C ' ' A' ' 41' ' ' ASP . 44.4 p -101.92 -151.91 0.43 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 109.475 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.444 ' HA ' HG13 ' A' ' 13' ' ' ILE . 43.1 t0 -42.71 -62.82 0.9 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.277 -0.89 . . . . 0.0 109.613 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.7 mttt -149.48 17.78 0.92 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.212 -0.93 . . . . 0.0 109.474 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 1.9 t -119.34 172.21 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.895 . . . . 0.0 109.503 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.408 ' O ' ' CG1' ' A' ' 44' ' ' VAL . 9.6 p -129.62 126.7 63.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.3 -0.875 . . . . 0.0 109.431 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' MET . . . . . 0.449 ' O ' HG23 ' A' ' 38' ' ' ILE . 1.3 mtt -113.83 124.43 52.21 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.186 -0.946 . . . . 0.0 109.484 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.6 147.32 26.46 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.334 -0.854 . . . . 0.0 109.443 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.449 ' O ' ' HB ' ' A' ' 35' ' ' ILE . 55.9 t -116.06 103.87 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.184 -0.947 . . . . 0.0 109.504 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -105.03 163.85 12.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.915 . . . . 0.0 109.396 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.458 ' CB ' HD12 ' A' ' 35' ' ' ILE . . . -84.88 164.83 18.16 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.159 -0.963 . . . . 0.0 109.456 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.526 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -105.82 3.67 28.97 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.542 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.526 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 163.94 167.54 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.184 -0.948 . . . . 0.0 109.455 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.502 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -49.96 170.98 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.291 -0.881 . . . . 0.0 109.313 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.502 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.93 -164.01 30.67 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.411 ' HB ' HG23 ' A' ' 76' ' ' THR . 48.7 t -136.85 125.35 34.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -1.142 . . . . 0.0 109.427 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.452 ' HA ' HD11 ' A' ' 75' ' ' LEU . 15.3 mm -61.68 160.08 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.294 -0.879 . . . . 0.0 109.448 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -100.51 -66.31 0.92 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.306 -0.871 . . . . 0.0 109.492 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.521 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 33.4 tt0 177.34 141.68 0.08 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.294 -0.879 . . . . 0.0 109.46 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.637 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 15.3 mm -91.42 158.28 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.273 -0.892 . . . . 0.0 109.449 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.405 HG22 ' O ' ' A' ' 71' ' ' LEU . 52.8 t -90.03 -67.52 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.261 -0.899 . . . . 0.0 109.342 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.459 ' HD3' ' CB ' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -101.1 174.99 5.75 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.254 -0.904 . . . . 0.0 109.399 179.926 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -95.87 155.43 16.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.931 . . . . 0.0 109.469 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.526 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -60.1 149.94 31.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.3 -0.875 . . . . 0.0 109.387 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 92.39 -12.62 69.25 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.499 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -87.3 170.94 10.99 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.295 -1.12 . . . . 0.0 109.286 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.499 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 99.0 m -100.73 135.41 42.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.519 -0.738 . . . . 0.0 109.461 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.416 ' C ' HD22 ' A' ' 67' ' ' LEU . 5.2 m -118.58 -176.8 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.448 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.416 HD22 ' C ' ' A' ' 66' ' ' VAL . 13.2 mt -121.45 162.38 20.56 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.248 -0.907 . . . . 0.0 109.441 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 t -64.25 122.54 16.88 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.238 -0.914 . . . . 0.0 109.494 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 91.31 10.16 62.53 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -84.98 112.56 20.7 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.191 -1.182 . . . . 0.0 109.447 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.468 ' CD1' ' OD1' ' A' ' 3' ' ' ASP . 1.2 tp -72.49 127.11 31.55 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.319 -0.863 . . . . 0.0 109.496 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 77.0 mt -93.92 -68.05 0.82 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.302 -0.874 . . . . 0.0 109.435 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -136.39 178.8 18.52 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.457 ' HD3' HD23 ' A' ' 71' ' ' LEU . 1.5 mtmp? -145.94 151.74 38.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -1.162 . . . . 0.0 109.472 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.512 ' CD2' HD12 ' A' ' 2' ' ' ILE . 13.2 tp -99.05 152.37 19.92 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.224 -0.923 . . . . 0.0 109.474 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.438 ' CG2' ' N ' ' A' ' 77' ' ' GLU . 3.0 t -106.55 -157.75 0.63 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.286 -0.884 . . . . 0.0 109.677 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.438 ' N ' ' CG2' ' A' ' 76' ' ' THR . 2.5 mt-10 -84.8 -82.0 0.18 Allowed 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 71.71 117.82 0.05 OUTLIER Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 CA-C-O 118.02 -1.433 . . . . 0.0 109.552 -179.996 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.41 ' HA ' HD11 ' A' ' 2' ' ' ILE . 24.3 mm -114.62 102.93 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.231 -0.918 . . . . 0.0 109.483 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.519 ' OD2' ' CD1' ' A' ' 71' ' ' LEU . 43.7 t0 -71.84 142.28 49.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.16 -0.963 . . . . 0.0 109.463 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.9 mm -112.19 103.83 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.225 -0.922 . . . . 0.0 109.415 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.63 166.02 10.67 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.225 -0.922 . . . . 0.0 109.468 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.446 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . . . -72.72 159.69 84.72 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.27 -0.894 . . . . 0.0 109.435 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.446 ' HD2' ' HB3' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.18 165.29 26.03 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.57 2.18 . . . . 0.0 110.368 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -90.28 108.8 19.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.472 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -60.86 149.24 81.23 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.442 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.08 -160.6 0.12 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.626 2.218 . . . . 0.0 110.369 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.3 OUTLIER -77.4 -58.88 3.03 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.247 -0.908 . . . . 0.0 109.497 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.2 t -42.93 -55.97 3.49 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.359 -0.838 . . . . 0.0 109.594 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.458 ' CD1' ' HB2' ' A' ' 41' ' ' ASP . 12.0 mm -95.1 136.55 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.275 -0.891 . . . . 0.0 109.444 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.78 14.48 10.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.216 -0.927 . . . . 0.0 109.436 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -156.53 -171.34 3.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.244 -0.91 . . . . 0.0 109.419 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.5 178.82 39.59 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.465 HG21 ' O ' ' A' ' 64' ' ' ASP . 17.8 m -150.03 119.25 6.79 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.23 -1.159 . . . . 0.0 109.367 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.471 HG13 ' N ' ' A' ' 19' ' ' ALA . 46.4 t -44.25 162.99 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.438 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.516 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -106.2 -75.47 0.63 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -0.906 . . . . 0.0 109.58 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.456 ' HA ' ' HB3' ' A' ' 62' ' ' GLU . 17.3 m -160.01 136.23 8.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.238 -0.914 . . . . 0.0 109.531 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.633 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.1 m95 -89.85 84.11 6.22 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.244 -0.91 . . . . 0.0 109.512 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.575 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.3 m80 -42.59 -55.64 3.44 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.44 -0.788 . . . . 0.0 109.531 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -109.82 158.71 17.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.098 -1.001 . . . . 0.0 109.612 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.447 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 4.9 mttt -97.22 167.99 10.99 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.275 -0.891 . . . . 0.0 109.428 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.462 ' HG3' HG12 ' A' ' 58' ' ' ILE . 35.2 Cg_endo -76.68 101.84 1.55 Allowed 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.625 2.216 . . . . 0.0 110.446 179.869 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.5 -5.08 4.48 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.477 ' N ' ' CD ' ' A' ' 27' ' ' GLU . 1.3 mp0 -90.36 -172.66 3.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.18 -1.188 . . . . 0.0 109.458 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -97.3 149.83 21.63 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.301 -0.874 . . . . 0.0 109.438 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.6 m -135.5 161.55 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.214 -0.929 . . . . 0.0 109.514 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.8 tttt -129.29 135.29 48.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.24 -0.912 . . . . 0.0 109.52 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.433 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 9.2 ttt180 -42.86 140.34 1.39 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.325 -0.86 . . . . 0.0 109.613 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 18.0 t0 70.82 47.0 0.47 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.23 -0.919 . . . . 0.0 109.516 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.434 ' O ' ' O ' ' A' ' 34' ' ' LEU . 29.4 tt0 -140.12 121.99 15.51 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.279 -0.888 . . . . 0.0 109.558 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.575 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 47.4 tp -43.14 164.56 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.278 -0.889 . . . . 0.0 109.587 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.51 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 25.4 mm -145.27 -42.56 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.185 -0.947 . . . . 0.0 109.535 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.524 HG22 ' CE2' ' A' ' 21' ' ' TRP . 12.7 p -154.7 134.18 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.234 -0.916 . . . . 0.0 109.551 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.516 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 22.1 m-20 -100.39 159.45 15.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.267 -0.896 . . . . 0.0 109.463 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.518 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 7.3 tt -128.87 156.9 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.463 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.404 ' N ' HG12 ' A' ' 38' ' ' ILE . 1.3 tt0 -129.65 142.78 50.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.208 -0.933 . . . . 0.0 109.423 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.464 HG21 ' O ' ' A' ' 43' ' ' VAL . 5.5 t -132.01 -163.45 1.34 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.256 -0.903 . . . . 0.0 109.362 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.458 ' HB2' ' CD1' ' A' ' 13' ' ' ILE . 2.2 t0 -42.34 -68.0 0.22 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.317 -0.864 . . . . 0.0 109.782 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.512 ' O ' ' CG2' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -142.97 48.76 1.49 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.136 -0.978 . . . . 0.0 109.541 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.512 ' CG2' ' O ' ' A' ' 42' ' ' LYS . 90.0 t -159.04 118.04 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.251 -0.906 . . . . 0.0 109.499 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.6 t -100.57 126.63 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.487 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' MET . . . . . 0.518 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 31.4 mtt -106.44 -179.65 4.0 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.448 ' HA ' ' OD1' ' A' ' 37' ' ' ASP . 3.7 mt-10 -133.52 146.96 51.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.249 -0.907 . . . . 0.0 109.44 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.499 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 36.2 t -117.76 106.68 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.492 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.429 HD11 ' HA ' ' A' ' 34' ' ' LEU . 0.6 OUTLIER -89.99 161.35 15.92 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.294 -0.879 . . . . 0.0 109.377 -179.964 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.03 160.91 24.42 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.44 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.508 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 0.5 OUTLIER -99.02 2.12 45.99 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.178 -0.951 . . . . 0.0 109.608 179.958 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.508 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 164.18 155.34 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.212 -0.93 . . . . 0.0 109.478 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.503 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -65.12 170.86 4.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.33 -0.856 . . . . 0.0 109.321 -179.995 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.503 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.45 -137.59 6.09 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.47 ' O ' ' CB ' ' A' ' 76' ' ' THR . 44.8 t -139.87 135.25 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.338 -1.095 . . . . 0.0 109.448 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 9.5 mm -75.74 153.9 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.332 -0.855 . . . . 0.0 109.457 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -87.94 -65.99 0.96 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.208 -0.933 . . . . 0.0 109.397 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.449 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -178.88 139.21 0.16 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -0.907 . . . . 0.0 109.399 179.949 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.633 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.1 mm -94.84 138.69 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.233 -0.917 . . . . 0.0 109.515 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 96.1 t -110.04 -14.52 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.309 -0.869 . . . . 0.0 109.425 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.522 ' CD ' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -91.04 -172.4 3.32 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.286 -0.884 . . . . 0.0 109.39 179.995 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.454 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 46.2 m-80 -137.05 155.95 49.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.328 -0.858 . . . . 0.0 109.576 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.456 ' HB3' ' HA ' ' A' ' 20' ' ' THR . 0.5 OUTLIER -72.18 144.14 48.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.265 -0.897 . . . . 0.0 109.518 -179.939 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 57.54 19.56 34.84 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.522 ' OD2' ' CD ' ' A' ' 60' ' ' LYS . 0.2 OUTLIER -99.4 170.95 8.27 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.262 -1.14 . . . . 0.0 109.352 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 11.5 t -88.17 154.25 20.6 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.525 -0.734 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.463 HG11 ' HD2' ' A' ' 60' ' ' LYS . 1.5 m -141.67 173.94 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.233 -0.917 . . . . 0.0 109.42 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.448 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.3 OUTLIER -127.99 162.56 26.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.301 -0.875 . . . . 0.0 109.433 -179.956 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 6.6 t -56.53 143.71 34.34 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.19 -0.944 . . . . 0.0 109.478 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 58.99 24.61 58.49 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.448 ' HB2' ' O ' ' A' ' 67' ' ' LEU . 13.9 tp10 -79.21 105.23 10.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -1.184 . . . . 0.0 109.491 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.519 ' CD1' ' OD2' ' A' ' 3' ' ' ASP . 0.4 OUTLIER -61.99 130.39 45.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.275 -0.89 . . . . 0.0 109.392 -179.915 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 7.9 mt -100.84 -71.12 0.72 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.27 -0.894 . . . . 0.0 109.45 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -144.39 -176.9 18.82 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 10.0 mtmt -128.26 151.67 49.01 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.313 -1.11 . . . . 0.0 109.462 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.406 HD22 ' O ' ' A' ' 76' ' ' THR . 0.5 OUTLIER -103.63 152.09 22.17 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.174 -0.954 . . . . 0.0 109.512 -179.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.47 ' CB ' ' O ' ' A' ' 54' ' ' VAL . 13.0 m -107.39 171.75 7.21 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 109.427 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -79.73 167.09 21.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.293 -0.88 . . . . 0.0 109.493 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -148.68 -65.16 0.01 OUTLIER Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 CA-C-O 117.997 -1.446 . . . . 0.0 109.53 179.999 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.44 ' HA ' ' O ' ' A' ' 75' ' ' LEU . . . . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 62.9 mt -137.33 126.1 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.192 -0.942 . . . . 0.0 109.461 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.506 ' OD2' ' CG ' ' A' ' 5' ' ' LYS . 24.9 t0 -61.04 154.54 22.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.2 -0.937 . . . . 0.0 109.496 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 16.4 mt -123.58 98.59 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.286 -0.884 . . . . 0.0 109.429 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.506 ' CG ' ' OD2' ' A' ' 3' ' ' ASP . 3.8 mtmt -122.39 154.76 37.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.914 . . . . 0.0 109.465 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -78.93 162.5 64.56 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.252 -0.905 . . . . 0.0 109.52 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.04 159.57 30.44 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.555 2.17 . . . . 0.0 110.485 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.1 m -73.74 142.36 46.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.348 -0.845 . . . . 0.0 109.436 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.568 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 25.6 m-85 -89.88 156.95 46.72 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.27 -0.894 . . . . 0.0 109.512 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -77.97 -167.12 0.45 Allowed 'Trans proline' 0 C--N 1.309 -1.516 0 C-N-CA 122.655 2.237 . . . . 0.0 110.48 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.438 ' O ' ' C ' ' A' ' 12' ' ' SER . 39.0 tt0 -75.24 -56.38 4.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.176 -0.953 . . . . 0.0 109.456 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 11' ' ' GLU . 4.9 t -42.72 -52.8 4.8 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.3 -0.875 . . . . 0.0 109.619 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 25.2 mt -94.1 147.42 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.236 -0.915 . . . . 0.0 109.494 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -124.33 6.54 8.4 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.183 -0.948 . . . . 0.0 109.615 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.568 ' HA ' ' CD2' ' A' ' 9' ' ' PHE . 0.7 OUTLIER 178.91 -172.53 0.15 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.236 -0.915 . . . . 0.0 109.488 -179.974 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.78 -157.41 8.18 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.461 ' O ' ' HB3' ' A' ' 39' ' ' GLU . 36.4 m -150.02 135.4 18.15 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -1.135 . . . . 0.0 109.529 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.5 t -55.88 158.78 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 109.461 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.506 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -101.94 -76.81 0.56 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.154 -0.967 . . . . 0.0 109.485 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 19.6 m -160.04 136.61 9.0 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.602 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.573 ' CZ2' HG21 ' A' ' 58' ' ' ILE . 32.4 m95 -89.99 83.15 6.09 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.259 -0.9 . . . . 0.0 109.491 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.578 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 1.7 m80 -43.02 -68.34 0.2 Allowed 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.313 -0.867 . . . . 0.0 109.395 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.11 -172.0 3.17 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.259 -0.9 . . . . 0.0 109.561 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.4 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 7.8 mttp -141.09 168.29 14.66 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.31 -0.869 . . . . 0.0 109.4 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.523 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.55 125.96 8.65 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.569 2.179 . . . . 0.0 110.467 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 117.19 10.96 9.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 45.6 mm-40 -128.4 -172.3 2.67 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.207 -1.172 . . . . 0.0 109.472 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -100.91 179.39 4.4 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.266 -0.896 . . . . 0.0 109.468 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.51 ' CG1' ' N ' ' A' ' 30' ' ' LYS . 64.6 t -147.04 165.95 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.293 -0.879 . . . . 0.0 109.451 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.51 ' N ' ' CG1' ' A' ' 29' ' ' VAL . 0.0 OUTLIER -112.34 132.38 55.02 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.565 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.477 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -43.01 121.01 1.96 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.291 -0.88 . . . . 0.0 109.604 -179.931 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.477 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 3.0 t70 73.94 55.21 0.1 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.26 -0.9 . . . . 0.0 109.484 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 34' ' ' LEU . 2.3 tp10 -131.74 126.51 34.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.278 -0.888 . . . . 0.0 109.475 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.578 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 48.6 tp -42.89 161.68 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.288 -0.882 . . . . 0.0 109.586 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.469 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 29.8 mm -144.72 -42.56 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.209 -0.932 . . . . 0.0 109.586 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.571 HG22 ' CE2' ' A' ' 21' ' ' TRP . 9.4 p -152.3 137.18 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.224 -0.923 . . . . 0.0 109.514 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.506 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 25.1 m-20 -100.71 163.14 12.47 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -0.871 . . . . 0.0 109.411 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.6 mt -129.86 154.34 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.232 -0.918 . . . . 0.0 109.517 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.461 ' HB3' ' O ' ' A' ' 17' ' ' THR . 27.8 tt0 -116.57 149.66 39.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.46 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.415 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -133.94 174.57 10.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -0.895 . . . . 0.0 109.487 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 40' ' ' THR . 5.6 t0 -42.9 -64.68 0.58 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.334 -0.853 . . . . 0.0 109.624 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.429 ' O ' ' CG2' ' A' ' 43' ' ' VAL . 11.6 mttp -134.06 39.76 3.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.217 -0.927 . . . . 0.0 109.479 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.429 ' CG2' ' O ' ' A' ' 42' ' ' LYS . 38.5 t -155.23 143.63 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.222 -0.924 . . . . 0.0 109.474 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 81.9 t -115.76 136.28 53.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.871 . . . . 0.0 109.487 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 84.4 mtp -121.36 178.27 4.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.213 -0.929 . . . . 0.0 109.456 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -137.27 160.03 40.22 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.218 -0.926 . . . . 0.0 109.467 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.522 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 21.3 t -127.2 104.78 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.94 . . . . 0.0 109.559 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.507 ' HG ' ' N ' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -95.58 158.16 15.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.347 -0.845 . . . . 0.0 109.491 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.56 161.94 22.12 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.271 -0.893 . . . . 0.0 109.45 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.524 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -89.3 -0.49 57.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.229 -0.919 . . . . 0.0 109.618 179.994 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.524 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 164.12 162.75 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.48 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.507 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -53.64 171.05 0.1 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.257 -0.902 . . . . 0.0 109.367 179.955 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.507 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 154.54 -150.88 22.57 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.8 t -136.2 123.11 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -1.172 . . . . 0.0 109.493 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.446 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 15.5 mm -61.66 166.29 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -0.915 . . . . 0.0 109.512 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.44 ' HB1' ' O ' ' A' ' 74' ' ' LYS . . . -105.46 -67.21 0.93 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.252 -0.905 . . . . 0.0 109.464 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.523 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 2.9 tm-20 -174.6 150.13 1.33 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.139 -0.976 . . . . 0.0 109.577 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.573 HG21 ' CZ2' ' A' ' 21' ' ' TRP . 8.1 mt -89.98 151.72 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.279 -0.888 . . . . 0.0 109.514 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 71' ' ' LEU . 56.0 t -97.16 -67.01 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.267 -0.896 . . . . 0.0 109.453 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.42 ' HD2' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -92.62 -170.71 2.54 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.232 -0.917 . . . . 0.0 109.451 179.988 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 12.6 m-80 -125.24 168.52 13.36 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.209 -0.932 . . . . 0.0 109.512 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -65.99 149.8 49.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.196 -0.94 . . . . 0.0 109.542 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 82.07 4.94 90.09 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -99.93 170.89 8.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.16 -1.2 . . . . 0.0 109.319 179.969 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 28.3 m -95.46 126.29 40.65 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.522 -0.737 . . . . 0.0 109.504 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 18.8 m -89.97 176.38 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.33 -0.856 . . . . 0.0 109.427 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -142.51 164.09 31.06 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.141 -0.974 . . . . 0.0 109.443 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.1 t -58.14 133.17 55.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 109.453 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 62.75 24.58 66.58 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 30.1 tp10 -73.47 119.55 17.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.255 -1.144 . . . . 0.0 109.431 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.459 ' O ' HG22 ' A' ' 59' ' ' VAL . 6.8 tt -75.93 109.08 9.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.199 -0.938 . . . . 0.0 109.444 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -88.81 -10.44 48.12 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.177 -0.952 . . . . 0.0 109.477 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 157.59 -175.4 34.94 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.44 ' O ' ' HB1' ' A' ' 56' ' ' ALA . 1.3 mtmm -138.84 149.08 44.52 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.193 -1.18 . . . . 0.0 109.498 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.44 ' O ' ' HA ' ' A' ' 1' ' ' ALA . 0.8 OUTLIER -100.3 146.95 26.32 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.264 -0.898 . . . . 0.0 109.448 -179.915 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 14.9 m -114.43 171.97 7.3 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.246 -0.909 . . . . 0.0 109.483 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.94 -148.81 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 0.0 109.434 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 156.98 147.38 4.76 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 CA-C-O 117.986 -1.452 . . . . 0.0 109.491 179.989 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.411 ' C ' HG13 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.411 HG13 ' C ' ' A' ' 1' ' ' ALA . 3.7 mt -149.14 124.07 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.249 -0.907 . . . . 0.0 109.503 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -71.13 150.91 44.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.318 -0.864 . . . . 0.0 109.486 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.3 mt -127.2 72.6 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.232 -0.918 . . . . 0.0 109.426 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.406 ' HA ' ' HG ' ' A' ' 72' ' ' LEU . 5.0 pttp -101.34 167.99 9.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.194 -0.941 . . . . 0.0 109.472 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -66.34 158.02 79.52 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.344 -0.848 . . . . 0.0 109.438 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -78.05 169.26 20.71 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.586 2.191 . . . . 0.0 110.422 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.7 141.35 40.94 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.464 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.52 ' CD2' ' HB2' ' A' ' 68' ' ' SER . 18.6 m-85 -107.91 153.07 41.86 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.23 -0.919 . . . . 0.0 109.462 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.441 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -78.06 167.41 23.49 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.593 2.195 . . . . 0.0 110.373 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.1 mt-10 -49.45 -53.52 22.53 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.2 -0.938 . . . . 0.0 109.54 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 11' ' ' GLU . 19.1 t -42.75 -48.88 5.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.385 -0.822 . . . . 0.0 109.631 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.472 ' CG2' HG23 ' A' ' 40' ' ' THR . 22.5 mt -96.18 122.05 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.223 -0.923 . . . . 0.0 109.402 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -101.13 11.46 39.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.214 -0.929 . . . . 0.0 109.439 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.438 ' O ' HG23 ' A' ' 13' ' ' ILE . 0.9 OUTLIER -176.67 -170.13 0.31 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.247 -0.908 . . . . 0.0 109.403 179.982 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.453 ' O ' HG22 ' A' ' 65' ' ' THR . . . -151.58 -173.33 21.28 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.464 HG21 ' O ' ' A' ' 64' ' ' ASP . 4.2 m -150.04 127.93 11.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -1.147 . . . . 0.0 109.411 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.521 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 47.9 t -54.31 164.05 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.218 -0.926 . . . . 0.0 109.45 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.442 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -109.7 -73.86 0.67 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.26 -0.9 . . . . 0.0 109.518 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.526 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 18.3 m -158.46 134.67 9.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.211 -0.931 . . . . 0.0 109.489 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.638 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.1 m95 -89.7 84.7 6.32 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.231 -0.918 . . . . 0.0 109.567 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.566 ' CD2' HD22 ' A' ' 34' ' ' LEU . 2.2 m80 -42.76 -60.31 1.62 Allowed 'General case' 0 N--CA 1.499 2.004 0 O-C-N 121.401 -0.812 . . . . 0.0 109.483 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.402 ' HA ' ' HD2' ' A' ' 23' ' ' LYS . 1.1 mmmt -100.28 -171.99 2.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -0.873 . . . . 0.0 109.562 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.426 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -124.54 169.17 11.31 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.254 -0.904 . . . . 0.0 109.483 -179.934 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.466 ' HG3' HG12 ' A' ' 58' ' ' ILE . 35.2 Cg_endo -76.48 94.24 1.04 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.67 2.247 . . . . 0.0 110.409 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 151.04 -17.45 0.92 Allowed Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -84.75 170.68 13.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -1.134 . . . . 0.0 109.541 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.11 127.94 42.57 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.886 . . . . 0.0 109.389 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.3 m -96.63 -172.04 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.464 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.426 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -148.4 136.97 21.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.47 -179.959 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.454 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 10.3 tmm_? -42.79 128.28 4.14 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.319 -0.863 . . . . 0.0 109.624 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 7.7 t70 72.81 54.36 0.14 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.276 -0.89 . . . . 0.0 109.453 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.496 ' N ' HD22 ' A' ' 48' ' ' LEU . 1.4 tp10 -141.91 120.78 12.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.296 -0.877 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.566 HD22 ' CD2' ' A' ' 22' ' ' HIS . 47.9 tp -42.87 142.31 0.92 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.309 -0.87 . . . . 0.0 109.581 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.441 HD12 ' O ' ' A' ' 33' ' ' GLU . 22.7 mm -129.75 -42.15 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.889 . . . . 0.0 109.443 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.525 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -157.53 144.43 9.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.296 -0.878 . . . . 0.0 109.466 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 46' ' ' GLU . 19.6 m-20 -102.68 150.3 23.58 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.452 HG13 ' CG2' ' A' ' 47' ' ' VAL . 21.8 mt -110.47 150.72 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.186 -0.946 . . . . 0.0 109.464 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -141.7 98.73 3.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.486 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.472 HG23 ' CG2' ' A' ' 13' ' ' ILE . 0.7 OUTLIER -90.19 -174.37 4.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.202 -0.936 . . . . 0.0 109.488 -179.996 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.446 ' O ' ' HG3' ' A' ' 42' ' ' LYS . 0.6 OUTLIER -42.87 -45.18 4.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.274 -0.891 . . . . 0.0 109.647 -179.866 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.446 ' HG3' ' O ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -156.28 27.33 0.35 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.199 -0.938 . . . . 0.0 109.446 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 3.5 t -128.36 106.66 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.327 -0.858 . . . . 0.0 109.42 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.5 t -90.31 130.48 39.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.242 -0.911 . . . . 0.0 109.484 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 10.2 mmt -141.86 108.45 5.34 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.181 -0.95 . . . . 0.0 109.476 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 5.4 mt-10 -63.0 172.08 1.92 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.278 -0.889 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.525 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 15.7 t -135.25 102.32 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.236 -0.915 . . . . 0.0 109.504 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.496 HD22 ' N ' ' A' ' 33' ' ' GLU . 0.0 OUTLIER -94.5 154.85 17.21 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.479 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.94 143.15 29.16 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.227 -0.921 . . . . 0.0 109.525 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.31 13.93 31.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.325 -0.859 . . . . 0.0 109.45 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -179.7 140.83 0.14 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.322 -0.862 . . . . 0.0 109.454 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -59.83 170.89 1.02 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.248 -0.908 . . . . 0.0 109.309 179.999 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 154.32 175.84 25.97 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.411 ' HB ' HG23 ' A' ' 76' ' ' THR . 49.2 t -112.93 124.83 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.206 -1.173 . . . . 0.0 109.498 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.448 HD12 ' CD1' ' A' ' 75' ' ' LEU . 15.6 mm -61.25 164.82 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.488 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -106.39 -63.7 1.24 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.314 -0.867 . . . . 0.0 109.462 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.457 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -170.41 136.43 1.33 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.16 -0.962 . . . . 0.0 109.528 -179.915 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.638 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 26.6 mm -89.94 141.37 14.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.343 -0.848 . . . . 0.0 109.452 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 89.1 t -90.18 -62.46 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -0.912 . . . . 0.0 109.55 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.451 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -89.95 155.1 19.35 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 109.44 -179.917 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -102.54 158.47 16.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.247 -0.908 . . . . 0.0 109.433 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.526 ' CB ' ' HA ' ' A' ' 20' ' ' THR . 2.1 pp20? -60.81 143.35 54.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.206 -0.934 . . . . 0.0 109.451 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 98.48 -10.32 62.99 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.513 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -100.16 170.9 8.15 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.239 -1.153 . . . . 0.0 109.274 -179.971 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.513 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 47.5 m -101.54 146.91 27.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.492 -0.755 . . . . 0.0 109.484 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.41 160.94 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.226 -0.921 . . . . 0.0 109.497 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 15.0 mt -90.42 145.28 25.05 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.246 -0.909 . . . . 0.0 109.476 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.52 ' HB2' ' CD2' ' A' ' 9' ' ' PHE . 1.9 t -49.33 114.32 1.0 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.295 -0.878 . . . . 0.0 109.515 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.45 22.43 24.34 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 38.9 tp10 -84.0 131.9 34.79 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.293 -1.122 . . . . 0.0 109.483 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 4.9 tt -66.09 114.25 5.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.261 -0.899 . . . . 0.0 109.501 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.406 ' HG ' ' HA ' ' A' ' 5' ' ' LYS . 6.1 mt -96.59 -22.17 17.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.266 -0.896 . . . . 0.0 109.456 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.38 159.83 23.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -124.32 133.98 53.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.265 -1.138 . . . . 0.0 109.483 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.448 ' CD1' HD12 ' A' ' 55' ' ' ILE . 4.5 tp -92.35 152.09 19.94 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.92 . . . . 0.0 109.503 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.515 HG22 ' N ' ' A' ' 77' ' ' GLU . 2.9 t -104.87 -157.8 0.63 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.313 -0.867 . . . . 0.0 109.727 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.515 ' N ' HG22 ' A' ' 76' ' ' THR . 8.5 mm-40 -74.08 -179.25 3.71 Favored 'General case' 0 C--N 1.295 -1.791 0 CA-C-O 121.313 0.578 . . . . 0.0 109.458 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.454 ' HA2' ' HA2' ' A' ' 53' ' ' GLY . . . -78.46 -37.61 27.03 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.286 0 CA-C-O 118.013 -1.437 . . . . 0.0 109.558 -179.971 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 121.287 0.565 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 25.1 mt -114.58 109.1 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.915 . . . . 0.0 109.494 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.427 ' OD1' HD13 ' A' ' 71' ' ' LEU . 39.9 t0 -77.67 124.03 27.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.244 -0.91 . . . . 0.0 109.459 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.6 mm -100.32 108.28 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.235 -0.916 . . . . 0.0 109.472 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.5 mtmt -125.15 165.72 17.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.59 163.41 67.53 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.207 -0.933 . . . . 0.0 109.528 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.479 ' O ' ' CE1' ' A' ' 9' ' ' PHE . 35.5 Cg_endo -78.09 134.69 13.23 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.637 2.225 . . . . 0.0 110.436 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.1 m -57.64 134.74 56.44 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.194 -0.941 . . . . 0.0 109.503 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.479 ' CE1' ' O ' ' A' ' 7' ' ' PRO . 4.2 m-85 -94.97 149.17 35.88 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.201 -0.937 . . . . 0.0 109.415 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.409 ' HD2' HD11 ' A' ' 13' ' ' ILE . 35.8 Cg_endo -78.09 -165.22 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.621 2.214 . . . . 0.0 110.456 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.1 OUTLIER -72.41 -49.19 35.53 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.414 179.995 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 11' ' ' GLU . 30.9 t -42.78 -52.12 5.12 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.308 -0.87 . . . . 0.0 109.635 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.409 HD11 ' HD2' ' A' ' 10' ' ' PRO . 3.2 mt -92.95 150.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.206 -0.934 . . . . 0.0 109.439 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.419 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -122.28 12.77 10.25 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.327 -0.858 . . . . 0.0 109.494 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.419 ' CB ' ' O ' ' A' ' 14' ' ' ALA . 0.3 OUTLIER 170.75 -170.76 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.256 -0.902 . . . . 0.0 109.499 -179.987 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.09 -169.92 18.09 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.461 ' O ' ' HB2' ' A' ' 39' ' ' GLU . 17.1 m -149.94 128.78 12.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -1.126 . . . . 0.0 109.469 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.42 HG13 ' N ' ' A' ' 19' ' ' ALA . 25.5 t -52.35 160.65 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.336 -0.852 . . . . 0.0 109.489 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.521 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -100.52 -75.63 0.58 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.473 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.7 m -160.11 136.11 8.57 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.564 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.573 ' CE2' HG22 ' A' ' 36' ' ' VAL . 33.4 m95 -89.76 82.46 6.26 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.256 -0.902 . . . . 0.0 109.64 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.552 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -43.57 -71.46 0.08 Allowed 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.284 -0.885 . . . . 0.0 109.362 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.0 mtmt -100.09 -171.93 2.13 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.245 -0.909 . . . . 0.0 109.571 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.62 167.39 19.41 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.328 -0.858 . . . . 0.0 109.465 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.524 ' CG ' ' HA ' ' A' ' 57' ' ' GLU . 35.5 Cg_endo -76.92 153.18 32.69 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.66 2.24 . . . . 0.0 110.412 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.11 9.49 67.48 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 41.5 mm-40 -113.38 -173.33 2.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.172 -1.193 . . . . 0.0 109.418 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -83.58 132.5 34.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.457 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.6 t -123.28 138.26 53.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.458 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.1 mttt -119.01 132.95 56.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.437 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -42.9 143.39 0.74 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.258 -0.901 . . . . 0.0 109.595 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.425 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 17.6 t0 69.56 46.76 0.7 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.224 -0.923 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.438 ' O ' HG12 ' A' ' 35' ' ' ILE . 1.8 tp10 -140.41 110.19 6.41 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.229 -0.92 . . . . 0.0 109.49 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.552 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 55.7 tp -42.97 161.51 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.27 -0.894 . . . . 0.0 109.604 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.516 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 22.2 mm -149.9 -40.25 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.213 -0.929 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.573 HG22 ' CE2' ' A' ' 21' ' ' TRP . 13.5 p -151.03 131.01 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.257 -0.902 . . . . 0.0 109.541 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.521 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 12.9 m-20 -97.96 171.94 7.95 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.247 -0.908 . . . . 0.0 109.485 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.514 ' N ' ' HB1' ' A' ' 19' ' ' ALA . 2.5 mt -138.74 164.49 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.288 -0.882 . . . . 0.0 109.44 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 17' ' ' THR . 37.4 mt-10 -132.95 141.6 48.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.238 -0.913 . . . . 0.0 109.419 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -126.35 -160.48 0.99 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 -179.992 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 40' ' ' THR . 3.8 t70 -42.87 -63.1 0.85 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.277 -0.889 . . . . 0.0 109.563 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.6 mttt -145.65 22.3 1.46 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 109.443 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 1.9 t -127.42 139.22 52.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.226 -0.921 . . . . 0.0 109.437 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.1 p -105.98 134.26 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.403 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' MET . . . . . 0.419 ' C ' ' HG3' ' A' ' 46' ' ' GLU . 8.8 mtm -113.55 -176.81 2.98 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.264 -0.897 . . . . 0.0 109.463 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.419 ' HG3' ' C ' ' A' ' 45' ' ' MET . 29.1 mt-10 -143.97 161.65 38.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.307 -0.87 . . . . 0.0 109.402 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.514 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 63.5 t -136.72 108.25 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.563 ' CD2' ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.89 148.9 25.07 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.286 -0.883 . . . . 0.0 109.381 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -63.55 147.62 50.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.442 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.518 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 1.1 mt-10 -93.05 10.49 31.28 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.239 -0.913 . . . . 0.0 109.473 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.518 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 164.34 157.23 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.257 -0.902 . . . . 0.0 109.479 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.508 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -65.55 170.96 4.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.336 -0.852 . . . . 0.0 109.348 -179.977 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.508 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.31 -143.79 10.94 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.8 t -138.21 124.46 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.249 -1.147 . . . . 0.0 109.489 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 9.6 mm -75.13 171.76 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.3 -0.875 . . . . 0.0 109.523 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -102.88 -62.45 1.27 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.203 -0.935 . . . . 0.0 109.514 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.524 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 5.3 pt-20 173.27 161.05 0.14 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 109.533 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.523 HD13 ' CG ' ' A' ' 25' ' ' PRO . 1.6 mp -90.43 143.84 10.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.255 -0.903 . . . . 0.0 109.44 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.445 HG22 HD22 ' A' ' 71' ' ' LEU . 53.5 t -99.42 -21.09 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.214 -0.929 . . . . 0.0 109.47 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.518 ' CG ' ' OD2' ' A' ' 64' ' ' ASP . 9.8 tptt -120.65 -171.87 2.27 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.248 -0.907 . . . . 0.0 109.559 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 17.1 m120 -123.25 167.9 13.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.896 . . . . 0.0 109.49 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -71.52 143.03 50.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.272 -0.893 . . . . 0.0 109.533 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 72.86 17.06 78.18 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.716 -1.353 . . . . 0.0 109.716 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.518 ' OD2' ' CG ' ' A' ' 60' ' ' LYS . 0.2 OUTLIER -100.65 170.83 8.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.232 -1.157 . . . . 0.0 109.331 179.966 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.513 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.8 t -90.94 153.78 19.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.481 -0.762 . . . . 0.0 109.53 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 16.1 m -133.39 144.49 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.227 -0.921 . . . . 0.0 109.517 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -92.67 160.73 14.86 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.3 -0.875 . . . . 0.0 109.387 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.2 t -52.89 119.3 4.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.129 -0.982 . . . . 0.0 109.493 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 74.53 33.36 56.24 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -76.8 137.73 39.43 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.277 -1.131 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.445 HD22 HG22 ' A' ' 59' ' ' VAL . 0.6 OUTLIER -78.19 128.32 33.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.456 -179.961 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 7.5 mt -105.76 -23.17 12.78 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.313 -0.867 . . . . 0.0 109.459 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 171.87 171.16 36.63 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 4.4 mtmt -127.78 136.81 52.0 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.27 -1.135 . . . . 0.0 109.509 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 2.7 tt -97.75 151.27 20.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.235 -0.916 . . . . 0.0 109.508 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 15.1 m -112.36 171.9 7.24 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.262 -0.899 . . . . 0.0 109.464 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -70.26 -68.86 0.39 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.177 -0.952 . . . . 0.0 109.462 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 134.99 -170.81 22.71 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 CA-C-O 118.0 -1.444 . . . . 0.0 109.535 179.983 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.1 pp -143.88 133.97 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.29 -0.881 . . . . 0.0 109.471 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -80.41 133.42 35.88 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.178 -0.951 . . . . 0.0 109.449 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 12.2 mt -96.45 107.76 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.1 mttt -121.28 173.36 7.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.909 . . . . 0.0 109.449 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.96 149.19 82.52 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.292 -0.88 . . . . 0.0 109.468 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.02 135.87 14.28 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.661 2.24 . . . . 0.0 110.372 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 t -56.73 112.33 1.27 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.202 -0.936 . . . . 0.0 109.474 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -67.24 157.45 85.19 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.867 . . . . 0.0 109.431 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.455 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.07 -159.61 0.1 Allowed 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.557 2.171 . . . . 0.0 110.423 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.416 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.1 tt0 -80.07 -61.94 1.83 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.25 -0.906 . . . . 0.0 109.521 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.416 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.9 t -42.81 -47.51 5.53 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.296 -0.877 . . . . 0.0 109.633 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.455 ' HB ' ' HD2' ' A' ' 10' ' ' PRO . 16.6 mt -99.81 130.16 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.234 -0.916 . . . . 0.0 109.418 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -118.79 28.15 8.47 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.274 -0.891 . . . . 0.0 109.383 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 176.42 -170.44 0.07 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.314 -0.866 . . . . 0.0 109.429 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.85 -173.53 33.58 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.452 HG21 ' O ' ' A' ' 64' ' ' ASP . 16.7 m -149.91 122.75 8.71 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.154 -1.204 . . . . 0.0 109.422 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.426 ' C ' ' O ' ' A' ' 17' ' ' THR . 47.1 t -44.24 156.96 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -0.905 . . . . 0.0 109.41 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -106.12 -74.9 0.64 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -0.906 . . . . 0.0 109.475 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.8 m -158.85 134.81 8.93 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.258 -0.901 . . . . 0.0 109.413 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.632 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 33.1 m95 -89.85 84.4 6.24 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.232 -0.917 . . . . 0.0 109.565 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.574 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 2.1 m80 -42.93 -63.25 0.83 Allowed 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.364 -0.835 . . . . 0.0 109.372 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -92.39 -172.07 2.98 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.187 -0.946 . . . . 0.0 109.509 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.467 ' HB2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.47 164.39 43.06 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.272 -0.893 . . . . 0.0 109.452 -179.95 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.468 ' HG3' HG12 ' A' ' 58' ' ' ILE . 35.2 Cg_endo -77.59 90.38 1.26 Allowed 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 122.688 2.259 . . . . 0.0 110.36 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 160.56 -23.28 0.25 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 49.6 mm-40 -94.38 -172.43 2.78 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.35 -1.088 . . . . 0.0 109.472 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -105.0 149.1 26.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.241 -0.912 . . . . 0.0 109.483 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.0 m -120.55 175.66 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.269 -0.894 . . . . 0.0 109.431 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.09 130.6 50.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.425 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 14.1 ttt180 -42.91 141.65 1.07 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.287 -0.883 . . . . 0.0 109.625 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.7 t70 65.55 45.56 2.71 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.434 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 34' ' ' LEU . 4.9 tt0 -136.52 124.83 23.25 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.334 -0.854 . . . . 0.0 109.502 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.574 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 49.8 tp -42.81 150.93 0.14 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.372 -0.83 . . . . 0.0 109.603 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.401 HD12 ' HB1' ' A' ' 49' ' ' ALA . 11.8 mt -139.49 -38.73 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.321 -0.862 . . . . 0.0 109.509 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.509 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 9.7 p -154.51 131.12 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.208 -0.933 . . . . 0.0 109.497 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.45 ' OD1' ' HA ' ' A' ' 46' ' ' GLU . 39.3 m-20 -97.0 152.18 18.98 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.176 -0.952 . . . . 0.0 109.443 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.461 ' O ' ' HA ' ' A' ' 44' ' ' VAL . 5.5 mt -115.91 146.69 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.275 -0.89 . . . . 0.0 109.482 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.68 111.54 21.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.315 -0.866 . . . . 0.0 109.495 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.511 HG22 ' N ' ' A' ' 41' ' ' ASP . 4.8 t -106.64 -153.73 0.5 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.191 -0.943 . . . . 0.0 109.385 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.511 ' N ' HG22 ' A' ' 40' ' ' THR . 0.3 OUTLIER -43.09 -71.53 0.08 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.898 . . . . 0.0 109.627 -179.882 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.456 ' O ' HG21 ' A' ' 43' ' ' VAL . 17.8 mtmm -143.88 36.9 1.29 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.519 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.456 HG21 ' O ' ' A' ' 42' ' ' LYS . 2.1 t -146.82 145.6 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.296 -0.877 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' A' ' 38' ' ' ILE . 10.6 p -109.8 133.51 54.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 0.0 109.438 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 2.7 mtt -105.35 126.95 52.68 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.454 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.45 ' HA ' ' OD1' ' A' ' 37' ' ' ASP . 6.7 mt-10 -81.4 131.25 35.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.179 -0.951 . . . . 0.0 109.466 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.509 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 92.8 t -116.4 102.03 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.247 -0.908 . . . . 0.0 109.509 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.434 HD11 ' O ' ' A' ' 48' ' ' LEU . 0.2 OUTLIER -102.91 163.24 12.32 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.211 -0.931 . . . . 0.0 109.406 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.401 ' HB1' HD12 ' A' ' 35' ' ' ILE . . . -79.45 142.35 35.96 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.207 -0.933 . . . . 0.0 109.48 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -82.5 8.21 12.28 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.281 -0.887 . . . . 0.0 109.535 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -177.08 141.73 0.34 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.889 . . . . 0.0 109.534 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.2 OUTLIER -57.93 170.93 0.56 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.223 -0.923 . . . . 0.0 109.312 -179.953 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.99 -145.09 12.25 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.4 t -138.4 125.21 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.3 -1.118 . . . . 0.0 109.433 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.478 HG23 ' N ' ' A' ' 56' ' ' ALA . 5.0 mt -58.17 161.75 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.316 -0.865 . . . . 0.0 109.529 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.515 ' CB ' ' HG3' ' A' ' 74' ' ' LYS . . . -97.66 -66.84 0.88 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.275 -0.891 . . . . 0.0 109.522 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.446 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 8.2 tt0 -175.05 138.75 0.45 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.207 -0.933 . . . . 0.0 109.456 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.632 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.9 mm -101.94 119.92 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.246 -0.909 . . . . 0.0 109.387 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.4 t -90.0 -19.11 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -0.929 . . . . 0.0 109.402 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.416 ' HG3' ' CG ' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -97.81 131.87 43.93 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.466 179.977 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.453 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 47.9 m-80 -97.55 156.35 16.55 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -0.867 . . . . 0.0 109.471 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -51.24 148.79 4.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.257 -0.902 . . . . 0.0 109.524 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 75.87 19.7 78.61 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.5 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -100.5 170.91 8.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.267 -1.137 . . . . 0.0 109.274 -179.978 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.5 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 65.1 m -106.67 133.6 51.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.539 -0.725 . . . . 0.0 109.475 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 25.0 m -100.79 163.73 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -0.884 . . . . 0.0 109.451 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -145.68 167.39 23.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.272 -0.893 . . . . 0.0 109.476 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.5 t -62.29 115.4 4.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.227 -0.921 . . . . 0.0 109.508 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 89.84 18.4 51.25 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 27.2 tp10 -83.19 121.75 27.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.229 -1.159 . . . . 0.0 109.485 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -83.98 119.2 24.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.211 -0.931 . . . . 0.0 109.422 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.438 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 12.0 mt -99.82 -19.09 16.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.268 -0.895 . . . . 0.0 109.44 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 159.5 168.12 21.07 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.515 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -127.21 158.51 36.92 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.16 -1.2 . . . . 0.0 109.487 179.982 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 8.8 tp -96.48 152.84 18.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.436 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.1 m -105.73 170.91 7.62 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.873 . . . . 0.0 109.523 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -64.82 -177.9 0.38 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.209 -0.932 . . . . 0.0 109.41 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -128.75 -150.71 7.25 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.958 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.43 ' O ' HG21 ' A' ' 2' ' ' ILE . 3.5 mp -133.55 91.25 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.277 -0.89 . . . . 0.0 109.459 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.463 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 63.2 t0 -57.85 123.26 15.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.531 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 53.0 mt -98.69 121.3 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.228 -0.92 . . . . 0.0 109.39 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.7 ptpp? -147.1 168.5 21.45 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.242 -0.911 . . . . 0.0 109.53 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.42 150.89 91.78 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.02 127.83 8.75 Favored 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.579 2.186 . . . . 0.0 110.423 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -45.84 143.46 2.12 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.27 -0.894 . . . . 0.0 109.451 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.517 ' CE2' ' C ' ' A' ' 15' ' ' ASP . 22.1 m-85 -102.84 154.5 37.47 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.923 . . . . 0.0 109.443 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -78.0 163.75 28.0 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.671 2.247 . . . . 0.0 110.415 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.0 OUTLIER -45.84 -49.77 14.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.141 -0.974 . . . . 0.0 109.505 179.985 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -43.17 -59.96 1.85 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.293 -0.879 . . . . 0.0 109.68 -179.936 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.497 HG22 ' CG2' ' A' ' 40' ' ' THR . 2.5 mp -90.28 132.94 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.267 -0.895 . . . . 0.0 109.48 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.76 25.98 11.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.906 . . . . 0.0 109.486 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.517 ' C ' ' CE2' ' A' ' 9' ' ' PHE . 0.2 OUTLIER 177.09 -171.09 0.09 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.24 -0.913 . . . . 0.0 109.487 -179.94 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.407 ' HA3' ' CZ ' ' A' ' 9' ' ' PHE . . . -159.14 -175.09 29.69 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.492 ' CG2' ' O ' ' A' ' 64' ' ' ASP . 85.2 m -150.02 122.59 8.55 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.292 -1.122 . . . . 0.0 109.45 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.518 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 38.2 t -48.14 168.97 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.297 -0.877 . . . . 0.0 109.453 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.484 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -111.1 -73.9 0.66 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.266 -0.897 . . . . 0.0 109.58 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.465 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 23.9 m -160.08 135.46 8.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.117 -0.989 . . . . 0.0 109.674 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.572 ' CZ2' HG21 ' A' ' 58' ' ' ILE . 34.2 m95 -89.94 83.38 6.13 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 121.161 -0.962 . . . . 0.0 109.494 179.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.576 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 1.5 m80 -43.16 -70.8 0.09 Allowed 'General case' 0 N--CA 1.501 2.109 0 O-C-N 121.315 -0.866 . . . . 0.0 109.425 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.85 -171.75 2.23 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.219 -0.926 . . . . 0.0 109.62 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.437 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.28 169.86 12.72 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.329 -0.857 . . . . 0.0 109.428 -179.903 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.528 ' HD3' ' CD1' ' A' ' 58' ' ' ILE . 34.9 Cg_endo -76.05 135.98 17.82 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 122.642 2.228 . . . . 0.0 110.377 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.13 10.61 27.59 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.421 ' CD ' ' O ' ' A' ' 28' ' ' ALA . 1.2 pp20? -115.51 173.16 6.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.225 -1.162 . . . . 0.0 109.471 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.421 ' O ' ' CD ' ' A' ' 27' ' ' GLU . . . -78.7 144.96 34.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.288 -0.883 . . . . 0.0 109.481 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.2 t -127.92 163.95 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.902 . . . . 0.0 109.472 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.422 ' O ' ' C ' ' A' ' 31' ' ' ARG . 4.3 tttp -156.8 141.85 17.17 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.275 -0.891 . . . . 0.0 109.474 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.465 ' HG2' ' N ' ' A' ' 32' ' ' ASP . 1.5 tmm_? -42.78 144.8 0.52 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.337 -0.852 . . . . 0.0 109.718 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.465 ' N ' ' HG2' ' A' ' 31' ' ' ARG . 16.4 t0 72.18 46.91 0.31 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.269 -0.894 . . . . 0.0 109.498 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 34' ' ' LEU . 3.6 tp10 -142.22 100.99 3.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.281 -0.887 . . . . 0.0 109.561 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.576 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 39.9 tp -43.36 146.9 0.43 Allowed 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.299 -0.875 . . . . 0.0 109.519 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 44.5 mt -121.86 -44.66 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.889 . . . . 0.0 109.652 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.515 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.9 p -160.09 139.24 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.2 -0.937 . . . . 0.0 109.566 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.484 ' CB ' ' HB2' ' A' ' 19' ' ' ALA . 11.5 m-20 -99.18 168.39 10.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.896 . . . . 0.0 109.478 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.438 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 12.8 mt -136.02 161.75 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.284 -0.885 . . . . 0.0 109.46 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -143.1 167.35 22.29 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.236 -0.915 . . . . 0.0 109.489 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.497 ' CG2' HG22 ' A' ' 13' ' ' ILE . 8.5 m -159.18 170.91 20.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.273 -0.892 . . . . 0.0 109.455 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 40' ' ' THR . 8.9 t0 -42.83 -40.61 2.95 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.252 -0.905 . . . . 0.0 109.631 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.434 ' O ' HG21 ' A' ' 43' ' ' VAL . 3.5 mtpm? -156.29 26.0 0.35 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.434 HG21 ' O ' ' A' ' 42' ' ' LYS . 78.6 t -140.64 105.09 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.33 -0.856 . . . . 0.0 109.46 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.458 HG21 ' N ' ' A' ' 45' ' ' MET . 3.7 p -95.48 139.32 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.186 -0.946 . . . . 0.0 109.531 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' MET . . . . . 0.458 ' N ' HG21 ' A' ' 44' ' ' VAL . 13.2 mmt -128.05 -167.88 1.82 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.275 -0.89 . . . . 0.0 109.477 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.5 pt-20 -158.39 167.06 30.7 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.169 -0.957 . . . . 0.0 109.486 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.515 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 71.3 t -138.31 104.02 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.381 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.446 ' HG ' ' HA ' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -95.98 171.02 8.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 -179.994 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.05 139.64 31.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 0.0 109.44 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.466 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 2.9 mm-40 -100.38 8.09 43.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -0.913 . . . . 0.0 109.548 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.466 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 166.57 142.99 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.958 . . . . 0.0 109.491 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.504 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.84 170.98 0.15 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.198 -0.939 . . . . 0.0 109.225 -179.926 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.504 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.95 -146.3 14.88 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.4 t -135.89 124.45 37.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.302 -1.117 . . . . 0.0 109.505 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.517 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 5.0 mt -61.17 158.65 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 109.567 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.498 ' N ' HG21 ' A' ' 55' ' ' ILE . . . -95.56 -69.41 0.76 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.249 -0.907 . . . . 0.0 109.549 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.521 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -178.97 152.9 0.6 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.241 -0.912 . . . . 0.0 109.471 179.992 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.572 HG21 ' CZ2' ' A' ' 21' ' ' TRP . 24.9 mt -89.91 141.28 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.219 -0.926 . . . . 0.0 109.412 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.448 HG22 ' O ' ' A' ' 71' ' ' LEU . 61.8 t -90.53 -66.77 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.172 -0.955 . . . . 0.0 109.411 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.459 ' O ' HG23 ' A' ' 58' ' ' ILE . 0.0 OUTLIER -92.79 -173.67 3.39 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.25 -0.906 . . . . 0.0 109.448 -179.983 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.449 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 70.7 m-80 -110.6 155.57 22.16 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.296 -0.878 . . . . 0.0 109.44 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.518 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -69.52 153.43 43.51 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.244 -0.91 . . . . 0.0 109.451 -179.984 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 77.49 7.45 87.09 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.502 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -105.29 170.95 7.59 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.238 -1.154 . . . . 0.0 109.32 -179.966 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.502 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 48.6 m -99.14 128.55 45.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.457 -0.777 . . . . 0.0 109.494 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.427 HG11 ' CD ' ' A' ' 60' ' ' LYS . 6.6 m -121.52 -169.7 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.329 -0.857 . . . . 0.0 109.455 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.2 tp -127.15 165.95 18.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -0.903 . . . . 0.0 109.445 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 t -61.7 138.76 58.34 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.279 -0.888 . . . . 0.0 109.505 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.02 15.4 81.4 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -79.05 116.63 19.47 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.243 -1.151 . . . . 0.0 109.51 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.463 ' CD1' ' OD1' ' A' ' 3' ' ' ASP . 10.9 tp -66.57 115.92 6.96 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.203 -0.935 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 15.4 mt -98.36 -12.35 21.55 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.245 -0.909 . . . . 0.0 109.404 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 164.1 169.96 28.36 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.461 ' O ' ' HB1' ' A' ' 56' ' ' ALA . 26.5 mtmt -132.25 139.09 48.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.188 -1.184 . . . . 0.0 109.504 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 12.8 tp -98.41 136.86 37.95 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.207 -0.933 . . . . 0.0 109.543 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 12.7 m -109.63 171.88 7.18 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.225 -0.922 . . . . 0.0 109.501 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -82.67 -170.53 3.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.256 -0.903 . . . . 0.0 109.494 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 171.29 157.4 13.16 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 CA-C-O 118.002 -1.443 . . . . 0.0 109.601 179.965 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.1 pp -149.07 120.48 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.255 -0.903 . . . . 0.0 109.452 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.464 ' OD2' ' CD1' ' A' ' 71' ' ' LEU . 26.1 t70 -74.53 166.4 23.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.3 -0.875 . . . . 0.0 109.521 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 61.1 mt -129.96 118.45 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.475 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 ptpp? -137.25 165.0 27.18 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.272 -0.893 . . . . 0.0 109.425 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.45 150.58 91.59 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.485 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.11 166.4 24.78 Favored 'Trans proline' 0 C--N 1.309 -1.524 0 C-N-CA 122.612 2.208 . . . . 0.0 110.409 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.09 94.96 2.98 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.173 -0.954 . . . . 0.0 109.445 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.526 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 21.5 m-85 -50.1 151.0 3.77 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.298 -0.877 . . . . 0.0 109.457 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.426 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.2 Cg_endo -78.14 177.31 8.93 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.559 2.173 . . . . 0.0 110.383 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 12' ' ' SER . 43.2 tt0 -66.0 -54.05 31.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.501 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.425 ' C ' ' O ' ' A' ' 11' ' ' GLU . 21.6 t -42.95 -46.41 5.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.34 -0.85 . . . . 0.0 109.628 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' A' ' 10' ' ' PRO . 11.6 mm -94.5 151.69 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.415 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -121.36 2.64 10.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.618 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.526 ' HA ' ' CD2' ' A' ' 9' ' ' PHE . 0.5 OUTLIER 167.96 -169.25 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.109 -0.995 . . . . 0.0 109.502 -179.992 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.67 -159.46 9.94 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.524 ' CG2' ' O ' ' A' ' 64' ' ' ASP . 0.2 OUTLIER -149.06 170.68 17.85 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.277 -1.131 . . . . 0.0 109.048 179.987 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.66 171.53 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.051 -1.031 . . . . 0.0 109.409 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.431 ' HB1' ' O ' ' A' ' 37' ' ' ASP . . . -118.91 -74.19 0.62 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.462 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.44 ' HA ' ' HG2' ' A' ' 62' ' ' GLU . 65.2 m -160.21 132.3 6.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.144 -0.972 . . . . 0.0 109.622 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.632 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.0 m95 -89.85 82.23 6.24 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.256 -0.902 . . . . 0.0 109.397 179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.625 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.4 m80 -42.67 -57.12 2.85 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.401 -0.812 . . . . 0.0 109.484 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.3 163.58 12.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.245 -0.909 . . . . 0.0 109.66 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.463 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 23.6 mttt -114.46 165.8 13.01 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.346 -0.846 . . . . 0.0 109.152 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.525 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.76 102.5 1.62 Allowed 'Trans proline' 0 C--N 1.308 -1.582 0 C-N-CA 122.544 2.163 . . . . 0.0 110.419 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 145.01 -13.43 1.91 Allowed Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.8 mm-40 -96.61 -172.13 2.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.234 -1.156 . . . . 0.0 109.512 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.68 161.99 13.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.533 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.462 ' O ' ' OD2' ' A' ' 52' ' ' ASP . 35.5 t -138.36 153.42 26.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.239 -0.913 . . . . 0.0 109.479 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.437 ' N ' HG11 ' A' ' 29' ' ' VAL . 0.6 OUTLIER -126.71 137.6 53.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.929 . . . . 0.0 109.5 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.515 ' HG2' ' N ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -42.98 146.04 0.43 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.302 -0.874 . . . . 0.0 109.639 -179.939 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.515 ' N ' ' HG2' ' A' ' 31' ' ' ARG . 3.1 t70 67.66 38.82 2.9 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.486 ' C ' ' CD1' ' A' ' 48' ' ' LEU . 8.6 tp10 -127.84 115.94 19.39 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.194 -0.941 . . . . 0.0 109.455 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.625 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 41.4 tp -43.25 162.37 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.283 -0.886 . . . . 0.0 109.463 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.451 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 29.6 mm -135.49 -48.05 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 109.63 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.494 HG11 ' CG2' ' A' ' 47' ' ' VAL . 14.3 p -160.18 131.55 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.158 -0.964 . . . . 0.0 109.539 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.431 ' O ' ' HB1' ' A' ' 19' ' ' ALA . 3.4 m-20 -90.32 150.82 21.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.5 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 60.9 mt -119.54 155.48 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -0.913 . . . . 0.0 109.501 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.452 ' CG ' ' HB ' ' A' ' 17' ' ' THR . 12.1 pt-20 -128.58 154.51 46.12 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.257 -0.902 . . . . 0.0 109.539 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -141.58 175.5 9.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.258 -0.902 . . . . 0.0 109.425 -179.93 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 4.2 t0 -42.83 -60.67 1.51 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.334 -0.853 . . . . 0.0 109.636 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 15.7 mttt -138.5 36.44 2.25 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.29 -0.881 . . . . 0.0 109.464 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 90.6 t -147.65 127.35 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.28 -0.887 . . . . 0.0 109.436 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.6 t -102.3 152.0 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.277 -0.889 . . . . 0.0 109.463 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.9 176.33 9.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 109.468 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -141.54 149.63 41.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 109.495 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.494 ' CG2' HG11 ' A' ' 36' ' ' VAL . 30.5 t -115.59 96.9 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.285 -0.885 . . . . 0.0 109.431 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.486 ' CD1' ' C ' ' A' ' 33' ' ' GLU . 29.8 tp -96.04 153.16 17.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.35 -0.843 . . . . 0.0 109.52 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.467 ' N ' ' HG ' ' A' ' 48' ' ' LEU . . . -83.41 148.07 27.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.192 -0.942 . . . . 0.0 109.446 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -99.77 17.98 19.34 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.936 . . . . 0.0 109.485 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . 171.87 154.01 0.07 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.288 -0.883 . . . . 0.0 109.483 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.501 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -66.09 170.94 5.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.308 -0.87 . . . . 0.0 109.289 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.501 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.26 -159.81 28.39 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.0 t -135.62 125.11 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -1.159 . . . . 0.0 109.51 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.527 ' CG2' ' N ' ' A' ' 56' ' ' ALA . 4.9 mt -59.11 165.5 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.938 . . . . 0.0 109.528 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.527 ' N ' ' CG2' ' A' ' 55' ' ' ILE . . . -104.45 -67.19 0.91 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.46 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.525 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -169.25 140.63 2.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.227 -0.921 . . . . 0.0 109.565 -179.991 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.632 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.3 mm -93.77 138.97 19.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.233 -0.917 . . . . 0.0 109.393 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 18.0 t -89.94 -39.42 12.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.237 -0.914 . . . . 0.0 109.435 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.464 ' HD3' ' O ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -102.39 158.06 16.47 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.222 -0.924 . . . . 0.0 109.411 179.974 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -117.27 163.32 16.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.303 -0.873 . . . . 0.0 109.432 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.44 ' HG2' ' HA ' ' A' ' 20' ' ' THR . 2.3 mp0 -55.28 134.41 49.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.22 -0.925 . . . . 0.0 109.447 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 100.68 -8.29 58.12 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.524 ' O ' ' CG2' ' A' ' 17' ' ' THR . 0.2 OUTLIER -92.06 170.44 9.84 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.244 -1.151 . . . . 0.0 109.362 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.498 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.6 t -100.36 164.15 12.06 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.565 -0.71 . . . . 0.0 109.511 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.42 ' O ' HG22 ' A' ' 66' ' ' VAL . 22.6 m -130.83 131.08 64.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -0.905 . . . . 0.0 109.44 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -101.59 162.04 13.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -0.885 . . . . 0.0 109.541 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.1 t -59.82 110.03 1.07 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.514 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.79 20.6 16.25 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -83.71 133.91 34.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.264 -1.139 . . . . 0.0 109.499 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.464 ' CD1' ' OD2' ' A' ' 3' ' ' ASP . 9.5 tp -83.26 125.38 31.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.504 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 4.5 mt -100.0 -22.17 15.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.264 -0.897 . . . . 0.0 109.477 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.67 173.49 27.14 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.439 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 39.7 pttt -129.46 153.01 48.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -1.122 . . . . 0.0 109.493 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 22.9 tp -96.22 153.02 18.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -0.898 . . . . 0.0 109.464 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 8.3 m -95.42 172.95 7.77 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.289 -0.882 . . . . 0.0 109.45 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -66.02 -172.73 0.15 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.226 -0.921 . . . . 0.0 109.434 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -119.31 -42.95 0.53 Allowed Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 CA-C-O 117.96 -1.467 . . . . 0.0 109.518 -179.977 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.414 ' C ' HG13 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.414 HG13 ' C ' ' A' ' 1' ' ' ALA . 8.5 mt -142.58 109.74 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.223 -0.923 . . . . 0.0 109.472 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' A' ' 4' ' ' ILE . 10.6 t0 -68.37 152.57 45.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.527 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.502 ' N ' ' OD1' ' A' ' 3' ' ' ASP . 8.2 mm -123.74 136.35 60.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.902 . . . . 0.0 109.524 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.34 172.5 12.67 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.281 -0.887 . . . . 0.0 109.447 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.413 ' HB2' ' HD2' ' A' ' 7' ' ' PRO . . . -69.06 158.82 85.47 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.413 ' HD2' ' HB2' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.04 114.86 3.66 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.707 2.271 . . . . 0.0 110.381 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 29.7 m -46.52 126.12 7.81 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.265 -0.897 . . . . 0.0 109.464 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.562 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 1.3 p90 -107.89 151.86 41.4 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.333 -0.854 . . . . 0.0 109.445 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.04 -169.64 0.8 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.68 2.253 . . . . 0.0 110.385 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.438 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.4 OUTLIER -66.61 -45.15 80.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.273 -0.892 . . . . 0.0 109.476 -179.984 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.6 OUTLIER -42.75 -36.85 1.57 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.373 -0.83 . . . . 0.0 109.578 -179.838 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.525 ' CG2' ' O ' ' A' ' 15' ' ' ASP . 18.5 mm -114.58 108.92 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.249 -0.907 . . . . 0.0 109.411 179.954 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.46 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -74.67 -1.48 21.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.217 -0.927 . . . . 0.0 109.667 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.562 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 0.8 OUTLIER 166.92 -174.12 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.917 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.63 -165.96 11.32 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.944 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.523 ' CG2' ' O ' ' A' ' 64' ' ' ASP . 0.4 OUTLIER -149.99 128.27 12.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.293 -1.122 . . . . 0.0 109.397 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.431 ' C ' ' O ' ' A' ' 17' ' ' THR . 61.3 t -43.83 159.49 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.217 -0.927 . . . . 0.0 109.529 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.455 ' HB3' ' OE2' ' A' ' 39' ' ' GLU . . . -111.99 -71.02 0.78 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.253 -0.904 . . . . 0.0 109.574 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.6 m -159.28 133.12 7.43 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.264 -0.897 . . . . 0.0 109.594 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.633 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.2 m95 -89.92 85.65 6.41 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.3 -0.875 . . . . 0.0 109.486 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.556 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.4 m80 -42.86 -60.09 1.73 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.325 -0.859 . . . . 0.0 109.352 -179.864 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -105.37 155.0 19.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.231 -0.918 . . . . 0.0 109.495 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.6 mttt -95.01 167.26 13.29 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.361 -0.837 . . . . 0.0 109.519 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.463 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.5 Cg_endo -76.75 104.56 1.93 Allowed 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.682 2.255 . . . . 0.0 110.494 179.892 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 140.45 -9.72 2.93 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -90.63 -172.17 3.3 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -1.151 . . . . 0.0 109.514 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -101.85 149.19 24.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -0.892 . . . . 0.0 109.421 -179.951 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -130.49 162.65 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.295 -0.878 . . . . 0.0 109.444 179.895 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 6.7 tttp -133.22 142.56 48.63 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.224 -0.923 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.46 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 10.5 ttp-105 -42.92 137.45 2.35 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.285 -0.884 . . . . 0.0 109.588 -179.863 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.463 ' HA ' ' CD2' ' A' ' 48' ' ' LEU . 23.9 t0 72.27 52.04 0.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.256 -0.902 . . . . 0.0 109.524 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.487 ' N ' HD13 ' A' ' 48' ' ' LEU . 0.5 OUTLIER -141.44 114.58 8.67 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.274 -0.891 . . . . 0.0 109.425 -179.978 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.556 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 54.3 tp -42.74 162.31 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.323 -0.861 . . . . 0.0 109.6 -179.937 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.501 HD13 ' N ' ' A' ' 49' ' ' ALA . 4.2 mt -140.84 -42.03 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.214 -0.929 . . . . 0.0 109.536 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.517 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.2 p -158.75 139.88 4.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.319 -0.863 . . . . 0.0 109.502 179.925 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -98.62 149.97 22.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.938 . . . . 0.0 109.544 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.428 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 32.8 mm -104.46 140.79 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.288 -0.883 . . . . 0.0 109.424 -179.993 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.455 ' OE2' ' HB3' ' A' ' 19' ' ' ALA . 0.7 OUTLIER -126.36 92.51 3.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.503 -179.975 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.434 ' OG1' ' HB ' ' A' ' 43' ' ' VAL . 3.0 p -87.81 -173.49 4.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.296 -0.878 . . . . 0.0 109.515 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 40' ' ' THR . 9.7 t0 -42.8 -61.56 1.23 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.367 -0.833 . . . . 0.0 109.626 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -141.62 33.25 1.63 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.477 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.434 ' HB ' ' OG1' ' A' ' 40' ' ' THR . 9.8 t -132.24 109.86 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.166 -0.959 . . . . 0.0 109.447 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.3 t -93.11 126.45 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.319 -0.863 . . . . 0.0 109.524 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' MET . . . . . 0.428 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 0.3 OUTLIER -123.95 -178.27 4.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.321 -0.862 . . . . 0.0 109.477 -180.0 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.414 ' HG3' ' C ' ' A' ' 45' ' ' MET . 0.7 OUTLIER -133.77 155.17 50.27 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.256 -0.902 . . . . 0.0 109.544 179.959 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.517 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 35.0 t -126.84 98.19 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.332 -0.855 . . . . 0.0 109.459 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.512 ' CD1' ' N ' ' A' ' 34' ' ' LEU . 2.6 tt -107.67 151.44 25.65 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.888 . . . . 0.0 109.426 -179.955 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.501 ' N ' HD13 ' A' ' 35' ' ' ILE . . . -83.76 161.12 21.09 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.205 -0.935 . . . . 0.0 109.485 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.86 17.83 23.27 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.194 -0.941 . . . . 0.0 109.396 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -178.58 173.75 1.29 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.298 -0.876 . . . . 0.0 109.494 -179.954 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -77.55 170.92 15.73 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.213 -0.929 . . . . 0.0 109.306 179.953 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.72 175.01 23.77 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.946 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.1 t -121.64 124.9 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.326 -1.102 . . . . 0.0 109.447 179.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.44 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 16.5 mm -58.22 162.36 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.256 -0.902 . . . . 0.0 109.509 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -101.67 -67.42 0.87 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.193 -0.942 . . . . 0.0 109.41 -179.965 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.463 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 2.2 mt-10 -162.46 135.09 5.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.445 -179.983 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.633 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 27.3 mm -93.17 122.23 44.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.224 -0.922 . . . . 0.0 109.409 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.5 t -89.95 -15.7 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.508 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.51 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 1.5 mptt -110.46 125.47 53.32 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.434 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 -92.99 173.59 7.66 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.905 . . . . 0.0 109.496 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -69.49 147.96 50.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 109.564 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.67 -8.76 76.42 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.523 ' O ' ' CG2' ' A' ' 17' ' ' THR . 0.1 OUTLIER -84.49 170.83 13.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.206 -1.173 . . . . 0.0 109.313 -179.92 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.51 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.8 t -99.9 159.29 15.18 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.511 -0.743 . . . . 0.0 109.48 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 29.9 m -122.54 160.51 24.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.222 -0.924 . . . . 0.0 109.452 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -125.36 174.54 8.09 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.179 -0.95 . . . . 0.0 109.492 179.983 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 35.9 t -72.92 85.97 1.28 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.495 -179.932 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 108.85 22.51 6.92 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -78.45 118.03 20.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -1.109 . . . . 0.0 109.459 -179.946 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 7.6 tt -65.77 131.68 46.88 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.281 -0.887 . . . . 0.0 109.448 179.995 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.477 HD21 ' CB ' ' A' ' 60' ' ' LYS . 4.4 mt -115.86 -13.47 11.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.281 -0.887 . . . . 0.0 109.491 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.77 163.69 22.12 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.98 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 7.2 mttt -124.54 145.95 49.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.24 -1.153 . . . . 0.0 109.483 179.939 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.416 HD22 ' O ' ' A' ' 76' ' ' THR . 0.6 OUTLIER -91.65 147.85 22.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.289 -0.882 . . . . 0.0 109.463 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.459 ' CG2' ' N ' ' A' ' 77' ' ' GLU . 2.9 t -107.04 -157.56 0.62 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.911 . . . . 0.0 109.787 179.976 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.459 ' N ' ' CG2' ' A' ' 76' ' ' THR . 42.2 mt-10 -83.38 175.11 10.09 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.986 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.437 ' HA3' ' HA2' ' A' ' 53' ' ' GLY . . . -171.54 140.1 5.7 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 CA-C-O 118.011 -1.438 . . . . 0.0 109.558 179.988 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.437 ' O ' HD11 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.513 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 . . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.437 HD11 ' O ' ' A' ' 1' ' ' ALA . 20.8 mm -117.17 97.9 6.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.273 -0.892 . . . . 0.0 109.439 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -60.5 136.42 58.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.24 -0.912 . . . . 0.0 109.472 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 80.5 mt -114.47 121.3 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.181 -0.949 . . . . 0.0 109.438 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 17.3 mtpt -123.25 178.15 5.25 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.213 -0.93 . . . . 0.0 109.508 179.966 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.18 164.58 42.99 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.255 -0.903 . . . . 0.0 109.505 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -77.99 117.76 4.25 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.644 2.229 . . . . 0.0 110.451 179.928 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -53.97 136.47 41.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.241 -0.912 . . . . 0.0 109.474 179.953 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.555 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 21.8 m-85 -95.33 155.34 38.9 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.469 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.416 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.1 Cg_endo -77.99 -178.53 4.68 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.71 2.273 . . . . 0.0 110.369 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.481 ' HG3' ' N ' ' A' ' 12' ' ' SER . 16.9 pt-20 -61.64 -43.85 98.08 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.481 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.82 -72.93 0.05 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.32 -0.863 . . . . 0.0 109.631 -179.88 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.416 ' O ' ' O ' ' A' ' 10' ' ' PRO . 1.8 mp -91.16 167.52 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.243 -0.911 . . . . 0.0 109.446 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.441 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -142.09 44.83 1.67 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.448 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.555 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 0.3 OUTLIER 168.74 -169.91 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.3 -0.875 . . . . 0.0 109.456 179.938 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -168.21 -170.04 32.43 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.996 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 29.9 m -150.07 126.69 10.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -1.146 . . . . 0.0 109.514 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.519 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 21.8 t -51.89 169.92 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.523 ' HB1' ' CB ' ' A' ' 37' ' ' ASP . . . -113.85 -75.34 0.6 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.229 -0.919 . . . . 0.0 109.534 -179.936 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.515 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 23.2 m -158.38 133.54 8.58 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.221 -0.924 . . . . 0.0 109.529 -179.918 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.623 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.85 84.77 6.26 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.232 -0.917 . . . . 0.0 109.524 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.628 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.9 m80 -43.07 -67.42 0.28 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.298 -0.876 . . . . 0.0 109.35 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -89.26 -171.92 3.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.42 179.911 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.472 ' HB2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.7 164.76 40.53 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.282 -0.886 . . . . 0.0 109.445 179.974 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.472 ' HD2' ' HB2' ' A' ' 24' ' ' LYS . 34.9 Cg_endo -77.18 101.21 1.48 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.559 2.173 . . . . 0.0 110.4 179.938 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 149.75 -16.8 1.09 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.896 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -93.0 -179.03 4.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -1.152 . . . . 0.0 109.437 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.52 159.62 18.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.21 -0.931 . . . . 0.0 109.519 179.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 80.5 t -143.57 156.33 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.393 -179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 31' ' ' ARG . 49.1 tttt -140.79 141.92 34.74 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 30' ' ' LYS . 5.7 ttm180 -42.82 151.34 0.13 Allowed 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.356 -0.84 . . . . 0.0 109.634 -179.848 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.9 t70 68.14 40.56 2.15 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.221 -0.924 . . . . 0.0 109.465 -179.982 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 34' ' ' LEU . 1.6 tt0 -140.14 111.05 6.9 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 0.0 109.467 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.628 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 51.2 tp -42.76 163.44 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.381 -0.825 . . . . 0.0 109.611 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.498 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 39.5 mt -147.18 -43.51 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.227 -0.921 . . . . 0.0 109.612 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.506 HG22 ' CE2' ' A' ' 21' ' ' TRP . 11.4 p -159.81 136.87 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.305 -0.872 . . . . 0.0 109.531 -179.925 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.523 ' CB ' ' HB1' ' A' ' 19' ' ' ALA . 3.5 m-20 -94.85 163.17 13.45 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.307 -0.871 . . . . 0.0 109.422 179.84 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.3 mt -129.33 156.87 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.119 -0.988 . . . . 0.0 109.527 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.17 134.45 50.16 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.288 -0.882 . . . . 0.0 109.503 179.938 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.462 HG21 ' O ' ' A' ' 43' ' ' VAL . 5.6 t -124.24 -163.94 1.2 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.183 -0.948 . . . . 0.0 109.392 180.0 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.438 ' C ' ' O ' ' A' ' 40' ' ' THR . 42.3 t0 -42.3 -68.87 0.16 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.247 -0.908 . . . . 0.0 109.741 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.419 ' O ' ' CG2' ' A' ' 43' ' ' VAL . 1.4 mttp -141.84 48.34 1.61 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.192 -0.942 . . . . 0.0 109.513 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.462 ' O ' HG21 ' A' ' 40' ' ' THR . 76.4 t -156.04 119.92 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.229 -0.92 . . . . 0.0 109.428 -179.956 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.0 t -89.95 118.11 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.216 -0.928 . . . . 0.0 109.523 -179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 1.6 mtp -96.79 -170.8 2.12 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.276 -0.89 . . . . 0.0 109.437 179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.46 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 5.2 pt-20 -149.15 159.6 44.1 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.287 -0.883 . . . . 0.0 109.448 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.43 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 68.0 t -130.74 108.28 15.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.263 -0.898 . . . . 0.0 109.459 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.497 ' HG ' ' N ' ' A' ' 34' ' ' LEU . 0.1 OUTLIER -93.85 172.59 8.15 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.294 -0.879 . . . . 0.0 109.537 179.962 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.413 ' HB1' HD13 ' A' ' 35' ' ' ILE . . . -76.16 136.01 39.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.278 -0.888 . . . . 0.0 109.419 -179.979 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.47 ' O ' ' CB ' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -95.67 10.12 37.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.531 179.975 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.47 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . 165.54 140.8 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.272 -0.892 . . . . 0.0 109.451 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.508 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.31 170.92 0.13 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 109.35 -179.982 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.508 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 140.29 -155.07 24.41 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 55.6 t -134.79 128.62 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.304 -1.116 . . . . 0.0 109.464 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 17.0 mm -56.35 159.36 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.28 -0.888 . . . . 0.0 109.511 179.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -99.66 -65.55 0.96 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.341 -0.849 . . . . 0.0 109.535 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.457 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 6.4 tt0 -173.1 132.77 0.51 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.158 -0.963 . . . . 0.0 109.528 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.623 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 28.4 mm -91.64 125.51 44.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.886 . . . . 0.0 109.391 179.953 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 23.2 t -90.08 -39.37 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.219 -0.926 . . . . 0.0 109.449 179.974 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.03 128.29 41.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.485 179.951 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 71.2 m-80 -87.91 155.98 19.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.303 -0.873 . . . . 0.0 109.446 -179.95 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.519 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -65.02 143.57 57.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.303 -0.873 . . . . 0.0 109.5 -179.937 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 97.11 -13.75 64.48 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.988 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.501 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -92.41 170.89 9.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.284 -1.127 . . . . 0.0 109.303 179.955 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.501 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 21.8 m -98.12 139.54 33.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.486 -0.759 . . . . 0.0 109.516 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.436 ' N ' HG21 ' A' ' 65' ' ' THR . 6.0 m -114.78 -161.95 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.289 -0.882 . . . . 0.0 109.391 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -146.62 170.84 16.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.278 -0.889 . . . . 0.0 109.49 -179.932 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 5.6 t -69.01 104.81 2.21 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.48 179.988 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 102.56 10.71 37.54 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.984 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 31.2 tp10 -72.3 125.53 27.58 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -1.132 . . . . 0.0 109.404 -179.967 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -74.58 121.42 21.56 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -0.917 . . . . 0.0 109.439 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.439 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 9.1 mt -95.85 -22.53 17.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.222 -0.923 . . . . 0.0 109.489 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 168.38 174.63 37.31 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -127.33 135.82 51.06 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.23 -1.159 . . . . 0.0 109.51 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -90.05 138.23 31.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.392 -179.92 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.2 m -96.9 171.25 8.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.268 -0.895 . . . . 0.0 109.481 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -84.98 -65.05 1.05 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.29 -0.881 . . . . 0.0 109.481 -179.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 129.6 117.64 1.98 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 CA-C-O 117.981 -1.455 . . . . 0.0 109.608 -179.959 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.451 ' HB2' HD21 ' A' ' 75' ' ' LEU . . . . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 49.9 mt -133.95 102.52 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.339 -0.85 . . . . 0.0 109.479 179.968 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -75.61 118.47 18.49 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.202 -0.936 . . . . 0.0 109.43 -179.933 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.8 mt -96.04 98.73 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.275 -0.89 . . . . 0.0 109.508 179.935 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.46 ' HG3' ' HA ' ' A' ' 71' ' ' LEU . 7.5 ttpt -118.78 163.93 16.15 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -0.884 . . . . 0.0 109.487 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.452 ' N ' HD13 ' A' ' 72' ' ' LEU . . . -65.5 160.78 57.08 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.897 . . . . 0.0 109.464 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -78.1 129.76 9.86 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.613 2.209 . . . . 0.0 110.396 -179.924 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.9 t -56.36 111.92 1.11 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.91 . . . . 0.0 109.445 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -74.24 126.6 88.91 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.329 -0.857 . . . . 0.0 109.345 -179.969 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.42 -159.44 0.1 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.398 2.065 . . . . 0.0 110.388 179.963 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.9 mm-40 -73.36 -55.0 6.98 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.161 -0.962 . . . . 0.0 109.398 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.435 ' C ' ' O ' ' A' ' 11' ' ' GLU . 17.0 t -42.87 -45.42 4.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.358 -0.839 . . . . 0.0 109.585 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 16.9 mt -91.3 163.61 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.293 -0.879 . . . . 0.0 109.491 -179.96 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -143.89 13.37 1.68 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.306 -0.871 . . . . 0.0 109.436 -179.965 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 172.23 -172.27 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.454 -179.968 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.42 172.45 40.19 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.445 ' O ' ' HB2' ' A' ' 39' ' ' GLU . 68.3 m -149.25 125.66 10.9 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.254 -1.145 . . . . 0.0 109.425 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.497 ' CG1' ' HA ' ' A' ' 62' ' ' GLU . 24.9 t -50.01 169.41 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.203 -0.935 . . . . 0.0 109.515 179.946 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.431 ' HB2' ' CB ' ' A' ' 37' ' ' ASP . . . -112.76 -73.27 0.67 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.158 -0.964 . . . . 0.0 109.502 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.462 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 52.4 m -159.62 131.21 6.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.483 -179.891 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.633 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.4 m95 -89.91 84.16 6.2 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 121.261 -0.899 . . . . 0.0 109.441 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.579 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 1.5 m80 -42.56 -64.89 0.54 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.373 -0.829 . . . . 0.0 109.454 -179.709 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 5.7 mptt -95.15 -172.19 2.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.244 -0.91 . . . . 0.0 109.532 -179.922 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.425 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.67 168.37 17.77 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.312 -0.868 . . . . 0.0 109.452 -179.965 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.471 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.64 133.09 13.86 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 C-N-CA 122.648 2.232 . . . . 0.0 110.409 179.878 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.8 -11.47 20.82 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.917 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 53.3 mm-40 -97.13 -174.91 3.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.241 -1.152 . . . . 0.0 109.502 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.03 172.65 8.42 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.222 -0.924 . . . . 0.0 109.51 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 t -141.91 155.08 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.974 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -131.65 128.26 38.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.228 -0.92 . . . . 0.0 109.496 179.969 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 3.2 ttt-85 -42.83 137.27 2.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.394 -0.817 . . . . 0.0 109.601 -179.822 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.497 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 10.7 t0 74.97 33.27 0.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.259 -0.901 . . . . 0.0 109.427 179.955 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.488 ' C ' ' CD1' ' A' ' 48' ' ' LEU . 1.2 tt0 -124.29 115.68 21.42 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.258 -0.902 . . . . 0.0 109.503 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.579 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 45.0 tp -43.11 150.94 0.16 Allowed 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.231 -0.918 . . . . 0.0 109.525 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.444 HD13 ' HB3' ' A' ' 49' ' ' ALA . 13.4 mt -129.69 -46.43 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.223 -0.923 . . . . 0.0 109.588 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.508 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.7 p -162.83 142.72 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.233 -0.917 . . . . 0.0 109.461 -179.908 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 46' ' ' GLU . 33.5 m-20 -100.73 163.03 12.51 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.284 -0.885 . . . . 0.0 109.437 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.473 ' CG2' ' N ' ' A' ' 39' ' ' GLU . 9.6 mt -129.33 162.86 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.174 -0.954 . . . . 0.0 109.483 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.473 ' N ' ' CG2' ' A' ' 38' ' ' ILE . 6.1 mm-40 -133.87 151.65 51.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 -179.978 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -140.25 -177.53 5.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.256 -0.903 . . . . 0.0 109.486 179.971 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 40' ' ' THR . 5.4 t70 -42.95 -66.47 0.37 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.326 -0.859 . . . . 0.0 109.629 -179.907 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.2 mttp -135.85 40.69 2.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.286 -0.884 . . . . 0.0 109.461 -179.974 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.426 ' O ' ' OG1' ' A' ' 40' ' ' THR . 52.5 t -151.49 128.18 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.273 -0.892 . . . . 0.0 109.463 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.0 p -98.58 134.41 37.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 0.0 109.442 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' MET . . . . . 0.42 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 1.3 mtt -114.59 -172.45 2.11 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.46 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 6.1 pt-20 -154.73 164.56 38.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.254 -0.904 . . . . 0.0 109.461 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.508 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 58.2 t -134.69 103.55 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 109.442 -179.927 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.488 ' CD1' ' C ' ' A' ' 33' ' ' GLU . 0.4 OUTLIER -93.96 167.04 11.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.2 -0.937 . . . . 0.0 109.52 179.984 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.444 ' HB3' HD13 ' A' ' 35' ' ' ILE . . . -84.54 136.1 33.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.405 -179.929 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.46 ' O ' ' HB1' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -95.87 9.9 39.03 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.162 -0.961 . . . . 0.0 109.466 -179.977 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.46 ' HB1' ' O ' ' A' ' 50' ' ' GLU . . . 167.06 142.93 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.233 -0.917 . . . . 0.0 109.478 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.505 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -58.63 170.96 0.69 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.317 -0.864 . . . . 0.0 109.375 179.96 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.505 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.78 -157.43 27.27 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.928 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.7 t -128.64 127.11 66.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.25 -1.147 . . . . 0.0 109.572 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.415 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 14.4 mm -64.0 156.79 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.27 -0.894 . . . . 0.0 109.437 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -95.55 -69.57 0.75 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.21 -0.931 . . . . 0.0 109.416 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.471 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 1.2 pt-20 -172.27 142.48 1.35 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.252 -0.905 . . . . 0.0 109.449 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.633 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 24.5 mm -94.8 129.54 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.23 -0.919 . . . . 0.0 109.48 -179.977 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.1 t -90.15 -28.99 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.29 -0.881 . . . . 0.0 109.442 179.987 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.443 ' HD3' ' HG2' ' A' ' 70' ' ' GLU . 0.0 OUTLIER -109.16 131.99 54.54 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.182 -0.949 . . . . 0.0 109.529 179.926 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -85.47 155.93 21.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.165 -0.96 . . . . 0.0 109.461 179.992 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.497 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -68.29 141.51 55.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.914 . . . . 0.0 109.476 179.958 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 96.12 -11.3 67.58 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.505 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -95.95 170.9 8.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.262 -1.14 . . . . 0.0 109.327 -179.986 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.505 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 13.0 t -89.02 157.95 18.18 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.492 -0.755 . . . . 0.0 109.516 -179.992 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 1.9 m -127.21 -174.82 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.245 -0.909 . . . . 0.0 109.464 -179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -140.96 177.81 7.79 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.336 -0.853 . . . . 0.0 109.481 -179.957 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.4 t -69.46 124.17 23.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.489 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 75.24 21.89 77.09 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 179.951 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.443 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 42.6 tp10 -74.58 103.65 4.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.191 -1.182 . . . . 0.0 109.472 179.966 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.46 ' HA ' ' HG3' ' A' ' 5' ' ' LYS . 0.7 OUTLIER -60.93 105.47 0.47 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.213 -0.929 . . . . 0.0 109.438 180.0 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 1.4 mt -84.22 -11.46 56.45 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.249 -0.907 . . . . 0.0 109.503 179.94 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.77 165.39 15.82 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.536 -1.425 . . . . 0.0 109.536 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.432 ' HE2' HD12 ' A' ' 71' ' ' LEU . 29.7 mtmt -125.83 151.85 46.27 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.23 -1.159 . . . . 0.0 109.484 179.967 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.451 HD21 ' HB2' ' A' ' 1' ' ' ALA . 1.9 tt -98.1 152.54 19.21 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.276 -0.89 . . . . 0.0 109.496 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 14.2 m -107.24 171.86 7.15 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.243 -0.911 . . . . 0.0 109.438 -179.974 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -75.35 172.17 12.94 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.177 -0.952 . . . . 0.0 109.532 179.983 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -95.94 -164.63 33.98 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.282 0 CA-C-O 117.982 -1.454 . . . . 0.0 109.602 -179.985 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 25.4 mm -136.09 109.85 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.179 -0.95 . . . . 0.0 109.409 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.458 ' OD2' HD13 ' A' ' 71' ' ' LEU . 11.7 t70 -89.3 129.93 35.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.192 -0.942 . . . . 0.0 109.562 179.9 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mp -104.81 128.84 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.265 -0.897 . . . . 0.0 109.469 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 48.3 mtpt -130.43 176.25 8.29 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.317 -0.864 . . . . 0.0 109.468 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.94 156.55 60.78 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.479 -179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.97 134.53 13.27 Favored 'Trans proline' 0 C--N 1.308 -1.554 0 C-N-CA 122.664 2.242 . . . . 0.0 110.404 179.959 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.432 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -45.49 115.04 0.85 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.223 -0.923 . . . . 0.0 109.502 179.995 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -64.34 149.27 94.96 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.487 179.969 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.406 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -78.02 174.81 11.95 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.598 2.198 . . . . 0.0 110.402 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 12' ' ' SER . 30.5 tt0 -66.75 -55.31 15.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.313 -0.867 . . . . 0.0 109.463 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 11' ' ' GLU . 35.1 t -42.81 -40.86 3.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.361 -0.837 . . . . 0.0 109.581 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.406 ' HB ' ' HD2' ' A' ' 10' ' ' PRO . 12.3 mm -94.35 152.4 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.266 -0.896 . . . . 0.0 109.452 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -126.43 9.29 7.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.26 -0.9 . . . . 0.0 109.497 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 173.64 -172.03 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.206 -0.934 . . . . 0.0 109.414 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.16 -176.09 27.88 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.988 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.515 ' CG2' ' O ' ' A' ' 64' ' ' ASP . 0.3 OUTLIER -150.03 128.94 12.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -1.121 . . . . 0.0 109.431 -179.961 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' A' ' 17' ' ' THR . 53.0 t -43.96 165.74 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.238 -0.914 . . . . 0.0 109.537 -179.943 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.456 ' HB2' ' O ' ' A' ' 37' ' ' ASP . . . -117.52 -72.8 0.67 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.266 -0.896 . . . . 0.0 109.422 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 34.5 m -160.05 127.48 4.57 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.261 -0.899 . . . . 0.0 109.579 -179.977 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.629 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 33.1 m95 -89.85 87.37 6.93 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 121.207 -0.933 . . . . 0.0 109.519 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.613 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.8 m80 -42.46 -57.91 2.45 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.416 -0.803 . . . . 0.0 109.522 -179.76 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 9.3 mttp -106.19 178.94 4.41 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.218 -0.927 . . . . 0.0 109.604 -179.953 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -118.31 167.51 11.32 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.271 -0.893 . . . . 0.0 109.497 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.459 ' HG3' HG12 ' A' ' 58' ' ' ILE . 35.3 Cg_endo -76.94 136.31 16.46 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.617 2.211 . . . . 0.0 110.413 179.96 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.34 -8.77 35.51 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -93.5 -175.39 3.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.227 -1.16 . . . . 0.0 109.477 179.997 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.461 ' O ' HG11 ' A' ' 29' ' ' VAL . . . -104.61 147.77 27.26 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.93 . . . . 0.0 109.462 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.461 HG11 ' O ' ' A' ' 28' ' ' ALA . 2.6 m -147.56 169.48 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.236 -0.915 . . . . 0.0 109.421 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.427 ' O ' ' C ' ' A' ' 31' ' ' ARG . 16.5 tttp -133.06 143.39 49.32 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.252 -0.905 . . . . 0.0 109.442 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.452 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.82 152.32 0.11 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.231 -0.918 . . . . 0.0 109.624 -179.89 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.452 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 26.0 t70 69.04 41.78 1.37 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -0.907 . . . . 0.0 109.418 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' A' ' 34' ' ' LEU . 10.8 tt0 -140.97 117.42 10.8 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.325 -0.859 . . . . 0.0 109.456 179.995 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.613 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 48.8 tp -42.96 163.34 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.241 -0.912 . . . . 0.0 109.562 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.498 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 59.5 mt -149.5 -43.27 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.156 -0.965 . . . . 0.0 109.522 -179.948 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.522 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 9.3 p -157.75 143.32 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.273 -0.892 . . . . 0.0 109.51 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.473 ' OD2' ' NE2' ' A' ' 22' ' ' HIS . 3.7 m-20 -108.54 147.49 31.67 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 109.458 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.461 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 46.7 mt -103.97 150.54 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.316 -0.865 . . . . 0.0 109.434 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -131.79 99.46 4.77 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.942 . . . . 0.0 109.468 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.525 ' CG2' ' HB ' ' A' ' 43' ' ' VAL . 6.6 t -93.62 -170.14 2.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.915 . . . . 0.0 109.476 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 2.6 t0 -42.5 -56.33 3.1 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.294 -0.879 . . . . 0.0 109.767 -179.923 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.473 ' C ' ' CG2' ' A' ' 43' ' ' VAL . 4.1 mtmp? -148.22 49.56 1.04 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -0.884 . . . . 0.0 109.561 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.525 ' HB ' ' CG2' ' A' ' 40' ' ' THR . 1.9 t -154.34 106.44 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.254 -0.904 . . . . 0.0 109.566 179.896 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 94.0 t -89.95 106.63 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.412 179.985 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' MET . . . . . 0.461 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 27.2 mtp -90.05 177.12 6.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 0.0 109.494 179.941 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -132.76 151.58 51.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.921 . . . . 0.0 109.425 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.522 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 85.7 t -127.11 107.55 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.246 -0.909 . . . . 0.0 109.456 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.463 ' CD1' ' HA ' ' A' ' 34' ' ' LEU . 1.1 mp -92.27 176.75 6.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.463 -179.96 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.439 ' CB ' HD12 ' A' ' 35' ' ' ILE . . . -81.9 123.78 29.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.174 -0.954 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.433 ' O ' ' HB1' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -92.92 14.5 17.38 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.174 -0.954 . . . . 0.0 109.419 -179.922 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.433 ' HB1' ' O ' ' A' ' 50' ' ' GLU . . . 174.49 124.96 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.287 -0.883 . . . . 0.0 109.411 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -59.43 170.91 0.9 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.206 -0.934 . . . . 0.0 109.298 -179.969 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.51 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 132.48 -140.56 11.93 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.968 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.462 ' O ' ' HB ' ' A' ' 76' ' ' THR . 46.4 t -139.12 132.12 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.16 -1.2 . . . . 0.0 109.433 179.979 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.458 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 14.7 mm -63.69 169.57 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.271 -0.893 . . . . 0.0 109.506 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -108.52 -65.86 1.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.235 -0.916 . . . . 0.0 109.481 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.456 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -165.47 141.53 5.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.212 -0.93 . . . . 0.0 109.474 179.994 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.629 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 22.7 mm -95.04 125.59 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.192 -0.943 . . . . 0.0 109.425 179.96 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.486 HG22 ' CD2' ' A' ' 71' ' ' LEU . 23.7 t -89.95 -15.26 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.529 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.517 ' CD ' ' HG2' ' A' ' 70' ' ' GLU . 0.0 OUTLIER -110.64 130.04 55.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.27 -0.894 . . . . 0.0 109.453 -179.991 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 57.9 m-80 -105.23 165.37 11.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.227 -0.921 . . . . 0.0 109.44 -179.931 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -67.2 136.6 55.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.538 179.931 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 95.08 2.74 62.21 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.515 ' O ' ' CG2' ' A' ' 17' ' ' THR . 0.1 OUTLIER -104.92 170.83 7.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.105 -1.233 . . . . 0.0 109.377 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.505 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.8 t -98.27 159.59 14.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.497 -0.752 . . . . 0.0 109.51 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 11.9 m -132.7 130.6 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.206 -0.934 . . . . 0.0 109.435 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -94.1 168.64 10.8 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.903 . . . . 0.0 109.509 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.432 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 44.5 t -60.75 130.25 45.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.521 179.989 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 72.74 27.44 69.12 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.999 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.517 ' HG2' ' CD ' ' A' ' 60' ' ' LYS . 0.4 OUTLIER -80.81 132.02 35.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.287 -1.125 . . . . 0.0 109.463 -179.989 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.504 HD22 ' N ' ' A' ' 73' ' ' GLY . 10.4 tt -78.31 122.09 25.28 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.294 -0.879 . . . . 0.0 109.46 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 5.7 mt -96.9 -25.53 15.4 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.352 -0.843 . . . . 0.0 109.469 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.504 ' N ' HD22 ' A' ' 71' ' ' LEU . . . 175.07 157.2 15.86 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.449 ' HG2' ' HA ' ' A' ' 3' ' ' ASP . 0.0 OUTLIER -113.82 159.14 20.13 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.319 -1.106 . . . . 0.0 109.481 179.982 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 19.7 tp -100.83 159.89 14.82 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.225 -0.922 . . . . 0.0 109.429 -179.986 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.499 HG22 ' N ' ' A' ' 77' ' ' GLU . 2.9 t -86.79 -157.65 0.38 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.278 -0.889 . . . . 0.0 109.703 179.971 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.499 ' N ' HG22 ' A' ' 76' ' ' THR . 55.5 mm-40 -71.36 -90.57 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.757 0 CA-C-O 121.284 0.564 . . . . 0.0 109.487 179.958 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 102.54 -30.13 11.04 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 CA-C-O 117.933 -1.482 . . . . 0.0 109.507 179.945 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.443 HD13 HD21 ' A' ' 75' ' ' LEU . 8.1 mt -106.29 106.12 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.311 -0.868 . . . . 0.0 109.458 179.968 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.469 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 11.4 t70 -75.91 127.08 32.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.46 -179.983 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 18.7 mt -103.38 126.18 57.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.271 -0.893 . . . . 0.0 109.432 -179.991 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -132.96 159.23 40.57 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.303 -0.873 . . . . 0.0 109.481 179.972 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.94 164.45 61.33 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.426 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.08 179.78 6.18 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.676 2.25 . . . . 0.0 110.382 179.979 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.87 126.55 36.07 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.206 -0.933 . . . . 0.0 109.471 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -81.61 156.08 70.8 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.257 -0.902 . . . . 0.0 109.458 -179.969 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.05 173.31 14.15 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.682 2.254 . . . . 0.0 110.363 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 12' ' ' SER . 7.8 pt-20 -65.9 -47.9 73.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.266 -0.896 . . . . 0.0 109.46 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.428 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.74 -49.37 5.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.312 -0.868 . . . . 0.0 109.617 -179.935 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.451 HG23 ' O ' ' A' ' 15' ' ' ASP . 8.7 mt -91.22 166.52 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.284 -0.885 . . . . 0.0 109.475 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.425 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -131.9 11.61 4.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.249 -0.907 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.451 ' O ' HG23 ' A' ' 13' ' ' ILE . 0.9 OUTLIER 169.96 -171.45 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.244 -0.91 . . . . 0.0 109.4 -179.966 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.23 -163.71 9.91 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.994 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.452 ' O ' ' CB ' ' A' ' 39' ' ' GLU . 26.5 m -149.95 128.21 12.08 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -1.123 . . . . 0.0 109.424 -179.962 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.464 HG11 ' N ' ' A' ' 19' ' ' ALA . 39.5 t -50.74 154.2 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.285 -0.885 . . . . 0.0 109.445 179.934 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.523 ' HB1' ' CB ' ' A' ' 37' ' ' ASP . . . -99.84 -76.84 0.54 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.161 -0.962 . . . . 0.0 109.511 179.972 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.2 m -159.89 130.16 5.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.541 -179.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.628 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.1 m95 -89.8 84.94 6.29 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.225 -0.922 . . . . 0.0 109.559 -179.893 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . 0.566 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -43.26 -61.59 1.29 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.313 -0.867 . . . . 0.0 109.335 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -94.67 -172.1 2.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.345 -0.847 . . . . 0.0 109.493 179.986 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.521 ' HD2' ' CD ' ' A' ' 25' ' ' PRO . 2.9 mmmt -130.81 163.87 45.77 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.24 -0.913 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.521 ' CD ' ' HD2' ' A' ' 24' ' ' LYS . 35.5 Cg_endo -77.48 106.43 2.21 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.562 2.175 . . . . 0.0 110.429 179.921 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 137.72 -10.28 3.7 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.939 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.1 -172.33 2.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.249 -1.148 . . . . 0.0 109.416 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -105.7 150.03 25.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.28 -0.888 . . . . 0.0 109.477 179.974 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.3 m -131.93 -170.93 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.244 -0.91 . . . . 0.0 109.459 -179.963 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.439 ' HA ' ' HB2' ' A' ' 52' ' ' ASP . 12.5 mttm -149.91 130.91 14.34 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.217 -0.927 . . . . 0.0 109.52 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.474 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 4.3 ttm105 -42.82 143.61 0.69 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.318 -0.864 . . . . 0.0 109.669 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.474 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 6.7 t70 73.84 38.28 0.6 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.316 -0.865 . . . . 0.0 109.476 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.434 ' O ' ' C ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -138.98 122.73 17.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.909 . . . . 0.0 109.436 179.96 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.566 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 36.0 tp -43.0 149.14 0.21 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.201 -0.937 . . . . 0.0 109.548 -179.939 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 35.4 mm -132.62 -42.86 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -0.915 . . . . 0.0 109.554 -179.921 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.447 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 4.4 p -162.1 147.48 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.244 -0.91 . . . . 0.0 109.546 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.523 ' CB ' ' HB1' ' A' ' 19' ' ' ALA . 1.3 m-20 -107.33 154.79 20.77 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.896 . . . . 0.0 109.396 179.966 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.414 ' O ' ' HA ' ' A' ' 44' ' ' VAL . 26.8 mm -122.73 148.09 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.218 -0.926 . . . . 0.0 109.489 -179.937 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.452 ' CB ' ' O ' ' A' ' 17' ' ' THR . 0.3 OUTLIER -107.14 109.69 21.59 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.535 179.941 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 41' ' ' ASP . 35.4 p -97.27 -150.35 0.34 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.202 -0.936 . . . . 0.0 109.434 -179.949 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 3.0 t0 -42.8 -70.05 0.12 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.318 -0.863 . . . . 0.0 109.668 -179.886 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -145.1 25.19 1.42 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.222 -0.924 . . . . 0.0 109.458 179.963 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.9 t -136.53 130.66 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -0.961 . . . . 0.0 109.466 179.947 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 38' ' ' ILE . 2.1 t -90.96 109.48 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.223 -0.923 . . . . 0.0 109.512 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -79.99 163.79 23.96 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.299 -0.875 . . . . 0.0 109.507 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -108.07 145.17 34.41 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.247 -0.908 . . . . 0.0 109.43 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.447 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 10.1 t -118.75 100.85 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.312 -0.868 . . . . 0.0 109.426 179.958 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.421 ' HG ' ' C ' ' A' ' 33' ' ' GLU . 0.4 OUTLIER -91.91 153.83 19.25 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.193 -0.942 . . . . 0.0 109.49 179.991 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.17 138.85 44.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.9 . . . . 0.0 109.49 179.983 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -88.51 13.52 11.8 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.294 -0.879 . . . . 0.0 109.505 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . 170.49 150.37 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.252 -0.905 . . . . 0.0 109.45 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -78.6 170.99 15.78 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.317 179.994 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.51 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 149.91 -137.69 6.34 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 50.9 t -136.07 125.6 39.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -1.129 . . . . 0.0 109.465 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 14.1 mm -64.58 161.78 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.925 . . . . 0.0 109.531 180.0 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -103.51 -67.02 0.91 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.256 -0.903 . . . . 0.0 109.466 -179.948 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.459 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 2.5 tt0 -169.83 140.59 2.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.286 -0.884 . . . . 0.0 109.463 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.628 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 22.5 mm -93.86 131.63 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.171 -0.956 . . . . 0.0 109.527 -179.965 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 72.0 t -89.96 -38.41 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.274 -0.892 . . . . 0.0 109.497 179.957 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.458 ' HA ' ' HE2' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -94.77 125.21 39.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.343 -0.848 . . . . 0.0 109.424 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 28.8 m-80 -89.64 176.24 6.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.253 -0.904 . . . . 0.0 109.482 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -74.9 153.33 38.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.246 -0.909 . . . . 0.0 109.502 179.957 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.94 15.12 62.13 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.515 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -104.58 170.88 7.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.177 -1.19 . . . . 0.0 109.312 179.993 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.1 m -100.45 138.31 37.69 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.445 -0.784 . . . . 0.0 109.5 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.453 HG11 ' HG2' ' A' ' 60' ' ' LYS . 4.9 m -115.8 172.75 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.207 -0.933 . . . . 0.0 109.461 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -136.06 -173.95 3.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.255 -0.903 . . . . 0.0 109.472 179.936 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.97 149.3 48.98 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.175 -0.953 . . . . 0.0 109.464 -179.965 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 49.69 29.95 13.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.986 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.436 ' OE2' ' HD3' ' A' ' 60' ' ' LYS . 49.6 tp10 -80.55 114.27 19.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.271 -1.135 . . . . 0.0 109.495 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.469 ' CD1' ' OD1' ' A' ' 3' ' ' ASP . 0.5 OUTLIER -66.31 118.69 10.35 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.191 -0.943 . . . . 0.0 109.47 179.95 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 8.7 mt -87.96 -28.27 21.58 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.483 179.968 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 176.96 170.59 39.6 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.429 ' HE3' HD23 ' A' ' 71' ' ' LEU . 10.0 mttt -128.44 134.45 48.76 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -1.158 . . . . 0.0 109.445 180.0 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.455 HD22 ' O ' ' A' ' 76' ' ' THR . 0.5 OUTLIER -91.56 147.2 23.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -0.88 . . . . 0.0 109.414 -179.974 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.455 ' O ' HD22 ' A' ' 75' ' ' LEU . 7.3 m -100.54 170.73 8.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.282 -0.886 . . . . 0.0 109.514 179.922 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -59.16 -72.91 0.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.238 -0.914 . . . . 0.0 109.454 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 128.75 150.84 7.28 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 CA-C-O 117.996 -1.447 . . . . 0.0 109.599 179.944 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.628 HD13 HD22 ' A' ' 75' ' ' LEU . 5.4 mp . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' A' ' 4' ' ' ILE . 39.6 t0 -88.98 132.82 34.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.239 -0.913 . . . . 0.0 109.452 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.481 ' N ' ' OD1' ' A' ' 3' ' ' ASP . 82.2 mt -99.99 124.24 53.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.424 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 70' ' ' GLU . 2.6 mttt -122.75 175.59 6.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.209 -0.932 . . . . 0.0 109.448 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.558 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -79.68 161.38 66.9 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.883 . . . . 0.0 109.49 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.558 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.6 Cg_endo -78.06 173.8 13.42 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.638 2.225 . . . . 0.0 110.389 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.5 m -92.07 134.68 34.61 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.478 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -100.14 155.82 35.98 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 109.438 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.432 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -77.99 -159.93 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.589 2.193 . . . . 0.0 110.473 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' A' ' 12' ' ' SER . 2.5 mt-10 -78.64 -58.69 3.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 109.497 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 11' ' ' GLU . 31.1 t -42.83 -45.09 4.75 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.295 -0.878 . . . . 0.0 109.628 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.577 HG22 ' H ' ' A' ' 15' ' ' ASP . 33.7 mm -104.43 136.92 35.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.297 -0.877 . . . . 0.0 109.472 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.407 ' C ' ' OD1' ' A' ' 15' ' ' ASP . . . -119.03 16.81 13.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.233 -0.917 . . . . 0.0 109.451 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.577 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.4 OUTLIER -169.18 -170.73 1.16 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 0.0 109.438 -179.982 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.68 -170.08 16.11 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.512 ' O ' ' CB ' ' A' ' 39' ' ' GLU . 1.4 m -150.0 128.57 12.3 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.221 -1.164 . . . . 0.0 109.499 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.1 t -56.42 153.82 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.226 -0.921 . . . . 0.0 109.406 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.578 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -96.86 -72.98 0.62 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.256 -0.903 . . . . 0.0 109.546 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.7 m -160.05 132.61 6.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.22 -0.925 . . . . 0.0 109.558 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.634 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.9 83.0 6.12 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.257 -0.902 . . . . 0.0 109.528 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.703 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.0 m80 -42.85 -64.84 0.55 Allowed 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.38 -0.825 . . . . 0.0 109.441 -179.771 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.17 -179.25 4.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.557 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.401 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -125.84 168.48 13.84 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.249 -0.907 . . . . 0.0 109.487 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.487 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 34.9 Cg_endo -76.66 123.26 6.84 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.626 2.218 . . . . 0.0 110.398 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.3 12.64 9.61 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -118.22 -172.44 2.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.205 -1.173 . . . . 0.0 109.457 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -98.68 153.56 18.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.242 -0.911 . . . . 0.0 109.462 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.526 HG22 ' N ' ' A' ' 30' ' ' LYS . 2.8 p -138.36 162.3 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 109.48 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.526 ' N ' HG22 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -134.59 126.13 28.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.256 -0.903 . . . . 0.0 109.517 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.506 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 16.8 ttp180 -42.72 146.82 0.34 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.323 -0.861 . . . . 0.0 109.664 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.506 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 2.9 t70 75.18 33.95 0.68 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.465 ' HB2' ' O ' ' A' ' 30' ' ' LYS . 3.4 tt0 -138.83 123.6 18.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -0.912 . . . . 0.0 109.444 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.703 HD21 ' NE2' ' A' ' 22' ' ' HIS . 50.6 tp -42.98 156.97 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.273 -0.892 . . . . 0.0 109.531 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.647 HG13 ' HB2' ' A' ' 49' ' ' ALA . 35.8 mm -139.11 -38.17 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.2 -0.937 . . . . 0.0 109.651 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.438 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.5 p -166.66 139.1 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.175 -0.953 . . . . 0.0 109.527 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.578 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 1.1 m-20 -98.61 158.5 15.56 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 36.1 mt -125.01 153.63 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.532 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.512 ' CB ' ' O ' ' A' ' 17' ' ' THR . 15.0 tt0 -109.88 123.61 49.89 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.236 -0.915 . . . . 0.0 109.454 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.435 ' O ' ' C ' ' A' ' 41' ' ' ASP . 3.9 p -107.54 -162.44 0.84 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.256 -0.903 . . . . 0.0 109.475 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.435 ' C ' ' O ' ' A' ' 40' ' ' THR . 16.7 t0 -42.72 -66.7 0.34 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.33 -0.856 . . . . 0.0 109.65 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 13.3 mtpt -142.79 26.16 1.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.31 -0.869 . . . . 0.0 109.476 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 42.1 t -136.48 136.5 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.28 -0.888 . . . . 0.0 109.504 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 56.4 t -95.65 119.26 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.292 -0.88 . . . . 0.0 109.458 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 4.2 mtt -93.71 179.7 5.28 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.242 -0.911 . . . . 0.0 109.503 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -131.96 148.9 52.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.514 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.438 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 21.2 t -121.91 107.95 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.256 -0.903 . . . . 0.0 109.441 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.436 ' HG ' ' C ' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -98.16 153.11 18.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 109.494 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.647 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -76.87 143.65 39.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.26 -0.9 . . . . 0.0 109.416 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.65 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.1 OUTLIER -96.25 15.42 21.08 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.469 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.65 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 166.9 148.28 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.468 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.496 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -69.96 170.96 10.22 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.348 179.978 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.496 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 157.27 -146.61 13.92 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.6 t -135.39 124.6 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.25 -1.147 . . . . 0.0 109.506 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.4 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 12.1 mm -70.03 158.88 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.275 -0.891 . . . . 0.0 109.496 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -95.13 -64.43 1.07 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.199 -0.938 . . . . 0.0 109.457 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.487 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 11.7 pt-20 -179.17 146.32 0.29 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.461 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.634 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 30.6 mm -99.07 127.42 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.245 -0.909 . . . . 0.0 109.475 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.3 t -90.08 -29.92 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.497 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 0.2 OUTLIER -90.78 148.1 22.77 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.234 -0.916 . . . . 0.0 109.481 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.468 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 4.5 m-80 -110.45 156.31 21.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.503 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -60.6 139.19 57.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.269 -0.894 . . . . 0.0 109.526 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 90.11 4.97 71.01 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -105.76 170.7 7.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -1.186 . . . . 0.0 109.355 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 7.3 t -102.21 154.26 19.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.528 -0.732 . . . . 0.0 109.564 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.453 HG11 HD21 ' A' ' 72' ' ' LEU . 30.3 m -130.66 133.81 62.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.47 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -92.43 169.86 10.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.465 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -59.51 143.21 50.74 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.248 -0.908 . . . . 0.0 109.451 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 67.7 12.02 61.18 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.416 ' O ' ' HA ' ' A' ' 5' ' ' LYS . 5.3 tp10 -70.33 120.58 16.21 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.287 -1.125 . . . . 0.0 109.467 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.545 HD23 ' C ' ' A' ' 71' ' ' LEU . 10.0 tt -77.97 111.92 14.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.301 -0.874 . . . . 0.0 109.459 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.453 HD21 HG11 ' A' ' 66' ' ' VAL . 1.9 mt -88.3 -21.12 24.59 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.267 -0.895 . . . . 0.0 109.462 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.5 -177.17 45.23 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.459 ' NZ ' ' OE2' ' A' ' 57' ' ' GLU . 0.0 OUTLIER -139.63 153.81 47.41 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.195 -1.18 . . . . 0.0 109.52 179.963 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.628 HD22 HD13 ' A' ' 2' ' ' ILE . 0.5 OUTLIER -94.69 155.61 16.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.267 -0.896 . . . . 0.0 109.435 -179.985 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.481 ' O ' HD23 ' A' ' 75' ' ' LEU . 9.4 m . . . . . 0 N--CA 1.49 1.554 0 O-C-N 121.204 -0.935 . . . . 0.0 109.456 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.469 HG13 ' HB3' ' A' ' 75' ' ' LEU . 2.0 pt . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.41 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 20.9 t0 -120.59 136.86 54.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.281 -0.887 . . . . 0.0 109.461 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 65.8 mt -110.46 118.85 58.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.189 -0.944 . . . . 0.0 109.481 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.86 156.77 48.34 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.289 -0.882 . . . . 0.0 109.418 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.626 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -58.7 163.54 5.11 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.202 -0.936 . . . . 0.0 109.46 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.626 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.7 Cg_endo -78.06 178.16 7.92 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.618 2.212 . . . . 0.0 110.41 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.43 ' O ' ' CD1' ' A' ' 9' ' ' PHE . 0.2 OUTLIER -76.56 176.42 8.35 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.896 . . . . 0.0 109.509 -179.966 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.462 ' CE1' HG23 ' A' ' 40' ' ' THR . 23.7 m-85 -138.7 71.78 43.11 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.453 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.93 -0.14 10.38 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.636 2.224 . . . . 0.0 110.432 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.515 ' O ' ' CD1' ' A' ' 13' ' ' ILE . 5.9 mm-40 -85.33 46.46 1.29 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.394 -0.816 . . . . 0.0 109.438 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.45 ' C ' ' O ' ' A' ' 11' ' ' GLU . 6.6 t 39.25 39.21 0.41 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.528 -0.733 . . . . 0.0 110.034 179.707 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.515 ' CD1' ' O ' ' A' ' 11' ' ' GLU . 15.0 mm -98.82 156.35 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.891 . . . . 0.0 109.374 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.496 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -93.83 -1.88 54.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.19 -0.944 . . . . 0.0 109.727 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.496 ' CB ' ' O ' ' A' ' 14' ' ' ALA . 1.1 p30 163.74 -169.63 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.227 -0.921 . . . . 0.0 109.442 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.0 -169.33 11.63 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.467 HG23 ' O ' ' A' ' 64' ' ' ASP . 93.6 m -150.02 123.26 8.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.204 -1.174 . . . . 0.0 109.534 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 19' ' ' ALA . 24.2 t -51.09 169.49 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.22 -0.925 . . . . 0.0 109.482 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.579 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -112.73 -73.14 0.68 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.179 -0.951 . . . . 0.0 109.609 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.482 HG23 ' OE1' ' A' ' 62' ' ' GLU . 16.4 m -159.98 137.13 9.44 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.53 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.704 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 32.7 m95 -89.98 83.85 6.14 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.259 -0.901 . . . . 0.0 109.501 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.803 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.2 m80 -42.86 -69.82 0.13 Allowed 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.39 -0.819 . . . . 0.0 109.487 -179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.05 -171.58 2.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 109.674 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.476 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 1.8 mttt -128.8 170.76 9.93 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.227 -0.92 . . . . 0.0 109.435 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.533 ' CG ' ' HA ' ' A' ' 57' ' ' GLU . 34.8 Cg_endo -75.61 129.52 11.88 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.657 2.238 . . . . 0.0 110.39 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 120.98 -11.88 9.95 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -95.84 166.48 11.78 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.254 -1.145 . . . . 0.0 109.472 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.29 133.39 35.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -0.907 . . . . 0.0 109.411 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 52' ' ' ASP . 25.1 m -136.31 135.84 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.162 -0.961 . . . . 0.0 109.528 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 31' ' ' ARG . 9.6 pttp -117.35 146.23 43.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.88 . . . . 0.0 109.389 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.465 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 4.0 ttt180 -42.9 156.23 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.244 -0.91 . . . . 0.0 109.623 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.465 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 18.8 t70 73.34 29.21 1.69 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -0.881 . . . . 0.0 109.453 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.536 ' N ' HD23 ' A' ' 48' ' ' LEU . 30.5 tt0 -137.71 111.63 8.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.285 -0.884 . . . . 0.0 109.446 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.803 HD21 ' NE2' ' A' ' 22' ' ' HIS . 43.4 tp -42.9 153.56 0.08 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.36 -0.837 . . . . 0.0 109.595 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.607 HD13 ' O ' ' A' ' 34' ' ' LEU . 11.1 mm -139.08 -38.51 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.15 -0.969 . . . . 0.0 109.55 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.521 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 10.8 p -160.21 131.53 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.263 -0.898 . . . . 0.0 109.466 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.507 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 32.4 m-20 -92.15 157.09 16.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.918 . . . . 0.0 109.482 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 20.6 tt -127.91 162.98 32.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.325 -0.859 . . . . 0.0 109.447 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -148.76 110.65 4.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.24 -0.912 . . . . 0.0 109.434 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.462 HG23 ' CE1' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -80.73 -160.65 0.32 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.29 -0.881 . . . . 0.0 109.503 179.94 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.423 ' HB2' HD12 ' A' ' 13' ' ' ILE . 50.0 t0 -42.83 -67.64 0.26 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.293 -0.88 . . . . 0.0 109.631 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -132.02 23.22 4.55 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -0.934 . . . . 0.0 109.491 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 1.9 t -117.97 162.13 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.226 -0.921 . . . . 0.0 109.437 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.9 t -137.35 126.7 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.284 -0.885 . . . . 0.0 109.51 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' MET . . . . . 0.53 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 1.7 mtt -123.63 -171.01 2.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.256 -0.903 . . . . 0.0 109.434 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.3 152.4 48.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.417 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.521 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 35.0 t -122.52 111.18 29.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.319 -0.863 . . . . 0.0 109.47 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.536 HD23 ' N ' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -102.02 165.78 10.98 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.281 -0.887 . . . . 0.0 109.464 -179.978 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -76.35 144.97 39.81 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.333 -0.855 . . . . 0.0 109.472 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -108.49 7.44 26.86 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.143 -0.973 . . . . 0.0 109.536 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -175.45 122.32 0.21 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.178 -0.951 . . . . 0.0 109.531 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.499 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -55.14 170.93 0.17 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.3 -0.875 . . . . 0.0 109.32 179.999 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.499 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 140.82 -139.34 9.57 Favored Glycine 0 N--CA 1.49 2.233 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 45.0 t -139.15 123.55 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -1.184 . . . . 0.0 109.429 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.561 HG22 ' N ' ' A' ' 56' ' ' ALA . 13.9 mm -65.06 167.75 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.249 -0.907 . . . . 0.0 109.537 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.561 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -101.72 -65.42 0.98 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.181 -0.95 . . . . 0.0 109.472 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.533 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -171.68 159.09 5.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.502 179.992 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.704 HG23 ' CZ2' ' A' ' 21' ' ' TRP . 74.2 mt -89.97 130.56 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.318 -0.864 . . . . 0.0 109.403 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.465 ' HB ' ' O ' ' A' ' 71' ' ' LEU . 50.0 t -89.99 -37.77 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.2 -0.938 . . . . 0.0 109.417 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.458 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -113.89 137.63 51.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.229 -0.92 . . . . 0.0 109.4 -179.989 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 60.9 m-20 -79.96 156.37 27.25 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.213 -0.929 . . . . 0.0 109.443 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.525 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -70.3 142.76 52.21 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 93.99 -15.62 62.74 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.506 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -84.24 170.88 13.28 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.181 -1.188 . . . . 0.0 109.365 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.506 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 88.5 m -96.78 133.49 41.29 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.518 -0.739 . . . . 0.0 109.477 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.619 ' C ' HD12 ' A' ' 67' ' ' LEU . 6.3 m -116.68 -154.66 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.26 -0.9 . . . . 0.0 109.429 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.619 HD12 ' C ' ' A' ' 66' ' ' VAL . 2.9 mp -149.65 176.64 10.48 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.262 -0.899 . . . . 0.0 109.495 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.2 t -69.41 109.21 4.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.251 -0.905 . . . . 0.0 109.449 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.55 21.47 26.57 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.43 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 11.3 tp10 -74.0 121.05 20.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -1.133 . . . . 0.0 109.428 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.465 ' O ' ' HB ' ' A' ' 59' ' ' VAL . 25.5 tp -64.9 111.62 2.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.255 -0.903 . . . . 0.0 109.492 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 8.4 mt -95.18 -10.91 29.13 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -0.887 . . . . 0.0 109.48 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.34 163.39 21.13 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 26.4 mttt -125.41 144.71 50.39 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -1.139 . . . . 0.0 109.456 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.56 HD12 HD13 ' A' ' 55' ' ' ILE . 12.4 tp -90.0 153.51 20.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.445 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.477 ' N ' ' HG ' ' A' ' 75' ' ' LEU . 14.6 m . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.903 . . . . 0.0 109.489 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.489 HG13 ' HB3' ' A' ' 75' ' ' LEU . 1.8 pp . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.455 ' OD2' HD13 ' A' ' 71' ' ' LEU . 8.3 t0 -89.72 129.28 36.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.313 -0.867 . . . . 0.0 109.483 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.609 HG23 HG11 ' A' ' 47' ' ' VAL . 87.4 mt -97.08 75.97 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.238 -0.914 . . . . 0.0 109.517 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.33 161.6 13.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.227 -0.92 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.611 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -74.51 163.11 70.54 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.216 -0.927 . . . . 0.0 109.437 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.611 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.8 Cg_endo -78.08 -179.85 5.83 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.632 2.222 . . . . 0.0 110.386 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.426 HG23 ' OG ' ' A' ' 68' ' ' SER . 3.0 m -93.82 106.99 18.93 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.297 -0.877 . . . . 0.0 109.443 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.417 ' HB3' ' HD2' ' A' ' 10' ' ' PRO . 80.9 m-85 -61.5 157.81 43.82 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.233 -0.917 . . . . 0.0 109.452 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.449 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.1 -163.08 0.2 Allowed 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.585 2.19 . . . . 0.0 110.415 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.6 OUTLIER -80.82 -59.06 2.82 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.265 -0.897 . . . . 0.0 109.436 -179.972 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 11' ' ' GLU . 35.3 t -42.82 -31.24 0.47 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.365 -0.835 . . . . 0.0 109.618 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.463 HG22 ' H ' ' A' ' 15' ' ' ASP . 24.4 mt -113.81 141.41 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.227 -0.921 . . . . 0.0 109.445 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -126.96 31.25 5.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.5 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.463 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.9 OUTLIER 174.8 -171.47 0.06 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.8 -164.71 13.82 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.471 ' HA ' ' O ' ' A' ' 64' ' ' ASP . 84.6 m -150.12 120.99 7.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.214 -1.168 . . . . 0.0 109.44 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.537 HG12 ' N ' ' A' ' 19' ' ' ALA . 60.0 t -43.79 162.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.302 -0.874 . . . . 0.0 109.487 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.537 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -108.11 -75.17 0.64 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.278 -0.889 . . . . 0.0 109.562 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.9 m -160.17 131.61 5.92 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.167 -0.958 . . . . 0.0 109.619 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.833 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 33.3 m95 -89.82 85.88 6.51 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.255 -0.903 . . . . 0.0 109.448 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.672 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.5 m80 -42.34 -69.88 0.12 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.356 -0.84 . . . . 0.0 109.654 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.69 -174.09 2.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.217 -0.927 . . . . 0.0 109.78 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.498 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -116.87 165.67 14.75 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.377 -0.827 . . . . 0.0 109.262 179.975 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.871 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.2 Cg_endo -77.18 145.43 24.38 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.552 2.168 . . . . 0.0 110.426 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.44 -8.89 60.58 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.473 ' HG2' ' O ' ' A' ' 24' ' ' LYS . 0.4 OUTLIER -94.1 176.74 6.21 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.202 -1.175 . . . . 0.0 109.453 -179.972 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.462 ' O ' ' OE1' ' A' ' 27' ' ' GLU . . . -91.37 158.4 16.55 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.291 -0.881 . . . . 0.0 109.486 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.493 HG22 ' O ' ' A' ' 53' ' ' GLY . 34.7 m -138.87 -167.53 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.257 -0.902 . . . . 0.0 109.506 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 31' ' ' ARG . 5.1 tptm -142.18 140.85 32.51 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.221 -0.925 . . . . 0.0 109.463 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.1 OUTLIER -42.84 123.48 2.74 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.311 -0.868 . . . . 0.0 109.649 -179.874 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.752 ' C ' HD21 ' A' ' 48' ' ' LEU . 6.1 t70 75.9 57.06 0.05 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.276 -0.89 . . . . 0.0 109.491 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.544 ' N ' HD21 ' A' ' 48' ' ' LEU . 0.9 OUTLIER -131.76 121.3 23.95 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.203 -0.936 . . . . 0.0 109.402 -179.934 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.672 HD21 ' NE2' ' A' ' 22' ' ' HIS . 51.3 tp -42.94 162.25 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.329 -0.857 . . . . 0.0 109.499 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.956 HD11 ' HB2' ' A' ' 49' ' ' ALA . 91.6 mt -141.52 -49.49 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.933 . . . . 0.0 109.48 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.637 HG12 ' HB ' ' A' ' 47' ' ' VAL . 7.9 p -152.25 151.93 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.915 . . . . 0.0 109.417 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.618 ' C ' HD13 ' A' ' 38' ' ' ILE . 49.8 m-20 -117.6 151.38 37.3 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.257 -0.902 . . . . 0.0 109.554 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.618 HD13 ' C ' ' A' ' 37' ' ' ASP . 3.6 mm -108.17 156.36 8.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.248 -0.907 . . . . 0.0 109.383 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -135.28 117.48 15.52 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.262 -0.899 . . . . 0.0 109.489 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.431 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -115.8 -167.48 1.27 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.229 -0.919 . . . . 0.0 109.495 -179.991 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.431 ' C ' ' O ' ' A' ' 40' ' ' THR . 53.8 t0 -42.7 -67.74 0.25 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.359 -0.838 . . . . 0.0 109.626 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 1.7 mtpp -139.16 34.25 2.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.205 -0.934 . . . . 0.0 109.468 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.4 t -135.73 107.35 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.952 . . . . 0.0 109.504 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.2 t -89.98 115.85 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' MET . . . . . 0.466 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 4.6 mtp -99.23 178.31 4.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.302 -0.874 . . . . 0.0 109.488 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.424 ' HA ' ' OD1' ' A' ' 37' ' ' ASP . 41.0 mt-10 -138.48 169.64 17.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.205 -0.935 . . . . 0.0 109.438 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.637 ' HB ' HG12 ' A' ' 36' ' ' VAL . 97.1 t -141.92 103.09 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.224 -0.923 . . . . 0.0 109.478 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.752 HD21 ' C ' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -104.38 155.31 18.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.218 -0.927 . . . . 0.0 109.506 -179.982 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.956 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.19 165.22 18.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.515 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.694 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.8 OUTLIER -103.44 13.15 34.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.694 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.7 164.2 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.455 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.503 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -58.18 170.95 0.61 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.26 -0.9 . . . . 0.0 109.336 179.979 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.503 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 150.07 -174.64 29.45 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 69.6 t -124.86 131.18 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -1.132 . . . . 0.0 109.418 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.741 HD13 ' N ' ' A' ' 55' ' ' ILE . 1.4 mm -71.24 -176.64 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.271 -0.893 . . . . 0.0 109.486 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.789 ' HB3' ' HG2' ' A' ' 74' ' ' LYS . . . -114.01 -59.57 2.0 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.235 -0.916 . . . . 0.0 109.409 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.529 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 17.5 pt-20 -178.88 157.47 0.89 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.26 -0.9 . . . . 0.0 109.548 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.871 HD11 ' HD3' ' A' ' 25' ' ' PRO . 1.7 mp -89.96 140.88 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 109.446 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.454 ' HB ' ' O ' ' A' ' 71' ' ' LEU . 11.1 t -100.67 -15.17 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.261 -0.899 . . . . 0.0 109.366 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.488 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -126.37 -172.58 2.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.31 -0.869 . . . . 0.0 109.403 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.473 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 17.3 m-80 -132.45 164.26 26.96 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.169 -0.957 . . . . 0.0 109.509 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.01 133.41 48.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.306 -0.871 . . . . 0.0 109.408 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.05 -6.78 82.67 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -79.72 170.76 16.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.219 -1.165 . . . . 0.0 109.428 179.902 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.516 ' N ' ' OD1' ' A' ' 64' ' ' ASP . 32.3 m -98.77 138.84 35.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.547 -0.721 . . . . 0.0 109.498 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 6.2 m -122.29 170.67 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.268 -0.895 . . . . 0.0 109.455 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.478 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.1 OUTLIER -132.94 177.6 7.53 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.474 -179.98 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.426 ' OG ' HG23 ' A' ' 8' ' ' THR . 9.1 t -62.85 146.61 52.35 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.914 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 57.85 28.59 60.71 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.478 ' HB2' ' O ' ' A' ' 67' ' ' LEU . 8.0 tp10 -84.06 115.28 22.28 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.174 -1.192 . . . . 0.0 109.419 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.63 HD21 ' HD2' ' A' ' 74' ' ' LYS . 16.0 tp -72.91 106.09 4.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.262 -0.898 . . . . 0.0 109.49 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 15.7 mt -89.36 -10.91 44.87 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.224 -0.922 . . . . 0.0 109.455 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.36 164.29 22.75 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.789 ' HG2' ' HB3' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -136.12 142.9 44.29 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -1.173 . . . . 0.0 109.451 179.985 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.807 HD23 ' O ' ' A' ' 76' ' ' THR . 2.7 tt -97.44 167.99 10.66 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.239 -0.913 . . . . 0.0 109.479 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.807 ' O ' HD23 ' A' ' 75' ' ' LEU . 5.0 m . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.448 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 30.3 mm . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -66.35 127.99 34.39 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.1 mt -102.54 97.97 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.319 -0.863 . . . . 0.0 109.495 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.471 ' HG3' ' HA ' ' A' ' 71' ' ' LEU . 0.0 OUTLIER -118.76 146.9 44.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.211 -0.931 . . . . 0.0 109.461 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.43 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -61.26 157.51 43.58 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.197 -0.939 . . . . 0.0 109.494 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.43 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.6 Cg_endo -78.07 122.85 5.92 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 C-N-CA 122.581 2.188 . . . . 0.0 110.379 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.563 HG23 ' OG ' ' A' ' 68' ' ' SER . 17.5 m -44.17 108.02 0.1 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.244 -0.91 . . . . 0.0 109.454 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -71.03 147.95 94.1 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.245 -0.909 . . . . 0.0 109.501 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.579 ' HG2' HD12 ' A' ' 13' ' ' ILE . 35.5 Cg_endo -78.18 -159.44 0.1 Allowed 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.599 2.199 . . . . 0.0 110.324 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.433 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.4 OUTLIER -75.98 -52.65 9.8 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -0.899 . . . . 0.0 109.47 -179.956 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.8 t -42.82 -56.14 3.36 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.252 -0.905 . . . . 0.0 109.628 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.579 HD12 ' HG2' ' A' ' 10' ' ' PRO . 2.5 mp -89.95 111.14 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.226 -0.921 . . . . 0.0 109.452 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.466 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -88.77 10.45 20.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.204 -0.935 . . . . 0.0 109.502 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.518 ' O ' ' CG2' ' A' ' 13' ' ' ILE . 0.8 OUTLIER 166.6 -172.39 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 -179.921 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.464 ' O ' HG23 ' A' ' 65' ' ' THR . . . -154.08 -167.87 16.81 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.477 HG23 ' O ' ' A' ' 64' ' ' ASP . 90.3 m -148.21 131.94 16.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.265 -1.138 . . . . 0.0 109.463 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.504 HG12 ' N ' ' A' ' 19' ' ' ALA . 27.1 t -52.56 163.93 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.218 -0.926 . . . . 0.0 109.435 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.514 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -108.96 -76.41 0.61 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.175 -0.953 . . . . 0.0 109.442 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.4 m -160.03 131.9 6.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.248 -0.908 . . . . 0.0 109.46 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.636 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 31.9 m95 -89.87 85.43 6.38 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.26 -0.9 . . . . 0.0 109.56 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.875 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.0 m80 -42.77 -58.25 2.43 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.355 -0.841 . . . . 0.0 109.38 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -101.43 -175.04 2.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.57 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.439 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -125.65 167.82 15.57 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.344 -0.847 . . . . 0.0 109.446 179.985 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.499 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.91 118.04 4.66 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.588 2.192 . . . . 0.0 110.418 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 124.56 7.52 6.21 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.794 ' O ' HG13 ' A' ' 54' ' ' VAL . 5.2 mm-40 -113.26 -172.25 2.03 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.223 -1.163 . . . . 0.0 109.55 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.449 ' HA ' HG22 ' A' ' 54' ' ' VAL . . . -105.02 158.02 16.83 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.169 -0.957 . . . . 0.0 109.448 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -142.49 -174.35 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 0.0 109.436 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 3.7 mttp -147.67 137.54 22.77 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.491 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.434 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.1 OUTLIER -42.78 137.21 2.35 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.344 -0.847 . . . . 0.0 109.63 -179.914 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.42 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 8.2 t0 70.06 51.23 0.41 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.314 -0.866 . . . . 0.0 109.521 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.474 ' O ' HG13 ' A' ' 35' ' ' ILE . 1.8 tm-20 -140.8 120.65 13.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.185 -0.947 . . . . 0.0 109.493 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.875 HD21 ' NE2' ' A' ' 22' ' ' HIS . 35.3 tp -42.93 142.82 0.83 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.301 -0.874 . . . . 0.0 109.57 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.474 HG13 ' O ' ' A' ' 33' ' ' GLU . 12.8 mt -134.97 -43.07 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.232 -0.917 . . . . 0.0 109.598 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.468 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.4 p -158.66 142.52 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.223 -0.923 . . . . 0.0 109.508 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.514 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 55.9 m-20 -105.46 152.44 23.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.214 -0.929 . . . . 0.0 109.404 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.413 HG21 HD13 ' A' ' 38' ' ' ILE . 10.9 mt -128.81 153.84 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.211 -0.93 . . . . 0.0 109.537 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -121.74 150.94 41.1 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.233 -0.917 . . . . 0.0 109.443 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.493 HG21 ' SD ' ' A' ' 45' ' ' MET . 28.1 p -133.62 -168.37 2.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.241 -0.912 . . . . 0.0 109.491 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.411 ' C ' ' O ' ' A' ' 40' ' ' THR . 27.2 t70 -42.68 -69.25 0.14 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.348 -0.845 . . . . 0.0 109.686 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.9 mtmt -136.64 27.15 3.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.227 -0.92 . . . . 0.0 109.425 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.439 ' O ' ' OG1' ' A' ' 40' ' ' THR . 1.9 t -135.86 162.1 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.259 -0.901 . . . . 0.0 109.507 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.3 p -122.53 138.81 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.352 -0.843 . . . . 0.0 109.479 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' MET . . . . . 0.493 ' SD ' HG21 ' A' ' 40' ' ' THR . 1.9 mpp? -127.05 101.94 6.76 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.254 -0.904 . . . . 0.0 109.453 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.462 ' HG2' ' OD1' ' A' ' 37' ' ' ASP . 15.0 mt-10 -73.9 163.81 27.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.277 -0.889 . . . . 0.0 109.475 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.468 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 71.6 t -131.04 107.69 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.281 -0.887 . . . . 0.0 109.44 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.721 HD12 ' HA ' ' A' ' 34' ' ' LEU . 1.3 mp -91.91 170.2 10.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.906 . . . . 0.0 109.536 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.442 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -71.91 124.7 25.43 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.257 -0.902 . . . . 0.0 109.458 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.701 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -82.68 6.85 16.57 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.9 . . . . 0.0 109.5 -179.947 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 163.94 141.46 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.516 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -49.01 170.97 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 109.338 -179.974 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 135.8 -155.84 22.51 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.794 HG13 ' O ' ' A' ' 27' ' ' GLU . 48.5 t -138.71 125.04 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.318 -1.107 . . . . 0.0 109.477 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.562 HG22 ' H ' ' A' ' 56' ' ' ALA . 4.6 mm -46.45 172.25 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.255 -0.903 . . . . 0.0 109.464 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.562 ' H ' HG22 ' A' ' 55' ' ' ILE . . . -110.91 -65.09 1.2 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.266 -0.896 . . . . 0.0 109.478 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.499 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -170.27 138.78 1.65 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.469 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.636 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 21.5 mm -101.38 128.53 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.245 -0.91 . . . . 0.0 109.49 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.2 t -98.06 -30.97 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.262 -0.898 . . . . 0.0 109.481 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.467 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -91.23 117.65 29.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.32 -0.862 . . . . 0.0 109.454 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 57.6 m-80 -84.06 157.23 21.85 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.311 -0.868 . . . . 0.0 109.451 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -57.19 142.44 42.78 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.26 -0.9 . . . . 0.0 109.463 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.76 11.29 68.42 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -104.69 170.92 7.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -1.125 . . . . 0.0 109.292 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 52.0 m -107.52 146.95 31.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.45 -0.781 . . . . 0.0 109.465 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.733 HG11 HD21 ' A' ' 72' ' ' LEU . 7.1 m -124.59 139.82 49.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.237 -0.914 . . . . 0.0 109.49 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -101.06 -175.55 2.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.316 -0.865 . . . . 0.0 109.436 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.563 ' OG ' HG23 ' A' ' 8' ' ' THR . 1.5 t -64.47 122.22 16.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.266 -0.897 . . . . 0.0 109.496 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.51 31.28 41.69 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -83.84 104.56 14.03 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.187 -1.184 . . . . 0.0 109.484 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.471 ' HA ' ' HG3' ' A' ' 5' ' ' LYS . 1.0 OUTLIER -66.4 120.28 13.06 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -0.912 . . . . 0.0 109.487 179.966 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.733 HD21 HG11 ' A' ' 66' ' ' VAL . 1.0 OUTLIER -95.81 -18.92 20.02 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.283 -0.886 . . . . 0.0 109.495 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.77 -179.64 41.0 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' A' ' 56' ' ' ALA . 2.1 mtmt -140.58 152.44 45.48 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.295 -1.12 . . . . 0.0 109.484 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -92.61 151.34 20.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.425 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 8.6 m . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.899 . . . . 0.0 109.434 -179.999 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.8 pt . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.447 ' OD2' ' HB3' ' A' ' 5' ' ' LYS . 29.5 t70 -117.47 135.92 53.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.23 -0.919 . . . . 0.0 109.432 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.495 HG22 ' O ' ' A' ' 4' ' ' ILE . 91.3 mt -99.47 73.08 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.216 -0.928 . . . . 0.0 109.517 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.447 ' HB3' ' OD2' ' A' ' 3' ' ' ASP . 0.9 OUTLIER -104.77 159.31 15.88 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.228 -0.92 . . . . 0.0 109.445 179.963 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.46 147.69 75.86 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.21 -0.931 . . . . 0.0 109.436 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.21 160.82 29.47 Favored 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.608 2.206 . . . . 0.0 110.379 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 9' ' ' PHE . 27.2 m -71.6 89.38 0.98 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.327 -0.858 . . . . 0.0 109.48 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.471 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 31.4 m-85 -44.07 147.98 0.86 Allowed Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.298 -0.876 . . . . 0.0 109.444 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 9' ' ' PHE . 35.8 Cg_endo -78.06 -159.96 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.691 2.261 . . . . 0.0 110.415 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 12' ' ' SER . 46.7 tt0 -77.38 -58.41 3.29 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.215 -0.928 . . . . 0.0 109.401 -179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.8 t -42.8 -55.71 3.53 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.273 -0.892 . . . . 0.0 109.693 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.512 HG22 ' H ' ' A' ' 15' ' ' ASP . 3.5 mt -91.45 134.08 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.251 -0.905 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.18 11.3 16.25 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.242 -0.911 . . . . 0.0 109.486 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.512 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 171.31 -171.15 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.182 -0.949 . . . . 0.0 109.477 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.76 -167.3 17.77 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.526 HG23 ' O ' ' A' ' 64' ' ' ASP . 94.6 m -150.0 125.83 10.46 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -1.156 . . . . 0.0 109.483 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.468 HG12 ' N ' ' A' ' 19' ' ' ALA . 47.0 t -45.26 160.07 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 109.454 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.608 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -106.16 -73.06 0.69 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.186 -0.946 . . . . 0.0 109.51 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.1 m -160.08 131.89 6.12 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.237 -0.914 . . . . 0.0 109.521 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.635 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.4 m95 -89.87 85.57 6.42 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 121.279 -0.888 . . . . 0.0 109.545 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.656 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.0 m80 -43.26 -62.21 1.12 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.32 -0.863 . . . . 0.0 109.392 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -100.58 176.66 5.25 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.929 . . . . 0.0 109.506 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.16 167.46 11.33 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.427 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.479 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.92 108.94 2.75 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.689 2.259 . . . . 0.0 110.422 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 139.01 -10.22 3.33 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.433 ' O ' HG13 ' A' ' 54' ' ' VAL . 1.4 mt-10 -97.48 -172.22 2.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.29 -1.123 . . . . 0.0 109.541 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -106.76 154.66 20.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.299 -0.875 . . . . 0.0 109.498 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.869 HG21 HD11 ' A' ' 35' ' ' ILE . 8.4 p -139.58 148.94 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.499 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -114.58 137.69 51.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.151 -0.968 . . . . 0.0 109.504 -179.972 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.461 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 29.5 ttt85 -42.73 150.03 0.17 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.331 -0.855 . . . . 0.0 109.663 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.683 ' HA ' HD21 ' A' ' 48' ' ' LEU . 8.5 t70 72.3 41.14 0.63 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.48 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.439 ' O ' ' O ' ' A' ' 34' ' ' LEU . 2.4 tp10 -141.94 124.23 15.61 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.147 -0.97 . . . . 0.0 109.448 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.656 HD21 ' NE2' ' A' ' 22' ' ' HIS . 45.7 tp -43.16 164.69 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.346 -0.846 . . . . 0.0 109.482 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.869 HD11 HG21 ' A' ' 29' ' ' VAL . 27.4 mm -139.52 -46.07 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.109 -0.994 . . . . 0.0 109.579 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.458 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.6 p -166.3 137.25 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.262 -0.899 . . . . 0.0 109.473 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.608 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 16.9 m-20 -97.96 152.67 19.01 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.253 -0.904 . . . . 0.0 109.44 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.485 HD13 ' O ' ' A' ' 37' ' ' ASP . 6.0 mm -119.52 156.15 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.461 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.47 ' HB2' ' O ' ' A' ' 17' ' ' THR . 1.1 mm-40 -118.23 128.91 55.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.425 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.1 OUTLIER -109.87 -161.23 0.75 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.266 -0.896 . . . . 0.0 109.429 179.992 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.425 ' C ' ' O ' ' A' ' 40' ' ' THR . 13.6 t0 -42.8 -71.01 0.09 Allowed 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.342 -0.849 . . . . 0.0 109.681 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.5 mmtm -137.29 28.24 2.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.274 -0.891 . . . . 0.0 109.475 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 44' ' ' VAL . 24.6 t -128.43 169.32 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.24 -0.913 . . . . 0.0 109.51 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.579 ' N ' HG12 ' A' ' 43' ' ' VAL . 7.5 p -129.66 122.43 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.302 -0.874 . . . . 0.0 109.457 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 87.2 mmm -103.89 176.51 5.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 0.0 109.476 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -136.21 153.15 51.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.215 -0.928 . . . . 0.0 109.543 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.458 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 45.8 t -125.09 102.58 10.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.336 -0.853 . . . . 0.0 109.454 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.683 HD21 ' HA ' ' A' ' 32' ' ' ASP . 0.5 OUTLIER -96.41 150.21 20.85 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.214 -0.929 . . . . 0.0 109.44 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.436 ' O ' HD23 ' A' ' 48' ' ' LEU . . . -78.8 137.71 37.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.469 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -101.33 19.96 16.75 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.332 -0.855 . . . . 0.0 109.496 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -176.57 134.61 0.23 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.244 -0.91 . . . . 0.0 109.5 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.5 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -62.75 170.94 2.31 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.263 -0.898 . . . . 0.0 109.377 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.5 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 146.71 -151.74 23.97 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 27' ' ' GLU . 71.4 t -134.28 130.63 54.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -1.149 . . . . 0.0 109.425 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.492 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.1 mt -52.15 160.5 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.338 -0.851 . . . . 0.0 109.524 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.492 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -97.69 -68.79 0.78 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.142 -0.974 . . . . 0.0 109.444 -179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.479 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 1.5 mt-10 -176.02 133.08 0.25 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.293 -0.879 . . . . 0.0 109.495 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.635 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 20.1 mm -95.33 125.22 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.309 -0.869 . . . . 0.0 109.47 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 44.3 t -89.91 -29.75 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.912 . . . . 0.0 109.425 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.521 ' CG ' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -90.0 162.72 15.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -0.912 . . . . 0.0 109.424 -179.986 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.475 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 13.7 m-80 -117.08 157.57 25.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.212 -0.93 . . . . 0.0 109.5 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -61.14 134.61 57.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.21 -0.931 . . . . 0.0 109.443 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 94.15 -7.05 72.65 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.526 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -86.06 170.71 11.99 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -1.145 . . . . 0.0 109.301 -179.996 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.502 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 9.6 t -99.58 163.09 12.65 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.536 -0.728 . . . . 0.0 109.521 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 5.7 m -127.02 144.32 37.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.199 -0.938 . . . . 0.0 109.468 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -107.1 167.81 9.65 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.216 -0.928 . . . . 0.0 109.54 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.6 t -67.44 101.83 1.03 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.311 -0.868 . . . . 0.0 109.458 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 107.47 13.2 21.36 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.425 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 46.9 tp10 -81.13 123.84 28.75 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.261 -1.14 . . . . 0.0 109.522 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 5.8 tt -81.88 114.22 20.34 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.184 -0.947 . . . . 0.0 109.517 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 22.3 mt -89.32 -20.02 24.56 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.17 -0.956 . . . . 0.0 109.495 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 161.29 179.96 36.34 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.474 ' HG2' ' HB3' ' A' ' 56' ' ' ALA . 0.6 OUTLIER -149.74 153.04 36.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -1.175 . . . . 0.0 109.458 -179.968 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.468 ' HG ' ' N ' ' A' ' 76' ' ' THR . 17.0 tp -90.26 153.17 20.67 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.315 -0.866 . . . . 0.0 109.47 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.468 ' N ' ' HG ' ' A' ' 75' ' ' LEU . 5.6 m . . . . . 0 N--CA 1.49 1.567 0 O-C-N 121.311 -0.868 . . . . 0.0 109.46 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.529 HD13 HD22 ' A' ' 75' ' ' LEU . 3.3 mp . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -60.81 130.77 48.15 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.272 -0.893 . . . . 0.0 109.502 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.651 HD12 ' HA ' ' A' ' 74' ' ' LYS . 2.7 mp -100.29 110.61 27.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.195 -0.941 . . . . 0.0 109.472 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.7 pttp -120.17 166.82 12.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.198 -0.939 . . . . 0.0 109.478 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.655 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -84.99 164.46 41.59 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.265 -0.897 . . . . 0.0 109.487 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.655 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.3 Cg_endo -78.02 153.54 28.84 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.625 2.217 . . . . 0.0 110.455 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.468 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 41.2 m -75.75 110.49 10.22 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.933 . . . . 0.0 109.455 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -69.92 153.31 95.56 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.205 -0.934 . . . . 0.0 109.482 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.11 176.74 9.61 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 C-N-CA 122.656 2.237 . . . . 0.0 110.453 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.533 ' HG3' ' N ' ' A' ' 12' ' ' SER . 22.5 pt-20 -65.24 -45.44 84.59 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.287 -0.883 . . . . 0.0 109.469 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.533 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 1.5 t -42.61 -40.12 2.59 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.379 -0.826 . . . . 0.0 109.699 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.704 HG22 ' H ' ' A' ' 15' ' ' ASP . 30.0 mm -108.11 154.05 9.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.259 -0.901 . . . . 0.0 109.453 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -118.18 0.16 11.7 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.235 -0.916 . . . . 0.0 109.611 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.704 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER 179.23 -174.45 0.21 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.189 -0.945 . . . . 0.0 109.506 -179.995 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -150.92 -160.56 9.47 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.543 HG23 ' O ' ' A' ' 64' ' ' ASP . 16.8 m -150.02 129.04 12.62 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.236 -1.155 . . . . 0.0 109.418 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.513 HG12 ' N ' ' A' ' 19' ' ' ALA . 60.8 t -44.45 161.26 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.398 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.627 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -106.65 -75.13 0.64 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.247 -0.908 . . . . 0.0 109.515 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.6 m -160.13 131.42 5.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.234 -0.917 . . . . 0.0 109.558 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.637 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.82 85.88 6.51 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.337 -0.852 . . . . 0.0 109.53 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.625 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.7 m80 -42.12 -69.02 0.15 Allowed 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.355 -0.841 . . . . 0.0 109.483 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -96.93 -177.24 3.81 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.215 -0.928 . . . . 0.0 109.628 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.44 ' CG ' ' HD2' ' A' ' 25' ' ' PRO . 4.5 mttp -122.76 169.4 9.9 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.292 -0.88 . . . . 0.0 109.453 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.508 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.1 Cg_endo -76.23 136.43 17.97 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.626 2.217 . . . . 0.0 110.416 179.813 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.73 14.07 35.69 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -112.5 -172.3 2.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -1.119 . . . . 0.0 109.508 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.75 138.93 31.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.346 -0.846 . . . . 0.0 109.456 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.9 t -118.5 141.76 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.406 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 8.8 ttpt -131.86 127.03 35.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.296 -0.878 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.534 ' CG ' ' HA ' ' A' ' 51' ' ' ALA . 0.2 OUTLIER -42.75 147.24 0.31 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.374 -0.829 . . . . 0.0 109.63 -179.889 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.484 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 11.8 t0 73.4 26.41 2.02 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -0.888 . . . . 0.0 109.463 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.427 ' O ' ' O ' ' A' ' 34' ' ' LEU . 12.5 tm-20 -126.8 110.24 12.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.363 -0.836 . . . . 0.0 109.474 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.625 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 47.4 tp -42.98 164.23 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.321 -0.862 . . . . 0.0 109.597 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.84 HD11 ' HB2' ' A' ' 49' ' ' ALA . 27.4 mt -138.18 -47.72 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.27 -0.894 . . . . 0.0 109.606 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.534 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 12.6 p -150.61 152.78 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.236 -0.915 . . . . 0.0 109.51 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.627 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 23.3 m-20 -113.99 150.63 33.56 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.27 -0.894 . . . . 0.0 109.461 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.534 HD11 ' CG2' ' A' ' 47' ' ' VAL . 3.3 mt -115.27 145.09 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.263 -0.898 . . . . 0.0 109.489 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -118.59 143.91 46.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.209 -0.932 . . . . 0.0 109.423 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.541 HG22 ' N ' ' A' ' 41' ' ' ASP . 55.7 m -134.96 165.35 25.54 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.199 -0.938 . . . . 0.0 109.422 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.541 ' N ' HG22 ' A' ' 40' ' ' THR . 45.0 t0 -42.79 -36.14 1.37 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.869 . . . . 0.0 109.639 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 20.3 mttp -158.48 28.91 0.24 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.277 -0.89 . . . . 0.0 109.503 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.464 ' O ' ' HB ' ' A' ' 40' ' ' THR . 7.6 t -142.05 117.79 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.501 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -107.04 124.86 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.251 -0.906 . . . . 0.0 109.461 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 4.0 mtp -117.2 -174.59 2.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.236 -0.915 . . . . 0.0 109.478 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -140.89 168.86 18.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.232 -0.918 . . . . 0.0 109.502 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.534 ' CG2' HD11 ' A' ' 38' ' ' ILE . 53.0 t -142.03 102.98 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.242 -0.912 . . . . 0.0 109.521 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.774 HD23 ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.46 166.49 10.51 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.192 -0.943 . . . . 0.0 109.418 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.84 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -83.52 157.57 22.32 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.918 . . . . 0.0 109.48 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.546 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 1.8 mm-40 -104.07 7.17 36.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.571 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.546 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 173.18 161.76 0.13 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.959 . . . . 0.0 109.51 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.514 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -59.99 171.0 1.04 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.218 -0.926 . . . . 0.0 109.322 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.514 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.19 -163.9 28.93 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' A' ' 55' ' ' ILE . 40.5 t -133.8 119.6 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.257 -1.143 . . . . 0.0 109.527 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.631 HG22 ' H ' ' A' ' 56' ' ' ALA . 2.3 mp -47.02 174.45 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.384 -0.823 . . . . 0.0 109.755 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.631 ' H ' HG22 ' A' ' 55' ' ' ILE . . . -111.99 -60.86 1.8 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.159 -0.963 . . . . 0.0 109.458 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 177.45 138.0 0.07 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.499 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.637 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.1 mm -95.14 128.48 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.337 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 83.7 t -90.04 -33.52 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.196 -0.94 . . . . 0.0 109.518 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.604 ' HZ2' HD23 ' A' ' 72' ' ' LEU . 1.0 OUTLIER -97.83 145.96 25.89 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.2 -0.937 . . . . 0.0 109.497 -179.928 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.403 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 7.1 m-80 -109.72 169.44 8.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.293 -0.879 . . . . 0.0 109.435 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -64.26 150.62 45.59 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.193 -0.942 . . . . 0.0 109.56 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.68 5.59 86.43 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.543 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -105.17 170.85 7.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.115 -1.226 . . . . 0.0 109.26 -179.991 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.507 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 9.8 t -99.35 153.77 18.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.607 -0.683 . . . . 0.0 109.467 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.458 HG12 ' HD2' ' A' ' 60' ' ' LYS . 28.5 m -124.75 136.82 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.233 -0.917 . . . . 0.0 109.472 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.455 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.1 OUTLIER -92.84 163.2 13.8 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.263 -0.898 . . . . 0.0 109.412 179.974 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.468 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 33.1 t -55.7 123.02 12.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 109.469 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 67.46 35.83 87.64 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.501 ' CG ' ' HE2' ' A' ' 60' ' ' LYS . 8.4 tp10 -79.91 136.91 36.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.259 -1.142 . . . . 0.0 109.442 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.562 HD23 ' C ' ' A' ' 71' ' ' LEU . 9.0 tt -77.88 117.72 19.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.279 -0.888 . . . . 0.0 109.432 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.604 HD23 ' HZ2' ' A' ' 60' ' ' LYS . 0.4 OUTLIER -99.41 -14.89 18.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.871 . . . . 0.0 109.397 179.972 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 160.14 -169.49 36.03 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.651 ' HA ' HD12 ' A' ' 4' ' ' ILE . 4.7 ptmt -150.1 152.82 35.38 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -1.154 . . . . 0.0 109.466 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.692 HD23 ' O ' ' A' ' 76' ' ' THR . 0.5 OUTLIER -104.15 156.51 17.82 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.466 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.692 ' O ' HD23 ' A' ' 75' ' ' LEU . 5.9 m . . . . . 0 N--CA 1.49 1.563 0 O-C-N 121.321 -0.862 . . . . 0.0 109.49 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.436 HG22 ' H ' ' A' ' 3' ' ' ASP . 4.7 mm . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.436 ' H ' HG22 ' A' ' 2' ' ' ILE . 27.2 t0 -114.87 137.9 51.42 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.249 -0.907 . . . . 0.0 109.536 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.415 ' CG2' HG11 ' A' ' 47' ' ' VAL . 2.9 mt -105.78 72.67 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.434 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.413 ' HD2' ' OD2' ' A' ' 3' ' ' ASP . 1.3 ptmt -102.85 149.8 24.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.27 -0.894 . . . . 0.0 109.421 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.464 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -61.63 158.55 39.86 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.292 -0.88 . . . . 0.0 109.534 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.464 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.4 Cg_endo -78.0 -178.96 5.0 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.676 2.251 . . . . 0.0 110.405 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 60.6 m -92.74 129.3 38.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.453 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -81.1 148.96 65.34 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.192 -0.943 . . . . 0.0 109.453 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.02 -165.99 0.37 Allowed 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.659 2.239 . . . . 0.0 110.393 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.426 ' HG3' ' N ' ' A' ' 12' ' ' SER . 12.7 pt-20 -73.69 -41.67 62.31 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.267 -0.896 . . . . 0.0 109.525 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.426 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 38.4 t -42.89 -72.95 0.05 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.367 -0.833 . . . . 0.0 109.634 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.665 HG21 HG22 ' A' ' 40' ' ' THR . 1.8 mp -90.71 150.57 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.522 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -121.29 31.48 6.32 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.212 -0.93 . . . . 0.0 109.514 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -177.33 -171.84 0.35 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.925 . . . . 0.0 109.439 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.75 ' HA2' HG23 ' A' ' 40' ' ' THR . . . -154.63 175.59 32.69 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.518 ' O ' ' CG ' ' A' ' 39' ' ' GLU . 98.1 m -150.07 114.97 5.33 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.144 -1.21 . . . . 0.0 109.527 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.593 HG12 ' N ' ' A' ' 19' ' ' ALA . 40.2 t -46.0 168.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.313 -0.867 . . . . 0.0 109.477 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.601 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -113.22 -71.08 0.77 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.254 -0.904 . . . . 0.0 109.58 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.49 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 20.7 m -160.03 134.75 7.73 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.197 -0.939 . . . . 0.0 109.572 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.626 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.5 m95 -89.89 84.01 6.2 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.26 -0.9 . . . . 0.0 109.505 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.629 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -42.72 -70.12 0.12 Allowed 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.39 -0.819 . . . . 0.0 109.469 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 7.6 mmtt -89.5 -172.2 3.5 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.61 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.491 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 8.2 mttp -136.66 165.24 36.75 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.27 -0.894 . . . . 0.0 109.247 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.534 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -77.21 114.44 3.77 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.553 2.169 . . . . 0.0 110.383 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 135.23 -9.9 4.42 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -100.21 -172.36 2.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.235 -1.156 . . . . 0.0 109.487 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.83 170.47 11.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.293 -0.879 . . . . 0.0 109.484 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.448 ' HB ' ' O ' ' A' ' 53' ' ' GLY . 52.2 t -142.08 148.27 20.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.212 -0.93 . . . . 0.0 109.482 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.2 OUTLIER -135.38 136.01 41.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.259 -0.901 . . . . 0.0 109.479 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.464 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 15.7 ttp180 -42.87 145.38 0.47 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.29 -0.881 . . . . 0.0 109.733 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.464 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 54.9 t0 67.45 48.11 1.17 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.285 -0.884 . . . . 0.0 109.477 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' A' ' 34' ' ' LEU . 1.2 tp10 -137.57 105.95 5.79 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.216 -0.927 . . . . 0.0 109.508 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.629 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 42.7 tp -43.13 164.89 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.302 -0.874 . . . . 0.0 109.537 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.91 HD11 ' HB2' ' A' ' 49' ' ' ALA . 49.3 mt -142.56 -47.64 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.245 -0.909 . . . . 0.0 109.615 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.527 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.9 p -151.47 134.98 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.168 -0.957 . . . . 0.0 109.552 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.601 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 6.4 m-20 -95.59 163.86 13.03 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.31 -0.868 . . . . 0.0 109.427 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.437 HD11 ' CG2' ' A' ' 47' ' ' VAL . 21.6 mt -134.0 152.8 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.185 -0.947 . . . . 0.0 109.399 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 17' ' ' THR . 10.9 pt-20 -146.43 144.56 29.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.204 -0.935 . . . . 0.0 109.557 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.75 HG23 ' HA2' ' A' ' 16' ' ' GLY . 0.2 OUTLIER -140.28 -172.04 3.33 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.281 -0.887 . . . . 0.0 109.481 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.58 ' H ' HG22 ' A' ' 40' ' ' THR . 3.0 t70 -42.89 -64.15 0.67 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.354 -0.841 . . . . 0.0 109.66 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.65 44.13 1.96 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.428 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 2.8 t -148.22 104.28 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.26 -0.9 . . . . 0.0 109.497 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.435 ' O ' ' HG2' ' A' ' 45' ' ' MET . 62.1 t -98.04 143.43 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.242 -0.911 . . . . 0.0 109.535 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' MET . . . . . 0.435 ' HG2' ' O ' ' A' ' 44' ' ' VAL . 2.7 mmt -143.52 -178.89 6.11 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.227 -0.921 . . . . 0.0 109.489 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -141.33 165.68 26.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.176 -0.953 . . . . 0.0 109.512 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.527 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 18.1 t -137.35 98.36 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.232 -0.918 . . . . 0.0 109.467 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.762 HD23 ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -103.18 160.58 14.53 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 121.227 -0.92 . . . . 0.0 109.371 179.943 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.91 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -77.9 132.63 38.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.459 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.433 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.2 OUTLIER -86.28 12.4 10.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.221 -0.924 . . . . 0.0 109.489 -179.974 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.433 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 178.86 155.12 0.43 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.295 -0.878 . . . . 0.0 109.446 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.499 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -65.97 170.94 4.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.178 -0.952 . . . . 0.0 109.392 179.94 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.499 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 149.9 -153.99 25.43 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.4 ' O ' ' HB ' ' A' ' 76' ' ' THR . 49.6 t -135.19 126.27 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -1.129 . . . . 0.0 109.45 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.573 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.1 mt -56.21 164.39 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.193 -0.942 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.573 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -105.08 -63.69 1.2 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.531 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.534 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 1.1 pt-20 -179.24 144.09 0.22 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.248 -0.907 . . . . 0.0 109.465 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.626 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 24.5 mm -105.3 123.91 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.279 -0.888 . . . . 0.0 109.503 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.0 t -89.91 -19.88 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.251 -0.905 . . . . 0.0 109.546 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.491 ' HG3' ' OD1' ' A' ' 64' ' ' ASP . 3.9 tptt -115.97 129.9 56.59 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.239 -0.913 . . . . 0.0 109.51 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 14.9 m-80 -87.62 157.03 19.22 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 0.0 109.454 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.525 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -60.66 151.81 28.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.31 -10.49 68.86 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.514 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -88.63 171.02 10.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -1.164 . . . . 0.0 109.321 -179.97 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.514 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 97.9 m -91.51 147.18 23.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.518 -0.739 . . . . 0.0 109.482 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 17.1 m -120.04 178.73 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.281 -0.887 . . . . 0.0 109.405 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -130.33 162.69 28.48 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.915 . . . . 0.0 109.466 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -65.16 97.22 0.24 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.225 -0.922 . . . . 0.0 109.441 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.77 27.74 7.78 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.504 -1.439 . . . . 0.0 109.504 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -84.08 132.06 34.74 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.201 -1.176 . . . . 0.0 109.49 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.404 HD23 ' C ' ' A' ' 71' ' ' LEU . 8.4 tt -78.9 114.98 18.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -0.924 . . . . 0.0 109.464 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.473 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 5.1 mt -91.24 -22.15 20.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.322 -0.861 . . . . 0.0 109.466 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 170.85 177.03 40.52 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.409 ' O ' ' CB ' ' A' ' 56' ' ' ALA . 12.5 mttt -124.94 138.36 54.24 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.3 -1.117 . . . . 0.0 109.492 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -94.71 144.16 25.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.499 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.4 ' HB ' ' O ' ' A' ' 54' ' ' VAL . 10.8 m . . . . . 0 N--CA 1.489 1.519 0 O-C-N 121.207 -0.933 . . . . 0.0 109.464 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.3 mt . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.404 ' OD2' ' HE3' ' A' ' 74' ' ' LYS . 46.2 t0 -72.71 127.7 33.34 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.296 -0.877 . . . . 0.0 109.513 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.578 HG22 ' O ' ' A' ' 4' ' ' ILE . 60.7 mt -95.63 80.28 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.33 -0.857 . . . . 0.0 109.504 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.421 ' O ' ' HG3' ' A' ' 5' ' ' LYS . 0.2 OUTLIER -100.14 145.94 27.4 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.537 179.971 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.597 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -52.15 162.9 0.77 Allowed Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.227 -0.921 . . . . 0.0 109.451 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.597 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 36.2 Cg_endo -77.95 162.81 28.99 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.642 2.228 . . . . 0.0 110.484 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.547 ' O ' HG23 ' A' ' 8' ' ' THR . 2.5 t -82.95 105.74 14.2 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.186 -0.947 . . . . 0.0 109.436 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.415 ' HB3' ' HB ' ' A' ' 13' ' ' ILE . 10.8 m-85 -72.4 150.72 91.76 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.187 -0.946 . . . . 0.0 109.492 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.612 ' HD2' HD12 ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.07 176.34 10.09 Favored 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.6 2.2 . . . . 0.0 110.42 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.436 ' O ' ' C ' ' A' ' 12' ' ' SER . 2.1 mt-10 -56.64 -50.98 70.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.309 -0.869 . . . . 0.0 109.441 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 11' ' ' GLU . 7.3 t -42.93 -46.65 5.46 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.37 -0.831 . . . . 0.0 109.58 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.738 HG22 ' H ' ' A' ' 15' ' ' ASP . 64.5 mt -92.76 150.34 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.212 -0.93 . . . . 0.0 109.477 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -127.0 17.07 7.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.942 . . . . 0.0 109.471 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.738 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 178.75 -169.08 0.09 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.196 -0.94 . . . . 0.0 109.499 -179.962 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.414 ' O ' HG23 ' A' ' 65' ' ' THR . . . -147.91 -176.17 21.23 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 69.4 m -149.91 115.27 5.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.254 -1.145 . . . . 0.0 109.495 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.585 HG12 ' N ' ' A' ' 19' ' ' ALA . 27.5 t -49.41 169.28 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.264 -0.898 . . . . 0.0 109.391 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.585 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -114.69 -73.97 0.63 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.191 -0.943 . . . . 0.0 109.53 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.0 m -160.07 133.72 7.09 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.198 -0.939 . . . . 0.0 109.523 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.734 ' CH2' HD12 ' A' ' 58' ' ' ILE . 34.5 m95 -89.87 92.9 9.21 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 121.155 -0.965 . . . . 0.0 109.556 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.714 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.6 m80 -54.98 -72.24 0.07 Allowed 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.324 -0.86 . . . . 0.0 109.421 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -84.18 -172.77 4.35 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.238 -0.914 . . . . 0.0 109.609 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -136.35 166.97 23.78 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.388 -0.82 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.496 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.6 Cg_endo -77.03 138.82 18.67 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.683 2.256 . . . . 0.0 110.493 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 106.79 -9.82 40.75 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -102.2 -174.37 2.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.315 -1.109 . . . . 0.0 109.417 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.82 147.77 27.36 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.302 -0.873 . . . . 0.0 109.466 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m -129.95 -169.53 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.212 -0.93 . . . . 0.0 109.467 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.448 ' O ' ' CB ' ' A' ' 33' ' ' GLU . 9.9 tptm -157.06 139.61 14.92 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.224 -0.923 . . . . 0.0 109.479 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.426 ' C ' ' O ' ' A' ' 30' ' ' LYS . 2.3 ttp180 -42.78 154.83 0.06 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.289 -0.882 . . . . 0.0 109.622 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.0 t70 60.24 33.44 20.97 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.244 -0.91 . . . . 0.0 109.47 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.448 ' CB ' ' O ' ' A' ' 30' ' ' LYS . 28.9 tt0 -126.45 113.92 17.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.223 -0.923 . . . . 0.0 109.508 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.714 HD21 ' NE2' ' A' ' 22' ' ' HIS . 56.8 tp -42.86 160.23 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.357 -0.839 . . . . 0.0 109.623 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.813 HD11 ' CA ' ' A' ' 49' ' ' ALA . 4.3 mt -142.77 -43.95 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.229 -0.919 . . . . 0.0 109.56 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.58 HG12 ' HB ' ' A' ' 47' ' ' VAL . 13.6 p -160.87 138.65 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.282 -0.886 . . . . 0.0 109.439 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.521 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 28.3 m-20 -97.76 149.5 22.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.139 -0.976 . . . . 0.0 109.39 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.416 HG22 ' N ' ' A' ' 39' ' ' GLU . 31.5 mt -122.46 156.3 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.196 -0.94 . . . . 0.0 109.42 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.416 ' N ' HG22 ' A' ' 38' ' ' ILE . 2.4 tm-20 -135.62 153.17 51.74 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.433 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.414 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -140.23 -178.98 5.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.195 -0.94 . . . . 0.0 109.509 -179.993 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.435 ' HB2' HG12 ' A' ' 13' ' ' ILE . 6.7 t0 -42.78 -70.02 0.12 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.344 -0.848 . . . . 0.0 109.593 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.2 mttt -129.38 35.05 4.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.255 -0.903 . . . . 0.0 109.392 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 9.7 t -144.09 152.71 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 109.447 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.4 t -130.5 153.88 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.184 -0.948 . . . . 0.0 109.487 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' MET . . . . . 0.415 ' C ' ' HG3' ' A' ' 46' ' ' GLU . 4.4 mmt -143.25 167.38 22.28 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.188 -0.945 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.415 ' HG3' ' C ' ' A' ' 45' ' ' MET . 0.7 OUTLIER -128.98 156.22 44.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.285 -0.884 . . . . 0.0 109.478 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.58 ' HB ' HG12 ' A' ' 36' ' ' VAL . 20.9 t -126.88 99.95 6.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.895 . . . . 0.0 109.502 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.768 HD23 ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.93 164.96 11.31 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.295 -0.878 . . . . 0.0 109.396 -179.992 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.813 ' CA ' HD11 ' A' ' 35' ' ' ILE . . . -83.34 129.41 34.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.291 -0.881 . . . . 0.0 109.522 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.581 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -91.35 10.84 25.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.197 -0.939 . . . . 0.0 109.443 -179.973 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.581 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 171.58 132.33 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.316 -0.865 . . . . 0.0 109.454 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.506 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -47.42 170.93 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.253 -0.904 . . . . 0.0 109.294 179.973 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.506 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 153.88 -160.95 29.67 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 46.5 t -124.56 123.91 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.272 -1.134 . . . . 0.0 109.494 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.556 HG22 ' N ' ' A' ' 56' ' ' ALA . 4.9 mt -61.52 163.7 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.338 -0.852 . . . . 0.0 109.615 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.556 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -103.22 -65.51 1.0 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -0.922 . . . . 0.0 109.485 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.496 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER 172.66 141.35 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.239 -0.913 . . . . 0.0 109.427 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.734 HD12 ' CH2' ' A' ' 21' ' ' TRP . 9.9 mm -89.97 140.38 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.279 -0.888 . . . . 0.0 109.398 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 98.8 t -89.99 -53.13 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.184 -0.947 . . . . 0.0 109.438 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.522 ' CE ' ' HA ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -94.87 167.17 11.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.251 -0.906 . . . . 0.0 109.391 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 49.3 m-80 -104.65 156.06 18.31 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.422 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.533 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -64.97 155.54 34.15 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.417 -179.933 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.08 2.54 89.4 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -105.28 170.96 7.58 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.196 -1.179 . . . . 0.0 109.313 -179.984 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.51 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 95.4 m -98.93 122.91 42.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.553 -0.717 . . . . 0.0 109.489 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.446 ' HB ' ' HG2' ' A' ' 70' ' ' GLU . 5.5 m -104.41 -172.37 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.273 -0.892 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -133.45 176.3 8.65 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.501 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.9 t -63.8 143.54 57.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.414 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 60.17 26.01 63.07 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.446 ' HG2' ' HB ' ' A' ' 66' ' ' VAL . 35.2 tp10 -82.92 110.43 17.9 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.455 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.768 HD11 ' HD2' ' A' ' 74' ' ' LYS . 9.6 tt -69.24 109.97 4.36 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.264 -0.897 . . . . 0.0 109.486 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.575 ' O ' HG23 ' A' ' 58' ' ' ILE . 35.9 mt -94.33 -11.8 29.29 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.521 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.45 ' O ' ' HG2' ' A' ' 74' ' ' LYS . . . 173.04 177.92 42.66 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.768 ' HD2' HD11 ' A' ' 71' ' ' LEU . 20.3 mtpt -147.7 129.2 14.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -1.127 . . . . 0.0 109.466 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.714 HD23 ' O ' ' A' ' 76' ' ' THR . 1.1 tt -96.02 147.66 23.47 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.238 -0.914 . . . . 0.0 109.539 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.714 ' O ' HD23 ' A' ' 75' ' ' LEU . 5.8 m . . . . . 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.513 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 36.8 pt . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.518 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 14.4 t0 -113.97 133.57 55.4 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.233 -0.917 . . . . 0.0 109.479 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.8 mt -105.57 98.08 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.193 -0.942 . . . . 0.0 109.48 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.02 168.69 14.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.17 -0.956 . . . . 0.0 109.5 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.2 153.73 92.33 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.307 -0.87 . . . . 0.0 109.47 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.99 140.64 18.23 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.565 2.177 . . . . 0.0 110.418 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.446 ' O ' HG23 ' A' ' 8' ' ' THR . 8.9 t -62.32 129.59 41.41 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -0.962 . . . . 0.0 109.451 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.497 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 23.4 m-85 -96.93 151.88 38.03 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.887 . . . . 0.0 109.472 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.448 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -78.08 171.31 17.33 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.671 2.247 . . . . 0.0 110.376 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.424 ' O ' ' C ' ' A' ' 12' ' ' SER . 4.5 mt-10 -45.67 -54.52 7.66 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.144 -0.973 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.424 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.95 -62.46 1.01 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.282 -0.886 . . . . 0.0 109.601 -179.917 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.573 HG22 ' H ' ' A' ' 15' ' ' ASP . 29.8 mm -92.85 119.13 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.181 -0.949 . . . . 0.0 109.482 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.438 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -96.18 13.21 28.13 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.262 -0.899 . . . . 0.0 109.484 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.573 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER 167.42 -171.82 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.884 . . . . 0.0 109.431 -179.957 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.34 -159.28 8.39 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.525 HG23 ' O ' ' A' ' 64' ' ' ASP . 52.1 m -149.57 123.29 9.23 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.243 -1.151 . . . . 0.0 109.502 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.592 HG12 ' N ' ' A' ' 19' ' ' ALA . 39.6 t -47.98 168.64 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.302 -0.874 . . . . 0.0 109.426 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.592 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -113.13 -75.0 0.61 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.413 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.5 m -160.08 134.7 7.66 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.336 -0.853 . . . . 0.0 109.451 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.673 ' CH2' HD12 ' A' ' 58' ' ' ILE . 34.1 m95 -89.78 84.9 6.3 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.231 -0.918 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.806 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.8 m80 -42.34 -60.46 1.48 Allowed 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.371 -0.831 . . . . 0.0 109.497 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 4.1 mmtt -99.66 -172.11 2.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.593 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.408 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -130.12 168.59 16.12 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.288 -0.882 . . . . 0.0 109.496 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.528 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.51 115.58 4.11 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 122.664 2.243 . . . . 0.0 110.39 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.83 -11.92 5.38 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.431 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 1.2 pp20? -95.6 -172.89 2.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.352 -1.087 . . . . 0.0 109.467 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.431 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -101.04 151.2 22.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.601 HG22 ' O ' ' A' ' 53' ' ' GLY . 20.1 m -114.9 166.63 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.358 -0.839 . . . . 0.0 109.429 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.436 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.3 mttt -121.3 134.5 55.15 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.262 -0.899 . . . . 0.0 109.506 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.51 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.81 113.42 0.47 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.352 -0.843 . . . . 0.0 109.684 -179.898 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.51 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 14.5 t0 75.99 56.37 0.05 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.293 -0.879 . . . . 0.0 109.495 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.479 ' O ' HG13 ' A' ' 35' ' ' ILE . 15.9 tt0 -131.24 124.15 29.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.319 -0.863 . . . . 0.0 109.437 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.806 HD21 ' NE2' ' A' ' 22' ' ' HIS . 51.1 tp -42.8 151.63 0.12 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.377 -0.827 . . . . 0.0 109.596 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.937 HD11 ' HB2' ' A' ' 49' ' ' ALA . 96.9 mt -137.84 -41.21 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.319 -0.863 . . . . 0.0 109.476 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.526 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 13.6 p -158.24 135.0 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.277 -0.89 . . . . 0.0 109.451 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.514 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 10.7 m-20 -93.28 153.83 18.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.287 -0.883 . . . . 0.0 109.438 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.537 HD11 ' CG2' ' A' ' 47' ' ' VAL . 2.8 mt -121.44 155.81 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.271 -0.893 . . . . 0.0 109.507 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.0 145.06 50.85 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.295 -0.878 . . . . 0.0 109.439 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.538 HG22 ' H ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -130.6 -176.98 4.15 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -0.932 . . . . 0.0 109.479 179.962 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.538 ' H ' HG22 ' A' ' 40' ' ' THR . 63.5 t0 -42.78 -55.08 3.8 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.286 -0.883 . . . . 0.0 109.686 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 18.3 mttm -147.45 25.45 1.08 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.246 -0.908 . . . . 0.0 109.396 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 2.1 t -134.05 130.87 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.231 -0.918 . . . . 0.0 109.457 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.0 t -108.57 139.78 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.218 -0.926 . . . . 0.0 109.512 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 18.7 mtp -131.62 175.28 9.31 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.212 -0.93 . . . . 0.0 109.467 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -124.59 159.91 29.62 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.508 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.537 ' CG2' HD11 ' A' ' 38' ' ' ILE . 5.4 t -130.14 89.5 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.286 -0.884 . . . . 0.0 109.45 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.781 HD23 ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.92 156.72 17.47 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.239 -0.913 . . . . 0.0 109.372 179.974 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.937 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -77.84 149.13 34.4 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.196 -0.94 . . . . 0.0 109.538 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 1.3 mt-10 -92.27 12.02 23.84 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.229 -0.92 . . . . 0.0 109.449 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.456 ' HA ' ' HG3' ' A' ' 31' ' ' ARG . . . 179.13 150.07 0.28 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.243 -0.911 . . . . 0.0 109.493 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -55.35 170.93 0.2 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.216 -0.928 . . . . 0.0 109.32 -179.97 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.601 ' O ' HG22 ' A' ' 29' ' ' VAL . . . 154.74 -153.88 25.12 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 52.4 t -138.75 127.0 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.247 -1.149 . . . . 0.0 109.442 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.501 HD13 ' CD1' ' A' ' 75' ' ' LEU . 14.9 mm -62.25 158.15 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.213 -0.929 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.418 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -97.37 -69.56 0.75 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.238 -0.914 . . . . 0.0 109.468 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.528 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 2.9 pt-20 -174.76 142.44 0.7 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.255 -0.903 . . . . 0.0 109.453 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.673 HD12 ' CH2' ' A' ' 21' ' ' TRP . 15.7 mm -93.86 138.05 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.208 -0.933 . . . . 0.0 109.498 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.7 t -90.56 -57.71 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.275 -0.891 . . . . 0.0 109.532 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.524 ' CE ' ' HA ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -89.93 163.22 15.06 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.17 -0.956 . . . . 0.0 109.439 -179.964 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 10.3 m120 -102.56 156.49 17.58 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 109.53 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.522 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.2 OUTLIER -66.49 160.1 25.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.245 -0.909 . . . . 0.0 109.432 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 81.75 -7.35 62.55 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.525 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -100.81 171.02 7.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -1.165 . . . . 0.0 109.333 179.997 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.9 t -92.4 153.77 18.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.546 -0.722 . . . . 0.0 109.441 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.453 ' HA ' ' OE1' ' A' ' 70' ' ' GLU . 18.0 m -129.0 -174.66 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.233 -0.917 . . . . 0.0 109.55 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -128.98 170.88 12.91 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.283 -0.886 . . . . 0.0 109.432 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.438 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 3.9 t -72.22 99.7 2.42 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.872 . . . . 0.0 109.474 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 109.51 14.86 13.28 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.584 ' OE2' HD23 ' A' ' 72' ' ' LEU . 3.9 tt0 -75.45 119.29 19.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -1.127 . . . . 0.0 109.448 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.518 ' CD1' ' OD1' ' A' ' 3' ' ' ASP . 68.4 tp -69.72 108.73 4.03 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.266 -0.896 . . . . 0.0 109.47 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.584 HD23 ' OE2' ' A' ' 70' ' ' GLU . 16.6 mt -88.39 -13.92 39.35 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.24 -0.913 . . . . 0.0 109.514 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 161.45 178.46 35.41 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.456 ' HG3' HD11 ' A' ' 71' ' ' LEU . 5.1 mtpt -137.91 144.17 41.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.22 -1.164 . . . . 0.0 109.444 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.501 ' CD1' HD13 ' A' ' 55' ' ' ILE . 17.1 tp -93.32 140.51 29.47 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.2 -0.937 . . . . 0.0 109.506 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 14.8 m . . . . . 0 N--CA 1.49 1.546 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.957 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.0 mm . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 121.263 0.554 . . . . 0.0 109.517 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.56 ' OD2' HD12 ' A' ' 71' ' ' LEU . 62.8 t0 -80.71 132.12 35.52 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.214 -0.929 . . . . 0.0 109.495 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 40.9 mt -104.23 99.1 7.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.327 -0.858 . . . . 0.0 109.481 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.43 ' HA ' ' HA ' ' A' ' 71' ' ' LEU . 4.2 mttp -106.66 177.03 4.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.244 -0.91 . . . . 0.0 109.508 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.711 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -77.98 165.8 48.06 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.264 -0.897 . . . . 0.0 109.493 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.711 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.3 Cg_endo -77.6 157.11 32.17 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.615 2.21 . . . . 0.0 110.44 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.3 t -62.77 146.63 52.02 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.848 . . . . 0.0 109.495 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.528 ' CZ ' ' HG2' ' A' ' 7' ' ' PRO . 24.0 m-85 -129.99 91.37 39.77 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.224 -0.922 . . . . 0.0 109.477 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.5 Cg_endo -78.03 -162.94 0.19 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.63 2.22 . . . . 0.0 110.445 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.429 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.0 OUTLIER -51.81 -54.83 24.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.293 -0.879 . . . . 0.0 109.446 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.429 ' C ' ' O ' ' A' ' 11' ' ' GLU . 34.4 t -42.94 -60.23 1.69 Allowed 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.324 -0.86 . . . . 0.0 109.626 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.472 HG22 ' O ' ' A' ' 15' ' ' ASP . 27.0 mt -102.47 119.03 50.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.215 -0.928 . . . . 0.0 109.56 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -96.88 -0.25 48.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.922 . . . . 0.0 109.549 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.472 ' O ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -173.53 -173.59 0.9 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.244 -0.91 . . . . 0.0 109.401 -179.976 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.885 ' O ' HG23 ' A' ' 65' ' ' THR . . . -154.6 170.79 32.99 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.684 HG23 ' O ' ' A' ' 64' ' ' ASP . 21.8 m -150.04 118.59 6.51 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.312 -1.111 . . . . 0.0 109.414 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.594 HG12 ' N ' ' A' ' 19' ' ' ALA . 42.8 t -45.25 168.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.204 -0.935 . . . . 0.0 109.506 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.594 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -113.65 -70.68 0.79 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.185 -0.947 . . . . 0.0 109.574 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.437 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 17.1 m -158.56 134.77 9.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.171 -0.955 . . . . 0.0 109.608 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.592 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 31.4 m95 -89.86 84.77 6.26 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.269 -0.894 . . . . 0.0 109.559 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.825 ' CE1' HD21 ' A' ' 34' ' ' LEU . 2.7 m80 -42.69 -70.41 0.11 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.37 -0.831 . . . . 0.0 109.48 -179.763 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -101.11 -172.11 2.11 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.223 -0.923 . . . . 0.0 109.534 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 4.0 mttt -125.92 167.41 16.92 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.264 -0.897 . . . . 0.0 109.441 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.986 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.0 Cg_endo -76.93 131.22 11.95 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.608 2.205 . . . . 0.0 110.49 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.45 -12.48 18.8 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -89.8 -174.33 4.24 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.3 -1.118 . . . . 0.0 109.398 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.7 140.31 42.42 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.288 -0.883 . . . . 0.0 109.456 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 1.039 HG21 HD11 ' A' ' 55' ' ' ILE . 47.3 t -128.21 161.68 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.431 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.496 ' N ' HG12 ' A' ' 29' ' ' VAL . 3.7 tptt -153.28 137.5 16.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.207 -0.933 . . . . 0.0 109.491 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 30' ' ' LYS . 8.3 tmm_? -42.8 139.61 1.59 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.296 -0.877 . . . . 0.0 109.593 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.41 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 20.0 t70 68.05 49.0 0.9 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.349 -0.844 . . . . 0.0 109.469 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.424 ' O ' ' C ' ' A' ' 34' ' ' LEU . 1.6 tt0 -133.95 103.88 6.02 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.921 . . . . 0.0 109.426 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.825 HD21 ' CE1' ' A' ' 22' ' ' HIS . 38.4 tp -42.58 151.54 0.12 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.357 -0.839 . . . . 0.0 109.632 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.98 HD11 ' HB2' ' A' ' 49' ' ' ALA . 5.1 mt -142.04 -40.18 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.166 -0.959 . . . . 0.0 109.542 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.512 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 12.2 p -151.92 128.2 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.489 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 12.9 m-20 -89.89 164.24 14.67 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.403 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.821 ' O ' HG23 ' A' ' 44' ' ' VAL . 80.8 mt -136.69 151.97 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.223 -0.923 . . . . 0.0 109.522 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 17' ' ' THR . 4.6 pt-20 -140.68 135.11 31.3 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.265 -0.897 . . . . 0.0 109.425 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.564 HG22 ' O ' ' A' ' 43' ' ' VAL . 5.3 t -128.31 -162.33 1.17 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.336 -0.853 . . . . 0.0 109.35 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.508 ' N ' HG23 ' A' ' 40' ' ' THR . 11.8 t70 -42.43 -61.85 1.11 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.325 -0.859 . . . . 0.0 109.697 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LYS . . . . . 0.454 ' HG3' ' O ' ' A' ' 41' ' ' ASP . 5.9 mtpm? -149.47 45.09 0.96 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.225 -0.922 . . . . 0.0 109.515 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.564 ' O ' HG22 ' A' ' 40' ' ' THR . 54.5 t -154.69 108.25 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.195 -0.94 . . . . 0.0 109.489 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.821 HG23 ' O ' ' A' ' 38' ' ' ILE . 3.8 p -96.43 140.01 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.343 -0.848 . . . . 0.0 109.396 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -131.77 134.23 45.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.261 -0.9 . . . . 0.0 109.499 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.543 ' HB3' HD13 ' A' ' 34' ' ' LEU . 25.2 mt-10 -89.64 151.49 21.86 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.296 -0.878 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.512 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 91.8 t -123.0 103.62 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.173 -0.954 . . . . 0.0 109.507 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.494 ' H ' HD12 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -102.78 171.2 7.55 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.276 -0.89 . . . . 0.0 109.37 179.966 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.98 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.98 134.81 34.22 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.255 -0.903 . . . . 0.0 109.464 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.543 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.9 OUTLIER -84.81 10.95 10.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.156 -0.965 . . . . 0.0 109.426 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.543 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 173.38 154.39 0.1 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 109.42 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.513 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -69.07 171.03 8.83 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.277 -179.939 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.513 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.22 -146.02 15.15 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.9 t -138.68 126.9 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -1.158 . . . . 0.0 109.492 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 1.039 HD11 HG21 ' A' ' 29' ' ' VAL . 1.1 mm -74.6 171.91 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.203 -0.936 . . . . 0.0 109.422 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.448 ' CB ' ' HG3' ' A' ' 74' ' ' LYS . . . -104.33 -63.85 1.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.227 -0.921 . . . . 0.0 109.509 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.528 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -179.29 158.39 0.87 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.246 -0.909 . . . . 0.0 109.5 180.0 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.986 HD11 ' HD3' ' A' ' 25' ' ' PRO . 1.5 mp -93.52 146.2 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.211 -0.93 . . . . 0.0 109.468 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.865 HG23 ' O ' ' A' ' 72' ' ' LEU . 49.5 t -89.9 -52.46 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.226 -0.921 . . . . 0.0 109.479 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.466 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 2.1 tptp -108.29 157.37 18.42 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.274 -0.891 . . . . 0.0 109.397 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 50.2 m-80 -88.82 156.18 19.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.482 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.492 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 2.4 pp20? -61.09 145.91 49.22 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.257 -0.902 . . . . 0.0 109.384 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 94.96 -12.15 68.79 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.684 ' O ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -89.04 170.9 10.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.273 -1.133 . . . . 0.0 109.325 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.885 HG23 ' O ' ' A' ' 16' ' ' GLY . 62.7 m -111.96 146.92 36.96 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.489 -0.757 . . . . 0.0 109.467 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.494 ' HB ' ' CB ' ' A' ' 70' ' ' GLU . 27.3 m -129.62 -176.21 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.8 mp -116.63 173.9 6.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.177 -0.952 . . . . 0.0 109.469 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -63.85 125.74 25.35 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.897 . . . . 0.0 109.384 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 86.85 19.6 55.73 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.494 ' CB ' ' HB ' ' A' ' 66' ' ' VAL . 4.6 tp10 -82.18 112.82 19.56 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -1.134 . . . . 0.0 109.465 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.734 HD23 ' C ' ' A' ' 71' ' ' LEU . 7.5 tt -78.26 128.42 33.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.307 -0.87 . . . . 0.0 109.491 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.865 ' O ' HG23 ' A' ' 59' ' ' VAL . 13.3 mt -97.05 -70.51 0.72 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.421 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -128.14 163.64 21.67 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.448 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 2.2 ptmt -126.33 147.97 49.64 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.27 -1.135 . . . . 0.0 109.493 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.707 HD23 ' O ' ' A' ' 76' ' ' THR . 6.0 tt -90.56 166.45 13.2 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.278 -0.889 . . . . 0.0 109.488 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.707 ' O ' HD23 ' A' ' 75' ' ' LEU . 3.0 t . . . . . 0 N--CA 1.489 1.513 0 O-C-N 121.268 -0.895 . . . . 0.0 109.735 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.473 HD12 HD22 ' A' ' 75' ' ' LEU . 15.4 mt . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -67.64 125.9 27.65 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.461 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.9 mm -104.61 120.64 55.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.262 -0.899 . . . . 0.0 109.424 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -136.83 176.23 8.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.169 -0.957 . . . . 0.0 109.469 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.428 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -80.44 157.78 72.26 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.282 -0.886 . . . . 0.0 109.439 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.428 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.6 Cg_endo -78.01 156.32 30.33 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.661 2.241 . . . . 0.0 110.48 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 77.0 m -68.53 119.36 12.86 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.301 -0.874 . . . . 0.0 109.478 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -73.85 154.58 89.06 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.294 -0.878 . . . . 0.0 109.539 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.55 ' HG2' HD12 ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.09 -173.93 2.03 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.677 2.252 . . . . 0.0 110.433 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.7 mp0 -73.15 -49.34 28.76 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.461 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.2 OUTLIER -42.82 -29.05 0.29 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.371 -0.831 . . . . 0.0 109.589 -179.87 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.692 HG22 ' H ' ' A' ' 15' ' ' ASP . 4.1 mt -121.17 146.04 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -0.895 . . . . 0.0 109.496 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -114.31 1.76 14.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.247 -0.908 . . . . 0.0 109.611 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.692 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -178.35 -171.41 0.26 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.18 -0.95 . . . . 0.0 109.457 -179.984 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.38 -167.44 17.69 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.852 HG23 ' O ' ' A' ' 64' ' ' ASP . 29.4 m -148.13 130.88 16.01 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -1.122 . . . . 0.0 109.468 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.548 HG12 ' N ' ' A' ' 19' ' ' ALA . 46.6 t -44.56 165.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.248 -0.907 . . . . 0.0 109.49 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.568 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -114.06 -73.12 0.67 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.301 -0.874 . . . . 0.0 109.53 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 38.5 m -160.01 132.19 6.32 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.205 -0.934 . . . . 0.0 109.518 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.667 ' CH2' HD12 ' A' ' 58' ' ' ILE . 36.0 m95 -89.84 81.78 6.3 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.259 -0.901 . . . . 0.0 109.517 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.776 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.1 m80 -42.87 -61.54 1.25 Allowed 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.305 -0.872 . . . . 0.0 109.42 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.478 ' O ' ' HE3' ' A' ' 24' ' ' LYS . 1.2 mtpt -96.89 -177.36 3.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.918 . . . . 0.0 109.584 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.478 ' HE3' ' O ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -120.95 167.72 12.44 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.248 -0.908 . . . . 0.0 109.516 179.989 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.504 ' HA ' ' CG2' ' A' ' 55' ' ' ILE . 35.1 Cg_endo -76.96 90.21 1.25 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.694 2.263 . . . . 0.0 110.395 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 138.59 45.03 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.46 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 2.2 pp20? -139.35 -173.37 3.58 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.317 -1.108 . . . . 0.0 109.462 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.46 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -90.68 128.78 36.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.206 -0.934 . . . . 0.0 109.474 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 12.4 p -127.11 155.15 38.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.215 -0.928 . . . . 0.0 109.528 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.409 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -134.63 133.72 40.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -0.949 . . . . 0.0 109.502 -179.989 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.506 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.78 143.26 0.73 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.288 -0.883 . . . . 0.0 109.658 -179.969 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.506 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 8.2 t70 75.51 41.59 0.26 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.262 -0.898 . . . . 0.0 109.452 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.445 ' O ' HG12 ' A' ' 35' ' ' ILE . 3.5 tt0 -141.83 121.75 13.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.229 -0.919 . . . . 0.0 109.477 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.835 ' O ' HD13 ' A' ' 35' ' ' ILE . 59.6 tp -42.84 156.1 0.05 OUTLIER 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.328 -0.858 . . . . 0.0 109.644 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.835 HD13 ' O ' ' A' ' 34' ' ' LEU . 15.7 mm -146.12 -39.12 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.276 -0.89 . . . . 0.0 109.505 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.516 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -159.79 141.95 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -0.891 . . . . 0.0 109.369 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.568 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 1.2 m-20 -104.93 146.37 29.12 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.251 -0.906 . . . . 0.0 109.465 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.452 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 57.2 mt -107.13 142.46 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.175 -0.953 . . . . 0.0 109.514 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.515 ' CB ' ' O ' ' A' ' 17' ' ' THR . 1.4 tt0 -105.35 129.21 53.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.209 -0.932 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -115.73 171.61 7.65 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.238 -0.914 . . . . 0.0 109.49 -179.948 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 40' ' ' THR . 12.7 t0 -42.87 -51.37 5.53 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.321 -0.862 . . . . 0.0 109.618 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LYS . . . . . 0.431 ' HG2' ' O ' ' A' ' 41' ' ' ASP . 7.8 mmtt -148.37 30.66 0.84 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.271 -0.893 . . . . 0.0 109.443 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.412 ' O ' ' OG1' ' A' ' 40' ' ' THR . 2.0 t -139.6 134.49 38.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.939 . . . . 0.0 109.436 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 8.1 p -98.76 136.86 28.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.255 -0.903 . . . . 0.0 109.474 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' MET . . . . . 0.452 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 0.9 OUTLIER -125.17 165.83 17.54 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.15 -0.969 . . . . 0.0 109.473 -179.983 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -129.26 161.91 29.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.501 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.516 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 78.7 t -140.73 108.89 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.214 -0.929 . . . . 0.0 109.501 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.49 ' H ' HD12 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -103.14 155.74 18.19 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.339 -0.851 . . . . 0.0 109.362 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -70.58 144.78 51.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.898 . . . . 0.0 109.521 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.422 ' C ' ' HG3' ' A' ' 31' ' ' ARG . 0.6 OUTLIER -101.87 11.23 38.97 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.276 -0.89 . . . . 0.0 109.475 179.988 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -178.57 138.2 0.17 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.305 -0.872 . . . . 0.0 109.428 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.504 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.2 OUTLIER -58.5 170.95 0.67 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.245 -0.91 . . . . 0.0 109.343 -179.977 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.504 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 145.65 -162.39 28.26 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.475 ' O ' HG22 ' A' ' 76' ' ' THR . 48.1 t -128.94 124.97 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.328 -1.101 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.577 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.0 mt -59.41 165.23 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.278 -0.889 . . . . 0.0 109.568 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.577 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -103.43 -66.08 0.97 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.188 -0.945 . . . . 0.0 109.518 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.476 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -167.75 139.11 2.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.206 -0.934 . . . . 0.0 109.55 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.667 HD12 ' CH2' ' A' ' 21' ' ' TRP . 23.9 mm -95.09 121.69 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.326 -0.859 . . . . 0.0 109.508 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.4 t -89.94 -27.99 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.19 -0.944 . . . . 0.0 109.428 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.502 ' HG2' ' CG1' ' A' ' 66' ' ' VAL . 0.0 OUTLIER -91.08 134.21 34.7 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.288 -0.882 . . . . 0.0 109.466 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.473 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 13.7 m120 -98.71 165.76 11.64 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.286 -0.884 . . . . 0.0 109.519 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -68.85 141.12 55.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 80.52 14.92 79.26 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.852 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -101.73 170.88 7.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -1.141 . . . . 0.0 109.277 -179.972 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 23.3 m -97.3 141.76 30.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.493 -0.754 . . . . 0.0 109.416 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.502 ' CG1' ' HG2' ' A' ' 60' ' ' LYS . 2.3 m -126.98 139.04 53.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.469 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.04 167.53 10.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.261 -0.899 . . . . 0.0 109.486 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 36.2 t -57.17 128.82 38.9 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 73.56 23.31 77.22 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -79.19 119.25 22.01 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.247 -1.149 . . . . 0.0 109.491 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.506 HD23 ' C ' ' A' ' 71' ' ' LEU . 10.2 tt -67.37 138.31 56.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.288 -0.882 . . . . 0.0 109.543 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -118.85 -24.86 6.47 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.293 -0.879 . . . . 0.0 109.428 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.64 159.67 26.6 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 8.3 mtpt -122.31 133.39 54.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.204 -1.174 . . . . 0.0 109.446 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.473 HD22 HD12 ' A' ' 2' ' ' ILE . 0.6 OUTLIER -92.1 147.57 22.84 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -0.948 . . . . 0.0 109.512 179.99 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.475 HG22 ' O ' ' A' ' 54' ' ' VAL . 3.0 t . . . . . 0 N--CA 1.489 1.503 0 O-C-N 121.272 -0.893 . . . . 0.0 109.724 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 61.7 mt . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.473 -0.565 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 74' ' ' LYS . 15.9 t70 -76.15 162.73 27.75 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.228 -0.92 . . . . 0.0 109.441 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mt -135.39 125.03 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.269 -0.894 . . . . 0.0 109.452 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.0 pttm -133.04 172.98 11.91 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.243 -0.911 . . . . 0.0 109.462 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.565 ' HB3' ' O ' ' A' ' 67' ' ' LEU . . . -81.46 147.72 60.63 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.144 -0.972 . . . . 0.0 109.447 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.03 155.11 29.79 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.649 2.233 . . . . 0.0 110.455 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.411 ' HA ' ' HB2' ' A' ' 68' ' ' SER . 1.3 m -71.11 132.49 45.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.414 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.404 ' HB3' ' HB ' ' A' ' 13' ' ' ILE . 63.0 m-85 -99.34 153.6 37.7 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.426 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.4 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -77.99 -159.65 0.1 Allowed 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.632 2.221 . . . . 0.0 110.454 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.0 OUTLIER -77.18 -55.6 5.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.464 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 11' ' ' GLU . 18.6 t -42.72 -50.3 5.55 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.278 -0.889 . . . . 0.0 109.617 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.49 HG22 ' H ' ' A' ' 15' ' ' ASP . 14.8 mt -90.11 143.45 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.418 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.517 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -115.1 -1.76 12.94 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.517 ' CB ' ' O ' ' A' ' 14' ' ' ALA . 0.5 OUTLIER 163.89 -169.09 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.212 -0.93 . . . . 0.0 109.464 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.673 ' O ' HG23 ' A' ' 65' ' ' THR . . . -142.97 -163.13 9.6 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.625 HG23 ' O ' ' A' ' 64' ' ' ASP . 17.0 m -150.0 133.07 16.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -1.114 . . . . 0.0 109.426 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.483 ' O ' ' HG3' ' A' ' 39' ' ' GLU . 39.4 t -49.08 159.73 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.216 -0.928 . . . . 0.0 109.419 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.519 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -104.35 -77.0 0.58 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.218 -0.926 . . . . 0.0 109.517 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 17.8 m -159.97 130.48 5.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.555 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.637 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.6 m95 -89.95 85.54 6.38 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.207 -0.933 . . . . 0.0 109.509 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.798 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.1 m80 -43.18 -67.28 0.29 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.346 -0.846 . . . . 0.0 109.419 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -93.81 -172.33 2.84 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.216 -0.927 . . . . 0.0 109.468 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.425 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -125.23 168.23 14.14 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.287 -0.883 . . . . 0.0 109.392 -179.894 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.498 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.3 Cg_endo -76.59 127.75 9.81 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.733 2.288 . . . . 0.0 110.373 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.65 18.99 9.01 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 13.8 mm-40 -119.69 -176.98 3.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.306 -1.114 . . . . 0.0 109.486 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -92.85 145.93 24.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.267 -0.896 . . . . 0.0 109.444 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 69.0 t -139.37 151.33 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -0.896 . . . . 0.0 109.532 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 11.0 mptt -126.64 140.11 52.66 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.228 -0.92 . . . . 0.0 109.463 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.434 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.7 OUTLIER -42.71 153.1 0.08 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.383 -0.823 . . . . 0.0 109.704 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.445 ' HA ' HD23 ' A' ' 48' ' ' LEU . 25.2 t0 63.19 41.8 7.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.927 . . . . 0.0 109.468 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.423 ' C ' ' HG ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -135.98 116.05 13.33 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.291 -0.88 . . . . 0.0 109.51 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.798 HD21 ' NE2' ' A' ' 22' ' ' HIS . 37.5 tp -43.1 142.9 0.88 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.275 -0.891 . . . . 0.0 109.556 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.798 HD11 ' HB2' ' A' ' 49' ' ' ALA . 10.9 mt -125.92 -46.08 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.272 -0.893 . . . . 0.0 109.585 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.405 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -162.8 147.5 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.277 -0.889 . . . . 0.0 109.528 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.519 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 1.2 m-20 -105.32 160.25 15.26 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.347 -0.845 . . . . 0.0 109.428 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.531 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 1.8 tt -129.31 148.54 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -0.933 . . . . 0.0 109.449 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.483 ' HG3' ' O ' ' A' ' 18' ' ' VAL . 4.8 mm-40 -106.96 150.33 26.58 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.305 -0.872 . . . . 0.0 109.481 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.404 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -135.47 -175.38 3.92 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 40' ' ' THR . 7.8 t0 -42.78 -68.9 0.16 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.307 -0.871 . . . . 0.0 109.643 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.7 mtmm -135.39 36.73 2.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.172 -0.955 . . . . 0.0 109.493 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 67.9 t -152.0 153.44 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.34 -0.85 . . . . 0.0 109.472 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.462 ' O ' HG13 ' A' ' 44' ' ' VAL . 11.7 p -124.2 131.04 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' MET . . . . . 0.531 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 0.0 OUTLIER -107.89 177.2 4.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.181 -0.949 . . . . 0.0 109.502 179.98 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -130.28 151.3 50.94 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.223 -0.923 . . . . 0.0 109.452 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.405 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 44.3 t -122.75 98.11 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.45 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.536 HD12 ' HA ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -90.99 168.72 11.45 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.195 -0.941 . . . . 0.0 109.487 -179.998 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.798 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -85.1 136.91 33.35 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.223 -0.923 . . . . 0.0 109.402 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.533 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 2.2 mm-40 -98.53 14.64 27.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.545 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.533 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 173.54 134.78 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.268 -0.895 . . . . 0.0 109.469 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.502 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.25 171.02 0.12 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -0.894 . . . . 0.0 109.3 179.999 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.502 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 142.77 -154.04 25.02 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.612 ' H ' HG22 ' A' ' 76' ' ' THR . 66.2 t -136.65 134.63 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.274 -1.133 . . . . 0.0 109.412 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.618 HD13 HD12 ' A' ' 75' ' ' LEU . 15.3 mm -61.85 168.84 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.218 -0.926 . . . . 0.0 109.516 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.574 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -101.42 -62.83 1.2 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.914 . . . . 0.0 109.53 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.498 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.7 OUTLIER -177.89 131.47 0.15 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.259 -0.9 . . . . 0.0 109.462 179.95 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.637 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 21.5 mm -90.09 125.63 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.435 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 42.2 t -89.93 -33.13 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.291 -0.88 . . . . 0.0 109.471 -179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.492 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 1.5 mptt -94.38 143.66 26.22 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.282 -0.886 . . . . 0.0 109.488 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.459 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 65.3 m-80 -111.0 164.74 12.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.248 -0.908 . . . . 0.0 109.526 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -59.06 146.43 38.47 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.493 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 86.75 7.74 77.82 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.625 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -105.35 170.71 7.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.221 -1.164 . . . . 0.0 109.411 -179.98 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.673 HG23 ' O ' ' A' ' 16' ' ' GLY . 11.9 m -107.77 145.69 33.2 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.536 -0.728 . . . . 0.0 109.458 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 4.9 m -114.98 137.37 48.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.471 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.565 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -106.08 174.53 5.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.192 -0.943 . . . . 0.0 109.522 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.411 ' HB2' ' HA ' ' A' ' 8' ' ' THR . 1.5 t -62.03 129.13 39.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.234 -0.917 . . . . 0.0 109.497 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.98 21.63 73.53 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -79.82 104.34 10.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.255 -1.144 . . . . 0.0 109.52 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.478 HD23 ' C ' ' A' ' 71' ' ' LEU . 9.1 tt -78.1 121.9 24.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.243 -0.911 . . . . 0.0 109.458 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.5 mp -92.69 -69.05 0.76 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.352 -0.843 . . . . 0.0 109.38 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -140.74 -175.82 14.87 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.43 ' HA ' ' HA ' ' A' ' 3' ' ' ASP . 0.3 OUTLIER -143.69 142.0 30.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.297 -1.119 . . . . 0.0 109.485 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.618 HD12 HD13 ' A' ' 55' ' ' ILE . 0.6 OUTLIER -90.51 144.52 25.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.886 . . . . 0.0 109.436 -179.96 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.612 HG22 ' H ' ' A' ' 54' ' ' VAL . 3.0 t . . . . . 0 N--CA 1.489 1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.74 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.777 HD13 ' CD2' ' A' ' 75' ' ' LEU . 3.2 mp . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.997 ' OD1' HD11 ' A' ' 71' ' ' LEU . 22.9 t70 -82.28 154.12 25.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.204 -0.935 . . . . 0.0 109.496 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.2 mt -130.86 122.34 51.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.883 . . . . 0.0 109.432 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.473 ' HD2' ' OD2' ' A' ' 3' ' ' ASP . 0.0 OUTLIER -144.89 164.85 29.82 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.234 -0.916 . . . . 0.0 109.464 179.958 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.404 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -67.34 148.13 98.77 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.291 -0.881 . . . . 0.0 109.495 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 35.9 Cg_endo -78.02 -172.2 1.42 Allowed 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.628 2.219 . . . . 0.0 110.417 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -97.86 96.52 8.26 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.235 -0.915 . . . . 0.0 109.449 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.54 ' CZ ' ' HA3' ' A' ' 16' ' ' GLY . 19.5 m-85 -59.81 149.34 72.98 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.245 -0.909 . . . . 0.0 109.493 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.04 -166.25 0.39 Allowed 'Trans proline' 0 C--N 1.308 -1.556 0 C-N-CA 122.61 2.207 . . . . 0.0 110.494 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' A' ' 12' ' ' SER . 4.8 tt0 -72.78 -42.43 63.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.231 -0.918 . . . . 0.0 109.484 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 11' ' ' GLU . 2.5 t -42.88 -64.54 0.61 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.298 -0.876 . . . . 0.0 109.554 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.584 HG22 ' H ' ' A' ' 15' ' ' ASP . 15.1 mm -104.95 145.86 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.216 -0.928 . . . . 0.0 109.445 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -114.36 21.77 14.33 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.294 -0.879 . . . . 0.0 109.485 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.584 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.3 OUTLIER -161.74 -173.11 3.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.135 -0.978 . . . . 0.0 109.572 -179.997 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.54 ' HA3' ' CZ ' ' A' ' 9' ' ' PHE . . . -150.56 -176.56 23.65 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.518 HG23 ' O ' ' A' ' 64' ' ' ASP . 25.8 m -150.06 122.09 8.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.176 -1.19 . . . . 0.0 109.5 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.581 HG12 ' N ' ' A' ' 19' ' ' ALA . 41.4 t -45.83 168.72 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.251 -0.906 . . . . 0.0 109.353 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.581 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -111.13 -74.34 0.65 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.117 -0.989 . . . . 0.0 109.589 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.403 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 16.2 m -160.05 127.78 4.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.254 -0.904 . . . . 0.0 109.605 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.705 ' CH2' HD12 ' A' ' 58' ' ' ILE . 36.7 m95 -89.91 83.4 6.15 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.26 -0.9 . . . . 0.0 109.461 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.604 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -42.95 -70.18 0.11 Allowed 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.322 -0.861 . . . . 0.0 109.424 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -93.67 177.98 5.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.25 -0.906 . . . . 0.0 109.678 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.455 ' HD3' ' HD2' ' A' ' 25' ' ' PRO . 5.4 mttp -121.39 169.48 9.06 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.283 -0.886 . . . . 0.0 109.445 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.529 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.3 Cg_endo -76.15 119.7 5.42 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.657 2.238 . . . . 0.0 110.463 179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 122.68 10.13 6.04 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.444 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 1.1 pp20? -112.4 173.88 6.15 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -1.129 . . . . 0.0 109.507 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.444 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -82.5 144.28 30.53 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.922 . . . . 0.0 109.511 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.8 t -112.31 156.85 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.287 -0.883 . . . . 0.0 109.47 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.1 OUTLIER -142.96 135.88 27.96 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.274 -0.892 . . . . 0.0 109.493 179.957 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.466 ' HG2' ' N ' ' A' ' 32' ' ' ASP . 2.7 ttm180 -42.8 141.13 1.14 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.337 -0.852 . . . . 0.0 109.651 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.466 ' N ' ' HG2' ' A' ' 31' ' ' ARG . 20.8 t70 69.71 49.66 0.53 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.289 -0.882 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' A' ' 34' ' ' LEU . 3.0 tt0 -138.5 106.89 5.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 0.0 109.429 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 40.1 tp -43.46 165.14 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.291 -0.88 . . . . 0.0 109.472 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.791 HD11 ' HB2' ' A' ' 49' ' ' ALA . 91.3 mt -134.26 -47.13 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.15 -0.969 . . . . 0.0 109.637 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.579 ' HB ' ' CE3' ' A' ' 21' ' ' TRP . 2.6 p -171.99 144.01 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.158 -0.964 . . . . 0.0 109.52 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.526 ' C ' ' HB3' ' A' ' 19' ' ' ALA . 1.3 m-20 -100.19 167.03 10.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.247 -0.908 . . . . 0.0 109.458 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.473 HG22 ' O ' ' A' ' 45' ' ' MET . 1.2 tt -142.63 156.33 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.253 -0.904 . . . . 0.0 109.539 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.58 122.14 38.99 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.268 -0.895 . . . . 0.0 109.47 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.418 ' O ' ' C ' ' A' ' 41' ' ' ASP . 44.4 p -101.92 -151.91 0.43 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 109.475 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.478 ' HA ' HG13 ' A' ' 13' ' ' ILE . 43.1 t0 -42.71 -62.82 0.9 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.277 -0.89 . . . . 0.0 109.613 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.7 mttt -149.48 17.78 0.92 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.212 -0.93 . . . . 0.0 109.474 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.469 HG12 ' H ' ' A' ' 44' ' ' VAL . 1.9 t -119.34 172.21 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.895 . . . . 0.0 109.503 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.537 ' O ' HG13 ' A' ' 44' ' ' VAL . 9.6 p -129.62 126.7 63.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.3 -0.875 . . . . 0.0 109.431 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' MET . . . . . 0.473 ' O ' HG22 ' A' ' 38' ' ' ILE . 1.3 mtt -113.83 124.43 52.21 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.186 -0.946 . . . . 0.0 109.484 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.6 147.32 26.46 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.334 -0.854 . . . . 0.0 109.443 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.455 ' O ' ' HB ' ' A' ' 35' ' ' ILE . 55.9 t -116.06 103.87 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.184 -0.947 . . . . 0.0 109.504 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.403 HD21 ' N ' ' A' ' 33' ' ' GLU . 0.3 OUTLIER -105.03 163.85 12.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.915 . . . . 0.0 109.396 -179.89 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.791 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.88 164.83 18.16 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.159 -0.963 . . . . 0.0 109.456 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.698 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -105.82 3.67 28.97 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.542 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.698 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 163.94 167.54 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.184 -0.948 . . . . 0.0 109.455 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.502 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -49.96 170.98 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.291 -0.881 . . . . 0.0 109.313 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.502 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.93 -164.01 30.67 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.818 ' O ' HG22 ' A' ' 76' ' ' THR . 48.7 t -136.85 125.35 34.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -1.142 . . . . 0.0 109.427 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.875 HD13 ' CD1' ' A' ' 75' ' ' LEU . 15.3 mm -61.68 160.08 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.294 -0.879 . . . . 0.0 109.448 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.448 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -100.51 -66.31 0.92 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.306 -0.871 . . . . 0.0 109.492 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.529 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 33.4 tt0 177.34 141.68 0.08 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.294 -0.879 . . . . 0.0 109.46 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.705 HD12 ' CH2' ' A' ' 21' ' ' TRP . 15.3 mm -91.42 158.28 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.273 -0.892 . . . . 0.0 109.449 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.823 HG23 ' O ' ' A' ' 72' ' ' LEU . 52.8 t -90.03 -67.52 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.261 -0.899 . . . . 0.0 109.342 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.483 ' HD3' ' CB ' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -101.1 174.99 5.75 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.254 -0.904 . . . . 0.0 109.399 179.926 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 7.6 m120 -95.87 155.43 16.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.931 . . . . 0.0 109.469 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.537 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -60.1 149.94 31.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.3 -0.875 . . . . 0.0 109.387 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 92.39 -12.62 69.25 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.518 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -87.3 170.94 10.99 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.295 -1.12 . . . . 0.0 109.286 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.499 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 99.0 m -100.73 135.41 42.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.519 -0.738 . . . . 0.0 109.461 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.665 ' O ' HD23 ' A' ' 67' ' ' LEU . 5.2 m -118.58 -176.8 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.448 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.665 HD23 ' O ' ' A' ' 66' ' ' VAL . 13.2 mt -121.45 162.38 20.56 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.248 -0.907 . . . . 0.0 109.441 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 t -64.25 122.54 16.88 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.238 -0.914 . . . . 0.0 109.494 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 91.31 10.16 62.53 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -84.98 112.56 20.7 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.191 -1.182 . . . . 0.0 109.447 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.997 HD11 ' OD1' ' A' ' 3' ' ' ASP . 1.2 tp -72.49 127.11 31.55 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.319 -0.863 . . . . 0.0 109.496 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.823 ' O ' HG23 ' A' ' 59' ' ' VAL . 77.0 mt -93.92 -68.05 0.82 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.302 -0.874 . . . . 0.0 109.435 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -136.39 178.8 18.52 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.53 ' CG ' HD21 ' A' ' 71' ' ' LEU . 1.5 mtmp? -145.94 151.74 38.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -1.162 . . . . 0.0 109.472 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.875 ' CD1' HD13 ' A' ' 55' ' ' ILE . 13.2 tp -99.05 152.37 19.92 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.224 -0.923 . . . . 0.0 109.474 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.818 HG22 ' O ' ' A' ' 54' ' ' VAL . 3.0 t . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.286 -0.884 . . . . 0.0 109.677 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 24.3 mm . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 121.296 0.57 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.519 ' OD2' ' CD1' ' A' ' 71' ' ' LEU . 43.7 t0 -71.84 142.28 49.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.16 -0.963 . . . . 0.0 109.463 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.414 HD12 HG23 ' A' ' 4' ' ' ILE . 4.9 mm -112.19 103.83 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.225 -0.922 . . . . 0.0 109.415 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.63 166.02 10.67 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.225 -0.922 . . . . 0.0 109.468 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.494 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -72.72 159.69 84.72 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.27 -0.894 . . . . 0.0 109.435 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.494 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.18 165.29 26.03 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.57 2.18 . . . . 0.0 110.368 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -90.28 108.8 19.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.472 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -60.86 149.24 81.23 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.442 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.08 -160.6 0.12 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.626 2.218 . . . . 0.0 110.369 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.3 OUTLIER -77.4 -58.88 3.03 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.247 -0.908 . . . . 0.0 109.497 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.2 t -42.93 -55.97 3.49 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.359 -0.838 . . . . 0.0 109.594 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.464 ' CD1' ' HB2' ' A' ' 41' ' ' ASP . 12.0 mm -95.1 136.55 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.275 -0.891 . . . . 0.0 109.444 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.78 14.48 10.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.216 -0.927 . . . . 0.0 109.436 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.415 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -156.53 -171.34 3.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.244 -0.91 . . . . 0.0 109.419 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.5 178.82 39.59 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.696 HG23 ' O ' ' A' ' 64' ' ' ASP . 17.8 m -150.03 119.25 6.79 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.23 -1.159 . . . . 0.0 109.367 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.503 HG12 ' N ' ' A' ' 19' ' ' ALA . 46.4 t -44.25 162.99 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.438 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.511 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -106.2 -75.47 0.63 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -0.906 . . . . 0.0 109.58 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.474 ' HA ' ' HB3' ' A' ' 62' ' ' GLU . 17.3 m -160.01 136.23 8.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.238 -0.914 . . . . 0.0 109.531 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.636 ' CH2' HD12 ' A' ' 58' ' ' ILE . 35.1 m95 -89.85 84.11 6.22 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.244 -0.91 . . . . 0.0 109.512 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.588 ' CE1' HD21 ' A' ' 34' ' ' LEU . 2.3 m80 -42.59 -55.64 3.44 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.44 -0.788 . . . . 0.0 109.531 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -109.82 158.71 17.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.098 -1.001 . . . . 0.0 109.612 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.426 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 4.9 mttt -97.22 167.99 10.99 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.275 -0.891 . . . . 0.0 109.428 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.485 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.68 101.84 1.55 Allowed 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.625 2.216 . . . . 0.0 110.446 179.869 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.5 -5.08 4.48 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.477 ' N ' ' CD ' ' A' ' 27' ' ' GLU . 1.3 mp0 -90.36 -172.66 3.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.18 -1.188 . . . . 0.0 109.458 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -97.3 149.83 21.63 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.301 -0.874 . . . . 0.0 109.438 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.6 m -135.5 161.55 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.214 -0.929 . . . . 0.0 109.514 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.8 tttt -129.29 135.29 48.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.24 -0.912 . . . . 0.0 109.52 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.433 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 9.2 ttt180 -42.86 140.34 1.39 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.325 -0.86 . . . . 0.0 109.613 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 18.0 t0 70.82 47.0 0.47 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.23 -0.919 . . . . 0.0 109.516 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.434 ' O ' ' O ' ' A' ' 34' ' ' LEU . 29.4 tt0 -140.12 121.99 15.51 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.279 -0.888 . . . . 0.0 109.558 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.588 HD21 ' CE1' ' A' ' 22' ' ' HIS . 47.4 tp -43.14 164.56 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.278 -0.889 . . . . 0.0 109.587 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.607 HG13 ' HB2' ' A' ' 49' ' ' ALA . 25.4 mm -145.27 -42.56 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.185 -0.947 . . . . 0.0 109.535 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.506 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 12.7 p -154.7 134.18 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.234 -0.916 . . . . 0.0 109.551 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.511 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 22.1 m-20 -100.39 159.45 15.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.267 -0.896 . . . . 0.0 109.463 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.519 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 7.3 tt -128.87 156.9 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.463 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.409 ' N ' HG12 ' A' ' 38' ' ' ILE . 1.3 tt0 -129.65 142.78 50.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.208 -0.933 . . . . 0.0 109.423 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.721 HG22 ' O ' ' A' ' 43' ' ' VAL . 5.5 t -132.01 -163.45 1.34 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.256 -0.903 . . . . 0.0 109.362 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.464 ' HB2' ' CD1' ' A' ' 13' ' ' ILE . 2.2 t0 -42.34 -68.0 0.22 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.317 -0.864 . . . . 0.0 109.782 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LYS . . . . . 0.512 ' O ' ' CG2' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -142.97 48.76 1.49 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.136 -0.978 . . . . 0.0 109.541 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.721 ' O ' HG22 ' A' ' 40' ' ' THR . 90.0 t -159.04 118.04 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.251 -0.906 . . . . 0.0 109.499 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.6 t -100.57 126.63 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.487 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' MET . . . . . 0.519 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 31.4 mtt -106.44 -179.65 4.0 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.456 ' HA ' ' OD1' ' A' ' 37' ' ' ASP . 3.7 mt-10 -133.52 146.96 51.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.249 -0.907 . . . . 0.0 109.44 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.506 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 36.2 t -117.76 106.68 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.492 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.515 HD12 ' HA ' ' A' ' 34' ' ' LEU . 0.6 OUTLIER -89.99 161.35 15.92 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.294 -0.879 . . . . 0.0 109.377 -179.964 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.607 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -81.03 160.91 24.42 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.44 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.701 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.5 OUTLIER -99.02 2.12 45.99 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.178 -0.951 . . . . 0.0 109.608 179.958 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.18 155.34 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.212 -0.93 . . . . 0.0 109.478 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.503 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -65.12 170.86 4.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.33 -0.856 . . . . 0.0 109.321 -179.995 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.503 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.45 -137.59 6.09 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.47 ' O ' ' CB ' ' A' ' 76' ' ' THR . 44.8 t -139.87 135.25 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.338 -1.095 . . . . 0.0 109.448 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.433 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 9.5 mm -75.74 153.9 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.332 -0.855 . . . . 0.0 109.457 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -87.94 -65.99 0.96 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.208 -0.933 . . . . 0.0 109.397 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.485 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -178.88 139.21 0.16 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -0.907 . . . . 0.0 109.399 179.949 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.636 HD12 ' CH2' ' A' ' 21' ' ' TRP . 23.1 mm -94.84 138.69 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.233 -0.917 . . . . 0.0 109.515 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 96.1 t -110.04 -14.52 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.309 -0.869 . . . . 0.0 109.425 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.711 ' HE2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -91.04 -172.4 3.32 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.286 -0.884 . . . . 0.0 109.39 179.995 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 46.2 m-80 -137.05 155.95 49.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.328 -0.858 . . . . 0.0 109.576 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.474 ' HB3' ' HA ' ' A' ' 20' ' ' THR . 0.5 OUTLIER -72.18 144.14 48.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.265 -0.897 . . . . 0.0 109.518 -179.939 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 57.54 19.56 34.84 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.696 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -99.4 170.95 8.27 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.262 -1.14 . . . . 0.0 109.352 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 11.5 t -88.17 154.25 20.6 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.525 -0.734 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.711 HG12 ' HE2' ' A' ' 60' ' ' LYS . 1.5 m -141.67 173.94 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.233 -0.917 . . . . 0.0 109.42 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.469 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.3 OUTLIER -127.99 162.56 26.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.301 -0.875 . . . . 0.0 109.433 -179.956 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 6.6 t -56.53 143.71 34.34 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.19 -0.944 . . . . 0.0 109.478 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 58.99 24.61 58.49 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.469 ' HB2' ' O ' ' A' ' 67' ' ' LEU . 13.9 tp10 -79.21 105.23 10.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -1.184 . . . . 0.0 109.491 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.519 ' CD1' ' OD2' ' A' ' 3' ' ' ASP . 0.4 OUTLIER -61.99 130.39 45.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.275 -0.89 . . . . 0.0 109.392 -179.915 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 7.9 mt -100.84 -71.12 0.72 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.27 -0.894 . . . . 0.0 109.45 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -144.39 -176.9 18.82 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 10.0 mtmt -128.26 151.67 49.01 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.313 -1.11 . . . . 0.0 109.462 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -103.63 152.09 22.17 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.174 -0.954 . . . . 0.0 109.512 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.47 ' CB ' ' O ' ' A' ' 54' ' ' VAL . 13.0 m . . . . . 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 109.427 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 62.9 mt . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.506 ' OD2' ' CG ' ' A' ' 5' ' ' LYS . 24.9 t0 -61.04 154.54 22.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.2 -0.937 . . . . 0.0 109.496 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 16.4 mt -123.58 98.59 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.286 -0.884 . . . . 0.0 109.429 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.506 ' CG ' ' OD2' ' A' ' 3' ' ' ASP . 3.8 mtmt -122.39 154.76 37.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.914 . . . . 0.0 109.465 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.579 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -78.93 162.5 64.56 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.252 -0.905 . . . . 0.0 109.52 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.579 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.8 Cg_endo -78.04 159.57 30.44 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.555 2.17 . . . . 0.0 110.485 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.1 m -73.74 142.36 46.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.348 -0.845 . . . . 0.0 109.436 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.574 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 25.6 m-85 -89.88 156.95 46.72 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.27 -0.894 . . . . 0.0 109.512 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -77.97 -167.12 0.45 Allowed 'Trans proline' 0 C--N 1.309 -1.516 0 C-N-CA 122.655 2.237 . . . . 0.0 110.48 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.438 ' O ' ' C ' ' A' ' 12' ' ' SER . 39.0 tt0 -75.24 -56.38 4.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.176 -0.953 . . . . 0.0 109.456 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 11' ' ' GLU . 4.9 t -42.72 -52.8 4.8 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.3 -0.875 . . . . 0.0 109.619 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.595 HG22 ' H ' ' A' ' 15' ' ' ASP . 25.2 mt -94.1 147.42 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.236 -0.915 . . . . 0.0 109.494 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -124.33 6.54 8.4 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.183 -0.948 . . . . 0.0 109.615 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.595 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER 178.91 -172.53 0.15 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.236 -0.915 . . . . 0.0 109.488 -179.974 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.413 ' C ' HG22 ' A' ' 66' ' ' VAL . . . -154.78 -157.41 8.18 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.65 HG23 ' O ' ' A' ' 64' ' ' ASP . 36.4 m -150.02 135.4 18.15 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -1.135 . . . . 0.0 109.529 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 19' ' ' ALA . 19.5 t -55.88 158.78 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 109.461 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.625 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -101.94 -76.81 0.56 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.154 -0.967 . . . . 0.0 109.485 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 19.6 m -160.04 136.61 9.0 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.602 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.839 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 32.4 m95 -89.99 83.15 6.09 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.259 -0.9 . . . . 0.0 109.491 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.64 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.7 m80 -43.02 -68.34 0.2 Allowed 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.313 -0.867 . . . . 0.0 109.395 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.11 -172.0 3.17 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.259 -0.9 . . . . 0.0 109.561 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.407 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 7.8 mttp -141.09 168.29 14.66 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.31 -0.869 . . . . 0.0 109.4 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.791 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.0 Cg_endo -76.55 125.96 8.65 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.569 2.179 . . . . 0.0 110.467 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 117.19 10.96 9.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 45.6 mm-40 -128.4 -172.3 2.67 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.207 -1.172 . . . . 0.0 109.472 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -100.91 179.39 4.4 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.266 -0.896 . . . . 0.0 109.468 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.612 HG12 ' N ' ' A' ' 30' ' ' LYS . 64.6 t -147.04 165.95 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.293 -0.879 . . . . 0.0 109.451 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.612 ' N ' HG12 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -112.34 132.38 55.02 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.565 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.477 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -43.01 121.01 1.96 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.291 -0.88 . . . . 0.0 109.604 -179.931 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.477 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 3.0 t70 73.94 55.21 0.1 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.26 -0.9 . . . . 0.0 109.484 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 34' ' ' LEU . 2.3 tp10 -131.74 126.51 34.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.278 -0.888 . . . . 0.0 109.475 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.64 HD21 ' NE2' ' A' ' 22' ' ' HIS . 48.6 tp -42.89 161.68 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.288 -0.882 . . . . 0.0 109.586 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 34' ' ' LEU . 29.8 mm -144.72 -42.56 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.209 -0.932 . . . . 0.0 109.586 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.541 HG12 ' HB ' ' A' ' 47' ' ' VAL . 9.4 p -152.3 137.18 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.224 -0.923 . . . . 0.0 109.514 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.625 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 25.1 m-20 -100.71 163.14 12.47 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -0.871 . . . . 0.0 109.411 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.6 mt -129.86 154.34 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.232 -0.918 . . . . 0.0 109.517 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.483 ' HB3' ' O ' ' A' ' 17' ' ' THR . 27.8 tt0 -116.57 149.66 39.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.46 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.415 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -133.94 174.57 10.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -0.895 . . . . 0.0 109.487 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 40' ' ' THR . 5.6 t0 -42.9 -64.68 0.58 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.334 -0.853 . . . . 0.0 109.624 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LYS . . . . . 0.46 ' C ' HG23 ' A' ' 43' ' ' VAL . 11.6 mttp -134.06 39.76 3.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.217 -0.927 . . . . 0.0 109.479 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.46 HG23 ' C ' ' A' ' 42' ' ' LYS . 38.5 t -155.23 143.63 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.222 -0.924 . . . . 0.0 109.474 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 81.9 t -115.76 136.28 53.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.871 . . . . 0.0 109.487 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 84.4 mtp -121.36 178.27 4.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.213 -0.929 . . . . 0.0 109.456 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -137.27 160.03 40.22 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.218 -0.926 . . . . 0.0 109.467 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.541 ' HB ' HG12 ' A' ' 36' ' ' VAL . 21.3 t -127.2 104.78 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.94 . . . . 0.0 109.559 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.522 HD12 ' CD1' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -95.58 158.16 15.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.347 -0.845 . . . . 0.0 109.491 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.464 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -82.56 161.94 22.12 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.271 -0.893 . . . . 0.0 109.45 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.707 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -89.3 -0.49 57.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.229 -0.919 . . . . 0.0 109.618 179.994 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.707 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.12 162.75 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.48 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.507 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -53.64 171.05 0.1 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.257 -0.902 . . . . 0.0 109.367 179.955 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.507 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 154.54 -150.88 22.57 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.8 t -136.2 123.11 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -1.172 . . . . 0.0 109.493 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.552 HG22 ' N ' ' A' ' 56' ' ' ALA . 15.5 mm -61.66 166.29 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -0.915 . . . . 0.0 109.512 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.552 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -105.46 -67.21 0.93 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.252 -0.905 . . . . 0.0 109.464 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.532 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 2.9 tm-20 -174.6 150.13 1.33 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.139 -0.976 . . . . 0.0 109.577 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.839 HG23 ' CZ2' ' A' ' 21' ' ' TRP . 8.1 mt -89.98 151.72 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.279 -0.888 . . . . 0.0 109.514 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.437 HG21 ' O ' ' A' ' 71' ' ' LEU . 56.0 t -97.16 -67.01 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.267 -0.896 . . . . 0.0 109.453 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.421 ' HD2' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -92.62 -170.71 2.54 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.232 -0.917 . . . . 0.0 109.451 179.988 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.468 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 12.6 m-80 -125.24 168.52 13.36 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.209 -0.932 . . . . 0.0 109.512 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.4 ' HA ' ' HB ' ' A' ' 18' ' ' VAL . 0.2 OUTLIER -65.99 149.8 49.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.196 -0.94 . . . . 0.0 109.542 179.931 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 82.07 4.94 90.09 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.65 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -99.93 170.89 8.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.16 -1.2 . . . . 0.0 109.319 179.969 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 28.3 m -95.46 126.29 40.65 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.522 -0.737 . . . . 0.0 109.504 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.413 HG22 ' C ' ' A' ' 16' ' ' GLY . 18.8 m -89.97 176.38 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.33 -0.856 . . . . 0.0 109.427 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -142.51 164.09 31.06 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.141 -0.974 . . . . 0.0 109.443 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.1 t -58.14 133.17 55.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 109.453 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 62.75 24.58 66.58 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 30.1 tp10 -73.47 119.55 17.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.255 -1.144 . . . . 0.0 109.431 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.45 HD23 ' N ' ' A' ' 73' ' ' GLY . 6.8 tt -75.93 109.08 9.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.199 -0.938 . . . . 0.0 109.444 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -88.81 -10.44 48.12 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.177 -0.952 . . . . 0.0 109.477 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.45 ' N ' HD23 ' A' ' 71' ' ' LEU . . . 157.59 -175.4 34.94 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 1.3 mtmm -138.84 149.08 44.52 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.193 -1.18 . . . . 0.0 109.498 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.427 HD12 HD13 ' A' ' 55' ' ' ILE . 0.8 OUTLIER -100.3 146.95 26.32 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.264 -0.898 . . . . 0.0 109.448 -179.915 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 14.9 m . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.246 -0.909 . . . . 0.0 109.483 -179.959 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.7 mt . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -71.13 150.91 44.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.318 -0.864 . . . . 0.0 109.486 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.3 mt -127.2 72.6 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.232 -0.918 . . . . 0.0 109.426 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.422 ' HA ' ' HG ' ' A' ' 72' ' ' LEU . 5.0 pttp -101.34 167.99 9.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.194 -0.941 . . . . 0.0 109.472 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.45 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -66.34 158.02 79.52 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.344 -0.848 . . . . 0.0 109.438 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.45 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.2 Cg_endo -78.05 169.26 20.71 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.586 2.191 . . . . 0.0 110.422 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.7 141.35 40.94 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.464 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.53 ' CD2' ' HB2' ' A' ' 68' ' ' SER . 18.6 m-85 -107.91 153.07 41.86 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.23 -0.919 . . . . 0.0 109.462 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.445 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -78.06 167.41 23.49 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.593 2.195 . . . . 0.0 110.373 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.1 mt-10 -49.45 -53.52 22.53 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.2 -0.938 . . . . 0.0 109.54 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 11' ' ' GLU . 19.1 t -42.75 -48.88 5.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.385 -0.822 . . . . 0.0 109.631 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.816 HG21 ' CG2' ' A' ' 40' ' ' THR . 22.5 mt -96.18 122.05 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.223 -0.923 . . . . 0.0 109.402 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -101.13 11.46 39.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.214 -0.929 . . . . 0.0 109.439 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.598 ' O ' HG22 ' A' ' 13' ' ' ILE . 0.9 OUTLIER -176.67 -170.13 0.31 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.247 -0.908 . . . . 0.0 109.403 179.982 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.613 ' O ' HG23 ' A' ' 65' ' ' THR . . . -151.58 -173.33 21.28 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.523 HG23 ' O ' ' A' ' 64' ' ' ASP . 4.2 m -150.04 127.93 11.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -1.147 . . . . 0.0 109.411 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.531 HG12 ' N ' ' A' ' 19' ' ' ALA . 47.9 t -54.31 164.05 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.218 -0.926 . . . . 0.0 109.45 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.558 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -109.7 -73.86 0.67 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.26 -0.9 . . . . 0.0 109.518 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.534 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 18.3 m -158.46 134.67 9.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.211 -0.931 . . . . 0.0 109.489 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.656 ' CH2' HD12 ' A' ' 58' ' ' ILE . 35.1 m95 -89.7 84.7 6.32 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.231 -0.918 . . . . 0.0 109.567 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.799 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.2 m80 -42.76 -60.31 1.62 Allowed 'General case' 0 N--CA 1.499 2.004 0 O-C-N 121.401 -0.812 . . . . 0.0 109.483 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.405 ' HA ' ' HD2' ' A' ' 23' ' ' LYS . 1.1 mmmt -100.28 -171.99 2.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -0.873 . . . . 0.0 109.562 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.439 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -124.54 169.17 11.31 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.254 -0.904 . . . . 0.0 109.483 -179.934 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.514 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.2 Cg_endo -76.48 94.24 1.04 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.67 2.247 . . . . 0.0 110.409 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 151.04 -17.45 0.92 Allowed Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -84.75 170.68 13.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -1.134 . . . . 0.0 109.541 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.11 127.94 42.57 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.886 . . . . 0.0 109.389 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.584 HG22 ' O ' ' A' ' 53' ' ' GLY . 18.3 m -96.63 -172.04 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.464 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.426 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -148.4 136.97 21.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.47 -179.959 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.454 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 10.3 tmm_? -42.79 128.28 4.14 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.319 -0.863 . . . . 0.0 109.624 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 7.7 t70 72.81 54.36 0.14 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.276 -0.89 . . . . 0.0 109.453 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.466 ' N ' HD23 ' A' ' 48' ' ' LEU . 1.4 tp10 -141.91 120.78 12.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.296 -0.877 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.799 HD21 ' NE2' ' A' ' 22' ' ' HIS . 47.9 tp -42.87 142.31 0.92 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.309 -0.87 . . . . 0.0 109.581 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.589 HG13 ' HB2' ' A' ' 49' ' ' ALA . 22.7 mm -129.75 -42.15 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.889 . . . . 0.0 109.443 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.585 HG12 ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -157.53 144.43 9.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.296 -0.878 . . . . 0.0 109.466 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.558 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 19.6 m-20 -102.68 150.3 23.58 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.627 HD11 HG22 ' A' ' 47' ' ' VAL . 21.8 mt -110.47 150.72 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.186 -0.946 . . . . 0.0 109.464 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -141.7 98.73 3.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.486 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.816 ' CG2' HG21 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -90.19 -174.37 4.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.202 -0.936 . . . . 0.0 109.488 -179.996 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.626 ' H ' HG22 ' A' ' 40' ' ' THR . 0.6 OUTLIER -42.87 -45.18 4.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.274 -0.891 . . . . 0.0 109.647 -179.866 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LYS . . . . . 0.434 ' HG3' ' O ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -156.28 27.33 0.35 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.199 -0.938 . . . . 0.0 109.446 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 3.5 t -128.36 106.66 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.327 -0.858 . . . . 0.0 109.42 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.5 t -90.31 130.48 39.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.242 -0.911 . . . . 0.0 109.484 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 10.2 mmt -141.86 108.45 5.34 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.181 -0.95 . . . . 0.0 109.476 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.477 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 5.4 mt-10 -63.0 172.08 1.92 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.278 -0.889 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.627 HG22 HD11 ' A' ' 38' ' ' ILE . 15.7 t -135.25 102.32 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.236 -0.915 . . . . 0.0 109.504 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.466 HD23 ' N ' ' A' ' 33' ' ' GLU . 0.0 OUTLIER -94.5 154.85 17.21 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.479 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.589 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -84.94 143.15 29.16 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.227 -0.921 . . . . 0.0 109.525 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.31 13.93 31.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.325 -0.859 . . . . 0.0 109.45 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -179.7 140.83 0.14 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.322 -0.862 . . . . 0.0 109.454 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -59.83 170.89 1.02 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.248 -0.908 . . . . 0.0 109.309 179.999 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.584 ' O ' HG22 ' A' ' 29' ' ' VAL . . . 154.32 175.84 25.97 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.576 ' O ' HG22 ' A' ' 76' ' ' THR . 49.2 t -112.93 124.83 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.206 -1.173 . . . . 0.0 109.498 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.939 HD13 HD12 ' A' ' 75' ' ' LEU . 15.6 mm -61.25 164.82 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.488 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.524 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -106.39 -63.7 1.24 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.314 -0.867 . . . . 0.0 109.462 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.488 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -170.41 136.43 1.33 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.16 -0.962 . . . . 0.0 109.528 -179.915 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.656 HD12 ' CH2' ' A' ' 21' ' ' TRP . 26.6 mm -89.94 141.37 14.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.343 -0.848 . . . . 0.0 109.452 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 89.1 t -90.18 -62.46 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -0.912 . . . . 0.0 109.55 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.474 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -89.95 155.1 19.35 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 109.44 -179.917 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 57.4 m-20 -102.54 158.47 16.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.247 -0.908 . . . . 0.0 109.433 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.534 ' CB ' ' HA ' ' A' ' 20' ' ' THR . 2.1 pp20? -60.81 143.35 54.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.206 -0.934 . . . . 0.0 109.451 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 98.48 -10.32 62.99 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.523 ' O ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -100.16 170.9 8.15 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.239 -1.153 . . . . 0.0 109.274 -179.971 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.613 HG23 ' O ' ' A' ' 16' ' ' GLY . 47.5 m -101.54 146.91 27.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.492 -0.755 . . . . 0.0 109.484 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.41 160.94 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.226 -0.921 . . . . 0.0 109.497 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 15.0 mt -90.42 145.28 25.05 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.246 -0.909 . . . . 0.0 109.476 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.53 ' HB2' ' CD2' ' A' ' 9' ' ' PHE . 1.9 t -49.33 114.32 1.0 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.295 -0.878 . . . . 0.0 109.515 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.45 22.43 24.34 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 38.9 tp10 -84.0 131.9 34.79 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.293 -1.122 . . . . 0.0 109.483 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 4.9 tt -66.09 114.25 5.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.261 -0.899 . . . . 0.0 109.501 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.55 ' O ' HG23 ' A' ' 58' ' ' ILE . 6.1 mt -96.59 -22.17 17.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.266 -0.896 . . . . 0.0 109.456 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.38 159.83 23.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -124.32 133.98 53.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.265 -1.138 . . . . 0.0 109.483 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.939 HD12 HD13 ' A' ' 55' ' ' ILE . 4.5 tp -92.35 152.09 19.94 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.92 . . . . 0.0 109.503 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.576 HG22 ' O ' ' A' ' 54' ' ' VAL . 2.9 t . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.313 -0.867 . . . . 0.0 109.727 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.575 HD12 HD22 ' A' ' 75' ' ' LEU . 25.1 mt . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -77.67 124.03 27.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.244 -0.91 . . . . 0.0 109.459 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.6 mm -100.32 108.28 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.235 -0.916 . . . . 0.0 109.472 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.5 mtmt -125.15 165.72 17.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.627 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -75.59 163.41 67.53 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.207 -0.933 . . . . 0.0 109.528 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.627 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.09 134.69 13.23 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.637 2.225 . . . . 0.0 110.436 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.1 m -57.64 134.74 56.44 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.194 -0.941 . . . . 0.0 109.503 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.479 ' CE1' ' O ' ' A' ' 7' ' ' PRO . 4.2 m-85 -94.97 149.17 35.88 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.201 -0.937 . . . . 0.0 109.415 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 9' ' ' PHE . 35.8 Cg_endo -78.09 -165.22 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.621 2.214 . . . . 0.0 110.456 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.1 OUTLIER -72.41 -49.19 35.53 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.414 179.995 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 11' ' ' GLU . 30.9 t -42.78 -52.12 5.12 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.308 -0.87 . . . . 0.0 109.635 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.783 HG22 ' H ' ' A' ' 15' ' ' ASP . 3.2 mt -92.95 150.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.206 -0.934 . . . . 0.0 109.439 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.419 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -122.28 12.77 10.25 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.327 -0.858 . . . . 0.0 109.494 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.783 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.3 OUTLIER 170.75 -170.76 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.256 -0.902 . . . . 0.0 109.499 -179.987 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.09 -169.92 18.09 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.471 HG23 ' O ' ' A' ' 64' ' ' ASP . 17.1 m -149.94 128.78 12.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -1.126 . . . . 0.0 109.469 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.44 HG12 ' N ' ' A' ' 19' ' ' ALA . 25.5 t -52.35 160.65 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.336 -0.852 . . . . 0.0 109.489 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.651 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -100.52 -75.63 0.58 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.473 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.7 m -160.11 136.11 8.57 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.564 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.721 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 33.4 m95 -89.76 82.46 6.26 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.256 -0.902 . . . . 0.0 109.64 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.668 ' CE1' HD21 ' A' ' 34' ' ' LEU . 1.8 m80 -43.57 -71.46 0.08 Allowed 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.284 -0.885 . . . . 0.0 109.362 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.404 ' HB2' ' HE3' ' A' ' 23' ' ' LYS . 30.0 mtmt -100.09 -171.93 2.13 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.245 -0.909 . . . . 0.0 109.571 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.62 167.39 19.41 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.328 -0.858 . . . . 0.0 109.465 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.835 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.5 Cg_endo -76.92 153.18 32.69 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.66 2.24 . . . . 0.0 110.412 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.11 9.49 67.48 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 41.5 mm-40 -113.38 -173.33 2.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.172 -1.193 . . . . 0.0 109.418 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -83.58 132.5 34.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.457 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.6 t -123.28 138.26 53.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.458 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.1 mttt -119.01 132.95 56.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.437 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -42.9 143.39 0.74 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.258 -0.901 . . . . 0.0 109.595 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.435 ' N ' ' HD2' ' A' ' 31' ' ' ARG . 17.6 t0 69.56 46.76 0.7 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.224 -0.923 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.452 ' O ' HG12 ' A' ' 35' ' ' ILE . 1.8 tp10 -140.41 110.19 6.41 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.229 -0.92 . . . . 0.0 109.49 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.668 HD21 ' CE1' ' A' ' 22' ' ' HIS . 55.7 tp -42.97 161.51 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.27 -0.894 . . . . 0.0 109.604 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.519 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 22.2 mm -149.9 -40.25 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.213 -0.929 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.522 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 13.5 p -151.03 131.01 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.257 -0.902 . . . . 0.0 109.541 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.651 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 12.9 m-20 -97.96 171.94 7.95 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.247 -0.908 . . . . 0.0 109.485 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 2.5 mt -138.74 164.49 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.288 -0.882 . . . . 0.0 109.44 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.446 ' HB2' ' O ' ' A' ' 17' ' ' THR . 37.4 mt-10 -132.95 141.6 48.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.238 -0.913 . . . . 0.0 109.419 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -126.35 -160.48 0.99 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 -179.992 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 40' ' ' THR . 3.8 t70 -42.87 -63.1 0.85 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.277 -0.889 . . . . 0.0 109.563 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LYS . . . . . 0.412 ' HG2' ' O ' ' A' ' 41' ' ' ASP . 6.6 mttt -145.65 22.3 1.46 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 1.9 t -127.42 139.22 52.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.226 -0.921 . . . . 0.0 109.437 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.415 ' O ' HG13 ' A' ' 44' ' ' VAL . 9.1 p -105.98 134.26 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.403 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' MET . . . . . 0.427 ' C ' ' HG3' ' A' ' 46' ' ' GLU . 8.8 mtm -113.55 -176.81 2.98 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.264 -0.897 . . . . 0.0 109.463 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.478 ' HB3' HD13 ' A' ' 34' ' ' LEU . 29.1 mt-10 -143.97 161.65 38.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.307 -0.87 . . . . 0.0 109.402 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.522 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 63.5 t -136.72 108.25 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.773 HD23 ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.89 148.9 25.07 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.286 -0.883 . . . . 0.0 109.381 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -63.55 147.62 50.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.442 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.699 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 1.1 mt-10 -93.05 10.49 31.28 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.239 -0.913 . . . . 0.0 109.473 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.699 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.34 157.23 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.257 -0.902 . . . . 0.0 109.479 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.508 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -65.55 170.96 4.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.336 -0.852 . . . . 0.0 109.348 -179.977 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.508 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.31 -143.79 10.94 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.8 t -138.21 124.46 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.249 -1.147 . . . . 0.0 109.489 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.552 HG22 ' N ' ' A' ' 56' ' ' ALA . 9.6 mm -75.13 171.76 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.3 -0.875 . . . . 0.0 109.523 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.552 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -102.88 -62.45 1.27 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.203 -0.935 . . . . 0.0 109.514 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.534 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 5.3 pt-20 173.27 161.05 0.14 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 109.533 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.835 HD11 ' HD3' ' A' ' 25' ' ' PRO . 1.6 mp -90.43 143.84 10.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.255 -0.903 . . . . 0.0 109.44 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.927 HG21 HD23 ' A' ' 71' ' ' LEU . 53.5 t -99.42 -21.09 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.214 -0.929 . . . . 0.0 109.47 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.518 ' CG ' ' OD2' ' A' ' 64' ' ' ASP . 9.8 tptt -120.65 -171.87 2.27 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.248 -0.907 . . . . 0.0 109.559 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.478 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 17.1 m120 -123.25 167.9 13.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.896 . . . . 0.0 109.49 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -71.52 143.03 50.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.272 -0.893 . . . . 0.0 109.533 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 72.86 17.06 78.18 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.716 -1.353 . . . . 0.0 109.716 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.518 ' OD2' ' CG ' ' A' ' 60' ' ' LYS . 0.2 OUTLIER -100.65 170.83 8.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.232 -1.157 . . . . 0.0 109.331 179.966 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.513 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.8 t -90.94 153.78 19.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.481 -0.762 . . . . 0.0 109.53 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 16.1 m -133.39 144.49 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.227 -0.921 . . . . 0.0 109.517 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -92.67 160.73 14.86 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.3 -0.875 . . . . 0.0 109.387 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.2 t -52.89 119.3 4.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.129 -0.982 . . . . 0.0 109.493 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 74.53 33.36 56.24 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -76.8 137.73 39.43 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.277 -1.131 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.927 HD23 HG21 ' A' ' 59' ' ' VAL . 0.6 OUTLIER -78.19 128.32 33.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.456 -179.961 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 7.5 mt -105.76 -23.17 12.78 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.313 -0.867 . . . . 0.0 109.459 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 171.87 171.16 36.63 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 4.4 mtmt -127.78 136.81 52.0 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.27 -1.135 . . . . 0.0 109.509 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.575 HD22 HD12 ' A' ' 2' ' ' ILE . 2.7 tt -97.75 151.27 20.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.235 -0.916 . . . . 0.0 109.508 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.574 ' O ' HD23 ' A' ' 75' ' ' LEU . 15.1 m . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.262 -0.899 . . . . 0.0 109.464 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.1 pp . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.508 ' OD2' HD11 ' A' ' 71' ' ' LEU . 8.9 t70 -80.41 133.42 35.88 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.178 -0.951 . . . . 0.0 109.449 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 12.2 mt -96.45 107.76 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.1 mttt -121.28 173.36 7.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.909 . . . . 0.0 109.449 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.96 149.19 82.52 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.292 -0.88 . . . . 0.0 109.468 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.02 135.87 14.28 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.661 2.24 . . . . 0.0 110.372 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.519 ' O ' HG23 ' A' ' 8' ' ' THR . 3.0 t -56.73 112.33 1.27 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.202 -0.936 . . . . 0.0 109.474 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -67.24 157.45 85.19 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.867 . . . . 0.0 109.431 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.455 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.07 -159.61 0.1 Allowed 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.557 2.171 . . . . 0.0 110.423 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.416 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.1 tt0 -80.07 -61.94 1.83 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.25 -0.906 . . . . 0.0 109.521 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.416 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.9 t -42.81 -47.51 5.53 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.296 -0.877 . . . . 0.0 109.633 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.522 HD11 ' HB2' ' A' ' 41' ' ' ASP . 16.6 mt -99.81 130.16 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.234 -0.916 . . . . 0.0 109.418 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -118.79 28.15 8.47 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.274 -0.891 . . . . 0.0 109.383 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.491 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 176.42 -170.44 0.07 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.314 -0.866 . . . . 0.0 109.429 -179.978 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.85 -173.53 33.58 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 18' ' ' VAL . 16.7 m -149.91 122.75 8.71 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.154 -1.204 . . . . 0.0 109.422 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.426 ' C ' ' O ' ' A' ' 17' ' ' THR . 47.1 t -44.24 156.96 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -0.905 . . . . 0.0 109.41 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.412 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -106.12 -74.9 0.64 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -0.906 . . . . 0.0 109.475 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.8 m -158.85 134.81 8.93 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.258 -0.901 . . . . 0.0 109.413 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.632 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 33.1 m95 -89.85 84.4 6.24 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.232 -0.917 . . . . 0.0 109.565 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.763 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.1 m80 -42.93 -63.25 0.83 Allowed 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.364 -0.835 . . . . 0.0 109.372 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -92.39 -172.07 2.98 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.187 -0.946 . . . . 0.0 109.509 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.48 ' HB2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.47 164.39 43.06 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.272 -0.893 . . . . 0.0 109.452 -179.95 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.482 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -77.59 90.38 1.26 Allowed 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 122.688 2.259 . . . . 0.0 110.36 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 160.56 -23.28 0.25 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 49.6 mm-40 -94.38 -172.43 2.78 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.35 -1.088 . . . . 0.0 109.472 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -105.0 149.1 26.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.241 -0.912 . . . . 0.0 109.483 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.0 m -120.55 175.66 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.269 -0.894 . . . . 0.0 109.431 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.09 130.6 50.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.425 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 14.1 ttt180 -42.91 141.65 1.07 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.287 -0.883 . . . . 0.0 109.625 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.7 t70 65.55 45.56 2.71 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.434 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 34' ' ' LEU . 4.9 tt0 -136.52 124.83 23.25 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.334 -0.854 . . . . 0.0 109.502 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.862 HD13 ' HB3' ' A' ' 46' ' ' GLU . 49.8 tp -42.81 150.93 0.14 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.372 -0.83 . . . . 0.0 109.603 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.765 HD11 ' HB2' ' A' ' 49' ' ' ALA . 11.8 mt -139.49 -38.73 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.321 -0.862 . . . . 0.0 109.509 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.518 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 9.7 p -154.51 131.12 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.208 -0.933 . . . . 0.0 109.497 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.46 ' OD1' ' HA ' ' A' ' 46' ' ' GLU . 39.3 m-20 -97.0 152.18 18.98 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.176 -0.952 . . . . 0.0 109.443 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.47 ' O ' ' HA ' ' A' ' 44' ' ' VAL . 5.5 mt -115.91 146.69 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.275 -0.89 . . . . 0.0 109.482 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.68 111.54 21.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.315 -0.866 . . . . 0.0 109.495 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.675 HG23 ' N ' ' A' ' 41' ' ' ASP . 4.8 t -106.64 -153.73 0.5 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.191 -0.943 . . . . 0.0 109.385 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.675 ' N ' HG23 ' A' ' 40' ' ' THR . 0.3 OUTLIER -43.09 -71.53 0.08 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.898 . . . . 0.0 109.627 -179.882 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 17.8 mtmm -143.88 36.9 1.29 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.519 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.587 ' O ' HG22 ' A' ' 40' ' ' THR . 2.1 t -146.82 145.6 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.296 -0.877 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.47 ' HA ' ' O ' ' A' ' 38' ' ' ILE . 10.6 p -109.8 133.51 54.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 0.0 109.438 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 2.7 mtt -105.35 126.95 52.68 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.454 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.862 ' HB3' HD13 ' A' ' 34' ' ' LEU . 6.7 mt-10 -81.4 131.25 35.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.179 -0.951 . . . . 0.0 109.466 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.518 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 92.8 t -116.4 102.03 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.247 -0.908 . . . . 0.0 109.509 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.498 ' H ' HD12 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -102.91 163.24 12.32 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.211 -0.931 . . . . 0.0 109.406 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.765 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -79.45 142.35 35.96 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.207 -0.933 . . . . 0.0 109.48 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -82.5 8.21 12.28 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.281 -0.887 . . . . 0.0 109.535 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -177.08 141.73 0.34 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.889 . . . . 0.0 109.534 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.2 OUTLIER -57.93 170.93 0.56 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.223 -0.923 . . . . 0.0 109.312 -179.953 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.99 -145.09 12.25 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.4 t -138.4 125.21 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.3 -1.118 . . . . 0.0 109.433 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.523 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.0 mt -58.17 161.75 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.316 -0.865 . . . . 0.0 109.529 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.54 ' CB ' ' HG3' ' A' ' 74' ' ' LYS . . . -97.66 -66.84 0.88 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.275 -0.891 . . . . 0.0 109.522 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.482 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 8.2 tt0 -175.05 138.75 0.45 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.207 -0.933 . . . . 0.0 109.456 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.632 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.9 mm -101.94 119.92 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.246 -0.909 . . . . 0.0 109.387 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.4 t -90.0 -19.11 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -0.929 . . . . 0.0 109.402 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.442 ' HG3' ' CG ' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -97.81 131.87 43.93 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.466 179.977 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 47.9 m-80 -97.55 156.35 16.55 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -0.867 . . . . 0.0 109.471 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -51.24 148.79 4.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.257 -0.902 . . . . 0.0 109.524 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 75.87 19.7 78.61 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.5 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -100.5 170.91 8.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.267 -1.137 . . . . 0.0 109.274 -179.978 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.5 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 65.1 m -106.67 133.6 51.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.539 -0.725 . . . . 0.0 109.475 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 25.0 m -100.79 163.73 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -0.884 . . . . 0.0 109.451 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.519 HD23 ' H ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -145.68 167.39 23.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.272 -0.893 . . . . 0.0 109.476 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.519 ' H ' HD23 ' A' ' 67' ' ' LEU . 1.5 t -62.29 115.4 4.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.227 -0.921 . . . . 0.0 109.508 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 89.84 18.4 51.25 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 27.2 tp10 -83.19 121.75 27.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.229 -1.159 . . . . 0.0 109.485 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.508 HD11 ' OD2' ' A' ' 3' ' ' ASP . 0.5 OUTLIER -83.98 119.2 24.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.211 -0.931 . . . . 0.0 109.422 -179.973 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 12.0 mt -99.82 -19.09 16.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.268 -0.895 . . . . 0.0 109.44 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 159.5 168.12 21.07 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.54 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -127.21 158.51 36.92 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.16 -1.2 . . . . 0.0 109.487 179.982 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 8.8 tp -96.48 152.84 18.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.436 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.1 m . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.873 . . . . 0.0 109.523 179.952 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.563 HD13 HD23 ' A' ' 75' ' ' LEU . 3.5 mp . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 121.311 0.577 . . . . 0.0 109.459 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.478 ' OD1' HD11 ' A' ' 71' ' ' LEU . 63.2 t0 -57.85 123.26 15.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.531 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 53.0 mt -98.69 121.3 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.228 -0.92 . . . . 0.0 109.39 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.7 ptpp? -147.1 168.5 21.45 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.242 -0.911 . . . . 0.0 109.53 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.42 150.89 91.78 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.02 127.83 8.75 Favored 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.579 2.186 . . . . 0.0 110.423 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -45.84 143.46 2.12 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.27 -0.894 . . . . 0.0 109.451 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.517 ' CE2' ' C ' ' A' ' 15' ' ' ASP . 22.1 m-85 -102.84 154.5 37.47 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.923 . . . . 0.0 109.443 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -78.0 163.75 28.0 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.671 2.247 . . . . 0.0 110.415 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.0 OUTLIER -45.84 -49.77 14.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.141 -0.974 . . . . 0.0 109.505 179.985 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -43.17 -59.96 1.85 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.293 -0.879 . . . . 0.0 109.68 -179.936 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.704 HG22 ' H ' ' A' ' 15' ' ' ASP . 2.5 mp -90.28 132.94 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.267 -0.895 . . . . 0.0 109.48 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.76 25.98 11.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.906 . . . . 0.0 109.486 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.704 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER 177.09 -171.09 0.09 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.24 -0.913 . . . . 0.0 109.487 -179.94 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.417 ' HA3' ' CZ ' ' A' ' 9' ' ' PHE . . . -159.14 -175.09 29.69 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.849 HG23 ' O ' ' A' ' 64' ' ' ASP . 85.2 m -150.02 122.59 8.55 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.292 -1.122 . . . . 0.0 109.45 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.585 HG12 ' N ' ' A' ' 19' ' ' ALA . 38.2 t -48.14 168.97 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.297 -0.877 . . . . 0.0 109.453 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.585 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -111.1 -73.9 0.66 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.266 -0.897 . . . . 0.0 109.58 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.491 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 23.9 m -160.08 135.46 8.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.117 -0.989 . . . . 0.0 109.674 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.655 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 34.2 m95 -89.94 83.38 6.13 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 121.161 -0.962 . . . . 0.0 109.494 179.857 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.576 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 1.5 m80 -43.16 -70.8 0.09 Allowed 'General case' 0 N--CA 1.501 2.109 0 O-C-N 121.315 -0.866 . . . . 0.0 109.425 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.85 -171.75 2.23 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.219 -0.926 . . . . 0.0 109.62 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.443 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.28 169.86 12.72 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.329 -0.857 . . . . 0.0 109.428 -179.903 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.613 ' HD3' HD11 ' A' ' 58' ' ' ILE . 34.9 Cg_endo -76.05 135.98 17.82 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 122.642 2.228 . . . . 0.0 110.377 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.13 10.61 27.59 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.421 ' CD ' ' O ' ' A' ' 28' ' ' ALA . 1.2 pp20? -115.51 173.16 6.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.225 -1.162 . . . . 0.0 109.471 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.421 ' O ' ' CD ' ' A' ' 27' ' ' GLU . . . -78.7 144.96 34.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.288 -0.883 . . . . 0.0 109.481 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.405 HG12 ' N ' ' A' ' 30' ' ' LYS . 5.2 t -127.92 163.95 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.902 . . . . 0.0 109.472 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.422 ' O ' ' C ' ' A' ' 31' ' ' ARG . 4.3 tttp -156.8 141.85 17.17 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.275 -0.891 . . . . 0.0 109.474 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.462 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 1.5 tmm_? -42.78 144.8 0.52 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.337 -0.852 . . . . 0.0 109.718 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.462 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 16.4 t0 72.18 46.91 0.31 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.269 -0.894 . . . . 0.0 109.498 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 34' ' ' LEU . 3.6 tp10 -142.22 100.99 3.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.281 -0.887 . . . . 0.0 109.561 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.576 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 39.9 tp -43.36 146.9 0.43 Allowed 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.299 -0.875 . . . . 0.0 109.519 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 44.5 mt -121.86 -44.66 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.889 . . . . 0.0 109.652 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.523 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.9 p -160.09 139.24 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.2 -0.937 . . . . 0.0 109.566 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.532 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 11.5 m-20 -99.18 168.39 10.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.896 . . . . 0.0 109.478 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.503 ' O ' HG23 ' A' ' 44' ' ' VAL . 12.8 mt -136.02 161.75 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.284 -0.885 . . . . 0.0 109.46 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.438 ' N ' HG22 ' A' ' 38' ' ' ILE . 2.4 tt0 -143.1 167.35 22.29 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.236 -0.915 . . . . 0.0 109.489 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.549 HG22 ' H ' ' A' ' 41' ' ' ASP . 8.5 m -159.18 170.91 20.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.273 -0.892 . . . . 0.0 109.455 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.549 ' H ' HG22 ' A' ' 40' ' ' THR . 8.9 t0 -42.83 -40.61 2.95 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.252 -0.905 . . . . 0.0 109.631 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -156.29 26.0 0.35 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 78.6 t -140.64 105.09 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.33 -0.856 . . . . 0.0 109.46 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 38' ' ' ILE . 3.7 p -95.48 139.32 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.186 -0.946 . . . . 0.0 109.531 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' MET . . . . . 0.451 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 13.2 mmt -128.05 -167.88 1.82 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.275 -0.89 . . . . 0.0 109.477 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.5 pt-20 -158.39 167.06 30.7 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.169 -0.957 . . . . 0.0 109.486 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.523 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 71.3 t -138.31 104.02 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.381 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.463 ' HG ' ' HA ' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -95.98 171.02 8.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 -179.994 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.05 139.64 31.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 0.0 109.44 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.659 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 2.9 mm-40 -100.38 8.09 43.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -0.913 . . . . 0.0 109.548 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.659 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 166.57 142.99 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.958 . . . . 0.0 109.491 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.504 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.84 170.98 0.15 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.198 -0.939 . . . . 0.0 109.225 -179.926 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.504 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.95 -146.3 14.88 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.4 t -135.89 124.45 37.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.302 -1.117 . . . . 0.0 109.505 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.526 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 5.0 mt -61.17 158.65 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 109.567 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.462 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -95.56 -69.41 0.76 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.249 -0.907 . . . . 0.0 109.549 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.528 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -178.97 152.9 0.6 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.241 -0.912 . . . . 0.0 109.471 179.992 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.655 HG23 ' CZ2' ' A' ' 21' ' ' TRP . 24.9 mt -89.91 141.28 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.219 -0.926 . . . . 0.0 109.412 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.8 t -90.53 -66.77 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.172 -0.955 . . . . 0.0 109.411 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.641 ' HD2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -92.79 -173.67 3.39 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.25 -0.906 . . . . 0.0 109.448 -179.983 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.461 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 70.7 m-80 -110.6 155.57 22.16 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.296 -0.878 . . . . 0.0 109.44 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.528 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -69.52 153.43 43.51 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.244 -0.91 . . . . 0.0 109.451 -179.984 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 77.49 7.45 87.09 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.849 ' O ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -105.29 170.95 7.59 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.238 -1.154 . . . . 0.0 109.32 -179.966 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.502 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 48.6 m -99.14 128.55 45.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.457 -0.777 . . . . 0.0 109.494 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.641 HG12 ' HD2' ' A' ' 60' ' ' LYS . 6.6 m -121.52 -169.7 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.329 -0.857 . . . . 0.0 109.455 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.472 HD12 ' HA ' ' A' ' 67' ' ' LEU . 1.2 tp -127.15 165.95 18.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -0.903 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 t -61.7 138.76 58.34 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.279 -0.888 . . . . 0.0 109.505 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.02 15.4 81.4 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -79.05 116.63 19.47 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.243 -1.151 . . . . 0.0 109.51 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.478 HD11 ' OD1' ' A' ' 3' ' ' ASP . 10.9 tp -66.57 115.92 6.96 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.203 -0.935 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 15.4 mt -98.36 -12.35 21.55 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.245 -0.909 . . . . 0.0 109.404 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 164.1 169.96 28.36 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 26.5 mtmt -132.25 139.09 48.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.188 -1.184 . . . . 0.0 109.504 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.563 HD23 HD13 ' A' ' 2' ' ' ILE . 12.8 tp -98.41 136.86 37.95 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.207 -0.933 . . . . 0.0 109.543 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 12.7 m . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.225 -0.922 . . . . 0.0 109.501 179.995 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.518 ' O ' HD12 ' A' ' 2' ' ' ILE . 2.1 pp . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.464 ' OD2' ' CD1' ' A' ' 71' ' ' LEU . 26.1 t70 -74.53 166.4 23.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.3 -0.875 . . . . 0.0 109.521 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 61.1 mt -129.96 118.45 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.475 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 ptpp? -137.25 165.0 27.18 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.272 -0.893 . . . . 0.0 109.425 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.45 150.58 91.59 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.485 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.11 166.4 24.78 Favored 'Trans proline' 0 C--N 1.309 -1.524 0 C-N-CA 122.612 2.208 . . . . 0.0 110.409 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.09 94.96 2.98 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.173 -0.954 . . . . 0.0 109.445 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.533 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 21.5 m-85 -50.1 151.0 3.77 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.298 -0.877 . . . . 0.0 109.457 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.436 ' HG2' HG12 ' A' ' 13' ' ' ILE . 35.2 Cg_endo -78.14 177.31 8.93 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.559 2.173 . . . . 0.0 110.383 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 12' ' ' SER . 43.2 tt0 -66.0 -54.05 31.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.501 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.425 ' C ' ' O ' ' A' ' 11' ' ' GLU . 21.6 t -42.95 -46.41 5.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.34 -0.85 . . . . 0.0 109.628 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.607 HG22 ' H ' ' A' ' 15' ' ' ASP . 11.6 mm -94.5 151.69 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.415 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -121.36 2.64 10.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.618 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.607 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 167.96 -169.25 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.109 -0.995 . . . . 0.0 109.502 -179.992 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.67 -159.46 9.94 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.691 HG22 ' O ' ' A' ' 64' ' ' ASP . 0.2 OUTLIER -149.06 170.68 17.85 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.277 -1.131 . . . . 0.0 109.048 179.987 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.552 HG12 ' H ' ' A' ' 19' ' ' ALA . 3.8 t -85.66 171.53 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.051 -1.031 . . . . 0.0 109.409 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.578 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -118.91 -74.19 0.62 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.462 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.453 ' HA ' ' HG2' ' A' ' 62' ' ' GLU . 65.2 m -160.21 132.3 6.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.144 -0.972 . . . . 0.0 109.622 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.675 ' CH2' HD12 ' A' ' 58' ' ' ILE . 34.0 m95 -89.85 82.23 6.24 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.256 -0.902 . . . . 0.0 109.397 179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.625 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.4 m80 -42.67 -57.12 2.85 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.401 -0.812 . . . . 0.0 109.484 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.3 163.58 12.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.245 -0.909 . . . . 0.0 109.66 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.498 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 23.6 mttt -114.46 165.8 13.01 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.346 -0.846 . . . . 0.0 109.152 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.533 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.76 102.5 1.62 Allowed 'Trans proline' 0 C--N 1.308 -1.582 0 C-N-CA 122.544 2.163 . . . . 0.0 110.419 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 145.01 -13.43 1.91 Allowed Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.8 mm-40 -96.61 -172.13 2.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.234 -1.156 . . . . 0.0 109.512 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.68 161.99 13.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.533 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.462 ' O ' ' OD2' ' A' ' 52' ' ' ASP . 35.5 t -138.36 153.42 26.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.239 -0.913 . . . . 0.0 109.479 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.409 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.6 OUTLIER -126.71 137.6 53.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.929 . . . . 0.0 109.5 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.514 ' HG2' ' N ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -42.98 146.04 0.43 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.302 -0.874 . . . . 0.0 109.639 -179.939 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.514 ' N ' ' HG2' ' A' ' 31' ' ' ARG . 3.1 t70 67.66 38.82 2.9 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.7 ' N ' HD11 ' A' ' 48' ' ' LEU . 8.6 tp10 -127.84 115.94 19.39 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.194 -0.941 . . . . 0.0 109.455 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.625 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 41.4 tp -43.25 162.37 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.283 -0.886 . . . . 0.0 109.463 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.456 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 29.6 mm -135.49 -48.05 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 109.63 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.506 HG12 ' HB ' ' A' ' 47' ' ' VAL . 14.3 p -160.18 131.55 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.158 -0.964 . . . . 0.0 109.539 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.578 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 3.4 m-20 -90.32 150.82 21.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.5 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 60.9 mt -119.54 155.48 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -0.913 . . . . 0.0 109.501 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.46 ' CG ' ' HB ' ' A' ' 17' ' ' THR . 12.1 pt-20 -128.58 154.51 46.12 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.257 -0.902 . . . . 0.0 109.539 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -141.58 175.5 9.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.258 -0.902 . . . . 0.0 109.425 -179.93 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 4.2 t0 -42.83 -60.67 1.51 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.334 -0.853 . . . . 0.0 109.636 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 15.7 mttt -138.5 36.44 2.25 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.29 -0.881 . . . . 0.0 109.464 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 90.6 t -147.65 127.35 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.28 -0.887 . . . . 0.0 109.436 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.6 t -102.3 152.0 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.277 -0.889 . . . . 0.0 109.463 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.9 176.33 9.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 109.468 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -141.54 149.63 41.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 109.495 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.506 ' HB ' HG12 ' A' ' 36' ' ' VAL . 30.5 t -115.59 96.9 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.285 -0.885 . . . . 0.0 109.431 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.7 HD11 ' N ' ' A' ' 33' ' ' GLU . 29.8 tp -96.04 153.16 17.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.35 -0.843 . . . . 0.0 109.52 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.471 ' N ' ' HG ' ' A' ' 48' ' ' LEU . . . -83.41 148.07 27.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.192 -0.942 . . . . 0.0 109.446 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.562 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -99.77 17.98 19.34 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.936 . . . . 0.0 109.485 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.562 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 171.87 154.01 0.07 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.288 -0.883 . . . . 0.0 109.483 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.501 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -66.09 170.94 5.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.308 -0.87 . . . . 0.0 109.289 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.501 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.26 -159.81 28.39 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.0 t -135.62 125.11 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -1.159 . . . . 0.0 109.51 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.59 HG22 ' N ' ' A' ' 56' ' ' ALA . 4.9 mt -59.11 165.5 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.938 . . . . 0.0 109.528 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.59 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -104.45 -67.19 0.91 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.46 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.533 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -169.25 140.63 2.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.227 -0.921 . . . . 0.0 109.565 -179.991 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.675 HD12 ' CH2' ' A' ' 21' ' ' TRP . 23.3 mm -93.77 138.97 19.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.233 -0.917 . . . . 0.0 109.393 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 18.0 t -89.94 -39.42 12.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.237 -0.914 . . . . 0.0 109.435 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.462 ' HD3' ' O ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -102.39 158.06 16.47 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.222 -0.924 . . . . 0.0 109.411 179.974 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -117.27 163.32 16.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.303 -0.873 . . . . 0.0 109.432 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.453 ' HG2' ' HA ' ' A' ' 20' ' ' THR . 2.3 mp0 -55.28 134.41 49.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.22 -0.925 . . . . 0.0 109.447 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 100.68 -8.29 58.12 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.691 ' O ' HG22 ' A' ' 17' ' ' THR . 0.2 OUTLIER -92.06 170.44 9.84 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.244 -1.151 . . . . 0.0 109.362 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.498 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.6 t -100.36 164.15 12.06 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.565 -0.71 . . . . 0.0 109.511 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 66' ' ' VAL . 22.6 m -130.83 131.08 64.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -0.905 . . . . 0.0 109.44 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -101.59 162.04 13.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -0.885 . . . . 0.0 109.541 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.1 t -59.82 110.03 1.07 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.514 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.79 20.6 16.25 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -83.71 133.91 34.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.264 -1.139 . . . . 0.0 109.499 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.464 ' CD1' ' OD2' ' A' ' 3' ' ' ASP . 9.5 tp -83.26 125.38 31.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.504 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.456 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 4.5 mt -100.0 -22.17 15.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.264 -0.897 . . . . 0.0 109.477 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.67 173.49 27.14 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.466 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 39.7 pttt -129.46 153.01 48.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -1.122 . . . . 0.0 109.493 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.48 HD12 ' HA ' ' A' ' 55' ' ' ILE . 22.9 tp -96.22 153.02 18.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -0.898 . . . . 0.0 109.464 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 8.3 m . . . . . 0 N--CA 1.491 1.601 0 O-C-N 121.289 -0.882 . . . . 0.0 109.45 179.984 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 8.5 mt . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' A' ' 4' ' ' ILE . 10.6 t0 -68.37 152.57 45.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.527 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.502 ' N ' ' OD1' ' A' ' 3' ' ' ASP . 8.2 mm -123.74 136.35 60.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.902 . . . . 0.0 109.524 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.34 172.5 12.67 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.281 -0.887 . . . . 0.0 109.447 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.475 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -69.06 158.82 85.47 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.475 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.04 114.86 3.66 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.707 2.271 . . . . 0.0 110.381 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 29.7 m -46.52 126.12 7.81 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.265 -0.897 . . . . 0.0 109.464 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.572 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 1.3 p90 -107.89 151.86 41.4 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.333 -0.854 . . . . 0.0 109.445 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.04 -169.64 0.8 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.68 2.253 . . . . 0.0 110.385 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.438 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.4 OUTLIER -66.61 -45.15 80.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.273 -0.892 . . . . 0.0 109.476 -179.984 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.6 OUTLIER -42.75 -36.85 1.57 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.373 -0.83 . . . . 0.0 109.578 -179.838 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.637 HG22 ' O ' ' A' ' 15' ' ' ASP . 18.5 mm -114.58 108.92 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.249 -0.907 . . . . 0.0 109.411 179.954 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.46 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -74.67 -1.48 21.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.217 -0.927 . . . . 0.0 109.667 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.637 ' O ' HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER 166.92 -174.12 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.917 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.463 ' C ' HG22 ' A' ' 66' ' ' VAL . . . -144.63 -165.96 11.32 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.523 ' CG2' ' O ' ' A' ' 64' ' ' ASP . 0.4 OUTLIER -149.99 128.27 12.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.293 -1.122 . . . . 0.0 109.397 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.476 HG12 ' N ' ' A' ' 19' ' ' ALA . 61.3 t -43.83 159.49 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.217 -0.927 . . . . 0.0 109.529 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.476 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -111.99 -71.02 0.78 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.253 -0.904 . . . . 0.0 109.574 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.6 m -159.28 133.12 7.43 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.264 -0.897 . . . . 0.0 109.594 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.633 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.2 m95 -89.92 85.65 6.41 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.3 -0.875 . . . . 0.0 109.486 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.604 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.4 m80 -42.86 -60.09 1.73 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.325 -0.859 . . . . 0.0 109.352 -179.864 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -105.37 155.0 19.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.231 -0.918 . . . . 0.0 109.495 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.413 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 9.6 mttt -95.01 167.26 13.29 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.361 -0.837 . . . . 0.0 109.519 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.49 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.5 Cg_endo -76.75 104.56 1.93 Allowed 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.682 2.255 . . . . 0.0 110.494 179.892 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 140.45 -9.72 2.93 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -90.63 -172.17 3.3 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -1.151 . . . . 0.0 109.514 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -101.85 149.19 24.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -0.892 . . . . 0.0 109.421 -179.951 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -130.49 162.65 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.295 -0.878 . . . . 0.0 109.444 179.895 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 6.7 tttp -133.22 142.56 48.63 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.224 -0.923 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.46 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 10.5 ttp-105 -42.92 137.45 2.35 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.285 -0.884 . . . . 0.0 109.588 -179.863 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.784 ' HA ' HD21 ' A' ' 48' ' ' LEU . 23.9 t0 72.27 52.04 0.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.256 -0.902 . . . . 0.0 109.524 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.485 ' N ' HD11 ' A' ' 48' ' ' LEU . 0.5 OUTLIER -141.44 114.58 8.67 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.274 -0.891 . . . . 0.0 109.425 -179.978 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.635 ' N ' HD12 ' A' ' 48' ' ' LEU . 54.3 tp -42.74 162.31 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.323 -0.861 . . . . 0.0 109.6 -179.937 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 1.088 HD11 ' HB2' ' A' ' 49' ' ' ALA . 4.2 mt -140.84 -42.03 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.214 -0.929 . . . . 0.0 109.536 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.639 HG12 ' HB ' ' A' ' 47' ' ' VAL . 7.2 p -158.75 139.88 4.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.319 -0.863 . . . . 0.0 109.502 179.925 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -98.62 149.97 22.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.938 . . . . 0.0 109.544 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.448 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 32.8 mm -104.46 140.79 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.288 -0.883 . . . . 0.0 109.424 -179.993 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -126.36 92.51 3.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.503 -179.975 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.44 ' OG1' ' HB ' ' A' ' 43' ' ' VAL . 3.0 p -87.81 -173.49 4.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.296 -0.878 . . . . 0.0 109.515 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 40' ' ' THR . 9.7 t0 -42.8 -61.56 1.23 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.367 -0.833 . . . . 0.0 109.626 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -141.62 33.25 1.63 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.477 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.44 ' HB ' ' OG1' ' A' ' 40' ' ' THR . 9.8 t -132.24 109.86 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.166 -0.959 . . . . 0.0 109.447 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.3 t -93.11 126.45 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.319 -0.863 . . . . 0.0 109.524 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 45' ' ' MET . . . . . 0.448 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 0.3 OUTLIER -123.95 -178.27 4.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.321 -0.862 . . . . 0.0 109.477 -180.0 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.424 ' HG3' ' C ' ' A' ' 45' ' ' MET . 0.7 OUTLIER -133.77 155.17 50.27 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.256 -0.902 . . . . 0.0 109.544 179.959 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.639 ' HB ' HG12 ' A' ' 36' ' ' VAL . 35.0 t -126.84 98.19 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.332 -0.855 . . . . 0.0 109.459 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.911 HD23 ' O ' ' A' ' 49' ' ' ALA . 2.6 tt -107.67 151.44 25.65 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.888 . . . . 0.0 109.426 -179.955 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 1.088 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -83.76 161.12 21.09 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.205 -0.935 . . . . 0.0 109.485 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.86 17.83 23.27 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.194 -0.941 . . . . 0.0 109.396 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -178.58 173.75 1.29 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.298 -0.876 . . . . 0.0 109.494 -179.954 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -77.55 170.92 15.73 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.213 -0.929 . . . . 0.0 109.306 179.953 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.72 175.01 23.77 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.946 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.779 ' O ' HG22 ' A' ' 76' ' ' THR . 47.1 t -121.64 124.9 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.326 -1.102 . . . . 0.0 109.447 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.49 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 16.5 mm -58.22 162.36 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.256 -0.902 . . . . 0.0 109.509 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.476 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -101.67 -67.42 0.87 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.193 -0.942 . . . . 0.0 109.41 -179.965 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.486 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 2.2 mt-10 -162.46 135.09 5.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.445 -179.983 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.633 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 27.3 mm -93.17 122.23 44.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.224 -0.922 . . . . 0.0 109.409 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.5 t -89.95 -15.7 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.508 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.629 ' HB2' HD23 ' A' ' 72' ' ' LEU . 1.5 mptt -110.46 125.47 53.32 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.434 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 -92.99 173.59 7.66 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.905 . . . . 0.0 109.496 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -69.49 147.96 50.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 109.564 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.67 -8.76 76.42 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.523 ' O ' ' CG2' ' A' ' 17' ' ' THR . 0.1 OUTLIER -84.49 170.83 13.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.206 -1.173 . . . . 0.0 109.313 -179.92 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.51 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.8 t -99.9 159.29 15.18 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.511 -0.743 . . . . 0.0 109.48 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.463 HG22 ' C ' ' A' ' 16' ' ' GLY . 29.9 m -122.54 160.51 24.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.222 -0.924 . . . . 0.0 109.452 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.532 HD23 ' N ' ' A' ' 68' ' ' SER . 0.6 OUTLIER -125.36 174.54 8.09 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.179 -0.95 . . . . 0.0 109.492 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.532 ' N ' HD23 ' A' ' 67' ' ' LEU . 35.9 t -72.92 85.97 1.28 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.495 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 108.85 22.51 6.92 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -78.45 118.03 20.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -1.109 . . . . 0.0 109.459 -179.946 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.414 HD23 ' C ' ' A' ' 71' ' ' LEU . 7.6 tt -65.77 131.68 46.88 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.281 -0.887 . . . . 0.0 109.448 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.629 HD23 ' HB2' ' A' ' 60' ' ' LYS . 4.4 mt -115.86 -13.47 11.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.281 -0.887 . . . . 0.0 109.491 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.77 163.69 22.12 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.98 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 7.2 mttt -124.54 145.95 49.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.24 -1.153 . . . . 0.0 109.483 179.939 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -91.65 147.85 22.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.289 -0.882 . . . . 0.0 109.463 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.779 HG22 ' O ' ' A' ' 54' ' ' VAL . 2.9 t . . . . . 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.911 . . . . 0.0 109.787 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.4 ' HB ' ' HB3' ' A' ' 75' ' ' LEU . 20.8 mm . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -60.5 136.42 58.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.24 -0.912 . . . . 0.0 109.472 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 80.5 mt -114.47 121.3 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.181 -0.949 . . . . 0.0 109.438 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 17.3 mtpt -123.25 178.15 5.25 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.213 -0.93 . . . . 0.0 109.508 179.966 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -84.18 164.58 42.99 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.255 -0.903 . . . . 0.0 109.505 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.9 Cg_endo -77.99 117.76 4.25 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.644 2.229 . . . . 0.0 110.451 179.928 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 8' ' ' THR . 0.0 OUTLIER -53.97 136.47 41.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.241 -0.912 . . . . 0.0 109.474 179.953 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.559 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 21.8 m-85 -95.33 155.34 38.9 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.469 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.416 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.1 Cg_endo -77.99 -178.53 4.68 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.71 2.273 . . . . 0.0 110.369 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.5 ' HG3' ' N ' ' A' ' 12' ' ' SER . 16.9 pt-20 -61.64 -43.85 98.08 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.5 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.82 -72.93 0.05 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.32 -0.863 . . . . 0.0 109.631 -179.88 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.474 HG22 ' N ' ' A' ' 14' ' ' ALA . 1.8 mp -91.16 167.52 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.243 -0.911 . . . . 0.0 109.446 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.474 ' N ' HG22 ' A' ' 13' ' ' ILE . . . -142.09 44.83 1.67 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.448 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.559 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 0.3 OUTLIER 168.74 -169.91 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.3 -0.875 . . . . 0.0 109.456 179.938 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.485 ' O ' HG23 ' A' ' 65' ' ' THR . . . -168.21 -170.04 32.43 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.996 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.541 HG23 ' O ' ' A' ' 64' ' ' ASP . 29.9 m -150.07 126.69 10.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -1.146 . . . . 0.0 109.514 179.986 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.572 HG12 ' N ' ' A' ' 19' ' ' ALA . 21.8 t -51.89 169.92 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.572 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -113.85 -75.34 0.6 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.229 -0.919 . . . . 0.0 109.534 -179.936 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.524 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 23.2 m -158.38 133.54 8.58 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.221 -0.924 . . . . 0.0 109.529 -179.918 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.623 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.85 84.77 6.26 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.232 -0.917 . . . . 0.0 109.524 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.769 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.9 m80 -43.07 -67.42 0.28 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.298 -0.876 . . . . 0.0 109.35 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -89.26 -171.92 3.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.42 179.911 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.488 ' HB2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.7 164.76 40.53 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.282 -0.886 . . . . 0.0 109.445 179.974 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.488 ' HD2' ' HB2' ' A' ' 24' ' ' LYS . 34.9 Cg_endo -77.18 101.21 1.48 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.559 2.173 . . . . 0.0 110.4 179.938 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 149.75 -16.8 1.09 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.896 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -93.0 -179.03 4.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -1.152 . . . . 0.0 109.437 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.52 159.62 18.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.21 -0.931 . . . . 0.0 109.519 179.953 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.417 HG12 ' N ' ' A' ' 30' ' ' LYS . 80.5 t -143.57 156.33 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.393 -179.973 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.417 ' N ' HG12 ' A' ' 29' ' ' VAL . 49.1 tttt -140.79 141.92 34.74 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 30' ' ' LYS . 5.7 ttm180 -42.82 151.34 0.13 Allowed 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.356 -0.84 . . . . 0.0 109.634 -179.848 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.416 ' HA ' HD23 ' A' ' 48' ' ' LEU . 7.9 t70 68.14 40.56 2.15 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.221 -0.924 . . . . 0.0 109.465 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 34' ' ' LEU . 1.6 tt0 -140.14 111.05 6.9 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 0.0 109.467 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.769 HD21 ' NE2' ' A' ' 22' ' ' HIS . 51.2 tp -42.76 163.44 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.381 -0.825 . . . . 0.0 109.611 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.501 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 39.5 mt -147.18 -43.51 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.227 -0.921 . . . . 0.0 109.612 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.435 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 11.4 p -159.81 136.87 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.305 -0.872 . . . . 0.0 109.531 -179.925 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.543 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 3.5 m-20 -94.85 163.17 13.45 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.307 -0.871 . . . . 0.0 109.422 179.84 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.422 HD11 ' CG2' ' A' ' 47' ' ' VAL . 24.3 mt -129.33 156.87 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.119 -0.988 . . . . 0.0 109.527 -179.969 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.17 134.45 50.16 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.288 -0.882 . . . . 0.0 109.503 179.938 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.674 HG22 ' O ' ' A' ' 43' ' ' VAL . 5.6 t -124.24 -163.94 1.2 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.183 -0.948 . . . . 0.0 109.392 180.0 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.471 ' N ' HG23 ' A' ' 40' ' ' THR . 42.3 t0 -42.3 -68.87 0.16 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.247 -0.908 . . . . 0.0 109.741 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 42' ' ' LYS . . . . . 0.462 ' O ' HG23 ' A' ' 43' ' ' VAL . 1.4 mttp -141.84 48.34 1.61 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.192 -0.942 . . . . 0.0 109.513 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.674 ' O ' HG22 ' A' ' 40' ' ' THR . 76.4 t -156.04 119.92 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.229 -0.92 . . . . 0.0 109.428 -179.956 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.0 t -89.95 118.11 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.216 -0.928 . . . . 0.0 109.523 -179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 1.6 mtp -96.79 -170.8 2.12 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.276 -0.89 . . . . 0.0 109.437 179.945 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 5.2 pt-20 -149.15 159.6 44.1 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.287 -0.883 . . . . 0.0 109.448 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.435 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 68.0 t -130.74 108.28 15.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.263 -0.898 . . . . 0.0 109.459 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.504 ' HG ' ' N ' ' A' ' 34' ' ' LEU . 0.1 OUTLIER -93.85 172.59 8.15 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.294 -0.879 . . . . 0.0 109.537 179.962 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.465 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -76.16 136.01 39.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.278 -0.888 . . . . 0.0 109.419 -179.979 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.676 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -95.67 10.12 37.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.531 179.975 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.676 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 165.54 140.8 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.272 -0.892 . . . . 0.0 109.451 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.508 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.31 170.92 0.13 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 109.35 -179.982 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.508 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 140.29 -155.07 24.41 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 55.6 t -134.79 128.62 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.304 -1.116 . . . . 0.0 109.464 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.457 HG22 ' N ' ' A' ' 56' ' ' ALA . 17.0 mm -56.35 159.36 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.28 -0.888 . . . . 0.0 109.511 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.457 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -99.66 -65.55 0.96 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.341 -0.849 . . . . 0.0 109.535 179.975 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.487 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 6.4 tt0 -173.1 132.77 0.51 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.158 -0.963 . . . . 0.0 109.528 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.623 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 28.4 mm -91.64 125.51 44.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.886 . . . . 0.0 109.391 179.953 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 23.2 t -90.08 -39.37 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.219 -0.926 . . . . 0.0 109.449 179.974 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.471 ' HG2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -95.03 128.29 41.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.485 179.951 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 71.2 m-80 -87.91 155.98 19.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.303 -0.873 . . . . 0.0 109.446 -179.95 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.529 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -65.02 143.57 57.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.303 -0.873 . . . . 0.0 109.5 -179.937 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 97.11 -13.75 64.48 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.988 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.541 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -92.41 170.89 9.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.284 -1.127 . . . . 0.0 109.303 179.955 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.501 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 21.8 m -98.12 139.54 33.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.486 -0.759 . . . . 0.0 109.516 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.471 HG12 ' HG2' ' A' ' 60' ' ' LYS . 6.0 m -114.78 -161.95 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.289 -0.882 . . . . 0.0 109.391 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -146.62 170.84 16.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.278 -0.889 . . . . 0.0 109.49 -179.932 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 5.6 t -69.01 104.81 2.21 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.48 179.988 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 102.56 10.71 37.54 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.984 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 31.2 tp10 -72.3 125.53 27.58 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -1.132 . . . . 0.0 109.404 -179.967 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -74.58 121.42 21.56 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -0.917 . . . . 0.0 109.439 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.447 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 9.1 mt -95.85 -22.53 17.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.222 -0.923 . . . . 0.0 109.489 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 168.38 174.63 37.31 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -127.33 135.82 51.06 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.23 -1.159 . . . . 0.0 109.51 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.4 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 0.6 OUTLIER -90.05 138.23 31.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.392 -179.92 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.2 m . . . . . 0 N--CA 1.489 1.522 0 O-C-N 121.268 -0.895 . . . . 0.0 109.481 179.96 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.66 HD12 HD13 ' A' ' 75' ' ' LEU . 49.9 mt . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -75.61 118.47 18.49 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.202 -0.936 . . . . 0.0 109.43 -179.933 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.8 mt -96.04 98.73 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.275 -0.89 . . . . 0.0 109.508 179.935 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.45 ' HG3' ' HA ' ' A' ' 71' ' ' LEU . 7.5 ttpt -118.78 163.93 16.15 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -0.884 . . . . 0.0 109.487 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.539 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -65.5 160.78 57.08 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.897 . . . . 0.0 109.464 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.539 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.1 Cg_endo -78.1 129.76 9.86 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.613 2.209 . . . . 0.0 110.396 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.633 ' O ' HG23 ' A' ' 8' ' ' THR . 6.9 t -56.36 111.92 1.11 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.91 . . . . 0.0 109.445 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -74.24 126.6 88.91 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.329 -0.857 . . . . 0.0 109.345 -179.969 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.464 ' HD2' HD12 ' A' ' 13' ' ' ILE . 36.1 Cg_endo -78.42 -159.44 0.1 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.398 2.065 . . . . 0.0 110.388 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.9 mm-40 -73.36 -55.0 6.98 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.161 -0.962 . . . . 0.0 109.398 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.435 ' C ' ' O ' ' A' ' 11' ' ' GLU . 17.0 t -42.87 -45.42 4.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.358 -0.839 . . . . 0.0 109.585 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.592 HG22 ' H ' ' A' ' 15' ' ' ASP . 16.9 mt -91.3 163.61 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.293 -0.879 . . . . 0.0 109.491 -179.96 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.416 ' N ' HG22 ' A' ' 13' ' ' ILE . . . -143.89 13.37 1.68 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.306 -0.871 . . . . 0.0 109.436 -179.965 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.592 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER 172.23 -172.27 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.454 -179.968 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.42 172.45 40.19 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.497 HG23 ' O ' ' A' ' 64' ' ' ASP . 68.3 m -149.25 125.66 10.9 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.254 -1.145 . . . . 0.0 109.425 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 19' ' ' ALA . 24.9 t -50.01 169.41 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.203 -0.935 . . . . 0.0 109.515 179.946 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.58 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -112.76 -73.27 0.67 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.158 -0.964 . . . . 0.0 109.502 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.552 HG23 ' OE1' ' A' ' 62' ' ' GLU . 52.4 m -159.62 131.21 6.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.483 -179.891 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.633 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.4 m95 -89.91 84.16 6.2 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 121.261 -0.899 . . . . 0.0 109.441 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.722 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.5 m80 -42.56 -64.89 0.54 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.373 -0.829 . . . . 0.0 109.454 -179.709 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 5.7 mptt -95.15 -172.19 2.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.244 -0.91 . . . . 0.0 109.532 -179.922 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.67 168.37 17.77 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.312 -0.868 . . . . 0.0 109.452 -179.965 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.494 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.64 133.09 13.86 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 C-N-CA 122.648 2.232 . . . . 0.0 110.409 179.878 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.8 -11.47 20.82 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.917 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 53.3 mm-40 -97.13 -174.91 3.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.241 -1.152 . . . . 0.0 109.502 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.03 172.65 8.42 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.222 -0.924 . . . . 0.0 109.51 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 t -141.91 155.08 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.974 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -131.65 128.26 38.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.228 -0.92 . . . . 0.0 109.496 179.969 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 3.2 ttt-85 -42.83 137.27 2.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.394 -0.817 . . . . 0.0 109.601 -179.822 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.497 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 10.7 t0 74.97 33.27 0.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.259 -0.901 . . . . 0.0 109.427 179.955 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.488 ' C ' ' CD1' ' A' ' 48' ' ' LEU . 1.2 tt0 -124.29 115.68 21.42 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.258 -0.902 . . . . 0.0 109.503 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.722 HD21 ' NE2' ' A' ' 22' ' ' HIS . 45.0 tp -43.11 150.94 0.16 Allowed 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.231 -0.918 . . . . 0.0 109.525 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.462 HD11 ' HB2' ' A' ' 49' ' ' ALA . 13.4 mt -129.69 -46.43 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.223 -0.923 . . . . 0.0 109.588 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.515 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.7 p -162.83 142.72 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.233 -0.917 . . . . 0.0 109.461 -179.908 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.49 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 33.5 m-20 -100.73 163.03 12.51 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.284 -0.885 . . . . 0.0 109.437 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.548 HG22 ' N ' ' A' ' 39' ' ' GLU . 9.6 mt -129.33 162.86 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.174 -0.954 . . . . 0.0 109.483 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.548 ' N ' HG22 ' A' ' 38' ' ' ILE . 6.1 mm-40 -133.87 151.65 51.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 -179.978 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -140.25 -177.53 5.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.256 -0.903 . . . . 0.0 109.486 179.971 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 40' ' ' THR . 5.4 t70 -42.95 -66.47 0.37 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.326 -0.859 . . . . 0.0 109.629 -179.907 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.2 mttp -135.85 40.69 2.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.286 -0.884 . . . . 0.0 109.461 -179.974 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 52.5 t -151.49 128.18 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.273 -0.892 . . . . 0.0 109.463 -179.994 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.413 ' O ' HG13 ' A' ' 44' ' ' VAL . 9.0 p -98.58 134.41 37.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 0.0 109.442 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 45' ' ' MET . . . . . 0.448 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 1.3 mtt -114.59 -172.45 2.11 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 6.1 pt-20 -154.73 164.56 38.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.254 -0.904 . . . . 0.0 109.461 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.515 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 58.2 t -134.69 103.55 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 109.442 -179.927 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.632 HD22 HD12 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -93.96 167.04 11.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.2 -0.937 . . . . 0.0 109.52 179.984 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.462 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.54 136.1 33.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.405 -179.929 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.645 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -95.87 9.9 39.03 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.162 -0.961 . . . . 0.0 109.466 -179.977 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.645 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 167.06 142.93 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.233 -0.917 . . . . 0.0 109.478 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.505 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -58.63 170.96 0.69 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.317 -0.864 . . . . 0.0 109.375 179.96 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.505 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.78 -157.43 27.27 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.928 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.7 t -128.64 127.11 66.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.25 -1.147 . . . . 0.0 109.572 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.462 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 14.4 mm -64.0 156.79 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.27 -0.894 . . . . 0.0 109.437 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -95.55 -69.57 0.75 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.21 -0.931 . . . . 0.0 109.416 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.494 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 1.2 pt-20 -172.27 142.48 1.35 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.252 -0.905 . . . . 0.0 109.449 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.633 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 24.5 mm -94.8 129.54 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.23 -0.919 . . . . 0.0 109.48 -179.977 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.1 t -90.15 -28.99 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.29 -0.881 . . . . 0.0 109.442 179.987 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.481 ' HD3' ' HG2' ' A' ' 70' ' ' GLU . 0.0 OUTLIER -109.16 131.99 54.54 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.182 -0.949 . . . . 0.0 109.529 179.926 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -85.47 155.93 21.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.165 -0.96 . . . . 0.0 109.461 179.992 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.552 ' OE1' HG23 ' A' ' 20' ' ' THR . 0.0 OUTLIER -68.29 141.51 55.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.914 . . . . 0.0 109.476 179.958 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 96.12 -11.3 67.58 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.505 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -95.95 170.9 8.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.262 -1.14 . . . . 0.0 109.327 -179.986 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.505 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 13.0 t -89.02 157.95 18.18 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.492 -0.755 . . . . 0.0 109.516 -179.992 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.687 HG11 HD21 ' A' ' 72' ' ' LEU . 1.9 m -127.21 -174.82 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.245 -0.909 . . . . 0.0 109.464 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -140.96 177.81 7.79 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.336 -0.853 . . . . 0.0 109.481 -179.957 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.4 t -69.46 124.17 23.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.489 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 75.24 21.89 77.09 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 179.951 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.481 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 42.6 tp10 -74.58 103.65 4.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.191 -1.182 . . . . 0.0 109.472 179.966 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.813 HD11 ' HG3' ' A' ' 74' ' ' LYS . 0.7 OUTLIER -60.93 105.47 0.47 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.213 -0.929 . . . . 0.0 109.438 180.0 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.687 HD21 HG11 ' A' ' 66' ' ' VAL . 1.4 mt -84.22 -11.46 56.45 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.249 -0.907 . . . . 0.0 109.503 179.94 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.77 165.39 15.82 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.536 -1.425 . . . . 0.0 109.536 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.813 ' HG3' HD11 ' A' ' 71' ' ' LEU . 29.7 mtmt -125.83 151.85 46.27 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.23 -1.159 . . . . 0.0 109.484 179.967 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.667 HD23 ' O ' ' A' ' 76' ' ' THR . 1.9 tt -98.1 152.54 19.21 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.276 -0.89 . . . . 0.0 109.496 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.667 ' O ' HD23 ' A' ' 75' ' ' LEU . 14.2 m . . . . . 0 N--CA 1.491 1.585 0 O-C-N 121.243 -0.911 . . . . 0.0 109.438 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.403 HD12 HG23 ' A' ' 2' ' ' ILE . 25.4 mm . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.464 ' HA ' ' HG2' ' A' ' 74' ' ' LYS . 11.7 t70 -89.3 129.93 35.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.192 -0.942 . . . . 0.0 109.562 179.9 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mp -104.81 128.84 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.265 -0.897 . . . . 0.0 109.469 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 48.3 mtpt -130.43 176.25 8.29 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.317 -0.864 . . . . 0.0 109.468 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.94 156.55 60.78 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.479 -179.97 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.97 134.53 13.27 Favored 'Trans proline' 0 C--N 1.308 -1.554 0 C-N-CA 122.664 2.242 . . . . 0.0 110.404 179.959 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.442 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -45.49 115.04 0.85 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.223 -0.923 . . . . 0.0 109.502 179.995 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -64.34 149.27 94.96 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.487 179.969 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.405 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -78.02 174.81 11.95 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.598 2.198 . . . . 0.0 110.402 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 12' ' ' SER . 30.5 tt0 -66.75 -55.31 15.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.313 -0.867 . . . . 0.0 109.463 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 11' ' ' GLU . 35.1 t -42.81 -40.86 3.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.361 -0.837 . . . . 0.0 109.581 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.64 HG22 ' H ' ' A' ' 15' ' ' ASP . 12.3 mm -94.35 152.4 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.266 -0.896 . . . . 0.0 109.452 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -126.43 9.29 7.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.26 -0.9 . . . . 0.0 109.497 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.64 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER 173.64 -172.03 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.206 -0.934 . . . . 0.0 109.414 -179.994 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.16 -176.09 27.88 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.988 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.566 HG22 ' O ' ' A' ' 64' ' ' ASP . 0.3 OUTLIER -150.03 128.94 12.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -1.121 . . . . 0.0 109.431 -179.961 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.572 HG12 ' N ' ' A' ' 19' ' ' ALA . 53.0 t -43.96 165.74 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.238 -0.914 . . . . 0.0 109.537 -179.943 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.58 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -117.52 -72.8 0.67 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.266 -0.896 . . . . 0.0 109.422 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 34.5 m -160.05 127.48 4.57 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.261 -0.899 . . . . 0.0 109.579 -179.977 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.629 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 33.1 m95 -89.85 87.37 6.93 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 121.207 -0.933 . . . . 0.0 109.519 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.772 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.8 m80 -42.46 -57.91 2.45 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.416 -0.803 . . . . 0.0 109.522 -179.76 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 9.3 mttp -106.19 178.94 4.41 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.218 -0.927 . . . . 0.0 109.604 -179.953 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -118.31 167.51 11.32 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.271 -0.893 . . . . 0.0 109.497 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.513 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.3 Cg_endo -76.94 136.31 16.46 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.617 2.211 . . . . 0.0 110.413 179.96 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.34 -8.77 35.51 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.518 ' O ' HG13 ' A' ' 54' ' ' VAL . 4.0 mt-10 -93.5 -175.39 3.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.227 -1.16 . . . . 0.0 109.477 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.61 147.77 27.26 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.93 . . . . 0.0 109.462 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 m -147.56 169.48 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.236 -0.915 . . . . 0.0 109.421 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.427 ' O ' ' C ' ' A' ' 31' ' ' ARG . 16.5 tttp -133.06 143.39 49.32 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.252 -0.905 . . . . 0.0 109.442 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.464 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.82 152.32 0.11 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.231 -0.918 . . . . 0.0 109.624 -179.89 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.464 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 26.0 t70 69.04 41.78 1.37 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -0.907 . . . . 0.0 109.418 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.437 ' C ' ' HG ' ' A' ' 48' ' ' LEU . 10.8 tt0 -140.97 117.42 10.8 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.325 -0.859 . . . . 0.0 109.456 179.995 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.772 HD21 ' NE2' ' A' ' 22' ' ' HIS . 48.8 tp -42.96 163.34 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.241 -0.912 . . . . 0.0 109.562 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.596 HD11 ' HB2' ' A' ' 49' ' ' ALA . 59.5 mt -149.5 -43.27 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.156 -0.965 . . . . 0.0 109.522 -179.948 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.526 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 9.3 p -157.75 143.32 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.273 -0.892 . . . . 0.0 109.51 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.58 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 3.7 m-20 -108.54 147.49 31.67 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 109.458 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.484 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 46.7 mt -103.97 150.54 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.316 -0.865 . . . . 0.0 109.434 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.669 ' HG2' HG22 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -131.79 99.46 4.77 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.942 . . . . 0.0 109.468 -179.984 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.529 ' CG2' ' HB ' ' A' ' 43' ' ' VAL . 6.6 t -93.62 -170.14 2.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.915 . . . . 0.0 109.476 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 2.6 t0 -42.5 -56.33 3.1 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.294 -0.879 . . . . 0.0 109.767 -179.923 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 42' ' ' LYS . . . . . 0.473 ' C ' ' CG2' ' A' ' 43' ' ' VAL . 4.1 mtmp? -148.22 49.56 1.04 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -0.884 . . . . 0.0 109.561 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.529 ' HB ' ' CG2' ' A' ' 40' ' ' THR . 1.9 t -154.34 106.44 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.254 -0.904 . . . . 0.0 109.566 179.896 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.669 HG22 ' HG2' ' A' ' 39' ' ' GLU . 94.0 t -89.95 106.63 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.412 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 45' ' ' MET . . . . . 0.484 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 27.2 mtp -90.05 177.12 6.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 0.0 109.494 179.941 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -132.76 151.58 51.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.921 . . . . 0.0 109.425 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.526 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 85.7 t -127.11 107.55 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.246 -0.909 . . . . 0.0 109.456 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.703 HD12 ' HA ' ' A' ' 34' ' ' LEU . 1.1 mp -92.27 176.75 6.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.463 -179.96 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.596 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -81.9 123.78 29.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.174 -0.954 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.527 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -92.92 14.5 17.38 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.174 -0.954 . . . . 0.0 109.419 -179.922 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.527 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 174.49 124.96 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.287 -0.883 . . . . 0.0 109.411 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -59.43 170.91 0.9 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.206 -0.934 . . . . 0.0 109.298 -179.969 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.51 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 132.48 -140.56 11.93 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.968 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.65 ' H ' HG22 ' A' ' 76' ' ' THR . 46.4 t -139.12 132.12 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.16 -1.2 . . . . 0.0 109.433 179.979 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.588 HG22 ' N ' ' A' ' 56' ' ' ALA . 14.7 mm -63.69 169.57 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.271 -0.893 . . . . 0.0 109.506 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.588 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -108.52 -65.86 1.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.235 -0.916 . . . . 0.0 109.481 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.479 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -165.47 141.53 5.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.212 -0.93 . . . . 0.0 109.474 179.994 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.629 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 22.7 mm -95.04 125.59 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.192 -0.943 . . . . 0.0 109.425 179.96 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.447 ' C ' ' HE3' ' A' ' 60' ' ' LYS . 23.7 t -89.95 -15.26 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.529 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.585 ' HG2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -110.64 130.04 55.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.27 -0.894 . . . . 0.0 109.453 -179.991 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 57.9 m-80 -105.23 165.37 11.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.227 -0.921 . . . . 0.0 109.44 -179.931 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.402 ' HA ' ' HB ' ' A' ' 18' ' ' VAL . 29.6 mt-10 -67.2 136.6 55.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.538 179.931 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 95.08 2.74 62.21 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.566 ' O ' HG22 ' A' ' 17' ' ' THR . 0.1 OUTLIER -104.92 170.83 7.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.105 -1.233 . . . . 0.0 109.377 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.505 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.8 t -98.27 159.59 14.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.497 -0.752 . . . . 0.0 109.51 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.585 HG12 ' HG2' ' A' ' 60' ' ' LYS . 11.9 m -132.7 130.6 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.206 -0.934 . . . . 0.0 109.435 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -94.1 168.64 10.8 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.903 . . . . 0.0 109.509 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.442 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 44.5 t -60.75 130.25 45.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.521 179.989 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 72.74 27.44 69.12 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.999 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.533 ' HG2' ' CD ' ' A' ' 60' ' ' LYS . 0.4 OUTLIER -80.81 132.02 35.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.287 -1.125 . . . . 0.0 109.463 -179.989 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.561 HD23 ' C ' ' A' ' 71' ' ' LEU . 10.4 tt -78.31 122.09 25.28 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.294 -0.879 . . . . 0.0 109.46 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.439 ' O ' HG23 ' A' ' 58' ' ' ILE . 5.7 mt -96.9 -25.53 15.4 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.352 -0.843 . . . . 0.0 109.469 179.936 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 175.07 157.2 15.86 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.978 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.464 ' HG2' ' HA ' ' A' ' 3' ' ' ASP . 0.0 OUTLIER -113.82 159.14 20.13 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.319 -1.106 . . . . 0.0 109.481 179.982 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.456 HD12 ' HA ' ' A' ' 75' ' ' LEU . 19.7 tp -100.83 159.89 14.82 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.225 -0.922 . . . . 0.0 109.429 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.65 HG22 ' H ' ' A' ' 54' ' ' VAL . 2.9 t . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.278 -0.889 . . . . 0.0 109.703 179.971 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.623 HD12 HD22 ' A' ' 75' ' ' LEU . 8.1 mt . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 3' ' ' ASP . . . . . 0.745 ' OD1' HD12 ' A' ' 71' ' ' LEU . 11.4 t70 -75.91 127.08 32.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.46 -179.983 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 18.7 mt -103.38 126.18 57.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.271 -0.893 . . . . 0.0 109.432 -179.991 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -132.96 159.23 40.57 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.303 -0.873 . . . . 0.0 109.481 179.972 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.643 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -74.94 164.45 61.33 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.426 -179.94 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.643 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.3 Cg_endo -78.08 179.78 6.18 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.676 2.25 . . . . 0.0 110.382 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.87 126.55 36.07 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.206 -0.933 . . . . 0.0 109.471 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -81.61 156.08 70.8 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.257 -0.902 . . . . 0.0 109.458 -179.969 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.451 ' HD2' HD12 ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.05 173.31 14.15 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.682 2.254 . . . . 0.0 110.363 179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 12' ' ' SER . 7.8 pt-20 -65.9 -47.9 73.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.266 -0.896 . . . . 0.0 109.46 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.428 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.74 -49.37 5.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.312 -0.868 . . . . 0.0 109.617 -179.935 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.552 HG22 ' H ' ' A' ' 15' ' ' ASP . 8.7 mt -91.22 166.52 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.284 -0.885 . . . . 0.0 109.475 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.425 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -131.9 11.61 4.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.249 -0.907 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.552 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.9 OUTLIER 169.96 -171.45 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.244 -0.91 . . . . 0.0 109.4 -179.966 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.23 -163.71 9.91 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.994 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.458 ' O ' ' HB2' ' A' ' 39' ' ' GLU . 26.5 m -149.95 128.21 12.08 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -1.123 . . . . 0.0 109.424 -179.962 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.5 t -50.74 154.2 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.285 -0.885 . . . . 0.0 109.445 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.532 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -99.84 -76.84 0.54 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.161 -0.962 . . . . 0.0 109.511 179.972 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.2 m -159.89 130.16 5.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.541 -179.998 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.657 ' CH2' HD12 ' A' ' 58' ' ' ILE . 35.1 m95 -89.8 84.94 6.29 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.225 -0.922 . . . . 0.0 109.559 -179.893 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 22' ' ' HIS . . . . . 0.735 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.8 m80 -43.26 -61.59 1.29 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.313 -0.867 . . . . 0.0 109.335 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -94.67 -172.1 2.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.345 -0.847 . . . . 0.0 109.493 179.986 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.516 ' HD2' ' CD ' ' A' ' 25' ' ' PRO . 2.9 mmmt -130.81 163.87 45.77 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.24 -0.913 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.516 ' CD ' ' HD2' ' A' ' 24' ' ' LYS . 35.5 Cg_endo -77.48 106.43 2.21 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.562 2.175 . . . . 0.0 110.429 179.921 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 137.72 -10.28 3.7 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.939 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.1 -172.33 2.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.249 -1.148 . . . . 0.0 109.416 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -105.7 150.03 25.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.28 -0.888 . . . . 0.0 109.477 179.974 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.3 m -131.93 -170.93 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.244 -0.91 . . . . 0.0 109.459 -179.963 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.448 ' HA ' ' HB2' ' A' ' 52' ' ' ASP . 12.5 mttm -149.91 130.91 14.34 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.217 -0.927 . . . . 0.0 109.52 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.474 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 4.3 ttm105 -42.82 143.61 0.69 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.318 -0.864 . . . . 0.0 109.669 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.53 ' HA ' HD23 ' A' ' 48' ' ' LEU . 6.7 t70 73.84 38.28 0.6 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.316 -0.865 . . . . 0.0 109.476 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.434 ' O ' ' C ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -138.98 122.73 17.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.909 . . . . 0.0 109.436 179.96 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.735 HD21 ' NE2' ' A' ' 22' ' ' HIS . 36.0 tp -43.0 149.14 0.21 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.201 -0.937 . . . . 0.0 109.548 -179.939 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.492 HG13 ' HB2' ' A' ' 49' ' ' ALA . 35.4 mm -132.62 -42.86 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -0.915 . . . . 0.0 109.554 -179.921 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.488 ' O ' HG23 ' A' ' 47' ' ' VAL . 4.4 p -162.1 147.48 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.244 -0.91 . . . . 0.0 109.546 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.532 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 1.3 m-20 -107.33 154.79 20.77 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.896 . . . . 0.0 109.396 179.966 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.419 ' O ' ' HA ' ' A' ' 44' ' ' VAL . 26.8 mm -122.73 148.09 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.218 -0.926 . . . . 0.0 109.489 -179.937 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.458 ' HB2' ' O ' ' A' ' 17' ' ' THR . 0.3 OUTLIER -107.14 109.69 21.59 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.535 179.941 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 41' ' ' ASP . 35.4 p -97.27 -150.35 0.34 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.202 -0.936 . . . . 0.0 109.434 -179.949 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 3.0 t0 -42.8 -70.05 0.12 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.318 -0.863 . . . . 0.0 109.668 -179.886 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -145.1 25.19 1.42 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.222 -0.924 . . . . 0.0 109.458 179.963 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.9 t -136.53 130.66 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -0.961 . . . . 0.0 109.466 179.947 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 38' ' ' ILE . 2.1 t -90.96 109.48 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.223 -0.923 . . . . 0.0 109.512 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -79.99 163.79 23.96 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.299 -0.875 . . . . 0.0 109.507 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -108.07 145.17 34.41 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.247 -0.908 . . . . 0.0 109.43 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 36' ' ' VAL . 10.1 t -118.75 100.85 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.312 -0.868 . . . . 0.0 109.426 179.958 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.53 HD23 ' HA ' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -91.91 153.83 19.25 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.193 -0.942 . . . . 0.0 109.49 179.991 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.492 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -74.17 138.85 44.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.9 . . . . 0.0 109.49 179.983 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.58 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -88.51 13.52 11.8 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.294 -0.879 . . . . 0.0 109.505 -179.995 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.58 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 170.49 150.37 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.252 -0.905 . . . . 0.0 109.45 -179.981 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -78.6 170.99 15.78 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.317 179.994 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.51 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 149.91 -137.69 6.34 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 50.9 t -136.07 125.6 39.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -1.129 . . . . 0.0 109.465 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.464 HG22 ' N ' ' A' ' 56' ' ' ALA . 14.1 mm -64.58 161.78 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.925 . . . . 0.0 109.531 180.0 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.464 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -103.51 -67.02 0.91 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.256 -0.903 . . . . 0.0 109.466 -179.948 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.491 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 2.5 tt0 -169.83 140.59 2.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.286 -0.884 . . . . 0.0 109.463 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.657 HD12 ' CH2' ' A' ' 21' ' ' TRP . 22.5 mm -93.86 131.63 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.171 -0.956 . . . . 0.0 109.527 -179.965 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 72.0 t -89.96 -38.41 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.274 -0.892 . . . . 0.0 109.497 179.957 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.925 ' HG2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -94.77 125.21 39.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.343 -0.848 . . . . 0.0 109.424 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.47 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 28.8 m-80 -89.64 176.24 6.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.253 -0.904 . . . . 0.0 109.482 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -74.9 153.33 38.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.246 -0.909 . . . . 0.0 109.502 179.957 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.94 15.12 62.13 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.515 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -104.58 170.88 7.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.177 -1.19 . . . . 0.0 109.312 179.993 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.1 m -100.45 138.31 37.69 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.445 -0.784 . . . . 0.0 109.5 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.925 HG12 ' HG2' ' A' ' 60' ' ' LYS . 4.9 m -115.8 172.75 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.207 -0.933 . . . . 0.0 109.461 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -136.06 -173.95 3.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.255 -0.903 . . . . 0.0 109.472 179.936 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.97 149.3 48.98 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.175 -0.953 . . . . 0.0 109.464 -179.965 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 49.69 29.95 13.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.986 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.456 ' OE2' ' HD3' ' A' ' 60' ' ' LYS . 49.6 tp10 -80.55 114.27 19.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.271 -1.135 . . . . 0.0 109.495 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.745 HD12 ' OD1' ' A' ' 3' ' ' ASP . 0.5 OUTLIER -66.31 118.69 10.35 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.191 -0.943 . . . . 0.0 109.47 179.95 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 8.7 mt -87.96 -28.27 21.58 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.483 179.968 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 176.96 170.59 39.6 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -128.44 134.45 48.76 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -1.158 . . . . 0.0 109.445 180.0 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.623 HD22 HD12 ' A' ' 2' ' ' ILE . 0.5 OUTLIER -91.56 147.2 23.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -0.88 . . . . 0.0 109.414 -179.974 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.3 m . . . . . 0 N--CA 1.49 1.543 0 O-C-N 121.282 -0.886 . . . . 0.0 109.514 179.922 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.628 HD13 HD22 ' A' ' 75' ' ' LEU . 5.4 mp -134.2 115.67 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -0.908 . . . . 0.0 109.454 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' A' ' 4' ' ' ILE . 39.6 t0 -88.98 132.82 34.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.239 -0.913 . . . . 0.0 109.452 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.481 ' N ' ' OD1' ' A' ' 3' ' ' ASP . 82.2 mt -99.99 124.24 53.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.424 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 70' ' ' GLU . 2.6 mttt -122.75 175.59 6.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.209 -0.932 . . . . 0.0 109.448 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.558 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -79.68 161.38 66.9 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.883 . . . . 0.0 109.49 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.558 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.6 Cg_endo -78.06 173.8 13.42 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.638 2.225 . . . . 0.0 110.389 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.5 m -92.07 134.68 34.61 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.478 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -100.14 155.82 35.98 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 109.438 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.432 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -77.99 -159.93 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.589 2.193 . . . . 0.0 110.473 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' A' ' 12' ' ' SER . 2.5 mt-10 -78.64 -58.69 3.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 109.497 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 11' ' ' GLU . 31.1 t -42.83 -45.09 4.75 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.295 -0.878 . . . . 0.0 109.628 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.577 HG22 ' H ' ' A' ' 15' ' ' ASP . 33.7 mm -104.43 136.92 35.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.297 -0.877 . . . . 0.0 109.472 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.407 ' C ' ' OD1' ' A' ' 15' ' ' ASP . . . -119.03 16.81 13.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.233 -0.917 . . . . 0.0 109.451 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.577 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.4 OUTLIER -169.18 -170.73 1.16 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 0.0 109.438 -179.982 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.68 -170.08 16.11 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.512 ' O ' ' CB ' ' A' ' 39' ' ' GLU . 1.4 m -150.0 128.57 12.3 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.221 -1.164 . . . . 0.0 109.499 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.1 t -56.42 153.82 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.226 -0.921 . . . . 0.0 109.406 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.578 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -96.86 -72.98 0.62 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.256 -0.903 . . . . 0.0 109.546 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.7 m -160.05 132.61 6.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.22 -0.925 . . . . 0.0 109.558 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.634 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.9 83.0 6.12 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.257 -0.902 . . . . 0.0 109.528 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.703 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.0 m80 -42.85 -64.84 0.55 Allowed 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.38 -0.825 . . . . 0.0 109.441 -179.771 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.17 -179.25 4.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.557 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.401 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -125.84 168.48 13.84 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.249 -0.907 . . . . 0.0 109.487 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.487 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 34.9 Cg_endo -76.66 123.26 6.84 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.626 2.218 . . . . 0.0 110.398 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.3 12.64 9.61 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -118.22 -172.44 2.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.205 -1.173 . . . . 0.0 109.457 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -98.68 153.56 18.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.242 -0.911 . . . . 0.0 109.462 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.526 HG22 ' N ' ' A' ' 30' ' ' LYS . 2.8 p -138.36 162.3 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 109.48 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.526 ' N ' HG22 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -134.59 126.13 28.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.256 -0.903 . . . . 0.0 109.517 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.506 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 16.8 ttp180 -42.72 146.82 0.34 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.323 -0.861 . . . . 0.0 109.664 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.506 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 2.9 t70 75.18 33.95 0.68 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.465 ' HB2' ' O ' ' A' ' 30' ' ' LYS . 3.4 tt0 -138.83 123.6 18.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -0.912 . . . . 0.0 109.444 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.703 HD21 ' NE2' ' A' ' 22' ' ' HIS . 50.6 tp -42.98 156.97 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.273 -0.892 . . . . 0.0 109.531 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.647 HG13 ' HB2' ' A' ' 49' ' ' ALA . 35.8 mm -139.11 -38.17 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.2 -0.937 . . . . 0.0 109.651 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.438 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.5 p -166.66 139.1 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.175 -0.953 . . . . 0.0 109.527 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.578 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 1.1 m-20 -98.61 158.5 15.56 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 36.1 mt -125.01 153.63 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.532 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.512 ' CB ' ' O ' ' A' ' 17' ' ' THR . 15.0 tt0 -109.88 123.61 49.89 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.236 -0.915 . . . . 0.0 109.454 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.435 ' O ' ' C ' ' A' ' 41' ' ' ASP . 3.9 p -107.54 -162.44 0.84 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.256 -0.903 . . . . 0.0 109.475 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.435 ' C ' ' O ' ' A' ' 40' ' ' THR . 16.7 t0 -42.72 -66.7 0.34 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.33 -0.856 . . . . 0.0 109.65 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 13.3 mtpt -142.79 26.16 1.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.31 -0.869 . . . . 0.0 109.476 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 42.1 t -136.48 136.5 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.28 -0.888 . . . . 0.0 109.504 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 56.4 t -95.65 119.26 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.292 -0.88 . . . . 0.0 109.458 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 4.2 mtt -93.71 179.7 5.28 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.242 -0.911 . . . . 0.0 109.503 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -131.96 148.9 52.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.514 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.438 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 21.2 t -121.91 107.95 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.256 -0.903 . . . . 0.0 109.441 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.436 ' HG ' ' C ' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -98.16 153.11 18.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 109.494 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.647 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -76.87 143.65 39.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.26 -0.9 . . . . 0.0 109.416 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.65 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.1 OUTLIER -96.25 15.42 21.08 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.469 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.65 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 166.9 148.28 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.468 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.496 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -69.96 170.96 10.22 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.348 179.978 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.496 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 157.27 -146.61 13.92 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.6 t -135.39 124.6 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.25 -1.147 . . . . 0.0 109.506 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.4 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 12.1 mm -70.03 158.88 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.275 -0.891 . . . . 0.0 109.496 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -95.13 -64.43 1.07 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.199 -0.938 . . . . 0.0 109.457 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.487 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 11.7 pt-20 -179.17 146.32 0.29 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.461 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.634 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 30.6 mm -99.07 127.42 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.245 -0.909 . . . . 0.0 109.475 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.3 t -90.08 -29.92 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.497 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 0.2 OUTLIER -90.78 148.1 22.77 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.234 -0.916 . . . . 0.0 109.481 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.468 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 4.5 m-80 -110.45 156.31 21.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.503 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -60.6 139.19 57.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.269 -0.894 . . . . 0.0 109.526 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 90.11 4.97 71.01 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -105.76 170.7 7.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -1.186 . . . . 0.0 109.355 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 7.3 t -102.21 154.26 19.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.528 -0.732 . . . . 0.0 109.564 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.453 HG11 HD21 ' A' ' 72' ' ' LEU . 30.3 m -130.66 133.81 62.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.47 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -92.43 169.86 10.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.465 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -59.51 143.21 50.74 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.248 -0.908 . . . . 0.0 109.451 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 67.7 12.02 61.18 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.416 ' O ' ' HA ' ' A' ' 5' ' ' LYS . 5.3 tp10 -70.33 120.58 16.21 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.287 -1.125 . . . . 0.0 109.467 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.545 HD23 ' C ' ' A' ' 71' ' ' LEU . 10.0 tt -77.97 111.92 14.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.301 -0.874 . . . . 0.0 109.459 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.453 HD21 HG11 ' A' ' 66' ' ' VAL . 1.9 mt -88.3 -21.12 24.59 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.267 -0.895 . . . . 0.0 109.462 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.5 -177.17 45.23 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.459 ' NZ ' ' OE2' ' A' ' 57' ' ' GLU . 0.0 OUTLIER -139.63 153.81 47.41 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.195 -1.18 . . . . 0.0 109.52 179.963 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.628 HD22 HD13 ' A' ' 2' ' ' ILE . 0.5 OUTLIER -94.69 155.61 16.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.267 -0.896 . . . . 0.0 109.435 -179.985 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.566 HG22 ' H ' ' A' ' 77' ' ' GLU . 9.4 m -106.23 171.48 7.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.204 -0.935 . . . . 0.0 109.456 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.566 ' H ' HG22 ' A' ' 76' ' ' THR . 5.7 mt-10 -78.77 143.77 35.8 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.241 -0.912 . . . . 0.0 109.452 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -102.57 -178.11 27.14 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.31 0 CA-C-O 117.992 -1.449 . . . . 0.0 109.533 179.999 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.469 HG13 ' HB3' ' A' ' 75' ' ' LEU . 2.0 pt -137.81 173.3 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.197 -0.939 . . . . 0.0 109.526 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.41 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 20.9 t0 -120.59 136.86 54.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.281 -0.887 . . . . 0.0 109.461 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 65.8 mt -110.46 118.85 58.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.189 -0.944 . . . . 0.0 109.481 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.86 156.77 48.34 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.289 -0.882 . . . . 0.0 109.418 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.626 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -58.7 163.54 5.11 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.202 -0.936 . . . . 0.0 109.46 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.626 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.7 Cg_endo -78.06 178.16 7.92 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.618 2.212 . . . . 0.0 110.41 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.43 ' O ' ' CD1' ' A' ' 9' ' ' PHE . 0.2 OUTLIER -76.56 176.42 8.35 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.896 . . . . 0.0 109.509 -179.966 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.462 ' CE1' HG23 ' A' ' 40' ' ' THR . 23.7 m-85 -138.7 71.78 43.11 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.453 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.93 -0.14 10.38 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.636 2.224 . . . . 0.0 110.432 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.515 ' O ' ' CD1' ' A' ' 13' ' ' ILE . 5.9 mm-40 -85.33 46.46 1.29 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.394 -0.816 . . . . 0.0 109.438 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.45 ' C ' ' O ' ' A' ' 11' ' ' GLU . 6.6 t 39.25 39.21 0.41 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.528 -0.733 . . . . 0.0 110.034 179.707 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.515 ' CD1' ' O ' ' A' ' 11' ' ' GLU . 15.0 mm -98.82 156.35 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.891 . . . . 0.0 109.374 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.496 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -93.83 -1.88 54.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.19 -0.944 . . . . 0.0 109.727 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.496 ' CB ' ' O ' ' A' ' 14' ' ' ALA . 1.1 p30 163.74 -169.63 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.227 -0.921 . . . . 0.0 109.442 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.0 -169.33 11.63 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.467 HG23 ' O ' ' A' ' 64' ' ' ASP . 93.6 m -150.02 123.26 8.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.204 -1.174 . . . . 0.0 109.534 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 19' ' ' ALA . 24.2 t -51.09 169.49 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.22 -0.925 . . . . 0.0 109.482 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.579 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -112.73 -73.14 0.68 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.179 -0.951 . . . . 0.0 109.609 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.482 HG23 ' OE1' ' A' ' 62' ' ' GLU . 16.4 m -159.98 137.13 9.44 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.53 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.704 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 32.7 m95 -89.98 83.85 6.14 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.259 -0.901 . . . . 0.0 109.501 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.803 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.2 m80 -42.86 -69.82 0.13 Allowed 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.39 -0.819 . . . . 0.0 109.487 -179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.05 -171.58 2.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 109.674 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.476 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 1.8 mttt -128.8 170.76 9.93 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.227 -0.92 . . . . 0.0 109.435 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.533 ' CG ' ' HA ' ' A' ' 57' ' ' GLU . 34.8 Cg_endo -75.61 129.52 11.88 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.657 2.238 . . . . 0.0 110.39 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 120.98 -11.88 9.95 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -95.84 166.48 11.78 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.254 -1.145 . . . . 0.0 109.472 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.29 133.39 35.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -0.907 . . . . 0.0 109.411 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 52' ' ' ASP . 25.1 m -136.31 135.84 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.162 -0.961 . . . . 0.0 109.528 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 31' ' ' ARG . 9.6 pttp -117.35 146.23 43.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.88 . . . . 0.0 109.389 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.465 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 4.0 ttt180 -42.9 156.23 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.244 -0.91 . . . . 0.0 109.623 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.465 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 18.8 t70 73.34 29.21 1.69 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -0.881 . . . . 0.0 109.453 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.536 ' N ' HD23 ' A' ' 48' ' ' LEU . 30.5 tt0 -137.71 111.63 8.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.285 -0.884 . . . . 0.0 109.446 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.803 HD21 ' NE2' ' A' ' 22' ' ' HIS . 43.4 tp -42.9 153.56 0.08 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.36 -0.837 . . . . 0.0 109.595 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.607 HD13 ' O ' ' A' ' 34' ' ' LEU . 11.1 mm -139.08 -38.51 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.15 -0.969 . . . . 0.0 109.55 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.521 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 10.8 p -160.21 131.53 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.263 -0.898 . . . . 0.0 109.466 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.507 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 32.4 m-20 -92.15 157.09 16.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.918 . . . . 0.0 109.482 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 20.6 tt -127.91 162.98 32.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.325 -0.859 . . . . 0.0 109.447 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -148.76 110.65 4.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.24 -0.912 . . . . 0.0 109.434 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.462 HG23 ' CE1' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -80.73 -160.65 0.32 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.29 -0.881 . . . . 0.0 109.503 179.94 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.423 ' HB2' HD12 ' A' ' 13' ' ' ILE . 50.0 t0 -42.83 -67.64 0.26 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.293 -0.88 . . . . 0.0 109.631 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -132.02 23.22 4.55 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -0.934 . . . . 0.0 109.491 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 1.9 t -117.97 162.13 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.226 -0.921 . . . . 0.0 109.437 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.9 t -137.35 126.7 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.284 -0.885 . . . . 0.0 109.51 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' MET . . . . . 0.53 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 1.7 mtt -123.63 -171.01 2.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.256 -0.903 . . . . 0.0 109.434 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.3 152.4 48.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.417 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.521 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 35.0 t -122.52 111.18 29.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.319 -0.863 . . . . 0.0 109.47 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.536 HD23 ' N ' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -102.02 165.78 10.98 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.281 -0.887 . . . . 0.0 109.464 -179.978 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -76.35 144.97 39.81 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.333 -0.855 . . . . 0.0 109.472 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -108.49 7.44 26.86 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.143 -0.973 . . . . 0.0 109.536 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -175.45 122.32 0.21 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.178 -0.951 . . . . 0.0 109.531 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.499 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -55.14 170.93 0.17 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.3 -0.875 . . . . 0.0 109.32 179.999 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.499 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 140.82 -139.34 9.57 Favored Glycine 0 N--CA 1.49 2.233 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 45.0 t -139.15 123.55 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -1.184 . . . . 0.0 109.429 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.561 HG22 ' N ' ' A' ' 56' ' ' ALA . 13.9 mm -65.06 167.75 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.249 -0.907 . . . . 0.0 109.537 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.561 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -101.72 -65.42 0.98 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.181 -0.95 . . . . 0.0 109.472 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.533 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -171.68 159.09 5.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.502 179.992 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.704 HG23 ' CZ2' ' A' ' 21' ' ' TRP . 74.2 mt -89.97 130.56 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.318 -0.864 . . . . 0.0 109.403 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.465 ' HB ' ' O ' ' A' ' 71' ' ' LEU . 50.0 t -89.99 -37.77 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.2 -0.938 . . . . 0.0 109.417 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.458 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -113.89 137.63 51.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.229 -0.92 . . . . 0.0 109.4 -179.989 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 60.9 m-20 -79.96 156.37 27.25 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.213 -0.929 . . . . 0.0 109.443 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.525 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -70.3 142.76 52.21 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 93.99 -15.62 62.74 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.506 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -84.24 170.88 13.28 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.181 -1.188 . . . . 0.0 109.365 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.506 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 88.5 m -96.78 133.49 41.29 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.518 -0.739 . . . . 0.0 109.477 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.619 ' C ' HD12 ' A' ' 67' ' ' LEU . 6.3 m -116.68 -154.66 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.26 -0.9 . . . . 0.0 109.429 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.619 HD12 ' C ' ' A' ' 66' ' ' VAL . 2.9 mp -149.65 176.64 10.48 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.262 -0.899 . . . . 0.0 109.495 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.2 t -69.41 109.21 4.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.251 -0.905 . . . . 0.0 109.449 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.55 21.47 26.57 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.43 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 11.3 tp10 -74.0 121.05 20.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -1.133 . . . . 0.0 109.428 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.465 ' O ' ' HB ' ' A' ' 59' ' ' VAL . 25.5 tp -64.9 111.62 2.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.255 -0.903 . . . . 0.0 109.492 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 8.4 mt -95.18 -10.91 29.13 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -0.887 . . . . 0.0 109.48 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.34 163.39 21.13 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 26.4 mttt -125.41 144.71 50.39 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -1.139 . . . . 0.0 109.456 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.56 HD12 HD13 ' A' ' 55' ' ' ILE . 12.4 tp -90.0 153.51 20.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.445 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.579 HG22 ' H ' ' A' ' 77' ' ' GLU . 14.6 m -113.49 171.99 7.23 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.903 . . . . 0.0 109.489 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.579 ' H ' HG22 ' A' ' 76' ' ' THR . 1.5 mp0 -82.1 149.3 28.09 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.229 -0.919 . . . . 0.0 109.478 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -114.13 120.52 5.11 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.95 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.489 HG13 ' HB3' ' A' ' 75' ' ' LEU . 1.8 pp -146.76 126.1 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.294 -0.879 . . . . 0.0 109.509 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.455 ' OD2' HD13 ' A' ' 71' ' ' LEU . 8.3 t0 -89.72 129.28 36.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.313 -0.867 . . . . 0.0 109.483 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.609 HG23 HG11 ' A' ' 47' ' ' VAL . 87.4 mt -97.08 75.97 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.238 -0.914 . . . . 0.0 109.517 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.33 161.6 13.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.227 -0.92 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.611 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -74.51 163.11 70.54 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.216 -0.927 . . . . 0.0 109.437 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.611 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.8 Cg_endo -78.08 -179.85 5.83 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.632 2.222 . . . . 0.0 110.386 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.426 HG23 ' OG ' ' A' ' 68' ' ' SER . 3.0 m -93.82 106.99 18.93 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.297 -0.877 . . . . 0.0 109.443 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.417 ' HB3' ' HD2' ' A' ' 10' ' ' PRO . 80.9 m-85 -61.5 157.81 43.82 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.233 -0.917 . . . . 0.0 109.452 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.449 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.1 -163.08 0.2 Allowed 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.585 2.19 . . . . 0.0 110.415 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.6 OUTLIER -80.82 -59.06 2.82 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.265 -0.897 . . . . 0.0 109.436 -179.972 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 11' ' ' GLU . 35.3 t -42.82 -31.24 0.47 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.365 -0.835 . . . . 0.0 109.618 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.463 HG22 ' H ' ' A' ' 15' ' ' ASP . 24.4 mt -113.81 141.41 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.227 -0.921 . . . . 0.0 109.445 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -126.96 31.25 5.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.5 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.463 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.9 OUTLIER 174.8 -171.47 0.06 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.8 -164.71 13.82 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.471 ' HA ' ' O ' ' A' ' 64' ' ' ASP . 84.6 m -150.12 120.99 7.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.214 -1.168 . . . . 0.0 109.44 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.537 HG12 ' N ' ' A' ' 19' ' ' ALA . 60.0 t -43.79 162.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.302 -0.874 . . . . 0.0 109.487 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.537 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -108.11 -75.17 0.64 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.278 -0.889 . . . . 0.0 109.562 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.9 m -160.17 131.61 5.92 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.167 -0.958 . . . . 0.0 109.619 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.833 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 33.3 m95 -89.82 85.88 6.51 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.255 -0.903 . . . . 0.0 109.448 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.672 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.5 m80 -42.34 -69.88 0.12 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.356 -0.84 . . . . 0.0 109.654 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.69 -174.09 2.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.217 -0.927 . . . . 0.0 109.78 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.498 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -116.87 165.67 14.75 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.377 -0.827 . . . . 0.0 109.262 179.975 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.871 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.2 Cg_endo -77.18 145.43 24.38 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.552 2.168 . . . . 0.0 110.426 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.44 -8.89 60.58 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.473 ' HG2' ' O ' ' A' ' 24' ' ' LYS . 0.4 OUTLIER -94.1 176.74 6.21 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.202 -1.175 . . . . 0.0 109.453 -179.972 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.462 ' O ' ' OE1' ' A' ' 27' ' ' GLU . . . -91.37 158.4 16.55 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.291 -0.881 . . . . 0.0 109.486 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.493 HG22 ' O ' ' A' ' 53' ' ' GLY . 34.7 m -138.87 -167.53 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.257 -0.902 . . . . 0.0 109.506 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 31' ' ' ARG . 5.1 tptm -142.18 140.85 32.51 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.221 -0.925 . . . . 0.0 109.463 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.1 OUTLIER -42.84 123.48 2.74 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.311 -0.868 . . . . 0.0 109.649 -179.874 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.752 ' C ' HD21 ' A' ' 48' ' ' LEU . 6.1 t70 75.9 57.06 0.05 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.276 -0.89 . . . . 0.0 109.491 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.544 ' N ' HD21 ' A' ' 48' ' ' LEU . 0.9 OUTLIER -131.76 121.3 23.95 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.203 -0.936 . . . . 0.0 109.402 -179.934 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.672 HD21 ' NE2' ' A' ' 22' ' ' HIS . 51.3 tp -42.94 162.25 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.329 -0.857 . . . . 0.0 109.499 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.956 HD11 ' HB2' ' A' ' 49' ' ' ALA . 91.6 mt -141.52 -49.49 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.933 . . . . 0.0 109.48 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.637 HG12 ' HB ' ' A' ' 47' ' ' VAL . 7.9 p -152.25 151.93 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.915 . . . . 0.0 109.417 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.618 ' C ' HD13 ' A' ' 38' ' ' ILE . 49.8 m-20 -117.6 151.38 37.3 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.257 -0.902 . . . . 0.0 109.554 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.618 HD13 ' C ' ' A' ' 37' ' ' ASP . 3.6 mm -108.17 156.36 8.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.248 -0.907 . . . . 0.0 109.383 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -135.28 117.48 15.52 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.262 -0.899 . . . . 0.0 109.489 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.431 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -115.8 -167.48 1.27 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.229 -0.919 . . . . 0.0 109.495 -179.991 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.431 ' C ' ' O ' ' A' ' 40' ' ' THR . 53.8 t0 -42.7 -67.74 0.25 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.359 -0.838 . . . . 0.0 109.626 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 1.7 mtpp -139.16 34.25 2.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.205 -0.934 . . . . 0.0 109.468 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.4 t -135.73 107.35 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.952 . . . . 0.0 109.504 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.2 t -89.98 115.85 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' MET . . . . . 0.466 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 4.6 mtp -99.23 178.31 4.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.302 -0.874 . . . . 0.0 109.488 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.424 ' HA ' ' OD1' ' A' ' 37' ' ' ASP . 41.0 mt-10 -138.48 169.64 17.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.205 -0.935 . . . . 0.0 109.438 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.637 ' HB ' HG12 ' A' ' 36' ' ' VAL . 97.1 t -141.92 103.09 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.224 -0.923 . . . . 0.0 109.478 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.752 HD21 ' C ' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -104.38 155.31 18.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.218 -0.927 . . . . 0.0 109.506 -179.982 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.956 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.19 165.22 18.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.515 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.694 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.8 OUTLIER -103.44 13.15 34.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.694 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.7 164.2 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.455 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.503 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -58.18 170.95 0.61 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.26 -0.9 . . . . 0.0 109.336 179.979 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.503 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 150.07 -174.64 29.45 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 69.6 t -124.86 131.18 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -1.132 . . . . 0.0 109.418 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.741 HD13 ' N ' ' A' ' 55' ' ' ILE . 1.4 mm -71.24 -176.64 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.271 -0.893 . . . . 0.0 109.486 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.789 ' HB3' ' HG2' ' A' ' 74' ' ' LYS . . . -114.01 -59.57 2.0 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.235 -0.916 . . . . 0.0 109.409 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.529 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 17.5 pt-20 -178.88 157.47 0.89 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.26 -0.9 . . . . 0.0 109.548 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.871 HD11 ' HD3' ' A' ' 25' ' ' PRO . 1.7 mp -89.96 140.88 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 109.446 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.454 ' HB ' ' O ' ' A' ' 71' ' ' LEU . 11.1 t -100.67 -15.17 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.261 -0.899 . . . . 0.0 109.366 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.488 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -126.37 -172.58 2.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.31 -0.869 . . . . 0.0 109.403 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.473 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 17.3 m-80 -132.45 164.26 26.96 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.169 -0.957 . . . . 0.0 109.509 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.01 133.41 48.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.306 -0.871 . . . . 0.0 109.408 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.05 -6.78 82.67 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -79.72 170.76 16.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.219 -1.165 . . . . 0.0 109.428 179.902 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.516 ' N ' ' OD1' ' A' ' 64' ' ' ASP . 32.3 m -98.77 138.84 35.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.547 -0.721 . . . . 0.0 109.498 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 6.2 m -122.29 170.67 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.268 -0.895 . . . . 0.0 109.455 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.478 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.1 OUTLIER -132.94 177.6 7.53 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.474 -179.98 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.426 ' OG ' HG23 ' A' ' 8' ' ' THR . 9.1 t -62.85 146.61 52.35 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.914 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 57.85 28.59 60.71 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.478 ' HB2' ' O ' ' A' ' 67' ' ' LEU . 8.0 tp10 -84.06 115.28 22.28 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.174 -1.192 . . . . 0.0 109.419 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.63 HD21 ' HD2' ' A' ' 74' ' ' LYS . 16.0 tp -72.91 106.09 4.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.262 -0.898 . . . . 0.0 109.49 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 15.7 mt -89.36 -10.91 44.87 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.224 -0.922 . . . . 0.0 109.455 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.36 164.29 22.75 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.789 ' HG2' ' HB3' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -136.12 142.9 44.29 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -1.173 . . . . 0.0 109.451 179.985 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.807 HD23 ' O ' ' A' ' 76' ' ' THR . 2.7 tt -97.44 167.99 10.66 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.239 -0.913 . . . . 0.0 109.479 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.807 ' O ' HD23 ' A' ' 75' ' ' LEU . 5.0 m -87.71 169.22 12.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.448 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.478 ' H ' HG22 ' A' ' 76' ' ' THR . 76.8 mt-10 -55.15 -54.49 42.63 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.282 -0.887 . . . . 0.0 109.487 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -148.43 -88.03 0.07 OUTLIER Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 CA-C-O 118.027 -1.429 . . . . 0.0 109.562 -179.938 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 30.3 mm -111.65 94.76 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.926 . . . . 0.0 109.486 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -66.35 127.99 34.39 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.1 mt -102.54 97.97 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.319 -0.863 . . . . 0.0 109.495 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.471 ' HG3' ' HA ' ' A' ' 71' ' ' LEU . 0.0 OUTLIER -118.76 146.9 44.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.211 -0.931 . . . . 0.0 109.461 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.43 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -61.26 157.51 43.58 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.197 -0.939 . . . . 0.0 109.494 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.43 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.6 Cg_endo -78.07 122.85 5.92 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 C-N-CA 122.581 2.188 . . . . 0.0 110.379 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.563 HG23 ' OG ' ' A' ' 68' ' ' SER . 17.5 m -44.17 108.02 0.1 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.244 -0.91 . . . . 0.0 109.454 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -71.03 147.95 94.1 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.245 -0.909 . . . . 0.0 109.501 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.579 ' HG2' HD12 ' A' ' 13' ' ' ILE . 35.5 Cg_endo -78.18 -159.44 0.1 Allowed 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.599 2.199 . . . . 0.0 110.324 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.433 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.4 OUTLIER -75.98 -52.65 9.8 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -0.899 . . . . 0.0 109.47 -179.956 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.8 t -42.82 -56.14 3.36 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.252 -0.905 . . . . 0.0 109.628 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.579 HD12 ' HG2' ' A' ' 10' ' ' PRO . 2.5 mp -89.95 111.14 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.226 -0.921 . . . . 0.0 109.452 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.466 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -88.77 10.45 20.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.204 -0.935 . . . . 0.0 109.502 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.518 ' O ' ' CG2' ' A' ' 13' ' ' ILE . 0.8 OUTLIER 166.6 -172.39 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 -179.921 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.464 ' O ' HG23 ' A' ' 65' ' ' THR . . . -154.08 -167.87 16.81 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.477 HG23 ' O ' ' A' ' 64' ' ' ASP . 90.3 m -148.21 131.94 16.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.265 -1.138 . . . . 0.0 109.463 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.504 HG12 ' N ' ' A' ' 19' ' ' ALA . 27.1 t -52.56 163.93 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.218 -0.926 . . . . 0.0 109.435 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.514 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -108.96 -76.41 0.61 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.175 -0.953 . . . . 0.0 109.442 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.4 m -160.03 131.9 6.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.248 -0.908 . . . . 0.0 109.46 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.636 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 31.9 m95 -89.87 85.43 6.38 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.26 -0.9 . . . . 0.0 109.56 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.875 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.0 m80 -42.77 -58.25 2.43 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.355 -0.841 . . . . 0.0 109.38 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -101.43 -175.04 2.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.57 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.439 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -125.65 167.82 15.57 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.344 -0.847 . . . . 0.0 109.446 179.985 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.499 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.91 118.04 4.66 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.588 2.192 . . . . 0.0 110.418 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 124.56 7.52 6.21 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.794 ' O ' HG13 ' A' ' 54' ' ' VAL . 5.2 mm-40 -113.26 -172.25 2.03 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.223 -1.163 . . . . 0.0 109.55 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.449 ' HA ' HG22 ' A' ' 54' ' ' VAL . . . -105.02 158.02 16.83 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.169 -0.957 . . . . 0.0 109.448 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -142.49 -174.35 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 0.0 109.436 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 3.7 mttp -147.67 137.54 22.77 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.491 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.434 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.1 OUTLIER -42.78 137.21 2.35 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.344 -0.847 . . . . 0.0 109.63 -179.914 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.42 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 8.2 t0 70.06 51.23 0.41 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.314 -0.866 . . . . 0.0 109.521 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.474 ' O ' HG13 ' A' ' 35' ' ' ILE . 1.8 tm-20 -140.8 120.65 13.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.185 -0.947 . . . . 0.0 109.493 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.875 HD21 ' NE2' ' A' ' 22' ' ' HIS . 35.3 tp -42.93 142.82 0.83 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.301 -0.874 . . . . 0.0 109.57 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.474 HG13 ' O ' ' A' ' 33' ' ' GLU . 12.8 mt -134.97 -43.07 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.232 -0.917 . . . . 0.0 109.598 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.468 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.4 p -158.66 142.52 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.223 -0.923 . . . . 0.0 109.508 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.514 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 55.9 m-20 -105.46 152.44 23.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.214 -0.929 . . . . 0.0 109.404 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.413 HG21 HD13 ' A' ' 38' ' ' ILE . 10.9 mt -128.81 153.84 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.211 -0.93 . . . . 0.0 109.537 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -121.74 150.94 41.1 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.233 -0.917 . . . . 0.0 109.443 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.493 HG21 ' SD ' ' A' ' 45' ' ' MET . 28.1 p -133.62 -168.37 2.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.241 -0.912 . . . . 0.0 109.491 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.411 ' C ' ' O ' ' A' ' 40' ' ' THR . 27.2 t70 -42.68 -69.25 0.14 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.348 -0.845 . . . . 0.0 109.686 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.9 mtmt -136.64 27.15 3.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.227 -0.92 . . . . 0.0 109.425 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.439 ' O ' ' OG1' ' A' ' 40' ' ' THR . 1.9 t -135.86 162.1 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.259 -0.901 . . . . 0.0 109.507 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.3 p -122.53 138.81 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.352 -0.843 . . . . 0.0 109.479 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' MET . . . . . 0.493 ' SD ' HG21 ' A' ' 40' ' ' THR . 1.9 mpp? -127.05 101.94 6.76 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.254 -0.904 . . . . 0.0 109.453 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.462 ' HG2' ' OD1' ' A' ' 37' ' ' ASP . 15.0 mt-10 -73.9 163.81 27.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.277 -0.889 . . . . 0.0 109.475 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.468 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 71.6 t -131.04 107.69 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.281 -0.887 . . . . 0.0 109.44 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.721 HD12 ' HA ' ' A' ' 34' ' ' LEU . 1.3 mp -91.91 170.2 10.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.906 . . . . 0.0 109.536 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.442 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -71.91 124.7 25.43 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.257 -0.902 . . . . 0.0 109.458 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.701 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -82.68 6.85 16.57 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.9 . . . . 0.0 109.5 -179.947 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 163.94 141.46 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.516 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -49.01 170.97 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 109.338 -179.974 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 135.8 -155.84 22.51 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.794 HG13 ' O ' ' A' ' 27' ' ' GLU . 48.5 t -138.71 125.04 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.318 -1.107 . . . . 0.0 109.477 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.562 HG22 ' H ' ' A' ' 56' ' ' ALA . 4.6 mm -46.45 172.25 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.255 -0.903 . . . . 0.0 109.464 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.562 ' H ' HG22 ' A' ' 55' ' ' ILE . . . -110.91 -65.09 1.2 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.266 -0.896 . . . . 0.0 109.478 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.499 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -170.27 138.78 1.65 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.469 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.636 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 21.5 mm -101.38 128.53 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.245 -0.91 . . . . 0.0 109.49 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.2 t -98.06 -30.97 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.262 -0.898 . . . . 0.0 109.481 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.467 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -91.23 117.65 29.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.32 -0.862 . . . . 0.0 109.454 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 57.6 m-80 -84.06 157.23 21.85 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.311 -0.868 . . . . 0.0 109.451 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -57.19 142.44 42.78 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.26 -0.9 . . . . 0.0 109.463 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.76 11.29 68.42 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -104.69 170.92 7.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -1.125 . . . . 0.0 109.292 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 52.0 m -107.52 146.95 31.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.45 -0.781 . . . . 0.0 109.465 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.733 HG11 HD21 ' A' ' 72' ' ' LEU . 7.1 m -124.59 139.82 49.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.237 -0.914 . . . . 0.0 109.49 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -101.06 -175.55 2.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.316 -0.865 . . . . 0.0 109.436 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.563 ' OG ' HG23 ' A' ' 8' ' ' THR . 1.5 t -64.47 122.22 16.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.266 -0.897 . . . . 0.0 109.496 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.51 31.28 41.69 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -83.84 104.56 14.03 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.187 -1.184 . . . . 0.0 109.484 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.471 ' HA ' ' HG3' ' A' ' 5' ' ' LYS . 1.0 OUTLIER -66.4 120.28 13.06 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -0.912 . . . . 0.0 109.487 179.966 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.733 HD21 HG11 ' A' ' 66' ' ' VAL . 1.0 OUTLIER -95.81 -18.92 20.02 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.283 -0.886 . . . . 0.0 109.495 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.77 -179.64 41.0 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' A' ' 56' ' ' ALA . 2.1 mtmt -140.58 152.44 45.48 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.295 -1.12 . . . . 0.0 109.484 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -92.61 151.34 20.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.425 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.58 HG22 ' H ' ' A' ' 77' ' ' GLU . 8.6 m -98.77 172.21 7.6 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.899 . . . . 0.0 109.434 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.58 ' H ' HG22 ' A' ' 76' ' ' THR . 5.5 mt-10 -74.49 -169.42 0.83 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.236 -0.915 . . . . 0.0 109.511 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 144.29 89.75 0.11 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.242 0 CA-C-O 118.025 -1.431 . . . . 0.0 109.55 -179.983 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.8 pt -131.99 176.59 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.235 -0.916 . . . . 0.0 109.482 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.447 ' OD2' ' HB3' ' A' ' 5' ' ' LYS . 29.5 t70 -117.47 135.92 53.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.23 -0.919 . . . . 0.0 109.432 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.495 HG22 ' O ' ' A' ' 4' ' ' ILE . 91.3 mt -99.47 73.08 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.216 -0.928 . . . . 0.0 109.517 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.447 ' HB3' ' OD2' ' A' ' 3' ' ' ASP . 0.9 OUTLIER -104.77 159.31 15.88 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.228 -0.92 . . . . 0.0 109.445 179.963 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.46 147.69 75.86 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.21 -0.931 . . . . 0.0 109.436 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.21 160.82 29.47 Favored 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.608 2.206 . . . . 0.0 110.379 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 9' ' ' PHE . 27.2 m -71.6 89.38 0.98 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.327 -0.858 . . . . 0.0 109.48 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.471 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 31.4 m-85 -44.07 147.98 0.86 Allowed Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.298 -0.876 . . . . 0.0 109.444 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 9' ' ' PHE . 35.8 Cg_endo -78.06 -159.96 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.691 2.261 . . . . 0.0 110.415 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 12' ' ' SER . 46.7 tt0 -77.38 -58.41 3.29 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.215 -0.928 . . . . 0.0 109.401 -179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.8 t -42.8 -55.71 3.53 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.273 -0.892 . . . . 0.0 109.693 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.512 HG22 ' H ' ' A' ' 15' ' ' ASP . 3.5 mt -91.45 134.08 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.251 -0.905 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.18 11.3 16.25 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.242 -0.911 . . . . 0.0 109.486 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.512 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 171.31 -171.15 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.182 -0.949 . . . . 0.0 109.477 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.76 -167.3 17.77 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.526 HG23 ' O ' ' A' ' 64' ' ' ASP . 94.6 m -150.0 125.83 10.46 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -1.156 . . . . 0.0 109.483 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.468 HG12 ' N ' ' A' ' 19' ' ' ALA . 47.0 t -45.26 160.07 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 109.454 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.608 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -106.16 -73.06 0.69 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.186 -0.946 . . . . 0.0 109.51 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.1 m -160.08 131.89 6.12 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.237 -0.914 . . . . 0.0 109.521 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.635 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.4 m95 -89.87 85.57 6.42 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 121.279 -0.888 . . . . 0.0 109.545 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.656 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.0 m80 -43.26 -62.21 1.12 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.32 -0.863 . . . . 0.0 109.392 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -100.58 176.66 5.25 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.929 . . . . 0.0 109.506 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.16 167.46 11.33 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.427 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.479 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.92 108.94 2.75 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.689 2.259 . . . . 0.0 110.422 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 139.01 -10.22 3.33 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.433 ' O ' HG13 ' A' ' 54' ' ' VAL . 1.4 mt-10 -97.48 -172.22 2.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.29 -1.123 . . . . 0.0 109.541 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -106.76 154.66 20.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.299 -0.875 . . . . 0.0 109.498 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.869 HG21 HD11 ' A' ' 35' ' ' ILE . 8.4 p -139.58 148.94 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.499 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -114.58 137.69 51.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.151 -0.968 . . . . 0.0 109.504 -179.972 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.461 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 29.5 ttt85 -42.73 150.03 0.17 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.331 -0.855 . . . . 0.0 109.663 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.683 ' HA ' HD21 ' A' ' 48' ' ' LEU . 8.5 t70 72.3 41.14 0.63 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.48 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.439 ' O ' ' O ' ' A' ' 34' ' ' LEU . 2.4 tp10 -141.94 124.23 15.61 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.147 -0.97 . . . . 0.0 109.448 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.656 HD21 ' NE2' ' A' ' 22' ' ' HIS . 45.7 tp -43.16 164.69 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.346 -0.846 . . . . 0.0 109.482 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.869 HD11 HG21 ' A' ' 29' ' ' VAL . 27.4 mm -139.52 -46.07 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.109 -0.994 . . . . 0.0 109.579 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.458 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.6 p -166.3 137.25 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.262 -0.899 . . . . 0.0 109.473 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.608 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 16.9 m-20 -97.96 152.67 19.01 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.253 -0.904 . . . . 0.0 109.44 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.485 HD13 ' O ' ' A' ' 37' ' ' ASP . 6.0 mm -119.52 156.15 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.461 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.47 ' HB2' ' O ' ' A' ' 17' ' ' THR . 1.1 mm-40 -118.23 128.91 55.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.425 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.1 OUTLIER -109.87 -161.23 0.75 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.266 -0.896 . . . . 0.0 109.429 179.992 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.425 ' C ' ' O ' ' A' ' 40' ' ' THR . 13.6 t0 -42.8 -71.01 0.09 Allowed 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.342 -0.849 . . . . 0.0 109.681 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.5 mmtm -137.29 28.24 2.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.274 -0.891 . . . . 0.0 109.475 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 44' ' ' VAL . 24.6 t -128.43 169.32 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.24 -0.913 . . . . 0.0 109.51 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.579 ' N ' HG12 ' A' ' 43' ' ' VAL . 7.5 p -129.66 122.43 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.302 -0.874 . . . . 0.0 109.457 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 87.2 mmm -103.89 176.51 5.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 0.0 109.476 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -136.21 153.15 51.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.215 -0.928 . . . . 0.0 109.543 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.458 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 45.8 t -125.09 102.58 10.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.336 -0.853 . . . . 0.0 109.454 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.683 HD21 ' HA ' ' A' ' 32' ' ' ASP . 0.5 OUTLIER -96.41 150.21 20.85 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.214 -0.929 . . . . 0.0 109.44 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.436 ' O ' HD23 ' A' ' 48' ' ' LEU . . . -78.8 137.71 37.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.469 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -101.33 19.96 16.75 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.332 -0.855 . . . . 0.0 109.496 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -176.57 134.61 0.23 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.244 -0.91 . . . . 0.0 109.5 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.5 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -62.75 170.94 2.31 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.263 -0.898 . . . . 0.0 109.377 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.5 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 146.71 -151.74 23.97 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 27' ' ' GLU . 71.4 t -134.28 130.63 54.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -1.149 . . . . 0.0 109.425 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.492 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.1 mt -52.15 160.5 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.338 -0.851 . . . . 0.0 109.524 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.492 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -97.69 -68.79 0.78 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.142 -0.974 . . . . 0.0 109.444 -179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.479 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 1.5 mt-10 -176.02 133.08 0.25 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.293 -0.879 . . . . 0.0 109.495 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.635 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 20.1 mm -95.33 125.22 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.309 -0.869 . . . . 0.0 109.47 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 44.3 t -89.91 -29.75 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.912 . . . . 0.0 109.425 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.521 ' CG ' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -90.0 162.72 15.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -0.912 . . . . 0.0 109.424 -179.986 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.475 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 13.7 m-80 -117.08 157.57 25.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.212 -0.93 . . . . 0.0 109.5 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -61.14 134.61 57.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.21 -0.931 . . . . 0.0 109.443 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 94.15 -7.05 72.65 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.526 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -86.06 170.71 11.99 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -1.145 . . . . 0.0 109.301 -179.996 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.502 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 9.6 t -99.58 163.09 12.65 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.536 -0.728 . . . . 0.0 109.521 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 5.7 m -127.02 144.32 37.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.199 -0.938 . . . . 0.0 109.468 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -107.1 167.81 9.65 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.216 -0.928 . . . . 0.0 109.54 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.6 t -67.44 101.83 1.03 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.311 -0.868 . . . . 0.0 109.458 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 107.47 13.2 21.36 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.425 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 46.9 tp10 -81.13 123.84 28.75 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.261 -1.14 . . . . 0.0 109.522 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 5.8 tt -81.88 114.22 20.34 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.184 -0.947 . . . . 0.0 109.517 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 22.3 mt -89.32 -20.02 24.56 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.17 -0.956 . . . . 0.0 109.495 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 161.29 179.96 36.34 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.474 ' HG2' ' HB3' ' A' ' 56' ' ' ALA . 0.6 OUTLIER -149.74 153.04 36.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -1.175 . . . . 0.0 109.458 -179.968 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.468 ' HG ' ' N ' ' A' ' 76' ' ' THR . 17.0 tp -90.26 153.17 20.67 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.315 -0.866 . . . . 0.0 109.47 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.525 HG22 ' H ' ' A' ' 77' ' ' GLU . 5.6 m -91.52 170.66 9.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.311 -0.868 . . . . 0.0 109.46 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.525 ' H ' HG22 ' A' ' 76' ' ' THR . 4.6 mt-10 -69.27 178.82 2.2 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.294 -0.879 . . . . 0.0 109.453 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.36 -44.99 0.85 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.3 0 CA-C-O 117.979 -1.456 . . . . 0.0 109.544 -179.973 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.529 HD13 HD22 ' A' ' 75' ' ' LEU . 3.3 mp -125.68 91.96 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.157 -0.965 . . . . 0.0 109.45 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -60.81 130.77 48.15 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.272 -0.893 . . . . 0.0 109.502 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.651 HD12 ' HA ' ' A' ' 74' ' ' LYS . 2.7 mp -100.29 110.61 27.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.195 -0.941 . . . . 0.0 109.472 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.7 pttp -120.17 166.82 12.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.198 -0.939 . . . . 0.0 109.478 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.655 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -84.99 164.46 41.59 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.265 -0.897 . . . . 0.0 109.487 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.655 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.3 Cg_endo -78.02 153.54 28.84 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.625 2.217 . . . . 0.0 110.455 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.468 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 41.2 m -75.75 110.49 10.22 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.933 . . . . 0.0 109.455 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -69.92 153.31 95.56 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.205 -0.934 . . . . 0.0 109.482 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.11 176.74 9.61 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 C-N-CA 122.656 2.237 . . . . 0.0 110.453 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.533 ' HG3' ' N ' ' A' ' 12' ' ' SER . 22.5 pt-20 -65.24 -45.44 84.59 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.287 -0.883 . . . . 0.0 109.469 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.533 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 1.5 t -42.61 -40.12 2.59 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.379 -0.826 . . . . 0.0 109.699 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.704 HG22 ' H ' ' A' ' 15' ' ' ASP . 30.0 mm -108.11 154.05 9.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.259 -0.901 . . . . 0.0 109.453 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -118.18 0.16 11.7 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.235 -0.916 . . . . 0.0 109.611 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.704 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER 179.23 -174.45 0.21 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.189 -0.945 . . . . 0.0 109.506 -179.995 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -150.92 -160.56 9.47 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.543 HG23 ' O ' ' A' ' 64' ' ' ASP . 16.8 m -150.02 129.04 12.62 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.236 -1.155 . . . . 0.0 109.418 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.513 HG12 ' N ' ' A' ' 19' ' ' ALA . 60.8 t -44.45 161.26 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.398 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.627 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -106.65 -75.13 0.64 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.247 -0.908 . . . . 0.0 109.515 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.6 m -160.13 131.42 5.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.234 -0.917 . . . . 0.0 109.558 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.637 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.82 85.88 6.51 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.337 -0.852 . . . . 0.0 109.53 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.625 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.7 m80 -42.12 -69.02 0.15 Allowed 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.355 -0.841 . . . . 0.0 109.483 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -96.93 -177.24 3.81 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.215 -0.928 . . . . 0.0 109.628 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.44 ' CG ' ' HD2' ' A' ' 25' ' ' PRO . 4.5 mttp -122.76 169.4 9.9 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.292 -0.88 . . . . 0.0 109.453 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.508 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.1 Cg_endo -76.23 136.43 17.97 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.626 2.217 . . . . 0.0 110.416 179.813 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.73 14.07 35.69 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -112.5 -172.3 2.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -1.119 . . . . 0.0 109.508 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.75 138.93 31.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.346 -0.846 . . . . 0.0 109.456 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.9 t -118.5 141.76 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.406 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 8.8 ttpt -131.86 127.03 35.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.296 -0.878 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.534 ' CG ' ' HA ' ' A' ' 51' ' ' ALA . 0.2 OUTLIER -42.75 147.24 0.31 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.374 -0.829 . . . . 0.0 109.63 -179.889 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.484 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 11.8 t0 73.4 26.41 2.02 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -0.888 . . . . 0.0 109.463 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.427 ' O ' ' O ' ' A' ' 34' ' ' LEU . 12.5 tm-20 -126.8 110.24 12.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.363 -0.836 . . . . 0.0 109.474 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.625 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 47.4 tp -42.98 164.23 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.321 -0.862 . . . . 0.0 109.597 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.84 HD11 ' HB2' ' A' ' 49' ' ' ALA . 27.4 mt -138.18 -47.72 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.27 -0.894 . . . . 0.0 109.606 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.534 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 12.6 p -150.61 152.78 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.236 -0.915 . . . . 0.0 109.51 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.627 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 23.3 m-20 -113.99 150.63 33.56 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.27 -0.894 . . . . 0.0 109.461 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.534 HD11 ' CG2' ' A' ' 47' ' ' VAL . 3.3 mt -115.27 145.09 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.263 -0.898 . . . . 0.0 109.489 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -118.59 143.91 46.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.209 -0.932 . . . . 0.0 109.423 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.541 HG22 ' N ' ' A' ' 41' ' ' ASP . 55.7 m -134.96 165.35 25.54 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.199 -0.938 . . . . 0.0 109.422 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.541 ' N ' HG22 ' A' ' 40' ' ' THR . 45.0 t0 -42.79 -36.14 1.37 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.869 . . . . 0.0 109.639 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 20.3 mttp -158.48 28.91 0.24 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.277 -0.89 . . . . 0.0 109.503 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.464 ' O ' ' HB ' ' A' ' 40' ' ' THR . 7.6 t -142.05 117.79 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.501 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -107.04 124.86 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.251 -0.906 . . . . 0.0 109.461 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 4.0 mtp -117.2 -174.59 2.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.236 -0.915 . . . . 0.0 109.478 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -140.89 168.86 18.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.232 -0.918 . . . . 0.0 109.502 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.534 ' CG2' HD11 ' A' ' 38' ' ' ILE . 53.0 t -142.03 102.98 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.242 -0.912 . . . . 0.0 109.521 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.774 HD23 ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.46 166.49 10.51 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.192 -0.943 . . . . 0.0 109.418 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.84 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -83.52 157.57 22.32 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.918 . . . . 0.0 109.48 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.546 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 1.8 mm-40 -104.07 7.17 36.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.571 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.546 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 173.18 161.76 0.13 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.959 . . . . 0.0 109.51 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.514 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -59.99 171.0 1.04 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.218 -0.926 . . . . 0.0 109.322 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.514 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.19 -163.9 28.93 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' A' ' 55' ' ' ILE . 40.5 t -133.8 119.6 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.257 -1.143 . . . . 0.0 109.527 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.631 HG22 ' H ' ' A' ' 56' ' ' ALA . 2.3 mp -47.02 174.45 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.384 -0.823 . . . . 0.0 109.755 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.631 ' H ' HG22 ' A' ' 55' ' ' ILE . . . -111.99 -60.86 1.8 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.159 -0.963 . . . . 0.0 109.458 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 177.45 138.0 0.07 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.499 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.637 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.1 mm -95.14 128.48 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.337 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 83.7 t -90.04 -33.52 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.196 -0.94 . . . . 0.0 109.518 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.604 ' HZ2' HD23 ' A' ' 72' ' ' LEU . 1.0 OUTLIER -97.83 145.96 25.89 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.2 -0.937 . . . . 0.0 109.497 -179.928 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.403 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 7.1 m-80 -109.72 169.44 8.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.293 -0.879 . . . . 0.0 109.435 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -64.26 150.62 45.59 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.193 -0.942 . . . . 0.0 109.56 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.68 5.59 86.43 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.543 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -105.17 170.85 7.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.115 -1.226 . . . . 0.0 109.26 -179.991 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.507 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 9.8 t -99.35 153.77 18.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.607 -0.683 . . . . 0.0 109.467 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.458 HG12 ' HD2' ' A' ' 60' ' ' LYS . 28.5 m -124.75 136.82 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.233 -0.917 . . . . 0.0 109.472 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.455 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.1 OUTLIER -92.84 163.2 13.8 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.263 -0.898 . . . . 0.0 109.412 179.974 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.468 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 33.1 t -55.7 123.02 12.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 109.469 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 67.46 35.83 87.64 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.501 ' CG ' ' HE2' ' A' ' 60' ' ' LYS . 8.4 tp10 -79.91 136.91 36.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.259 -1.142 . . . . 0.0 109.442 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.562 HD23 ' C ' ' A' ' 71' ' ' LEU . 9.0 tt -77.88 117.72 19.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.279 -0.888 . . . . 0.0 109.432 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.604 HD23 ' HZ2' ' A' ' 60' ' ' LYS . 0.4 OUTLIER -99.41 -14.89 18.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.871 . . . . 0.0 109.397 179.972 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 160.14 -169.49 36.03 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.651 ' HA ' HD12 ' A' ' 4' ' ' ILE . 4.7 ptmt -150.1 152.82 35.38 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -1.154 . . . . 0.0 109.466 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.692 HD23 ' O ' ' A' ' 76' ' ' THR . 0.5 OUTLIER -104.15 156.51 17.82 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.466 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.692 ' O ' HD23 ' A' ' 75' ' ' LEU . 5.9 m -93.75 169.52 10.25 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.321 -0.862 . . . . 0.0 109.49 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.499 ' H ' HG22 ' A' ' 76' ' ' THR . 84.4 mt-10 -54.69 134.49 47.31 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.244 -0.91 . . . . 0.0 109.457 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -83.07 131.91 10.71 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.453 ' O ' ' OD1' ' A' ' 52' ' ' ASP . . . . . . . . 0 N--CA 1.491 2.305 0 CA-C-O 118.0 -1.444 . . . . 0.0 109.561 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.704 ' O ' HD13 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.704 HD13 ' O ' ' A' ' 1' ' ' ALA . 4.7 mm -128.99 170.13 19.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.149 -0.969 . . . . 0.0 109.462 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.436 ' H ' HG22 ' A' ' 2' ' ' ILE . 27.2 t0 -114.87 137.9 51.42 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.249 -0.907 . . . . 0.0 109.536 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.415 ' CG2' HG11 ' A' ' 47' ' ' VAL . 2.9 mt -105.78 72.67 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.434 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.413 ' HD2' ' OD2' ' A' ' 3' ' ' ASP . 1.3 ptmt -102.85 149.8 24.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.27 -0.894 . . . . 0.0 109.421 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.464 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -61.63 158.55 39.86 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.292 -0.88 . . . . 0.0 109.534 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.464 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.4 Cg_endo -78.0 -178.96 5.0 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.676 2.251 . . . . 0.0 110.405 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 60.6 m -92.74 129.3 38.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.453 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -81.1 148.96 65.34 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.192 -0.943 . . . . 0.0 109.453 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.02 -165.99 0.37 Allowed 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.659 2.239 . . . . 0.0 110.393 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.426 ' HG3' ' N ' ' A' ' 12' ' ' SER . 12.7 pt-20 -73.69 -41.67 62.31 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.267 -0.896 . . . . 0.0 109.525 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.426 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 38.4 t -42.89 -72.95 0.05 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.367 -0.833 . . . . 0.0 109.634 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.665 HG21 HG22 ' A' ' 40' ' ' THR . 1.8 mp -90.71 150.57 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.522 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -121.29 31.48 6.32 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.212 -0.93 . . . . 0.0 109.514 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -177.33 -171.84 0.35 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.925 . . . . 0.0 109.439 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.75 ' HA2' HG23 ' A' ' 40' ' ' THR . . . -154.63 175.59 32.69 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.518 ' O ' ' CG ' ' A' ' 39' ' ' GLU . 98.1 m -150.07 114.97 5.33 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.144 -1.21 . . . . 0.0 109.527 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.593 HG12 ' N ' ' A' ' 19' ' ' ALA . 40.2 t -46.0 168.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.313 -0.867 . . . . 0.0 109.477 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.601 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -113.22 -71.08 0.77 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.254 -0.904 . . . . 0.0 109.58 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.49 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 20.7 m -160.03 134.75 7.73 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.197 -0.939 . . . . 0.0 109.572 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.626 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.5 m95 -89.89 84.01 6.2 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.26 -0.9 . . . . 0.0 109.505 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.629 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -42.72 -70.12 0.12 Allowed 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.39 -0.819 . . . . 0.0 109.469 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 7.6 mmtt -89.5 -172.2 3.5 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.61 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.491 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 8.2 mttp -136.66 165.24 36.75 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.27 -0.894 . . . . 0.0 109.247 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.534 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -77.21 114.44 3.77 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.553 2.169 . . . . 0.0 110.383 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 135.23 -9.9 4.42 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -100.21 -172.36 2.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.235 -1.156 . . . . 0.0 109.487 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.83 170.47 11.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.293 -0.879 . . . . 0.0 109.484 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.448 ' HB ' ' O ' ' A' ' 53' ' ' GLY . 52.2 t -142.08 148.27 20.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.212 -0.93 . . . . 0.0 109.482 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.2 OUTLIER -135.38 136.01 41.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.259 -0.901 . . . . 0.0 109.479 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.464 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 15.7 ttp180 -42.87 145.38 0.47 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.29 -0.881 . . . . 0.0 109.733 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.464 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 54.9 t0 67.45 48.11 1.17 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.285 -0.884 . . . . 0.0 109.477 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' A' ' 34' ' ' LEU . 1.2 tp10 -137.57 105.95 5.79 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.216 -0.927 . . . . 0.0 109.508 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.629 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 42.7 tp -43.13 164.89 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.302 -0.874 . . . . 0.0 109.537 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.91 HD11 ' HB2' ' A' ' 49' ' ' ALA . 49.3 mt -142.56 -47.64 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.245 -0.909 . . . . 0.0 109.615 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.527 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.9 p -151.47 134.98 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.168 -0.957 . . . . 0.0 109.552 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.601 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 6.4 m-20 -95.59 163.86 13.03 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.31 -0.868 . . . . 0.0 109.427 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.437 HD11 ' CG2' ' A' ' 47' ' ' VAL . 21.6 mt -134.0 152.8 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.185 -0.947 . . . . 0.0 109.399 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 17' ' ' THR . 10.9 pt-20 -146.43 144.56 29.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.204 -0.935 . . . . 0.0 109.557 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.75 HG23 ' HA2' ' A' ' 16' ' ' GLY . 0.2 OUTLIER -140.28 -172.04 3.33 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.281 -0.887 . . . . 0.0 109.481 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.58 ' H ' HG22 ' A' ' 40' ' ' THR . 3.0 t70 -42.89 -64.15 0.67 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.354 -0.841 . . . . 0.0 109.66 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.65 44.13 1.96 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.428 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 2.8 t -148.22 104.28 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.26 -0.9 . . . . 0.0 109.497 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.435 ' O ' ' HG2' ' A' ' 45' ' ' MET . 62.1 t -98.04 143.43 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.242 -0.911 . . . . 0.0 109.535 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' MET . . . . . 0.435 ' HG2' ' O ' ' A' ' 44' ' ' VAL . 2.7 mmt -143.52 -178.89 6.11 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.227 -0.921 . . . . 0.0 109.489 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -141.33 165.68 26.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.176 -0.953 . . . . 0.0 109.512 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.527 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 18.1 t -137.35 98.36 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.232 -0.918 . . . . 0.0 109.467 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.762 HD23 ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -103.18 160.58 14.53 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 121.227 -0.92 . . . . 0.0 109.371 179.943 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.91 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -77.9 132.63 38.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.459 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.433 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.2 OUTLIER -86.28 12.4 10.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.221 -0.924 . . . . 0.0 109.489 -179.974 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.433 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 178.86 155.12 0.43 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.295 -0.878 . . . . 0.0 109.446 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.499 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -65.97 170.94 4.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.178 -0.952 . . . . 0.0 109.392 179.94 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.499 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 149.9 -153.99 25.43 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.4 ' O ' ' HB ' ' A' ' 76' ' ' THR . 49.6 t -135.19 126.27 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -1.129 . . . . 0.0 109.45 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.573 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.1 mt -56.21 164.39 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.193 -0.942 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.573 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -105.08 -63.69 1.2 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.531 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.534 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 1.1 pt-20 -179.24 144.09 0.22 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.248 -0.907 . . . . 0.0 109.465 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.626 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 24.5 mm -105.3 123.91 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.279 -0.888 . . . . 0.0 109.503 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.0 t -89.91 -19.88 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.251 -0.905 . . . . 0.0 109.546 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.491 ' HG3' ' OD1' ' A' ' 64' ' ' ASP . 3.9 tptt -115.97 129.9 56.59 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.239 -0.913 . . . . 0.0 109.51 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 14.9 m-80 -87.62 157.03 19.22 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 0.0 109.454 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.525 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -60.66 151.81 28.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.31 -10.49 68.86 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.514 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -88.63 171.02 10.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -1.164 . . . . 0.0 109.321 -179.97 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.514 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 97.9 m -91.51 147.18 23.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.518 -0.739 . . . . 0.0 109.482 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 17.1 m -120.04 178.73 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.281 -0.887 . . . . 0.0 109.405 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -130.33 162.69 28.48 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.915 . . . . 0.0 109.466 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -65.16 97.22 0.24 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.225 -0.922 . . . . 0.0 109.441 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.77 27.74 7.78 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.504 -1.439 . . . . 0.0 109.504 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -84.08 132.06 34.74 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.201 -1.176 . . . . 0.0 109.49 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.404 HD23 ' C ' ' A' ' 71' ' ' LEU . 8.4 tt -78.9 114.98 18.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -0.924 . . . . 0.0 109.464 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.473 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 5.1 mt -91.24 -22.15 20.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.322 -0.861 . . . . 0.0 109.466 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 170.85 177.03 40.52 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.409 ' O ' ' CB ' ' A' ' 56' ' ' ALA . 12.5 mttt -124.94 138.36 54.24 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.3 -1.117 . . . . 0.0 109.492 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -94.71 144.16 25.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.499 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.564 HG22 ' H ' ' A' ' 77' ' ' GLU . 10.8 m -107.59 171.75 7.21 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.207 -0.933 . . . . 0.0 109.464 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.564 ' H ' HG22 ' A' ' 76' ' ' THR . 1.2 mt-10 -84.72 -168.67 2.29 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.223 -0.923 . . . . 0.0 109.4 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.442 ' HA3' ' HA2' ' A' ' 53' ' ' GLY . . . -160.58 75.29 0.19 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 CA-C-O 118.0 -1.444 . . . . 0.0 109.513 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.3 mt -122.69 101.9 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 109.493 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.404 ' OD2' ' HE3' ' A' ' 74' ' ' LYS . 46.2 t0 -72.71 127.7 33.34 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.296 -0.877 . . . . 0.0 109.513 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.578 HG22 ' O ' ' A' ' 4' ' ' ILE . 60.7 mt -95.63 80.28 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.33 -0.857 . . . . 0.0 109.504 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.421 ' O ' ' HG3' ' A' ' 5' ' ' LYS . 0.2 OUTLIER -100.14 145.94 27.4 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.537 179.971 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.597 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -52.15 162.9 0.77 Allowed Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.227 -0.921 . . . . 0.0 109.451 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.597 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 36.2 Cg_endo -77.95 162.81 28.99 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.642 2.228 . . . . 0.0 110.484 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.547 ' O ' HG23 ' A' ' 8' ' ' THR . 2.5 t -82.95 105.74 14.2 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.186 -0.947 . . . . 0.0 109.436 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.415 ' HB3' ' HB ' ' A' ' 13' ' ' ILE . 10.8 m-85 -72.4 150.72 91.76 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.187 -0.946 . . . . 0.0 109.492 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.612 ' HD2' HD12 ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.07 176.34 10.09 Favored 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.6 2.2 . . . . 0.0 110.42 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.436 ' O ' ' C ' ' A' ' 12' ' ' SER . 2.1 mt-10 -56.64 -50.98 70.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.309 -0.869 . . . . 0.0 109.441 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 11' ' ' GLU . 7.3 t -42.93 -46.65 5.46 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.37 -0.831 . . . . 0.0 109.58 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.738 HG22 ' H ' ' A' ' 15' ' ' ASP . 64.5 mt -92.76 150.34 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.212 -0.93 . . . . 0.0 109.477 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -127.0 17.07 7.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.942 . . . . 0.0 109.471 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.738 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 178.75 -169.08 0.09 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.196 -0.94 . . . . 0.0 109.499 -179.962 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.414 ' O ' HG23 ' A' ' 65' ' ' THR . . . -147.91 -176.17 21.23 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 69.4 m -149.91 115.27 5.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.254 -1.145 . . . . 0.0 109.495 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.585 HG12 ' N ' ' A' ' 19' ' ' ALA . 27.5 t -49.41 169.28 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.264 -0.898 . . . . 0.0 109.391 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.585 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -114.69 -73.97 0.63 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.191 -0.943 . . . . 0.0 109.53 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.0 m -160.07 133.72 7.09 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.198 -0.939 . . . . 0.0 109.523 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.734 ' CH2' HD12 ' A' ' 58' ' ' ILE . 34.5 m95 -89.87 92.9 9.21 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 121.155 -0.965 . . . . 0.0 109.556 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.714 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.6 m80 -54.98 -72.24 0.07 Allowed 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.324 -0.86 . . . . 0.0 109.421 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -84.18 -172.77 4.35 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.238 -0.914 . . . . 0.0 109.609 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -136.35 166.97 23.78 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.388 -0.82 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.496 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.6 Cg_endo -77.03 138.82 18.67 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.683 2.256 . . . . 0.0 110.493 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 106.79 -9.82 40.75 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -102.2 -174.37 2.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.315 -1.109 . . . . 0.0 109.417 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.82 147.77 27.36 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.302 -0.873 . . . . 0.0 109.466 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m -129.95 -169.53 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.212 -0.93 . . . . 0.0 109.467 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.448 ' O ' ' CB ' ' A' ' 33' ' ' GLU . 9.9 tptm -157.06 139.61 14.92 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.224 -0.923 . . . . 0.0 109.479 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.426 ' C ' ' O ' ' A' ' 30' ' ' LYS . 2.3 ttp180 -42.78 154.83 0.06 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.289 -0.882 . . . . 0.0 109.622 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.0 t70 60.24 33.44 20.97 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.244 -0.91 . . . . 0.0 109.47 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.448 ' CB ' ' O ' ' A' ' 30' ' ' LYS . 28.9 tt0 -126.45 113.92 17.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.223 -0.923 . . . . 0.0 109.508 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.714 HD21 ' NE2' ' A' ' 22' ' ' HIS . 56.8 tp -42.86 160.23 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.357 -0.839 . . . . 0.0 109.623 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.813 HD11 ' CA ' ' A' ' 49' ' ' ALA . 4.3 mt -142.77 -43.95 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.229 -0.919 . . . . 0.0 109.56 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.58 HG12 ' HB ' ' A' ' 47' ' ' VAL . 13.6 p -160.87 138.65 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.282 -0.886 . . . . 0.0 109.439 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.521 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 28.3 m-20 -97.76 149.5 22.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.139 -0.976 . . . . 0.0 109.39 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.416 HG22 ' N ' ' A' ' 39' ' ' GLU . 31.5 mt -122.46 156.3 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.196 -0.94 . . . . 0.0 109.42 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.416 ' N ' HG22 ' A' ' 38' ' ' ILE . 2.4 tm-20 -135.62 153.17 51.74 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.433 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.414 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -140.23 -178.98 5.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.195 -0.94 . . . . 0.0 109.509 -179.993 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.435 ' HB2' HG12 ' A' ' 13' ' ' ILE . 6.7 t0 -42.78 -70.02 0.12 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.344 -0.848 . . . . 0.0 109.593 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.2 mttt -129.38 35.05 4.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.255 -0.903 . . . . 0.0 109.392 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 9.7 t -144.09 152.71 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 109.447 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.4 t -130.5 153.88 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.184 -0.948 . . . . 0.0 109.487 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' MET . . . . . 0.415 ' C ' ' HG3' ' A' ' 46' ' ' GLU . 4.4 mmt -143.25 167.38 22.28 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.188 -0.945 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.415 ' HG3' ' C ' ' A' ' 45' ' ' MET . 0.7 OUTLIER -128.98 156.22 44.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.285 -0.884 . . . . 0.0 109.478 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.58 ' HB ' HG12 ' A' ' 36' ' ' VAL . 20.9 t -126.88 99.95 6.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.895 . . . . 0.0 109.502 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.768 HD23 ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.93 164.96 11.31 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.295 -0.878 . . . . 0.0 109.396 -179.992 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.813 ' CA ' HD11 ' A' ' 35' ' ' ILE . . . -83.34 129.41 34.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.291 -0.881 . . . . 0.0 109.522 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.581 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -91.35 10.84 25.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.197 -0.939 . . . . 0.0 109.443 -179.973 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.581 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 171.58 132.33 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.316 -0.865 . . . . 0.0 109.454 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.506 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -47.42 170.93 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.253 -0.904 . . . . 0.0 109.294 179.973 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.506 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 153.88 -160.95 29.67 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 46.5 t -124.56 123.91 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.272 -1.134 . . . . 0.0 109.494 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.556 HG22 ' N ' ' A' ' 56' ' ' ALA . 4.9 mt -61.52 163.7 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.338 -0.852 . . . . 0.0 109.615 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.556 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -103.22 -65.51 1.0 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -0.922 . . . . 0.0 109.485 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.496 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER 172.66 141.35 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.239 -0.913 . . . . 0.0 109.427 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.734 HD12 ' CH2' ' A' ' 21' ' ' TRP . 9.9 mm -89.97 140.38 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.279 -0.888 . . . . 0.0 109.398 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 98.8 t -89.99 -53.13 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.184 -0.947 . . . . 0.0 109.438 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.522 ' CE ' ' HA ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -94.87 167.17 11.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.251 -0.906 . . . . 0.0 109.391 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 49.3 m-80 -104.65 156.06 18.31 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.422 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.533 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -64.97 155.54 34.15 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.417 -179.933 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.08 2.54 89.4 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -105.28 170.96 7.58 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.196 -1.179 . . . . 0.0 109.313 -179.984 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.51 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 95.4 m -98.93 122.91 42.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.553 -0.717 . . . . 0.0 109.489 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.446 ' HB ' ' HG2' ' A' ' 70' ' ' GLU . 5.5 m -104.41 -172.37 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.273 -0.892 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -133.45 176.3 8.65 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.501 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.9 t -63.8 143.54 57.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.414 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 60.17 26.01 63.07 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.446 ' HG2' ' HB ' ' A' ' 66' ' ' VAL . 35.2 tp10 -82.92 110.43 17.9 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.455 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.768 HD11 ' HD2' ' A' ' 74' ' ' LYS . 9.6 tt -69.24 109.97 4.36 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.264 -0.897 . . . . 0.0 109.486 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.575 ' O ' HG23 ' A' ' 58' ' ' ILE . 35.9 mt -94.33 -11.8 29.29 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.521 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.45 ' O ' ' HG2' ' A' ' 74' ' ' LYS . . . 173.04 177.92 42.66 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.768 ' HD2' HD11 ' A' ' 71' ' ' LEU . 20.3 mtpt -147.7 129.2 14.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -1.127 . . . . 0.0 109.466 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.714 HD23 ' O ' ' A' ' 76' ' ' THR . 1.1 tt -96.02 147.66 23.47 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.238 -0.914 . . . . 0.0 109.539 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.714 ' O ' HD23 ' A' ' 75' ' ' LEU . 5.8 m -91.86 169.67 10.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.513 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.504 ' H ' HG22 ' A' ' 76' ' ' THR . 10.4 mt-10 -57.7 -65.51 0.62 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.205 -0.934 . . . . 0.0 109.466 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 114.33 73.7 0.59 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 CA-C-O 117.924 -1.487 . . . . 0.0 109.523 -179.99 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 36.8 pt -139.6 178.13 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.292 -0.88 . . . . 0.0 109.451 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.518 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 14.4 t0 -113.97 133.57 55.4 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.233 -0.917 . . . . 0.0 109.479 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.8 mt -105.57 98.08 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.193 -0.942 . . . . 0.0 109.48 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.02 168.69 14.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.17 -0.956 . . . . 0.0 109.5 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.2 153.73 92.33 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.307 -0.87 . . . . 0.0 109.47 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.99 140.64 18.23 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.565 2.177 . . . . 0.0 110.418 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.446 ' O ' HG23 ' A' ' 8' ' ' THR . 8.9 t -62.32 129.59 41.41 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -0.962 . . . . 0.0 109.451 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.497 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 23.4 m-85 -96.93 151.88 38.03 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.887 . . . . 0.0 109.472 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.448 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -78.08 171.31 17.33 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.671 2.247 . . . . 0.0 110.376 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.424 ' O ' ' C ' ' A' ' 12' ' ' SER . 4.5 mt-10 -45.67 -54.52 7.66 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.144 -0.973 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.424 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.95 -62.46 1.01 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.282 -0.886 . . . . 0.0 109.601 -179.917 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.573 HG22 ' H ' ' A' ' 15' ' ' ASP . 29.8 mm -92.85 119.13 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.181 -0.949 . . . . 0.0 109.482 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.438 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -96.18 13.21 28.13 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.262 -0.899 . . . . 0.0 109.484 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.573 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER 167.42 -171.82 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.884 . . . . 0.0 109.431 -179.957 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.34 -159.28 8.39 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.525 HG23 ' O ' ' A' ' 64' ' ' ASP . 52.1 m -149.57 123.29 9.23 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.243 -1.151 . . . . 0.0 109.502 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.592 HG12 ' N ' ' A' ' 19' ' ' ALA . 39.6 t -47.98 168.64 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.302 -0.874 . . . . 0.0 109.426 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.592 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -113.13 -75.0 0.61 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.413 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.5 m -160.08 134.7 7.66 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.336 -0.853 . . . . 0.0 109.451 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.673 ' CH2' HD12 ' A' ' 58' ' ' ILE . 34.1 m95 -89.78 84.9 6.3 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.231 -0.918 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.806 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.8 m80 -42.34 -60.46 1.48 Allowed 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.371 -0.831 . . . . 0.0 109.497 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 4.1 mmtt -99.66 -172.11 2.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.593 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.408 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -130.12 168.59 16.12 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.288 -0.882 . . . . 0.0 109.496 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.528 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.51 115.58 4.11 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 122.664 2.243 . . . . 0.0 110.39 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.83 -11.92 5.38 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.431 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 1.2 pp20? -95.6 -172.89 2.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.352 -1.087 . . . . 0.0 109.467 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.431 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -101.04 151.2 22.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.601 HG22 ' O ' ' A' ' 53' ' ' GLY . 20.1 m -114.9 166.63 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.358 -0.839 . . . . 0.0 109.429 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.436 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.3 mttt -121.3 134.5 55.15 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.262 -0.899 . . . . 0.0 109.506 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.51 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.81 113.42 0.47 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.352 -0.843 . . . . 0.0 109.684 -179.898 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.51 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 14.5 t0 75.99 56.37 0.05 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.293 -0.879 . . . . 0.0 109.495 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.479 ' O ' HG13 ' A' ' 35' ' ' ILE . 15.9 tt0 -131.24 124.15 29.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.319 -0.863 . . . . 0.0 109.437 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.806 HD21 ' NE2' ' A' ' 22' ' ' HIS . 51.1 tp -42.8 151.63 0.12 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.377 -0.827 . . . . 0.0 109.596 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.937 HD11 ' HB2' ' A' ' 49' ' ' ALA . 96.9 mt -137.84 -41.21 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.319 -0.863 . . . . 0.0 109.476 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.526 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 13.6 p -158.24 135.0 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.277 -0.89 . . . . 0.0 109.451 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.514 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 10.7 m-20 -93.28 153.83 18.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.287 -0.883 . . . . 0.0 109.438 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.537 HD11 ' CG2' ' A' ' 47' ' ' VAL . 2.8 mt -121.44 155.81 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.271 -0.893 . . . . 0.0 109.507 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.0 145.06 50.85 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.295 -0.878 . . . . 0.0 109.439 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.538 HG22 ' H ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -130.6 -176.98 4.15 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -0.932 . . . . 0.0 109.479 179.962 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.538 ' H ' HG22 ' A' ' 40' ' ' THR . 63.5 t0 -42.78 -55.08 3.8 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.286 -0.883 . . . . 0.0 109.686 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 18.3 mttm -147.45 25.45 1.08 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.246 -0.908 . . . . 0.0 109.396 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 2.1 t -134.05 130.87 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.231 -0.918 . . . . 0.0 109.457 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.0 t -108.57 139.78 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.218 -0.926 . . . . 0.0 109.512 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 18.7 mtp -131.62 175.28 9.31 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.212 -0.93 . . . . 0.0 109.467 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -124.59 159.91 29.62 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.508 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.537 ' CG2' HD11 ' A' ' 38' ' ' ILE . 5.4 t -130.14 89.5 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.286 -0.884 . . . . 0.0 109.45 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.781 HD23 ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.92 156.72 17.47 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.239 -0.913 . . . . 0.0 109.372 179.974 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.937 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -77.84 149.13 34.4 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.196 -0.94 . . . . 0.0 109.538 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 1.3 mt-10 -92.27 12.02 23.84 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.229 -0.92 . . . . 0.0 109.449 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.456 ' HA ' ' HG3' ' A' ' 31' ' ' ARG . . . 179.13 150.07 0.28 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.243 -0.911 . . . . 0.0 109.493 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -55.35 170.93 0.2 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.216 -0.928 . . . . 0.0 109.32 -179.97 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.601 ' O ' HG22 ' A' ' 29' ' ' VAL . . . 154.74 -153.88 25.12 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 52.4 t -138.75 127.0 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.247 -1.149 . . . . 0.0 109.442 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.501 HD13 ' CD1' ' A' ' 75' ' ' LEU . 14.9 mm -62.25 158.15 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.213 -0.929 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.418 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -97.37 -69.56 0.75 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.238 -0.914 . . . . 0.0 109.468 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.528 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 2.9 pt-20 -174.76 142.44 0.7 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.255 -0.903 . . . . 0.0 109.453 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.673 HD12 ' CH2' ' A' ' 21' ' ' TRP . 15.7 mm -93.86 138.05 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.208 -0.933 . . . . 0.0 109.498 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.7 t -90.56 -57.71 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.275 -0.891 . . . . 0.0 109.532 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.524 ' CE ' ' HA ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -89.93 163.22 15.06 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.17 -0.956 . . . . 0.0 109.439 -179.964 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 10.3 m120 -102.56 156.49 17.58 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 109.53 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.522 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.2 OUTLIER -66.49 160.1 25.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.245 -0.909 . . . . 0.0 109.432 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 81.75 -7.35 62.55 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.525 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -100.81 171.02 7.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -1.165 . . . . 0.0 109.333 179.997 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.9 t -92.4 153.77 18.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.546 -0.722 . . . . 0.0 109.441 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.453 ' HA ' ' OE1' ' A' ' 70' ' ' GLU . 18.0 m -129.0 -174.66 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.233 -0.917 . . . . 0.0 109.55 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -128.98 170.88 12.91 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.283 -0.886 . . . . 0.0 109.432 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.438 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 3.9 t -72.22 99.7 2.42 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.872 . . . . 0.0 109.474 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 109.51 14.86 13.28 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.584 ' OE2' HD23 ' A' ' 72' ' ' LEU . 3.9 tt0 -75.45 119.29 19.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -1.127 . . . . 0.0 109.448 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.518 ' CD1' ' OD1' ' A' ' 3' ' ' ASP . 68.4 tp -69.72 108.73 4.03 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.266 -0.896 . . . . 0.0 109.47 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.584 HD23 ' OE2' ' A' ' 70' ' ' GLU . 16.6 mt -88.39 -13.92 39.35 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.24 -0.913 . . . . 0.0 109.514 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 161.45 178.46 35.41 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.456 ' HG3' HD11 ' A' ' 71' ' ' LEU . 5.1 mtpt -137.91 144.17 41.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.22 -1.164 . . . . 0.0 109.444 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.501 ' CD1' HD13 ' A' ' 55' ' ' ILE . 17.1 tp -93.32 140.51 29.47 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.2 -0.937 . . . . 0.0 109.506 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.576 HG22 ' H ' ' A' ' 77' ' ' GLU . 14.8 m -112.85 171.94 7.23 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.576 ' H ' HG22 ' A' ' 76' ' ' THR . 3.0 mt-10 -74.23 -72.33 0.28 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.901 . . . . 0.0 109.425 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -139.44 -152.89 5.96 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.939 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.587 ' O ' HD13 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.587 HD13 ' O ' ' A' ' 1' ' ' ALA . 35.0 mm -145.9 99.11 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.29 -0.882 . . . . 0.0 109.517 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.56 ' OD2' HD12 ' A' ' 71' ' ' LEU . 62.8 t0 -80.71 132.12 35.52 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.214 -0.929 . . . . 0.0 109.495 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 40.9 mt -104.23 99.1 7.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.327 -0.858 . . . . 0.0 109.481 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.43 ' HA ' ' HA ' ' A' ' 71' ' ' LEU . 4.2 mttp -106.66 177.03 4.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.244 -0.91 . . . . 0.0 109.508 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.711 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -77.98 165.8 48.06 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.264 -0.897 . . . . 0.0 109.493 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.711 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.3 Cg_endo -77.6 157.11 32.17 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.615 2.21 . . . . 0.0 110.44 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.3 t -62.77 146.63 52.02 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.848 . . . . 0.0 109.495 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.528 ' CZ ' ' HG2' ' A' ' 7' ' ' PRO . 24.0 m-85 -129.99 91.37 39.77 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.224 -0.922 . . . . 0.0 109.477 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.5 Cg_endo -78.03 -162.94 0.19 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.63 2.22 . . . . 0.0 110.445 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.429 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.0 OUTLIER -51.81 -54.83 24.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.293 -0.879 . . . . 0.0 109.446 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.429 ' C ' ' O ' ' A' ' 11' ' ' GLU . 34.4 t -42.94 -60.23 1.69 Allowed 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.324 -0.86 . . . . 0.0 109.626 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.472 HG22 ' O ' ' A' ' 15' ' ' ASP . 27.0 mt -102.47 119.03 50.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.215 -0.928 . . . . 0.0 109.56 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -96.88 -0.25 48.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.922 . . . . 0.0 109.549 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.472 ' O ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -173.53 -173.59 0.9 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.244 -0.91 . . . . 0.0 109.401 -179.976 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.885 ' O ' HG23 ' A' ' 65' ' ' THR . . . -154.6 170.79 32.99 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.684 HG23 ' O ' ' A' ' 64' ' ' ASP . 21.8 m -150.04 118.59 6.51 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.312 -1.111 . . . . 0.0 109.414 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.594 HG12 ' N ' ' A' ' 19' ' ' ALA . 42.8 t -45.25 168.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.204 -0.935 . . . . 0.0 109.506 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.594 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -113.65 -70.68 0.79 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.185 -0.947 . . . . 0.0 109.574 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.437 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 17.1 m -158.56 134.77 9.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.171 -0.955 . . . . 0.0 109.608 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.592 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 31.4 m95 -89.86 84.77 6.26 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.269 -0.894 . . . . 0.0 109.559 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.825 ' CE1' HD21 ' A' ' 34' ' ' LEU . 2.7 m80 -42.69 -70.41 0.11 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.37 -0.831 . . . . 0.0 109.48 -179.763 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -101.11 -172.11 2.11 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.223 -0.923 . . . . 0.0 109.534 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 4.0 mttt -125.92 167.41 16.92 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.264 -0.897 . . . . 0.0 109.441 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.986 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.0 Cg_endo -76.93 131.22 11.95 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.608 2.205 . . . . 0.0 110.49 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.45 -12.48 18.8 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -89.8 -174.33 4.24 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.3 -1.118 . . . . 0.0 109.398 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.7 140.31 42.42 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.288 -0.883 . . . . 0.0 109.456 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 1.039 HG21 HD11 ' A' ' 55' ' ' ILE . 47.3 t -128.21 161.68 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.431 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.496 ' N ' HG12 ' A' ' 29' ' ' VAL . 3.7 tptt -153.28 137.5 16.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.207 -0.933 . . . . 0.0 109.491 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 30' ' ' LYS . 8.3 tmm_? -42.8 139.61 1.59 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.296 -0.877 . . . . 0.0 109.593 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.41 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 20.0 t70 68.05 49.0 0.9 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.349 -0.844 . . . . 0.0 109.469 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.424 ' O ' ' C ' ' A' ' 34' ' ' LEU . 1.6 tt0 -133.95 103.88 6.02 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.921 . . . . 0.0 109.426 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.825 HD21 ' CE1' ' A' ' 22' ' ' HIS . 38.4 tp -42.58 151.54 0.12 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.357 -0.839 . . . . 0.0 109.632 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.98 HD11 ' HB2' ' A' ' 49' ' ' ALA . 5.1 mt -142.04 -40.18 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.166 -0.959 . . . . 0.0 109.542 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.512 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 12.2 p -151.92 128.2 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.489 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 12.9 m-20 -89.89 164.24 14.67 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.403 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.821 ' O ' HG23 ' A' ' 44' ' ' VAL . 80.8 mt -136.69 151.97 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.223 -0.923 . . . . 0.0 109.522 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 17' ' ' THR . 4.6 pt-20 -140.68 135.11 31.3 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.265 -0.897 . . . . 0.0 109.425 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.564 HG22 ' O ' ' A' ' 43' ' ' VAL . 5.3 t -128.31 -162.33 1.17 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.336 -0.853 . . . . 0.0 109.35 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.508 ' N ' HG23 ' A' ' 40' ' ' THR . 11.8 t70 -42.43 -61.85 1.11 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.325 -0.859 . . . . 0.0 109.697 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LYS . . . . . 0.454 ' HG3' ' O ' ' A' ' 41' ' ' ASP . 5.9 mtpm? -149.47 45.09 0.96 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.225 -0.922 . . . . 0.0 109.515 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.564 ' O ' HG22 ' A' ' 40' ' ' THR . 54.5 t -154.69 108.25 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.195 -0.94 . . . . 0.0 109.489 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.821 HG23 ' O ' ' A' ' 38' ' ' ILE . 3.8 p -96.43 140.01 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.343 -0.848 . . . . 0.0 109.396 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -131.77 134.23 45.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.261 -0.9 . . . . 0.0 109.499 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.543 ' HB3' HD13 ' A' ' 34' ' ' LEU . 25.2 mt-10 -89.64 151.49 21.86 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.296 -0.878 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.512 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 91.8 t -123.0 103.62 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.173 -0.954 . . . . 0.0 109.507 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.494 ' H ' HD12 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -102.78 171.2 7.55 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.276 -0.89 . . . . 0.0 109.37 179.966 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.98 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.98 134.81 34.22 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.255 -0.903 . . . . 0.0 109.464 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.543 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.9 OUTLIER -84.81 10.95 10.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.156 -0.965 . . . . 0.0 109.426 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.543 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 173.38 154.39 0.1 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 109.42 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.513 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -69.07 171.03 8.83 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.277 -179.939 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.513 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.22 -146.02 15.15 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.9 t -138.68 126.9 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -1.158 . . . . 0.0 109.492 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 1.039 HD11 HG21 ' A' ' 29' ' ' VAL . 1.1 mm -74.6 171.91 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.203 -0.936 . . . . 0.0 109.422 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.448 ' CB ' ' HG3' ' A' ' 74' ' ' LYS . . . -104.33 -63.85 1.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.227 -0.921 . . . . 0.0 109.509 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.528 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -179.29 158.39 0.87 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.246 -0.909 . . . . 0.0 109.5 180.0 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.986 HD11 ' HD3' ' A' ' 25' ' ' PRO . 1.5 mp -93.52 146.2 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.211 -0.93 . . . . 0.0 109.468 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.865 HG23 ' O ' ' A' ' 72' ' ' LEU . 49.5 t -89.9 -52.46 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.226 -0.921 . . . . 0.0 109.479 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.466 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 2.1 tptp -108.29 157.37 18.42 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.274 -0.891 . . . . 0.0 109.397 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 50.2 m-80 -88.82 156.18 19.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.482 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.492 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 2.4 pp20? -61.09 145.91 49.22 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.257 -0.902 . . . . 0.0 109.384 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 94.96 -12.15 68.79 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.684 ' O ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -89.04 170.9 10.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.273 -1.133 . . . . 0.0 109.325 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.885 HG23 ' O ' ' A' ' 16' ' ' GLY . 62.7 m -111.96 146.92 36.96 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.489 -0.757 . . . . 0.0 109.467 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.494 ' HB ' ' CB ' ' A' ' 70' ' ' GLU . 27.3 m -129.62 -176.21 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.8 mp -116.63 173.9 6.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.177 -0.952 . . . . 0.0 109.469 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -63.85 125.74 25.35 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.897 . . . . 0.0 109.384 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 86.85 19.6 55.73 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.494 ' CB ' ' HB ' ' A' ' 66' ' ' VAL . 4.6 tp10 -82.18 112.82 19.56 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -1.134 . . . . 0.0 109.465 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.734 HD23 ' C ' ' A' ' 71' ' ' LEU . 7.5 tt -78.26 128.42 33.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.307 -0.87 . . . . 0.0 109.491 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.865 ' O ' HG23 ' A' ' 59' ' ' VAL . 13.3 mt -97.05 -70.51 0.72 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.421 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -128.14 163.64 21.67 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.448 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 2.2 ptmt -126.33 147.97 49.64 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.27 -1.135 . . . . 0.0 109.493 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.707 HD23 ' O ' ' A' ' 76' ' ' THR . 6.0 tt -90.56 166.45 13.2 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.278 -0.889 . . . . 0.0 109.488 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.707 ' O ' HD23 ' A' ' 75' ' ' LEU . 3.0 t -89.35 -157.74 0.47 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.268 -0.895 . . . . 0.0 109.735 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.671 ' N ' HG23 ' A' ' 76' ' ' THR . 4.4 mm-40 -79.61 163.17 24.82 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 121.804 -0.56 . . . . 0.0 109.544 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -136.62 -110.27 1.01 Allowed Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 CA-C-O 117.967 -1.463 . . . . 0.0 109.523 179.93 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.777 ' HB1' ' O ' ' A' ' 75' ' ' LEU . . . . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.473 HD12 HD22 ' A' ' 75' ' ' LEU . 15.4 mt -141.98 104.8 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.187 -0.946 . . . . 0.0 109.482 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -67.64 125.9 27.65 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.461 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.9 mm -104.61 120.64 55.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.262 -0.899 . . . . 0.0 109.424 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -136.83 176.23 8.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.169 -0.957 . . . . 0.0 109.469 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.428 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -80.44 157.78 72.26 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.282 -0.886 . . . . 0.0 109.439 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.428 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.6 Cg_endo -78.01 156.32 30.33 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.661 2.241 . . . . 0.0 110.48 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 77.0 m -68.53 119.36 12.86 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.301 -0.874 . . . . 0.0 109.478 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -73.85 154.58 89.06 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.294 -0.878 . . . . 0.0 109.539 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.55 ' HG2' HD12 ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.09 -173.93 2.03 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.677 2.252 . . . . 0.0 110.433 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.7 mp0 -73.15 -49.34 28.76 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.461 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.2 OUTLIER -42.82 -29.05 0.29 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.371 -0.831 . . . . 0.0 109.589 -179.87 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.692 HG22 ' H ' ' A' ' 15' ' ' ASP . 4.1 mt -121.17 146.04 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -0.895 . . . . 0.0 109.496 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -114.31 1.76 14.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.247 -0.908 . . . . 0.0 109.611 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.692 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -178.35 -171.41 0.26 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.18 -0.95 . . . . 0.0 109.457 -179.984 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.38 -167.44 17.69 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.852 HG23 ' O ' ' A' ' 64' ' ' ASP . 29.4 m -148.13 130.88 16.01 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -1.122 . . . . 0.0 109.468 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.548 HG12 ' N ' ' A' ' 19' ' ' ALA . 46.6 t -44.56 165.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.248 -0.907 . . . . 0.0 109.49 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.568 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -114.06 -73.12 0.67 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.301 -0.874 . . . . 0.0 109.53 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 38.5 m -160.01 132.19 6.32 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.205 -0.934 . . . . 0.0 109.518 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.667 ' CH2' HD12 ' A' ' 58' ' ' ILE . 36.0 m95 -89.84 81.78 6.3 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.259 -0.901 . . . . 0.0 109.517 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.776 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.1 m80 -42.87 -61.54 1.25 Allowed 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.305 -0.872 . . . . 0.0 109.42 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.478 ' O ' ' HE3' ' A' ' 24' ' ' LYS . 1.2 mtpt -96.89 -177.36 3.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.918 . . . . 0.0 109.584 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.478 ' HE3' ' O ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -120.95 167.72 12.44 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.248 -0.908 . . . . 0.0 109.516 179.989 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.504 ' HA ' ' CG2' ' A' ' 55' ' ' ILE . 35.1 Cg_endo -76.96 90.21 1.25 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.694 2.263 . . . . 0.0 110.395 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 138.59 45.03 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.46 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 2.2 pp20? -139.35 -173.37 3.58 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.317 -1.108 . . . . 0.0 109.462 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.46 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -90.68 128.78 36.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.206 -0.934 . . . . 0.0 109.474 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 12.4 p -127.11 155.15 38.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.215 -0.928 . . . . 0.0 109.528 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.409 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -134.63 133.72 40.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -0.949 . . . . 0.0 109.502 -179.989 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.506 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.78 143.26 0.73 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.288 -0.883 . . . . 0.0 109.658 -179.969 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.506 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 8.2 t70 75.51 41.59 0.26 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.262 -0.898 . . . . 0.0 109.452 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.445 ' O ' HG12 ' A' ' 35' ' ' ILE . 3.5 tt0 -141.83 121.75 13.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.229 -0.919 . . . . 0.0 109.477 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.835 ' O ' HD13 ' A' ' 35' ' ' ILE . 59.6 tp -42.84 156.1 0.05 OUTLIER 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.328 -0.858 . . . . 0.0 109.644 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.835 HD13 ' O ' ' A' ' 34' ' ' LEU . 15.7 mm -146.12 -39.12 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.276 -0.89 . . . . 0.0 109.505 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.516 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -159.79 141.95 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -0.891 . . . . 0.0 109.369 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.568 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 1.2 m-20 -104.93 146.37 29.12 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.251 -0.906 . . . . 0.0 109.465 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.452 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 57.2 mt -107.13 142.46 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.175 -0.953 . . . . 0.0 109.514 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.515 ' CB ' ' O ' ' A' ' 17' ' ' THR . 1.4 tt0 -105.35 129.21 53.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.209 -0.932 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -115.73 171.61 7.65 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.238 -0.914 . . . . 0.0 109.49 -179.948 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 40' ' ' THR . 12.7 t0 -42.87 -51.37 5.53 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.321 -0.862 . . . . 0.0 109.618 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LYS . . . . . 0.431 ' HG2' ' O ' ' A' ' 41' ' ' ASP . 7.8 mmtt -148.37 30.66 0.84 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.271 -0.893 . . . . 0.0 109.443 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.412 ' O ' ' OG1' ' A' ' 40' ' ' THR . 2.0 t -139.6 134.49 38.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.939 . . . . 0.0 109.436 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 8.1 p -98.76 136.86 28.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.255 -0.903 . . . . 0.0 109.474 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' MET . . . . . 0.452 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 0.9 OUTLIER -125.17 165.83 17.54 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.15 -0.969 . . . . 0.0 109.473 -179.983 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -129.26 161.91 29.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.501 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.516 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 78.7 t -140.73 108.89 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.214 -0.929 . . . . 0.0 109.501 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.49 ' H ' HD12 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -103.14 155.74 18.19 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.339 -0.851 . . . . 0.0 109.362 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -70.58 144.78 51.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.898 . . . . 0.0 109.521 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.422 ' C ' ' HG3' ' A' ' 31' ' ' ARG . 0.6 OUTLIER -101.87 11.23 38.97 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.276 -0.89 . . . . 0.0 109.475 179.988 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -178.57 138.2 0.17 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.305 -0.872 . . . . 0.0 109.428 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.504 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.2 OUTLIER -58.5 170.95 0.67 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.245 -0.91 . . . . 0.0 109.343 -179.977 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.504 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 145.65 -162.39 28.26 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.475 ' O ' HG22 ' A' ' 76' ' ' THR . 48.1 t -128.94 124.97 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.328 -1.101 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.577 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.0 mt -59.41 165.23 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.278 -0.889 . . . . 0.0 109.568 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.577 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -103.43 -66.08 0.97 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.188 -0.945 . . . . 0.0 109.518 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.476 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -167.75 139.11 2.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.206 -0.934 . . . . 0.0 109.55 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.667 HD12 ' CH2' ' A' ' 21' ' ' TRP . 23.9 mm -95.09 121.69 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.326 -0.859 . . . . 0.0 109.508 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.4 t -89.94 -27.99 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.19 -0.944 . . . . 0.0 109.428 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.502 ' HG2' ' CG1' ' A' ' 66' ' ' VAL . 0.0 OUTLIER -91.08 134.21 34.7 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.288 -0.882 . . . . 0.0 109.466 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.473 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 13.7 m120 -98.71 165.76 11.64 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.286 -0.884 . . . . 0.0 109.519 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -68.85 141.12 55.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 80.52 14.92 79.26 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.852 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -101.73 170.88 7.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -1.141 . . . . 0.0 109.277 -179.972 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 23.3 m -97.3 141.76 30.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.493 -0.754 . . . . 0.0 109.416 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.502 ' CG1' ' HG2' ' A' ' 60' ' ' LYS . 2.3 m -126.98 139.04 53.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.469 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.04 167.53 10.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.261 -0.899 . . . . 0.0 109.486 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 36.2 t -57.17 128.82 38.9 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 73.56 23.31 77.22 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -79.19 119.25 22.01 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.247 -1.149 . . . . 0.0 109.491 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.506 HD23 ' C ' ' A' ' 71' ' ' LEU . 10.2 tt -67.37 138.31 56.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.288 -0.882 . . . . 0.0 109.543 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -118.85 -24.86 6.47 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.293 -0.879 . . . . 0.0 109.428 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.64 159.67 26.6 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 8.3 mtpt -122.31 133.39 54.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.204 -1.174 . . . . 0.0 109.446 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.777 ' O ' ' HB1' ' A' ' 1' ' ' ALA . 0.6 OUTLIER -92.1 147.57 22.84 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -0.948 . . . . 0.0 109.512 179.99 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.675 HG23 ' N ' ' A' ' 77' ' ' GLU . 3.0 t -97.72 -157.77 0.62 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.272 -0.893 . . . . 0.0 109.724 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.675 ' N ' HG23 ' A' ' 76' ' ' THR . 64.7 mm-40 -81.57 177.18 9.09 Favored 'General case' 0 C--N 1.295 -1.774 0 O-C-N 121.728 -0.608 . . . . 0.0 109.508 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.405 ' HA2' ' HA2' ' A' ' 53' ' ' GLY . . . -78.61 -51.25 5.64 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.223 0 CA-C-O 117.997 -1.446 . . . . 0.0 109.602 -179.931 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 61.7 mt -133.92 93.2 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.32 -0.863 . . . . 0.0 109.473 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 74' ' ' LYS . 15.9 t70 -76.15 162.73 27.75 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.228 -0.92 . . . . 0.0 109.441 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mt -135.39 125.03 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.269 -0.894 . . . . 0.0 109.452 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.0 pttm -133.04 172.98 11.91 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.243 -0.911 . . . . 0.0 109.462 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.565 ' HB3' ' O ' ' A' ' 67' ' ' LEU . . . -81.46 147.72 60.63 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.144 -0.972 . . . . 0.0 109.447 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.03 155.11 29.79 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.649 2.233 . . . . 0.0 110.455 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.411 ' HA ' ' HB2' ' A' ' 68' ' ' SER . 1.3 m -71.11 132.49 45.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.414 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.404 ' HB3' ' HB ' ' A' ' 13' ' ' ILE . 63.0 m-85 -99.34 153.6 37.7 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.426 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.4 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -77.99 -159.65 0.1 Allowed 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.632 2.221 . . . . 0.0 110.454 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.0 OUTLIER -77.18 -55.6 5.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.464 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 11' ' ' GLU . 18.6 t -42.72 -50.3 5.55 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.278 -0.889 . . . . 0.0 109.617 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.49 HG22 ' H ' ' A' ' 15' ' ' ASP . 14.8 mt -90.11 143.45 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.418 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.517 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -115.1 -1.76 12.94 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.517 ' CB ' ' O ' ' A' ' 14' ' ' ALA . 0.5 OUTLIER 163.89 -169.09 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.212 -0.93 . . . . 0.0 109.464 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.673 ' O ' HG23 ' A' ' 65' ' ' THR . . . -142.97 -163.13 9.6 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.625 HG23 ' O ' ' A' ' 64' ' ' ASP . 17.0 m -150.0 133.07 16.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -1.114 . . . . 0.0 109.426 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.483 ' O ' ' HG3' ' A' ' 39' ' ' GLU . 39.4 t -49.08 159.73 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.216 -0.928 . . . . 0.0 109.419 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.519 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -104.35 -77.0 0.58 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.218 -0.926 . . . . 0.0 109.517 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 17.8 m -159.97 130.48 5.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.555 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.637 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.6 m95 -89.95 85.54 6.38 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.207 -0.933 . . . . 0.0 109.509 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.798 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.1 m80 -43.18 -67.28 0.29 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.346 -0.846 . . . . 0.0 109.419 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -93.81 -172.33 2.84 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.216 -0.927 . . . . 0.0 109.468 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.425 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -125.23 168.23 14.14 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.287 -0.883 . . . . 0.0 109.392 -179.894 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.498 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.3 Cg_endo -76.59 127.75 9.81 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.733 2.288 . . . . 0.0 110.373 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.65 18.99 9.01 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 13.8 mm-40 -119.69 -176.98 3.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.306 -1.114 . . . . 0.0 109.486 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -92.85 145.93 24.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.267 -0.896 . . . . 0.0 109.444 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 69.0 t -139.37 151.33 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -0.896 . . . . 0.0 109.532 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 11.0 mptt -126.64 140.11 52.66 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.228 -0.92 . . . . 0.0 109.463 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.434 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.7 OUTLIER -42.71 153.1 0.08 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.383 -0.823 . . . . 0.0 109.704 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.445 ' HA ' HD23 ' A' ' 48' ' ' LEU . 25.2 t0 63.19 41.8 7.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.927 . . . . 0.0 109.468 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.423 ' C ' ' HG ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -135.98 116.05 13.33 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.291 -0.88 . . . . 0.0 109.51 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.798 HD21 ' NE2' ' A' ' 22' ' ' HIS . 37.5 tp -43.1 142.9 0.88 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.275 -0.891 . . . . 0.0 109.556 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.798 HD11 ' HB2' ' A' ' 49' ' ' ALA . 10.9 mt -125.92 -46.08 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.272 -0.893 . . . . 0.0 109.585 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.405 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -162.8 147.5 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.277 -0.889 . . . . 0.0 109.528 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.519 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 1.2 m-20 -105.32 160.25 15.26 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.347 -0.845 . . . . 0.0 109.428 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.531 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 1.8 tt -129.31 148.54 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -0.933 . . . . 0.0 109.449 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.483 ' HG3' ' O ' ' A' ' 18' ' ' VAL . 4.8 mm-40 -106.96 150.33 26.58 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.305 -0.872 . . . . 0.0 109.481 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.404 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -135.47 -175.38 3.92 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 40' ' ' THR . 7.8 t0 -42.78 -68.9 0.16 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.307 -0.871 . . . . 0.0 109.643 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.7 mtmm -135.39 36.73 2.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.172 -0.955 . . . . 0.0 109.493 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 67.9 t -152.0 153.44 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.34 -0.85 . . . . 0.0 109.472 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.462 ' O ' HG13 ' A' ' 44' ' ' VAL . 11.7 p -124.2 131.04 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' MET . . . . . 0.531 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 0.0 OUTLIER -107.89 177.2 4.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.181 -0.949 . . . . 0.0 109.502 179.98 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -130.28 151.3 50.94 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.223 -0.923 . . . . 0.0 109.452 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.405 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 44.3 t -122.75 98.11 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.45 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.536 HD12 ' HA ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -90.99 168.72 11.45 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.195 -0.941 . . . . 0.0 109.487 -179.998 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.798 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -85.1 136.91 33.35 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.223 -0.923 . . . . 0.0 109.402 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.533 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 2.2 mm-40 -98.53 14.64 27.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.545 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.533 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 173.54 134.78 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.268 -0.895 . . . . 0.0 109.469 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.502 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.25 171.02 0.12 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -0.894 . . . . 0.0 109.3 179.999 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.502 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 142.77 -154.04 25.02 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.612 ' H ' HG22 ' A' ' 76' ' ' THR . 66.2 t -136.65 134.63 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.274 -1.133 . . . . 0.0 109.412 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.618 HD13 HD12 ' A' ' 75' ' ' LEU . 15.3 mm -61.85 168.84 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.218 -0.926 . . . . 0.0 109.516 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.574 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -101.42 -62.83 1.2 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.914 . . . . 0.0 109.53 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.498 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.7 OUTLIER -177.89 131.47 0.15 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.259 -0.9 . . . . 0.0 109.462 179.95 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.637 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 21.5 mm -90.09 125.63 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.435 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 42.2 t -89.93 -33.13 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.291 -0.88 . . . . 0.0 109.471 -179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.492 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 1.5 mptt -94.38 143.66 26.22 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.282 -0.886 . . . . 0.0 109.488 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.459 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 65.3 m-80 -111.0 164.74 12.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.248 -0.908 . . . . 0.0 109.526 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -59.06 146.43 38.47 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.493 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 86.75 7.74 77.82 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.625 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -105.35 170.71 7.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.221 -1.164 . . . . 0.0 109.411 -179.98 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.673 HG23 ' O ' ' A' ' 16' ' ' GLY . 11.9 m -107.77 145.69 33.2 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.536 -0.728 . . . . 0.0 109.458 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 4.9 m -114.98 137.37 48.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.471 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.565 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -106.08 174.53 5.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.192 -0.943 . . . . 0.0 109.522 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.411 ' HB2' ' HA ' ' A' ' 8' ' ' THR . 1.5 t -62.03 129.13 39.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.234 -0.917 . . . . 0.0 109.497 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.98 21.63 73.53 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -79.82 104.34 10.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.255 -1.144 . . . . 0.0 109.52 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.478 HD23 ' C ' ' A' ' 71' ' ' LEU . 9.1 tt -78.1 121.9 24.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.243 -0.911 . . . . 0.0 109.458 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.5 mp -92.69 -69.05 0.76 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.352 -0.843 . . . . 0.0 109.38 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -140.74 -175.82 14.87 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.43 ' HA ' ' HA ' ' A' ' 3' ' ' ASP . 0.3 OUTLIER -143.69 142.0 30.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.297 -1.119 . . . . 0.0 109.485 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.618 HD12 HD13 ' A' ' 55' ' ' ILE . 0.6 OUTLIER -90.51 144.52 25.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.886 . . . . 0.0 109.436 -179.96 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.67 HG23 ' N ' ' A' ' 77' ' ' GLU . 3.0 t -81.78 -157.83 0.21 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.74 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.67 ' N ' HG23 ' A' ' 76' ' ' THR . 79.7 mm-40 -57.94 174.09 0.28 Allowed 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -173.78 -62.82 0.05 OUTLIER Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.282 0 CA-C-O 118.02 -1.434 . . . . 0.0 109.565 179.966 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.433 ' C ' HD12 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.777 HD13 ' CD2' ' A' ' 75' ' ' LEU . 3.2 mp -148.13 88.05 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.326 -0.859 . . . . 0.0 109.476 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.997 ' OD1' HD11 ' A' ' 71' ' ' LEU . 22.9 t70 -82.28 154.12 25.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.204 -0.935 . . . . 0.0 109.496 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.2 mt -130.86 122.34 51.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.883 . . . . 0.0 109.432 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.473 ' HD2' ' OD2' ' A' ' 3' ' ' ASP . 0.0 OUTLIER -144.89 164.85 29.82 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.234 -0.916 . . . . 0.0 109.464 179.958 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.404 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -67.34 148.13 98.77 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.291 -0.881 . . . . 0.0 109.495 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 35.9 Cg_endo -78.02 -172.2 1.42 Allowed 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.628 2.219 . . . . 0.0 110.417 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -97.86 96.52 8.26 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.235 -0.915 . . . . 0.0 109.449 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.54 ' CZ ' ' HA3' ' A' ' 16' ' ' GLY . 19.5 m-85 -59.81 149.34 72.98 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.245 -0.909 . . . . 0.0 109.493 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.04 -166.25 0.39 Allowed 'Trans proline' 0 C--N 1.308 -1.556 0 C-N-CA 122.61 2.207 . . . . 0.0 110.494 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' A' ' 12' ' ' SER . 4.8 tt0 -72.78 -42.43 63.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.231 -0.918 . . . . 0.0 109.484 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 11' ' ' GLU . 2.5 t -42.88 -64.54 0.61 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.298 -0.876 . . . . 0.0 109.554 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.584 HG22 ' H ' ' A' ' 15' ' ' ASP . 15.1 mm -104.95 145.86 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.216 -0.928 . . . . 0.0 109.445 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -114.36 21.77 14.33 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.294 -0.879 . . . . 0.0 109.485 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.584 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.3 OUTLIER -161.74 -173.11 3.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.135 -0.978 . . . . 0.0 109.572 -179.997 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.54 ' HA3' ' CZ ' ' A' ' 9' ' ' PHE . . . -150.56 -176.56 23.65 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.518 HG23 ' O ' ' A' ' 64' ' ' ASP . 25.8 m -150.06 122.09 8.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.176 -1.19 . . . . 0.0 109.5 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.581 HG12 ' N ' ' A' ' 19' ' ' ALA . 41.4 t -45.83 168.72 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.251 -0.906 . . . . 0.0 109.353 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.581 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -111.13 -74.34 0.65 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.117 -0.989 . . . . 0.0 109.589 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.403 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 16.2 m -160.05 127.78 4.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.254 -0.904 . . . . 0.0 109.605 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.705 ' CH2' HD12 ' A' ' 58' ' ' ILE . 36.7 m95 -89.91 83.4 6.15 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.26 -0.9 . . . . 0.0 109.461 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.604 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -42.95 -70.18 0.11 Allowed 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.322 -0.861 . . . . 0.0 109.424 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -93.67 177.98 5.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.25 -0.906 . . . . 0.0 109.678 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.455 ' HD3' ' HD2' ' A' ' 25' ' ' PRO . 5.4 mttp -121.39 169.48 9.06 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.283 -0.886 . . . . 0.0 109.445 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.529 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.3 Cg_endo -76.15 119.7 5.42 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.657 2.238 . . . . 0.0 110.463 179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 122.68 10.13 6.04 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.444 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 1.1 pp20? -112.4 173.88 6.15 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -1.129 . . . . 0.0 109.507 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.444 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -82.5 144.28 30.53 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.922 . . . . 0.0 109.511 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.8 t -112.31 156.85 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.287 -0.883 . . . . 0.0 109.47 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.1 OUTLIER -142.96 135.88 27.96 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.274 -0.892 . . . . 0.0 109.493 179.957 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.466 ' HG2' ' N ' ' A' ' 32' ' ' ASP . 2.7 ttm180 -42.8 141.13 1.14 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.337 -0.852 . . . . 0.0 109.651 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.466 ' N ' ' HG2' ' A' ' 31' ' ' ARG . 20.8 t70 69.71 49.66 0.53 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.289 -0.882 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' A' ' 34' ' ' LEU . 3.0 tt0 -138.5 106.89 5.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 0.0 109.429 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 40.1 tp -43.46 165.14 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.291 -0.88 . . . . 0.0 109.472 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.791 HD11 ' HB2' ' A' ' 49' ' ' ALA . 91.3 mt -134.26 -47.13 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.15 -0.969 . . . . 0.0 109.637 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.579 ' HB ' ' CE3' ' A' ' 21' ' ' TRP . 2.6 p -171.99 144.01 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.158 -0.964 . . . . 0.0 109.52 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.526 ' C ' ' HB3' ' A' ' 19' ' ' ALA . 1.3 m-20 -100.19 167.03 10.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.247 -0.908 . . . . 0.0 109.458 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.473 HG22 ' O ' ' A' ' 45' ' ' MET . 1.2 tt -142.63 156.33 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.253 -0.904 . . . . 0.0 109.539 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.58 122.14 38.99 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.268 -0.895 . . . . 0.0 109.47 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.418 ' O ' ' C ' ' A' ' 41' ' ' ASP . 44.4 p -101.92 -151.91 0.43 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 109.475 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.478 ' HA ' HG13 ' A' ' 13' ' ' ILE . 43.1 t0 -42.71 -62.82 0.9 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.277 -0.89 . . . . 0.0 109.613 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.7 mttt -149.48 17.78 0.92 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.212 -0.93 . . . . 0.0 109.474 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.469 HG12 ' H ' ' A' ' 44' ' ' VAL . 1.9 t -119.34 172.21 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.895 . . . . 0.0 109.503 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.537 ' O ' HG13 ' A' ' 44' ' ' VAL . 9.6 p -129.62 126.7 63.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.3 -0.875 . . . . 0.0 109.431 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' MET . . . . . 0.473 ' O ' HG22 ' A' ' 38' ' ' ILE . 1.3 mtt -113.83 124.43 52.21 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.186 -0.946 . . . . 0.0 109.484 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.6 147.32 26.46 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.334 -0.854 . . . . 0.0 109.443 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.455 ' O ' ' HB ' ' A' ' 35' ' ' ILE . 55.9 t -116.06 103.87 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.184 -0.947 . . . . 0.0 109.504 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.403 HD21 ' N ' ' A' ' 33' ' ' GLU . 0.3 OUTLIER -105.03 163.85 12.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.915 . . . . 0.0 109.396 -179.89 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.791 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.88 164.83 18.16 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.159 -0.963 . . . . 0.0 109.456 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.698 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -105.82 3.67 28.97 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.542 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.698 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 163.94 167.54 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.184 -0.948 . . . . 0.0 109.455 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.502 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -49.96 170.98 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.291 -0.881 . . . . 0.0 109.313 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.502 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.93 -164.01 30.67 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.818 ' O ' HG22 ' A' ' 76' ' ' THR . 48.7 t -136.85 125.35 34.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -1.142 . . . . 0.0 109.427 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.875 HD13 ' CD1' ' A' ' 75' ' ' LEU . 15.3 mm -61.68 160.08 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.294 -0.879 . . . . 0.0 109.448 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.448 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -100.51 -66.31 0.92 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.306 -0.871 . . . . 0.0 109.492 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.529 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 33.4 tt0 177.34 141.68 0.08 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.294 -0.879 . . . . 0.0 109.46 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.705 HD12 ' CH2' ' A' ' 21' ' ' TRP . 15.3 mm -91.42 158.28 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.273 -0.892 . . . . 0.0 109.449 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.823 HG23 ' O ' ' A' ' 72' ' ' LEU . 52.8 t -90.03 -67.52 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.261 -0.899 . . . . 0.0 109.342 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.483 ' HD3' ' CB ' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -101.1 174.99 5.75 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.254 -0.904 . . . . 0.0 109.399 179.926 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 7.6 m120 -95.87 155.43 16.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.931 . . . . 0.0 109.469 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.537 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -60.1 149.94 31.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.3 -0.875 . . . . 0.0 109.387 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 92.39 -12.62 69.25 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.518 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -87.3 170.94 10.99 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.295 -1.12 . . . . 0.0 109.286 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.499 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 99.0 m -100.73 135.41 42.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.519 -0.738 . . . . 0.0 109.461 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.665 ' O ' HD23 ' A' ' 67' ' ' LEU . 5.2 m -118.58 -176.8 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.448 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.665 HD23 ' O ' ' A' ' 66' ' ' VAL . 13.2 mt -121.45 162.38 20.56 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.248 -0.907 . . . . 0.0 109.441 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 t -64.25 122.54 16.88 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.238 -0.914 . . . . 0.0 109.494 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 91.31 10.16 62.53 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -84.98 112.56 20.7 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.191 -1.182 . . . . 0.0 109.447 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.997 HD11 ' OD1' ' A' ' 3' ' ' ASP . 1.2 tp -72.49 127.11 31.55 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.319 -0.863 . . . . 0.0 109.496 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.823 ' O ' HG23 ' A' ' 59' ' ' VAL . 77.0 mt -93.92 -68.05 0.82 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.302 -0.874 . . . . 0.0 109.435 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -136.39 178.8 18.52 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.53 ' CG ' HD21 ' A' ' 71' ' ' LEU . 1.5 mtmp? -145.94 151.74 38.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -1.162 . . . . 0.0 109.472 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.875 ' CD1' HD13 ' A' ' 55' ' ' ILE . 13.2 tp -99.05 152.37 19.92 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.224 -0.923 . . . . 0.0 109.474 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.818 HG22 ' O ' ' A' ' 54' ' ' VAL . 3.0 t -106.55 -157.75 0.63 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.286 -0.884 . . . . 0.0 109.677 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.674 ' N ' HG23 ' A' ' 76' ' ' THR . 2.5 mt-10 -84.8 -82.0 0.18 Allowed 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 71.71 117.82 0.05 OUTLIER Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 CA-C-O 118.02 -1.433 . . . . 0.0 109.552 -179.996 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 24.3 mm -114.62 102.93 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.231 -0.918 . . . . 0.0 109.483 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.519 ' OD2' ' CD1' ' A' ' 71' ' ' LEU . 43.7 t0 -71.84 142.28 49.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.16 -0.963 . . . . 0.0 109.463 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.414 HD12 HG23 ' A' ' 4' ' ' ILE . 4.9 mm -112.19 103.83 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.225 -0.922 . . . . 0.0 109.415 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.63 166.02 10.67 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.225 -0.922 . . . . 0.0 109.468 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.494 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -72.72 159.69 84.72 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.27 -0.894 . . . . 0.0 109.435 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.494 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.18 165.29 26.03 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.57 2.18 . . . . 0.0 110.368 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -90.28 108.8 19.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.472 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -60.86 149.24 81.23 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.442 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.08 -160.6 0.12 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.626 2.218 . . . . 0.0 110.369 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.3 OUTLIER -77.4 -58.88 3.03 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.247 -0.908 . . . . 0.0 109.497 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.2 t -42.93 -55.97 3.49 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.359 -0.838 . . . . 0.0 109.594 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.464 ' CD1' ' HB2' ' A' ' 41' ' ' ASP . 12.0 mm -95.1 136.55 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.275 -0.891 . . . . 0.0 109.444 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.78 14.48 10.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.216 -0.927 . . . . 0.0 109.436 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.415 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -156.53 -171.34 3.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.244 -0.91 . . . . 0.0 109.419 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.5 178.82 39.59 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.696 HG23 ' O ' ' A' ' 64' ' ' ASP . 17.8 m -150.03 119.25 6.79 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.23 -1.159 . . . . 0.0 109.367 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.503 HG12 ' N ' ' A' ' 19' ' ' ALA . 46.4 t -44.25 162.99 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.438 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.511 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -106.2 -75.47 0.63 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -0.906 . . . . 0.0 109.58 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.474 ' HA ' ' HB3' ' A' ' 62' ' ' GLU . 17.3 m -160.01 136.23 8.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.238 -0.914 . . . . 0.0 109.531 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.636 ' CH2' HD12 ' A' ' 58' ' ' ILE . 35.1 m95 -89.85 84.11 6.22 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.244 -0.91 . . . . 0.0 109.512 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.588 ' CE1' HD21 ' A' ' 34' ' ' LEU . 2.3 m80 -42.59 -55.64 3.44 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.44 -0.788 . . . . 0.0 109.531 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -109.82 158.71 17.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.098 -1.001 . . . . 0.0 109.612 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.426 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 4.9 mttt -97.22 167.99 10.99 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.275 -0.891 . . . . 0.0 109.428 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.485 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.68 101.84 1.55 Allowed 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.625 2.216 . . . . 0.0 110.446 179.869 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.5 -5.08 4.48 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.477 ' N ' ' CD ' ' A' ' 27' ' ' GLU . 1.3 mp0 -90.36 -172.66 3.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.18 -1.188 . . . . 0.0 109.458 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -97.3 149.83 21.63 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.301 -0.874 . . . . 0.0 109.438 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.6 m -135.5 161.55 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.214 -0.929 . . . . 0.0 109.514 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.8 tttt -129.29 135.29 48.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.24 -0.912 . . . . 0.0 109.52 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.433 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 9.2 ttt180 -42.86 140.34 1.39 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.325 -0.86 . . . . 0.0 109.613 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 18.0 t0 70.82 47.0 0.47 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.23 -0.919 . . . . 0.0 109.516 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.434 ' O ' ' O ' ' A' ' 34' ' ' LEU . 29.4 tt0 -140.12 121.99 15.51 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.279 -0.888 . . . . 0.0 109.558 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.588 HD21 ' CE1' ' A' ' 22' ' ' HIS . 47.4 tp -43.14 164.56 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.278 -0.889 . . . . 0.0 109.587 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.607 HG13 ' HB2' ' A' ' 49' ' ' ALA . 25.4 mm -145.27 -42.56 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.185 -0.947 . . . . 0.0 109.535 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.506 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 12.7 p -154.7 134.18 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.234 -0.916 . . . . 0.0 109.551 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.511 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 22.1 m-20 -100.39 159.45 15.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.267 -0.896 . . . . 0.0 109.463 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.519 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 7.3 tt -128.87 156.9 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.463 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.409 ' N ' HG12 ' A' ' 38' ' ' ILE . 1.3 tt0 -129.65 142.78 50.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.208 -0.933 . . . . 0.0 109.423 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.721 HG22 ' O ' ' A' ' 43' ' ' VAL . 5.5 t -132.01 -163.45 1.34 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.256 -0.903 . . . . 0.0 109.362 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.464 ' HB2' ' CD1' ' A' ' 13' ' ' ILE . 2.2 t0 -42.34 -68.0 0.22 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.317 -0.864 . . . . 0.0 109.782 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LYS . . . . . 0.512 ' O ' ' CG2' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -142.97 48.76 1.49 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.136 -0.978 . . . . 0.0 109.541 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.721 ' O ' HG22 ' A' ' 40' ' ' THR . 90.0 t -159.04 118.04 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.251 -0.906 . . . . 0.0 109.499 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.6 t -100.57 126.63 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.487 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' MET . . . . . 0.519 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 31.4 mtt -106.44 -179.65 4.0 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.456 ' HA ' ' OD1' ' A' ' 37' ' ' ASP . 3.7 mt-10 -133.52 146.96 51.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.249 -0.907 . . . . 0.0 109.44 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.506 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 36.2 t -117.76 106.68 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.492 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.515 HD12 ' HA ' ' A' ' 34' ' ' LEU . 0.6 OUTLIER -89.99 161.35 15.92 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.294 -0.879 . . . . 0.0 109.377 -179.964 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.607 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -81.03 160.91 24.42 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.44 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.701 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.5 OUTLIER -99.02 2.12 45.99 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.178 -0.951 . . . . 0.0 109.608 179.958 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.18 155.34 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.212 -0.93 . . . . 0.0 109.478 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.503 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -65.12 170.86 4.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.33 -0.856 . . . . 0.0 109.321 -179.995 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.503 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.45 -137.59 6.09 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.47 ' O ' ' CB ' ' A' ' 76' ' ' THR . 44.8 t -139.87 135.25 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.338 -1.095 . . . . 0.0 109.448 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.433 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 9.5 mm -75.74 153.9 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.332 -0.855 . . . . 0.0 109.457 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -87.94 -65.99 0.96 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.208 -0.933 . . . . 0.0 109.397 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.485 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -178.88 139.21 0.16 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -0.907 . . . . 0.0 109.399 179.949 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.636 HD12 ' CH2' ' A' ' 21' ' ' TRP . 23.1 mm -94.84 138.69 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.233 -0.917 . . . . 0.0 109.515 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 96.1 t -110.04 -14.52 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.309 -0.869 . . . . 0.0 109.425 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.711 ' HE2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -91.04 -172.4 3.32 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.286 -0.884 . . . . 0.0 109.39 179.995 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 46.2 m-80 -137.05 155.95 49.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.328 -0.858 . . . . 0.0 109.576 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.474 ' HB3' ' HA ' ' A' ' 20' ' ' THR . 0.5 OUTLIER -72.18 144.14 48.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.265 -0.897 . . . . 0.0 109.518 -179.939 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 57.54 19.56 34.84 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.696 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -99.4 170.95 8.27 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.262 -1.14 . . . . 0.0 109.352 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 11.5 t -88.17 154.25 20.6 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.525 -0.734 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.711 HG12 ' HE2' ' A' ' 60' ' ' LYS . 1.5 m -141.67 173.94 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.233 -0.917 . . . . 0.0 109.42 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.469 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.3 OUTLIER -127.99 162.56 26.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.301 -0.875 . . . . 0.0 109.433 -179.956 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 6.6 t -56.53 143.71 34.34 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.19 -0.944 . . . . 0.0 109.478 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 58.99 24.61 58.49 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.469 ' HB2' ' O ' ' A' ' 67' ' ' LEU . 13.9 tp10 -79.21 105.23 10.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -1.184 . . . . 0.0 109.491 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.519 ' CD1' ' OD2' ' A' ' 3' ' ' ASP . 0.4 OUTLIER -61.99 130.39 45.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.275 -0.89 . . . . 0.0 109.392 -179.915 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 7.9 mt -100.84 -71.12 0.72 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.27 -0.894 . . . . 0.0 109.45 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -144.39 -176.9 18.82 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 10.0 mtmt -128.26 151.67 49.01 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.313 -1.11 . . . . 0.0 109.462 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -103.63 152.09 22.17 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.174 -0.954 . . . . 0.0 109.512 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.575 HG22 ' H ' ' A' ' 77' ' ' GLU . 13.0 m -107.39 171.75 7.21 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 109.427 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.575 ' H ' HG22 ' A' ' 76' ' ' THR . 1.3 mm-40 -79.73 167.09 21.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.293 -0.88 . . . . 0.0 109.493 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -148.68 -65.16 0.01 OUTLIER Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 CA-C-O 117.997 -1.446 . . . . 0.0 109.53 179.999 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.448 ' HA ' ' O ' ' A' ' 75' ' ' LEU . . . . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 62.9 mt -137.33 126.1 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.192 -0.942 . . . . 0.0 109.461 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.506 ' OD2' ' CG ' ' A' ' 5' ' ' LYS . 24.9 t0 -61.04 154.54 22.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.2 -0.937 . . . . 0.0 109.496 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 16.4 mt -123.58 98.59 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.286 -0.884 . . . . 0.0 109.429 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.506 ' CG ' ' OD2' ' A' ' 3' ' ' ASP . 3.8 mtmt -122.39 154.76 37.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.914 . . . . 0.0 109.465 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.579 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -78.93 162.5 64.56 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.252 -0.905 . . . . 0.0 109.52 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.579 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.8 Cg_endo -78.04 159.57 30.44 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.555 2.17 . . . . 0.0 110.485 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.1 m -73.74 142.36 46.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.348 -0.845 . . . . 0.0 109.436 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.574 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 25.6 m-85 -89.88 156.95 46.72 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.27 -0.894 . . . . 0.0 109.512 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -77.97 -167.12 0.45 Allowed 'Trans proline' 0 C--N 1.309 -1.516 0 C-N-CA 122.655 2.237 . . . . 0.0 110.48 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.438 ' O ' ' C ' ' A' ' 12' ' ' SER . 39.0 tt0 -75.24 -56.38 4.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.176 -0.953 . . . . 0.0 109.456 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 11' ' ' GLU . 4.9 t -42.72 -52.8 4.8 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.3 -0.875 . . . . 0.0 109.619 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.595 HG22 ' H ' ' A' ' 15' ' ' ASP . 25.2 mt -94.1 147.42 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.236 -0.915 . . . . 0.0 109.494 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -124.33 6.54 8.4 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.183 -0.948 . . . . 0.0 109.615 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.595 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER 178.91 -172.53 0.15 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.236 -0.915 . . . . 0.0 109.488 -179.974 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.413 ' C ' HG22 ' A' ' 66' ' ' VAL . . . -154.78 -157.41 8.18 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.65 HG23 ' O ' ' A' ' 64' ' ' ASP . 36.4 m -150.02 135.4 18.15 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -1.135 . . . . 0.0 109.529 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 19' ' ' ALA . 19.5 t -55.88 158.78 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 109.461 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.625 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -101.94 -76.81 0.56 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.154 -0.967 . . . . 0.0 109.485 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 19.6 m -160.04 136.61 9.0 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.602 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.839 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 32.4 m95 -89.99 83.15 6.09 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.259 -0.9 . . . . 0.0 109.491 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.64 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.7 m80 -43.02 -68.34 0.2 Allowed 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.313 -0.867 . . . . 0.0 109.395 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.11 -172.0 3.17 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.259 -0.9 . . . . 0.0 109.561 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.407 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 7.8 mttp -141.09 168.29 14.66 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.31 -0.869 . . . . 0.0 109.4 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.791 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.0 Cg_endo -76.55 125.96 8.65 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.569 2.179 . . . . 0.0 110.467 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 117.19 10.96 9.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 45.6 mm-40 -128.4 -172.3 2.67 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.207 -1.172 . . . . 0.0 109.472 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -100.91 179.39 4.4 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.266 -0.896 . . . . 0.0 109.468 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.612 HG12 ' N ' ' A' ' 30' ' ' LYS . 64.6 t -147.04 165.95 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.293 -0.879 . . . . 0.0 109.451 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.612 ' N ' HG12 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -112.34 132.38 55.02 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.565 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.477 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -43.01 121.01 1.96 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.291 -0.88 . . . . 0.0 109.604 -179.931 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.477 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 3.0 t70 73.94 55.21 0.1 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.26 -0.9 . . . . 0.0 109.484 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 34' ' ' LEU . 2.3 tp10 -131.74 126.51 34.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.278 -0.888 . . . . 0.0 109.475 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.64 HD21 ' NE2' ' A' ' 22' ' ' HIS . 48.6 tp -42.89 161.68 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.288 -0.882 . . . . 0.0 109.586 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 34' ' ' LEU . 29.8 mm -144.72 -42.56 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.209 -0.932 . . . . 0.0 109.586 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.541 HG12 ' HB ' ' A' ' 47' ' ' VAL . 9.4 p -152.3 137.18 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.224 -0.923 . . . . 0.0 109.514 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.625 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 25.1 m-20 -100.71 163.14 12.47 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -0.871 . . . . 0.0 109.411 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.6 mt -129.86 154.34 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.232 -0.918 . . . . 0.0 109.517 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.483 ' HB3' ' O ' ' A' ' 17' ' ' THR . 27.8 tt0 -116.57 149.66 39.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.46 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.415 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -133.94 174.57 10.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -0.895 . . . . 0.0 109.487 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 40' ' ' THR . 5.6 t0 -42.9 -64.68 0.58 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.334 -0.853 . . . . 0.0 109.624 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LYS . . . . . 0.46 ' C ' HG23 ' A' ' 43' ' ' VAL . 11.6 mttp -134.06 39.76 3.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.217 -0.927 . . . . 0.0 109.479 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.46 HG23 ' C ' ' A' ' 42' ' ' LYS . 38.5 t -155.23 143.63 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.222 -0.924 . . . . 0.0 109.474 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 81.9 t -115.76 136.28 53.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.871 . . . . 0.0 109.487 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 84.4 mtp -121.36 178.27 4.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.213 -0.929 . . . . 0.0 109.456 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -137.27 160.03 40.22 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.218 -0.926 . . . . 0.0 109.467 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.541 ' HB ' HG12 ' A' ' 36' ' ' VAL . 21.3 t -127.2 104.78 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.94 . . . . 0.0 109.559 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.522 HD12 ' CD1' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -95.58 158.16 15.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.347 -0.845 . . . . 0.0 109.491 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.464 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -82.56 161.94 22.12 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.271 -0.893 . . . . 0.0 109.45 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.707 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -89.3 -0.49 57.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.229 -0.919 . . . . 0.0 109.618 179.994 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.707 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.12 162.75 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.48 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.507 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -53.64 171.05 0.1 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.257 -0.902 . . . . 0.0 109.367 179.955 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.507 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 154.54 -150.88 22.57 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.8 t -136.2 123.11 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -1.172 . . . . 0.0 109.493 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.552 HG22 ' N ' ' A' ' 56' ' ' ALA . 15.5 mm -61.66 166.29 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -0.915 . . . . 0.0 109.512 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.552 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -105.46 -67.21 0.93 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.252 -0.905 . . . . 0.0 109.464 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.532 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 2.9 tm-20 -174.6 150.13 1.33 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.139 -0.976 . . . . 0.0 109.577 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.839 HG23 ' CZ2' ' A' ' 21' ' ' TRP . 8.1 mt -89.98 151.72 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.279 -0.888 . . . . 0.0 109.514 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.437 HG21 ' O ' ' A' ' 71' ' ' LEU . 56.0 t -97.16 -67.01 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.267 -0.896 . . . . 0.0 109.453 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.421 ' HD2' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -92.62 -170.71 2.54 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.232 -0.917 . . . . 0.0 109.451 179.988 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.468 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 12.6 m-80 -125.24 168.52 13.36 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.209 -0.932 . . . . 0.0 109.512 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.4 ' HA ' ' HB ' ' A' ' 18' ' ' VAL . 0.2 OUTLIER -65.99 149.8 49.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.196 -0.94 . . . . 0.0 109.542 179.931 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 82.07 4.94 90.09 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.65 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -99.93 170.89 8.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.16 -1.2 . . . . 0.0 109.319 179.969 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 28.3 m -95.46 126.29 40.65 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.522 -0.737 . . . . 0.0 109.504 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.413 HG22 ' C ' ' A' ' 16' ' ' GLY . 18.8 m -89.97 176.38 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.33 -0.856 . . . . 0.0 109.427 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -142.51 164.09 31.06 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.141 -0.974 . . . . 0.0 109.443 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.1 t -58.14 133.17 55.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 109.453 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 62.75 24.58 66.58 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 30.1 tp10 -73.47 119.55 17.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.255 -1.144 . . . . 0.0 109.431 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.45 HD23 ' N ' ' A' ' 73' ' ' GLY . 6.8 tt -75.93 109.08 9.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.199 -0.938 . . . . 0.0 109.444 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -88.81 -10.44 48.12 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.177 -0.952 . . . . 0.0 109.477 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.45 ' N ' HD23 ' A' ' 71' ' ' LEU . . . 157.59 -175.4 34.94 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 1.3 mtmm -138.84 149.08 44.52 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.193 -1.18 . . . . 0.0 109.498 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 1' ' ' ALA . 0.8 OUTLIER -100.3 146.95 26.32 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.264 -0.898 . . . . 0.0 109.448 -179.915 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.569 HG22 ' H ' ' A' ' 77' ' ' GLU . 14.9 m -114.43 171.97 7.3 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.246 -0.909 . . . . 0.0 109.483 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.569 ' H ' HG22 ' A' ' 76' ' ' THR . 0.8 OUTLIER -77.94 -148.81 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 0.0 109.434 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 156.98 147.38 4.76 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 CA-C-O 117.986 -1.452 . . . . 0.0 109.491 179.989 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.43 ' C ' HG13 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.43 HG13 ' C ' ' A' ' 1' ' ' ALA . 3.7 mt -149.14 124.07 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.249 -0.907 . . . . 0.0 109.503 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -71.13 150.91 44.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.318 -0.864 . . . . 0.0 109.486 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.3 mt -127.2 72.6 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.232 -0.918 . . . . 0.0 109.426 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.422 ' HA ' ' HG ' ' A' ' 72' ' ' LEU . 5.0 pttp -101.34 167.99 9.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.194 -0.941 . . . . 0.0 109.472 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.45 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -66.34 158.02 79.52 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.344 -0.848 . . . . 0.0 109.438 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.45 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.2 Cg_endo -78.05 169.26 20.71 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.586 2.191 . . . . 0.0 110.422 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.7 141.35 40.94 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.464 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.53 ' CD2' ' HB2' ' A' ' 68' ' ' SER . 18.6 m-85 -107.91 153.07 41.86 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.23 -0.919 . . . . 0.0 109.462 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.445 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -78.06 167.41 23.49 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.593 2.195 . . . . 0.0 110.373 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.1 mt-10 -49.45 -53.52 22.53 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.2 -0.938 . . . . 0.0 109.54 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 11' ' ' GLU . 19.1 t -42.75 -48.88 5.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.385 -0.822 . . . . 0.0 109.631 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.816 HG21 ' CG2' ' A' ' 40' ' ' THR . 22.5 mt -96.18 122.05 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.223 -0.923 . . . . 0.0 109.402 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -101.13 11.46 39.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.214 -0.929 . . . . 0.0 109.439 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.598 ' O ' HG22 ' A' ' 13' ' ' ILE . 0.9 OUTLIER -176.67 -170.13 0.31 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.247 -0.908 . . . . 0.0 109.403 179.982 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.613 ' O ' HG23 ' A' ' 65' ' ' THR . . . -151.58 -173.33 21.28 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.523 HG23 ' O ' ' A' ' 64' ' ' ASP . 4.2 m -150.04 127.93 11.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -1.147 . . . . 0.0 109.411 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.531 HG12 ' N ' ' A' ' 19' ' ' ALA . 47.9 t -54.31 164.05 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.218 -0.926 . . . . 0.0 109.45 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.558 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -109.7 -73.86 0.67 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.26 -0.9 . . . . 0.0 109.518 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.534 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 18.3 m -158.46 134.67 9.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.211 -0.931 . . . . 0.0 109.489 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.656 ' CH2' HD12 ' A' ' 58' ' ' ILE . 35.1 m95 -89.7 84.7 6.32 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.231 -0.918 . . . . 0.0 109.567 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.799 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.2 m80 -42.76 -60.31 1.62 Allowed 'General case' 0 N--CA 1.499 2.004 0 O-C-N 121.401 -0.812 . . . . 0.0 109.483 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.405 ' HA ' ' HD2' ' A' ' 23' ' ' LYS . 1.1 mmmt -100.28 -171.99 2.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -0.873 . . . . 0.0 109.562 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.439 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -124.54 169.17 11.31 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.254 -0.904 . . . . 0.0 109.483 -179.934 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.514 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.2 Cg_endo -76.48 94.24 1.04 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.67 2.247 . . . . 0.0 110.409 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 151.04 -17.45 0.92 Allowed Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -84.75 170.68 13.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -1.134 . . . . 0.0 109.541 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.11 127.94 42.57 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.886 . . . . 0.0 109.389 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.584 HG22 ' O ' ' A' ' 53' ' ' GLY . 18.3 m -96.63 -172.04 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.464 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.426 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -148.4 136.97 21.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.47 -179.959 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.454 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 10.3 tmm_? -42.79 128.28 4.14 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.319 -0.863 . . . . 0.0 109.624 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 7.7 t70 72.81 54.36 0.14 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.276 -0.89 . . . . 0.0 109.453 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.466 ' N ' HD23 ' A' ' 48' ' ' LEU . 1.4 tp10 -141.91 120.78 12.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.296 -0.877 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.799 HD21 ' NE2' ' A' ' 22' ' ' HIS . 47.9 tp -42.87 142.31 0.92 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.309 -0.87 . . . . 0.0 109.581 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.589 HG13 ' HB2' ' A' ' 49' ' ' ALA . 22.7 mm -129.75 -42.15 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.889 . . . . 0.0 109.443 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.585 HG12 ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -157.53 144.43 9.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.296 -0.878 . . . . 0.0 109.466 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.558 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 19.6 m-20 -102.68 150.3 23.58 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.627 HD11 HG22 ' A' ' 47' ' ' VAL . 21.8 mt -110.47 150.72 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.186 -0.946 . . . . 0.0 109.464 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -141.7 98.73 3.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.486 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.816 ' CG2' HG21 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -90.19 -174.37 4.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.202 -0.936 . . . . 0.0 109.488 -179.996 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.626 ' H ' HG22 ' A' ' 40' ' ' THR . 0.6 OUTLIER -42.87 -45.18 4.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.274 -0.891 . . . . 0.0 109.647 -179.866 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LYS . . . . . 0.434 ' HG3' ' O ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -156.28 27.33 0.35 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.199 -0.938 . . . . 0.0 109.446 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 3.5 t -128.36 106.66 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.327 -0.858 . . . . 0.0 109.42 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.5 t -90.31 130.48 39.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.242 -0.911 . . . . 0.0 109.484 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 10.2 mmt -141.86 108.45 5.34 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.181 -0.95 . . . . 0.0 109.476 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.477 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 5.4 mt-10 -63.0 172.08 1.92 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.278 -0.889 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.627 HG22 HD11 ' A' ' 38' ' ' ILE . 15.7 t -135.25 102.32 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.236 -0.915 . . . . 0.0 109.504 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.466 HD23 ' N ' ' A' ' 33' ' ' GLU . 0.0 OUTLIER -94.5 154.85 17.21 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.479 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.589 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -84.94 143.15 29.16 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.227 -0.921 . . . . 0.0 109.525 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.31 13.93 31.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.325 -0.859 . . . . 0.0 109.45 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -179.7 140.83 0.14 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.322 -0.862 . . . . 0.0 109.454 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -59.83 170.89 1.02 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.248 -0.908 . . . . 0.0 109.309 179.999 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.584 ' O ' HG22 ' A' ' 29' ' ' VAL . . . 154.32 175.84 25.97 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.576 ' O ' HG22 ' A' ' 76' ' ' THR . 49.2 t -112.93 124.83 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.206 -1.173 . . . . 0.0 109.498 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.939 HD13 HD12 ' A' ' 75' ' ' LEU . 15.6 mm -61.25 164.82 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.488 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.524 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -106.39 -63.7 1.24 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.314 -0.867 . . . . 0.0 109.462 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.488 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -170.41 136.43 1.33 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.16 -0.962 . . . . 0.0 109.528 -179.915 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.656 HD12 ' CH2' ' A' ' 21' ' ' TRP . 26.6 mm -89.94 141.37 14.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.343 -0.848 . . . . 0.0 109.452 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 89.1 t -90.18 -62.46 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -0.912 . . . . 0.0 109.55 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.474 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -89.95 155.1 19.35 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 109.44 -179.917 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 57.4 m-20 -102.54 158.47 16.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.247 -0.908 . . . . 0.0 109.433 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.534 ' CB ' ' HA ' ' A' ' 20' ' ' THR . 2.1 pp20? -60.81 143.35 54.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.206 -0.934 . . . . 0.0 109.451 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 98.48 -10.32 62.99 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.523 ' O ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -100.16 170.9 8.15 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.239 -1.153 . . . . 0.0 109.274 -179.971 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.613 HG23 ' O ' ' A' ' 16' ' ' GLY . 47.5 m -101.54 146.91 27.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.492 -0.755 . . . . 0.0 109.484 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.41 160.94 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.226 -0.921 . . . . 0.0 109.497 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 15.0 mt -90.42 145.28 25.05 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.246 -0.909 . . . . 0.0 109.476 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.53 ' HB2' ' CD2' ' A' ' 9' ' ' PHE . 1.9 t -49.33 114.32 1.0 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.295 -0.878 . . . . 0.0 109.515 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.45 22.43 24.34 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 38.9 tp10 -84.0 131.9 34.79 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.293 -1.122 . . . . 0.0 109.483 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 4.9 tt -66.09 114.25 5.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.261 -0.899 . . . . 0.0 109.501 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.55 ' O ' HG23 ' A' ' 58' ' ' ILE . 6.1 mt -96.59 -22.17 17.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.266 -0.896 . . . . 0.0 109.456 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.38 159.83 23.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -124.32 133.98 53.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.265 -1.138 . . . . 0.0 109.483 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.939 HD12 HD13 ' A' ' 55' ' ' ILE . 4.5 tp -92.35 152.09 19.94 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.92 . . . . 0.0 109.503 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.667 HG23 ' N ' ' A' ' 77' ' ' GLU . 2.9 t -104.87 -157.8 0.63 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.313 -0.867 . . . . 0.0 109.727 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.667 ' N ' HG23 ' A' ' 76' ' ' THR . 8.5 mm-40 -74.08 -179.25 3.71 Favored 'General case' 0 C--N 1.295 -1.791 0 CA-C-O 121.313 0.578 . . . . 0.0 109.458 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.463 ' HA2' ' HA2' ' A' ' 53' ' ' GLY . . . -78.46 -37.61 27.03 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.286 0 CA-C-O 118.013 -1.437 . . . . 0.0 109.558 -179.971 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 121.287 0.565 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.575 HD12 HD22 ' A' ' 75' ' ' LEU . 25.1 mt -114.58 109.1 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.915 . . . . 0.0 109.494 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -77.67 124.03 27.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.244 -0.91 . . . . 0.0 109.459 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.6 mm -100.32 108.28 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.235 -0.916 . . . . 0.0 109.472 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.5 mtmt -125.15 165.72 17.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.627 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -75.59 163.41 67.53 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.207 -0.933 . . . . 0.0 109.528 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.627 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.09 134.69 13.23 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.637 2.225 . . . . 0.0 110.436 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.1 m -57.64 134.74 56.44 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.194 -0.941 . . . . 0.0 109.503 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.479 ' CE1' ' O ' ' A' ' 7' ' ' PRO . 4.2 m-85 -94.97 149.17 35.88 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.201 -0.937 . . . . 0.0 109.415 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 9' ' ' PHE . 35.8 Cg_endo -78.09 -165.22 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.621 2.214 . . . . 0.0 110.456 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.1 OUTLIER -72.41 -49.19 35.53 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.414 179.995 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 11' ' ' GLU . 30.9 t -42.78 -52.12 5.12 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.308 -0.87 . . . . 0.0 109.635 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.783 HG22 ' H ' ' A' ' 15' ' ' ASP . 3.2 mt -92.95 150.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.206 -0.934 . . . . 0.0 109.439 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.419 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -122.28 12.77 10.25 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.327 -0.858 . . . . 0.0 109.494 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.783 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.3 OUTLIER 170.75 -170.76 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.256 -0.902 . . . . 0.0 109.499 -179.987 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.09 -169.92 18.09 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.471 HG23 ' O ' ' A' ' 64' ' ' ASP . 17.1 m -149.94 128.78 12.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -1.126 . . . . 0.0 109.469 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.44 HG12 ' N ' ' A' ' 19' ' ' ALA . 25.5 t -52.35 160.65 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.336 -0.852 . . . . 0.0 109.489 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.651 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -100.52 -75.63 0.58 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.473 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.7 m -160.11 136.11 8.57 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.564 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.721 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 33.4 m95 -89.76 82.46 6.26 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.256 -0.902 . . . . 0.0 109.64 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.668 ' CE1' HD21 ' A' ' 34' ' ' LEU . 1.8 m80 -43.57 -71.46 0.08 Allowed 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.284 -0.885 . . . . 0.0 109.362 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.404 ' HB2' ' HE3' ' A' ' 23' ' ' LYS . 30.0 mtmt -100.09 -171.93 2.13 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.245 -0.909 . . . . 0.0 109.571 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.62 167.39 19.41 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.328 -0.858 . . . . 0.0 109.465 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.835 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.5 Cg_endo -76.92 153.18 32.69 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.66 2.24 . . . . 0.0 110.412 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.11 9.49 67.48 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 41.5 mm-40 -113.38 -173.33 2.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.172 -1.193 . . . . 0.0 109.418 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -83.58 132.5 34.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.457 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.6 t -123.28 138.26 53.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.458 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.1 mttt -119.01 132.95 56.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.437 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -42.9 143.39 0.74 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.258 -0.901 . . . . 0.0 109.595 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.435 ' N ' ' HD2' ' A' ' 31' ' ' ARG . 17.6 t0 69.56 46.76 0.7 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.224 -0.923 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.452 ' O ' HG12 ' A' ' 35' ' ' ILE . 1.8 tp10 -140.41 110.19 6.41 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.229 -0.92 . . . . 0.0 109.49 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.668 HD21 ' CE1' ' A' ' 22' ' ' HIS . 55.7 tp -42.97 161.51 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.27 -0.894 . . . . 0.0 109.604 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.519 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 22.2 mm -149.9 -40.25 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.213 -0.929 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.522 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 13.5 p -151.03 131.01 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.257 -0.902 . . . . 0.0 109.541 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.651 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 12.9 m-20 -97.96 171.94 7.95 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.247 -0.908 . . . . 0.0 109.485 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 2.5 mt -138.74 164.49 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.288 -0.882 . . . . 0.0 109.44 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.446 ' HB2' ' O ' ' A' ' 17' ' ' THR . 37.4 mt-10 -132.95 141.6 48.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.238 -0.913 . . . . 0.0 109.419 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -126.35 -160.48 0.99 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 -179.992 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 40' ' ' THR . 3.8 t70 -42.87 -63.1 0.85 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.277 -0.889 . . . . 0.0 109.563 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LYS . . . . . 0.412 ' HG2' ' O ' ' A' ' 41' ' ' ASP . 6.6 mttt -145.65 22.3 1.46 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 1.9 t -127.42 139.22 52.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.226 -0.921 . . . . 0.0 109.437 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.415 ' O ' HG13 ' A' ' 44' ' ' VAL . 9.1 p -105.98 134.26 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.403 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' MET . . . . . 0.427 ' C ' ' HG3' ' A' ' 46' ' ' GLU . 8.8 mtm -113.55 -176.81 2.98 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.264 -0.897 . . . . 0.0 109.463 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.478 ' HB3' HD13 ' A' ' 34' ' ' LEU . 29.1 mt-10 -143.97 161.65 38.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.307 -0.87 . . . . 0.0 109.402 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.522 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 63.5 t -136.72 108.25 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.773 HD23 ' N ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.89 148.9 25.07 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.286 -0.883 . . . . 0.0 109.381 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -63.55 147.62 50.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.442 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.699 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 1.1 mt-10 -93.05 10.49 31.28 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.239 -0.913 . . . . 0.0 109.473 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.699 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.34 157.23 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.257 -0.902 . . . . 0.0 109.479 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.508 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -65.55 170.96 4.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.336 -0.852 . . . . 0.0 109.348 -179.977 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.508 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.31 -143.79 10.94 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.8 t -138.21 124.46 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.249 -1.147 . . . . 0.0 109.489 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.552 HG22 ' N ' ' A' ' 56' ' ' ALA . 9.6 mm -75.13 171.76 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.3 -0.875 . . . . 0.0 109.523 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.552 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -102.88 -62.45 1.27 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.203 -0.935 . . . . 0.0 109.514 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.534 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 5.3 pt-20 173.27 161.05 0.14 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 109.533 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.835 HD11 ' HD3' ' A' ' 25' ' ' PRO . 1.6 mp -90.43 143.84 10.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.255 -0.903 . . . . 0.0 109.44 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.927 HG21 HD23 ' A' ' 71' ' ' LEU . 53.5 t -99.42 -21.09 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.214 -0.929 . . . . 0.0 109.47 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.518 ' CG ' ' OD2' ' A' ' 64' ' ' ASP . 9.8 tptt -120.65 -171.87 2.27 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.248 -0.907 . . . . 0.0 109.559 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.478 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 17.1 m120 -123.25 167.9 13.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.896 . . . . 0.0 109.49 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -71.52 143.03 50.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.272 -0.893 . . . . 0.0 109.533 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 72.86 17.06 78.18 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.716 -1.353 . . . . 0.0 109.716 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.518 ' OD2' ' CG ' ' A' ' 60' ' ' LYS . 0.2 OUTLIER -100.65 170.83 8.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.232 -1.157 . . . . 0.0 109.331 179.966 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.513 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.8 t -90.94 153.78 19.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.481 -0.762 . . . . 0.0 109.53 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 16.1 m -133.39 144.49 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.227 -0.921 . . . . 0.0 109.517 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -92.67 160.73 14.86 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.3 -0.875 . . . . 0.0 109.387 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.2 t -52.89 119.3 4.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.129 -0.982 . . . . 0.0 109.493 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 74.53 33.36 56.24 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -76.8 137.73 39.43 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.277 -1.131 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.927 HD23 HG21 ' A' ' 59' ' ' VAL . 0.6 OUTLIER -78.19 128.32 33.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.456 -179.961 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 7.5 mt -105.76 -23.17 12.78 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.313 -0.867 . . . . 0.0 109.459 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 171.87 171.16 36.63 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 4.4 mtmt -127.78 136.81 52.0 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.27 -1.135 . . . . 0.0 109.509 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.575 HD22 HD12 ' A' ' 2' ' ' ILE . 2.7 tt -97.75 151.27 20.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.235 -0.916 . . . . 0.0 109.508 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.574 ' O ' HD23 ' A' ' 75' ' ' LEU . 15.1 m -112.36 171.9 7.24 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.262 -0.899 . . . . 0.0 109.464 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.56 ' H ' HG22 ' A' ' 76' ' ' THR . 19.0 mt-10 -70.26 -68.86 0.39 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.177 -0.952 . . . . 0.0 109.462 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 134.99 -170.81 22.71 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 CA-C-O 118.0 -1.444 . . . . 0.0 109.535 179.983 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.1 pp -143.88 133.97 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.29 -0.881 . . . . 0.0 109.471 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.508 ' OD2' HD11 ' A' ' 71' ' ' LEU . 8.9 t70 -80.41 133.42 35.88 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.178 -0.951 . . . . 0.0 109.449 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 12.2 mt -96.45 107.76 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.1 mttt -121.28 173.36 7.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.909 . . . . 0.0 109.449 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.96 149.19 82.52 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.292 -0.88 . . . . 0.0 109.468 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.02 135.87 14.28 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.661 2.24 . . . . 0.0 110.372 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.519 ' O ' HG23 ' A' ' 8' ' ' THR . 3.0 t -56.73 112.33 1.27 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.202 -0.936 . . . . 0.0 109.474 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -67.24 157.45 85.19 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.867 . . . . 0.0 109.431 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.455 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.07 -159.61 0.1 Allowed 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.557 2.171 . . . . 0.0 110.423 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.416 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.1 tt0 -80.07 -61.94 1.83 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.25 -0.906 . . . . 0.0 109.521 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.416 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.9 t -42.81 -47.51 5.53 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.296 -0.877 . . . . 0.0 109.633 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.522 HD11 ' HB2' ' A' ' 41' ' ' ASP . 16.6 mt -99.81 130.16 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.234 -0.916 . . . . 0.0 109.418 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -118.79 28.15 8.47 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.274 -0.891 . . . . 0.0 109.383 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.491 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 176.42 -170.44 0.07 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.314 -0.866 . . . . 0.0 109.429 -179.978 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.85 -173.53 33.58 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 18' ' ' VAL . 16.7 m -149.91 122.75 8.71 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.154 -1.204 . . . . 0.0 109.422 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.426 ' C ' ' O ' ' A' ' 17' ' ' THR . 47.1 t -44.24 156.96 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -0.905 . . . . 0.0 109.41 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.412 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -106.12 -74.9 0.64 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -0.906 . . . . 0.0 109.475 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.8 m -158.85 134.81 8.93 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.258 -0.901 . . . . 0.0 109.413 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.632 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 33.1 m95 -89.85 84.4 6.24 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.232 -0.917 . . . . 0.0 109.565 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.763 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.1 m80 -42.93 -63.25 0.83 Allowed 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.364 -0.835 . . . . 0.0 109.372 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -92.39 -172.07 2.98 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.187 -0.946 . . . . 0.0 109.509 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.48 ' HB2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.47 164.39 43.06 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.272 -0.893 . . . . 0.0 109.452 -179.95 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.482 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -77.59 90.38 1.26 Allowed 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 122.688 2.259 . . . . 0.0 110.36 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 160.56 -23.28 0.25 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 49.6 mm-40 -94.38 -172.43 2.78 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.35 -1.088 . . . . 0.0 109.472 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -105.0 149.1 26.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.241 -0.912 . . . . 0.0 109.483 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.0 m -120.55 175.66 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.269 -0.894 . . . . 0.0 109.431 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.09 130.6 50.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.425 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 14.1 ttt180 -42.91 141.65 1.07 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.287 -0.883 . . . . 0.0 109.625 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.7 t70 65.55 45.56 2.71 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.434 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 34' ' ' LEU . 4.9 tt0 -136.52 124.83 23.25 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.334 -0.854 . . . . 0.0 109.502 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.862 HD13 ' HB3' ' A' ' 46' ' ' GLU . 49.8 tp -42.81 150.93 0.14 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.372 -0.83 . . . . 0.0 109.603 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.765 HD11 ' HB2' ' A' ' 49' ' ' ALA . 11.8 mt -139.49 -38.73 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.321 -0.862 . . . . 0.0 109.509 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.518 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 9.7 p -154.51 131.12 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.208 -0.933 . . . . 0.0 109.497 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.46 ' OD1' ' HA ' ' A' ' 46' ' ' GLU . 39.3 m-20 -97.0 152.18 18.98 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.176 -0.952 . . . . 0.0 109.443 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.47 ' O ' ' HA ' ' A' ' 44' ' ' VAL . 5.5 mt -115.91 146.69 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.275 -0.89 . . . . 0.0 109.482 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.68 111.54 21.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.315 -0.866 . . . . 0.0 109.495 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.675 HG23 ' N ' ' A' ' 41' ' ' ASP . 4.8 t -106.64 -153.73 0.5 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.191 -0.943 . . . . 0.0 109.385 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.675 ' N ' HG23 ' A' ' 40' ' ' THR . 0.3 OUTLIER -43.09 -71.53 0.08 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.898 . . . . 0.0 109.627 -179.882 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 17.8 mtmm -143.88 36.9 1.29 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.519 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.587 ' O ' HG22 ' A' ' 40' ' ' THR . 2.1 t -146.82 145.6 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.296 -0.877 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.47 ' HA ' ' O ' ' A' ' 38' ' ' ILE . 10.6 p -109.8 133.51 54.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 0.0 109.438 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 2.7 mtt -105.35 126.95 52.68 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.454 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.862 ' HB3' HD13 ' A' ' 34' ' ' LEU . 6.7 mt-10 -81.4 131.25 35.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.179 -0.951 . . . . 0.0 109.466 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.518 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 92.8 t -116.4 102.03 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.247 -0.908 . . . . 0.0 109.509 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.498 ' H ' HD12 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -102.91 163.24 12.32 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.211 -0.931 . . . . 0.0 109.406 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.765 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -79.45 142.35 35.96 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.207 -0.933 . . . . 0.0 109.48 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -82.5 8.21 12.28 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.281 -0.887 . . . . 0.0 109.535 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -177.08 141.73 0.34 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.889 . . . . 0.0 109.534 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.2 OUTLIER -57.93 170.93 0.56 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.223 -0.923 . . . . 0.0 109.312 -179.953 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.99 -145.09 12.25 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.4 t -138.4 125.21 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.3 -1.118 . . . . 0.0 109.433 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.523 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.0 mt -58.17 161.75 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.316 -0.865 . . . . 0.0 109.529 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.54 ' CB ' ' HG3' ' A' ' 74' ' ' LYS . . . -97.66 -66.84 0.88 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.275 -0.891 . . . . 0.0 109.522 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.482 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 8.2 tt0 -175.05 138.75 0.45 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.207 -0.933 . . . . 0.0 109.456 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.632 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.9 mm -101.94 119.92 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.246 -0.909 . . . . 0.0 109.387 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.4 t -90.0 -19.11 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -0.929 . . . . 0.0 109.402 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.442 ' HG3' ' CG ' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -97.81 131.87 43.93 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.466 179.977 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 47.9 m-80 -97.55 156.35 16.55 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -0.867 . . . . 0.0 109.471 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -51.24 148.79 4.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.257 -0.902 . . . . 0.0 109.524 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 75.87 19.7 78.61 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.5 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -100.5 170.91 8.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.267 -1.137 . . . . 0.0 109.274 -179.978 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.5 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 65.1 m -106.67 133.6 51.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.539 -0.725 . . . . 0.0 109.475 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 25.0 m -100.79 163.73 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -0.884 . . . . 0.0 109.451 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.519 HD23 ' H ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -145.68 167.39 23.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.272 -0.893 . . . . 0.0 109.476 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.519 ' H ' HD23 ' A' ' 67' ' ' LEU . 1.5 t -62.29 115.4 4.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.227 -0.921 . . . . 0.0 109.508 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 89.84 18.4 51.25 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 27.2 tp10 -83.19 121.75 27.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.229 -1.159 . . . . 0.0 109.485 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.508 HD11 ' OD2' ' A' ' 3' ' ' ASP . 0.5 OUTLIER -83.98 119.2 24.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.211 -0.931 . . . . 0.0 109.422 -179.973 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 12.0 mt -99.82 -19.09 16.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.268 -0.895 . . . . 0.0 109.44 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 159.5 168.12 21.07 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.54 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -127.21 158.51 36.92 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.16 -1.2 . . . . 0.0 109.487 179.982 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 8.8 tp -96.48 152.84 18.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.436 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.543 HG22 ' H ' ' A' ' 77' ' ' GLU . 9.1 m -105.73 170.91 7.62 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.873 . . . . 0.0 109.523 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.543 ' H ' HG22 ' A' ' 76' ' ' THR . 42.4 mt-10 -64.82 -177.9 0.38 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.209 -0.932 . . . . 0.0 109.41 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -128.75 -150.71 7.25 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.958 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.632 ' C ' HD12 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.632 HD12 ' C ' ' A' ' 1' ' ' ALA . 3.5 mp -133.55 91.25 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.277 -0.89 . . . . 0.0 109.459 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.478 ' OD1' HD11 ' A' ' 71' ' ' LEU . 63.2 t0 -57.85 123.26 15.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.531 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 53.0 mt -98.69 121.3 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.228 -0.92 . . . . 0.0 109.39 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.7 ptpp? -147.1 168.5 21.45 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.242 -0.911 . . . . 0.0 109.53 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.42 150.89 91.78 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.02 127.83 8.75 Favored 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.579 2.186 . . . . 0.0 110.423 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -45.84 143.46 2.12 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.27 -0.894 . . . . 0.0 109.451 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.517 ' CE2' ' C ' ' A' ' 15' ' ' ASP . 22.1 m-85 -102.84 154.5 37.47 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.923 . . . . 0.0 109.443 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -78.0 163.75 28.0 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.671 2.247 . . . . 0.0 110.415 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.0 OUTLIER -45.84 -49.77 14.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.141 -0.974 . . . . 0.0 109.505 179.985 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -43.17 -59.96 1.85 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.293 -0.879 . . . . 0.0 109.68 -179.936 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.704 HG22 ' H ' ' A' ' 15' ' ' ASP . 2.5 mp -90.28 132.94 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.267 -0.895 . . . . 0.0 109.48 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.76 25.98 11.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.906 . . . . 0.0 109.486 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.704 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER 177.09 -171.09 0.09 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.24 -0.913 . . . . 0.0 109.487 -179.94 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.417 ' HA3' ' CZ ' ' A' ' 9' ' ' PHE . . . -159.14 -175.09 29.69 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.849 HG23 ' O ' ' A' ' 64' ' ' ASP . 85.2 m -150.02 122.59 8.55 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.292 -1.122 . . . . 0.0 109.45 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.585 HG12 ' N ' ' A' ' 19' ' ' ALA . 38.2 t -48.14 168.97 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.297 -0.877 . . . . 0.0 109.453 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.585 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -111.1 -73.9 0.66 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.266 -0.897 . . . . 0.0 109.58 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.491 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 23.9 m -160.08 135.46 8.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.117 -0.989 . . . . 0.0 109.674 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.655 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 34.2 m95 -89.94 83.38 6.13 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 121.161 -0.962 . . . . 0.0 109.494 179.857 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.576 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 1.5 m80 -43.16 -70.8 0.09 Allowed 'General case' 0 N--CA 1.501 2.109 0 O-C-N 121.315 -0.866 . . . . 0.0 109.425 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.85 -171.75 2.23 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.219 -0.926 . . . . 0.0 109.62 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.443 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.28 169.86 12.72 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.329 -0.857 . . . . 0.0 109.428 -179.903 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.613 ' HD3' HD11 ' A' ' 58' ' ' ILE . 34.9 Cg_endo -76.05 135.98 17.82 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 122.642 2.228 . . . . 0.0 110.377 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.13 10.61 27.59 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.421 ' CD ' ' O ' ' A' ' 28' ' ' ALA . 1.2 pp20? -115.51 173.16 6.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.225 -1.162 . . . . 0.0 109.471 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.421 ' O ' ' CD ' ' A' ' 27' ' ' GLU . . . -78.7 144.96 34.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.288 -0.883 . . . . 0.0 109.481 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.405 HG12 ' N ' ' A' ' 30' ' ' LYS . 5.2 t -127.92 163.95 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.902 . . . . 0.0 109.472 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.422 ' O ' ' C ' ' A' ' 31' ' ' ARG . 4.3 tttp -156.8 141.85 17.17 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.275 -0.891 . . . . 0.0 109.474 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.462 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 1.5 tmm_? -42.78 144.8 0.52 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.337 -0.852 . . . . 0.0 109.718 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.462 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 16.4 t0 72.18 46.91 0.31 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.269 -0.894 . . . . 0.0 109.498 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 34' ' ' LEU . 3.6 tp10 -142.22 100.99 3.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.281 -0.887 . . . . 0.0 109.561 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.576 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 39.9 tp -43.36 146.9 0.43 Allowed 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.299 -0.875 . . . . 0.0 109.519 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 44.5 mt -121.86 -44.66 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.889 . . . . 0.0 109.652 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.523 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.9 p -160.09 139.24 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.2 -0.937 . . . . 0.0 109.566 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.532 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 11.5 m-20 -99.18 168.39 10.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.896 . . . . 0.0 109.478 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.503 ' O ' HG23 ' A' ' 44' ' ' VAL . 12.8 mt -136.02 161.75 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.284 -0.885 . . . . 0.0 109.46 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.438 ' N ' HG22 ' A' ' 38' ' ' ILE . 2.4 tt0 -143.1 167.35 22.29 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.236 -0.915 . . . . 0.0 109.489 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.549 HG22 ' H ' ' A' ' 41' ' ' ASP . 8.5 m -159.18 170.91 20.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.273 -0.892 . . . . 0.0 109.455 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.549 ' H ' HG22 ' A' ' 40' ' ' THR . 8.9 t0 -42.83 -40.61 2.95 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.252 -0.905 . . . . 0.0 109.631 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -156.29 26.0 0.35 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 78.6 t -140.64 105.09 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.33 -0.856 . . . . 0.0 109.46 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 38' ' ' ILE . 3.7 p -95.48 139.32 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.186 -0.946 . . . . 0.0 109.531 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' MET . . . . . 0.451 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 13.2 mmt -128.05 -167.88 1.82 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.275 -0.89 . . . . 0.0 109.477 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.5 pt-20 -158.39 167.06 30.7 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.169 -0.957 . . . . 0.0 109.486 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.523 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 71.3 t -138.31 104.02 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.381 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.463 ' HG ' ' HA ' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -95.98 171.02 8.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 -179.994 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.05 139.64 31.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 0.0 109.44 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.659 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 2.9 mm-40 -100.38 8.09 43.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -0.913 . . . . 0.0 109.548 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.659 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 166.57 142.99 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.958 . . . . 0.0 109.491 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.504 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.84 170.98 0.15 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.198 -0.939 . . . . 0.0 109.225 -179.926 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.504 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.95 -146.3 14.88 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.4 t -135.89 124.45 37.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.302 -1.117 . . . . 0.0 109.505 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.526 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 5.0 mt -61.17 158.65 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 109.567 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.462 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -95.56 -69.41 0.76 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.249 -0.907 . . . . 0.0 109.549 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.528 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -178.97 152.9 0.6 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.241 -0.912 . . . . 0.0 109.471 179.992 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.655 HG23 ' CZ2' ' A' ' 21' ' ' TRP . 24.9 mt -89.91 141.28 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.219 -0.926 . . . . 0.0 109.412 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.8 t -90.53 -66.77 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.172 -0.955 . . . . 0.0 109.411 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.641 ' HD2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -92.79 -173.67 3.39 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.25 -0.906 . . . . 0.0 109.448 -179.983 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.461 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 70.7 m-80 -110.6 155.57 22.16 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.296 -0.878 . . . . 0.0 109.44 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.528 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -69.52 153.43 43.51 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.244 -0.91 . . . . 0.0 109.451 -179.984 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 77.49 7.45 87.09 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.849 ' O ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -105.29 170.95 7.59 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.238 -1.154 . . . . 0.0 109.32 -179.966 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.502 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 48.6 m -99.14 128.55 45.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.457 -0.777 . . . . 0.0 109.494 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.641 HG12 ' HD2' ' A' ' 60' ' ' LYS . 6.6 m -121.52 -169.7 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.329 -0.857 . . . . 0.0 109.455 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.472 HD12 ' HA ' ' A' ' 67' ' ' LEU . 1.2 tp -127.15 165.95 18.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -0.903 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 t -61.7 138.76 58.34 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.279 -0.888 . . . . 0.0 109.505 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.02 15.4 81.4 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -79.05 116.63 19.47 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.243 -1.151 . . . . 0.0 109.51 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.478 HD11 ' OD1' ' A' ' 3' ' ' ASP . 10.9 tp -66.57 115.92 6.96 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.203 -0.935 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 15.4 mt -98.36 -12.35 21.55 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.245 -0.909 . . . . 0.0 109.404 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 164.1 169.96 28.36 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 26.5 mtmt -132.25 139.09 48.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.188 -1.184 . . . . 0.0 109.504 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.563 HD23 HD13 ' A' ' 2' ' ' ILE . 12.8 tp -98.41 136.86 37.95 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.207 -0.933 . . . . 0.0 109.543 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.558 HG22 ' H ' ' A' ' 77' ' ' GLU . 12.7 m -109.63 171.88 7.18 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.225 -0.922 . . . . 0.0 109.501 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.558 ' H ' HG22 ' A' ' 76' ' ' THR . 1.1 mm-40 -82.67 -170.53 3.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.256 -0.903 . . . . 0.0 109.494 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 171.29 157.4 13.16 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 CA-C-O 118.002 -1.443 . . . . 0.0 109.601 179.965 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.518 ' O ' HD12 ' A' ' 2' ' ' ILE . 2.1 pp -149.07 120.48 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.255 -0.903 . . . . 0.0 109.452 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.464 ' OD2' ' CD1' ' A' ' 71' ' ' LEU . 26.1 t70 -74.53 166.4 23.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.3 -0.875 . . . . 0.0 109.521 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 61.1 mt -129.96 118.45 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.475 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 ptpp? -137.25 165.0 27.18 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.272 -0.893 . . . . 0.0 109.425 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.45 150.58 91.59 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.485 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.11 166.4 24.78 Favored 'Trans proline' 0 C--N 1.309 -1.524 0 C-N-CA 122.612 2.208 . . . . 0.0 110.409 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.09 94.96 2.98 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.173 -0.954 . . . . 0.0 109.445 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.533 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 21.5 m-85 -50.1 151.0 3.77 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.298 -0.877 . . . . 0.0 109.457 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.436 ' HG2' HG12 ' A' ' 13' ' ' ILE . 35.2 Cg_endo -78.14 177.31 8.93 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.559 2.173 . . . . 0.0 110.383 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 12' ' ' SER . 43.2 tt0 -66.0 -54.05 31.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.501 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.425 ' C ' ' O ' ' A' ' 11' ' ' GLU . 21.6 t -42.95 -46.41 5.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.34 -0.85 . . . . 0.0 109.628 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.607 HG22 ' H ' ' A' ' 15' ' ' ASP . 11.6 mm -94.5 151.69 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.415 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -121.36 2.64 10.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.618 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.607 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 167.96 -169.25 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.109 -0.995 . . . . 0.0 109.502 -179.992 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.67 -159.46 9.94 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.691 HG22 ' O ' ' A' ' 64' ' ' ASP . 0.2 OUTLIER -149.06 170.68 17.85 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.277 -1.131 . . . . 0.0 109.048 179.987 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.552 HG12 ' H ' ' A' ' 19' ' ' ALA . 3.8 t -85.66 171.53 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.051 -1.031 . . . . 0.0 109.409 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.578 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -118.91 -74.19 0.62 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.462 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.453 ' HA ' ' HG2' ' A' ' 62' ' ' GLU . 65.2 m -160.21 132.3 6.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.144 -0.972 . . . . 0.0 109.622 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.675 ' CH2' HD12 ' A' ' 58' ' ' ILE . 34.0 m95 -89.85 82.23 6.24 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.256 -0.902 . . . . 0.0 109.397 179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.625 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.4 m80 -42.67 -57.12 2.85 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.401 -0.812 . . . . 0.0 109.484 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.3 163.58 12.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.245 -0.909 . . . . 0.0 109.66 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.498 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 23.6 mttt -114.46 165.8 13.01 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.346 -0.846 . . . . 0.0 109.152 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.533 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.76 102.5 1.62 Allowed 'Trans proline' 0 C--N 1.308 -1.582 0 C-N-CA 122.544 2.163 . . . . 0.0 110.419 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 145.01 -13.43 1.91 Allowed Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.8 mm-40 -96.61 -172.13 2.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.234 -1.156 . . . . 0.0 109.512 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.68 161.99 13.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.533 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.462 ' O ' ' OD2' ' A' ' 52' ' ' ASP . 35.5 t -138.36 153.42 26.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.239 -0.913 . . . . 0.0 109.479 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.409 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.6 OUTLIER -126.71 137.6 53.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.929 . . . . 0.0 109.5 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.514 ' HG2' ' N ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -42.98 146.04 0.43 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.302 -0.874 . . . . 0.0 109.639 -179.939 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.514 ' N ' ' HG2' ' A' ' 31' ' ' ARG . 3.1 t70 67.66 38.82 2.9 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.7 ' N ' HD11 ' A' ' 48' ' ' LEU . 8.6 tp10 -127.84 115.94 19.39 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.194 -0.941 . . . . 0.0 109.455 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.625 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 41.4 tp -43.25 162.37 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.283 -0.886 . . . . 0.0 109.463 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.456 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 29.6 mm -135.49 -48.05 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 109.63 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.506 HG12 ' HB ' ' A' ' 47' ' ' VAL . 14.3 p -160.18 131.55 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.158 -0.964 . . . . 0.0 109.539 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.578 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 3.4 m-20 -90.32 150.82 21.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.5 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 60.9 mt -119.54 155.48 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -0.913 . . . . 0.0 109.501 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.46 ' CG ' ' HB ' ' A' ' 17' ' ' THR . 12.1 pt-20 -128.58 154.51 46.12 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.257 -0.902 . . . . 0.0 109.539 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -141.58 175.5 9.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.258 -0.902 . . . . 0.0 109.425 -179.93 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 4.2 t0 -42.83 -60.67 1.51 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.334 -0.853 . . . . 0.0 109.636 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 15.7 mttt -138.5 36.44 2.25 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.29 -0.881 . . . . 0.0 109.464 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 90.6 t -147.65 127.35 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.28 -0.887 . . . . 0.0 109.436 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.6 t -102.3 152.0 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.277 -0.889 . . . . 0.0 109.463 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.9 176.33 9.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 109.468 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -141.54 149.63 41.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 109.495 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.506 ' HB ' HG12 ' A' ' 36' ' ' VAL . 30.5 t -115.59 96.9 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.285 -0.885 . . . . 0.0 109.431 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.7 HD11 ' N ' ' A' ' 33' ' ' GLU . 29.8 tp -96.04 153.16 17.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.35 -0.843 . . . . 0.0 109.52 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.471 ' N ' ' HG ' ' A' ' 48' ' ' LEU . . . -83.41 148.07 27.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.192 -0.942 . . . . 0.0 109.446 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.562 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -99.77 17.98 19.34 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.936 . . . . 0.0 109.485 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.562 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 171.87 154.01 0.07 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.288 -0.883 . . . . 0.0 109.483 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.501 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -66.09 170.94 5.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.308 -0.87 . . . . 0.0 109.289 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.501 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.26 -159.81 28.39 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.0 t -135.62 125.11 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -1.159 . . . . 0.0 109.51 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.59 HG22 ' N ' ' A' ' 56' ' ' ALA . 4.9 mt -59.11 165.5 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.938 . . . . 0.0 109.528 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.59 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -104.45 -67.19 0.91 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.46 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.533 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -169.25 140.63 2.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.227 -0.921 . . . . 0.0 109.565 -179.991 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.675 HD12 ' CH2' ' A' ' 21' ' ' TRP . 23.3 mm -93.77 138.97 19.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.233 -0.917 . . . . 0.0 109.393 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 18.0 t -89.94 -39.42 12.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.237 -0.914 . . . . 0.0 109.435 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.462 ' HD3' ' O ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -102.39 158.06 16.47 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.222 -0.924 . . . . 0.0 109.411 179.974 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -117.27 163.32 16.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.303 -0.873 . . . . 0.0 109.432 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.453 ' HG2' ' HA ' ' A' ' 20' ' ' THR . 2.3 mp0 -55.28 134.41 49.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.22 -0.925 . . . . 0.0 109.447 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 100.68 -8.29 58.12 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.691 ' O ' HG22 ' A' ' 17' ' ' THR . 0.2 OUTLIER -92.06 170.44 9.84 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.244 -1.151 . . . . 0.0 109.362 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.498 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.6 t -100.36 164.15 12.06 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.565 -0.71 . . . . 0.0 109.511 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 66' ' ' VAL . 22.6 m -130.83 131.08 64.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -0.905 . . . . 0.0 109.44 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -101.59 162.04 13.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -0.885 . . . . 0.0 109.541 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.1 t -59.82 110.03 1.07 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.514 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.79 20.6 16.25 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -83.71 133.91 34.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.264 -1.139 . . . . 0.0 109.499 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.464 ' CD1' ' OD2' ' A' ' 3' ' ' ASP . 9.5 tp -83.26 125.38 31.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.504 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.456 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 4.5 mt -100.0 -22.17 15.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.264 -0.897 . . . . 0.0 109.477 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.67 173.49 27.14 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.466 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 39.7 pttt -129.46 153.01 48.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -1.122 . . . . 0.0 109.493 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.48 HD12 ' HA ' ' A' ' 55' ' ' ILE . 22.9 tp -96.22 153.02 18.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -0.898 . . . . 0.0 109.464 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.599 HG22 ' H ' ' A' ' 77' ' ' GLU . 8.3 m -95.42 172.95 7.77 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.289 -0.882 . . . . 0.0 109.45 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.599 ' H ' HG22 ' A' ' 76' ' ' THR . 5.0 mt-10 -66.02 -172.73 0.15 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.226 -0.921 . . . . 0.0 109.434 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -119.31 -42.95 0.53 Allowed Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 CA-C-O 117.96 -1.467 . . . . 0.0 109.518 -179.977 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.435 ' C ' HG13 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.435 HG13 ' C ' ' A' ' 1' ' ' ALA . 8.5 mt -142.58 109.74 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.223 -0.923 . . . . 0.0 109.472 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' A' ' 4' ' ' ILE . 10.6 t0 -68.37 152.57 45.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.527 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.502 ' N ' ' OD1' ' A' ' 3' ' ' ASP . 8.2 mm -123.74 136.35 60.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.902 . . . . 0.0 109.524 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.34 172.5 12.67 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.281 -0.887 . . . . 0.0 109.447 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.475 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -69.06 158.82 85.47 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.475 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.04 114.86 3.66 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.707 2.271 . . . . 0.0 110.381 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 29.7 m -46.52 126.12 7.81 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.265 -0.897 . . . . 0.0 109.464 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.572 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 1.3 p90 -107.89 151.86 41.4 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.333 -0.854 . . . . 0.0 109.445 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.04 -169.64 0.8 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.68 2.253 . . . . 0.0 110.385 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.438 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.4 OUTLIER -66.61 -45.15 80.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.273 -0.892 . . . . 0.0 109.476 -179.984 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.6 OUTLIER -42.75 -36.85 1.57 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.373 -0.83 . . . . 0.0 109.578 -179.838 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.637 HG22 ' O ' ' A' ' 15' ' ' ASP . 18.5 mm -114.58 108.92 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.249 -0.907 . . . . 0.0 109.411 179.954 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.46 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -74.67 -1.48 21.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.217 -0.927 . . . . 0.0 109.667 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.637 ' O ' HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER 166.92 -174.12 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.917 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.463 ' C ' HG22 ' A' ' 66' ' ' VAL . . . -144.63 -165.96 11.32 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.523 ' CG2' ' O ' ' A' ' 64' ' ' ASP . 0.4 OUTLIER -149.99 128.27 12.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.293 -1.122 . . . . 0.0 109.397 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.476 HG12 ' N ' ' A' ' 19' ' ' ALA . 61.3 t -43.83 159.49 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.217 -0.927 . . . . 0.0 109.529 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.476 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -111.99 -71.02 0.78 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.253 -0.904 . . . . 0.0 109.574 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.6 m -159.28 133.12 7.43 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.264 -0.897 . . . . 0.0 109.594 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.633 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.2 m95 -89.92 85.65 6.41 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.3 -0.875 . . . . 0.0 109.486 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.604 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.4 m80 -42.86 -60.09 1.73 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.325 -0.859 . . . . 0.0 109.352 -179.864 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -105.37 155.0 19.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.231 -0.918 . . . . 0.0 109.495 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.413 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 9.6 mttt -95.01 167.26 13.29 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.361 -0.837 . . . . 0.0 109.519 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.49 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.5 Cg_endo -76.75 104.56 1.93 Allowed 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.682 2.255 . . . . 0.0 110.494 179.892 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 140.45 -9.72 2.93 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -90.63 -172.17 3.3 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -1.151 . . . . 0.0 109.514 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -101.85 149.19 24.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -0.892 . . . . 0.0 109.421 -179.951 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -130.49 162.65 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.295 -0.878 . . . . 0.0 109.444 179.895 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 6.7 tttp -133.22 142.56 48.63 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.224 -0.923 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.46 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 10.5 ttp-105 -42.92 137.45 2.35 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.285 -0.884 . . . . 0.0 109.588 -179.863 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.784 ' HA ' HD21 ' A' ' 48' ' ' LEU . 23.9 t0 72.27 52.04 0.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.256 -0.902 . . . . 0.0 109.524 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.485 ' N ' HD11 ' A' ' 48' ' ' LEU . 0.5 OUTLIER -141.44 114.58 8.67 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.274 -0.891 . . . . 0.0 109.425 -179.978 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.635 ' N ' HD12 ' A' ' 48' ' ' LEU . 54.3 tp -42.74 162.31 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.323 -0.861 . . . . 0.0 109.6 -179.937 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 1.088 HD11 ' HB2' ' A' ' 49' ' ' ALA . 4.2 mt -140.84 -42.03 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.214 -0.929 . . . . 0.0 109.536 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.639 HG12 ' HB ' ' A' ' 47' ' ' VAL . 7.2 p -158.75 139.88 4.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.319 -0.863 . . . . 0.0 109.502 179.925 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -98.62 149.97 22.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.938 . . . . 0.0 109.544 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.448 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 32.8 mm -104.46 140.79 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.288 -0.883 . . . . 0.0 109.424 -179.993 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -126.36 92.51 3.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.503 -179.975 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.44 ' OG1' ' HB ' ' A' ' 43' ' ' VAL . 3.0 p -87.81 -173.49 4.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.296 -0.878 . . . . 0.0 109.515 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 40' ' ' THR . 9.7 t0 -42.8 -61.56 1.23 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.367 -0.833 . . . . 0.0 109.626 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -141.62 33.25 1.63 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.477 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.44 ' HB ' ' OG1' ' A' ' 40' ' ' THR . 9.8 t -132.24 109.86 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.166 -0.959 . . . . 0.0 109.447 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.3 t -93.11 126.45 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.319 -0.863 . . . . 0.0 109.524 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 45' ' ' MET . . . . . 0.448 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 0.3 OUTLIER -123.95 -178.27 4.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.321 -0.862 . . . . 0.0 109.477 -180.0 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.424 ' HG3' ' C ' ' A' ' 45' ' ' MET . 0.7 OUTLIER -133.77 155.17 50.27 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.256 -0.902 . . . . 0.0 109.544 179.959 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.639 ' HB ' HG12 ' A' ' 36' ' ' VAL . 35.0 t -126.84 98.19 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.332 -0.855 . . . . 0.0 109.459 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.911 HD23 ' O ' ' A' ' 49' ' ' ALA . 2.6 tt -107.67 151.44 25.65 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.888 . . . . 0.0 109.426 -179.955 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 1.088 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -83.76 161.12 21.09 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.205 -0.935 . . . . 0.0 109.485 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.86 17.83 23.27 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.194 -0.941 . . . . 0.0 109.396 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -178.58 173.75 1.29 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.298 -0.876 . . . . 0.0 109.494 -179.954 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -77.55 170.92 15.73 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.213 -0.929 . . . . 0.0 109.306 179.953 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.72 175.01 23.77 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.946 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.779 ' O ' HG22 ' A' ' 76' ' ' THR . 47.1 t -121.64 124.9 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.326 -1.102 . . . . 0.0 109.447 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.49 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 16.5 mm -58.22 162.36 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.256 -0.902 . . . . 0.0 109.509 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.476 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -101.67 -67.42 0.87 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.193 -0.942 . . . . 0.0 109.41 -179.965 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.486 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 2.2 mt-10 -162.46 135.09 5.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.445 -179.983 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.633 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 27.3 mm -93.17 122.23 44.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.224 -0.922 . . . . 0.0 109.409 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.5 t -89.95 -15.7 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.508 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.629 ' HB2' HD23 ' A' ' 72' ' ' LEU . 1.5 mptt -110.46 125.47 53.32 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.434 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 -92.99 173.59 7.66 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.905 . . . . 0.0 109.496 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -69.49 147.96 50.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 109.564 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.67 -8.76 76.42 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.523 ' O ' ' CG2' ' A' ' 17' ' ' THR . 0.1 OUTLIER -84.49 170.83 13.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.206 -1.173 . . . . 0.0 109.313 -179.92 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.51 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.8 t -99.9 159.29 15.18 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.511 -0.743 . . . . 0.0 109.48 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.463 HG22 ' C ' ' A' ' 16' ' ' GLY . 29.9 m -122.54 160.51 24.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.222 -0.924 . . . . 0.0 109.452 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.532 HD23 ' N ' ' A' ' 68' ' ' SER . 0.6 OUTLIER -125.36 174.54 8.09 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.179 -0.95 . . . . 0.0 109.492 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.532 ' N ' HD23 ' A' ' 67' ' ' LEU . 35.9 t -72.92 85.97 1.28 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.495 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 108.85 22.51 6.92 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -78.45 118.03 20.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -1.109 . . . . 0.0 109.459 -179.946 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.414 HD23 ' C ' ' A' ' 71' ' ' LEU . 7.6 tt -65.77 131.68 46.88 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.281 -0.887 . . . . 0.0 109.448 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.629 HD23 ' HB2' ' A' ' 60' ' ' LYS . 4.4 mt -115.86 -13.47 11.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.281 -0.887 . . . . 0.0 109.491 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.77 163.69 22.12 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.98 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 7.2 mttt -124.54 145.95 49.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.24 -1.153 . . . . 0.0 109.483 179.939 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -91.65 147.85 22.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.289 -0.882 . . . . 0.0 109.463 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.779 HG22 ' O ' ' A' ' 54' ' ' VAL . 2.9 t -107.04 -157.56 0.62 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.911 . . . . 0.0 109.787 179.976 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.675 ' N ' HG23 ' A' ' 76' ' ' THR . 42.2 mt-10 -83.38 175.11 10.09 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.986 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.463 ' HA3' ' HA2' ' A' ' 53' ' ' GLY . . . -171.54 140.1 5.7 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 CA-C-O 118.011 -1.438 . . . . 0.0 109.558 179.988 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.49 ' O ' HD13 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.513 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.49 HD13 ' O ' ' A' ' 1' ' ' ALA . 20.8 mm -117.17 97.9 6.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.273 -0.892 . . . . 0.0 109.439 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -60.5 136.42 58.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.24 -0.912 . . . . 0.0 109.472 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 80.5 mt -114.47 121.3 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.181 -0.949 . . . . 0.0 109.438 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 17.3 mtpt -123.25 178.15 5.25 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.213 -0.93 . . . . 0.0 109.508 179.966 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -84.18 164.58 42.99 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.255 -0.903 . . . . 0.0 109.505 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.9 Cg_endo -77.99 117.76 4.25 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.644 2.229 . . . . 0.0 110.451 179.928 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 8' ' ' THR . 0.0 OUTLIER -53.97 136.47 41.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.241 -0.912 . . . . 0.0 109.474 179.953 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.559 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 21.8 m-85 -95.33 155.34 38.9 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.469 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.416 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.1 Cg_endo -77.99 -178.53 4.68 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.71 2.273 . . . . 0.0 110.369 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.5 ' HG3' ' N ' ' A' ' 12' ' ' SER . 16.9 pt-20 -61.64 -43.85 98.08 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.5 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.82 -72.93 0.05 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.32 -0.863 . . . . 0.0 109.631 -179.88 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.474 HG22 ' N ' ' A' ' 14' ' ' ALA . 1.8 mp -91.16 167.52 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.243 -0.911 . . . . 0.0 109.446 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.474 ' N ' HG22 ' A' ' 13' ' ' ILE . . . -142.09 44.83 1.67 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.448 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.559 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 0.3 OUTLIER 168.74 -169.91 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.3 -0.875 . . . . 0.0 109.456 179.938 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.485 ' O ' HG23 ' A' ' 65' ' ' THR . . . -168.21 -170.04 32.43 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.996 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.541 HG23 ' O ' ' A' ' 64' ' ' ASP . 29.9 m -150.07 126.69 10.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -1.146 . . . . 0.0 109.514 179.986 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.572 HG12 ' N ' ' A' ' 19' ' ' ALA . 21.8 t -51.89 169.92 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.572 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -113.85 -75.34 0.6 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.229 -0.919 . . . . 0.0 109.534 -179.936 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.524 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 23.2 m -158.38 133.54 8.58 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.221 -0.924 . . . . 0.0 109.529 -179.918 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.623 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.85 84.77 6.26 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.232 -0.917 . . . . 0.0 109.524 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.769 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.9 m80 -43.07 -67.42 0.28 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.298 -0.876 . . . . 0.0 109.35 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -89.26 -171.92 3.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.42 179.911 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.488 ' HB2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.7 164.76 40.53 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.282 -0.886 . . . . 0.0 109.445 179.974 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.488 ' HD2' ' HB2' ' A' ' 24' ' ' LYS . 34.9 Cg_endo -77.18 101.21 1.48 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.559 2.173 . . . . 0.0 110.4 179.938 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 149.75 -16.8 1.09 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.896 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -93.0 -179.03 4.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -1.152 . . . . 0.0 109.437 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.52 159.62 18.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.21 -0.931 . . . . 0.0 109.519 179.953 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.417 HG12 ' N ' ' A' ' 30' ' ' LYS . 80.5 t -143.57 156.33 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.393 -179.973 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.417 ' N ' HG12 ' A' ' 29' ' ' VAL . 49.1 tttt -140.79 141.92 34.74 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 30' ' ' LYS . 5.7 ttm180 -42.82 151.34 0.13 Allowed 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.356 -0.84 . . . . 0.0 109.634 -179.848 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.416 ' HA ' HD23 ' A' ' 48' ' ' LEU . 7.9 t70 68.14 40.56 2.15 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.221 -0.924 . . . . 0.0 109.465 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 34' ' ' LEU . 1.6 tt0 -140.14 111.05 6.9 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 0.0 109.467 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.769 HD21 ' NE2' ' A' ' 22' ' ' HIS . 51.2 tp -42.76 163.44 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.381 -0.825 . . . . 0.0 109.611 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.501 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 39.5 mt -147.18 -43.51 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.227 -0.921 . . . . 0.0 109.612 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.435 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 11.4 p -159.81 136.87 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.305 -0.872 . . . . 0.0 109.531 -179.925 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.543 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 3.5 m-20 -94.85 163.17 13.45 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.307 -0.871 . . . . 0.0 109.422 179.84 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.422 HD11 ' CG2' ' A' ' 47' ' ' VAL . 24.3 mt -129.33 156.87 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.119 -0.988 . . . . 0.0 109.527 -179.969 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.17 134.45 50.16 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.288 -0.882 . . . . 0.0 109.503 179.938 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.674 HG22 ' O ' ' A' ' 43' ' ' VAL . 5.6 t -124.24 -163.94 1.2 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.183 -0.948 . . . . 0.0 109.392 180.0 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.471 ' N ' HG23 ' A' ' 40' ' ' THR . 42.3 t0 -42.3 -68.87 0.16 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.247 -0.908 . . . . 0.0 109.741 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 42' ' ' LYS . . . . . 0.462 ' O ' HG23 ' A' ' 43' ' ' VAL . 1.4 mttp -141.84 48.34 1.61 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.192 -0.942 . . . . 0.0 109.513 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.674 ' O ' HG22 ' A' ' 40' ' ' THR . 76.4 t -156.04 119.92 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.229 -0.92 . . . . 0.0 109.428 -179.956 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.0 t -89.95 118.11 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.216 -0.928 . . . . 0.0 109.523 -179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 1.6 mtp -96.79 -170.8 2.12 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.276 -0.89 . . . . 0.0 109.437 179.945 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 5.2 pt-20 -149.15 159.6 44.1 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.287 -0.883 . . . . 0.0 109.448 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.435 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 68.0 t -130.74 108.28 15.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.263 -0.898 . . . . 0.0 109.459 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.504 ' HG ' ' N ' ' A' ' 34' ' ' LEU . 0.1 OUTLIER -93.85 172.59 8.15 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.294 -0.879 . . . . 0.0 109.537 179.962 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.465 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -76.16 136.01 39.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.278 -0.888 . . . . 0.0 109.419 -179.979 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.676 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -95.67 10.12 37.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.531 179.975 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.676 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 165.54 140.8 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.272 -0.892 . . . . 0.0 109.451 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.508 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.31 170.92 0.13 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 109.35 -179.982 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.508 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 140.29 -155.07 24.41 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 55.6 t -134.79 128.62 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.304 -1.116 . . . . 0.0 109.464 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.457 HG22 ' N ' ' A' ' 56' ' ' ALA . 17.0 mm -56.35 159.36 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.28 -0.888 . . . . 0.0 109.511 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.457 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -99.66 -65.55 0.96 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.341 -0.849 . . . . 0.0 109.535 179.975 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.487 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 6.4 tt0 -173.1 132.77 0.51 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.158 -0.963 . . . . 0.0 109.528 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.623 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 28.4 mm -91.64 125.51 44.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.886 . . . . 0.0 109.391 179.953 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 23.2 t -90.08 -39.37 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.219 -0.926 . . . . 0.0 109.449 179.974 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.471 ' HG2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -95.03 128.29 41.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.485 179.951 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 71.2 m-80 -87.91 155.98 19.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.303 -0.873 . . . . 0.0 109.446 -179.95 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.529 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -65.02 143.57 57.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.303 -0.873 . . . . 0.0 109.5 -179.937 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 97.11 -13.75 64.48 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.988 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.541 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -92.41 170.89 9.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.284 -1.127 . . . . 0.0 109.303 179.955 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.501 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 21.8 m -98.12 139.54 33.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.486 -0.759 . . . . 0.0 109.516 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.471 HG12 ' HG2' ' A' ' 60' ' ' LYS . 6.0 m -114.78 -161.95 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.289 -0.882 . . . . 0.0 109.391 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -146.62 170.84 16.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.278 -0.889 . . . . 0.0 109.49 -179.932 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 5.6 t -69.01 104.81 2.21 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.48 179.988 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 102.56 10.71 37.54 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.984 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 31.2 tp10 -72.3 125.53 27.58 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -1.132 . . . . 0.0 109.404 -179.967 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -74.58 121.42 21.56 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -0.917 . . . . 0.0 109.439 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.447 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 9.1 mt -95.85 -22.53 17.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.222 -0.923 . . . . 0.0 109.489 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 168.38 174.63 37.31 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -127.33 135.82 51.06 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.23 -1.159 . . . . 0.0 109.51 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.4 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 0.6 OUTLIER -90.05 138.23 31.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.392 -179.92 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.537 HG22 ' H ' ' A' ' 77' ' ' GLU . 9.2 m -96.9 171.25 8.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.268 -0.895 . . . . 0.0 109.481 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.537 ' H ' HG22 ' A' ' 76' ' ' THR . 3.0 mp0 -84.98 -65.05 1.05 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.29 -0.881 . . . . 0.0 109.481 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 129.6 117.64 1.98 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 CA-C-O 117.981 -1.455 . . . . 0.0 109.608 -179.959 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.66 HD12 HD13 ' A' ' 75' ' ' LEU . 49.9 mt -133.95 102.52 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.339 -0.85 . . . . 0.0 109.479 179.968 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -75.61 118.47 18.49 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.202 -0.936 . . . . 0.0 109.43 -179.933 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.8 mt -96.04 98.73 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.275 -0.89 . . . . 0.0 109.508 179.935 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.45 ' HG3' ' HA ' ' A' ' 71' ' ' LEU . 7.5 ttpt -118.78 163.93 16.15 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -0.884 . . . . 0.0 109.487 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.539 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -65.5 160.78 57.08 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.897 . . . . 0.0 109.464 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.539 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.1 Cg_endo -78.1 129.76 9.86 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.613 2.209 . . . . 0.0 110.396 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.633 ' O ' HG23 ' A' ' 8' ' ' THR . 6.9 t -56.36 111.92 1.11 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.91 . . . . 0.0 109.445 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -74.24 126.6 88.91 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.329 -0.857 . . . . 0.0 109.345 -179.969 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.464 ' HD2' HD12 ' A' ' 13' ' ' ILE . 36.1 Cg_endo -78.42 -159.44 0.1 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.398 2.065 . . . . 0.0 110.388 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.9 mm-40 -73.36 -55.0 6.98 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.161 -0.962 . . . . 0.0 109.398 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.435 ' C ' ' O ' ' A' ' 11' ' ' GLU . 17.0 t -42.87 -45.42 4.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.358 -0.839 . . . . 0.0 109.585 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.592 HG22 ' H ' ' A' ' 15' ' ' ASP . 16.9 mt -91.3 163.61 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.293 -0.879 . . . . 0.0 109.491 -179.96 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.416 ' N ' HG22 ' A' ' 13' ' ' ILE . . . -143.89 13.37 1.68 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.306 -0.871 . . . . 0.0 109.436 -179.965 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.592 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER 172.23 -172.27 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.454 -179.968 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.42 172.45 40.19 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.497 HG23 ' O ' ' A' ' 64' ' ' ASP . 68.3 m -149.25 125.66 10.9 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.254 -1.145 . . . . 0.0 109.425 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 19' ' ' ALA . 24.9 t -50.01 169.41 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.203 -0.935 . . . . 0.0 109.515 179.946 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.58 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -112.76 -73.27 0.67 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.158 -0.964 . . . . 0.0 109.502 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.552 HG23 ' OE1' ' A' ' 62' ' ' GLU . 52.4 m -159.62 131.21 6.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.483 -179.891 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.633 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.4 m95 -89.91 84.16 6.2 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 121.261 -0.899 . . . . 0.0 109.441 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.722 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.5 m80 -42.56 -64.89 0.54 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.373 -0.829 . . . . 0.0 109.454 -179.709 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 5.7 mptt -95.15 -172.19 2.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.244 -0.91 . . . . 0.0 109.532 -179.922 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.67 168.37 17.77 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.312 -0.868 . . . . 0.0 109.452 -179.965 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.494 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.64 133.09 13.86 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 C-N-CA 122.648 2.232 . . . . 0.0 110.409 179.878 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.8 -11.47 20.82 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.917 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 53.3 mm-40 -97.13 -174.91 3.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.241 -1.152 . . . . 0.0 109.502 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.03 172.65 8.42 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.222 -0.924 . . . . 0.0 109.51 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 t -141.91 155.08 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.974 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -131.65 128.26 38.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.228 -0.92 . . . . 0.0 109.496 179.969 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 3.2 ttt-85 -42.83 137.27 2.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.394 -0.817 . . . . 0.0 109.601 -179.822 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.497 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 10.7 t0 74.97 33.27 0.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.259 -0.901 . . . . 0.0 109.427 179.955 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.488 ' C ' ' CD1' ' A' ' 48' ' ' LEU . 1.2 tt0 -124.29 115.68 21.42 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.258 -0.902 . . . . 0.0 109.503 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.722 HD21 ' NE2' ' A' ' 22' ' ' HIS . 45.0 tp -43.11 150.94 0.16 Allowed 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.231 -0.918 . . . . 0.0 109.525 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.462 HD11 ' HB2' ' A' ' 49' ' ' ALA . 13.4 mt -129.69 -46.43 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.223 -0.923 . . . . 0.0 109.588 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.515 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.7 p -162.83 142.72 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.233 -0.917 . . . . 0.0 109.461 -179.908 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.49 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 33.5 m-20 -100.73 163.03 12.51 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.284 -0.885 . . . . 0.0 109.437 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.548 HG22 ' N ' ' A' ' 39' ' ' GLU . 9.6 mt -129.33 162.86 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.174 -0.954 . . . . 0.0 109.483 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.548 ' N ' HG22 ' A' ' 38' ' ' ILE . 6.1 mm-40 -133.87 151.65 51.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 -179.978 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -140.25 -177.53 5.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.256 -0.903 . . . . 0.0 109.486 179.971 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 40' ' ' THR . 5.4 t70 -42.95 -66.47 0.37 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.326 -0.859 . . . . 0.0 109.629 -179.907 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.2 mttp -135.85 40.69 2.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.286 -0.884 . . . . 0.0 109.461 -179.974 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 52.5 t -151.49 128.18 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.273 -0.892 . . . . 0.0 109.463 -179.994 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.413 ' O ' HG13 ' A' ' 44' ' ' VAL . 9.0 p -98.58 134.41 37.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 0.0 109.442 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 45' ' ' MET . . . . . 0.448 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 1.3 mtt -114.59 -172.45 2.11 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 6.1 pt-20 -154.73 164.56 38.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.254 -0.904 . . . . 0.0 109.461 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.515 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 58.2 t -134.69 103.55 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 109.442 -179.927 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.632 HD22 HD12 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -93.96 167.04 11.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.2 -0.937 . . . . 0.0 109.52 179.984 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.462 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.54 136.1 33.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.405 -179.929 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.645 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -95.87 9.9 39.03 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.162 -0.961 . . . . 0.0 109.466 -179.977 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.645 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 167.06 142.93 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.233 -0.917 . . . . 0.0 109.478 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.505 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -58.63 170.96 0.69 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.317 -0.864 . . . . 0.0 109.375 179.96 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.505 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.78 -157.43 27.27 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.928 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.7 t -128.64 127.11 66.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.25 -1.147 . . . . 0.0 109.572 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.462 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 14.4 mm -64.0 156.79 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.27 -0.894 . . . . 0.0 109.437 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -95.55 -69.57 0.75 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.21 -0.931 . . . . 0.0 109.416 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.494 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 1.2 pt-20 -172.27 142.48 1.35 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.252 -0.905 . . . . 0.0 109.449 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.633 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 24.5 mm -94.8 129.54 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.23 -0.919 . . . . 0.0 109.48 -179.977 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.1 t -90.15 -28.99 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.29 -0.881 . . . . 0.0 109.442 179.987 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.481 ' HD3' ' HG2' ' A' ' 70' ' ' GLU . 0.0 OUTLIER -109.16 131.99 54.54 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.182 -0.949 . . . . 0.0 109.529 179.926 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -85.47 155.93 21.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.165 -0.96 . . . . 0.0 109.461 179.992 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.552 ' OE1' HG23 ' A' ' 20' ' ' THR . 0.0 OUTLIER -68.29 141.51 55.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.914 . . . . 0.0 109.476 179.958 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 96.12 -11.3 67.58 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.505 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -95.95 170.9 8.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.262 -1.14 . . . . 0.0 109.327 -179.986 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.505 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 13.0 t -89.02 157.95 18.18 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.492 -0.755 . . . . 0.0 109.516 -179.992 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.687 HG11 HD21 ' A' ' 72' ' ' LEU . 1.9 m -127.21 -174.82 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.245 -0.909 . . . . 0.0 109.464 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -140.96 177.81 7.79 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.336 -0.853 . . . . 0.0 109.481 -179.957 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.4 t -69.46 124.17 23.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.489 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 75.24 21.89 77.09 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 179.951 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.481 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 42.6 tp10 -74.58 103.65 4.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.191 -1.182 . . . . 0.0 109.472 179.966 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.813 HD11 ' HG3' ' A' ' 74' ' ' LYS . 0.7 OUTLIER -60.93 105.47 0.47 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.213 -0.929 . . . . 0.0 109.438 180.0 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.687 HD21 HG11 ' A' ' 66' ' ' VAL . 1.4 mt -84.22 -11.46 56.45 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.249 -0.907 . . . . 0.0 109.503 179.94 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.77 165.39 15.82 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.536 -1.425 . . . . 0.0 109.536 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.813 ' HG3' HD11 ' A' ' 71' ' ' LEU . 29.7 mtmt -125.83 151.85 46.27 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.23 -1.159 . . . . 0.0 109.484 179.967 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.667 HD23 ' O ' ' A' ' 76' ' ' THR . 1.9 tt -98.1 152.54 19.21 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.276 -0.89 . . . . 0.0 109.496 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.667 ' O ' HD23 ' A' ' 75' ' ' LEU . 14.2 m -107.24 171.86 7.15 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.243 -0.911 . . . . 0.0 109.438 -179.974 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.565 ' H ' HG22 ' A' ' 76' ' ' THR . 19.0 mt-10 -75.35 172.17 12.94 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.177 -0.952 . . . . 0.0 109.532 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -95.94 -164.63 33.98 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.282 0 CA-C-O 117.982 -1.454 . . . . 0.0 109.602 -179.985 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.43 ' O ' HD13 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 . . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.43 HD13 ' O ' ' A' ' 1' ' ' ALA . 25.4 mm -136.09 109.85 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.179 -0.95 . . . . 0.0 109.409 -179.982 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.464 ' HA ' ' HG2' ' A' ' 74' ' ' LYS . 11.7 t70 -89.3 129.93 35.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.192 -0.942 . . . . 0.0 109.562 179.9 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mp -104.81 128.84 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.265 -0.897 . . . . 0.0 109.469 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 48.3 mtpt -130.43 176.25 8.29 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.317 -0.864 . . . . 0.0 109.468 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.94 156.55 60.78 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.479 -179.97 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.97 134.53 13.27 Favored 'Trans proline' 0 C--N 1.308 -1.554 0 C-N-CA 122.664 2.242 . . . . 0.0 110.404 179.959 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.442 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -45.49 115.04 0.85 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.223 -0.923 . . . . 0.0 109.502 179.995 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -64.34 149.27 94.96 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.487 179.969 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.405 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -78.02 174.81 11.95 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.598 2.198 . . . . 0.0 110.402 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 12' ' ' SER . 30.5 tt0 -66.75 -55.31 15.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.313 -0.867 . . . . 0.0 109.463 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 11' ' ' GLU . 35.1 t -42.81 -40.86 3.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.361 -0.837 . . . . 0.0 109.581 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.64 HG22 ' H ' ' A' ' 15' ' ' ASP . 12.3 mm -94.35 152.4 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.266 -0.896 . . . . 0.0 109.452 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -126.43 9.29 7.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.26 -0.9 . . . . 0.0 109.497 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.64 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER 173.64 -172.03 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.206 -0.934 . . . . 0.0 109.414 -179.994 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.16 -176.09 27.88 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.988 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.566 HG22 ' O ' ' A' ' 64' ' ' ASP . 0.3 OUTLIER -150.03 128.94 12.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -1.121 . . . . 0.0 109.431 -179.961 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.572 HG12 ' N ' ' A' ' 19' ' ' ALA . 53.0 t -43.96 165.74 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.238 -0.914 . . . . 0.0 109.537 -179.943 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.58 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -117.52 -72.8 0.67 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.266 -0.896 . . . . 0.0 109.422 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 34.5 m -160.05 127.48 4.57 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.261 -0.899 . . . . 0.0 109.579 -179.977 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.629 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 33.1 m95 -89.85 87.37 6.93 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 121.207 -0.933 . . . . 0.0 109.519 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.772 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.8 m80 -42.46 -57.91 2.45 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.416 -0.803 . . . . 0.0 109.522 -179.76 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 9.3 mttp -106.19 178.94 4.41 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.218 -0.927 . . . . 0.0 109.604 -179.953 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -118.31 167.51 11.32 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.271 -0.893 . . . . 0.0 109.497 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.513 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.3 Cg_endo -76.94 136.31 16.46 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.617 2.211 . . . . 0.0 110.413 179.96 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.34 -8.77 35.51 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.518 ' O ' HG13 ' A' ' 54' ' ' VAL . 4.0 mt-10 -93.5 -175.39 3.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.227 -1.16 . . . . 0.0 109.477 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.61 147.77 27.26 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.93 . . . . 0.0 109.462 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 m -147.56 169.48 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.236 -0.915 . . . . 0.0 109.421 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.427 ' O ' ' C ' ' A' ' 31' ' ' ARG . 16.5 tttp -133.06 143.39 49.32 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.252 -0.905 . . . . 0.0 109.442 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.464 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.82 152.32 0.11 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.231 -0.918 . . . . 0.0 109.624 -179.89 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.464 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 26.0 t70 69.04 41.78 1.37 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -0.907 . . . . 0.0 109.418 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.437 ' C ' ' HG ' ' A' ' 48' ' ' LEU . 10.8 tt0 -140.97 117.42 10.8 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.325 -0.859 . . . . 0.0 109.456 179.995 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.772 HD21 ' NE2' ' A' ' 22' ' ' HIS . 48.8 tp -42.96 163.34 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.241 -0.912 . . . . 0.0 109.562 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.596 HD11 ' HB2' ' A' ' 49' ' ' ALA . 59.5 mt -149.5 -43.27 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.156 -0.965 . . . . 0.0 109.522 -179.948 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.526 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 9.3 p -157.75 143.32 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.273 -0.892 . . . . 0.0 109.51 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.58 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 3.7 m-20 -108.54 147.49 31.67 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 109.458 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.484 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 46.7 mt -103.97 150.54 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.316 -0.865 . . . . 0.0 109.434 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.669 ' HG2' HG22 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -131.79 99.46 4.77 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.942 . . . . 0.0 109.468 -179.984 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.529 ' CG2' ' HB ' ' A' ' 43' ' ' VAL . 6.6 t -93.62 -170.14 2.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.915 . . . . 0.0 109.476 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 2.6 t0 -42.5 -56.33 3.1 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.294 -0.879 . . . . 0.0 109.767 -179.923 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 42' ' ' LYS . . . . . 0.473 ' C ' ' CG2' ' A' ' 43' ' ' VAL . 4.1 mtmp? -148.22 49.56 1.04 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -0.884 . . . . 0.0 109.561 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.529 ' HB ' ' CG2' ' A' ' 40' ' ' THR . 1.9 t -154.34 106.44 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.254 -0.904 . . . . 0.0 109.566 179.896 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.669 HG22 ' HG2' ' A' ' 39' ' ' GLU . 94.0 t -89.95 106.63 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.412 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 45' ' ' MET . . . . . 0.484 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 27.2 mtp -90.05 177.12 6.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 0.0 109.494 179.941 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -132.76 151.58 51.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.921 . . . . 0.0 109.425 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.526 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 85.7 t -127.11 107.55 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.246 -0.909 . . . . 0.0 109.456 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.703 HD12 ' HA ' ' A' ' 34' ' ' LEU . 1.1 mp -92.27 176.75 6.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.463 -179.96 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.596 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -81.9 123.78 29.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.174 -0.954 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.527 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -92.92 14.5 17.38 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.174 -0.954 . . . . 0.0 109.419 -179.922 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.527 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 174.49 124.96 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.287 -0.883 . . . . 0.0 109.411 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -59.43 170.91 0.9 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.206 -0.934 . . . . 0.0 109.298 -179.969 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.51 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 132.48 -140.56 11.93 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.968 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.65 ' H ' HG22 ' A' ' 76' ' ' THR . 46.4 t -139.12 132.12 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.16 -1.2 . . . . 0.0 109.433 179.979 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.588 HG22 ' N ' ' A' ' 56' ' ' ALA . 14.7 mm -63.69 169.57 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.271 -0.893 . . . . 0.0 109.506 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.588 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -108.52 -65.86 1.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.235 -0.916 . . . . 0.0 109.481 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.479 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -165.47 141.53 5.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.212 -0.93 . . . . 0.0 109.474 179.994 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.629 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 22.7 mm -95.04 125.59 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.192 -0.943 . . . . 0.0 109.425 179.96 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.447 ' C ' ' HE3' ' A' ' 60' ' ' LYS . 23.7 t -89.95 -15.26 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.529 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.585 ' HG2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -110.64 130.04 55.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.27 -0.894 . . . . 0.0 109.453 -179.991 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 57.9 m-80 -105.23 165.37 11.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.227 -0.921 . . . . 0.0 109.44 -179.931 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.402 ' HA ' ' HB ' ' A' ' 18' ' ' VAL . 29.6 mt-10 -67.2 136.6 55.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.538 179.931 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 95.08 2.74 62.21 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.566 ' O ' HG22 ' A' ' 17' ' ' THR . 0.1 OUTLIER -104.92 170.83 7.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.105 -1.233 . . . . 0.0 109.377 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.505 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.8 t -98.27 159.59 14.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.497 -0.752 . . . . 0.0 109.51 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.585 HG12 ' HG2' ' A' ' 60' ' ' LYS . 11.9 m -132.7 130.6 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.206 -0.934 . . . . 0.0 109.435 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -94.1 168.64 10.8 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.903 . . . . 0.0 109.509 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.442 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 44.5 t -60.75 130.25 45.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.521 179.989 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 72.74 27.44 69.12 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.999 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.533 ' HG2' ' CD ' ' A' ' 60' ' ' LYS . 0.4 OUTLIER -80.81 132.02 35.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.287 -1.125 . . . . 0.0 109.463 -179.989 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.561 HD23 ' C ' ' A' ' 71' ' ' LEU . 10.4 tt -78.31 122.09 25.28 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.294 -0.879 . . . . 0.0 109.46 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.439 ' O ' HG23 ' A' ' 58' ' ' ILE . 5.7 mt -96.9 -25.53 15.4 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.352 -0.843 . . . . 0.0 109.469 179.936 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 175.07 157.2 15.86 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.978 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.464 ' HG2' ' HA ' ' A' ' 3' ' ' ASP . 0.0 OUTLIER -113.82 159.14 20.13 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.319 -1.106 . . . . 0.0 109.481 179.982 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.456 HD12 ' HA ' ' A' ' 75' ' ' LEU . 19.7 tp -100.83 159.89 14.82 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.225 -0.922 . . . . 0.0 109.429 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.665 HG23 ' N ' ' A' ' 77' ' ' GLU . 2.9 t -86.79 -157.65 0.38 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.278 -0.889 . . . . 0.0 109.703 179.971 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.665 ' N ' HG23 ' A' ' 76' ' ' THR . 55.5 mm-40 -71.36 -90.57 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.757 0 CA-C-O 121.284 0.564 . . . . 0.0 109.487 179.958 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 102.54 -30.13 11.04 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 CA-C-O 117.933 -1.482 . . . . 0.0 109.507 179.945 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.623 HD12 HD22 ' A' ' 75' ' ' LEU . 8.1 mt -106.29 106.12 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.311 -0.868 . . . . 0.0 109.458 179.968 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.745 ' OD1' HD12 ' A' ' 71' ' ' LEU . 11.4 t70 -75.91 127.08 32.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.46 -179.983 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 18.7 mt -103.38 126.18 57.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.271 -0.893 . . . . 0.0 109.432 -179.991 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -132.96 159.23 40.57 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.303 -0.873 . . . . 0.0 109.481 179.972 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.643 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -74.94 164.45 61.33 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.426 -179.94 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.643 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.3 Cg_endo -78.08 179.78 6.18 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.676 2.25 . . . . 0.0 110.382 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.87 126.55 36.07 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.206 -0.933 . . . . 0.0 109.471 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -81.61 156.08 70.8 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.257 -0.902 . . . . 0.0 109.458 -179.969 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.451 ' HD2' HD12 ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.05 173.31 14.15 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.682 2.254 . . . . 0.0 110.363 179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 12' ' ' SER . 7.8 pt-20 -65.9 -47.9 73.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.266 -0.896 . . . . 0.0 109.46 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.428 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.74 -49.37 5.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.312 -0.868 . . . . 0.0 109.617 -179.935 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.552 HG22 ' H ' ' A' ' 15' ' ' ASP . 8.7 mt -91.22 166.52 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.284 -0.885 . . . . 0.0 109.475 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.425 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -131.9 11.61 4.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.249 -0.907 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.552 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.9 OUTLIER 169.96 -171.45 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.244 -0.91 . . . . 0.0 109.4 -179.966 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.23 -163.71 9.91 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.994 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.458 ' O ' ' HB2' ' A' ' 39' ' ' GLU . 26.5 m -149.95 128.21 12.08 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -1.123 . . . . 0.0 109.424 -179.962 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.5 t -50.74 154.2 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.285 -0.885 . . . . 0.0 109.445 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.532 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -99.84 -76.84 0.54 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.161 -0.962 . . . . 0.0 109.511 179.972 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.2 m -159.89 130.16 5.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.541 -179.998 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.657 ' CH2' HD12 ' A' ' 58' ' ' ILE . 35.1 m95 -89.8 84.94 6.29 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.225 -0.922 . . . . 0.0 109.559 -179.893 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 22' ' ' HIS . . . . . 0.735 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.8 m80 -43.26 -61.59 1.29 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.313 -0.867 . . . . 0.0 109.335 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -94.67 -172.1 2.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.345 -0.847 . . . . 0.0 109.493 179.986 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.516 ' HD2' ' CD ' ' A' ' 25' ' ' PRO . 2.9 mmmt -130.81 163.87 45.77 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.24 -0.913 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.516 ' CD ' ' HD2' ' A' ' 24' ' ' LYS . 35.5 Cg_endo -77.48 106.43 2.21 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.562 2.175 . . . . 0.0 110.429 179.921 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 137.72 -10.28 3.7 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.939 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.1 -172.33 2.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.249 -1.148 . . . . 0.0 109.416 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -105.7 150.03 25.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.28 -0.888 . . . . 0.0 109.477 179.974 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.3 m -131.93 -170.93 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.244 -0.91 . . . . 0.0 109.459 -179.963 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.448 ' HA ' ' HB2' ' A' ' 52' ' ' ASP . 12.5 mttm -149.91 130.91 14.34 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.217 -0.927 . . . . 0.0 109.52 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.474 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 4.3 ttm105 -42.82 143.61 0.69 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.318 -0.864 . . . . 0.0 109.669 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.53 ' HA ' HD23 ' A' ' 48' ' ' LEU . 6.7 t70 73.84 38.28 0.6 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.316 -0.865 . . . . 0.0 109.476 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.434 ' O ' ' C ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -138.98 122.73 17.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.909 . . . . 0.0 109.436 179.96 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.735 HD21 ' NE2' ' A' ' 22' ' ' HIS . 36.0 tp -43.0 149.14 0.21 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.201 -0.937 . . . . 0.0 109.548 -179.939 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.492 HG13 ' HB2' ' A' ' 49' ' ' ALA . 35.4 mm -132.62 -42.86 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -0.915 . . . . 0.0 109.554 -179.921 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.488 ' O ' HG23 ' A' ' 47' ' ' VAL . 4.4 p -162.1 147.48 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.244 -0.91 . . . . 0.0 109.546 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.532 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 1.3 m-20 -107.33 154.79 20.77 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.896 . . . . 0.0 109.396 179.966 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.419 ' O ' ' HA ' ' A' ' 44' ' ' VAL . 26.8 mm -122.73 148.09 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.218 -0.926 . . . . 0.0 109.489 -179.937 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.458 ' HB2' ' O ' ' A' ' 17' ' ' THR . 0.3 OUTLIER -107.14 109.69 21.59 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.535 179.941 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 41' ' ' ASP . 35.4 p -97.27 -150.35 0.34 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.202 -0.936 . . . . 0.0 109.434 -179.949 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 3.0 t0 -42.8 -70.05 0.12 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.318 -0.863 . . . . 0.0 109.668 -179.886 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -145.1 25.19 1.42 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.222 -0.924 . . . . 0.0 109.458 179.963 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.9 t -136.53 130.66 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -0.961 . . . . 0.0 109.466 179.947 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 38' ' ' ILE . 2.1 t -90.96 109.48 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.223 -0.923 . . . . 0.0 109.512 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -79.99 163.79 23.96 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.299 -0.875 . . . . 0.0 109.507 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -108.07 145.17 34.41 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.247 -0.908 . . . . 0.0 109.43 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 36' ' ' VAL . 10.1 t -118.75 100.85 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.312 -0.868 . . . . 0.0 109.426 179.958 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.53 HD23 ' HA ' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -91.91 153.83 19.25 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.193 -0.942 . . . . 0.0 109.49 179.991 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.492 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -74.17 138.85 44.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.9 . . . . 0.0 109.49 179.983 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.58 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -88.51 13.52 11.8 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.294 -0.879 . . . . 0.0 109.505 -179.995 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.58 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 170.49 150.37 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.252 -0.905 . . . . 0.0 109.45 -179.981 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -78.6 170.99 15.78 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.317 179.994 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.51 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 149.91 -137.69 6.34 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 50.9 t -136.07 125.6 39.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -1.129 . . . . 0.0 109.465 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.464 HG22 ' N ' ' A' ' 56' ' ' ALA . 14.1 mm -64.58 161.78 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.925 . . . . 0.0 109.531 180.0 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.464 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -103.51 -67.02 0.91 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.256 -0.903 . . . . 0.0 109.466 -179.948 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.491 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 2.5 tt0 -169.83 140.59 2.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.286 -0.884 . . . . 0.0 109.463 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.657 HD12 ' CH2' ' A' ' 21' ' ' TRP . 22.5 mm -93.86 131.63 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.171 -0.956 . . . . 0.0 109.527 -179.965 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 72.0 t -89.96 -38.41 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.274 -0.892 . . . . 0.0 109.497 179.957 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.925 ' HG2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -94.77 125.21 39.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.343 -0.848 . . . . 0.0 109.424 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.47 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 28.8 m-80 -89.64 176.24 6.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.253 -0.904 . . . . 0.0 109.482 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -74.9 153.33 38.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.246 -0.909 . . . . 0.0 109.502 179.957 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.94 15.12 62.13 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.515 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -104.58 170.88 7.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.177 -1.19 . . . . 0.0 109.312 179.993 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.1 m -100.45 138.31 37.69 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.445 -0.784 . . . . 0.0 109.5 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.925 HG12 ' HG2' ' A' ' 60' ' ' LYS . 4.9 m -115.8 172.75 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.207 -0.933 . . . . 0.0 109.461 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -136.06 -173.95 3.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.255 -0.903 . . . . 0.0 109.472 179.936 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.97 149.3 48.98 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.175 -0.953 . . . . 0.0 109.464 -179.965 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 49.69 29.95 13.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.986 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.456 ' OE2' ' HD3' ' A' ' 60' ' ' LYS . 49.6 tp10 -80.55 114.27 19.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.271 -1.135 . . . . 0.0 109.495 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.745 HD12 ' OD1' ' A' ' 3' ' ' ASP . 0.5 OUTLIER -66.31 118.69 10.35 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.191 -0.943 . . . . 0.0 109.47 179.95 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 8.7 mt -87.96 -28.27 21.58 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.483 179.968 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 176.96 170.59 39.6 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -128.44 134.45 48.76 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -1.158 . . . . 0.0 109.445 180.0 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.623 HD22 HD12 ' A' ' 2' ' ' ILE . 0.5 OUTLIER -91.56 147.2 23.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -0.88 . . . . 0.0 109.414 -179.974 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.524 HG22 ' H ' ' A' ' 77' ' ' GLU . 7.3 m -100.54 170.73 8.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.282 -0.886 . . . . 0.0 109.514 179.922 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.524 ' H ' HG22 ' A' ' 76' ' ' THR . 4.5 mm-40 -59.16 -72.91 0.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.238 -0.914 . . . . 0.0 109.454 179.998 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 128.75 150.84 7.28 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 CA-C-O 117.996 -1.447 . . . . 0.0 109.599 179.944 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.628 HD13 HD22 ' A' ' 75' ' ' LEU . 5.4 mp . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' A' ' 4' ' ' ILE . 39.6 t0 -88.98 132.82 34.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.239 -0.913 . . . . 0.0 109.452 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.481 ' N ' ' OD1' ' A' ' 3' ' ' ASP . 82.2 mt -99.99 124.24 53.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.424 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 70' ' ' GLU . 2.6 mttt -122.75 175.59 6.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.209 -0.932 . . . . 0.0 109.448 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.558 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -79.68 161.38 66.9 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.883 . . . . 0.0 109.49 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.558 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.6 Cg_endo -78.06 173.8 13.42 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.638 2.225 . . . . 0.0 110.389 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.5 m -92.07 134.68 34.61 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.478 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -100.14 155.82 35.98 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 109.438 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.432 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -77.99 -159.93 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.589 2.193 . . . . 0.0 110.473 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' A' ' 12' ' ' SER . 2.5 mt-10 -78.64 -58.69 3.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 109.497 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 11' ' ' GLU . 31.1 t -42.83 -45.09 4.75 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.295 -0.878 . . . . 0.0 109.628 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.577 HG22 ' H ' ' A' ' 15' ' ' ASP . 33.7 mm -104.43 136.92 35.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.297 -0.877 . . . . 0.0 109.472 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.407 ' C ' ' OD1' ' A' ' 15' ' ' ASP . . . -119.03 16.81 13.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.233 -0.917 . . . . 0.0 109.451 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.577 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.4 OUTLIER -169.18 -170.73 1.16 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 0.0 109.438 -179.982 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.68 -170.08 16.11 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.512 ' O ' ' CB ' ' A' ' 39' ' ' GLU . 1.4 m -150.0 128.57 12.3 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.221 -1.164 . . . . 0.0 109.499 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.1 t -56.42 153.82 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.226 -0.921 . . . . 0.0 109.406 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.578 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -96.86 -72.98 0.62 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.256 -0.903 . . . . 0.0 109.546 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.7 m -160.05 132.61 6.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.22 -0.925 . . . . 0.0 109.558 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.634 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.9 83.0 6.12 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.257 -0.902 . . . . 0.0 109.528 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.703 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.0 m80 -42.85 -64.84 0.55 Allowed 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.38 -0.825 . . . . 0.0 109.441 -179.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.17 -179.25 4.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.557 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.401 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -125.84 168.48 13.84 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.249 -0.907 . . . . 0.0 109.487 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.487 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 34.9 Cg_endo -76.66 123.26 6.84 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.626 2.218 . . . . 0.0 110.398 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.3 12.64 9.61 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -118.22 -172.44 2.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.205 -1.173 . . . . 0.0 109.457 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -98.68 153.56 18.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.242 -0.911 . . . . 0.0 109.462 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.526 HG22 ' N ' ' A' ' 30' ' ' LYS . 2.8 p -138.36 162.3 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 109.48 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.526 ' N ' HG22 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -134.59 126.13 28.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.256 -0.903 . . . . 0.0 109.517 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.506 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 16.8 ttp180 -42.72 146.82 0.34 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.323 -0.861 . . . . 0.0 109.664 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.506 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 2.9 t70 75.18 33.95 0.68 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.465 ' HB2' ' O ' ' A' ' 30' ' ' LYS . 3.4 tt0 -138.83 123.6 18.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -0.912 . . . . 0.0 109.444 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.703 HD21 ' NE2' ' A' ' 22' ' ' HIS . 50.6 tp -42.98 156.97 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.273 -0.892 . . . . 0.0 109.531 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.647 HG13 ' HB2' ' A' ' 49' ' ' ALA . 35.8 mm -139.11 -38.17 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.2 -0.937 . . . . 0.0 109.651 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.438 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.5 p -166.66 139.1 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.175 -0.953 . . . . 0.0 109.527 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.578 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 1.1 m-20 -98.61 158.5 15.56 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 36.1 mt -125.01 153.63 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.532 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.512 ' CB ' ' O ' ' A' ' 17' ' ' THR . 15.0 tt0 -109.88 123.61 49.89 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.236 -0.915 . . . . 0.0 109.454 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.435 ' O ' ' C ' ' A' ' 41' ' ' ASP . 3.9 p -107.54 -162.44 0.84 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.256 -0.903 . . . . 0.0 109.475 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.435 ' C ' ' O ' ' A' ' 40' ' ' THR . 16.7 t0 -42.72 -66.7 0.34 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.33 -0.856 . . . . 0.0 109.65 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 13.3 mtpt -142.79 26.16 1.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.31 -0.869 . . . . 0.0 109.476 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 42.1 t -136.48 136.5 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.28 -0.888 . . . . 0.0 109.504 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 56.4 t -95.65 119.26 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.292 -0.88 . . . . 0.0 109.458 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 4.2 mtt -93.71 179.7 5.28 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.242 -0.911 . . . . 0.0 109.503 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -131.96 148.9 52.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.514 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.438 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 21.2 t -121.91 107.95 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.256 -0.903 . . . . 0.0 109.441 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.436 ' HG ' ' C ' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -98.16 153.11 18.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 109.494 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.647 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -76.87 143.65 39.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.26 -0.9 . . . . 0.0 109.416 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.65 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.1 OUTLIER -96.25 15.42 21.08 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.469 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.65 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 166.9 148.28 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.468 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.496 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -69.96 170.96 10.22 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.348 179.978 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.496 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 157.27 -146.61 13.92 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.6 t -135.39 124.6 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.25 -1.147 . . . . 0.0 109.506 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.4 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 12.1 mm -70.03 158.88 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.275 -0.891 . . . . 0.0 109.496 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -95.13 -64.43 1.07 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.199 -0.938 . . . . 0.0 109.457 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.487 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 11.7 pt-20 -179.17 146.32 0.29 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.461 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.634 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 30.6 mm -99.07 127.42 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.245 -0.909 . . . . 0.0 109.475 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.3 t -90.08 -29.92 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.497 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 0.2 OUTLIER -90.78 148.1 22.77 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.234 -0.916 . . . . 0.0 109.481 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.468 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 4.5 m-80 -110.45 156.31 21.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.503 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -60.6 139.19 57.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.269 -0.894 . . . . 0.0 109.526 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 90.11 4.97 71.01 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -105.76 170.7 7.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -1.186 . . . . 0.0 109.355 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 7.3 t -102.21 154.26 19.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.528 -0.732 . . . . 0.0 109.564 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.453 HG11 HD21 ' A' ' 72' ' ' LEU . 30.3 m -130.66 133.81 62.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.47 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -92.43 169.86 10.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.465 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -59.51 143.21 50.74 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.248 -0.908 . . . . 0.0 109.451 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 67.7 12.02 61.18 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.416 ' O ' ' HA ' ' A' ' 5' ' ' LYS . 5.3 tp10 -70.33 120.58 16.21 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.287 -1.125 . . . . 0.0 109.467 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.545 ' C ' HD23 ' A' ' 71' ' ' LEU . 10.0 tt -77.97 111.92 14.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.301 -0.874 . . . . 0.0 109.459 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.453 HD21 HG11 ' A' ' 66' ' ' VAL . 1.9 mt -88.3 -21.12 24.59 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.267 -0.895 . . . . 0.0 109.462 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.5 -177.17 45.23 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.459 ' NZ ' ' OE2' ' A' ' 57' ' ' GLU . 0.0 OUTLIER -139.63 153.81 47.41 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.195 -1.18 . . . . 0.0 109.52 179.963 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.628 HD22 HD13 ' A' ' 2' ' ' ILE . 0.5 OUTLIER -94.69 155.61 16.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.267 -0.896 . . . . 0.0 109.435 -179.985 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.481 ' O ' HD23 ' A' ' 75' ' ' LEU . 9.4 m . . . . . 0 N--CA 1.49 1.554 0 O-C-N 121.204 -0.935 . . . . 0.0 109.456 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.469 HG13 ' HB3' ' A' ' 75' ' ' LEU . 2.0 pt . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.41 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 20.9 t0 -120.59 136.86 54.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.281 -0.887 . . . . 0.0 109.461 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 65.8 mt -110.46 118.85 58.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.189 -0.944 . . . . 0.0 109.481 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.86 156.77 48.34 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.289 -0.882 . . . . 0.0 109.418 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.626 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -58.7 163.54 5.11 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.202 -0.936 . . . . 0.0 109.46 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.626 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.7 Cg_endo -78.06 178.16 7.92 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.618 2.212 . . . . 0.0 110.41 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.43 ' O ' ' CD1' ' A' ' 9' ' ' PHE . 0.2 OUTLIER -76.56 176.42 8.35 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.896 . . . . 0.0 109.509 -179.966 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.462 ' CE1' HG23 ' A' ' 40' ' ' THR . 23.7 m-85 -138.7 71.78 43.11 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.453 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.93 -0.14 10.38 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.636 2.224 . . . . 0.0 110.432 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.515 ' O ' ' CD1' ' A' ' 13' ' ' ILE . 5.9 mm-40 -85.33 46.46 1.29 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.394 -0.816 . . . . 0.0 109.438 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.45 ' C ' ' O ' ' A' ' 11' ' ' GLU . 6.6 t 39.25 39.21 0.41 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.528 -0.733 . . . . 0.0 110.034 179.707 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.515 ' CD1' ' O ' ' A' ' 11' ' ' GLU . 15.0 mm -98.82 156.35 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.891 . . . . 0.0 109.374 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.496 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -93.83 -1.88 54.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.19 -0.944 . . . . 0.0 109.727 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.496 ' CB ' ' O ' ' A' ' 14' ' ' ALA . 1.1 p30 163.74 -169.63 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.227 -0.921 . . . . 0.0 109.442 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.0 -169.33 11.63 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.467 HG23 ' O ' ' A' ' 64' ' ' ASP . 93.6 m -150.02 123.26 8.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.204 -1.174 . . . . 0.0 109.534 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 19' ' ' ALA . 24.2 t -51.09 169.49 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.22 -0.925 . . . . 0.0 109.482 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.579 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -112.73 -73.14 0.68 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.179 -0.951 . . . . 0.0 109.609 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.482 HG23 ' OE1' ' A' ' 62' ' ' GLU . 16.4 m -159.98 137.13 9.44 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.53 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.704 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 32.7 m95 -89.98 83.85 6.14 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.259 -0.901 . . . . 0.0 109.501 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.803 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.2 m80 -42.86 -69.82 0.13 Allowed 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.39 -0.819 . . . . 0.0 109.487 -179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.05 -171.58 2.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 109.674 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.476 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 1.8 mttt -128.8 170.76 9.93 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.227 -0.92 . . . . 0.0 109.435 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.533 ' CG ' ' HA ' ' A' ' 57' ' ' GLU . 34.8 Cg_endo -75.61 129.52 11.88 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.657 2.238 . . . . 0.0 110.39 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 120.98 -11.88 9.95 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -95.84 166.48 11.78 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.254 -1.145 . . . . 0.0 109.472 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.29 133.39 35.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -0.907 . . . . 0.0 109.411 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 52' ' ' ASP . 25.1 m -136.31 135.84 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.162 -0.961 . . . . 0.0 109.528 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 31' ' ' ARG . 9.6 pttp -117.35 146.23 43.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.88 . . . . 0.0 109.389 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.465 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 4.0 ttt180 -42.9 156.23 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.244 -0.91 . . . . 0.0 109.623 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.465 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 18.8 t70 73.34 29.21 1.69 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -0.881 . . . . 0.0 109.453 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.536 ' N ' HD23 ' A' ' 48' ' ' LEU . 30.5 tt0 -137.71 111.63 8.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.285 -0.884 . . . . 0.0 109.446 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.803 HD21 ' NE2' ' A' ' 22' ' ' HIS . 43.4 tp -42.9 153.56 0.08 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.36 -0.837 . . . . 0.0 109.595 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.607 HD13 ' O ' ' A' ' 34' ' ' LEU . 11.1 mm -139.08 -38.51 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.15 -0.969 . . . . 0.0 109.55 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.521 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 10.8 p -160.21 131.53 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.263 -0.898 . . . . 0.0 109.466 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.507 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 32.4 m-20 -92.15 157.09 16.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.918 . . . . 0.0 109.482 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 20.6 tt -127.91 162.98 32.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.325 -0.859 . . . . 0.0 109.447 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -148.76 110.65 4.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.24 -0.912 . . . . 0.0 109.434 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.462 HG23 ' CE1' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -80.73 -160.65 0.32 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.29 -0.881 . . . . 0.0 109.503 179.94 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.423 ' HB2' HD12 ' A' ' 13' ' ' ILE . 50.0 t0 -42.83 -67.64 0.26 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.293 -0.88 . . . . 0.0 109.631 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -132.02 23.22 4.55 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -0.934 . . . . 0.0 109.491 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 1.9 t -117.97 162.13 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.226 -0.921 . . . . 0.0 109.437 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.9 t -137.35 126.7 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.284 -0.885 . . . . 0.0 109.51 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . 0.53 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 1.7 mtt -123.63 -171.01 2.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.256 -0.903 . . . . 0.0 109.434 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.3 152.4 48.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.417 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.521 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 35.0 t -122.52 111.18 29.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.319 -0.863 . . . . 0.0 109.47 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.536 HD23 ' N ' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -102.02 165.78 10.98 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.281 -0.887 . . . . 0.0 109.464 -179.978 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -76.35 144.97 39.81 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.333 -0.855 . . . . 0.0 109.472 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -108.49 7.44 26.86 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.143 -0.973 . . . . 0.0 109.536 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -175.45 122.32 0.21 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.178 -0.951 . . . . 0.0 109.531 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.499 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -55.14 170.93 0.17 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.3 -0.875 . . . . 0.0 109.32 179.999 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.499 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 140.82 -139.34 9.57 Favored Glycine 0 N--CA 1.49 2.233 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 45.0 t -139.15 123.55 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -1.184 . . . . 0.0 109.429 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.561 HG22 ' N ' ' A' ' 56' ' ' ALA . 13.9 mm -65.06 167.75 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.249 -0.907 . . . . 0.0 109.537 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.561 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -101.72 -65.42 0.98 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.181 -0.95 . . . . 0.0 109.472 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.533 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -171.68 159.09 5.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.502 179.992 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.704 HG23 ' CZ2' ' A' ' 21' ' ' TRP . 74.2 mt -89.97 130.56 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.318 -0.864 . . . . 0.0 109.403 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.465 ' HB ' ' O ' ' A' ' 71' ' ' LEU . 50.0 t -89.99 -37.77 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.2 -0.938 . . . . 0.0 109.417 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.458 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -113.89 137.63 51.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.229 -0.92 . . . . 0.0 109.4 -179.989 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -79.96 156.37 27.25 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.213 -0.929 . . . . 0.0 109.443 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.525 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -70.3 142.76 52.21 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 93.99 -15.62 62.74 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.506 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -84.24 170.88 13.28 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.181 -1.188 . . . . 0.0 109.365 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.506 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 88.5 m -96.78 133.49 41.29 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.518 -0.739 . . . . 0.0 109.477 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.619 ' C ' HD12 ' A' ' 67' ' ' LEU . 6.3 m -116.68 -154.66 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.26 -0.9 . . . . 0.0 109.429 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.619 HD12 ' C ' ' A' ' 66' ' ' VAL . 2.9 mp -149.65 176.64 10.48 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.262 -0.899 . . . . 0.0 109.495 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.2 t -69.41 109.21 4.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.251 -0.905 . . . . 0.0 109.449 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.55 21.47 26.57 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.43 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 11.3 tp10 -74.0 121.05 20.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -1.133 . . . . 0.0 109.428 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.465 ' O ' ' HB ' ' A' ' 59' ' ' VAL . 25.5 tp -64.9 111.62 2.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.255 -0.903 . . . . 0.0 109.492 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 8.4 mt -95.18 -10.91 29.13 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -0.887 . . . . 0.0 109.48 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.34 163.39 21.13 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 26.4 mttt -125.41 144.71 50.39 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -1.139 . . . . 0.0 109.456 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.56 HD12 HD13 ' A' ' 55' ' ' ILE . 12.4 tp -90.0 153.51 20.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.445 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.477 ' N ' ' HG ' ' A' ' 75' ' ' LEU . 14.6 m . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.903 . . . . 0.0 109.489 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.489 HG13 ' HB3' ' A' ' 75' ' ' LEU . 1.8 pp . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.455 ' OD2' HD13 ' A' ' 71' ' ' LEU . 8.3 t0 -89.72 129.28 36.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.313 -0.867 . . . . 0.0 109.483 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.609 HG23 HG11 ' A' ' 47' ' ' VAL . 87.4 mt -97.08 75.97 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.238 -0.914 . . . . 0.0 109.517 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.33 161.6 13.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.227 -0.92 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.611 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -74.51 163.11 70.54 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.216 -0.927 . . . . 0.0 109.437 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.611 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.8 Cg_endo -78.08 -179.85 5.83 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.632 2.222 . . . . 0.0 110.386 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.426 HG23 ' OG ' ' A' ' 68' ' ' SER . 3.0 m -93.82 106.99 18.93 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.297 -0.877 . . . . 0.0 109.443 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.417 ' HB3' ' HD2' ' A' ' 10' ' ' PRO . 80.9 m-85 -61.5 157.81 43.82 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.233 -0.917 . . . . 0.0 109.452 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.449 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.1 -163.08 0.2 Allowed 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.585 2.19 . . . . 0.0 110.415 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.6 OUTLIER -80.82 -59.06 2.82 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.265 -0.897 . . . . 0.0 109.436 -179.972 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 11' ' ' GLU . 35.3 t -42.82 -31.24 0.47 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.365 -0.835 . . . . 0.0 109.618 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.463 HG22 ' H ' ' A' ' 15' ' ' ASP . 24.4 mt -113.81 141.41 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.227 -0.921 . . . . 0.0 109.445 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -126.96 31.25 5.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.5 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.463 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.9 OUTLIER 174.8 -171.47 0.06 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.8 -164.71 13.82 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.471 ' HA ' ' O ' ' A' ' 64' ' ' ASP . 84.6 m -150.12 120.99 7.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.214 -1.168 . . . . 0.0 109.44 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.537 HG12 ' N ' ' A' ' 19' ' ' ALA . 60.0 t -43.79 162.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.302 -0.874 . . . . 0.0 109.487 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.537 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -108.11 -75.17 0.64 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.278 -0.889 . . . . 0.0 109.562 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.9 m -160.17 131.61 5.92 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.167 -0.958 . . . . 0.0 109.619 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.833 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 33.3 m95 -89.82 85.88 6.51 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.255 -0.903 . . . . 0.0 109.448 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.672 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.5 m80 -42.34 -69.88 0.12 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.356 -0.84 . . . . 0.0 109.654 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.69 -174.09 2.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.217 -0.927 . . . . 0.0 109.78 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.498 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -116.87 165.67 14.75 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.377 -0.827 . . . . 0.0 109.262 179.975 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.871 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.2 Cg_endo -77.18 145.43 24.38 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.552 2.168 . . . . 0.0 110.426 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.44 -8.89 60.58 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.473 ' HG2' ' O ' ' A' ' 24' ' ' LYS . 0.4 OUTLIER -94.1 176.74 6.21 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.202 -1.175 . . . . 0.0 109.453 -179.972 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.462 ' O ' ' OE1' ' A' ' 27' ' ' GLU . . . -91.37 158.4 16.55 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.291 -0.881 . . . . 0.0 109.486 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.493 HG22 ' O ' ' A' ' 53' ' ' GLY . 34.7 m -138.87 -167.53 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.257 -0.902 . . . . 0.0 109.506 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 31' ' ' ARG . 5.1 tptm -142.18 140.85 32.51 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.221 -0.925 . . . . 0.0 109.463 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.1 OUTLIER -42.84 123.48 2.74 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.311 -0.868 . . . . 0.0 109.649 -179.874 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.752 ' C ' HD21 ' A' ' 48' ' ' LEU . 6.1 t70 75.9 57.06 0.05 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.276 -0.89 . . . . 0.0 109.491 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.544 ' N ' HD21 ' A' ' 48' ' ' LEU . 0.9 OUTLIER -131.76 121.3 23.95 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.203 -0.936 . . . . 0.0 109.402 -179.934 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.672 HD21 ' NE2' ' A' ' 22' ' ' HIS . 51.3 tp -42.94 162.25 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.329 -0.857 . . . . 0.0 109.499 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.956 HD11 ' HB2' ' A' ' 49' ' ' ALA . 91.6 mt -141.52 -49.49 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.933 . . . . 0.0 109.48 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.637 HG12 ' HB ' ' A' ' 47' ' ' VAL . 7.9 p -152.25 151.93 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.915 . . . . 0.0 109.417 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.618 ' C ' HD13 ' A' ' 38' ' ' ILE . 49.8 m-20 -117.6 151.38 37.3 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.257 -0.902 . . . . 0.0 109.554 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.618 HD13 ' C ' ' A' ' 37' ' ' ASP . 3.6 mm -108.17 156.36 8.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.248 -0.907 . . . . 0.0 109.383 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -135.28 117.48 15.52 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.262 -0.899 . . . . 0.0 109.489 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.431 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -115.8 -167.48 1.27 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.229 -0.919 . . . . 0.0 109.495 -179.991 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.431 ' C ' ' O ' ' A' ' 40' ' ' THR . 53.8 t0 -42.7 -67.74 0.25 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.359 -0.838 . . . . 0.0 109.626 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 1.7 mtpp -139.16 34.25 2.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.205 -0.934 . . . . 0.0 109.468 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.4 t -135.73 107.35 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.952 . . . . 0.0 109.504 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.2 t -89.98 115.85 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . 0.466 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 4.6 mtp -99.23 178.31 4.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.302 -0.874 . . . . 0.0 109.488 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.424 ' HA ' ' OD1' ' A' ' 37' ' ' ASP . 41.0 mt-10 -138.48 169.64 17.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.205 -0.935 . . . . 0.0 109.438 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.637 ' HB ' HG12 ' A' ' 36' ' ' VAL . 97.1 t -141.92 103.09 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.224 -0.923 . . . . 0.0 109.478 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.752 HD21 ' C ' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -104.38 155.31 18.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.218 -0.927 . . . . 0.0 109.506 -179.982 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.956 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.19 165.22 18.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.515 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.694 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.8 OUTLIER -103.44 13.15 34.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.694 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.7 164.2 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.455 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.503 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -58.18 170.95 0.61 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.26 -0.9 . . . . 0.0 109.336 179.979 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.503 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 150.07 -174.64 29.45 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 69.6 t -124.86 131.18 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -1.132 . . . . 0.0 109.418 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.741 ' N ' HD13 ' A' ' 55' ' ' ILE . 1.4 mm -71.24 -176.64 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.271 -0.893 . . . . 0.0 109.486 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.789 ' HB3' ' HG2' ' A' ' 74' ' ' LYS . . . -114.01 -59.57 2.0 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.235 -0.916 . . . . 0.0 109.409 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.529 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 17.5 pt-20 -178.88 157.47 0.89 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.26 -0.9 . . . . 0.0 109.548 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.871 HD11 ' HD3' ' A' ' 25' ' ' PRO . 1.7 mp -89.96 140.88 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 109.446 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.454 ' HB ' ' O ' ' A' ' 71' ' ' LEU . 11.1 t -100.67 -15.17 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.261 -0.899 . . . . 0.0 109.366 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.488 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -126.37 -172.58 2.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.31 -0.869 . . . . 0.0 109.403 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.473 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 17.3 m-80 -132.45 164.26 26.96 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.169 -0.957 . . . . 0.0 109.509 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.01 133.41 48.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.306 -0.871 . . . . 0.0 109.408 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.05 -6.78 82.67 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -79.72 170.76 16.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.219 -1.165 . . . . 0.0 109.428 179.902 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.516 ' N ' ' OD1' ' A' ' 64' ' ' ASP . 32.3 m -98.77 138.84 35.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.547 -0.721 . . . . 0.0 109.498 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 6.2 m -122.29 170.67 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.268 -0.895 . . . . 0.0 109.455 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.478 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.1 OUTLIER -132.94 177.6 7.53 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.474 -179.98 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.426 ' OG ' HG23 ' A' ' 8' ' ' THR . 9.1 t -62.85 146.61 52.35 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.914 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 57.85 28.59 60.71 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.478 ' HB2' ' O ' ' A' ' 67' ' ' LEU . 8.0 tp10 -84.06 115.28 22.28 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.174 -1.192 . . . . 0.0 109.419 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.63 HD21 ' HD2' ' A' ' 74' ' ' LYS . 16.0 tp -72.91 106.09 4.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.262 -0.898 . . . . 0.0 109.49 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 15.7 mt -89.36 -10.91 44.87 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.224 -0.922 . . . . 0.0 109.455 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.36 164.29 22.75 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.789 ' HG2' ' HB3' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -136.12 142.9 44.29 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -1.173 . . . . 0.0 109.451 179.985 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.807 HD23 ' O ' ' A' ' 76' ' ' THR . 2.7 tt -97.44 167.99 10.66 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.239 -0.913 . . . . 0.0 109.479 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.807 ' O ' HD23 ' A' ' 75' ' ' LEU . 5.0 m . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.448 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 30.3 mm . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -66.35 127.99 34.39 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.1 mt -102.54 97.97 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.319 -0.863 . . . . 0.0 109.495 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.471 ' HG3' ' HA ' ' A' ' 71' ' ' LEU . 0.0 OUTLIER -118.76 146.9 44.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.211 -0.931 . . . . 0.0 109.461 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.43 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -61.26 157.51 43.58 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.197 -0.939 . . . . 0.0 109.494 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.43 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.6 Cg_endo -78.07 122.85 5.92 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 C-N-CA 122.581 2.188 . . . . 0.0 110.379 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.563 HG23 ' OG ' ' A' ' 68' ' ' SER . 17.5 m -44.17 108.02 0.1 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.244 -0.91 . . . . 0.0 109.454 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -71.03 147.95 94.1 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.245 -0.909 . . . . 0.0 109.501 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.579 ' HG2' HD12 ' A' ' 13' ' ' ILE . 35.5 Cg_endo -78.18 -159.44 0.1 Allowed 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.599 2.199 . . . . 0.0 110.324 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.433 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.4 OUTLIER -75.98 -52.65 9.8 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -0.899 . . . . 0.0 109.47 -179.956 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.8 t -42.82 -56.14 3.36 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.252 -0.905 . . . . 0.0 109.628 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.579 HD12 ' HG2' ' A' ' 10' ' ' PRO . 2.5 mp -89.95 111.14 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.226 -0.921 . . . . 0.0 109.452 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.466 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -88.77 10.45 20.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.204 -0.935 . . . . 0.0 109.502 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.518 ' O ' ' CG2' ' A' ' 13' ' ' ILE . 0.8 OUTLIER 166.6 -172.39 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 -179.921 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.464 ' O ' HG23 ' A' ' 65' ' ' THR . . . -154.08 -167.87 16.81 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.477 HG23 ' O ' ' A' ' 64' ' ' ASP . 90.3 m -148.21 131.94 16.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.265 -1.138 . . . . 0.0 109.463 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.504 HG12 ' N ' ' A' ' 19' ' ' ALA . 27.1 t -52.56 163.93 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.218 -0.926 . . . . 0.0 109.435 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.514 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -108.96 -76.41 0.61 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.175 -0.953 . . . . 0.0 109.442 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.4 m -160.03 131.9 6.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.248 -0.908 . . . . 0.0 109.46 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.636 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 31.9 m95 -89.87 85.43 6.38 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.26 -0.9 . . . . 0.0 109.56 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.875 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.0 m80 -42.77 -58.25 2.43 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.355 -0.841 . . . . 0.0 109.38 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -101.43 -175.04 2.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.57 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.439 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -125.65 167.82 15.57 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.344 -0.847 . . . . 0.0 109.446 179.985 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.499 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.91 118.04 4.66 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.588 2.192 . . . . 0.0 110.418 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 124.56 7.52 6.21 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.794 ' O ' HG13 ' A' ' 54' ' ' VAL . 5.2 mm-40 -113.26 -172.25 2.03 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.223 -1.163 . . . . 0.0 109.55 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.449 ' HA ' HG22 ' A' ' 54' ' ' VAL . . . -105.02 158.02 16.83 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.169 -0.957 . . . . 0.0 109.448 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -142.49 -174.35 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 0.0 109.436 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 3.7 mttp -147.67 137.54 22.77 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.491 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.434 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.1 OUTLIER -42.78 137.21 2.35 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.344 -0.847 . . . . 0.0 109.63 -179.914 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.42 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 8.2 t0 70.06 51.23 0.41 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.314 -0.866 . . . . 0.0 109.521 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.474 ' O ' HG13 ' A' ' 35' ' ' ILE . 1.8 tm-20 -140.8 120.65 13.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.185 -0.947 . . . . 0.0 109.493 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.875 HD21 ' NE2' ' A' ' 22' ' ' HIS . 35.3 tp -42.93 142.82 0.83 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.301 -0.874 . . . . 0.0 109.57 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.474 HG13 ' O ' ' A' ' 33' ' ' GLU . 12.8 mt -134.97 -43.07 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.232 -0.917 . . . . 0.0 109.598 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.468 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.4 p -158.66 142.52 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.223 -0.923 . . . . 0.0 109.508 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.514 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 55.9 m-20 -105.46 152.44 23.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.214 -0.929 . . . . 0.0 109.404 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.413 HG21 HD13 ' A' ' 38' ' ' ILE . 10.9 mt -128.81 153.84 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.211 -0.93 . . . . 0.0 109.537 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -121.74 150.94 41.1 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.233 -0.917 . . . . 0.0 109.443 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.493 HG21 ' SD ' ' A' ' 45' ' ' MET . 28.1 p -133.62 -168.37 2.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.241 -0.912 . . . . 0.0 109.491 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.411 ' C ' ' O ' ' A' ' 40' ' ' THR . 27.2 t70 -42.68 -69.25 0.14 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.348 -0.845 . . . . 0.0 109.686 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.9 mtmt -136.64 27.15 3.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.227 -0.92 . . . . 0.0 109.425 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.439 ' O ' ' OG1' ' A' ' 40' ' ' THR . 1.9 t -135.86 162.1 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.259 -0.901 . . . . 0.0 109.507 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.3 p -122.53 138.81 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.352 -0.843 . . . . 0.0 109.479 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . 0.493 ' SD ' HG21 ' A' ' 40' ' ' THR . 1.9 mpp? -127.05 101.94 6.76 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.254 -0.904 . . . . 0.0 109.453 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.462 ' HG2' ' OD1' ' A' ' 37' ' ' ASP . 15.0 mt-10 -73.9 163.81 27.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.277 -0.889 . . . . 0.0 109.475 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.468 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 71.6 t -131.04 107.69 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.281 -0.887 . . . . 0.0 109.44 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.721 HD12 ' HA ' ' A' ' 34' ' ' LEU . 1.3 mp -91.91 170.2 10.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.906 . . . . 0.0 109.536 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.442 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -71.91 124.7 25.43 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.257 -0.902 . . . . 0.0 109.458 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.701 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -82.68 6.85 16.57 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.9 . . . . 0.0 109.5 -179.947 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 163.94 141.46 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.516 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -49.01 170.97 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 109.338 -179.974 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 135.8 -155.84 22.51 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.794 HG13 ' O ' ' A' ' 27' ' ' GLU . 48.5 t -138.71 125.04 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.318 -1.107 . . . . 0.0 109.477 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.562 HG22 ' H ' ' A' ' 56' ' ' ALA . 4.6 mm -46.45 172.25 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.255 -0.903 . . . . 0.0 109.464 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.562 ' H ' HG22 ' A' ' 55' ' ' ILE . . . -110.91 -65.09 1.2 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.266 -0.896 . . . . 0.0 109.478 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.499 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -170.27 138.78 1.65 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.469 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.636 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 21.5 mm -101.38 128.53 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.245 -0.91 . . . . 0.0 109.49 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.2 t -98.06 -30.97 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.262 -0.898 . . . . 0.0 109.481 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.467 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -91.23 117.65 29.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.32 -0.862 . . . . 0.0 109.454 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 57.6 m-80 -84.06 157.23 21.85 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.311 -0.868 . . . . 0.0 109.451 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -57.19 142.44 42.78 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.26 -0.9 . . . . 0.0 109.463 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.76 11.29 68.42 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -104.69 170.92 7.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -1.125 . . . . 0.0 109.292 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 52.0 m -107.52 146.95 31.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.45 -0.781 . . . . 0.0 109.465 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.733 HG11 HD21 ' A' ' 72' ' ' LEU . 7.1 m -124.59 139.82 49.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.237 -0.914 . . . . 0.0 109.49 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -101.06 -175.55 2.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.316 -0.865 . . . . 0.0 109.436 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.563 ' OG ' HG23 ' A' ' 8' ' ' THR . 1.5 t -64.47 122.22 16.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.266 -0.897 . . . . 0.0 109.496 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.51 31.28 41.69 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -83.84 104.56 14.03 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.187 -1.184 . . . . 0.0 109.484 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.471 ' HA ' ' HG3' ' A' ' 5' ' ' LYS . 1.0 OUTLIER -66.4 120.28 13.06 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -0.912 . . . . 0.0 109.487 179.966 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.733 HD21 HG11 ' A' ' 66' ' ' VAL . 1.0 OUTLIER -95.81 -18.92 20.02 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.283 -0.886 . . . . 0.0 109.495 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.77 -179.64 41.0 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' A' ' 56' ' ' ALA . 2.1 mtmt -140.58 152.44 45.48 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.295 -1.12 . . . . 0.0 109.484 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -92.61 151.34 20.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.425 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 8.6 m . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.899 . . . . 0.0 109.434 -179.999 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.8 pt . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.447 ' OD2' ' HB3' ' A' ' 5' ' ' LYS . 29.5 t70 -117.47 135.92 53.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.23 -0.919 . . . . 0.0 109.432 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.495 ' O ' HG22 ' A' ' 4' ' ' ILE . 91.3 mt -99.47 73.08 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.216 -0.928 . . . . 0.0 109.517 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.447 ' HB3' ' OD2' ' A' ' 3' ' ' ASP . 0.9 OUTLIER -104.77 159.31 15.88 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.228 -0.92 . . . . 0.0 109.445 179.963 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.46 147.69 75.86 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.21 -0.931 . . . . 0.0 109.436 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.21 160.82 29.47 Favored 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.608 2.206 . . . . 0.0 110.379 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 9' ' ' PHE . 27.2 m -71.6 89.38 0.98 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.327 -0.858 . . . . 0.0 109.48 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.471 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 31.4 m-85 -44.07 147.98 0.86 Allowed Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.298 -0.876 . . . . 0.0 109.444 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 9' ' ' PHE . 35.8 Cg_endo -78.06 -159.96 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.691 2.261 . . . . 0.0 110.415 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 12' ' ' SER . 46.7 tt0 -77.38 -58.41 3.29 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.215 -0.928 . . . . 0.0 109.401 -179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.8 t -42.8 -55.71 3.53 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.273 -0.892 . . . . 0.0 109.693 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.512 HG22 ' H ' ' A' ' 15' ' ' ASP . 3.5 mt -91.45 134.08 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.251 -0.905 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.18 11.3 16.25 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.242 -0.911 . . . . 0.0 109.486 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.512 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 171.31 -171.15 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.182 -0.949 . . . . 0.0 109.477 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.76 -167.3 17.77 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.526 HG23 ' O ' ' A' ' 64' ' ' ASP . 94.6 m -150.0 125.83 10.46 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -1.156 . . . . 0.0 109.483 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.468 HG12 ' N ' ' A' ' 19' ' ' ALA . 47.0 t -45.26 160.07 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 109.454 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.608 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -106.16 -73.06 0.69 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.186 -0.946 . . . . 0.0 109.51 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.1 m -160.08 131.89 6.12 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.237 -0.914 . . . . 0.0 109.521 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.635 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.4 m95 -89.87 85.57 6.42 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 121.279 -0.888 . . . . 0.0 109.545 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.656 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.0 m80 -43.26 -62.21 1.12 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.32 -0.863 . . . . 0.0 109.392 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -100.58 176.66 5.25 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.929 . . . . 0.0 109.506 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.16 167.46 11.33 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.427 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.479 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.92 108.94 2.75 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.689 2.259 . . . . 0.0 110.422 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 139.01 -10.22 3.33 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.433 ' O ' HG13 ' A' ' 54' ' ' VAL . 1.4 mt-10 -97.48 -172.22 2.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.29 -1.123 . . . . 0.0 109.541 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -106.76 154.66 20.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.299 -0.875 . . . . 0.0 109.498 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.869 HG21 HD11 ' A' ' 35' ' ' ILE . 8.4 p -139.58 148.94 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.499 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -114.58 137.69 51.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.151 -0.968 . . . . 0.0 109.504 -179.972 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.461 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 29.5 ttt85 -42.73 150.03 0.17 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.331 -0.855 . . . . 0.0 109.663 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.683 ' HA ' HD21 ' A' ' 48' ' ' LEU . 8.5 t70 72.3 41.14 0.63 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.48 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.439 ' O ' ' O ' ' A' ' 34' ' ' LEU . 2.4 tp10 -141.94 124.23 15.61 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.147 -0.97 . . . . 0.0 109.448 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.656 HD21 ' NE2' ' A' ' 22' ' ' HIS . 45.7 tp -43.16 164.69 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.346 -0.846 . . . . 0.0 109.482 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.869 HD11 HG21 ' A' ' 29' ' ' VAL . 27.4 mm -139.52 -46.07 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.109 -0.994 . . . . 0.0 109.579 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.458 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.6 p -166.3 137.25 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.262 -0.899 . . . . 0.0 109.473 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.608 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 16.9 m-20 -97.96 152.67 19.01 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.253 -0.904 . . . . 0.0 109.44 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.485 HD13 ' O ' ' A' ' 37' ' ' ASP . 6.0 mm -119.52 156.15 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.461 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.47 ' HB2' ' O ' ' A' ' 17' ' ' THR . 1.1 mm-40 -118.23 128.91 55.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.425 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.1 OUTLIER -109.87 -161.23 0.75 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.266 -0.896 . . . . 0.0 109.429 179.992 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.425 ' C ' ' O ' ' A' ' 40' ' ' THR . 13.6 t0 -42.8 -71.01 0.09 Allowed 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.342 -0.849 . . . . 0.0 109.681 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.5 mmtm -137.29 28.24 2.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.274 -0.891 . . . . 0.0 109.475 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 44' ' ' VAL . 24.6 t -128.43 169.32 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.24 -0.913 . . . . 0.0 109.51 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.579 ' N ' HG12 ' A' ' 43' ' ' VAL . 7.5 p -129.66 122.43 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.302 -0.874 . . . . 0.0 109.457 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 87.2 mmm -103.89 176.51 5.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 0.0 109.476 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -136.21 153.15 51.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.215 -0.928 . . . . 0.0 109.543 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.458 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 45.8 t -125.09 102.58 10.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.336 -0.853 . . . . 0.0 109.454 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.683 HD21 ' HA ' ' A' ' 32' ' ' ASP . 0.5 OUTLIER -96.41 150.21 20.85 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.214 -0.929 . . . . 0.0 109.44 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.436 ' O ' HD23 ' A' ' 48' ' ' LEU . . . -78.8 137.71 37.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.469 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -101.33 19.96 16.75 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.332 -0.855 . . . . 0.0 109.496 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -176.57 134.61 0.23 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.244 -0.91 . . . . 0.0 109.5 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.5 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -62.75 170.94 2.31 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.263 -0.898 . . . . 0.0 109.377 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.5 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 146.71 -151.74 23.97 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 27' ' ' GLU . 71.4 t -134.28 130.63 54.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -1.149 . . . . 0.0 109.425 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.492 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.1 mt -52.15 160.5 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.338 -0.851 . . . . 0.0 109.524 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.492 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -97.69 -68.79 0.78 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.142 -0.974 . . . . 0.0 109.444 -179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.479 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 1.5 mt-10 -176.02 133.08 0.25 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.293 -0.879 . . . . 0.0 109.495 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.635 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 20.1 mm -95.33 125.22 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.309 -0.869 . . . . 0.0 109.47 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 44.3 t -89.91 -29.75 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.912 . . . . 0.0 109.425 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.521 ' CG ' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -90.0 162.72 15.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -0.912 . . . . 0.0 109.424 -179.986 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.475 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 13.7 m-80 -117.08 157.57 25.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.212 -0.93 . . . . 0.0 109.5 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -61.14 134.61 57.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.21 -0.931 . . . . 0.0 109.443 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 94.15 -7.05 72.65 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.526 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -86.06 170.71 11.99 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -1.145 . . . . 0.0 109.301 -179.996 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.502 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 9.6 t -99.58 163.09 12.65 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.536 -0.728 . . . . 0.0 109.521 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 5.7 m -127.02 144.32 37.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.199 -0.938 . . . . 0.0 109.468 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -107.1 167.81 9.65 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.216 -0.928 . . . . 0.0 109.54 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.6 t -67.44 101.83 1.03 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.311 -0.868 . . . . 0.0 109.458 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 107.47 13.2 21.36 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.425 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 46.9 tp10 -81.13 123.84 28.75 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.261 -1.14 . . . . 0.0 109.522 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 5.8 tt -81.88 114.22 20.34 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.184 -0.947 . . . . 0.0 109.517 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 22.3 mt -89.32 -20.02 24.56 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.17 -0.956 . . . . 0.0 109.495 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 161.29 179.96 36.34 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.474 ' HG2' ' HB3' ' A' ' 56' ' ' ALA . 0.6 OUTLIER -149.74 153.04 36.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -1.175 . . . . 0.0 109.458 -179.968 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.468 ' HG ' ' N ' ' A' ' 76' ' ' THR . 17.0 tp -90.26 153.17 20.67 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.315 -0.866 . . . . 0.0 109.47 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.468 ' N ' ' HG ' ' A' ' 75' ' ' LEU . 5.6 m . . . . . 0 N--CA 1.49 1.567 0 O-C-N 121.311 -0.868 . . . . 0.0 109.46 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.529 HD13 HD22 ' A' ' 75' ' ' LEU . 3.3 mp . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -60.81 130.77 48.15 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.272 -0.893 . . . . 0.0 109.502 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.651 HD12 ' HA ' ' A' ' 74' ' ' LYS . 2.7 mp -100.29 110.61 27.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.195 -0.941 . . . . 0.0 109.472 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.7 pttp -120.17 166.82 12.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.198 -0.939 . . . . 0.0 109.478 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.655 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -84.99 164.46 41.59 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.265 -0.897 . . . . 0.0 109.487 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.655 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.3 Cg_endo -78.02 153.54 28.84 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.625 2.217 . . . . 0.0 110.455 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.468 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 41.2 m -75.75 110.49 10.22 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.933 . . . . 0.0 109.455 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -69.92 153.31 95.56 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.205 -0.934 . . . . 0.0 109.482 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.11 176.74 9.61 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 C-N-CA 122.656 2.237 . . . . 0.0 110.453 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.533 ' HG3' ' N ' ' A' ' 12' ' ' SER . 22.5 pt-20 -65.24 -45.44 84.59 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.287 -0.883 . . . . 0.0 109.469 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.533 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 1.5 t -42.61 -40.12 2.59 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.379 -0.826 . . . . 0.0 109.699 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.704 HG22 ' H ' ' A' ' 15' ' ' ASP . 30.0 mm -108.11 154.05 9.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.259 -0.901 . . . . 0.0 109.453 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -118.18 0.16 11.7 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.235 -0.916 . . . . 0.0 109.611 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.704 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER 179.23 -174.45 0.21 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.189 -0.945 . . . . 0.0 109.506 -179.995 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -150.92 -160.56 9.47 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.543 HG23 ' O ' ' A' ' 64' ' ' ASP . 16.8 m -150.02 129.04 12.62 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.236 -1.155 . . . . 0.0 109.418 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.513 HG12 ' N ' ' A' ' 19' ' ' ALA . 60.8 t -44.45 161.26 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.398 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.627 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -106.65 -75.13 0.64 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.247 -0.908 . . . . 0.0 109.515 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.6 m -160.13 131.42 5.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.234 -0.917 . . . . 0.0 109.558 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.637 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.82 85.88 6.51 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.337 -0.852 . . . . 0.0 109.53 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.625 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.7 m80 -42.12 -69.02 0.15 Allowed 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.355 -0.841 . . . . 0.0 109.483 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -96.93 -177.24 3.81 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.215 -0.928 . . . . 0.0 109.628 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.44 ' CG ' ' HD2' ' A' ' 25' ' ' PRO . 4.5 mttp -122.76 169.4 9.9 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.292 -0.88 . . . . 0.0 109.453 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.508 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.1 Cg_endo -76.23 136.43 17.97 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.626 2.217 . . . . 0.0 110.416 179.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.73 14.07 35.69 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -112.5 -172.3 2.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -1.119 . . . . 0.0 109.508 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.75 138.93 31.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.346 -0.846 . . . . 0.0 109.456 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.9 t -118.5 141.76 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.406 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 8.8 ttpt -131.86 127.03 35.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.296 -0.878 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.534 ' CG ' ' HA ' ' A' ' 51' ' ' ALA . 0.2 OUTLIER -42.75 147.24 0.31 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.374 -0.829 . . . . 0.0 109.63 -179.889 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.484 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 11.8 t0 73.4 26.41 2.02 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -0.888 . . . . 0.0 109.463 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.427 ' O ' ' O ' ' A' ' 34' ' ' LEU . 12.5 tm-20 -126.8 110.24 12.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.363 -0.836 . . . . 0.0 109.474 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.625 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 47.4 tp -42.98 164.23 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.321 -0.862 . . . . 0.0 109.597 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.84 HD11 ' HB2' ' A' ' 49' ' ' ALA . 27.4 mt -138.18 -47.72 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.27 -0.894 . . . . 0.0 109.606 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.534 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 12.6 p -150.61 152.78 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.236 -0.915 . . . . 0.0 109.51 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.627 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 23.3 m-20 -113.99 150.63 33.56 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.27 -0.894 . . . . 0.0 109.461 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.534 HD11 ' CG2' ' A' ' 47' ' ' VAL . 3.3 mt -115.27 145.09 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.263 -0.898 . . . . 0.0 109.489 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -118.59 143.91 46.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.209 -0.932 . . . . 0.0 109.423 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.541 HG22 ' N ' ' A' ' 41' ' ' ASP . 55.7 m -134.96 165.35 25.54 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.199 -0.938 . . . . 0.0 109.422 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.541 ' N ' HG22 ' A' ' 40' ' ' THR . 45.0 t0 -42.79 -36.14 1.37 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.869 . . . . 0.0 109.639 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 20.3 mttp -158.48 28.91 0.24 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.277 -0.89 . . . . 0.0 109.503 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.464 ' O ' ' HB ' ' A' ' 40' ' ' THR . 7.6 t -142.05 117.79 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.501 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -107.04 124.86 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.251 -0.906 . . . . 0.0 109.461 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 4.0 mtp -117.2 -174.59 2.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.236 -0.915 . . . . 0.0 109.478 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -140.89 168.86 18.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.232 -0.918 . . . . 0.0 109.502 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.534 ' CG2' HD11 ' A' ' 38' ' ' ILE . 53.0 t -142.03 102.98 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.242 -0.912 . . . . 0.0 109.521 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.774 ' N ' HD23 ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.46 166.49 10.51 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.192 -0.943 . . . . 0.0 109.418 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.84 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -83.52 157.57 22.32 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.918 . . . . 0.0 109.48 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.546 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 1.8 mm-40 -104.07 7.17 36.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.571 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.546 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 173.18 161.76 0.13 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.959 . . . . 0.0 109.51 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.514 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -59.99 171.0 1.04 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.218 -0.926 . . . . 0.0 109.322 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.514 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.19 -163.9 28.93 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' A' ' 55' ' ' ILE . 40.5 t -133.8 119.6 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.257 -1.143 . . . . 0.0 109.527 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.631 HG22 ' H ' ' A' ' 56' ' ' ALA . 2.3 mp -47.02 174.45 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.384 -0.823 . . . . 0.0 109.755 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.631 ' H ' HG22 ' A' ' 55' ' ' ILE . . . -111.99 -60.86 1.8 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.159 -0.963 . . . . 0.0 109.458 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 177.45 138.0 0.07 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.499 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.637 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.1 mm -95.14 128.48 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.337 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 83.7 t -90.04 -33.52 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.196 -0.94 . . . . 0.0 109.518 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.604 ' HZ2' HD23 ' A' ' 72' ' ' LEU . 1.0 OUTLIER -97.83 145.96 25.89 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.2 -0.937 . . . . 0.0 109.497 -179.928 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.403 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 7.1 m-80 -109.72 169.44 8.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.293 -0.879 . . . . 0.0 109.435 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -64.26 150.62 45.59 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.193 -0.942 . . . . 0.0 109.56 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.68 5.59 86.43 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.543 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -105.17 170.85 7.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.115 -1.226 . . . . 0.0 109.26 -179.991 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.507 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 9.8 t -99.35 153.77 18.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.607 -0.683 . . . . 0.0 109.467 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.458 HG12 ' HD2' ' A' ' 60' ' ' LYS . 28.5 m -124.75 136.82 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.233 -0.917 . . . . 0.0 109.472 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.455 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.1 OUTLIER -92.84 163.2 13.8 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.263 -0.898 . . . . 0.0 109.412 179.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.468 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 33.1 t -55.7 123.02 12.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 109.469 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 67.46 35.83 87.64 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.501 ' CG ' ' HE2' ' A' ' 60' ' ' LYS . 8.4 tp10 -79.91 136.91 36.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.259 -1.142 . . . . 0.0 109.442 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.562 ' C ' HD23 ' A' ' 71' ' ' LEU . 9.0 tt -77.88 117.72 19.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.279 -0.888 . . . . 0.0 109.432 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.604 HD23 ' HZ2' ' A' ' 60' ' ' LYS . 0.4 OUTLIER -99.41 -14.89 18.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.871 . . . . 0.0 109.397 179.972 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 160.14 -169.49 36.03 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.651 ' HA ' HD12 ' A' ' 4' ' ' ILE . 4.7 ptmt -150.1 152.82 35.38 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -1.154 . . . . 0.0 109.466 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.692 HD23 ' O ' ' A' ' 76' ' ' THR . 0.5 OUTLIER -104.15 156.51 17.82 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.466 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.692 ' O ' HD23 ' A' ' 75' ' ' LEU . 5.9 m . . . . . 0 N--CA 1.49 1.563 0 O-C-N 121.321 -0.862 . . . . 0.0 109.49 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.436 HG22 ' H ' ' A' ' 3' ' ' ASP . 4.7 mm . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.436 ' H ' HG22 ' A' ' 2' ' ' ILE . 27.2 t0 -114.87 137.9 51.42 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.249 -0.907 . . . . 0.0 109.536 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.415 ' CG2' HG11 ' A' ' 47' ' ' VAL . 2.9 mt -105.78 72.67 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.434 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.413 ' HD2' ' OD2' ' A' ' 3' ' ' ASP . 1.3 ptmt -102.85 149.8 24.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.27 -0.894 . . . . 0.0 109.421 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.464 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -61.63 158.55 39.86 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.292 -0.88 . . . . 0.0 109.534 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.464 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.4 Cg_endo -78.0 -178.96 5.0 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.676 2.251 . . . . 0.0 110.405 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 60.6 m -92.74 129.3 38.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.453 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -81.1 148.96 65.34 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.192 -0.943 . . . . 0.0 109.453 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.02 -165.99 0.37 Allowed 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.659 2.239 . . . . 0.0 110.393 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.426 ' HG3' ' N ' ' A' ' 12' ' ' SER . 12.7 pt-20 -73.69 -41.67 62.31 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.267 -0.896 . . . . 0.0 109.525 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.426 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 38.4 t -42.89 -72.95 0.05 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.367 -0.833 . . . . 0.0 109.634 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.665 HG21 HG22 ' A' ' 40' ' ' THR . 1.8 mp -90.71 150.57 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.522 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -121.29 31.48 6.32 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.212 -0.93 . . . . 0.0 109.514 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -177.33 -171.84 0.35 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.925 . . . . 0.0 109.439 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.75 ' HA2' HG23 ' A' ' 40' ' ' THR . . . -154.63 175.59 32.69 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.518 ' O ' ' CG ' ' A' ' 39' ' ' GLU . 98.1 m -150.07 114.97 5.33 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.144 -1.21 . . . . 0.0 109.527 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.593 HG12 ' N ' ' A' ' 19' ' ' ALA . 40.2 t -46.0 168.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.313 -0.867 . . . . 0.0 109.477 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.601 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -113.22 -71.08 0.77 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.254 -0.904 . . . . 0.0 109.58 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.49 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 20.7 m -160.03 134.75 7.73 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.197 -0.939 . . . . 0.0 109.572 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.626 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.5 m95 -89.89 84.01 6.2 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.26 -0.9 . . . . 0.0 109.505 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.629 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -42.72 -70.12 0.12 Allowed 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.39 -0.819 . . . . 0.0 109.469 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 7.6 mmtt -89.5 -172.2 3.5 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.61 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.491 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 8.2 mttp -136.66 165.24 36.75 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.27 -0.894 . . . . 0.0 109.247 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.534 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -77.21 114.44 3.77 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.553 2.169 . . . . 0.0 110.383 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 135.23 -9.9 4.42 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -100.21 -172.36 2.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.235 -1.156 . . . . 0.0 109.487 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.83 170.47 11.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.293 -0.879 . . . . 0.0 109.484 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.448 ' HB ' ' O ' ' A' ' 53' ' ' GLY . 52.2 t -142.08 148.27 20.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.212 -0.93 . . . . 0.0 109.482 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.2 OUTLIER -135.38 136.01 41.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.259 -0.901 . . . . 0.0 109.479 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.464 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 15.7 ttp180 -42.87 145.38 0.47 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.29 -0.881 . . . . 0.0 109.733 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.464 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 54.9 t0 67.45 48.11 1.17 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.285 -0.884 . . . . 0.0 109.477 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' A' ' 34' ' ' LEU . 1.2 tp10 -137.57 105.95 5.79 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.216 -0.927 . . . . 0.0 109.508 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.629 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 42.7 tp -43.13 164.89 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.302 -0.874 . . . . 0.0 109.537 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.91 HD11 ' HB2' ' A' ' 49' ' ' ALA . 49.3 mt -142.56 -47.64 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.245 -0.909 . . . . 0.0 109.615 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.527 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.9 p -151.47 134.98 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.168 -0.957 . . . . 0.0 109.552 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.601 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 6.4 m-20 -95.59 163.86 13.03 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.31 -0.868 . . . . 0.0 109.427 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.437 HD11 ' CG2' ' A' ' 47' ' ' VAL . 21.6 mt -134.0 152.8 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.185 -0.947 . . . . 0.0 109.399 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 17' ' ' THR . 10.9 pt-20 -146.43 144.56 29.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.204 -0.935 . . . . 0.0 109.557 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.75 HG23 ' HA2' ' A' ' 16' ' ' GLY . 0.2 OUTLIER -140.28 -172.04 3.33 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.281 -0.887 . . . . 0.0 109.481 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.58 ' H ' HG22 ' A' ' 40' ' ' THR . 3.0 t70 -42.89 -64.15 0.67 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.354 -0.841 . . . . 0.0 109.66 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.65 44.13 1.96 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.428 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 2.8 t -148.22 104.28 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.26 -0.9 . . . . 0.0 109.497 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.435 ' O ' ' HG2' ' A' ' 45' ' ' MET . 62.1 t -98.04 143.43 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.242 -0.911 . . . . 0.0 109.535 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . 0.435 ' HG2' ' O ' ' A' ' 44' ' ' VAL . 2.7 mmt -143.52 -178.89 6.11 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.227 -0.921 . . . . 0.0 109.489 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -141.33 165.68 26.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.176 -0.953 . . . . 0.0 109.512 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.527 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 18.1 t -137.35 98.36 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.232 -0.918 . . . . 0.0 109.467 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.762 ' N ' HD23 ' A' ' 48' ' ' LEU . 0.1 OUTLIER -103.18 160.58 14.53 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 121.227 -0.92 . . . . 0.0 109.371 179.943 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.91 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -77.9 132.63 38.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.459 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.433 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.2 OUTLIER -86.28 12.4 10.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.221 -0.924 . . . . 0.0 109.489 -179.974 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.433 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 178.86 155.12 0.43 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.295 -0.878 . . . . 0.0 109.446 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.499 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -65.97 170.94 4.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.178 -0.952 . . . . 0.0 109.392 179.94 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.499 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 149.9 -153.99 25.43 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.4 ' O ' ' HB ' ' A' ' 76' ' ' THR . 49.6 t -135.19 126.27 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -1.129 . . . . 0.0 109.45 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.573 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.1 mt -56.21 164.39 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.193 -0.942 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.573 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -105.08 -63.69 1.2 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.531 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.534 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 1.1 pt-20 -179.24 144.09 0.22 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.248 -0.907 . . . . 0.0 109.465 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.626 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 24.5 mm -105.3 123.91 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.279 -0.888 . . . . 0.0 109.503 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.0 t -89.91 -19.88 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.251 -0.905 . . . . 0.0 109.546 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.491 ' HG3' ' OD1' ' A' ' 64' ' ' ASP . 3.9 tptt -115.97 129.9 56.59 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.239 -0.913 . . . . 0.0 109.51 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 14.9 m-80 -87.62 157.03 19.22 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 0.0 109.454 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.525 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -60.66 151.81 28.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.31 -10.49 68.86 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.514 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -88.63 171.02 10.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -1.164 . . . . 0.0 109.321 -179.97 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.514 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 97.9 m -91.51 147.18 23.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.518 -0.739 . . . . 0.0 109.482 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 17.1 m -120.04 178.73 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.281 -0.887 . . . . 0.0 109.405 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -130.33 162.69 28.48 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.915 . . . . 0.0 109.466 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -65.16 97.22 0.24 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.225 -0.922 . . . . 0.0 109.441 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.77 27.74 7.78 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.504 -1.439 . . . . 0.0 109.504 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -84.08 132.06 34.74 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.201 -1.176 . . . . 0.0 109.49 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.404 ' C ' HD23 ' A' ' 71' ' ' LEU . 8.4 tt -78.9 114.98 18.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -0.924 . . . . 0.0 109.464 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.473 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 5.1 mt -91.24 -22.15 20.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.322 -0.861 . . . . 0.0 109.466 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 170.85 177.03 40.52 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.409 ' O ' ' CB ' ' A' ' 56' ' ' ALA . 12.5 mttt -124.94 138.36 54.24 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.3 -1.117 . . . . 0.0 109.492 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -94.71 144.16 25.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.499 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.4 ' HB ' ' O ' ' A' ' 54' ' ' VAL . 10.8 m . . . . . 0 N--CA 1.489 1.519 0 O-C-N 121.207 -0.933 . . . . 0.0 109.464 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.3 mt . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.404 ' OD2' ' HE3' ' A' ' 74' ' ' LYS . 46.2 t0 -72.71 127.7 33.34 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.296 -0.877 . . . . 0.0 109.513 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.578 ' O ' HG22 ' A' ' 4' ' ' ILE . 60.7 mt -95.63 80.28 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.33 -0.857 . . . . 0.0 109.504 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.421 ' O ' ' HG3' ' A' ' 5' ' ' LYS . 0.2 OUTLIER -100.14 145.94 27.4 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.537 179.971 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.597 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -52.15 162.9 0.77 Allowed Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.227 -0.921 . . . . 0.0 109.451 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.597 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 36.2 Cg_endo -77.95 162.81 28.99 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.642 2.228 . . . . 0.0 110.484 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.547 HG23 ' O ' ' A' ' 8' ' ' THR . 2.5 t -82.95 105.74 14.2 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.186 -0.947 . . . . 0.0 109.436 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.415 ' HB3' ' HB ' ' A' ' 13' ' ' ILE . 10.8 m-85 -72.4 150.72 91.76 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.187 -0.946 . . . . 0.0 109.492 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.612 ' HD2' HD12 ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.07 176.34 10.09 Favored 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.6 2.2 . . . . 0.0 110.42 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.436 ' O ' ' C ' ' A' ' 12' ' ' SER . 2.1 mt-10 -56.64 -50.98 70.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.309 -0.869 . . . . 0.0 109.441 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 11' ' ' GLU . 7.3 t -42.93 -46.65 5.46 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.37 -0.831 . . . . 0.0 109.58 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.738 HG22 ' H ' ' A' ' 15' ' ' ASP . 64.5 mt -92.76 150.34 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.212 -0.93 . . . . 0.0 109.477 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -127.0 17.07 7.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.942 . . . . 0.0 109.471 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.738 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 178.75 -169.08 0.09 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.196 -0.94 . . . . 0.0 109.499 -179.962 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.414 ' O ' HG23 ' A' ' 65' ' ' THR . . . -147.91 -176.17 21.23 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 69.4 m -149.91 115.27 5.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.254 -1.145 . . . . 0.0 109.495 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.585 HG12 ' N ' ' A' ' 19' ' ' ALA . 27.5 t -49.41 169.28 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.264 -0.898 . . . . 0.0 109.391 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.585 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -114.69 -73.97 0.63 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.191 -0.943 . . . . 0.0 109.53 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.0 m -160.07 133.72 7.09 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.198 -0.939 . . . . 0.0 109.523 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.734 ' CH2' HD12 ' A' ' 58' ' ' ILE . 34.5 m95 -89.87 92.9 9.21 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 121.155 -0.965 . . . . 0.0 109.556 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.714 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.6 m80 -54.98 -72.24 0.07 Allowed 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.324 -0.86 . . . . 0.0 109.421 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -84.18 -172.77 4.35 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.238 -0.914 . . . . 0.0 109.609 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -136.35 166.97 23.78 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.388 -0.82 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.496 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.6 Cg_endo -77.03 138.82 18.67 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.683 2.256 . . . . 0.0 110.493 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 106.79 -9.82 40.75 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -102.2 -174.37 2.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.315 -1.109 . . . . 0.0 109.417 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.82 147.77 27.36 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.302 -0.873 . . . . 0.0 109.466 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m -129.95 -169.53 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.212 -0.93 . . . . 0.0 109.467 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.448 ' O ' ' CB ' ' A' ' 33' ' ' GLU . 9.9 tptm -157.06 139.61 14.92 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.224 -0.923 . . . . 0.0 109.479 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.426 ' C ' ' O ' ' A' ' 30' ' ' LYS . 2.3 ttp180 -42.78 154.83 0.06 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.289 -0.882 . . . . 0.0 109.622 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.0 t70 60.24 33.44 20.97 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.244 -0.91 . . . . 0.0 109.47 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.448 ' CB ' ' O ' ' A' ' 30' ' ' LYS . 28.9 tt0 -126.45 113.92 17.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.223 -0.923 . . . . 0.0 109.508 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.714 HD21 ' NE2' ' A' ' 22' ' ' HIS . 56.8 tp -42.86 160.23 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.357 -0.839 . . . . 0.0 109.623 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.813 HD11 ' CA ' ' A' ' 49' ' ' ALA . 4.3 mt -142.77 -43.95 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.229 -0.919 . . . . 0.0 109.56 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.58 HG12 ' HB ' ' A' ' 47' ' ' VAL . 13.6 p -160.87 138.65 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.282 -0.886 . . . . 0.0 109.439 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.521 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 28.3 m-20 -97.76 149.5 22.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.139 -0.976 . . . . 0.0 109.39 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.416 HG22 ' N ' ' A' ' 39' ' ' GLU . 31.5 mt -122.46 156.3 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.196 -0.94 . . . . 0.0 109.42 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.416 ' N ' HG22 ' A' ' 38' ' ' ILE . 2.4 tm-20 -135.62 153.17 51.74 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.433 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.414 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -140.23 -178.98 5.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.195 -0.94 . . . . 0.0 109.509 -179.993 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.435 ' HB2' HG12 ' A' ' 13' ' ' ILE . 6.7 t0 -42.78 -70.02 0.12 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.344 -0.848 . . . . 0.0 109.593 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.2 mttt -129.38 35.05 4.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.255 -0.903 . . . . 0.0 109.392 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 9.7 t -144.09 152.71 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 109.447 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.4 t -130.5 153.88 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.184 -0.948 . . . . 0.0 109.487 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . 0.415 ' C ' ' HG3' ' A' ' 46' ' ' GLU . 4.4 mmt -143.25 167.38 22.28 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.188 -0.945 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.415 ' HG3' ' C ' ' A' ' 45' ' ' MET . 0.7 OUTLIER -128.98 156.22 44.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.285 -0.884 . . . . 0.0 109.478 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.58 ' HB ' HG12 ' A' ' 36' ' ' VAL . 20.9 t -126.88 99.95 6.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.895 . . . . 0.0 109.502 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.768 ' N ' HD23 ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.93 164.96 11.31 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.295 -0.878 . . . . 0.0 109.396 -179.992 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.813 ' CA ' HD11 ' A' ' 35' ' ' ILE . . . -83.34 129.41 34.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.291 -0.881 . . . . 0.0 109.522 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.581 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -91.35 10.84 25.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.197 -0.939 . . . . 0.0 109.443 -179.973 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.581 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 171.58 132.33 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.316 -0.865 . . . . 0.0 109.454 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.506 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -47.42 170.93 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.253 -0.904 . . . . 0.0 109.294 179.973 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.506 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 153.88 -160.95 29.67 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 46.5 t -124.56 123.91 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.272 -1.134 . . . . 0.0 109.494 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.556 HG22 ' N ' ' A' ' 56' ' ' ALA . 4.9 mt -61.52 163.7 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.338 -0.852 . . . . 0.0 109.615 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.556 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -103.22 -65.51 1.0 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -0.922 . . . . 0.0 109.485 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.496 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER 172.66 141.35 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.239 -0.913 . . . . 0.0 109.427 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.734 HD12 ' CH2' ' A' ' 21' ' ' TRP . 9.9 mm -89.97 140.38 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.279 -0.888 . . . . 0.0 109.398 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 98.8 t -89.99 -53.13 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.184 -0.947 . . . . 0.0 109.438 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.522 ' HA ' ' CE ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -94.87 167.17 11.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.251 -0.906 . . . . 0.0 109.391 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 49.3 m-80 -104.65 156.06 18.31 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.422 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.533 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -64.97 155.54 34.15 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.417 -179.933 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.08 2.54 89.4 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -105.28 170.96 7.58 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.196 -1.179 . . . . 0.0 109.313 -179.984 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.51 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 95.4 m -98.93 122.91 42.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.553 -0.717 . . . . 0.0 109.489 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.446 ' HB ' ' HG2' ' A' ' 70' ' ' GLU . 5.5 m -104.41 -172.37 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.273 -0.892 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -133.45 176.3 8.65 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.501 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.9 t -63.8 143.54 57.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.414 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 60.17 26.01 63.07 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.446 ' HG2' ' HB ' ' A' ' 66' ' ' VAL . 35.2 tp10 -82.92 110.43 17.9 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.455 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.768 HD11 ' HD2' ' A' ' 74' ' ' LYS . 9.6 tt -69.24 109.97 4.36 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.264 -0.897 . . . . 0.0 109.486 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.575 ' O ' HG23 ' A' ' 58' ' ' ILE . 35.9 mt -94.33 -11.8 29.29 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.521 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.45 ' O ' ' HG2' ' A' ' 74' ' ' LYS . . . 173.04 177.92 42.66 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.768 ' HD2' HD11 ' A' ' 71' ' ' LEU . 20.3 mtpt -147.7 129.2 14.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -1.127 . . . . 0.0 109.466 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.714 HD23 ' O ' ' A' ' 76' ' ' THR . 1.1 tt -96.02 147.66 23.47 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.238 -0.914 . . . . 0.0 109.539 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.714 ' O ' HD23 ' A' ' 75' ' ' LEU . 5.8 m . . . . . 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.513 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 36.8 pt . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.518 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 14.4 t0 -113.97 133.57 55.4 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.233 -0.917 . . . . 0.0 109.479 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.8 mt -105.57 98.08 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.193 -0.942 . . . . 0.0 109.48 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.02 168.69 14.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.17 -0.956 . . . . 0.0 109.5 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.2 153.73 92.33 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.307 -0.87 . . . . 0.0 109.47 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.99 140.64 18.23 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.565 2.177 . . . . 0.0 110.418 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.446 HG23 ' O ' ' A' ' 8' ' ' THR . 8.9 t -62.32 129.59 41.41 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -0.962 . . . . 0.0 109.451 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.497 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 23.4 m-85 -96.93 151.88 38.03 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.887 . . . . 0.0 109.472 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.448 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -78.08 171.31 17.33 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.671 2.247 . . . . 0.0 110.376 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.424 ' O ' ' C ' ' A' ' 12' ' ' SER . 4.5 mt-10 -45.67 -54.52 7.66 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.144 -0.973 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.424 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.95 -62.46 1.01 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.282 -0.886 . . . . 0.0 109.601 -179.917 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.573 HG22 ' H ' ' A' ' 15' ' ' ASP . 29.8 mm -92.85 119.13 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.181 -0.949 . . . . 0.0 109.482 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.438 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -96.18 13.21 28.13 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.262 -0.899 . . . . 0.0 109.484 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.573 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER 167.42 -171.82 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.884 . . . . 0.0 109.431 -179.957 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.34 -159.28 8.39 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.525 HG23 ' O ' ' A' ' 64' ' ' ASP . 52.1 m -149.57 123.29 9.23 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.243 -1.151 . . . . 0.0 109.502 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.592 HG12 ' N ' ' A' ' 19' ' ' ALA . 39.6 t -47.98 168.64 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.302 -0.874 . . . . 0.0 109.426 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.592 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -113.13 -75.0 0.61 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.413 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.5 m -160.08 134.7 7.66 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.336 -0.853 . . . . 0.0 109.451 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.673 ' CH2' HD12 ' A' ' 58' ' ' ILE . 34.1 m95 -89.78 84.9 6.3 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.231 -0.918 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.806 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.8 m80 -42.34 -60.46 1.48 Allowed 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.371 -0.831 . . . . 0.0 109.497 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 4.1 mmtt -99.66 -172.11 2.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.593 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.408 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -130.12 168.59 16.12 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.288 -0.882 . . . . 0.0 109.496 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.528 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.51 115.58 4.11 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 122.664 2.243 . . . . 0.0 110.39 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.83 -11.92 5.38 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.431 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 1.2 pp20? -95.6 -172.89 2.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.352 -1.087 . . . . 0.0 109.467 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.431 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -101.04 151.2 22.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.601 HG22 ' O ' ' A' ' 53' ' ' GLY . 20.1 m -114.9 166.63 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.358 -0.839 . . . . 0.0 109.429 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.436 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.3 mttt -121.3 134.5 55.15 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.262 -0.899 . . . . 0.0 109.506 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.51 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.81 113.42 0.47 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.352 -0.843 . . . . 0.0 109.684 -179.898 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.51 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 14.5 t0 75.99 56.37 0.05 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.293 -0.879 . . . . 0.0 109.495 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.479 ' O ' HG13 ' A' ' 35' ' ' ILE . 15.9 tt0 -131.24 124.15 29.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.319 -0.863 . . . . 0.0 109.437 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.806 HD21 ' NE2' ' A' ' 22' ' ' HIS . 51.1 tp -42.8 151.63 0.12 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.377 -0.827 . . . . 0.0 109.596 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.937 HD11 ' HB2' ' A' ' 49' ' ' ALA . 96.9 mt -137.84 -41.21 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.319 -0.863 . . . . 0.0 109.476 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.526 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 13.6 p -158.24 135.0 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.277 -0.89 . . . . 0.0 109.451 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.514 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 10.7 m-20 -93.28 153.83 18.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.287 -0.883 . . . . 0.0 109.438 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.537 HD11 ' CG2' ' A' ' 47' ' ' VAL . 2.8 mt -121.44 155.81 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.271 -0.893 . . . . 0.0 109.507 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.0 145.06 50.85 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.295 -0.878 . . . . 0.0 109.439 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.538 HG22 ' H ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -130.6 -176.98 4.15 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -0.932 . . . . 0.0 109.479 179.962 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.538 ' H ' HG22 ' A' ' 40' ' ' THR . 63.5 t0 -42.78 -55.08 3.8 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.286 -0.883 . . . . 0.0 109.686 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 18.3 mttm -147.45 25.45 1.08 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.246 -0.908 . . . . 0.0 109.396 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 2.1 t -134.05 130.87 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.231 -0.918 . . . . 0.0 109.457 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.0 t -108.57 139.78 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.218 -0.926 . . . . 0.0 109.512 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 18.7 mtp -131.62 175.28 9.31 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.212 -0.93 . . . . 0.0 109.467 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -124.59 159.91 29.62 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.508 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.537 ' CG2' HD11 ' A' ' 38' ' ' ILE . 5.4 t -130.14 89.5 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.286 -0.884 . . . . 0.0 109.45 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.781 ' N ' HD23 ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.92 156.72 17.47 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.239 -0.913 . . . . 0.0 109.372 179.974 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.937 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -77.84 149.13 34.4 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.196 -0.94 . . . . 0.0 109.538 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 1.3 mt-10 -92.27 12.02 23.84 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.229 -0.92 . . . . 0.0 109.449 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.456 ' HA ' ' HG3' ' A' ' 31' ' ' ARG . . . 179.13 150.07 0.28 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.243 -0.911 . . . . 0.0 109.493 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -55.35 170.93 0.2 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.216 -0.928 . . . . 0.0 109.32 -179.97 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.601 ' O ' HG22 ' A' ' 29' ' ' VAL . . . 154.74 -153.88 25.12 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 52.4 t -138.75 127.0 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.247 -1.149 . . . . 0.0 109.442 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.501 HD13 ' CD1' ' A' ' 75' ' ' LEU . 14.9 mm -62.25 158.15 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.213 -0.929 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.418 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -97.37 -69.56 0.75 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.238 -0.914 . . . . 0.0 109.468 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.528 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 2.9 pt-20 -174.76 142.44 0.7 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.255 -0.903 . . . . 0.0 109.453 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.673 HD12 ' CH2' ' A' ' 21' ' ' TRP . 15.7 mm -93.86 138.05 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.208 -0.933 . . . . 0.0 109.498 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.7 t -90.56 -57.71 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.275 -0.891 . . . . 0.0 109.532 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.524 ' HA ' ' CE ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -89.93 163.22 15.06 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.17 -0.956 . . . . 0.0 109.439 -179.964 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 -102.56 156.49 17.58 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 109.53 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.522 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.2 OUTLIER -66.49 160.1 25.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.245 -0.909 . . . . 0.0 109.432 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 81.75 -7.35 62.55 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.525 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -100.81 171.02 7.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -1.165 . . . . 0.0 109.333 179.997 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.9 t -92.4 153.77 18.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.546 -0.722 . . . . 0.0 109.441 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.453 ' HA ' ' OE1' ' A' ' 70' ' ' GLU . 18.0 m -129.0 -174.66 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.233 -0.917 . . . . 0.0 109.55 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -128.98 170.88 12.91 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.283 -0.886 . . . . 0.0 109.432 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.438 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 3.9 t -72.22 99.7 2.42 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.872 . . . . 0.0 109.474 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 109.51 14.86 13.28 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.584 ' OE2' HD23 ' A' ' 72' ' ' LEU . 3.9 tt0 -75.45 119.29 19.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -1.127 . . . . 0.0 109.448 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.518 ' CD1' ' OD1' ' A' ' 3' ' ' ASP . 68.4 tp -69.72 108.73 4.03 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.266 -0.896 . . . . 0.0 109.47 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.584 HD23 ' OE2' ' A' ' 70' ' ' GLU . 16.6 mt -88.39 -13.92 39.35 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.24 -0.913 . . . . 0.0 109.514 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 161.45 178.46 35.41 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.456 ' HG3' HD11 ' A' ' 71' ' ' LEU . 5.1 mtpt -137.91 144.17 41.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.22 -1.164 . . . . 0.0 109.444 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.501 ' CD1' HD13 ' A' ' 55' ' ' ILE . 17.1 tp -93.32 140.51 29.47 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.2 -0.937 . . . . 0.0 109.506 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 14.8 m . . . . . 0 N--CA 1.49 1.546 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.957 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.0 mm . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 121.263 0.554 . . . . 0.0 109.517 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.56 ' OD2' HD12 ' A' ' 71' ' ' LEU . 62.8 t0 -80.71 132.12 35.52 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.214 -0.929 . . . . 0.0 109.495 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 40.9 mt -104.23 99.1 7.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.327 -0.858 . . . . 0.0 109.481 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.43 ' HA ' ' HA ' ' A' ' 71' ' ' LEU . 4.2 mttp -106.66 177.03 4.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.244 -0.91 . . . . 0.0 109.508 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.711 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -77.98 165.8 48.06 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.264 -0.897 . . . . 0.0 109.493 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.711 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.3 Cg_endo -77.6 157.11 32.17 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.615 2.21 . . . . 0.0 110.44 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.3 t -62.77 146.63 52.02 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.848 . . . . 0.0 109.495 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.528 ' CZ ' ' HG2' ' A' ' 7' ' ' PRO . 24.0 m-85 -129.99 91.37 39.77 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.224 -0.922 . . . . 0.0 109.477 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.5 Cg_endo -78.03 -162.94 0.19 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.63 2.22 . . . . 0.0 110.445 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.429 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.0 OUTLIER -51.81 -54.83 24.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.293 -0.879 . . . . 0.0 109.446 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.429 ' C ' ' O ' ' A' ' 11' ' ' GLU . 34.4 t -42.94 -60.23 1.69 Allowed 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.324 -0.86 . . . . 0.0 109.626 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.472 HG22 ' O ' ' A' ' 15' ' ' ASP . 27.0 mt -102.47 119.03 50.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.215 -0.928 . . . . 0.0 109.56 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -96.88 -0.25 48.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.922 . . . . 0.0 109.549 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.472 ' O ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -173.53 -173.59 0.9 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.244 -0.91 . . . . 0.0 109.401 -179.976 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.885 ' O ' HG23 ' A' ' 65' ' ' THR . . . -154.6 170.79 32.99 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.684 HG23 ' O ' ' A' ' 64' ' ' ASP . 21.8 m -150.04 118.59 6.51 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.312 -1.111 . . . . 0.0 109.414 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.594 HG12 ' N ' ' A' ' 19' ' ' ALA . 42.8 t -45.25 168.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.204 -0.935 . . . . 0.0 109.506 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.594 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -113.65 -70.68 0.79 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.185 -0.947 . . . . 0.0 109.574 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.437 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 17.1 m -158.56 134.77 9.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.171 -0.955 . . . . 0.0 109.608 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.592 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 31.4 m95 -89.86 84.77 6.26 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.269 -0.894 . . . . 0.0 109.559 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.825 ' CE1' HD21 ' A' ' 34' ' ' LEU . 2.7 m80 -42.69 -70.41 0.11 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.37 -0.831 . . . . 0.0 109.48 -179.763 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -101.11 -172.11 2.11 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.223 -0.923 . . . . 0.0 109.534 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 4.0 mttt -125.92 167.41 16.92 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.264 -0.897 . . . . 0.0 109.441 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.986 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.0 Cg_endo -76.93 131.22 11.95 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.608 2.205 . . . . 0.0 110.49 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.45 -12.48 18.8 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -89.8 -174.33 4.24 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.3 -1.118 . . . . 0.0 109.398 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.7 140.31 42.42 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.288 -0.883 . . . . 0.0 109.456 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 1.039 HG21 HD11 ' A' ' 55' ' ' ILE . 47.3 t -128.21 161.68 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.431 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.496 ' N ' HG12 ' A' ' 29' ' ' VAL . 3.7 tptt -153.28 137.5 16.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.207 -0.933 . . . . 0.0 109.491 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 30' ' ' LYS . 8.3 tmm_? -42.8 139.61 1.59 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.296 -0.877 . . . . 0.0 109.593 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.41 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 20.0 t70 68.05 49.0 0.9 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.349 -0.844 . . . . 0.0 109.469 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.424 ' O ' ' C ' ' A' ' 34' ' ' LEU . 1.6 tt0 -133.95 103.88 6.02 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.921 . . . . 0.0 109.426 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.825 HD21 ' CE1' ' A' ' 22' ' ' HIS . 38.4 tp -42.58 151.54 0.12 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.357 -0.839 . . . . 0.0 109.632 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.98 HD11 ' HB2' ' A' ' 49' ' ' ALA . 5.1 mt -142.04 -40.18 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.166 -0.959 . . . . 0.0 109.542 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.512 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 12.2 p -151.92 128.2 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.489 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 12.9 m-20 -89.89 164.24 14.67 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.403 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.821 ' O ' HG23 ' A' ' 44' ' ' VAL . 80.8 mt -136.69 151.97 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.223 -0.923 . . . . 0.0 109.522 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 17' ' ' THR . 4.6 pt-20 -140.68 135.11 31.3 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.265 -0.897 . . . . 0.0 109.425 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.564 HG22 ' O ' ' A' ' 43' ' ' VAL . 5.3 t -128.31 -162.33 1.17 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.336 -0.853 . . . . 0.0 109.35 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.508 ' N ' HG23 ' A' ' 40' ' ' THR . 11.8 t70 -42.43 -61.85 1.11 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.325 -0.859 . . . . 0.0 109.697 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . 0.454 ' HG3' ' O ' ' A' ' 41' ' ' ASP . 5.9 mtpm? -149.47 45.09 0.96 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.225 -0.922 . . . . 0.0 109.515 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.564 ' O ' HG22 ' A' ' 40' ' ' THR . 54.5 t -154.69 108.25 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.195 -0.94 . . . . 0.0 109.489 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.821 HG23 ' O ' ' A' ' 38' ' ' ILE . 3.8 p -96.43 140.01 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.343 -0.848 . . . . 0.0 109.396 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -131.77 134.23 45.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.261 -0.9 . . . . 0.0 109.499 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.543 ' HB3' HD13 ' A' ' 34' ' ' LEU . 25.2 mt-10 -89.64 151.49 21.86 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.296 -0.878 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.512 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 91.8 t -123.0 103.62 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.173 -0.954 . . . . 0.0 109.507 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.494 ' H ' HD12 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -102.78 171.2 7.55 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.276 -0.89 . . . . 0.0 109.37 179.966 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.98 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.98 134.81 34.22 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.255 -0.903 . . . . 0.0 109.464 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.543 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.9 OUTLIER -84.81 10.95 10.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.156 -0.965 . . . . 0.0 109.426 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.543 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 173.38 154.39 0.1 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 109.42 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.513 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -69.07 171.03 8.83 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.277 -179.939 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.513 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.22 -146.02 15.15 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.9 t -138.68 126.9 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -1.158 . . . . 0.0 109.492 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 1.039 HD11 HG21 ' A' ' 29' ' ' VAL . 1.1 mm -74.6 171.91 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.203 -0.936 . . . . 0.0 109.422 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.448 ' CB ' ' HG3' ' A' ' 74' ' ' LYS . . . -104.33 -63.85 1.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.227 -0.921 . . . . 0.0 109.509 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.528 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -179.29 158.39 0.87 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.246 -0.909 . . . . 0.0 109.5 180.0 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.986 HD11 ' HD3' ' A' ' 25' ' ' PRO . 1.5 mp -93.52 146.2 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.211 -0.93 . . . . 0.0 109.468 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.865 HG23 ' O ' ' A' ' 72' ' ' LEU . 49.5 t -89.9 -52.46 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.226 -0.921 . . . . 0.0 109.479 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.466 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 2.1 tptp -108.29 157.37 18.42 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.274 -0.891 . . . . 0.0 109.397 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 50.2 m-80 -88.82 156.18 19.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.482 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.492 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 2.4 pp20? -61.09 145.91 49.22 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.257 -0.902 . . . . 0.0 109.384 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 94.96 -12.15 68.79 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.684 ' O ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -89.04 170.9 10.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.273 -1.133 . . . . 0.0 109.325 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.885 HG23 ' O ' ' A' ' 16' ' ' GLY . 62.7 m -111.96 146.92 36.96 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.489 -0.757 . . . . 0.0 109.467 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.494 ' HB ' ' CB ' ' A' ' 70' ' ' GLU . 27.3 m -129.62 -176.21 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.8 mp -116.63 173.9 6.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.177 -0.952 . . . . 0.0 109.469 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -63.85 125.74 25.35 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.897 . . . . 0.0 109.384 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 86.85 19.6 55.73 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.494 ' CB ' ' HB ' ' A' ' 66' ' ' VAL . 4.6 tp10 -82.18 112.82 19.56 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -1.134 . . . . 0.0 109.465 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.734 ' C ' HD23 ' A' ' 71' ' ' LEU . 7.5 tt -78.26 128.42 33.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.307 -0.87 . . . . 0.0 109.491 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.865 ' O ' HG23 ' A' ' 59' ' ' VAL . 13.3 mt -97.05 -70.51 0.72 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.421 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -128.14 163.64 21.67 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.448 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 2.2 ptmt -126.33 147.97 49.64 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.27 -1.135 . . . . 0.0 109.493 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.707 HD23 ' O ' ' A' ' 76' ' ' THR . 6.0 tt -90.56 166.45 13.2 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.278 -0.889 . . . . 0.0 109.488 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.707 ' O ' HD23 ' A' ' 75' ' ' LEU . 3.0 t . . . . . 0 N--CA 1.489 1.513 0 O-C-N 121.268 -0.895 . . . . 0.0 109.735 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.473 HD12 HD22 ' A' ' 75' ' ' LEU . 15.4 mt . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -67.64 125.9 27.65 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.461 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.9 mm -104.61 120.64 55.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.262 -0.899 . . . . 0.0 109.424 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -136.83 176.23 8.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.169 -0.957 . . . . 0.0 109.469 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.428 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -80.44 157.78 72.26 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.282 -0.886 . . . . 0.0 109.439 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.428 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.6 Cg_endo -78.01 156.32 30.33 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.661 2.241 . . . . 0.0 110.48 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 77.0 m -68.53 119.36 12.86 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.301 -0.874 . . . . 0.0 109.478 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -73.85 154.58 89.06 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.294 -0.878 . . . . 0.0 109.539 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.55 ' HG2' HD12 ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.09 -173.93 2.03 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.677 2.252 . . . . 0.0 110.433 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.7 mp0 -73.15 -49.34 28.76 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.461 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.2 OUTLIER -42.82 -29.05 0.29 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.371 -0.831 . . . . 0.0 109.589 -179.87 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.692 HG22 ' H ' ' A' ' 15' ' ' ASP . 4.1 mt -121.17 146.04 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -0.895 . . . . 0.0 109.496 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -114.31 1.76 14.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.247 -0.908 . . . . 0.0 109.611 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.692 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -178.35 -171.41 0.26 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.18 -0.95 . . . . 0.0 109.457 -179.984 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.38 -167.44 17.69 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.852 HG23 ' O ' ' A' ' 64' ' ' ASP . 29.4 m -148.13 130.88 16.01 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -1.122 . . . . 0.0 109.468 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.548 HG12 ' N ' ' A' ' 19' ' ' ALA . 46.6 t -44.56 165.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.248 -0.907 . . . . 0.0 109.49 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.568 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -114.06 -73.12 0.67 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.301 -0.874 . . . . 0.0 109.53 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 38.5 m -160.01 132.19 6.32 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.205 -0.934 . . . . 0.0 109.518 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.667 ' CH2' HD12 ' A' ' 58' ' ' ILE . 36.0 m95 -89.84 81.78 6.3 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.259 -0.901 . . . . 0.0 109.517 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.776 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.1 m80 -42.87 -61.54 1.25 Allowed 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.305 -0.872 . . . . 0.0 109.42 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.478 ' O ' ' HE3' ' A' ' 24' ' ' LYS . 1.2 mtpt -96.89 -177.36 3.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.918 . . . . 0.0 109.584 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.478 ' HE3' ' O ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -120.95 167.72 12.44 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.248 -0.908 . . . . 0.0 109.516 179.989 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.504 ' HA ' ' CG2' ' A' ' 55' ' ' ILE . 35.1 Cg_endo -76.96 90.21 1.25 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.694 2.263 . . . . 0.0 110.395 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 138.59 45.03 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.46 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 2.2 pp20? -139.35 -173.37 3.58 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.317 -1.108 . . . . 0.0 109.462 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.46 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -90.68 128.78 36.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.206 -0.934 . . . . 0.0 109.474 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 12.4 p -127.11 155.15 38.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.215 -0.928 . . . . 0.0 109.528 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.409 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -134.63 133.72 40.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -0.949 . . . . 0.0 109.502 -179.989 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.506 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.78 143.26 0.73 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.288 -0.883 . . . . 0.0 109.658 -179.969 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.506 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 8.2 t70 75.51 41.59 0.26 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.262 -0.898 . . . . 0.0 109.452 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.445 ' O ' HG12 ' A' ' 35' ' ' ILE . 3.5 tt0 -141.83 121.75 13.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.229 -0.919 . . . . 0.0 109.477 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.835 ' O ' HD13 ' A' ' 35' ' ' ILE . 59.6 tp -42.84 156.1 0.05 OUTLIER 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.328 -0.858 . . . . 0.0 109.644 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.835 HD13 ' O ' ' A' ' 34' ' ' LEU . 15.7 mm -146.12 -39.12 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.276 -0.89 . . . . 0.0 109.505 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.516 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -159.79 141.95 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -0.891 . . . . 0.0 109.369 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.568 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 1.2 m-20 -104.93 146.37 29.12 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.251 -0.906 . . . . 0.0 109.465 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.452 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 57.2 mt -107.13 142.46 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.175 -0.953 . . . . 0.0 109.514 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.515 ' CB ' ' O ' ' A' ' 17' ' ' THR . 1.4 tt0 -105.35 129.21 53.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.209 -0.932 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -115.73 171.61 7.65 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.238 -0.914 . . . . 0.0 109.49 -179.948 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 40' ' ' THR . 12.7 t0 -42.87 -51.37 5.53 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.321 -0.862 . . . . 0.0 109.618 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . 0.431 ' HG2' ' O ' ' A' ' 41' ' ' ASP . 7.8 mmtt -148.37 30.66 0.84 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.271 -0.893 . . . . 0.0 109.443 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.412 ' O ' ' OG1' ' A' ' 40' ' ' THR . 2.0 t -139.6 134.49 38.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.939 . . . . 0.0 109.436 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 8.1 p -98.76 136.86 28.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.255 -0.903 . . . . 0.0 109.474 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . 0.452 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 0.9 OUTLIER -125.17 165.83 17.54 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.15 -0.969 . . . . 0.0 109.473 -179.983 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -129.26 161.91 29.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.501 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.516 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 78.7 t -140.73 108.89 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.214 -0.929 . . . . 0.0 109.501 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.49 ' H ' HD12 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -103.14 155.74 18.19 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.339 -0.851 . . . . 0.0 109.362 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -70.58 144.78 51.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.898 . . . . 0.0 109.521 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.422 ' C ' ' HG3' ' A' ' 31' ' ' ARG . 0.6 OUTLIER -101.87 11.23 38.97 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.276 -0.89 . . . . 0.0 109.475 179.988 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -178.57 138.2 0.17 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.305 -0.872 . . . . 0.0 109.428 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.504 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.2 OUTLIER -58.5 170.95 0.67 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.245 -0.91 . . . . 0.0 109.343 -179.977 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.504 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 145.65 -162.39 28.26 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.475 ' O ' HG22 ' A' ' 76' ' ' THR . 48.1 t -128.94 124.97 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.328 -1.101 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.577 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.0 mt -59.41 165.23 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.278 -0.889 . . . . 0.0 109.568 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.577 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -103.43 -66.08 0.97 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.188 -0.945 . . . . 0.0 109.518 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.476 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -167.75 139.11 2.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.206 -0.934 . . . . 0.0 109.55 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.667 HD12 ' CH2' ' A' ' 21' ' ' TRP . 23.9 mm -95.09 121.69 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.326 -0.859 . . . . 0.0 109.508 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.4 t -89.94 -27.99 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.19 -0.944 . . . . 0.0 109.428 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.502 ' HG2' ' CG1' ' A' ' 66' ' ' VAL . 0.0 OUTLIER -91.08 134.21 34.7 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.288 -0.882 . . . . 0.0 109.466 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.473 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 13.7 m120 -98.71 165.76 11.64 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.286 -0.884 . . . . 0.0 109.519 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -68.85 141.12 55.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 80.52 14.92 79.26 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.852 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -101.73 170.88 7.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -1.141 . . . . 0.0 109.277 -179.972 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 23.3 m -97.3 141.76 30.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.493 -0.754 . . . . 0.0 109.416 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.502 ' CG1' ' HG2' ' A' ' 60' ' ' LYS . 2.3 m -126.98 139.04 53.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.469 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.04 167.53 10.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.261 -0.899 . . . . 0.0 109.486 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 36.2 t -57.17 128.82 38.9 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 73.56 23.31 77.22 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -79.19 119.25 22.01 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.247 -1.149 . . . . 0.0 109.491 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.506 ' C ' HD23 ' A' ' 71' ' ' LEU . 10.2 tt -67.37 138.31 56.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.288 -0.882 . . . . 0.0 109.543 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -118.85 -24.86 6.47 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.293 -0.879 . . . . 0.0 109.428 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.64 159.67 26.6 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 8.3 mtpt -122.31 133.39 54.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.204 -1.174 . . . . 0.0 109.446 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.473 HD22 HD12 ' A' ' 2' ' ' ILE . 0.6 OUTLIER -92.1 147.57 22.84 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -0.948 . . . . 0.0 109.512 179.99 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.475 HG22 ' O ' ' A' ' 54' ' ' VAL . 3.0 t . . . . . 0 N--CA 1.489 1.503 0 O-C-N 121.272 -0.893 . . . . 0.0 109.724 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 61.7 mt . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.473 -0.565 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 74' ' ' LYS . 15.9 t70 -76.15 162.73 27.75 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.228 -0.92 . . . . 0.0 109.441 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mt -135.39 125.03 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.269 -0.894 . . . . 0.0 109.452 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.0 pttm -133.04 172.98 11.91 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.243 -0.911 . . . . 0.0 109.462 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.565 ' HB3' ' O ' ' A' ' 67' ' ' LEU . . . -81.46 147.72 60.63 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.144 -0.972 . . . . 0.0 109.447 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.03 155.11 29.79 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.649 2.233 . . . . 0.0 110.455 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.411 ' HA ' ' HB2' ' A' ' 68' ' ' SER . 1.3 m -71.11 132.49 45.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.414 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.404 ' HB3' ' HB ' ' A' ' 13' ' ' ILE . 63.0 m-85 -99.34 153.6 37.7 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.426 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.4 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -77.99 -159.65 0.1 Allowed 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.632 2.221 . . . . 0.0 110.454 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.0 OUTLIER -77.18 -55.6 5.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.464 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 11' ' ' GLU . 18.6 t -42.72 -50.3 5.55 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.278 -0.889 . . . . 0.0 109.617 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.49 HG22 ' H ' ' A' ' 15' ' ' ASP . 14.8 mt -90.11 143.45 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.418 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.517 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -115.1 -1.76 12.94 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.517 ' CB ' ' O ' ' A' ' 14' ' ' ALA . 0.5 OUTLIER 163.89 -169.09 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.212 -0.93 . . . . 0.0 109.464 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.673 ' O ' HG23 ' A' ' 65' ' ' THR . . . -142.97 -163.13 9.6 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.625 HG23 ' O ' ' A' ' 64' ' ' ASP . 17.0 m -150.0 133.07 16.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -1.114 . . . . 0.0 109.426 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.483 ' O ' ' HG3' ' A' ' 39' ' ' GLU . 39.4 t -49.08 159.73 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.216 -0.928 . . . . 0.0 109.419 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.519 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -104.35 -77.0 0.58 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.218 -0.926 . . . . 0.0 109.517 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 17.8 m -159.97 130.48 5.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.555 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.637 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.6 m95 -89.95 85.54 6.38 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.207 -0.933 . . . . 0.0 109.509 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.798 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.1 m80 -43.18 -67.28 0.29 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.346 -0.846 . . . . 0.0 109.419 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -93.81 -172.33 2.84 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.216 -0.927 . . . . 0.0 109.468 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.425 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -125.23 168.23 14.14 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.287 -0.883 . . . . 0.0 109.392 -179.894 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.498 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.3 Cg_endo -76.59 127.75 9.81 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.733 2.288 . . . . 0.0 110.373 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.65 18.99 9.01 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 13.8 mm-40 -119.69 -176.98 3.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.306 -1.114 . . . . 0.0 109.486 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -92.85 145.93 24.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.267 -0.896 . . . . 0.0 109.444 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 69.0 t -139.37 151.33 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -0.896 . . . . 0.0 109.532 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 11.0 mptt -126.64 140.11 52.66 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.228 -0.92 . . . . 0.0 109.463 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.434 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.7 OUTLIER -42.71 153.1 0.08 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.383 -0.823 . . . . 0.0 109.704 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.445 ' HA ' HD23 ' A' ' 48' ' ' LEU . 25.2 t0 63.19 41.8 7.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.927 . . . . 0.0 109.468 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.423 ' C ' ' HG ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -135.98 116.05 13.33 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.291 -0.88 . . . . 0.0 109.51 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.798 HD21 ' NE2' ' A' ' 22' ' ' HIS . 37.5 tp -43.1 142.9 0.88 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.275 -0.891 . . . . 0.0 109.556 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.798 HD11 ' HB2' ' A' ' 49' ' ' ALA . 10.9 mt -125.92 -46.08 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.272 -0.893 . . . . 0.0 109.585 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.405 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -162.8 147.5 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.277 -0.889 . . . . 0.0 109.528 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.519 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 1.2 m-20 -105.32 160.25 15.26 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.347 -0.845 . . . . 0.0 109.428 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.531 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 1.8 tt -129.31 148.54 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -0.933 . . . . 0.0 109.449 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.483 ' HG3' ' O ' ' A' ' 18' ' ' VAL . 4.8 mm-40 -106.96 150.33 26.58 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.305 -0.872 . . . . 0.0 109.481 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.404 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -135.47 -175.38 3.92 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 40' ' ' THR . 7.8 t0 -42.78 -68.9 0.16 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.307 -0.871 . . . . 0.0 109.643 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.7 mtmm -135.39 36.73 2.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.172 -0.955 . . . . 0.0 109.493 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 67.9 t -152.0 153.44 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.34 -0.85 . . . . 0.0 109.472 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.462 ' O ' HG13 ' A' ' 44' ' ' VAL . 11.7 p -124.2 131.04 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . 0.531 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 0.0 OUTLIER -107.89 177.2 4.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.181 -0.949 . . . . 0.0 109.502 179.98 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -130.28 151.3 50.94 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.223 -0.923 . . . . 0.0 109.452 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.405 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 44.3 t -122.75 98.11 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.45 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.536 HD12 ' HA ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -90.99 168.72 11.45 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.195 -0.941 . . . . 0.0 109.487 -179.998 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.798 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -85.1 136.91 33.35 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.223 -0.923 . . . . 0.0 109.402 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.533 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 2.2 mm-40 -98.53 14.64 27.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.545 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.533 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 173.54 134.78 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.268 -0.895 . . . . 0.0 109.469 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.502 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.25 171.02 0.12 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -0.894 . . . . 0.0 109.3 179.999 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.502 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 142.77 -154.04 25.02 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.612 ' H ' HG22 ' A' ' 76' ' ' THR . 66.2 t -136.65 134.63 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.274 -1.133 . . . . 0.0 109.412 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.618 HD13 HD12 ' A' ' 75' ' ' LEU . 15.3 mm -61.85 168.84 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.218 -0.926 . . . . 0.0 109.516 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.574 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -101.42 -62.83 1.2 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.914 . . . . 0.0 109.53 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.498 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.7 OUTLIER -177.89 131.47 0.15 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.259 -0.9 . . . . 0.0 109.462 179.95 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.637 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 21.5 mm -90.09 125.63 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.435 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 42.2 t -89.93 -33.13 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.291 -0.88 . . . . 0.0 109.471 -179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.492 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 1.5 mptt -94.38 143.66 26.22 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.282 -0.886 . . . . 0.0 109.488 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.459 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 65.3 m-80 -111.0 164.74 12.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.248 -0.908 . . . . 0.0 109.526 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -59.06 146.43 38.47 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.493 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 86.75 7.74 77.82 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.625 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -105.35 170.71 7.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.221 -1.164 . . . . 0.0 109.411 -179.98 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.673 HG23 ' O ' ' A' ' 16' ' ' GLY . 11.9 m -107.77 145.69 33.2 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.536 -0.728 . . . . 0.0 109.458 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 4.9 m -114.98 137.37 48.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.471 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.565 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -106.08 174.53 5.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.192 -0.943 . . . . 0.0 109.522 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.411 ' HB2' ' HA ' ' A' ' 8' ' ' THR . 1.5 t -62.03 129.13 39.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.234 -0.917 . . . . 0.0 109.497 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.98 21.63 73.53 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -79.82 104.34 10.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.255 -1.144 . . . . 0.0 109.52 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.478 ' C ' HD23 ' A' ' 71' ' ' LEU . 9.1 tt -78.1 121.9 24.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.243 -0.911 . . . . 0.0 109.458 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.5 mp -92.69 -69.05 0.76 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.352 -0.843 . . . . 0.0 109.38 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -140.74 -175.82 14.87 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.43 ' HA ' ' HA ' ' A' ' 3' ' ' ASP . 0.3 OUTLIER -143.69 142.0 30.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.297 -1.119 . . . . 0.0 109.485 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.618 HD12 HD13 ' A' ' 55' ' ' ILE . 0.6 OUTLIER -90.51 144.52 25.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.886 . . . . 0.0 109.436 -179.96 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.612 HG22 ' H ' ' A' ' 54' ' ' VAL . 3.0 t . . . . . 0 N--CA 1.489 1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.74 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.777 HD13 ' CD2' ' A' ' 75' ' ' LEU . 3.2 mp . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.997 ' OD1' HD11 ' A' ' 71' ' ' LEU . 22.9 t70 -82.28 154.12 25.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.204 -0.935 . . . . 0.0 109.496 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.2 mt -130.86 122.34 51.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.883 . . . . 0.0 109.432 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.473 ' HD2' ' OD2' ' A' ' 3' ' ' ASP . 0.0 OUTLIER -144.89 164.85 29.82 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.234 -0.916 . . . . 0.0 109.464 179.958 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.404 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -67.34 148.13 98.77 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.291 -0.881 . . . . 0.0 109.495 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 35.9 Cg_endo -78.02 -172.2 1.42 Allowed 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.628 2.219 . . . . 0.0 110.417 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -97.86 96.52 8.26 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.235 -0.915 . . . . 0.0 109.449 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.54 ' CZ ' ' HA3' ' A' ' 16' ' ' GLY . 19.5 m-85 -59.81 149.34 72.98 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.245 -0.909 . . . . 0.0 109.493 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.04 -166.25 0.39 Allowed 'Trans proline' 0 C--N 1.308 -1.556 0 C-N-CA 122.61 2.207 . . . . 0.0 110.494 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' A' ' 12' ' ' SER . 4.8 tt0 -72.78 -42.43 63.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.231 -0.918 . . . . 0.0 109.484 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 11' ' ' GLU . 2.5 t -42.88 -64.54 0.61 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.298 -0.876 . . . . 0.0 109.554 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.584 HG22 ' H ' ' A' ' 15' ' ' ASP . 15.1 mm -104.95 145.86 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.216 -0.928 . . . . 0.0 109.445 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -114.36 21.77 14.33 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.294 -0.879 . . . . 0.0 109.485 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.584 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.3 OUTLIER -161.74 -173.11 3.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.135 -0.978 . . . . 0.0 109.572 -179.997 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.54 ' HA3' ' CZ ' ' A' ' 9' ' ' PHE . . . -150.56 -176.56 23.65 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.518 HG23 ' O ' ' A' ' 64' ' ' ASP . 25.8 m -150.06 122.09 8.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.176 -1.19 . . . . 0.0 109.5 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.581 HG12 ' N ' ' A' ' 19' ' ' ALA . 41.4 t -45.83 168.72 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.251 -0.906 . . . . 0.0 109.353 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.581 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -111.13 -74.34 0.65 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.117 -0.989 . . . . 0.0 109.589 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.403 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 16.2 m -160.05 127.78 4.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.254 -0.904 . . . . 0.0 109.605 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.705 ' CH2' HD12 ' A' ' 58' ' ' ILE . 36.7 m95 -89.91 83.4 6.15 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.26 -0.9 . . . . 0.0 109.461 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.604 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -42.95 -70.18 0.11 Allowed 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.322 -0.861 . . . . 0.0 109.424 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -93.67 177.98 5.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.25 -0.906 . . . . 0.0 109.678 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.455 ' HD3' ' HD2' ' A' ' 25' ' ' PRO . 5.4 mttp -121.39 169.48 9.06 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.283 -0.886 . . . . 0.0 109.445 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.529 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.3 Cg_endo -76.15 119.7 5.42 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.657 2.238 . . . . 0.0 110.463 179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 122.68 10.13 6.04 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.444 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 1.1 pp20? -112.4 173.88 6.15 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -1.129 . . . . 0.0 109.507 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.444 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -82.5 144.28 30.53 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.922 . . . . 0.0 109.511 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.8 t -112.31 156.85 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.287 -0.883 . . . . 0.0 109.47 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.1 OUTLIER -142.96 135.88 27.96 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.274 -0.892 . . . . 0.0 109.493 179.957 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.466 ' HG2' ' N ' ' A' ' 32' ' ' ASP . 2.7 ttm180 -42.8 141.13 1.14 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.337 -0.852 . . . . 0.0 109.651 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.466 ' N ' ' HG2' ' A' ' 31' ' ' ARG . 20.8 t70 69.71 49.66 0.53 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.289 -0.882 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' A' ' 34' ' ' LEU . 3.0 tt0 -138.5 106.89 5.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 0.0 109.429 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 40.1 tp -43.46 165.14 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.291 -0.88 . . . . 0.0 109.472 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.791 HD11 ' HB2' ' A' ' 49' ' ' ALA . 91.3 mt -134.26 -47.13 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.15 -0.969 . . . . 0.0 109.637 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.579 ' HB ' ' CE3' ' A' ' 21' ' ' TRP . 2.6 p -171.99 144.01 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.158 -0.964 . . . . 0.0 109.52 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.526 ' C ' ' HB3' ' A' ' 19' ' ' ALA . 1.3 m-20 -100.19 167.03 10.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.247 -0.908 . . . . 0.0 109.458 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.473 HG22 ' O ' ' A' ' 45' ' ' MET . 1.2 tt -142.63 156.33 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.253 -0.904 . . . . 0.0 109.539 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.58 122.14 38.99 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.268 -0.895 . . . . 0.0 109.47 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.418 ' O ' ' C ' ' A' ' 41' ' ' ASP . 44.4 p -101.92 -151.91 0.43 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 109.475 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.478 ' HA ' HG13 ' A' ' 13' ' ' ILE . 43.1 t0 -42.71 -62.82 0.9 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.277 -0.89 . . . . 0.0 109.613 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.7 mttt -149.48 17.78 0.92 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.212 -0.93 . . . . 0.0 109.474 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.469 HG12 ' H ' ' A' ' 44' ' ' VAL . 1.9 t -119.34 172.21 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.895 . . . . 0.0 109.503 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.537 ' O ' HG13 ' A' ' 44' ' ' VAL . 9.6 p -129.62 126.7 63.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.3 -0.875 . . . . 0.0 109.431 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . 0.473 ' O ' HG22 ' A' ' 38' ' ' ILE . 1.3 mtt -113.83 124.43 52.21 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.186 -0.946 . . . . 0.0 109.484 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.6 147.32 26.46 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.334 -0.854 . . . . 0.0 109.443 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.455 ' O ' ' HB ' ' A' ' 35' ' ' ILE . 55.9 t -116.06 103.87 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.184 -0.947 . . . . 0.0 109.504 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.403 HD21 ' N ' ' A' ' 33' ' ' GLU . 0.3 OUTLIER -105.03 163.85 12.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.915 . . . . 0.0 109.396 -179.89 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.791 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.88 164.83 18.16 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.159 -0.963 . . . . 0.0 109.456 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.698 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -105.82 3.67 28.97 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.542 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.698 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 163.94 167.54 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.184 -0.948 . . . . 0.0 109.455 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.502 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -49.96 170.98 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.291 -0.881 . . . . 0.0 109.313 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.502 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.93 -164.01 30.67 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.818 ' O ' HG22 ' A' ' 76' ' ' THR . 48.7 t -136.85 125.35 34.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -1.142 . . . . 0.0 109.427 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.875 HD13 ' CD1' ' A' ' 75' ' ' LEU . 15.3 mm -61.68 160.08 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.294 -0.879 . . . . 0.0 109.448 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.448 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -100.51 -66.31 0.92 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.306 -0.871 . . . . 0.0 109.492 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.529 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 33.4 tt0 177.34 141.68 0.08 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.294 -0.879 . . . . 0.0 109.46 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.705 HD12 ' CH2' ' A' ' 21' ' ' TRP . 15.3 mm -91.42 158.28 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.273 -0.892 . . . . 0.0 109.449 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.823 HG23 ' O ' ' A' ' 72' ' ' LEU . 52.8 t -90.03 -67.52 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.261 -0.899 . . . . 0.0 109.342 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.483 ' HD3' ' CB ' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -101.1 174.99 5.75 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.254 -0.904 . . . . 0.0 109.399 179.926 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -95.87 155.43 16.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.931 . . . . 0.0 109.469 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.537 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -60.1 149.94 31.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.3 -0.875 . . . . 0.0 109.387 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 92.39 -12.62 69.25 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.518 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -87.3 170.94 10.99 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.295 -1.12 . . . . 0.0 109.286 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.499 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 99.0 m -100.73 135.41 42.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.519 -0.738 . . . . 0.0 109.461 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.665 ' O ' HD23 ' A' ' 67' ' ' LEU . 5.2 m -118.58 -176.8 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.448 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.665 HD23 ' O ' ' A' ' 66' ' ' VAL . 13.2 mt -121.45 162.38 20.56 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.248 -0.907 . . . . 0.0 109.441 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 t -64.25 122.54 16.88 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.238 -0.914 . . . . 0.0 109.494 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 91.31 10.16 62.53 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -84.98 112.56 20.7 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.191 -1.182 . . . . 0.0 109.447 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.997 HD11 ' OD1' ' A' ' 3' ' ' ASP . 1.2 tp -72.49 127.11 31.55 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.319 -0.863 . . . . 0.0 109.496 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.823 ' O ' HG23 ' A' ' 59' ' ' VAL . 77.0 mt -93.92 -68.05 0.82 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.302 -0.874 . . . . 0.0 109.435 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -136.39 178.8 18.52 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.53 ' CG ' HD21 ' A' ' 71' ' ' LEU . 1.5 mtmp? -145.94 151.74 38.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -1.162 . . . . 0.0 109.472 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.875 ' CD1' HD13 ' A' ' 55' ' ' ILE . 13.2 tp -99.05 152.37 19.92 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.224 -0.923 . . . . 0.0 109.474 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.818 HG22 ' O ' ' A' ' 54' ' ' VAL . 3.0 t . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.286 -0.884 . . . . 0.0 109.677 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 24.3 mm . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 121.296 0.57 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.519 ' OD2' ' CD1' ' A' ' 71' ' ' LEU . 43.7 t0 -71.84 142.28 49.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.16 -0.963 . . . . 0.0 109.463 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.414 HD12 HG23 ' A' ' 4' ' ' ILE . 4.9 mm -112.19 103.83 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.225 -0.922 . . . . 0.0 109.415 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.63 166.02 10.67 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.225 -0.922 . . . . 0.0 109.468 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.494 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -72.72 159.69 84.72 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.27 -0.894 . . . . 0.0 109.435 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.494 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.18 165.29 26.03 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.57 2.18 . . . . 0.0 110.368 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -90.28 108.8 19.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.472 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -60.86 149.24 81.23 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.442 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.08 -160.6 0.12 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.626 2.218 . . . . 0.0 110.369 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.3 OUTLIER -77.4 -58.88 3.03 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.247 -0.908 . . . . 0.0 109.497 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.2 t -42.93 -55.97 3.49 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.359 -0.838 . . . . 0.0 109.594 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.464 ' CD1' ' HB2' ' A' ' 41' ' ' ASP . 12.0 mm -95.1 136.55 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.275 -0.891 . . . . 0.0 109.444 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.78 14.48 10.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.216 -0.927 . . . . 0.0 109.436 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.415 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -156.53 -171.34 3.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.244 -0.91 . . . . 0.0 109.419 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.5 178.82 39.59 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.696 HG23 ' O ' ' A' ' 64' ' ' ASP . 17.8 m -150.03 119.25 6.79 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.23 -1.159 . . . . 0.0 109.367 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.503 HG12 ' N ' ' A' ' 19' ' ' ALA . 46.4 t -44.25 162.99 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.438 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.511 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -106.2 -75.47 0.63 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -0.906 . . . . 0.0 109.58 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.474 ' HA ' ' HB3' ' A' ' 62' ' ' GLU . 17.3 m -160.01 136.23 8.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.238 -0.914 . . . . 0.0 109.531 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.636 ' CH2' HD12 ' A' ' 58' ' ' ILE . 35.1 m95 -89.85 84.11 6.22 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.244 -0.91 . . . . 0.0 109.512 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.588 ' CE1' HD21 ' A' ' 34' ' ' LEU . 2.3 m80 -42.59 -55.64 3.44 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.44 -0.788 . . . . 0.0 109.531 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -109.82 158.71 17.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.098 -1.001 . . . . 0.0 109.612 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.426 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 4.9 mttt -97.22 167.99 10.99 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.275 -0.891 . . . . 0.0 109.428 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.485 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.68 101.84 1.55 Allowed 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.625 2.216 . . . . 0.0 110.446 179.869 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.5 -5.08 4.48 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.477 ' N ' ' CD ' ' A' ' 27' ' ' GLU . 1.3 mp0 -90.36 -172.66 3.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.18 -1.188 . . . . 0.0 109.458 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -97.3 149.83 21.63 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.301 -0.874 . . . . 0.0 109.438 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.6 m -135.5 161.55 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.214 -0.929 . . . . 0.0 109.514 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.8 tttt -129.29 135.29 48.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.24 -0.912 . . . . 0.0 109.52 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.433 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 9.2 ttt180 -42.86 140.34 1.39 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.325 -0.86 . . . . 0.0 109.613 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 18.0 t0 70.82 47.0 0.47 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.23 -0.919 . . . . 0.0 109.516 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.434 ' O ' ' O ' ' A' ' 34' ' ' LEU . 29.4 tt0 -140.12 121.99 15.51 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.279 -0.888 . . . . 0.0 109.558 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.588 HD21 ' CE1' ' A' ' 22' ' ' HIS . 47.4 tp -43.14 164.56 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.278 -0.889 . . . . 0.0 109.587 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.607 HG13 ' HB2' ' A' ' 49' ' ' ALA . 25.4 mm -145.27 -42.56 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.185 -0.947 . . . . 0.0 109.535 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.506 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 12.7 p -154.7 134.18 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.234 -0.916 . . . . 0.0 109.551 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.511 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 22.1 m-20 -100.39 159.45 15.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.267 -0.896 . . . . 0.0 109.463 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.519 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 7.3 tt -128.87 156.9 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.463 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.409 ' N ' HG12 ' A' ' 38' ' ' ILE . 1.3 tt0 -129.65 142.78 50.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.208 -0.933 . . . . 0.0 109.423 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.721 HG22 ' O ' ' A' ' 43' ' ' VAL . 5.5 t -132.01 -163.45 1.34 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.256 -0.903 . . . . 0.0 109.362 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.464 ' HB2' ' CD1' ' A' ' 13' ' ' ILE . 2.2 t0 -42.34 -68.0 0.22 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.317 -0.864 . . . . 0.0 109.782 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . 0.512 ' O ' ' CG2' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -142.97 48.76 1.49 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.136 -0.978 . . . . 0.0 109.541 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.721 ' O ' HG22 ' A' ' 40' ' ' THR . 90.0 t -159.04 118.04 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.251 -0.906 . . . . 0.0 109.499 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.6 t -100.57 126.63 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.487 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . 0.519 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 31.4 mtt -106.44 -179.65 4.0 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.456 ' HA ' ' OD1' ' A' ' 37' ' ' ASP . 3.7 mt-10 -133.52 146.96 51.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.249 -0.907 . . . . 0.0 109.44 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.506 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 36.2 t -117.76 106.68 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.492 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.515 HD12 ' HA ' ' A' ' 34' ' ' LEU . 0.6 OUTLIER -89.99 161.35 15.92 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.294 -0.879 . . . . 0.0 109.377 -179.964 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.607 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -81.03 160.91 24.42 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.44 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.701 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.5 OUTLIER -99.02 2.12 45.99 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.178 -0.951 . . . . 0.0 109.608 179.958 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.18 155.34 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.212 -0.93 . . . . 0.0 109.478 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.503 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -65.12 170.86 4.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.33 -0.856 . . . . 0.0 109.321 -179.995 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.503 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.45 -137.59 6.09 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.47 ' O ' ' CB ' ' A' ' 76' ' ' THR . 44.8 t -139.87 135.25 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.338 -1.095 . . . . 0.0 109.448 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.433 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 9.5 mm -75.74 153.9 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.332 -0.855 . . . . 0.0 109.457 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -87.94 -65.99 0.96 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.208 -0.933 . . . . 0.0 109.397 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.485 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -178.88 139.21 0.16 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -0.907 . . . . 0.0 109.399 179.949 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.636 HD12 ' CH2' ' A' ' 21' ' ' TRP . 23.1 mm -94.84 138.69 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.233 -0.917 . . . . 0.0 109.515 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 96.1 t -110.04 -14.52 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.309 -0.869 . . . . 0.0 109.425 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.711 ' HE2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -91.04 -172.4 3.32 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.286 -0.884 . . . . 0.0 109.39 179.995 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 46.2 m-80 -137.05 155.95 49.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.328 -0.858 . . . . 0.0 109.576 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.474 ' HB3' ' HA ' ' A' ' 20' ' ' THR . 0.5 OUTLIER -72.18 144.14 48.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.265 -0.897 . . . . 0.0 109.518 -179.939 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 57.54 19.56 34.84 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.696 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -99.4 170.95 8.27 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.262 -1.14 . . . . 0.0 109.352 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 11.5 t -88.17 154.25 20.6 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.525 -0.734 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.711 HG12 ' HE2' ' A' ' 60' ' ' LYS . 1.5 m -141.67 173.94 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.233 -0.917 . . . . 0.0 109.42 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.469 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.3 OUTLIER -127.99 162.56 26.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.301 -0.875 . . . . 0.0 109.433 -179.956 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 6.6 t -56.53 143.71 34.34 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.19 -0.944 . . . . 0.0 109.478 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 58.99 24.61 58.49 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.469 ' HB2' ' O ' ' A' ' 67' ' ' LEU . 13.9 tp10 -79.21 105.23 10.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -1.184 . . . . 0.0 109.491 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.519 ' CD1' ' OD2' ' A' ' 3' ' ' ASP . 0.4 OUTLIER -61.99 130.39 45.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.275 -0.89 . . . . 0.0 109.392 -179.915 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 7.9 mt -100.84 -71.12 0.72 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.27 -0.894 . . . . 0.0 109.45 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -144.39 -176.9 18.82 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 10.0 mtmt -128.26 151.67 49.01 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.313 -1.11 . . . . 0.0 109.462 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -103.63 152.09 22.17 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.174 -0.954 . . . . 0.0 109.512 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.47 ' CB ' ' O ' ' A' ' 54' ' ' VAL . 13.0 m . . . . . 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 109.427 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 62.9 mt . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.506 ' OD2' ' CG ' ' A' ' 5' ' ' LYS . 24.9 t0 -61.04 154.54 22.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.2 -0.937 . . . . 0.0 109.496 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 16.4 mt -123.58 98.59 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.286 -0.884 . . . . 0.0 109.429 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.506 ' CG ' ' OD2' ' A' ' 3' ' ' ASP . 3.8 mtmt -122.39 154.76 37.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.914 . . . . 0.0 109.465 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.579 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -78.93 162.5 64.56 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.252 -0.905 . . . . 0.0 109.52 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.579 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.8 Cg_endo -78.04 159.57 30.44 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.555 2.17 . . . . 0.0 110.485 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.1 m -73.74 142.36 46.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.348 -0.845 . . . . 0.0 109.436 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.574 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 25.6 m-85 -89.88 156.95 46.72 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.27 -0.894 . . . . 0.0 109.512 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -77.97 -167.12 0.45 Allowed 'Trans proline' 0 C--N 1.309 -1.516 0 C-N-CA 122.655 2.237 . . . . 0.0 110.48 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.438 ' O ' ' C ' ' A' ' 12' ' ' SER . 39.0 tt0 -75.24 -56.38 4.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.176 -0.953 . . . . 0.0 109.456 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 11' ' ' GLU . 4.9 t -42.72 -52.8 4.8 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.3 -0.875 . . . . 0.0 109.619 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.595 HG22 ' H ' ' A' ' 15' ' ' ASP . 25.2 mt -94.1 147.42 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.236 -0.915 . . . . 0.0 109.494 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -124.33 6.54 8.4 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.183 -0.948 . . . . 0.0 109.615 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.595 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER 178.91 -172.53 0.15 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.236 -0.915 . . . . 0.0 109.488 -179.974 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.413 ' C ' HG22 ' A' ' 66' ' ' VAL . . . -154.78 -157.41 8.18 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.65 HG23 ' O ' ' A' ' 64' ' ' ASP . 36.4 m -150.02 135.4 18.15 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -1.135 . . . . 0.0 109.529 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 19' ' ' ALA . 19.5 t -55.88 158.78 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 109.461 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.625 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -101.94 -76.81 0.56 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.154 -0.967 . . . . 0.0 109.485 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 19.6 m -160.04 136.61 9.0 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.602 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.839 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 32.4 m95 -89.99 83.15 6.09 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.259 -0.9 . . . . 0.0 109.491 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.64 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.7 m80 -43.02 -68.34 0.2 Allowed 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.313 -0.867 . . . . 0.0 109.395 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.11 -172.0 3.17 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.259 -0.9 . . . . 0.0 109.561 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.407 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 7.8 mttp -141.09 168.29 14.66 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.31 -0.869 . . . . 0.0 109.4 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.791 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.0 Cg_endo -76.55 125.96 8.65 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.569 2.179 . . . . 0.0 110.467 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 117.19 10.96 9.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 45.6 mm-40 -128.4 -172.3 2.67 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.207 -1.172 . . . . 0.0 109.472 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -100.91 179.39 4.4 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.266 -0.896 . . . . 0.0 109.468 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.612 HG12 ' N ' ' A' ' 30' ' ' LYS . 64.6 t -147.04 165.95 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.293 -0.879 . . . . 0.0 109.451 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.612 ' N ' HG12 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -112.34 132.38 55.02 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.565 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.477 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -43.01 121.01 1.96 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.291 -0.88 . . . . 0.0 109.604 -179.931 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.477 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 3.0 t70 73.94 55.21 0.1 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.26 -0.9 . . . . 0.0 109.484 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 34' ' ' LEU . 2.3 tp10 -131.74 126.51 34.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.278 -0.888 . . . . 0.0 109.475 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.64 HD21 ' NE2' ' A' ' 22' ' ' HIS . 48.6 tp -42.89 161.68 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.288 -0.882 . . . . 0.0 109.586 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 34' ' ' LEU . 29.8 mm -144.72 -42.56 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.209 -0.932 . . . . 0.0 109.586 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.541 HG12 ' HB ' ' A' ' 47' ' ' VAL . 9.4 p -152.3 137.18 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.224 -0.923 . . . . 0.0 109.514 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.625 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 25.1 m-20 -100.71 163.14 12.47 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -0.871 . . . . 0.0 109.411 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.6 mt -129.86 154.34 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.232 -0.918 . . . . 0.0 109.517 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.483 ' HB3' ' O ' ' A' ' 17' ' ' THR . 27.8 tt0 -116.57 149.66 39.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.46 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.415 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -133.94 174.57 10.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -0.895 . . . . 0.0 109.487 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 40' ' ' THR . 5.6 t0 -42.9 -64.68 0.58 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.334 -0.853 . . . . 0.0 109.624 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . 0.46 ' C ' HG23 ' A' ' 43' ' ' VAL . 11.6 mttp -134.06 39.76 3.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.217 -0.927 . . . . 0.0 109.479 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.46 HG23 ' C ' ' A' ' 42' ' ' LYS . 38.5 t -155.23 143.63 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.222 -0.924 . . . . 0.0 109.474 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 81.9 t -115.76 136.28 53.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.871 . . . . 0.0 109.487 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 84.4 mtp -121.36 178.27 4.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.213 -0.929 . . . . 0.0 109.456 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -137.27 160.03 40.22 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.218 -0.926 . . . . 0.0 109.467 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.541 ' HB ' HG12 ' A' ' 36' ' ' VAL . 21.3 t -127.2 104.78 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.94 . . . . 0.0 109.559 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.522 HD12 ' CD1' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -95.58 158.16 15.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.347 -0.845 . . . . 0.0 109.491 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.464 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -82.56 161.94 22.12 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.271 -0.893 . . . . 0.0 109.45 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.707 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -89.3 -0.49 57.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.229 -0.919 . . . . 0.0 109.618 179.994 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.707 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.12 162.75 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.48 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.507 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -53.64 171.05 0.1 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.257 -0.902 . . . . 0.0 109.367 179.955 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.507 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 154.54 -150.88 22.57 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.8 t -136.2 123.11 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -1.172 . . . . 0.0 109.493 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.552 HG22 ' N ' ' A' ' 56' ' ' ALA . 15.5 mm -61.66 166.29 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -0.915 . . . . 0.0 109.512 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.552 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -105.46 -67.21 0.93 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.252 -0.905 . . . . 0.0 109.464 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.532 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 2.9 tm-20 -174.6 150.13 1.33 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.139 -0.976 . . . . 0.0 109.577 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.839 HG23 ' CZ2' ' A' ' 21' ' ' TRP . 8.1 mt -89.98 151.72 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.279 -0.888 . . . . 0.0 109.514 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.437 HG21 ' O ' ' A' ' 71' ' ' LEU . 56.0 t -97.16 -67.01 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.267 -0.896 . . . . 0.0 109.453 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.421 ' HD2' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -92.62 -170.71 2.54 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.232 -0.917 . . . . 0.0 109.451 179.988 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.468 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 12.6 m-80 -125.24 168.52 13.36 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.209 -0.932 . . . . 0.0 109.512 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.4 ' HA ' ' HB ' ' A' ' 18' ' ' VAL . 0.2 OUTLIER -65.99 149.8 49.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.196 -0.94 . . . . 0.0 109.542 179.931 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 82.07 4.94 90.09 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.65 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -99.93 170.89 8.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.16 -1.2 . . . . 0.0 109.319 179.969 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 28.3 m -95.46 126.29 40.65 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.522 -0.737 . . . . 0.0 109.504 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.413 HG22 ' C ' ' A' ' 16' ' ' GLY . 18.8 m -89.97 176.38 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.33 -0.856 . . . . 0.0 109.427 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -142.51 164.09 31.06 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.141 -0.974 . . . . 0.0 109.443 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.1 t -58.14 133.17 55.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 109.453 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 62.75 24.58 66.58 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 30.1 tp10 -73.47 119.55 17.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.255 -1.144 . . . . 0.0 109.431 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.45 HD23 ' N ' ' A' ' 73' ' ' GLY . 6.8 tt -75.93 109.08 9.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.199 -0.938 . . . . 0.0 109.444 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -88.81 -10.44 48.12 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.177 -0.952 . . . . 0.0 109.477 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.45 ' N ' HD23 ' A' ' 71' ' ' LEU . . . 157.59 -175.4 34.94 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 1.3 mtmm -138.84 149.08 44.52 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.193 -1.18 . . . . 0.0 109.498 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.427 HD12 HD13 ' A' ' 55' ' ' ILE . 0.8 OUTLIER -100.3 146.95 26.32 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.264 -0.898 . . . . 0.0 109.448 -179.915 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 14.9 m . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.246 -0.909 . . . . 0.0 109.483 -179.959 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.7 mt . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -71.13 150.91 44.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.318 -0.864 . . . . 0.0 109.486 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.3 mt -127.2 72.6 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.232 -0.918 . . . . 0.0 109.426 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.422 ' HA ' ' HG ' ' A' ' 72' ' ' LEU . 5.0 pttp -101.34 167.99 9.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.194 -0.941 . . . . 0.0 109.472 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.45 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -66.34 158.02 79.52 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.344 -0.848 . . . . 0.0 109.438 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.45 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.2 Cg_endo -78.05 169.26 20.71 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.586 2.191 . . . . 0.0 110.422 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.7 141.35 40.94 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.464 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.53 ' CD2' ' HB2' ' A' ' 68' ' ' SER . 18.6 m-85 -107.91 153.07 41.86 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.23 -0.919 . . . . 0.0 109.462 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.445 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -78.06 167.41 23.49 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.593 2.195 . . . . 0.0 110.373 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.1 mt-10 -49.45 -53.52 22.53 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.2 -0.938 . . . . 0.0 109.54 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 11' ' ' GLU . 19.1 t -42.75 -48.88 5.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.385 -0.822 . . . . 0.0 109.631 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.816 HG21 ' CG2' ' A' ' 40' ' ' THR . 22.5 mt -96.18 122.05 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.223 -0.923 . . . . 0.0 109.402 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -101.13 11.46 39.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.214 -0.929 . . . . 0.0 109.439 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.598 ' O ' HG22 ' A' ' 13' ' ' ILE . 0.9 OUTLIER -176.67 -170.13 0.31 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.247 -0.908 . . . . 0.0 109.403 179.982 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.613 ' O ' HG23 ' A' ' 65' ' ' THR . . . -151.58 -173.33 21.28 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.523 HG23 ' O ' ' A' ' 64' ' ' ASP . 4.2 m -150.04 127.93 11.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -1.147 . . . . 0.0 109.411 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.531 HG12 ' N ' ' A' ' 19' ' ' ALA . 47.9 t -54.31 164.05 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.218 -0.926 . . . . 0.0 109.45 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.558 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -109.7 -73.86 0.67 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.26 -0.9 . . . . 0.0 109.518 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.534 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 18.3 m -158.46 134.67 9.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.211 -0.931 . . . . 0.0 109.489 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.656 ' CH2' HD12 ' A' ' 58' ' ' ILE . 35.1 m95 -89.7 84.7 6.32 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.231 -0.918 . . . . 0.0 109.567 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.799 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.2 m80 -42.76 -60.31 1.62 Allowed 'General case' 0 N--CA 1.499 2.004 0 O-C-N 121.401 -0.812 . . . . 0.0 109.483 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.405 ' HA ' ' HD2' ' A' ' 23' ' ' LYS . 1.1 mmmt -100.28 -171.99 2.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -0.873 . . . . 0.0 109.562 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.439 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -124.54 169.17 11.31 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.254 -0.904 . . . . 0.0 109.483 -179.934 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.514 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.2 Cg_endo -76.48 94.24 1.04 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.67 2.247 . . . . 0.0 110.409 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 151.04 -17.45 0.92 Allowed Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -84.75 170.68 13.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -1.134 . . . . 0.0 109.541 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.11 127.94 42.57 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.886 . . . . 0.0 109.389 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.584 HG22 ' O ' ' A' ' 53' ' ' GLY . 18.3 m -96.63 -172.04 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.464 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.426 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -148.4 136.97 21.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.47 -179.959 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.454 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 10.3 tmm_? -42.79 128.28 4.14 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.319 -0.863 . . . . 0.0 109.624 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 7.7 t70 72.81 54.36 0.14 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.276 -0.89 . . . . 0.0 109.453 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.466 ' N ' HD23 ' A' ' 48' ' ' LEU . 1.4 tp10 -141.91 120.78 12.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.296 -0.877 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.799 HD21 ' NE2' ' A' ' 22' ' ' HIS . 47.9 tp -42.87 142.31 0.92 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.309 -0.87 . . . . 0.0 109.581 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.589 HG13 ' HB2' ' A' ' 49' ' ' ALA . 22.7 mm -129.75 -42.15 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.889 . . . . 0.0 109.443 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.585 HG12 ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -157.53 144.43 9.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.296 -0.878 . . . . 0.0 109.466 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.558 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 19.6 m-20 -102.68 150.3 23.58 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.627 HD11 HG22 ' A' ' 47' ' ' VAL . 21.8 mt -110.47 150.72 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.186 -0.946 . . . . 0.0 109.464 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -141.7 98.73 3.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.486 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.816 ' CG2' HG21 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -90.19 -174.37 4.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.202 -0.936 . . . . 0.0 109.488 -179.996 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.626 ' H ' HG22 ' A' ' 40' ' ' THR . 0.6 OUTLIER -42.87 -45.18 4.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.274 -0.891 . . . . 0.0 109.647 -179.866 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . 0.434 ' HG3' ' O ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -156.28 27.33 0.35 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.199 -0.938 . . . . 0.0 109.446 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 3.5 t -128.36 106.66 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.327 -0.858 . . . . 0.0 109.42 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.5 t -90.31 130.48 39.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.242 -0.911 . . . . 0.0 109.484 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 10.2 mmt -141.86 108.45 5.34 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.181 -0.95 . . . . 0.0 109.476 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.477 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 5.4 mt-10 -63.0 172.08 1.92 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.278 -0.889 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.627 HG22 HD11 ' A' ' 38' ' ' ILE . 15.7 t -135.25 102.32 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.236 -0.915 . . . . 0.0 109.504 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.466 HD23 ' N ' ' A' ' 33' ' ' GLU . 0.0 OUTLIER -94.5 154.85 17.21 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.479 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.589 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -84.94 143.15 29.16 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.227 -0.921 . . . . 0.0 109.525 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.31 13.93 31.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.325 -0.859 . . . . 0.0 109.45 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -179.7 140.83 0.14 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.322 -0.862 . . . . 0.0 109.454 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -59.83 170.89 1.02 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.248 -0.908 . . . . 0.0 109.309 179.999 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.584 ' O ' HG22 ' A' ' 29' ' ' VAL . . . 154.32 175.84 25.97 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.576 ' O ' HG22 ' A' ' 76' ' ' THR . 49.2 t -112.93 124.83 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.206 -1.173 . . . . 0.0 109.498 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.939 HD13 HD12 ' A' ' 75' ' ' LEU . 15.6 mm -61.25 164.82 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.488 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.524 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -106.39 -63.7 1.24 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.314 -0.867 . . . . 0.0 109.462 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.488 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -170.41 136.43 1.33 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.16 -0.962 . . . . 0.0 109.528 -179.915 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.656 HD12 ' CH2' ' A' ' 21' ' ' TRP . 26.6 mm -89.94 141.37 14.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.343 -0.848 . . . . 0.0 109.452 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 89.1 t -90.18 -62.46 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -0.912 . . . . 0.0 109.55 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.474 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -89.95 155.1 19.35 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 109.44 -179.917 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -102.54 158.47 16.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.247 -0.908 . . . . 0.0 109.433 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.534 ' CB ' ' HA ' ' A' ' 20' ' ' THR . 2.1 pp20? -60.81 143.35 54.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.206 -0.934 . . . . 0.0 109.451 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 98.48 -10.32 62.99 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.523 ' O ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -100.16 170.9 8.15 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.239 -1.153 . . . . 0.0 109.274 -179.971 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.613 HG23 ' O ' ' A' ' 16' ' ' GLY . 47.5 m -101.54 146.91 27.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.492 -0.755 . . . . 0.0 109.484 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.41 160.94 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.226 -0.921 . . . . 0.0 109.497 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 15.0 mt -90.42 145.28 25.05 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.246 -0.909 . . . . 0.0 109.476 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.53 ' HB2' ' CD2' ' A' ' 9' ' ' PHE . 1.9 t -49.33 114.32 1.0 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.295 -0.878 . . . . 0.0 109.515 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.45 22.43 24.34 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 38.9 tp10 -84.0 131.9 34.79 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.293 -1.122 . . . . 0.0 109.483 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 4.9 tt -66.09 114.25 5.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.261 -0.899 . . . . 0.0 109.501 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.55 ' O ' HG23 ' A' ' 58' ' ' ILE . 6.1 mt -96.59 -22.17 17.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.266 -0.896 . . . . 0.0 109.456 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.38 159.83 23.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -124.32 133.98 53.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.265 -1.138 . . . . 0.0 109.483 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.939 HD12 HD13 ' A' ' 55' ' ' ILE . 4.5 tp -92.35 152.09 19.94 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.92 . . . . 0.0 109.503 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.576 HG22 ' O ' ' A' ' 54' ' ' VAL . 2.9 t . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.313 -0.867 . . . . 0.0 109.727 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.575 HD12 HD22 ' A' ' 75' ' ' LEU . 25.1 mt . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -77.67 124.03 27.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.244 -0.91 . . . . 0.0 109.459 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.6 mm -100.32 108.28 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.235 -0.916 . . . . 0.0 109.472 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.5 mtmt -125.15 165.72 17.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.627 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -75.59 163.41 67.53 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.207 -0.933 . . . . 0.0 109.528 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.627 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.09 134.69 13.23 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.637 2.225 . . . . 0.0 110.436 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.1 m -57.64 134.74 56.44 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.194 -0.941 . . . . 0.0 109.503 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.479 ' CE1' ' O ' ' A' ' 7' ' ' PRO . 4.2 m-85 -94.97 149.17 35.88 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.201 -0.937 . . . . 0.0 109.415 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 9' ' ' PHE . 35.8 Cg_endo -78.09 -165.22 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.621 2.214 . . . . 0.0 110.456 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.1 OUTLIER -72.41 -49.19 35.53 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.414 179.995 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 11' ' ' GLU . 30.9 t -42.78 -52.12 5.12 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.308 -0.87 . . . . 0.0 109.635 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.783 HG22 ' H ' ' A' ' 15' ' ' ASP . 3.2 mt -92.95 150.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.206 -0.934 . . . . 0.0 109.439 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.419 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -122.28 12.77 10.25 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.327 -0.858 . . . . 0.0 109.494 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.783 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.3 OUTLIER 170.75 -170.76 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.256 -0.902 . . . . 0.0 109.499 -179.987 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.09 -169.92 18.09 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.471 HG23 ' O ' ' A' ' 64' ' ' ASP . 17.1 m -149.94 128.78 12.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -1.126 . . . . 0.0 109.469 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.44 HG12 ' N ' ' A' ' 19' ' ' ALA . 25.5 t -52.35 160.65 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.336 -0.852 . . . . 0.0 109.489 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.651 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -100.52 -75.63 0.58 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.473 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.7 m -160.11 136.11 8.57 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.564 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.721 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 33.4 m95 -89.76 82.46 6.26 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.256 -0.902 . . . . 0.0 109.64 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.668 ' CE1' HD21 ' A' ' 34' ' ' LEU . 1.8 m80 -43.57 -71.46 0.08 Allowed 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.284 -0.885 . . . . 0.0 109.362 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.404 ' HB2' ' HE3' ' A' ' 23' ' ' LYS . 30.0 mtmt -100.09 -171.93 2.13 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.245 -0.909 . . . . 0.0 109.571 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.62 167.39 19.41 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.328 -0.858 . . . . 0.0 109.465 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.835 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.5 Cg_endo -76.92 153.18 32.69 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.66 2.24 . . . . 0.0 110.412 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.11 9.49 67.48 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 41.5 mm-40 -113.38 -173.33 2.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.172 -1.193 . . . . 0.0 109.418 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -83.58 132.5 34.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.457 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.6 t -123.28 138.26 53.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.458 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.1 mttt -119.01 132.95 56.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.437 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -42.9 143.39 0.74 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.258 -0.901 . . . . 0.0 109.595 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.435 ' N ' ' HD2' ' A' ' 31' ' ' ARG . 17.6 t0 69.56 46.76 0.7 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.224 -0.923 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.452 ' O ' HG12 ' A' ' 35' ' ' ILE . 1.8 tp10 -140.41 110.19 6.41 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.229 -0.92 . . . . 0.0 109.49 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.668 HD21 ' CE1' ' A' ' 22' ' ' HIS . 55.7 tp -42.97 161.51 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.27 -0.894 . . . . 0.0 109.604 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.519 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 22.2 mm -149.9 -40.25 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.213 -0.929 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.522 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 13.5 p -151.03 131.01 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.257 -0.902 . . . . 0.0 109.541 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.651 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 12.9 m-20 -97.96 171.94 7.95 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.247 -0.908 . . . . 0.0 109.485 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 2.5 mt -138.74 164.49 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.288 -0.882 . . . . 0.0 109.44 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.446 ' HB2' ' O ' ' A' ' 17' ' ' THR . 37.4 mt-10 -132.95 141.6 48.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.238 -0.913 . . . . 0.0 109.419 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -126.35 -160.48 0.99 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 -179.992 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 40' ' ' THR . 3.8 t70 -42.87 -63.1 0.85 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.277 -0.889 . . . . 0.0 109.563 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . 0.412 ' HG2' ' O ' ' A' ' 41' ' ' ASP . 6.6 mttt -145.65 22.3 1.46 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 1.9 t -127.42 139.22 52.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.226 -0.921 . . . . 0.0 109.437 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.415 ' O ' HG13 ' A' ' 44' ' ' VAL . 9.1 p -105.98 134.26 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.403 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . 0.427 ' C ' ' HG3' ' A' ' 46' ' ' GLU . 8.8 mtm -113.55 -176.81 2.98 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.264 -0.897 . . . . 0.0 109.463 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.478 ' HB3' HD13 ' A' ' 34' ' ' LEU . 29.1 mt-10 -143.97 161.65 38.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.307 -0.87 . . . . 0.0 109.402 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.522 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 63.5 t -136.72 108.25 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.773 ' N ' HD23 ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.89 148.9 25.07 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.286 -0.883 . . . . 0.0 109.381 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -63.55 147.62 50.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.442 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.699 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 1.1 mt-10 -93.05 10.49 31.28 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.239 -0.913 . . . . 0.0 109.473 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.699 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.34 157.23 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.257 -0.902 . . . . 0.0 109.479 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.508 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -65.55 170.96 4.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.336 -0.852 . . . . 0.0 109.348 -179.977 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.508 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.31 -143.79 10.94 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.8 t -138.21 124.46 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.249 -1.147 . . . . 0.0 109.489 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.552 HG22 ' N ' ' A' ' 56' ' ' ALA . 9.6 mm -75.13 171.76 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.3 -0.875 . . . . 0.0 109.523 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.552 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -102.88 -62.45 1.27 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.203 -0.935 . . . . 0.0 109.514 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.534 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 5.3 pt-20 173.27 161.05 0.14 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 109.533 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.835 HD11 ' HD3' ' A' ' 25' ' ' PRO . 1.6 mp -90.43 143.84 10.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.255 -0.903 . . . . 0.0 109.44 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.927 HG21 HD23 ' A' ' 71' ' ' LEU . 53.5 t -99.42 -21.09 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.214 -0.929 . . . . 0.0 109.47 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.518 ' CG ' ' OD2' ' A' ' 64' ' ' ASP . 9.8 tptt -120.65 -171.87 2.27 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.248 -0.907 . . . . 0.0 109.559 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.478 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 17.1 m120 -123.25 167.9 13.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.896 . . . . 0.0 109.49 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -71.52 143.03 50.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.272 -0.893 . . . . 0.0 109.533 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 72.86 17.06 78.18 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.716 -1.353 . . . . 0.0 109.716 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.518 ' OD2' ' CG ' ' A' ' 60' ' ' LYS . 0.2 OUTLIER -100.65 170.83 8.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.232 -1.157 . . . . 0.0 109.331 179.966 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.513 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.8 t -90.94 153.78 19.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.481 -0.762 . . . . 0.0 109.53 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 16.1 m -133.39 144.49 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.227 -0.921 . . . . 0.0 109.517 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -92.67 160.73 14.86 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.3 -0.875 . . . . 0.0 109.387 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.2 t -52.89 119.3 4.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.129 -0.982 . . . . 0.0 109.493 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 74.53 33.36 56.24 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -76.8 137.73 39.43 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.277 -1.131 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.927 HD23 HG21 ' A' ' 59' ' ' VAL . 0.6 OUTLIER -78.19 128.32 33.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.456 -179.961 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 7.5 mt -105.76 -23.17 12.78 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.313 -0.867 . . . . 0.0 109.459 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 171.87 171.16 36.63 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 4.4 mtmt -127.78 136.81 52.0 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.27 -1.135 . . . . 0.0 109.509 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.575 HD22 HD12 ' A' ' 2' ' ' ILE . 2.7 tt -97.75 151.27 20.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.235 -0.916 . . . . 0.0 109.508 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.574 ' O ' HD23 ' A' ' 75' ' ' LEU . 15.1 m . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.262 -0.899 . . . . 0.0 109.464 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.1 pp . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.508 ' OD2' HD11 ' A' ' 71' ' ' LEU . 8.9 t70 -80.41 133.42 35.88 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.178 -0.951 . . . . 0.0 109.449 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 12.2 mt -96.45 107.76 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.1 mttt -121.28 173.36 7.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.909 . . . . 0.0 109.449 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.96 149.19 82.52 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.292 -0.88 . . . . 0.0 109.468 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.02 135.87 14.28 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.661 2.24 . . . . 0.0 110.372 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.519 HG23 ' O ' ' A' ' 8' ' ' THR . 3.0 t -56.73 112.33 1.27 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.202 -0.936 . . . . 0.0 109.474 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -67.24 157.45 85.19 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.867 . . . . 0.0 109.431 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.455 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.07 -159.61 0.1 Allowed 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.557 2.171 . . . . 0.0 110.423 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.416 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.1 tt0 -80.07 -61.94 1.83 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.25 -0.906 . . . . 0.0 109.521 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.416 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.9 t -42.81 -47.51 5.53 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.296 -0.877 . . . . 0.0 109.633 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.522 HD11 ' HB2' ' A' ' 41' ' ' ASP . 16.6 mt -99.81 130.16 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.234 -0.916 . . . . 0.0 109.418 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -118.79 28.15 8.47 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.274 -0.891 . . . . 0.0 109.383 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.491 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 176.42 -170.44 0.07 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.314 -0.866 . . . . 0.0 109.429 -179.978 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.85 -173.53 33.58 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 18' ' ' VAL . 16.7 m -149.91 122.75 8.71 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.154 -1.204 . . . . 0.0 109.422 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.426 ' C ' ' O ' ' A' ' 17' ' ' THR . 47.1 t -44.24 156.96 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -0.905 . . . . 0.0 109.41 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.412 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -106.12 -74.9 0.64 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -0.906 . . . . 0.0 109.475 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.8 m -158.85 134.81 8.93 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.258 -0.901 . . . . 0.0 109.413 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.632 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 33.1 m95 -89.85 84.4 6.24 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.232 -0.917 . . . . 0.0 109.565 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.763 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.1 m80 -42.93 -63.25 0.83 Allowed 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.364 -0.835 . . . . 0.0 109.372 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -92.39 -172.07 2.98 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.187 -0.946 . . . . 0.0 109.509 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.48 ' HB2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.47 164.39 43.06 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.272 -0.893 . . . . 0.0 109.452 -179.95 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.482 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -77.59 90.38 1.26 Allowed 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 122.688 2.259 . . . . 0.0 110.36 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 160.56 -23.28 0.25 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 49.6 mm-40 -94.38 -172.43 2.78 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.35 -1.088 . . . . 0.0 109.472 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -105.0 149.1 26.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.241 -0.912 . . . . 0.0 109.483 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.0 m -120.55 175.66 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.269 -0.894 . . . . 0.0 109.431 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.09 130.6 50.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.425 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 14.1 ttt180 -42.91 141.65 1.07 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.287 -0.883 . . . . 0.0 109.625 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.7 t70 65.55 45.56 2.71 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.434 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 34' ' ' LEU . 4.9 tt0 -136.52 124.83 23.25 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.334 -0.854 . . . . 0.0 109.502 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.862 HD13 ' HB3' ' A' ' 46' ' ' GLU . 49.8 tp -42.81 150.93 0.14 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.372 -0.83 . . . . 0.0 109.603 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.765 HD11 ' HB2' ' A' ' 49' ' ' ALA . 11.8 mt -139.49 -38.73 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.321 -0.862 . . . . 0.0 109.509 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.518 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 9.7 p -154.51 131.12 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.208 -0.933 . . . . 0.0 109.497 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.46 ' OD1' ' HA ' ' A' ' 46' ' ' GLU . 39.3 m-20 -97.0 152.18 18.98 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.176 -0.952 . . . . 0.0 109.443 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.47 ' O ' ' HA ' ' A' ' 44' ' ' VAL . 5.5 mt -115.91 146.69 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.275 -0.89 . . . . 0.0 109.482 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.68 111.54 21.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.315 -0.866 . . . . 0.0 109.495 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.675 HG23 ' N ' ' A' ' 41' ' ' ASP . 4.8 t -106.64 -153.73 0.5 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.191 -0.943 . . . . 0.0 109.385 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.675 ' N ' HG23 ' A' ' 40' ' ' THR . 0.3 OUTLIER -43.09 -71.53 0.08 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.898 . . . . 0.0 109.627 -179.882 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 17.8 mtmm -143.88 36.9 1.29 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.519 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.587 ' O ' HG22 ' A' ' 40' ' ' THR . 2.1 t -146.82 145.6 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.296 -0.877 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.47 ' HA ' ' O ' ' A' ' 38' ' ' ILE . 10.6 p -109.8 133.51 54.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 0.0 109.438 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 2.7 mtt -105.35 126.95 52.68 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.454 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.862 ' HB3' HD13 ' A' ' 34' ' ' LEU . 6.7 mt-10 -81.4 131.25 35.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.179 -0.951 . . . . 0.0 109.466 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.518 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 92.8 t -116.4 102.03 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.247 -0.908 . . . . 0.0 109.509 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.498 ' H ' HD12 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -102.91 163.24 12.32 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.211 -0.931 . . . . 0.0 109.406 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.765 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -79.45 142.35 35.96 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.207 -0.933 . . . . 0.0 109.48 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -82.5 8.21 12.28 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.281 -0.887 . . . . 0.0 109.535 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -177.08 141.73 0.34 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.889 . . . . 0.0 109.534 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.2 OUTLIER -57.93 170.93 0.56 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.223 -0.923 . . . . 0.0 109.312 -179.953 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.99 -145.09 12.25 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.4 t -138.4 125.21 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.3 -1.118 . . . . 0.0 109.433 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.523 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.0 mt -58.17 161.75 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.316 -0.865 . . . . 0.0 109.529 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.54 ' CB ' ' HG3' ' A' ' 74' ' ' LYS . . . -97.66 -66.84 0.88 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.275 -0.891 . . . . 0.0 109.522 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.482 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 8.2 tt0 -175.05 138.75 0.45 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.207 -0.933 . . . . 0.0 109.456 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.632 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.9 mm -101.94 119.92 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.246 -0.909 . . . . 0.0 109.387 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.4 t -90.0 -19.11 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -0.929 . . . . 0.0 109.402 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.442 ' HG3' ' CG ' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -97.81 131.87 43.93 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.466 179.977 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 47.9 m-80 -97.55 156.35 16.55 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -0.867 . . . . 0.0 109.471 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -51.24 148.79 4.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.257 -0.902 . . . . 0.0 109.524 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 75.87 19.7 78.61 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.5 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -100.5 170.91 8.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.267 -1.137 . . . . 0.0 109.274 -179.978 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.5 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 65.1 m -106.67 133.6 51.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.539 -0.725 . . . . 0.0 109.475 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 25.0 m -100.79 163.73 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -0.884 . . . . 0.0 109.451 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.519 HD23 ' H ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -145.68 167.39 23.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.272 -0.893 . . . . 0.0 109.476 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.519 ' H ' HD23 ' A' ' 67' ' ' LEU . 1.5 t -62.29 115.4 4.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.227 -0.921 . . . . 0.0 109.508 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 89.84 18.4 51.25 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 27.2 tp10 -83.19 121.75 27.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.229 -1.159 . . . . 0.0 109.485 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.508 HD11 ' OD2' ' A' ' 3' ' ' ASP . 0.5 OUTLIER -83.98 119.2 24.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.211 -0.931 . . . . 0.0 109.422 -179.973 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 12.0 mt -99.82 -19.09 16.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.268 -0.895 . . . . 0.0 109.44 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 159.5 168.12 21.07 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.54 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -127.21 158.51 36.92 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.16 -1.2 . . . . 0.0 109.487 179.982 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 8.8 tp -96.48 152.84 18.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.436 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.1 m . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.873 . . . . 0.0 109.523 179.952 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.563 HD13 HD23 ' A' ' 75' ' ' LEU . 3.5 mp . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 121.311 0.577 . . . . 0.0 109.459 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.478 ' OD1' HD11 ' A' ' 71' ' ' LEU . 63.2 t0 -57.85 123.26 15.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.531 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 53.0 mt -98.69 121.3 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.228 -0.92 . . . . 0.0 109.39 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.7 ptpp? -147.1 168.5 21.45 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.242 -0.911 . . . . 0.0 109.53 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.42 150.89 91.78 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.02 127.83 8.75 Favored 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.579 2.186 . . . . 0.0 110.423 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -45.84 143.46 2.12 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.27 -0.894 . . . . 0.0 109.451 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.517 ' CE2' ' C ' ' A' ' 15' ' ' ASP . 22.1 m-85 -102.84 154.5 37.47 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.923 . . . . 0.0 109.443 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -78.0 163.75 28.0 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.671 2.247 . . . . 0.0 110.415 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.0 OUTLIER -45.84 -49.77 14.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.141 -0.974 . . . . 0.0 109.505 179.985 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -43.17 -59.96 1.85 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.293 -0.879 . . . . 0.0 109.68 -179.936 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.704 HG22 ' H ' ' A' ' 15' ' ' ASP . 2.5 mp -90.28 132.94 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.267 -0.895 . . . . 0.0 109.48 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.76 25.98 11.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.906 . . . . 0.0 109.486 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.704 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER 177.09 -171.09 0.09 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.24 -0.913 . . . . 0.0 109.487 -179.94 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.417 ' HA3' ' CZ ' ' A' ' 9' ' ' PHE . . . -159.14 -175.09 29.69 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.849 HG23 ' O ' ' A' ' 64' ' ' ASP . 85.2 m -150.02 122.59 8.55 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.292 -1.122 . . . . 0.0 109.45 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.585 HG12 ' N ' ' A' ' 19' ' ' ALA . 38.2 t -48.14 168.97 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.297 -0.877 . . . . 0.0 109.453 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.585 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -111.1 -73.9 0.66 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.266 -0.897 . . . . 0.0 109.58 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.491 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 23.9 m -160.08 135.46 8.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.117 -0.989 . . . . 0.0 109.674 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.655 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 34.2 m95 -89.94 83.38 6.13 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 121.161 -0.962 . . . . 0.0 109.494 179.857 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.576 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 1.5 m80 -43.16 -70.8 0.09 Allowed 'General case' 0 N--CA 1.501 2.109 0 O-C-N 121.315 -0.866 . . . . 0.0 109.425 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.85 -171.75 2.23 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.219 -0.926 . . . . 0.0 109.62 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.443 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.28 169.86 12.72 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.329 -0.857 . . . . 0.0 109.428 -179.903 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.613 ' HD3' HD11 ' A' ' 58' ' ' ILE . 34.9 Cg_endo -76.05 135.98 17.82 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 122.642 2.228 . . . . 0.0 110.377 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.13 10.61 27.59 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.421 ' CD ' ' O ' ' A' ' 28' ' ' ALA . 1.2 pp20? -115.51 173.16 6.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.225 -1.162 . . . . 0.0 109.471 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.421 ' O ' ' CD ' ' A' ' 27' ' ' GLU . . . -78.7 144.96 34.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.288 -0.883 . . . . 0.0 109.481 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.405 HG12 ' N ' ' A' ' 30' ' ' LYS . 5.2 t -127.92 163.95 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.902 . . . . 0.0 109.472 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.422 ' O ' ' C ' ' A' ' 31' ' ' ARG . 4.3 tttp -156.8 141.85 17.17 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.275 -0.891 . . . . 0.0 109.474 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.462 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 1.5 tmm_? -42.78 144.8 0.52 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.337 -0.852 . . . . 0.0 109.718 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.462 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 16.4 t0 72.18 46.91 0.31 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.269 -0.894 . . . . 0.0 109.498 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 34' ' ' LEU . 3.6 tp10 -142.22 100.99 3.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.281 -0.887 . . . . 0.0 109.561 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.576 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 39.9 tp -43.36 146.9 0.43 Allowed 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.299 -0.875 . . . . 0.0 109.519 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 44.5 mt -121.86 -44.66 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.889 . . . . 0.0 109.652 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.523 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.9 p -160.09 139.24 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.2 -0.937 . . . . 0.0 109.566 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.532 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 11.5 m-20 -99.18 168.39 10.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.896 . . . . 0.0 109.478 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.503 ' O ' HG23 ' A' ' 44' ' ' VAL . 12.8 mt -136.02 161.75 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.284 -0.885 . . . . 0.0 109.46 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.438 ' N ' HG22 ' A' ' 38' ' ' ILE . 2.4 tt0 -143.1 167.35 22.29 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.236 -0.915 . . . . 0.0 109.489 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.549 HG22 ' H ' ' A' ' 41' ' ' ASP . 8.5 m -159.18 170.91 20.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.273 -0.892 . . . . 0.0 109.455 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.549 ' H ' HG22 ' A' ' 40' ' ' THR . 8.9 t0 -42.83 -40.61 2.95 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.252 -0.905 . . . . 0.0 109.631 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -156.29 26.0 0.35 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 78.6 t -140.64 105.09 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.33 -0.856 . . . . 0.0 109.46 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 38' ' ' ILE . 3.7 p -95.48 139.32 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.186 -0.946 . . . . 0.0 109.531 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . 0.451 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 13.2 mmt -128.05 -167.88 1.82 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.275 -0.89 . . . . 0.0 109.477 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.5 pt-20 -158.39 167.06 30.7 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.169 -0.957 . . . . 0.0 109.486 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.523 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 71.3 t -138.31 104.02 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.381 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.463 ' HG ' ' HA ' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -95.98 171.02 8.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 -179.994 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.05 139.64 31.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 0.0 109.44 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.659 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 2.9 mm-40 -100.38 8.09 43.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -0.913 . . . . 0.0 109.548 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.659 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 166.57 142.99 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.958 . . . . 0.0 109.491 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.504 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.84 170.98 0.15 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.198 -0.939 . . . . 0.0 109.225 -179.926 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.504 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.95 -146.3 14.88 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.4 t -135.89 124.45 37.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.302 -1.117 . . . . 0.0 109.505 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.526 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 5.0 mt -61.17 158.65 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 109.567 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.462 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -95.56 -69.41 0.76 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.249 -0.907 . . . . 0.0 109.549 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.528 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -178.97 152.9 0.6 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.241 -0.912 . . . . 0.0 109.471 179.992 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.655 HG23 ' CZ2' ' A' ' 21' ' ' TRP . 24.9 mt -89.91 141.28 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.219 -0.926 . . . . 0.0 109.412 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.8 t -90.53 -66.77 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.172 -0.955 . . . . 0.0 109.411 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.641 ' HD2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -92.79 -173.67 3.39 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.25 -0.906 . . . . 0.0 109.448 -179.983 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.461 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 70.7 m-80 -110.6 155.57 22.16 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.296 -0.878 . . . . 0.0 109.44 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.528 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -69.52 153.43 43.51 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.244 -0.91 . . . . 0.0 109.451 -179.984 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 77.49 7.45 87.09 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.849 ' O ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -105.29 170.95 7.59 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.238 -1.154 . . . . 0.0 109.32 -179.966 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.502 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 48.6 m -99.14 128.55 45.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.457 -0.777 . . . . 0.0 109.494 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.641 HG12 ' HD2' ' A' ' 60' ' ' LYS . 6.6 m -121.52 -169.7 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.329 -0.857 . . . . 0.0 109.455 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.472 HD12 ' HA ' ' A' ' 67' ' ' LEU . 1.2 tp -127.15 165.95 18.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -0.903 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 t -61.7 138.76 58.34 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.279 -0.888 . . . . 0.0 109.505 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.02 15.4 81.4 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -79.05 116.63 19.47 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.243 -1.151 . . . . 0.0 109.51 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.478 HD11 ' OD1' ' A' ' 3' ' ' ASP . 10.9 tp -66.57 115.92 6.96 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.203 -0.935 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 15.4 mt -98.36 -12.35 21.55 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.245 -0.909 . . . . 0.0 109.404 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 164.1 169.96 28.36 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 26.5 mtmt -132.25 139.09 48.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.188 -1.184 . . . . 0.0 109.504 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.563 HD23 HD13 ' A' ' 2' ' ' ILE . 12.8 tp -98.41 136.86 37.95 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.207 -0.933 . . . . 0.0 109.543 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 12.7 m . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.225 -0.922 . . . . 0.0 109.501 179.995 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.518 ' O ' HD12 ' A' ' 2' ' ' ILE . 2.1 pp . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.464 ' OD2' ' CD1' ' A' ' 71' ' ' LEU . 26.1 t70 -74.53 166.4 23.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.3 -0.875 . . . . 0.0 109.521 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 61.1 mt -129.96 118.45 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.475 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 ptpp? -137.25 165.0 27.18 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.272 -0.893 . . . . 0.0 109.425 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.45 150.58 91.59 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.485 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.11 166.4 24.78 Favored 'Trans proline' 0 C--N 1.309 -1.524 0 C-N-CA 122.612 2.208 . . . . 0.0 110.409 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.09 94.96 2.98 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.173 -0.954 . . . . 0.0 109.445 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.533 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 21.5 m-85 -50.1 151.0 3.77 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.298 -0.877 . . . . 0.0 109.457 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.436 ' HG2' HG12 ' A' ' 13' ' ' ILE . 35.2 Cg_endo -78.14 177.31 8.93 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.559 2.173 . . . . 0.0 110.383 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 12' ' ' SER . 43.2 tt0 -66.0 -54.05 31.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.501 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.425 ' C ' ' O ' ' A' ' 11' ' ' GLU . 21.6 t -42.95 -46.41 5.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.34 -0.85 . . . . 0.0 109.628 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.607 HG22 ' H ' ' A' ' 15' ' ' ASP . 11.6 mm -94.5 151.69 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.415 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -121.36 2.64 10.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.618 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.607 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 167.96 -169.25 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.109 -0.995 . . . . 0.0 109.502 -179.992 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.67 -159.46 9.94 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.691 HG22 ' O ' ' A' ' 64' ' ' ASP . 0.2 OUTLIER -149.06 170.68 17.85 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.277 -1.131 . . . . 0.0 109.048 179.987 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.552 HG12 ' H ' ' A' ' 19' ' ' ALA . 3.8 t -85.66 171.53 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.051 -1.031 . . . . 0.0 109.409 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.578 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -118.91 -74.19 0.62 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.462 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.453 ' HA ' ' HG2' ' A' ' 62' ' ' GLU . 65.2 m -160.21 132.3 6.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.144 -0.972 . . . . 0.0 109.622 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.675 ' CH2' HD12 ' A' ' 58' ' ' ILE . 34.0 m95 -89.85 82.23 6.24 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.256 -0.902 . . . . 0.0 109.397 179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.625 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.4 m80 -42.67 -57.12 2.85 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.401 -0.812 . . . . 0.0 109.484 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.3 163.58 12.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.245 -0.909 . . . . 0.0 109.66 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.498 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 23.6 mttt -114.46 165.8 13.01 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.346 -0.846 . . . . 0.0 109.152 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.533 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.76 102.5 1.62 Allowed 'Trans proline' 0 C--N 1.308 -1.582 0 C-N-CA 122.544 2.163 . . . . 0.0 110.419 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 145.01 -13.43 1.91 Allowed Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.8 mm-40 -96.61 -172.13 2.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.234 -1.156 . . . . 0.0 109.512 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.68 161.99 13.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.533 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.462 ' O ' ' OD2' ' A' ' 52' ' ' ASP . 35.5 t -138.36 153.42 26.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.239 -0.913 . . . . 0.0 109.479 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.409 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.6 OUTLIER -126.71 137.6 53.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.929 . . . . 0.0 109.5 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.514 ' HG2' ' N ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -42.98 146.04 0.43 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.302 -0.874 . . . . 0.0 109.639 -179.939 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.514 ' N ' ' HG2' ' A' ' 31' ' ' ARG . 3.1 t70 67.66 38.82 2.9 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.7 ' N ' HD11 ' A' ' 48' ' ' LEU . 8.6 tp10 -127.84 115.94 19.39 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.194 -0.941 . . . . 0.0 109.455 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.625 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 41.4 tp -43.25 162.37 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.283 -0.886 . . . . 0.0 109.463 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.456 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 29.6 mm -135.49 -48.05 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 109.63 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.506 HG12 ' HB ' ' A' ' 47' ' ' VAL . 14.3 p -160.18 131.55 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.158 -0.964 . . . . 0.0 109.539 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.578 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 3.4 m-20 -90.32 150.82 21.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.5 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 60.9 mt -119.54 155.48 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -0.913 . . . . 0.0 109.501 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.46 ' CG ' ' HB ' ' A' ' 17' ' ' THR . 12.1 pt-20 -128.58 154.51 46.12 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.257 -0.902 . . . . 0.0 109.539 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -141.58 175.5 9.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.258 -0.902 . . . . 0.0 109.425 -179.93 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 4.2 t0 -42.83 -60.67 1.51 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.334 -0.853 . . . . 0.0 109.636 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 15.7 mttt -138.5 36.44 2.25 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.29 -0.881 . . . . 0.0 109.464 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 90.6 t -147.65 127.35 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.28 -0.887 . . . . 0.0 109.436 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.6 t -102.3 152.0 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.277 -0.889 . . . . 0.0 109.463 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.9 176.33 9.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 109.468 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -141.54 149.63 41.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 109.495 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.506 ' HB ' HG12 ' A' ' 36' ' ' VAL . 30.5 t -115.59 96.9 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.285 -0.885 . . . . 0.0 109.431 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.7 HD11 ' N ' ' A' ' 33' ' ' GLU . 29.8 tp -96.04 153.16 17.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.35 -0.843 . . . . 0.0 109.52 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.471 ' N ' ' HG ' ' A' ' 48' ' ' LEU . . . -83.41 148.07 27.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.192 -0.942 . . . . 0.0 109.446 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.562 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -99.77 17.98 19.34 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.936 . . . . 0.0 109.485 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.562 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 171.87 154.01 0.07 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.288 -0.883 . . . . 0.0 109.483 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.501 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -66.09 170.94 5.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.308 -0.87 . . . . 0.0 109.289 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.501 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.26 -159.81 28.39 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.0 t -135.62 125.11 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -1.159 . . . . 0.0 109.51 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.59 HG22 ' N ' ' A' ' 56' ' ' ALA . 4.9 mt -59.11 165.5 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.938 . . . . 0.0 109.528 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.59 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -104.45 -67.19 0.91 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.46 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.533 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -169.25 140.63 2.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.227 -0.921 . . . . 0.0 109.565 -179.991 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.675 HD12 ' CH2' ' A' ' 21' ' ' TRP . 23.3 mm -93.77 138.97 19.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.233 -0.917 . . . . 0.0 109.393 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 18.0 t -89.94 -39.42 12.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.237 -0.914 . . . . 0.0 109.435 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.462 ' HD3' ' O ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -102.39 158.06 16.47 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.222 -0.924 . . . . 0.0 109.411 179.974 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -117.27 163.32 16.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.303 -0.873 . . . . 0.0 109.432 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.453 ' HG2' ' HA ' ' A' ' 20' ' ' THR . 2.3 mp0 -55.28 134.41 49.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.22 -0.925 . . . . 0.0 109.447 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 100.68 -8.29 58.12 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.691 ' O ' HG22 ' A' ' 17' ' ' THR . 0.2 OUTLIER -92.06 170.44 9.84 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.244 -1.151 . . . . 0.0 109.362 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.498 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.6 t -100.36 164.15 12.06 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.565 -0.71 . . . . 0.0 109.511 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.452 ' O ' HG23 ' A' ' 66' ' ' VAL . 22.6 m -130.83 131.08 64.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -0.905 . . . . 0.0 109.44 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -101.59 162.04 13.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -0.885 . . . . 0.0 109.541 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.1 t -59.82 110.03 1.07 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.514 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.79 20.6 16.25 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -83.71 133.91 34.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.264 -1.139 . . . . 0.0 109.499 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.464 ' CD1' ' OD2' ' A' ' 3' ' ' ASP . 9.5 tp -83.26 125.38 31.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.504 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.456 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 4.5 mt -100.0 -22.17 15.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.264 -0.897 . . . . 0.0 109.477 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.67 173.49 27.14 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.466 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 39.7 pttt -129.46 153.01 48.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -1.122 . . . . 0.0 109.493 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.48 HD12 ' HA ' ' A' ' 55' ' ' ILE . 22.9 tp -96.22 153.02 18.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -0.898 . . . . 0.0 109.464 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 8.3 m . . . . . 0 N--CA 1.491 1.601 0 O-C-N 121.289 -0.882 . . . . 0.0 109.45 179.984 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 8.5 mt . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' A' ' 4' ' ' ILE . 10.6 t0 -68.37 152.57 45.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.527 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.502 ' N ' ' OD1' ' A' ' 3' ' ' ASP . 8.2 mm -123.74 136.35 60.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.902 . . . . 0.0 109.524 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.34 172.5 12.67 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.281 -0.887 . . . . 0.0 109.447 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.475 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -69.06 158.82 85.47 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.475 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.04 114.86 3.66 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.707 2.271 . . . . 0.0 110.381 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 29.7 m -46.52 126.12 7.81 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.265 -0.897 . . . . 0.0 109.464 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.572 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 1.3 p90 -107.89 151.86 41.4 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.333 -0.854 . . . . 0.0 109.445 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.04 -169.64 0.8 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.68 2.253 . . . . 0.0 110.385 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.438 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.4 OUTLIER -66.61 -45.15 80.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.273 -0.892 . . . . 0.0 109.476 -179.984 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.6 OUTLIER -42.75 -36.85 1.57 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.373 -0.83 . . . . 0.0 109.578 -179.838 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.637 HG22 ' O ' ' A' ' 15' ' ' ASP . 18.5 mm -114.58 108.92 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.249 -0.907 . . . . 0.0 109.411 179.954 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.46 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -74.67 -1.48 21.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.217 -0.927 . . . . 0.0 109.667 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.637 ' O ' HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER 166.92 -174.12 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.917 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.463 ' C ' HG22 ' A' ' 66' ' ' VAL . . . -144.63 -165.96 11.32 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.523 ' CG2' ' O ' ' A' ' 64' ' ' ASP . 0.4 OUTLIER -149.99 128.27 12.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.293 -1.122 . . . . 0.0 109.397 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.476 HG12 ' N ' ' A' ' 19' ' ' ALA . 61.3 t -43.83 159.49 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.217 -0.927 . . . . 0.0 109.529 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.476 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -111.99 -71.02 0.78 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.253 -0.904 . . . . 0.0 109.574 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.6 m -159.28 133.12 7.43 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.264 -0.897 . . . . 0.0 109.594 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.633 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.2 m95 -89.92 85.65 6.41 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.3 -0.875 . . . . 0.0 109.486 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.604 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.4 m80 -42.86 -60.09 1.73 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.325 -0.859 . . . . 0.0 109.352 -179.864 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -105.37 155.0 19.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.231 -0.918 . . . . 0.0 109.495 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.413 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 9.6 mttt -95.01 167.26 13.29 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.361 -0.837 . . . . 0.0 109.519 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.49 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.5 Cg_endo -76.75 104.56 1.93 Allowed 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.682 2.255 . . . . 0.0 110.494 179.892 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 140.45 -9.72 2.93 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -90.63 -172.17 3.3 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -1.151 . . . . 0.0 109.514 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -101.85 149.19 24.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -0.892 . . . . 0.0 109.421 -179.951 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -130.49 162.65 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.295 -0.878 . . . . 0.0 109.444 179.895 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 6.7 tttp -133.22 142.56 48.63 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.224 -0.923 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.46 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 10.5 ttp-105 -42.92 137.45 2.35 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.285 -0.884 . . . . 0.0 109.588 -179.863 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.784 ' HA ' HD21 ' A' ' 48' ' ' LEU . 23.9 t0 72.27 52.04 0.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.256 -0.902 . . . . 0.0 109.524 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.485 ' N ' HD11 ' A' ' 48' ' ' LEU . 0.5 OUTLIER -141.44 114.58 8.67 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.274 -0.891 . . . . 0.0 109.425 -179.978 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.635 ' N ' HD12 ' A' ' 48' ' ' LEU . 54.3 tp -42.74 162.31 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.323 -0.861 . . . . 0.0 109.6 -179.937 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 1.088 HD11 ' HB2' ' A' ' 49' ' ' ALA . 4.2 mt -140.84 -42.03 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.214 -0.929 . . . . 0.0 109.536 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.639 HG12 ' HB ' ' A' ' 47' ' ' VAL . 7.2 p -158.75 139.88 4.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.319 -0.863 . . . . 0.0 109.502 179.925 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -98.62 149.97 22.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.938 . . . . 0.0 109.544 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.448 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 32.8 mm -104.46 140.79 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.288 -0.883 . . . . 0.0 109.424 -179.993 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -126.36 92.51 3.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.503 -179.975 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.44 ' OG1' ' HB ' ' A' ' 43' ' ' VAL . 3.0 p -87.81 -173.49 4.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.296 -0.878 . . . . 0.0 109.515 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 40' ' ' THR . 9.7 t0 -42.8 -61.56 1.23 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.367 -0.833 . . . . 0.0 109.626 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -141.62 33.25 1.63 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.477 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.44 ' HB ' ' OG1' ' A' ' 40' ' ' THR . 9.8 t -132.24 109.86 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.166 -0.959 . . . . 0.0 109.447 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.3 t -93.11 126.45 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.319 -0.863 . . . . 0.0 109.524 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . 0.448 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 0.3 OUTLIER -123.95 -178.27 4.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.321 -0.862 . . . . 0.0 109.477 -180.0 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.424 ' HG3' ' C ' ' A' ' 45' ' ' MET . 0.7 OUTLIER -133.77 155.17 50.27 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.256 -0.902 . . . . 0.0 109.544 179.959 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.639 ' HB ' HG12 ' A' ' 36' ' ' VAL . 35.0 t -126.84 98.19 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.332 -0.855 . . . . 0.0 109.459 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.911 HD23 ' O ' ' A' ' 49' ' ' ALA . 2.6 tt -107.67 151.44 25.65 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.888 . . . . 0.0 109.426 -179.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 1.088 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -83.76 161.12 21.09 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.205 -0.935 . . . . 0.0 109.485 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.86 17.83 23.27 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.194 -0.941 . . . . 0.0 109.396 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -178.58 173.75 1.29 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.298 -0.876 . . . . 0.0 109.494 -179.954 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -77.55 170.92 15.73 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.213 -0.929 . . . . 0.0 109.306 179.953 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.72 175.01 23.77 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.946 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.779 ' O ' HG22 ' A' ' 76' ' ' THR . 47.1 t -121.64 124.9 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.326 -1.102 . . . . 0.0 109.447 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.49 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 16.5 mm -58.22 162.36 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.256 -0.902 . . . . 0.0 109.509 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.476 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -101.67 -67.42 0.87 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.193 -0.942 . . . . 0.0 109.41 -179.965 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.486 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 2.2 mt-10 -162.46 135.09 5.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.445 -179.983 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.633 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 27.3 mm -93.17 122.23 44.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.224 -0.922 . . . . 0.0 109.409 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.5 t -89.95 -15.7 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.508 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.629 ' HB2' HD23 ' A' ' 72' ' ' LEU . 1.5 mptt -110.46 125.47 53.32 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.434 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 -92.99 173.59 7.66 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.905 . . . . 0.0 109.496 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -69.49 147.96 50.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 109.564 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.67 -8.76 76.42 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.523 ' O ' ' CG2' ' A' ' 17' ' ' THR . 0.1 OUTLIER -84.49 170.83 13.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.206 -1.173 . . . . 0.0 109.313 -179.92 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.51 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.8 t -99.9 159.29 15.18 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.511 -0.743 . . . . 0.0 109.48 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.463 HG22 ' C ' ' A' ' 16' ' ' GLY . 29.9 m -122.54 160.51 24.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.222 -0.924 . . . . 0.0 109.452 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.532 HD23 ' N ' ' A' ' 68' ' ' SER . 0.6 OUTLIER -125.36 174.54 8.09 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.179 -0.95 . . . . 0.0 109.492 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.532 ' N ' HD23 ' A' ' 67' ' ' LEU . 35.9 t -72.92 85.97 1.28 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.495 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 108.85 22.51 6.92 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -78.45 118.03 20.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -1.109 . . . . 0.0 109.459 -179.946 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.414 ' C ' HD23 ' A' ' 71' ' ' LEU . 7.6 tt -65.77 131.68 46.88 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.281 -0.887 . . . . 0.0 109.448 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.629 HD23 ' HB2' ' A' ' 60' ' ' LYS . 4.4 mt -115.86 -13.47 11.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.281 -0.887 . . . . 0.0 109.491 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.77 163.69 22.12 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.98 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 7.2 mttt -124.54 145.95 49.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.24 -1.153 . . . . 0.0 109.483 179.939 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -91.65 147.85 22.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.289 -0.882 . . . . 0.0 109.463 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.779 HG22 ' O ' ' A' ' 54' ' ' VAL . 2.9 t . . . . . 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.911 . . . . 0.0 109.787 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.4 ' HB ' ' HB3' ' A' ' 75' ' ' LEU . 20.8 mm . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -60.5 136.42 58.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.24 -0.912 . . . . 0.0 109.472 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 80.5 mt -114.47 121.3 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.181 -0.949 . . . . 0.0 109.438 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 17.3 mtpt -123.25 178.15 5.25 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.213 -0.93 . . . . 0.0 109.508 179.966 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -84.18 164.58 42.99 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.255 -0.903 . . . . 0.0 109.505 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.9 Cg_endo -77.99 117.76 4.25 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.644 2.229 . . . . 0.0 110.451 179.928 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 8' ' ' THR . 0.0 OUTLIER -53.97 136.47 41.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.241 -0.912 . . . . 0.0 109.474 179.953 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.559 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 21.8 m-85 -95.33 155.34 38.9 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.469 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.416 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.1 Cg_endo -77.99 -178.53 4.68 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.71 2.273 . . . . 0.0 110.369 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.5 ' HG3' ' N ' ' A' ' 12' ' ' SER . 16.9 pt-20 -61.64 -43.85 98.08 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.5 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.82 -72.93 0.05 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.32 -0.863 . . . . 0.0 109.631 -179.88 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.474 HG22 ' N ' ' A' ' 14' ' ' ALA . 1.8 mp -91.16 167.52 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.243 -0.911 . . . . 0.0 109.446 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.474 ' N ' HG22 ' A' ' 13' ' ' ILE . . . -142.09 44.83 1.67 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.448 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.559 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 0.3 OUTLIER 168.74 -169.91 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.3 -0.875 . . . . 0.0 109.456 179.938 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.485 ' O ' HG23 ' A' ' 65' ' ' THR . . . -168.21 -170.04 32.43 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.996 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.541 HG23 ' O ' ' A' ' 64' ' ' ASP . 29.9 m -150.07 126.69 10.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -1.146 . . . . 0.0 109.514 179.986 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.572 HG12 ' N ' ' A' ' 19' ' ' ALA . 21.8 t -51.89 169.92 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.572 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -113.85 -75.34 0.6 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.229 -0.919 . . . . 0.0 109.534 -179.936 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.524 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 23.2 m -158.38 133.54 8.58 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.221 -0.924 . . . . 0.0 109.529 -179.918 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.623 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.85 84.77 6.26 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.232 -0.917 . . . . 0.0 109.524 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.769 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.9 m80 -43.07 -67.42 0.28 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.298 -0.876 . . . . 0.0 109.35 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -89.26 -171.92 3.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.42 179.911 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.488 ' HB2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.7 164.76 40.53 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.282 -0.886 . . . . 0.0 109.445 179.974 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.488 ' HD2' ' HB2' ' A' ' 24' ' ' LYS . 34.9 Cg_endo -77.18 101.21 1.48 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.559 2.173 . . . . 0.0 110.4 179.938 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 149.75 -16.8 1.09 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.896 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -93.0 -179.03 4.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -1.152 . . . . 0.0 109.437 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.52 159.62 18.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.21 -0.931 . . . . 0.0 109.519 179.953 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.417 HG12 ' N ' ' A' ' 30' ' ' LYS . 80.5 t -143.57 156.33 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.393 -179.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.417 ' N ' HG12 ' A' ' 29' ' ' VAL . 49.1 tttt -140.79 141.92 34.74 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 30' ' ' LYS . 5.7 ttm180 -42.82 151.34 0.13 Allowed 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.356 -0.84 . . . . 0.0 109.634 -179.848 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.416 ' HA ' HD23 ' A' ' 48' ' ' LEU . 7.9 t70 68.14 40.56 2.15 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.221 -0.924 . . . . 0.0 109.465 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 34' ' ' LEU . 1.6 tt0 -140.14 111.05 6.9 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 0.0 109.467 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.769 HD21 ' NE2' ' A' ' 22' ' ' HIS . 51.2 tp -42.76 163.44 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.381 -0.825 . . . . 0.0 109.611 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.501 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 39.5 mt -147.18 -43.51 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.227 -0.921 . . . . 0.0 109.612 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.435 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 11.4 p -159.81 136.87 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.305 -0.872 . . . . 0.0 109.531 -179.925 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.543 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 3.5 m-20 -94.85 163.17 13.45 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.307 -0.871 . . . . 0.0 109.422 179.84 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.422 HD11 ' CG2' ' A' ' 47' ' ' VAL . 24.3 mt -129.33 156.87 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.119 -0.988 . . . . 0.0 109.527 -179.969 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.17 134.45 50.16 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.288 -0.882 . . . . 0.0 109.503 179.938 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.674 HG22 ' O ' ' A' ' 43' ' ' VAL . 5.6 t -124.24 -163.94 1.2 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.183 -0.948 . . . . 0.0 109.392 180.0 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.471 ' N ' HG23 ' A' ' 40' ' ' THR . 42.3 t0 -42.3 -68.87 0.16 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.247 -0.908 . . . . 0.0 109.741 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . 0.462 ' O ' HG23 ' A' ' 43' ' ' VAL . 1.4 mttp -141.84 48.34 1.61 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.192 -0.942 . . . . 0.0 109.513 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.674 ' O ' HG22 ' A' ' 40' ' ' THR . 76.4 t -156.04 119.92 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.229 -0.92 . . . . 0.0 109.428 -179.956 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.0 t -89.95 118.11 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.216 -0.928 . . . . 0.0 109.523 -179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 1.6 mtp -96.79 -170.8 2.12 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.276 -0.89 . . . . 0.0 109.437 179.945 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 5.2 pt-20 -149.15 159.6 44.1 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.287 -0.883 . . . . 0.0 109.448 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.435 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 68.0 t -130.74 108.28 15.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.263 -0.898 . . . . 0.0 109.459 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.504 ' HG ' ' N ' ' A' ' 34' ' ' LEU . 0.1 OUTLIER -93.85 172.59 8.15 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.294 -0.879 . . . . 0.0 109.537 179.962 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.465 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -76.16 136.01 39.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.278 -0.888 . . . . 0.0 109.419 -179.979 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.676 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -95.67 10.12 37.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.531 179.975 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.676 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 165.54 140.8 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.272 -0.892 . . . . 0.0 109.451 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.508 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.31 170.92 0.13 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 109.35 -179.982 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.508 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 140.29 -155.07 24.41 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 55.6 t -134.79 128.62 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.304 -1.116 . . . . 0.0 109.464 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.457 HG22 ' N ' ' A' ' 56' ' ' ALA . 17.0 mm -56.35 159.36 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.28 -0.888 . . . . 0.0 109.511 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.457 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -99.66 -65.55 0.96 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.341 -0.849 . . . . 0.0 109.535 179.975 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.487 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 6.4 tt0 -173.1 132.77 0.51 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.158 -0.963 . . . . 0.0 109.528 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.623 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 28.4 mm -91.64 125.51 44.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.886 . . . . 0.0 109.391 179.953 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 23.2 t -90.08 -39.37 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.219 -0.926 . . . . 0.0 109.449 179.974 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.471 ' HG2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -95.03 128.29 41.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.485 179.951 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 71.2 m-80 -87.91 155.98 19.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.303 -0.873 . . . . 0.0 109.446 -179.95 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.529 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -65.02 143.57 57.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.303 -0.873 . . . . 0.0 109.5 -179.937 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 97.11 -13.75 64.48 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.988 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.541 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -92.41 170.89 9.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.284 -1.127 . . . . 0.0 109.303 179.955 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.501 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 21.8 m -98.12 139.54 33.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.486 -0.759 . . . . 0.0 109.516 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.471 HG12 ' HG2' ' A' ' 60' ' ' LYS . 6.0 m -114.78 -161.95 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.289 -0.882 . . . . 0.0 109.391 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -146.62 170.84 16.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.278 -0.889 . . . . 0.0 109.49 -179.932 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 5.6 t -69.01 104.81 2.21 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.48 179.988 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 102.56 10.71 37.54 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.984 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 31.2 tp10 -72.3 125.53 27.58 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -1.132 . . . . 0.0 109.404 -179.967 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -74.58 121.42 21.56 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -0.917 . . . . 0.0 109.439 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.447 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 9.1 mt -95.85 -22.53 17.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.222 -0.923 . . . . 0.0 109.489 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 168.38 174.63 37.31 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -127.33 135.82 51.06 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.23 -1.159 . . . . 0.0 109.51 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.4 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 0.6 OUTLIER -90.05 138.23 31.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.392 -179.92 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.2 m . . . . . 0 N--CA 1.489 1.522 0 O-C-N 121.268 -0.895 . . . . 0.0 109.481 179.96 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.66 HD12 HD13 ' A' ' 75' ' ' LEU . 49.9 mt . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -75.61 118.47 18.49 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.202 -0.936 . . . . 0.0 109.43 -179.933 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.8 mt -96.04 98.73 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.275 -0.89 . . . . 0.0 109.508 179.935 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.45 ' HG3' ' HA ' ' A' ' 71' ' ' LEU . 7.5 ttpt -118.78 163.93 16.15 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -0.884 . . . . 0.0 109.487 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.539 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -65.5 160.78 57.08 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.897 . . . . 0.0 109.464 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.539 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.1 Cg_endo -78.1 129.76 9.86 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.613 2.209 . . . . 0.0 110.396 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.633 HG23 ' O ' ' A' ' 8' ' ' THR . 6.9 t -56.36 111.92 1.11 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.91 . . . . 0.0 109.445 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -74.24 126.6 88.91 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.329 -0.857 . . . . 0.0 109.345 -179.969 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.464 ' HD2' HD12 ' A' ' 13' ' ' ILE . 36.1 Cg_endo -78.42 -159.44 0.1 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.398 2.065 . . . . 0.0 110.388 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.9 mm-40 -73.36 -55.0 6.98 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.161 -0.962 . . . . 0.0 109.398 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.435 ' C ' ' O ' ' A' ' 11' ' ' GLU . 17.0 t -42.87 -45.42 4.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.358 -0.839 . . . . 0.0 109.585 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.592 HG22 ' H ' ' A' ' 15' ' ' ASP . 16.9 mt -91.3 163.61 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.293 -0.879 . . . . 0.0 109.491 -179.96 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.416 ' N ' HG22 ' A' ' 13' ' ' ILE . . . -143.89 13.37 1.68 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.306 -0.871 . . . . 0.0 109.436 -179.965 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.592 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER 172.23 -172.27 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.454 -179.968 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.42 172.45 40.19 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.497 HG23 ' O ' ' A' ' 64' ' ' ASP . 68.3 m -149.25 125.66 10.9 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.254 -1.145 . . . . 0.0 109.425 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 19' ' ' ALA . 24.9 t -50.01 169.41 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.203 -0.935 . . . . 0.0 109.515 179.946 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.58 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -112.76 -73.27 0.67 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.158 -0.964 . . . . 0.0 109.502 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.552 HG23 ' OE1' ' A' ' 62' ' ' GLU . 52.4 m -159.62 131.21 6.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.483 -179.891 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.633 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.4 m95 -89.91 84.16 6.2 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 121.261 -0.899 . . . . 0.0 109.441 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.722 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.5 m80 -42.56 -64.89 0.54 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.373 -0.829 . . . . 0.0 109.454 -179.709 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 5.7 mptt -95.15 -172.19 2.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.244 -0.91 . . . . 0.0 109.532 -179.922 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.67 168.37 17.77 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.312 -0.868 . . . . 0.0 109.452 -179.965 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.494 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.64 133.09 13.86 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 C-N-CA 122.648 2.232 . . . . 0.0 110.409 179.878 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.8 -11.47 20.82 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.917 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 53.3 mm-40 -97.13 -174.91 3.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.241 -1.152 . . . . 0.0 109.502 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.03 172.65 8.42 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.222 -0.924 . . . . 0.0 109.51 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 t -141.91 155.08 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.974 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -131.65 128.26 38.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.228 -0.92 . . . . 0.0 109.496 179.969 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 3.2 ttt-85 -42.83 137.27 2.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.394 -0.817 . . . . 0.0 109.601 -179.822 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.497 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 10.7 t0 74.97 33.27 0.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.259 -0.901 . . . . 0.0 109.427 179.955 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.488 ' C ' ' CD1' ' A' ' 48' ' ' LEU . 1.2 tt0 -124.29 115.68 21.42 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.258 -0.902 . . . . 0.0 109.503 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.722 HD21 ' NE2' ' A' ' 22' ' ' HIS . 45.0 tp -43.11 150.94 0.16 Allowed 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.231 -0.918 . . . . 0.0 109.525 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.462 HD11 ' HB2' ' A' ' 49' ' ' ALA . 13.4 mt -129.69 -46.43 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.223 -0.923 . . . . 0.0 109.588 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.515 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.7 p -162.83 142.72 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.233 -0.917 . . . . 0.0 109.461 -179.908 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.49 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 33.5 m-20 -100.73 163.03 12.51 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.284 -0.885 . . . . 0.0 109.437 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.548 HG22 ' N ' ' A' ' 39' ' ' GLU . 9.6 mt -129.33 162.86 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.174 -0.954 . . . . 0.0 109.483 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.548 ' N ' HG22 ' A' ' 38' ' ' ILE . 6.1 mm-40 -133.87 151.65 51.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 -179.978 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -140.25 -177.53 5.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.256 -0.903 . . . . 0.0 109.486 179.971 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 40' ' ' THR . 5.4 t70 -42.95 -66.47 0.37 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.326 -0.859 . . . . 0.0 109.629 -179.907 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.2 mttp -135.85 40.69 2.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.286 -0.884 . . . . 0.0 109.461 -179.974 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 52.5 t -151.49 128.18 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.273 -0.892 . . . . 0.0 109.463 -179.994 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.413 ' O ' HG13 ' A' ' 44' ' ' VAL . 9.0 p -98.58 134.41 37.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 0.0 109.442 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . 0.448 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 1.3 mtt -114.59 -172.45 2.11 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 6.1 pt-20 -154.73 164.56 38.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.254 -0.904 . . . . 0.0 109.461 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.515 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 58.2 t -134.69 103.55 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 109.442 -179.927 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.632 HD22 HD12 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -93.96 167.04 11.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.2 -0.937 . . . . 0.0 109.52 179.984 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.462 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.54 136.1 33.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.405 -179.929 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.645 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -95.87 9.9 39.03 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.162 -0.961 . . . . 0.0 109.466 -179.977 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.645 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 167.06 142.93 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.233 -0.917 . . . . 0.0 109.478 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.505 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -58.63 170.96 0.69 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.317 -0.864 . . . . 0.0 109.375 179.96 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.505 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.78 -157.43 27.27 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.928 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.7 t -128.64 127.11 66.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.25 -1.147 . . . . 0.0 109.572 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.462 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 14.4 mm -64.0 156.79 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.27 -0.894 . . . . 0.0 109.437 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -95.55 -69.57 0.75 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.21 -0.931 . . . . 0.0 109.416 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.494 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 1.2 pt-20 -172.27 142.48 1.35 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.252 -0.905 . . . . 0.0 109.449 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.633 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 24.5 mm -94.8 129.54 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.23 -0.919 . . . . 0.0 109.48 -179.977 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.1 t -90.15 -28.99 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.29 -0.881 . . . . 0.0 109.442 179.987 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.481 ' HD3' ' HG2' ' A' ' 70' ' ' GLU . 0.0 OUTLIER -109.16 131.99 54.54 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.182 -0.949 . . . . 0.0 109.529 179.926 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -85.47 155.93 21.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.165 -0.96 . . . . 0.0 109.461 179.992 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.552 ' OE1' HG23 ' A' ' 20' ' ' THR . 0.0 OUTLIER -68.29 141.51 55.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.914 . . . . 0.0 109.476 179.958 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 96.12 -11.3 67.58 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.505 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -95.95 170.9 8.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.262 -1.14 . . . . 0.0 109.327 -179.986 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.505 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 13.0 t -89.02 157.95 18.18 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.492 -0.755 . . . . 0.0 109.516 -179.992 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.687 HG11 HD21 ' A' ' 72' ' ' LEU . 1.9 m -127.21 -174.82 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.245 -0.909 . . . . 0.0 109.464 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -140.96 177.81 7.79 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.336 -0.853 . . . . 0.0 109.481 -179.957 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.4 t -69.46 124.17 23.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.489 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 75.24 21.89 77.09 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 179.951 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.481 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 42.6 tp10 -74.58 103.65 4.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.191 -1.182 . . . . 0.0 109.472 179.966 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.813 HD11 ' HG3' ' A' ' 74' ' ' LYS . 0.7 OUTLIER -60.93 105.47 0.47 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.213 -0.929 . . . . 0.0 109.438 180.0 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.687 HD21 HG11 ' A' ' 66' ' ' VAL . 1.4 mt -84.22 -11.46 56.45 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.249 -0.907 . . . . 0.0 109.503 179.94 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.77 165.39 15.82 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.536 -1.425 . . . . 0.0 109.536 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.813 ' HG3' HD11 ' A' ' 71' ' ' LEU . 29.7 mtmt -125.83 151.85 46.27 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.23 -1.159 . . . . 0.0 109.484 179.967 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.667 HD23 ' O ' ' A' ' 76' ' ' THR . 1.9 tt -98.1 152.54 19.21 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.276 -0.89 . . . . 0.0 109.496 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.667 ' O ' HD23 ' A' ' 75' ' ' LEU . 14.2 m . . . . . 0 N--CA 1.491 1.585 0 O-C-N 121.243 -0.911 . . . . 0.0 109.438 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.403 HD12 HG23 ' A' ' 2' ' ' ILE . 25.4 mm . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.464 ' HA ' ' HG2' ' A' ' 74' ' ' LYS . 11.7 t70 -89.3 129.93 35.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.192 -0.942 . . . . 0.0 109.562 179.9 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mp -104.81 128.84 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.265 -0.897 . . . . 0.0 109.469 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 48.3 mtpt -130.43 176.25 8.29 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.317 -0.864 . . . . 0.0 109.468 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.94 156.55 60.78 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.479 -179.97 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.97 134.53 13.27 Favored 'Trans proline' 0 C--N 1.308 -1.554 0 C-N-CA 122.664 2.242 . . . . 0.0 110.404 179.959 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.442 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -45.49 115.04 0.85 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.223 -0.923 . . . . 0.0 109.502 179.995 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -64.34 149.27 94.96 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.487 179.969 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.405 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -78.02 174.81 11.95 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.598 2.198 . . . . 0.0 110.402 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 12' ' ' SER . 30.5 tt0 -66.75 -55.31 15.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.313 -0.867 . . . . 0.0 109.463 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 11' ' ' GLU . 35.1 t -42.81 -40.86 3.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.361 -0.837 . . . . 0.0 109.581 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.64 HG22 ' H ' ' A' ' 15' ' ' ASP . 12.3 mm -94.35 152.4 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.266 -0.896 . . . . 0.0 109.452 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -126.43 9.29 7.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.26 -0.9 . . . . 0.0 109.497 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.64 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER 173.64 -172.03 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.206 -0.934 . . . . 0.0 109.414 -179.994 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.16 -176.09 27.88 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.988 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.566 HG22 ' O ' ' A' ' 64' ' ' ASP . 0.3 OUTLIER -150.03 128.94 12.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -1.121 . . . . 0.0 109.431 -179.961 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.572 HG12 ' N ' ' A' ' 19' ' ' ALA . 53.0 t -43.96 165.74 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.238 -0.914 . . . . 0.0 109.537 -179.943 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.58 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -117.52 -72.8 0.67 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.266 -0.896 . . . . 0.0 109.422 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 34.5 m -160.05 127.48 4.57 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.261 -0.899 . . . . 0.0 109.579 -179.977 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.629 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 33.1 m95 -89.85 87.37 6.93 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 121.207 -0.933 . . . . 0.0 109.519 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.772 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.8 m80 -42.46 -57.91 2.45 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.416 -0.803 . . . . 0.0 109.522 -179.76 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 9.3 mttp -106.19 178.94 4.41 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.218 -0.927 . . . . 0.0 109.604 -179.953 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -118.31 167.51 11.32 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.271 -0.893 . . . . 0.0 109.497 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.513 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.3 Cg_endo -76.94 136.31 16.46 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.617 2.211 . . . . 0.0 110.413 179.96 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.34 -8.77 35.51 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.518 ' O ' HG13 ' A' ' 54' ' ' VAL . 4.0 mt-10 -93.5 -175.39 3.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.227 -1.16 . . . . 0.0 109.477 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.61 147.77 27.26 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.93 . . . . 0.0 109.462 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 m -147.56 169.48 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.236 -0.915 . . . . 0.0 109.421 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.427 ' O ' ' C ' ' A' ' 31' ' ' ARG . 16.5 tttp -133.06 143.39 49.32 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.252 -0.905 . . . . 0.0 109.442 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.464 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.82 152.32 0.11 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.231 -0.918 . . . . 0.0 109.624 -179.89 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.464 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 26.0 t70 69.04 41.78 1.37 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -0.907 . . . . 0.0 109.418 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.437 ' C ' ' HG ' ' A' ' 48' ' ' LEU . 10.8 tt0 -140.97 117.42 10.8 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.325 -0.859 . . . . 0.0 109.456 179.995 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.772 HD21 ' NE2' ' A' ' 22' ' ' HIS . 48.8 tp -42.96 163.34 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.241 -0.912 . . . . 0.0 109.562 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.596 HD11 ' HB2' ' A' ' 49' ' ' ALA . 59.5 mt -149.5 -43.27 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.156 -0.965 . . . . 0.0 109.522 -179.948 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.526 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 9.3 p -157.75 143.32 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.273 -0.892 . . . . 0.0 109.51 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.58 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 3.7 m-20 -108.54 147.49 31.67 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 109.458 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.484 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 46.7 mt -103.97 150.54 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.316 -0.865 . . . . 0.0 109.434 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.669 ' HG2' HG22 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -131.79 99.46 4.77 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.942 . . . . 0.0 109.468 -179.984 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.529 ' CG2' ' HB ' ' A' ' 43' ' ' VAL . 6.6 t -93.62 -170.14 2.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.915 . . . . 0.0 109.476 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 2.6 t0 -42.5 -56.33 3.1 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.294 -0.879 . . . . 0.0 109.767 -179.923 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . 0.473 ' C ' ' CG2' ' A' ' 43' ' ' VAL . 4.1 mtmp? -148.22 49.56 1.04 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -0.884 . . . . 0.0 109.561 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.529 ' HB ' ' CG2' ' A' ' 40' ' ' THR . 1.9 t -154.34 106.44 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.254 -0.904 . . . . 0.0 109.566 179.896 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.669 HG22 ' HG2' ' A' ' 39' ' ' GLU . 94.0 t -89.95 106.63 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.412 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . 0.484 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 27.2 mtp -90.05 177.12 6.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 0.0 109.494 179.941 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -132.76 151.58 51.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.921 . . . . 0.0 109.425 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.526 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 85.7 t -127.11 107.55 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.246 -0.909 . . . . 0.0 109.456 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.703 HD12 ' HA ' ' A' ' 34' ' ' LEU . 1.1 mp -92.27 176.75 6.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.463 -179.96 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.596 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -81.9 123.78 29.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.174 -0.954 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.527 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -92.92 14.5 17.38 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.174 -0.954 . . . . 0.0 109.419 -179.922 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.527 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 174.49 124.96 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.287 -0.883 . . . . 0.0 109.411 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -59.43 170.91 0.9 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.206 -0.934 . . . . 0.0 109.298 -179.969 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.51 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 132.48 -140.56 11.93 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.968 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.65 ' H ' HG22 ' A' ' 76' ' ' THR . 46.4 t -139.12 132.12 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.16 -1.2 . . . . 0.0 109.433 179.979 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.588 HG22 ' N ' ' A' ' 56' ' ' ALA . 14.7 mm -63.69 169.57 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.271 -0.893 . . . . 0.0 109.506 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.588 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -108.52 -65.86 1.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.235 -0.916 . . . . 0.0 109.481 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.479 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -165.47 141.53 5.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.212 -0.93 . . . . 0.0 109.474 179.994 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.629 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 22.7 mm -95.04 125.59 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.192 -0.943 . . . . 0.0 109.425 179.96 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.447 ' C ' ' HE3' ' A' ' 60' ' ' LYS . 23.7 t -89.95 -15.26 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.529 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.585 ' HG2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -110.64 130.04 55.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.27 -0.894 . . . . 0.0 109.453 -179.991 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 57.9 m-80 -105.23 165.37 11.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.227 -0.921 . . . . 0.0 109.44 -179.931 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.402 ' HA ' ' HB ' ' A' ' 18' ' ' VAL . 29.6 mt-10 -67.2 136.6 55.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.538 179.931 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 95.08 2.74 62.21 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.566 ' O ' HG22 ' A' ' 17' ' ' THR . 0.1 OUTLIER -104.92 170.83 7.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.105 -1.233 . . . . 0.0 109.377 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.505 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.8 t -98.27 159.59 14.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.497 -0.752 . . . . 0.0 109.51 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.585 HG12 ' HG2' ' A' ' 60' ' ' LYS . 11.9 m -132.7 130.6 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.206 -0.934 . . . . 0.0 109.435 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -94.1 168.64 10.8 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.903 . . . . 0.0 109.509 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.442 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 44.5 t -60.75 130.25 45.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.521 179.989 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 72.74 27.44 69.12 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.999 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.533 ' HG2' ' CD ' ' A' ' 60' ' ' LYS . 0.4 OUTLIER -80.81 132.02 35.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.287 -1.125 . . . . 0.0 109.463 -179.989 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.561 ' C ' HD23 ' A' ' 71' ' ' LEU . 10.4 tt -78.31 122.09 25.28 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.294 -0.879 . . . . 0.0 109.46 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.439 ' O ' HG23 ' A' ' 58' ' ' ILE . 5.7 mt -96.9 -25.53 15.4 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.352 -0.843 . . . . 0.0 109.469 179.936 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 175.07 157.2 15.86 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.978 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.464 ' HG2' ' HA ' ' A' ' 3' ' ' ASP . 0.0 OUTLIER -113.82 159.14 20.13 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.319 -1.106 . . . . 0.0 109.481 179.982 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.456 ' HA ' HD12 ' A' ' 75' ' ' LEU . 19.7 tp -100.83 159.89 14.82 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.225 -0.922 . . . . 0.0 109.429 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.65 HG22 ' H ' ' A' ' 54' ' ' VAL . 2.9 t . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.278 -0.889 . . . . 0.0 109.703 179.971 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.623 HD12 HD22 ' A' ' 75' ' ' LEU . 8.1 mt . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 3' ' ' ASP . . . . . 0.745 ' OD1' HD12 ' A' ' 71' ' ' LEU . 11.4 t70 -75.91 127.08 32.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.46 -179.983 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 18.7 mt -103.38 126.18 57.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.271 -0.893 . . . . 0.0 109.432 -179.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -132.96 159.23 40.57 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.303 -0.873 . . . . 0.0 109.481 179.972 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.643 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -74.94 164.45 61.33 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.426 -179.94 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.643 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.3 Cg_endo -78.08 179.78 6.18 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.676 2.25 . . . . 0.0 110.382 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.87 126.55 36.07 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.206 -0.933 . . . . 0.0 109.471 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -81.61 156.08 70.8 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.257 -0.902 . . . . 0.0 109.458 -179.969 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.451 ' HD2' HD12 ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.05 173.31 14.15 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.682 2.254 . . . . 0.0 110.363 179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 12' ' ' SER . 7.8 pt-20 -65.9 -47.9 73.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.266 -0.896 . . . . 0.0 109.46 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.428 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.74 -49.37 5.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.312 -0.868 . . . . 0.0 109.617 -179.935 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.552 HG22 ' H ' ' A' ' 15' ' ' ASP . 8.7 mt -91.22 166.52 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.284 -0.885 . . . . 0.0 109.475 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.425 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -131.9 11.61 4.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.249 -0.907 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.552 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.9 OUTLIER 169.96 -171.45 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.244 -0.91 . . . . 0.0 109.4 -179.966 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.23 -163.71 9.91 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.994 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.458 ' O ' ' HB2' ' A' ' 39' ' ' GLU . 26.5 m -149.95 128.21 12.08 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -1.123 . . . . 0.0 109.424 -179.962 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.5 t -50.74 154.2 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.285 -0.885 . . . . 0.0 109.445 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.532 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -99.84 -76.84 0.54 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.161 -0.962 . . . . 0.0 109.511 179.972 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.2 m -159.89 130.16 5.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.541 -179.998 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.657 ' CH2' HD12 ' A' ' 58' ' ' ILE . 35.1 m95 -89.8 84.94 6.29 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.225 -0.922 . . . . 0.0 109.559 -179.893 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' HIS . . . . . 0.735 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.8 m80 -43.26 -61.59 1.29 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.313 -0.867 . . . . 0.0 109.335 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -94.67 -172.1 2.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.345 -0.847 . . . . 0.0 109.493 179.986 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.516 ' HD2' ' CD ' ' A' ' 25' ' ' PRO . 2.9 mmmt -130.81 163.87 45.77 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.24 -0.913 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.516 ' CD ' ' HD2' ' A' ' 24' ' ' LYS . 35.5 Cg_endo -77.48 106.43 2.21 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.562 2.175 . . . . 0.0 110.429 179.921 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 137.72 -10.28 3.7 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.939 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.1 -172.33 2.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.249 -1.148 . . . . 0.0 109.416 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -105.7 150.03 25.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.28 -0.888 . . . . 0.0 109.477 179.974 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.3 m -131.93 -170.93 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.244 -0.91 . . . . 0.0 109.459 -179.963 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.448 ' HA ' ' HB2' ' A' ' 52' ' ' ASP . 12.5 mttm -149.91 130.91 14.34 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.217 -0.927 . . . . 0.0 109.52 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.474 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 4.3 ttm105 -42.82 143.61 0.69 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.318 -0.864 . . . . 0.0 109.669 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.53 ' HA ' HD23 ' A' ' 48' ' ' LEU . 6.7 t70 73.84 38.28 0.6 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.316 -0.865 . . . . 0.0 109.476 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.434 ' O ' ' C ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -138.98 122.73 17.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.909 . . . . 0.0 109.436 179.96 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.735 HD21 ' NE2' ' A' ' 22' ' ' HIS . 36.0 tp -43.0 149.14 0.21 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.201 -0.937 . . . . 0.0 109.548 -179.939 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.492 HG13 ' HB2' ' A' ' 49' ' ' ALA . 35.4 mm -132.62 -42.86 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -0.915 . . . . 0.0 109.554 -179.921 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.488 ' O ' HG23 ' A' ' 47' ' ' VAL . 4.4 p -162.1 147.48 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.244 -0.91 . . . . 0.0 109.546 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.532 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 1.3 m-20 -107.33 154.79 20.77 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.896 . . . . 0.0 109.396 179.966 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.419 ' O ' ' HA ' ' A' ' 44' ' ' VAL . 26.8 mm -122.73 148.09 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.218 -0.926 . . . . 0.0 109.489 -179.937 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.458 ' HB2' ' O ' ' A' ' 17' ' ' THR . 0.3 OUTLIER -107.14 109.69 21.59 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.535 179.941 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 41' ' ' ASP . 35.4 p -97.27 -150.35 0.34 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.202 -0.936 . . . . 0.0 109.434 -179.949 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 3.0 t0 -42.8 -70.05 0.12 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.318 -0.863 . . . . 0.0 109.668 -179.886 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -145.1 25.19 1.42 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.222 -0.924 . . . . 0.0 109.458 179.963 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.9 t -136.53 130.66 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -0.961 . . . . 0.0 109.466 179.947 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 38' ' ' ILE . 2.1 t -90.96 109.48 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.223 -0.923 . . . . 0.0 109.512 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -79.99 163.79 23.96 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.299 -0.875 . . . . 0.0 109.507 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -108.07 145.17 34.41 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.247 -0.908 . . . . 0.0 109.43 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 36' ' ' VAL . 10.1 t -118.75 100.85 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.312 -0.868 . . . . 0.0 109.426 179.958 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.53 HD23 ' HA ' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -91.91 153.83 19.25 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.193 -0.942 . . . . 0.0 109.49 179.991 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.492 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -74.17 138.85 44.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.9 . . . . 0.0 109.49 179.983 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.58 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -88.51 13.52 11.8 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.294 -0.879 . . . . 0.0 109.505 -179.995 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.58 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 170.49 150.37 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.252 -0.905 . . . . 0.0 109.45 -179.981 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -78.6 170.99 15.78 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.317 179.994 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.51 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 149.91 -137.69 6.34 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 50.9 t -136.07 125.6 39.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -1.129 . . . . 0.0 109.465 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.464 HG22 ' N ' ' A' ' 56' ' ' ALA . 14.1 mm -64.58 161.78 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.925 . . . . 0.0 109.531 180.0 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.464 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -103.51 -67.02 0.91 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.256 -0.903 . . . . 0.0 109.466 -179.948 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.491 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 2.5 tt0 -169.83 140.59 2.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.286 -0.884 . . . . 0.0 109.463 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.657 HD12 ' CH2' ' A' ' 21' ' ' TRP . 22.5 mm -93.86 131.63 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.171 -0.956 . . . . 0.0 109.527 -179.965 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 72.0 t -89.96 -38.41 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.274 -0.892 . . . . 0.0 109.497 179.957 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.925 ' HG2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -94.77 125.21 39.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.343 -0.848 . . . . 0.0 109.424 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.47 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 28.8 m-80 -89.64 176.24 6.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.253 -0.904 . . . . 0.0 109.482 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -74.9 153.33 38.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.246 -0.909 . . . . 0.0 109.502 179.957 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.94 15.12 62.13 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.515 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -104.58 170.88 7.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.177 -1.19 . . . . 0.0 109.312 179.993 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.1 m -100.45 138.31 37.69 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.445 -0.784 . . . . 0.0 109.5 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.925 HG12 ' HG2' ' A' ' 60' ' ' LYS . 4.9 m -115.8 172.75 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.207 -0.933 . . . . 0.0 109.461 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -136.06 -173.95 3.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.255 -0.903 . . . . 0.0 109.472 179.936 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.97 149.3 48.98 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.175 -0.953 . . . . 0.0 109.464 -179.965 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 49.69 29.95 13.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.986 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.456 ' OE2' ' HD3' ' A' ' 60' ' ' LYS . 49.6 tp10 -80.55 114.27 19.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.271 -1.135 . . . . 0.0 109.495 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.745 HD12 ' OD1' ' A' ' 3' ' ' ASP . 0.5 OUTLIER -66.31 118.69 10.35 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.191 -0.943 . . . . 0.0 109.47 179.95 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 8.7 mt -87.96 -28.27 21.58 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.483 179.968 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 176.96 170.59 39.6 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -128.44 134.45 48.76 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -1.158 . . . . 0.0 109.445 180.0 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.623 HD22 HD12 ' A' ' 2' ' ' ILE . 0.5 OUTLIER -91.56 147.2 23.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -0.88 . . . . 0.0 109.414 -179.974 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.3 m . . . . . 0 N--CA 1.49 1.543 0 O-C-N 121.282 -0.886 . . . . 0.0 109.514 179.922 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.628 HD13 HD22 ' A' ' 75' ' ' LEU . 5.4 mp -134.2 115.67 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -0.908 . . . . 0.0 109.454 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' A' ' 4' ' ' ILE . 39.6 t0 -88.98 132.82 34.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.239 -0.913 . . . . 0.0 109.452 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.481 ' N ' ' OD1' ' A' ' 3' ' ' ASP . 82.2 mt -99.99 124.24 53.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.424 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 70' ' ' GLU . 2.6 mttt -122.75 175.59 6.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.209 -0.932 . . . . 0.0 109.448 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.558 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -79.68 161.38 66.9 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.883 . . . . 0.0 109.49 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.558 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.6 Cg_endo -78.06 173.8 13.42 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.638 2.225 . . . . 0.0 110.389 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.5 m -92.07 134.68 34.61 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.478 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -100.14 155.82 35.98 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 109.438 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.432 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -77.99 -159.93 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.589 2.193 . . . . 0.0 110.473 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' A' ' 12' ' ' SER . 2.5 mt-10 -78.64 -58.69 3.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 109.497 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 11' ' ' GLU . 31.1 t -42.83 -45.09 4.75 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.295 -0.878 . . . . 0.0 109.628 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.577 HG22 ' H ' ' A' ' 15' ' ' ASP . 33.7 mm -104.43 136.92 35.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.297 -0.877 . . . . 0.0 109.472 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.407 ' C ' ' OD1' ' A' ' 15' ' ' ASP . . . -119.03 16.81 13.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.233 -0.917 . . . . 0.0 109.451 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.577 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.4 OUTLIER -169.18 -170.73 1.16 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 0.0 109.438 -179.982 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.68 -170.08 16.11 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.512 ' O ' ' CB ' ' A' ' 39' ' ' GLU . 1.4 m -150.0 128.57 12.3 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.221 -1.164 . . . . 0.0 109.499 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.1 t -56.42 153.82 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.226 -0.921 . . . . 0.0 109.406 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.578 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -96.86 -72.98 0.62 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.256 -0.903 . . . . 0.0 109.546 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.7 m -160.05 132.61 6.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.22 -0.925 . . . . 0.0 109.558 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.634 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.9 83.0 6.12 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.257 -0.902 . . . . 0.0 109.528 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.703 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.0 m80 -42.85 -64.84 0.55 Allowed 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.38 -0.825 . . . . 0.0 109.441 -179.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.17 -179.25 4.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.557 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.401 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -125.84 168.48 13.84 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.249 -0.907 . . . . 0.0 109.487 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.487 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 34.9 Cg_endo -76.66 123.26 6.84 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.626 2.218 . . . . 0.0 110.398 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.3 12.64 9.61 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -118.22 -172.44 2.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.205 -1.173 . . . . 0.0 109.457 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -98.68 153.56 18.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.242 -0.911 . . . . 0.0 109.462 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.526 HG22 ' N ' ' A' ' 30' ' ' LYS . 2.8 p -138.36 162.3 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 109.48 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.526 ' N ' HG22 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -134.59 126.13 28.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.256 -0.903 . . . . 0.0 109.517 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.506 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 16.8 ttp180 -42.72 146.82 0.34 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.323 -0.861 . . . . 0.0 109.664 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.506 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 2.9 t70 75.18 33.95 0.68 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.465 ' HB2' ' O ' ' A' ' 30' ' ' LYS . 3.4 tt0 -138.83 123.6 18.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -0.912 . . . . 0.0 109.444 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.703 HD21 ' NE2' ' A' ' 22' ' ' HIS . 50.6 tp -42.98 156.97 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.273 -0.892 . . . . 0.0 109.531 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.647 HG13 ' HB2' ' A' ' 49' ' ' ALA . 35.8 mm -139.11 -38.17 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.2 -0.937 . . . . 0.0 109.651 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.438 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.5 p -166.66 139.1 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.175 -0.953 . . . . 0.0 109.527 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.578 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 1.1 m-20 -98.61 158.5 15.56 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 36.1 mt -125.01 153.63 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.532 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.512 ' CB ' ' O ' ' A' ' 17' ' ' THR . 15.0 tt0 -109.88 123.61 49.89 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.236 -0.915 . . . . 0.0 109.454 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.435 ' O ' ' C ' ' A' ' 41' ' ' ASP . 3.9 p -107.54 -162.44 0.84 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.256 -0.903 . . . . 0.0 109.475 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.435 ' C ' ' O ' ' A' ' 40' ' ' THR . 16.7 t0 -42.72 -66.7 0.34 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.33 -0.856 . . . . 0.0 109.65 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 13.3 mtpt -142.79 26.16 1.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.31 -0.869 . . . . 0.0 109.476 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 42.1 t -136.48 136.5 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.28 -0.888 . . . . 0.0 109.504 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 56.4 t -95.65 119.26 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.292 -0.88 . . . . 0.0 109.458 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 4.2 mtt -93.71 179.7 5.28 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.242 -0.911 . . . . 0.0 109.503 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -131.96 148.9 52.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.514 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.438 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 21.2 t -121.91 107.95 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.256 -0.903 . . . . 0.0 109.441 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.436 ' HG ' ' C ' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -98.16 153.11 18.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 109.494 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.647 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -76.87 143.65 39.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.26 -0.9 . . . . 0.0 109.416 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.65 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.1 OUTLIER -96.25 15.42 21.08 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.469 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.65 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 166.9 148.28 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.468 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.496 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -69.96 170.96 10.22 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.348 179.978 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.496 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 157.27 -146.61 13.92 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.6 t -135.39 124.6 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.25 -1.147 . . . . 0.0 109.506 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.4 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 12.1 mm -70.03 158.88 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.275 -0.891 . . . . 0.0 109.496 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -95.13 -64.43 1.07 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.199 -0.938 . . . . 0.0 109.457 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.487 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 11.7 pt-20 -179.17 146.32 0.29 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.461 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.634 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 30.6 mm -99.07 127.42 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.245 -0.909 . . . . 0.0 109.475 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.3 t -90.08 -29.92 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.497 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 0.2 OUTLIER -90.78 148.1 22.77 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.234 -0.916 . . . . 0.0 109.481 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.468 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 4.5 m-80 -110.45 156.31 21.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.503 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -60.6 139.19 57.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.269 -0.894 . . . . 0.0 109.526 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 90.11 4.97 71.01 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -105.76 170.7 7.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -1.186 . . . . 0.0 109.355 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 7.3 t -102.21 154.26 19.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.528 -0.732 . . . . 0.0 109.564 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.453 HG11 HD21 ' A' ' 72' ' ' LEU . 30.3 m -130.66 133.81 62.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.47 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -92.43 169.86 10.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.465 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -59.51 143.21 50.74 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.248 -0.908 . . . . 0.0 109.451 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 67.7 12.02 61.18 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.416 ' O ' ' HA ' ' A' ' 5' ' ' LYS . 5.3 tp10 -70.33 120.58 16.21 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.287 -1.125 . . . . 0.0 109.467 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.545 ' C ' HD23 ' A' ' 71' ' ' LEU . 10.0 tt -77.97 111.92 14.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.301 -0.874 . . . . 0.0 109.459 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.453 HD21 HG11 ' A' ' 66' ' ' VAL . 1.9 mt -88.3 -21.12 24.59 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.267 -0.895 . . . . 0.0 109.462 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.5 -177.17 45.23 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.459 ' NZ ' ' OE2' ' A' ' 57' ' ' GLU . 0.0 OUTLIER -139.63 153.81 47.41 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.195 -1.18 . . . . 0.0 109.52 179.963 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.628 HD22 HD13 ' A' ' 2' ' ' ILE . 0.5 OUTLIER -94.69 155.61 16.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.267 -0.896 . . . . 0.0 109.435 -179.985 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.566 HG22 ' H ' ' A' ' 77' ' ' GLU . 9.4 m -106.23 171.48 7.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.204 -0.935 . . . . 0.0 109.456 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.566 ' H ' HG22 ' A' ' 76' ' ' THR . 5.7 mt-10 -78.77 143.77 35.8 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.241 -0.912 . . . . 0.0 109.452 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -102.57 -178.11 27.14 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.31 0 CA-C-O 117.992 -1.449 . . . . 0.0 109.533 179.999 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.469 HG13 ' HB3' ' A' ' 75' ' ' LEU . 2.0 pt -137.81 173.3 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.197 -0.939 . . . . 0.0 109.526 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.41 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 20.9 t0 -120.59 136.86 54.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.281 -0.887 . . . . 0.0 109.461 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 65.8 mt -110.46 118.85 58.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.189 -0.944 . . . . 0.0 109.481 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.86 156.77 48.34 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.289 -0.882 . . . . 0.0 109.418 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.626 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -58.7 163.54 5.11 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.202 -0.936 . . . . 0.0 109.46 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.626 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.7 Cg_endo -78.06 178.16 7.92 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.618 2.212 . . . . 0.0 110.41 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.43 ' O ' ' CD1' ' A' ' 9' ' ' PHE . 0.2 OUTLIER -76.56 176.42 8.35 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.896 . . . . 0.0 109.509 -179.966 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.462 ' CE1' HG23 ' A' ' 40' ' ' THR . 23.7 m-85 -138.7 71.78 43.11 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.453 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.93 -0.14 10.38 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.636 2.224 . . . . 0.0 110.432 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.515 ' O ' ' CD1' ' A' ' 13' ' ' ILE . 5.9 mm-40 -85.33 46.46 1.29 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.394 -0.816 . . . . 0.0 109.438 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.45 ' C ' ' O ' ' A' ' 11' ' ' GLU . 6.6 t 39.25 39.21 0.41 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.528 -0.733 . . . . 0.0 110.034 179.707 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.515 ' CD1' ' O ' ' A' ' 11' ' ' GLU . 15.0 mm -98.82 156.35 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.891 . . . . 0.0 109.374 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.496 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -93.83 -1.88 54.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.19 -0.944 . . . . 0.0 109.727 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.496 ' CB ' ' O ' ' A' ' 14' ' ' ALA . 1.1 p30 163.74 -169.63 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.227 -0.921 . . . . 0.0 109.442 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.0 -169.33 11.63 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.467 HG23 ' O ' ' A' ' 64' ' ' ASP . 93.6 m -150.02 123.26 8.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.204 -1.174 . . . . 0.0 109.534 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 19' ' ' ALA . 24.2 t -51.09 169.49 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.22 -0.925 . . . . 0.0 109.482 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.579 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -112.73 -73.14 0.68 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.179 -0.951 . . . . 0.0 109.609 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.482 HG23 ' OE1' ' A' ' 62' ' ' GLU . 16.4 m -159.98 137.13 9.44 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.53 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.704 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 32.7 m95 -89.98 83.85 6.14 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.259 -0.901 . . . . 0.0 109.501 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.803 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.2 m80 -42.86 -69.82 0.13 Allowed 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.39 -0.819 . . . . 0.0 109.487 -179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.05 -171.58 2.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 109.674 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.476 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 1.8 mttt -128.8 170.76 9.93 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.227 -0.92 . . . . 0.0 109.435 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.533 ' CG ' ' HA ' ' A' ' 57' ' ' GLU . 34.8 Cg_endo -75.61 129.52 11.88 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.657 2.238 . . . . 0.0 110.39 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 120.98 -11.88 9.95 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -95.84 166.48 11.78 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.254 -1.145 . . . . 0.0 109.472 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.29 133.39 35.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -0.907 . . . . 0.0 109.411 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 52' ' ' ASP . 25.1 m -136.31 135.84 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.162 -0.961 . . . . 0.0 109.528 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 31' ' ' ARG . 9.6 pttp -117.35 146.23 43.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.88 . . . . 0.0 109.389 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.465 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 4.0 ttt180 -42.9 156.23 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.244 -0.91 . . . . 0.0 109.623 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.465 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 18.8 t70 73.34 29.21 1.69 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -0.881 . . . . 0.0 109.453 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.536 ' N ' HD23 ' A' ' 48' ' ' LEU . 30.5 tt0 -137.71 111.63 8.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.285 -0.884 . . . . 0.0 109.446 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.803 HD21 ' NE2' ' A' ' 22' ' ' HIS . 43.4 tp -42.9 153.56 0.08 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.36 -0.837 . . . . 0.0 109.595 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.607 HD13 ' O ' ' A' ' 34' ' ' LEU . 11.1 mm -139.08 -38.51 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.15 -0.969 . . . . 0.0 109.55 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.521 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 10.8 p -160.21 131.53 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.263 -0.898 . . . . 0.0 109.466 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.507 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 32.4 m-20 -92.15 157.09 16.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.918 . . . . 0.0 109.482 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.53 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 20.6 tt -127.91 162.98 32.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.325 -0.859 . . . . 0.0 109.447 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -148.76 110.65 4.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.24 -0.912 . . . . 0.0 109.434 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.462 HG23 ' CE1' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -80.73 -160.65 0.32 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.29 -0.881 . . . . 0.0 109.503 179.94 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.423 ' HB2' HD12 ' A' ' 13' ' ' ILE . 50.0 t0 -42.83 -67.64 0.26 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.293 -0.88 . . . . 0.0 109.631 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -132.02 23.22 4.55 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -0.934 . . . . 0.0 109.491 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 1.9 t -117.97 162.13 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.226 -0.921 . . . . 0.0 109.437 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.9 t -137.35 126.7 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.284 -0.885 . . . . 0.0 109.51 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . 0.53 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 1.7 mtt -123.63 -171.01 2.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.256 -0.903 . . . . 0.0 109.434 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.3 152.4 48.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.417 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.521 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 35.0 t -122.52 111.18 29.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.319 -0.863 . . . . 0.0 109.47 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.536 HD23 ' N ' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -102.02 165.78 10.98 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.281 -0.887 . . . . 0.0 109.464 -179.978 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -76.35 144.97 39.81 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.333 -0.855 . . . . 0.0 109.472 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -108.49 7.44 26.86 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.143 -0.973 . . . . 0.0 109.536 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -175.45 122.32 0.21 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.178 -0.951 . . . . 0.0 109.531 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.499 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -55.14 170.93 0.17 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.3 -0.875 . . . . 0.0 109.32 179.999 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.499 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 140.82 -139.34 9.57 Favored Glycine 0 N--CA 1.49 2.233 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 45.0 t -139.15 123.55 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -1.184 . . . . 0.0 109.429 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.561 HG22 ' N ' ' A' ' 56' ' ' ALA . 13.9 mm -65.06 167.75 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.249 -0.907 . . . . 0.0 109.537 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.561 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -101.72 -65.42 0.98 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.181 -0.95 . . . . 0.0 109.472 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.533 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -171.68 159.09 5.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.502 179.992 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.704 HG23 ' CZ2' ' A' ' 21' ' ' TRP . 74.2 mt -89.97 130.56 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.318 -0.864 . . . . 0.0 109.403 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.465 ' HB ' ' O ' ' A' ' 71' ' ' LEU . 50.0 t -89.99 -37.77 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.2 -0.938 . . . . 0.0 109.417 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.458 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -113.89 137.63 51.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.229 -0.92 . . . . 0.0 109.4 -179.989 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -79.96 156.37 27.25 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.213 -0.929 . . . . 0.0 109.443 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.525 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -70.3 142.76 52.21 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 93.99 -15.62 62.74 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.506 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -84.24 170.88 13.28 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.181 -1.188 . . . . 0.0 109.365 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.506 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 88.5 m -96.78 133.49 41.29 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.518 -0.739 . . . . 0.0 109.477 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.619 ' C ' HD12 ' A' ' 67' ' ' LEU . 6.3 m -116.68 -154.66 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.26 -0.9 . . . . 0.0 109.429 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.619 HD12 ' C ' ' A' ' 66' ' ' VAL . 2.9 mp -149.65 176.64 10.48 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.262 -0.899 . . . . 0.0 109.495 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.2 t -69.41 109.21 4.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.251 -0.905 . . . . 0.0 109.449 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.55 21.47 26.57 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.43 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 11.3 tp10 -74.0 121.05 20.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -1.133 . . . . 0.0 109.428 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.465 ' O ' ' HB ' ' A' ' 59' ' ' VAL . 25.5 tp -64.9 111.62 2.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.255 -0.903 . . . . 0.0 109.492 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 8.4 mt -95.18 -10.91 29.13 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -0.887 . . . . 0.0 109.48 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.34 163.39 21.13 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 26.4 mttt -125.41 144.71 50.39 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -1.139 . . . . 0.0 109.456 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.56 HD12 HD13 ' A' ' 55' ' ' ILE . 12.4 tp -90.0 153.51 20.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.445 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.579 HG22 ' H ' ' A' ' 77' ' ' GLU . 14.6 m -113.49 171.99 7.23 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.903 . . . . 0.0 109.489 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.579 ' H ' HG22 ' A' ' 76' ' ' THR . 1.5 mp0 -82.1 149.3 28.09 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.229 -0.919 . . . . 0.0 109.478 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -114.13 120.52 5.11 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.95 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.489 HG13 ' HB3' ' A' ' 75' ' ' LEU . 1.8 pp -146.76 126.1 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.294 -0.879 . . . . 0.0 109.509 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.455 ' OD2' HD13 ' A' ' 71' ' ' LEU . 8.3 t0 -89.72 129.28 36.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.313 -0.867 . . . . 0.0 109.483 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.609 HG23 HG11 ' A' ' 47' ' ' VAL . 87.4 mt -97.08 75.97 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.238 -0.914 . . . . 0.0 109.517 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.33 161.6 13.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.227 -0.92 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.611 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -74.51 163.11 70.54 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.216 -0.927 . . . . 0.0 109.437 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.611 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.8 Cg_endo -78.08 -179.85 5.83 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.632 2.222 . . . . 0.0 110.386 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.426 HG23 ' OG ' ' A' ' 68' ' ' SER . 3.0 m -93.82 106.99 18.93 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.297 -0.877 . . . . 0.0 109.443 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.417 ' HB3' ' HD2' ' A' ' 10' ' ' PRO . 80.9 m-85 -61.5 157.81 43.82 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.233 -0.917 . . . . 0.0 109.452 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.449 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.1 -163.08 0.2 Allowed 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.585 2.19 . . . . 0.0 110.415 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.6 OUTLIER -80.82 -59.06 2.82 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.265 -0.897 . . . . 0.0 109.436 -179.972 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 11' ' ' GLU . 35.3 t -42.82 -31.24 0.47 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.365 -0.835 . . . . 0.0 109.618 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.463 HG22 ' H ' ' A' ' 15' ' ' ASP . 24.4 mt -113.81 141.41 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.227 -0.921 . . . . 0.0 109.445 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -126.96 31.25 5.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.5 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.463 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.9 OUTLIER 174.8 -171.47 0.06 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.8 -164.71 13.82 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.471 ' HA ' ' O ' ' A' ' 64' ' ' ASP . 84.6 m -150.12 120.99 7.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.214 -1.168 . . . . 0.0 109.44 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.537 HG12 ' N ' ' A' ' 19' ' ' ALA . 60.0 t -43.79 162.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.302 -0.874 . . . . 0.0 109.487 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.537 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -108.11 -75.17 0.64 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.278 -0.889 . . . . 0.0 109.562 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.9 m -160.17 131.61 5.92 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.167 -0.958 . . . . 0.0 109.619 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.833 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 33.3 m95 -89.82 85.88 6.51 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.255 -0.903 . . . . 0.0 109.448 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.672 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.5 m80 -42.34 -69.88 0.12 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.356 -0.84 . . . . 0.0 109.654 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.69 -174.09 2.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.217 -0.927 . . . . 0.0 109.78 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.498 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -116.87 165.67 14.75 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.377 -0.827 . . . . 0.0 109.262 179.975 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.871 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.2 Cg_endo -77.18 145.43 24.38 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.552 2.168 . . . . 0.0 110.426 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.44 -8.89 60.58 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.473 ' HG2' ' O ' ' A' ' 24' ' ' LYS . 0.4 OUTLIER -94.1 176.74 6.21 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.202 -1.175 . . . . 0.0 109.453 -179.972 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.462 ' O ' ' OE1' ' A' ' 27' ' ' GLU . . . -91.37 158.4 16.55 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.291 -0.881 . . . . 0.0 109.486 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.493 HG22 ' O ' ' A' ' 53' ' ' GLY . 34.7 m -138.87 -167.53 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.257 -0.902 . . . . 0.0 109.506 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 31' ' ' ARG . 5.1 tptm -142.18 140.85 32.51 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.221 -0.925 . . . . 0.0 109.463 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.1 OUTLIER -42.84 123.48 2.74 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.311 -0.868 . . . . 0.0 109.649 -179.874 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.752 ' C ' HD21 ' A' ' 48' ' ' LEU . 6.1 t70 75.9 57.06 0.05 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.276 -0.89 . . . . 0.0 109.491 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.544 ' N ' HD21 ' A' ' 48' ' ' LEU . 0.9 OUTLIER -131.76 121.3 23.95 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.203 -0.936 . . . . 0.0 109.402 -179.934 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.672 HD21 ' NE2' ' A' ' 22' ' ' HIS . 51.3 tp -42.94 162.25 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.329 -0.857 . . . . 0.0 109.499 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.956 HD11 ' HB2' ' A' ' 49' ' ' ALA . 91.6 mt -141.52 -49.49 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.933 . . . . 0.0 109.48 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.637 HG12 ' HB ' ' A' ' 47' ' ' VAL . 7.9 p -152.25 151.93 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.915 . . . . 0.0 109.417 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.618 ' C ' HD13 ' A' ' 38' ' ' ILE . 49.8 m-20 -117.6 151.38 37.3 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.257 -0.902 . . . . 0.0 109.554 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.618 HD13 ' C ' ' A' ' 37' ' ' ASP . 3.6 mm -108.17 156.36 8.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.248 -0.907 . . . . 0.0 109.383 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -135.28 117.48 15.52 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.262 -0.899 . . . . 0.0 109.489 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.431 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -115.8 -167.48 1.27 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.229 -0.919 . . . . 0.0 109.495 -179.991 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.431 ' C ' ' O ' ' A' ' 40' ' ' THR . 53.8 t0 -42.7 -67.74 0.25 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.359 -0.838 . . . . 0.0 109.626 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 1.7 mtpp -139.16 34.25 2.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.205 -0.934 . . . . 0.0 109.468 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.4 t -135.73 107.35 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.952 . . . . 0.0 109.504 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.2 t -89.98 115.85 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . 0.466 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 4.6 mtp -99.23 178.31 4.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.302 -0.874 . . . . 0.0 109.488 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.424 ' HA ' ' OD1' ' A' ' 37' ' ' ASP . 41.0 mt-10 -138.48 169.64 17.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.205 -0.935 . . . . 0.0 109.438 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.637 ' HB ' HG12 ' A' ' 36' ' ' VAL . 97.1 t -141.92 103.09 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.224 -0.923 . . . . 0.0 109.478 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.752 HD21 ' C ' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -104.38 155.31 18.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.218 -0.927 . . . . 0.0 109.506 -179.982 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.956 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.19 165.22 18.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.515 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.694 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.8 OUTLIER -103.44 13.15 34.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.694 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.7 164.2 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.455 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.503 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -58.18 170.95 0.61 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.26 -0.9 . . . . 0.0 109.336 179.979 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.503 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 150.07 -174.64 29.45 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 69.6 t -124.86 131.18 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -1.132 . . . . 0.0 109.418 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.741 ' N ' HD13 ' A' ' 55' ' ' ILE . 1.4 mm -71.24 -176.64 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.271 -0.893 . . . . 0.0 109.486 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.789 ' HB3' ' HG2' ' A' ' 74' ' ' LYS . . . -114.01 -59.57 2.0 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.235 -0.916 . . . . 0.0 109.409 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.529 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 17.5 pt-20 -178.88 157.47 0.89 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.26 -0.9 . . . . 0.0 109.548 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.871 HD11 ' HD3' ' A' ' 25' ' ' PRO . 1.7 mp -89.96 140.88 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 109.446 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.454 ' HB ' ' O ' ' A' ' 71' ' ' LEU . 11.1 t -100.67 -15.17 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.261 -0.899 . . . . 0.0 109.366 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.488 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -126.37 -172.58 2.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.31 -0.869 . . . . 0.0 109.403 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.473 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 17.3 m-80 -132.45 164.26 26.96 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.169 -0.957 . . . . 0.0 109.509 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.01 133.41 48.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.306 -0.871 . . . . 0.0 109.408 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.05 -6.78 82.67 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -79.72 170.76 16.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.219 -1.165 . . . . 0.0 109.428 179.902 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.516 ' N ' ' OD1' ' A' ' 64' ' ' ASP . 32.3 m -98.77 138.84 35.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.547 -0.721 . . . . 0.0 109.498 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 6.2 m -122.29 170.67 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.268 -0.895 . . . . 0.0 109.455 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.478 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.1 OUTLIER -132.94 177.6 7.53 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.474 -179.98 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.426 ' OG ' HG23 ' A' ' 8' ' ' THR . 9.1 t -62.85 146.61 52.35 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.914 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 57.85 28.59 60.71 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.478 ' HB2' ' O ' ' A' ' 67' ' ' LEU . 8.0 tp10 -84.06 115.28 22.28 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.174 -1.192 . . . . 0.0 109.419 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.63 HD21 ' HD2' ' A' ' 74' ' ' LYS . 16.0 tp -72.91 106.09 4.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.262 -0.898 . . . . 0.0 109.49 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 15.7 mt -89.36 -10.91 44.87 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.224 -0.922 . . . . 0.0 109.455 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.36 164.29 22.75 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.789 ' HG2' ' HB3' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -136.12 142.9 44.29 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -1.173 . . . . 0.0 109.451 179.985 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.807 HD23 ' O ' ' A' ' 76' ' ' THR . 2.7 tt -97.44 167.99 10.66 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.239 -0.913 . . . . 0.0 109.479 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.807 ' O ' HD23 ' A' ' 75' ' ' LEU . 5.0 m -87.71 169.22 12.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.448 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.478 ' H ' HG22 ' A' ' 76' ' ' THR . 76.8 mt-10 -55.15 -54.49 42.63 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.282 -0.887 . . . . 0.0 109.487 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -148.43 -88.03 0.07 OUTLIER Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 CA-C-O 118.027 -1.429 . . . . 0.0 109.562 -179.938 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 30.3 mm -111.65 94.76 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.926 . . . . 0.0 109.486 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -66.35 127.99 34.39 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.1 mt -102.54 97.97 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.319 -0.863 . . . . 0.0 109.495 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.471 ' HG3' ' HA ' ' A' ' 71' ' ' LEU . 0.0 OUTLIER -118.76 146.9 44.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.211 -0.931 . . . . 0.0 109.461 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.43 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -61.26 157.51 43.58 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.197 -0.939 . . . . 0.0 109.494 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.43 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.6 Cg_endo -78.07 122.85 5.92 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 C-N-CA 122.581 2.188 . . . . 0.0 110.379 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.563 HG23 ' OG ' ' A' ' 68' ' ' SER . 17.5 m -44.17 108.02 0.1 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.244 -0.91 . . . . 0.0 109.454 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -71.03 147.95 94.1 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.245 -0.909 . . . . 0.0 109.501 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.579 ' HG2' HD12 ' A' ' 13' ' ' ILE . 35.5 Cg_endo -78.18 -159.44 0.1 Allowed 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.599 2.199 . . . . 0.0 110.324 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.433 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.4 OUTLIER -75.98 -52.65 9.8 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -0.899 . . . . 0.0 109.47 -179.956 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.8 t -42.82 -56.14 3.36 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.252 -0.905 . . . . 0.0 109.628 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.579 HD12 ' HG2' ' A' ' 10' ' ' PRO . 2.5 mp -89.95 111.14 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.226 -0.921 . . . . 0.0 109.452 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.466 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -88.77 10.45 20.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.204 -0.935 . . . . 0.0 109.502 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.518 ' O ' ' CG2' ' A' ' 13' ' ' ILE . 0.8 OUTLIER 166.6 -172.39 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 -179.921 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.464 ' O ' HG23 ' A' ' 65' ' ' THR . . . -154.08 -167.87 16.81 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.477 HG23 ' O ' ' A' ' 64' ' ' ASP . 90.3 m -148.21 131.94 16.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.265 -1.138 . . . . 0.0 109.463 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.504 HG12 ' N ' ' A' ' 19' ' ' ALA . 27.1 t -52.56 163.93 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.218 -0.926 . . . . 0.0 109.435 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.514 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -108.96 -76.41 0.61 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.175 -0.953 . . . . 0.0 109.442 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.4 m -160.03 131.9 6.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.248 -0.908 . . . . 0.0 109.46 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.636 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 31.9 m95 -89.87 85.43 6.38 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.26 -0.9 . . . . 0.0 109.56 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.875 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.0 m80 -42.77 -58.25 2.43 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.355 -0.841 . . . . 0.0 109.38 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -101.43 -175.04 2.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.57 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.439 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -125.65 167.82 15.57 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.344 -0.847 . . . . 0.0 109.446 179.985 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.499 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.91 118.04 4.66 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.588 2.192 . . . . 0.0 110.418 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 124.56 7.52 6.21 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.794 ' O ' HG13 ' A' ' 54' ' ' VAL . 5.2 mm-40 -113.26 -172.25 2.03 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.223 -1.163 . . . . 0.0 109.55 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.449 ' HA ' HG22 ' A' ' 54' ' ' VAL . . . -105.02 158.02 16.83 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.169 -0.957 . . . . 0.0 109.448 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -142.49 -174.35 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 0.0 109.436 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 3.7 mttp -147.67 137.54 22.77 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.491 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.434 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.1 OUTLIER -42.78 137.21 2.35 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.344 -0.847 . . . . 0.0 109.63 -179.914 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.42 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 8.2 t0 70.06 51.23 0.41 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.314 -0.866 . . . . 0.0 109.521 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.474 ' O ' HG13 ' A' ' 35' ' ' ILE . 1.8 tm-20 -140.8 120.65 13.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.185 -0.947 . . . . 0.0 109.493 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.875 HD21 ' NE2' ' A' ' 22' ' ' HIS . 35.3 tp -42.93 142.82 0.83 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.301 -0.874 . . . . 0.0 109.57 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.474 HG13 ' O ' ' A' ' 33' ' ' GLU . 12.8 mt -134.97 -43.07 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.232 -0.917 . . . . 0.0 109.598 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.468 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.4 p -158.66 142.52 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.223 -0.923 . . . . 0.0 109.508 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.514 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 55.9 m-20 -105.46 152.44 23.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.214 -0.929 . . . . 0.0 109.404 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.413 HG21 HD13 ' A' ' 38' ' ' ILE . 10.9 mt -128.81 153.84 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.211 -0.93 . . . . 0.0 109.537 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -121.74 150.94 41.1 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.233 -0.917 . . . . 0.0 109.443 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.493 HG21 ' SD ' ' A' ' 45' ' ' MET . 28.1 p -133.62 -168.37 2.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.241 -0.912 . . . . 0.0 109.491 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.411 ' C ' ' O ' ' A' ' 40' ' ' THR . 27.2 t70 -42.68 -69.25 0.14 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.348 -0.845 . . . . 0.0 109.686 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.9 mtmt -136.64 27.15 3.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.227 -0.92 . . . . 0.0 109.425 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.439 ' O ' ' OG1' ' A' ' 40' ' ' THR . 1.9 t -135.86 162.1 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.259 -0.901 . . . . 0.0 109.507 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.3 p -122.53 138.81 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.352 -0.843 . . . . 0.0 109.479 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . 0.493 ' SD ' HG21 ' A' ' 40' ' ' THR . 1.9 mpp? -127.05 101.94 6.76 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.254 -0.904 . . . . 0.0 109.453 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.462 ' HG2' ' OD1' ' A' ' 37' ' ' ASP . 15.0 mt-10 -73.9 163.81 27.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.277 -0.889 . . . . 0.0 109.475 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.468 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 71.6 t -131.04 107.69 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.281 -0.887 . . . . 0.0 109.44 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.721 HD12 ' HA ' ' A' ' 34' ' ' LEU . 1.3 mp -91.91 170.2 10.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.906 . . . . 0.0 109.536 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.442 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -71.91 124.7 25.43 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.257 -0.902 . . . . 0.0 109.458 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.701 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -82.68 6.85 16.57 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.9 . . . . 0.0 109.5 -179.947 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 163.94 141.46 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.516 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -49.01 170.97 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 109.338 -179.974 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 135.8 -155.84 22.51 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.794 HG13 ' O ' ' A' ' 27' ' ' GLU . 48.5 t -138.71 125.04 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.318 -1.107 . . . . 0.0 109.477 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.562 HG22 ' H ' ' A' ' 56' ' ' ALA . 4.6 mm -46.45 172.25 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.255 -0.903 . . . . 0.0 109.464 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.562 ' H ' HG22 ' A' ' 55' ' ' ILE . . . -110.91 -65.09 1.2 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.266 -0.896 . . . . 0.0 109.478 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.499 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -170.27 138.78 1.65 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.469 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.636 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 21.5 mm -101.38 128.53 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.245 -0.91 . . . . 0.0 109.49 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.2 t -98.06 -30.97 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.262 -0.898 . . . . 0.0 109.481 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.467 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -91.23 117.65 29.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.32 -0.862 . . . . 0.0 109.454 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 57.6 m-80 -84.06 157.23 21.85 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.311 -0.868 . . . . 0.0 109.451 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -57.19 142.44 42.78 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.26 -0.9 . . . . 0.0 109.463 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.76 11.29 68.42 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -104.69 170.92 7.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -1.125 . . . . 0.0 109.292 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 52.0 m -107.52 146.95 31.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.45 -0.781 . . . . 0.0 109.465 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.733 HG11 HD21 ' A' ' 72' ' ' LEU . 7.1 m -124.59 139.82 49.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.237 -0.914 . . . . 0.0 109.49 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -101.06 -175.55 2.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.316 -0.865 . . . . 0.0 109.436 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.563 ' OG ' HG23 ' A' ' 8' ' ' THR . 1.5 t -64.47 122.22 16.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.266 -0.897 . . . . 0.0 109.496 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.51 31.28 41.69 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -83.84 104.56 14.03 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.187 -1.184 . . . . 0.0 109.484 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.471 ' HA ' ' HG3' ' A' ' 5' ' ' LYS . 1.0 OUTLIER -66.4 120.28 13.06 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -0.912 . . . . 0.0 109.487 179.966 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.733 HD21 HG11 ' A' ' 66' ' ' VAL . 1.0 OUTLIER -95.81 -18.92 20.02 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.283 -0.886 . . . . 0.0 109.495 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.77 -179.64 41.0 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' A' ' 56' ' ' ALA . 2.1 mtmt -140.58 152.44 45.48 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.295 -1.12 . . . . 0.0 109.484 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -92.61 151.34 20.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.425 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.58 HG22 ' H ' ' A' ' 77' ' ' GLU . 8.6 m -98.77 172.21 7.6 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.899 . . . . 0.0 109.434 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.58 ' H ' HG22 ' A' ' 76' ' ' THR . 5.5 mt-10 -74.49 -169.42 0.83 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.236 -0.915 . . . . 0.0 109.511 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 144.29 89.75 0.11 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.242 0 CA-C-O 118.025 -1.431 . . . . 0.0 109.55 -179.983 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.8 pt -131.99 176.59 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.235 -0.916 . . . . 0.0 109.482 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.447 ' OD2' ' HB3' ' A' ' 5' ' ' LYS . 29.5 t70 -117.47 135.92 53.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.23 -0.919 . . . . 0.0 109.432 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.495 ' O ' HG22 ' A' ' 4' ' ' ILE . 91.3 mt -99.47 73.08 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.216 -0.928 . . . . 0.0 109.517 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.447 ' HB3' ' OD2' ' A' ' 3' ' ' ASP . 0.9 OUTLIER -104.77 159.31 15.88 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.228 -0.92 . . . . 0.0 109.445 179.963 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.46 147.69 75.86 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.21 -0.931 . . . . 0.0 109.436 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.21 160.82 29.47 Favored 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.608 2.206 . . . . 0.0 110.379 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 9' ' ' PHE . 27.2 m -71.6 89.38 0.98 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.327 -0.858 . . . . 0.0 109.48 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.471 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 31.4 m-85 -44.07 147.98 0.86 Allowed Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.298 -0.876 . . . . 0.0 109.444 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 9' ' ' PHE . 35.8 Cg_endo -78.06 -159.96 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.691 2.261 . . . . 0.0 110.415 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 12' ' ' SER . 46.7 tt0 -77.38 -58.41 3.29 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.215 -0.928 . . . . 0.0 109.401 -179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.8 t -42.8 -55.71 3.53 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.273 -0.892 . . . . 0.0 109.693 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.512 HG22 ' H ' ' A' ' 15' ' ' ASP . 3.5 mt -91.45 134.08 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.251 -0.905 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.18 11.3 16.25 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.242 -0.911 . . . . 0.0 109.486 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.512 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 171.31 -171.15 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.182 -0.949 . . . . 0.0 109.477 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.76 -167.3 17.77 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.526 HG23 ' O ' ' A' ' 64' ' ' ASP . 94.6 m -150.0 125.83 10.46 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -1.156 . . . . 0.0 109.483 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.468 HG12 ' N ' ' A' ' 19' ' ' ALA . 47.0 t -45.26 160.07 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 109.454 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.608 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -106.16 -73.06 0.69 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.186 -0.946 . . . . 0.0 109.51 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.1 m -160.08 131.89 6.12 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.237 -0.914 . . . . 0.0 109.521 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.635 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.4 m95 -89.87 85.57 6.42 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 121.279 -0.888 . . . . 0.0 109.545 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.656 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.0 m80 -43.26 -62.21 1.12 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.32 -0.863 . . . . 0.0 109.392 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -100.58 176.66 5.25 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.929 . . . . 0.0 109.506 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.16 167.46 11.33 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.427 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.479 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.92 108.94 2.75 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.689 2.259 . . . . 0.0 110.422 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 139.01 -10.22 3.33 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.433 ' O ' HG13 ' A' ' 54' ' ' VAL . 1.4 mt-10 -97.48 -172.22 2.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.29 -1.123 . . . . 0.0 109.541 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -106.76 154.66 20.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.299 -0.875 . . . . 0.0 109.498 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.869 HG21 HD11 ' A' ' 35' ' ' ILE . 8.4 p -139.58 148.94 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.499 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -114.58 137.69 51.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.151 -0.968 . . . . 0.0 109.504 -179.972 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.461 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 29.5 ttt85 -42.73 150.03 0.17 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.331 -0.855 . . . . 0.0 109.663 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.683 ' HA ' HD21 ' A' ' 48' ' ' LEU . 8.5 t70 72.3 41.14 0.63 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.48 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.439 ' O ' ' O ' ' A' ' 34' ' ' LEU . 2.4 tp10 -141.94 124.23 15.61 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.147 -0.97 . . . . 0.0 109.448 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.656 HD21 ' NE2' ' A' ' 22' ' ' HIS . 45.7 tp -43.16 164.69 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.346 -0.846 . . . . 0.0 109.482 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.869 HD11 HG21 ' A' ' 29' ' ' VAL . 27.4 mm -139.52 -46.07 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.109 -0.994 . . . . 0.0 109.579 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.458 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.6 p -166.3 137.25 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.262 -0.899 . . . . 0.0 109.473 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.608 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 16.9 m-20 -97.96 152.67 19.01 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.253 -0.904 . . . . 0.0 109.44 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.485 HD13 ' O ' ' A' ' 37' ' ' ASP . 6.0 mm -119.52 156.15 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.461 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.47 ' HB2' ' O ' ' A' ' 17' ' ' THR . 1.1 mm-40 -118.23 128.91 55.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.425 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.1 OUTLIER -109.87 -161.23 0.75 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.266 -0.896 . . . . 0.0 109.429 179.992 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.425 ' C ' ' O ' ' A' ' 40' ' ' THR . 13.6 t0 -42.8 -71.01 0.09 Allowed 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.342 -0.849 . . . . 0.0 109.681 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.5 mmtm -137.29 28.24 2.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.274 -0.891 . . . . 0.0 109.475 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 44' ' ' VAL . 24.6 t -128.43 169.32 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.24 -0.913 . . . . 0.0 109.51 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.579 ' N ' HG12 ' A' ' 43' ' ' VAL . 7.5 p -129.66 122.43 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.302 -0.874 . . . . 0.0 109.457 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 87.2 mmm -103.89 176.51 5.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 0.0 109.476 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -136.21 153.15 51.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.215 -0.928 . . . . 0.0 109.543 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.458 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 45.8 t -125.09 102.58 10.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.336 -0.853 . . . . 0.0 109.454 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.683 HD21 ' HA ' ' A' ' 32' ' ' ASP . 0.5 OUTLIER -96.41 150.21 20.85 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.214 -0.929 . . . . 0.0 109.44 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.436 ' O ' HD23 ' A' ' 48' ' ' LEU . . . -78.8 137.71 37.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.469 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -101.33 19.96 16.75 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.332 -0.855 . . . . 0.0 109.496 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -176.57 134.61 0.23 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.244 -0.91 . . . . 0.0 109.5 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.5 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -62.75 170.94 2.31 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.263 -0.898 . . . . 0.0 109.377 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.5 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 146.71 -151.74 23.97 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 27' ' ' GLU . 71.4 t -134.28 130.63 54.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -1.149 . . . . 0.0 109.425 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.492 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.1 mt -52.15 160.5 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.338 -0.851 . . . . 0.0 109.524 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.492 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -97.69 -68.79 0.78 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.142 -0.974 . . . . 0.0 109.444 -179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.479 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 1.5 mt-10 -176.02 133.08 0.25 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.293 -0.879 . . . . 0.0 109.495 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.635 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 20.1 mm -95.33 125.22 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.309 -0.869 . . . . 0.0 109.47 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 44.3 t -89.91 -29.75 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.912 . . . . 0.0 109.425 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.521 ' CG ' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -90.0 162.72 15.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -0.912 . . . . 0.0 109.424 -179.986 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.475 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 13.7 m-80 -117.08 157.57 25.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.212 -0.93 . . . . 0.0 109.5 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -61.14 134.61 57.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.21 -0.931 . . . . 0.0 109.443 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 94.15 -7.05 72.65 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.526 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -86.06 170.71 11.99 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -1.145 . . . . 0.0 109.301 -179.996 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.502 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 9.6 t -99.58 163.09 12.65 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.536 -0.728 . . . . 0.0 109.521 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 5.7 m -127.02 144.32 37.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.199 -0.938 . . . . 0.0 109.468 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -107.1 167.81 9.65 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.216 -0.928 . . . . 0.0 109.54 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.6 t -67.44 101.83 1.03 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.311 -0.868 . . . . 0.0 109.458 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 107.47 13.2 21.36 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.425 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 46.9 tp10 -81.13 123.84 28.75 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.261 -1.14 . . . . 0.0 109.522 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 5.8 tt -81.88 114.22 20.34 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.184 -0.947 . . . . 0.0 109.517 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 22.3 mt -89.32 -20.02 24.56 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.17 -0.956 . . . . 0.0 109.495 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 161.29 179.96 36.34 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.474 ' HG2' ' HB3' ' A' ' 56' ' ' ALA . 0.6 OUTLIER -149.74 153.04 36.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -1.175 . . . . 0.0 109.458 -179.968 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.468 ' HG ' ' N ' ' A' ' 76' ' ' THR . 17.0 tp -90.26 153.17 20.67 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.315 -0.866 . . . . 0.0 109.47 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.525 HG22 ' H ' ' A' ' 77' ' ' GLU . 5.6 m -91.52 170.66 9.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.311 -0.868 . . . . 0.0 109.46 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.525 ' H ' HG22 ' A' ' 76' ' ' THR . 4.6 mt-10 -69.27 178.82 2.2 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.294 -0.879 . . . . 0.0 109.453 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.36 -44.99 0.85 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.3 0 CA-C-O 117.979 -1.456 . . . . 0.0 109.544 -179.973 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.529 HD13 HD22 ' A' ' 75' ' ' LEU . 3.3 mp -125.68 91.96 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.157 -0.965 . . . . 0.0 109.45 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -60.81 130.77 48.15 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.272 -0.893 . . . . 0.0 109.502 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.651 HD12 ' HA ' ' A' ' 74' ' ' LYS . 2.7 mp -100.29 110.61 27.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.195 -0.941 . . . . 0.0 109.472 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.7 pttp -120.17 166.82 12.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.198 -0.939 . . . . 0.0 109.478 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.655 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -84.99 164.46 41.59 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.265 -0.897 . . . . 0.0 109.487 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.655 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.3 Cg_endo -78.02 153.54 28.84 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.625 2.217 . . . . 0.0 110.455 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.468 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 41.2 m -75.75 110.49 10.22 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.933 . . . . 0.0 109.455 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -69.92 153.31 95.56 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.205 -0.934 . . . . 0.0 109.482 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.11 176.74 9.61 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 C-N-CA 122.656 2.237 . . . . 0.0 110.453 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.533 ' HG3' ' N ' ' A' ' 12' ' ' SER . 22.5 pt-20 -65.24 -45.44 84.59 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.287 -0.883 . . . . 0.0 109.469 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.533 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 1.5 t -42.61 -40.12 2.59 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.379 -0.826 . . . . 0.0 109.699 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.704 HG22 ' H ' ' A' ' 15' ' ' ASP . 30.0 mm -108.11 154.05 9.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.259 -0.901 . . . . 0.0 109.453 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -118.18 0.16 11.7 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.235 -0.916 . . . . 0.0 109.611 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.704 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER 179.23 -174.45 0.21 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.189 -0.945 . . . . 0.0 109.506 -179.995 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -150.92 -160.56 9.47 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.543 HG23 ' O ' ' A' ' 64' ' ' ASP . 16.8 m -150.02 129.04 12.62 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.236 -1.155 . . . . 0.0 109.418 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.513 HG12 ' N ' ' A' ' 19' ' ' ALA . 60.8 t -44.45 161.26 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.398 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.627 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -106.65 -75.13 0.64 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.247 -0.908 . . . . 0.0 109.515 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.6 m -160.13 131.42 5.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.234 -0.917 . . . . 0.0 109.558 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.637 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.82 85.88 6.51 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.337 -0.852 . . . . 0.0 109.53 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.625 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 2.7 m80 -42.12 -69.02 0.15 Allowed 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.355 -0.841 . . . . 0.0 109.483 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -96.93 -177.24 3.81 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.215 -0.928 . . . . 0.0 109.628 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.44 ' CG ' ' HD2' ' A' ' 25' ' ' PRO . 4.5 mttp -122.76 169.4 9.9 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.292 -0.88 . . . . 0.0 109.453 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.508 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.1 Cg_endo -76.23 136.43 17.97 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.626 2.217 . . . . 0.0 110.416 179.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.73 14.07 35.69 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -112.5 -172.3 2.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -1.119 . . . . 0.0 109.508 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.75 138.93 31.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.346 -0.846 . . . . 0.0 109.456 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.9 t -118.5 141.76 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.406 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 8.8 ttpt -131.86 127.03 35.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.296 -0.878 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.534 ' CG ' ' HA ' ' A' ' 51' ' ' ALA . 0.2 OUTLIER -42.75 147.24 0.31 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.374 -0.829 . . . . 0.0 109.63 -179.889 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.484 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 11.8 t0 73.4 26.41 2.02 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -0.888 . . . . 0.0 109.463 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.427 ' O ' ' O ' ' A' ' 34' ' ' LEU . 12.5 tm-20 -126.8 110.24 12.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.363 -0.836 . . . . 0.0 109.474 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.625 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 47.4 tp -42.98 164.23 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.321 -0.862 . . . . 0.0 109.597 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.84 HD11 ' HB2' ' A' ' 49' ' ' ALA . 27.4 mt -138.18 -47.72 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.27 -0.894 . . . . 0.0 109.606 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.534 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 12.6 p -150.61 152.78 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.236 -0.915 . . . . 0.0 109.51 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.627 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 23.3 m-20 -113.99 150.63 33.56 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.27 -0.894 . . . . 0.0 109.461 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.534 HD11 ' CG2' ' A' ' 47' ' ' VAL . 3.3 mt -115.27 145.09 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.263 -0.898 . . . . 0.0 109.489 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -118.59 143.91 46.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.209 -0.932 . . . . 0.0 109.423 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.541 HG22 ' N ' ' A' ' 41' ' ' ASP . 55.7 m -134.96 165.35 25.54 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.199 -0.938 . . . . 0.0 109.422 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.541 ' N ' HG22 ' A' ' 40' ' ' THR . 45.0 t0 -42.79 -36.14 1.37 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.869 . . . . 0.0 109.639 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 20.3 mttp -158.48 28.91 0.24 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.277 -0.89 . . . . 0.0 109.503 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.464 ' O ' ' HB ' ' A' ' 40' ' ' THR . 7.6 t -142.05 117.79 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.501 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -107.04 124.86 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.251 -0.906 . . . . 0.0 109.461 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 4.0 mtp -117.2 -174.59 2.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.236 -0.915 . . . . 0.0 109.478 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -140.89 168.86 18.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.232 -0.918 . . . . 0.0 109.502 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.534 ' CG2' HD11 ' A' ' 38' ' ' ILE . 53.0 t -142.03 102.98 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.242 -0.912 . . . . 0.0 109.521 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.774 ' N ' HD23 ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.46 166.49 10.51 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.192 -0.943 . . . . 0.0 109.418 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.84 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -83.52 157.57 22.32 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.918 . . . . 0.0 109.48 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.546 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 1.8 mm-40 -104.07 7.17 36.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.571 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.546 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 173.18 161.76 0.13 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.959 . . . . 0.0 109.51 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.514 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -59.99 171.0 1.04 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.218 -0.926 . . . . 0.0 109.322 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.514 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.19 -163.9 28.93 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' A' ' 55' ' ' ILE . 40.5 t -133.8 119.6 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.257 -1.143 . . . . 0.0 109.527 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.631 HG22 ' H ' ' A' ' 56' ' ' ALA . 2.3 mp -47.02 174.45 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.384 -0.823 . . . . 0.0 109.755 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.631 ' H ' HG22 ' A' ' 55' ' ' ILE . . . -111.99 -60.86 1.8 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.159 -0.963 . . . . 0.0 109.458 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 177.45 138.0 0.07 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.499 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.637 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.1 mm -95.14 128.48 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.337 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 83.7 t -90.04 -33.52 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.196 -0.94 . . . . 0.0 109.518 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.604 ' HZ2' HD23 ' A' ' 72' ' ' LEU . 1.0 OUTLIER -97.83 145.96 25.89 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.2 -0.937 . . . . 0.0 109.497 -179.928 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.403 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 7.1 m-80 -109.72 169.44 8.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.293 -0.879 . . . . 0.0 109.435 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -64.26 150.62 45.59 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.193 -0.942 . . . . 0.0 109.56 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.68 5.59 86.43 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.543 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -105.17 170.85 7.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.115 -1.226 . . . . 0.0 109.26 -179.991 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.507 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 9.8 t -99.35 153.77 18.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.607 -0.683 . . . . 0.0 109.467 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.458 HG12 ' HD2' ' A' ' 60' ' ' LYS . 28.5 m -124.75 136.82 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.233 -0.917 . . . . 0.0 109.472 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.455 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.1 OUTLIER -92.84 163.2 13.8 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.263 -0.898 . . . . 0.0 109.412 179.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.468 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 33.1 t -55.7 123.02 12.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 109.469 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 67.46 35.83 87.64 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.501 ' CG ' ' HE2' ' A' ' 60' ' ' LYS . 8.4 tp10 -79.91 136.91 36.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.259 -1.142 . . . . 0.0 109.442 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.562 ' C ' HD23 ' A' ' 71' ' ' LEU . 9.0 tt -77.88 117.72 19.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.279 -0.888 . . . . 0.0 109.432 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.604 HD23 ' HZ2' ' A' ' 60' ' ' LYS . 0.4 OUTLIER -99.41 -14.89 18.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.871 . . . . 0.0 109.397 179.972 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 160.14 -169.49 36.03 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.651 ' HA ' HD12 ' A' ' 4' ' ' ILE . 4.7 ptmt -150.1 152.82 35.38 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -1.154 . . . . 0.0 109.466 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.692 HD23 ' O ' ' A' ' 76' ' ' THR . 0.5 OUTLIER -104.15 156.51 17.82 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.466 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.692 ' O ' HD23 ' A' ' 75' ' ' LEU . 5.9 m -93.75 169.52 10.25 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.321 -0.862 . . . . 0.0 109.49 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.499 ' H ' HG22 ' A' ' 76' ' ' THR . 84.4 mt-10 -54.69 134.49 47.31 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.244 -0.91 . . . . 0.0 109.457 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -83.07 131.91 10.71 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.453 ' O ' ' OD1' ' A' ' 52' ' ' ASP . . . . . . . . 0 N--CA 1.491 2.305 0 CA-C-O 118.0 -1.444 . . . . 0.0 109.561 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.704 ' O ' HD13 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.704 HD13 ' O ' ' A' ' 1' ' ' ALA . 4.7 mm -128.99 170.13 19.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.149 -0.969 . . . . 0.0 109.462 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.436 ' H ' HG22 ' A' ' 2' ' ' ILE . 27.2 t0 -114.87 137.9 51.42 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.249 -0.907 . . . . 0.0 109.536 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.415 ' CG2' HG11 ' A' ' 47' ' ' VAL . 2.9 mt -105.78 72.67 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.434 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.413 ' HD2' ' OD2' ' A' ' 3' ' ' ASP . 1.3 ptmt -102.85 149.8 24.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.27 -0.894 . . . . 0.0 109.421 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.464 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -61.63 158.55 39.86 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.292 -0.88 . . . . 0.0 109.534 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.464 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.4 Cg_endo -78.0 -178.96 5.0 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.676 2.251 . . . . 0.0 110.405 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 60.6 m -92.74 129.3 38.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.453 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -81.1 148.96 65.34 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.192 -0.943 . . . . 0.0 109.453 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.02 -165.99 0.37 Allowed 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.659 2.239 . . . . 0.0 110.393 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.426 ' HG3' ' N ' ' A' ' 12' ' ' SER . 12.7 pt-20 -73.69 -41.67 62.31 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.267 -0.896 . . . . 0.0 109.525 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.426 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 38.4 t -42.89 -72.95 0.05 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.367 -0.833 . . . . 0.0 109.634 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.665 HG21 HG22 ' A' ' 40' ' ' THR . 1.8 mp -90.71 150.57 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.522 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -121.29 31.48 6.32 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.212 -0.93 . . . . 0.0 109.514 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -177.33 -171.84 0.35 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.925 . . . . 0.0 109.439 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.75 ' HA2' HG23 ' A' ' 40' ' ' THR . . . -154.63 175.59 32.69 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.518 ' O ' ' CG ' ' A' ' 39' ' ' GLU . 98.1 m -150.07 114.97 5.33 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.144 -1.21 . . . . 0.0 109.527 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.593 HG12 ' N ' ' A' ' 19' ' ' ALA . 40.2 t -46.0 168.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.313 -0.867 . . . . 0.0 109.477 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.601 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -113.22 -71.08 0.77 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.254 -0.904 . . . . 0.0 109.58 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.49 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 20.7 m -160.03 134.75 7.73 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.197 -0.939 . . . . 0.0 109.572 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.626 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.5 m95 -89.89 84.01 6.2 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.26 -0.9 . . . . 0.0 109.505 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.629 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -42.72 -70.12 0.12 Allowed 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.39 -0.819 . . . . 0.0 109.469 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 7.6 mmtt -89.5 -172.2 3.5 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.61 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.491 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 8.2 mttp -136.66 165.24 36.75 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.27 -0.894 . . . . 0.0 109.247 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.534 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -77.21 114.44 3.77 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.553 2.169 . . . . 0.0 110.383 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 135.23 -9.9 4.42 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -100.21 -172.36 2.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.235 -1.156 . . . . 0.0 109.487 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.83 170.47 11.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.293 -0.879 . . . . 0.0 109.484 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.448 ' HB ' ' O ' ' A' ' 53' ' ' GLY . 52.2 t -142.08 148.27 20.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.212 -0.93 . . . . 0.0 109.482 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.2 OUTLIER -135.38 136.01 41.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.259 -0.901 . . . . 0.0 109.479 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.464 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 15.7 ttp180 -42.87 145.38 0.47 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.29 -0.881 . . . . 0.0 109.733 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.464 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 54.9 t0 67.45 48.11 1.17 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.285 -0.884 . . . . 0.0 109.477 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' A' ' 34' ' ' LEU . 1.2 tp10 -137.57 105.95 5.79 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.216 -0.927 . . . . 0.0 109.508 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.629 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 42.7 tp -43.13 164.89 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.302 -0.874 . . . . 0.0 109.537 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.91 HD11 ' HB2' ' A' ' 49' ' ' ALA . 49.3 mt -142.56 -47.64 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.245 -0.909 . . . . 0.0 109.615 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.527 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.9 p -151.47 134.98 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.168 -0.957 . . . . 0.0 109.552 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.601 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 6.4 m-20 -95.59 163.86 13.03 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.31 -0.868 . . . . 0.0 109.427 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.437 HD11 ' CG2' ' A' ' 47' ' ' VAL . 21.6 mt -134.0 152.8 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.185 -0.947 . . . . 0.0 109.399 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 17' ' ' THR . 10.9 pt-20 -146.43 144.56 29.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.204 -0.935 . . . . 0.0 109.557 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.75 HG23 ' HA2' ' A' ' 16' ' ' GLY . 0.2 OUTLIER -140.28 -172.04 3.33 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.281 -0.887 . . . . 0.0 109.481 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.58 ' H ' HG22 ' A' ' 40' ' ' THR . 3.0 t70 -42.89 -64.15 0.67 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.354 -0.841 . . . . 0.0 109.66 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.65 44.13 1.96 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.428 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 2.8 t -148.22 104.28 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.26 -0.9 . . . . 0.0 109.497 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.435 ' O ' ' HG2' ' A' ' 45' ' ' MET . 62.1 t -98.04 143.43 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.242 -0.911 . . . . 0.0 109.535 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . 0.435 ' HG2' ' O ' ' A' ' 44' ' ' VAL . 2.7 mmt -143.52 -178.89 6.11 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.227 -0.921 . . . . 0.0 109.489 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -141.33 165.68 26.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.176 -0.953 . . . . 0.0 109.512 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.527 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 18.1 t -137.35 98.36 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.232 -0.918 . . . . 0.0 109.467 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.762 ' N ' HD23 ' A' ' 48' ' ' LEU . 0.1 OUTLIER -103.18 160.58 14.53 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 121.227 -0.92 . . . . 0.0 109.371 179.943 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.91 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -77.9 132.63 38.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.459 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.433 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.2 OUTLIER -86.28 12.4 10.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.221 -0.924 . . . . 0.0 109.489 -179.974 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.433 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 178.86 155.12 0.43 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.295 -0.878 . . . . 0.0 109.446 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.499 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -65.97 170.94 4.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.178 -0.952 . . . . 0.0 109.392 179.94 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.499 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 149.9 -153.99 25.43 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.4 ' O ' ' HB ' ' A' ' 76' ' ' THR . 49.6 t -135.19 126.27 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -1.129 . . . . 0.0 109.45 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.573 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.1 mt -56.21 164.39 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.193 -0.942 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.573 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -105.08 -63.69 1.2 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.531 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.534 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 1.1 pt-20 -179.24 144.09 0.22 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.248 -0.907 . . . . 0.0 109.465 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.626 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 24.5 mm -105.3 123.91 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.279 -0.888 . . . . 0.0 109.503 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.0 t -89.91 -19.88 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.251 -0.905 . . . . 0.0 109.546 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.491 ' HG3' ' OD1' ' A' ' 64' ' ' ASP . 3.9 tptt -115.97 129.9 56.59 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.239 -0.913 . . . . 0.0 109.51 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 14.9 m-80 -87.62 157.03 19.22 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 0.0 109.454 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.525 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -60.66 151.81 28.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.31 -10.49 68.86 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.514 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -88.63 171.02 10.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -1.164 . . . . 0.0 109.321 -179.97 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.514 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 97.9 m -91.51 147.18 23.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.518 -0.739 . . . . 0.0 109.482 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 17.1 m -120.04 178.73 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.281 -0.887 . . . . 0.0 109.405 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -130.33 162.69 28.48 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.915 . . . . 0.0 109.466 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -65.16 97.22 0.24 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.225 -0.922 . . . . 0.0 109.441 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.77 27.74 7.78 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.504 -1.439 . . . . 0.0 109.504 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -84.08 132.06 34.74 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.201 -1.176 . . . . 0.0 109.49 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.404 ' C ' HD23 ' A' ' 71' ' ' LEU . 8.4 tt -78.9 114.98 18.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -0.924 . . . . 0.0 109.464 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.473 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 5.1 mt -91.24 -22.15 20.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.322 -0.861 . . . . 0.0 109.466 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 170.85 177.03 40.52 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.409 ' O ' ' CB ' ' A' ' 56' ' ' ALA . 12.5 mttt -124.94 138.36 54.24 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.3 -1.117 . . . . 0.0 109.492 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -94.71 144.16 25.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.499 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.564 HG22 ' H ' ' A' ' 77' ' ' GLU . 10.8 m -107.59 171.75 7.21 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.207 -0.933 . . . . 0.0 109.464 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.564 ' H ' HG22 ' A' ' 76' ' ' THR . 1.2 mt-10 -84.72 -168.67 2.29 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.223 -0.923 . . . . 0.0 109.4 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.442 ' HA3' ' HA2' ' A' ' 53' ' ' GLY . . . -160.58 75.29 0.19 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 CA-C-O 118.0 -1.444 . . . . 0.0 109.513 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.3 mt -122.69 101.9 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 109.493 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.404 ' OD2' ' HE3' ' A' ' 74' ' ' LYS . 46.2 t0 -72.71 127.7 33.34 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.296 -0.877 . . . . 0.0 109.513 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.578 ' O ' HG22 ' A' ' 4' ' ' ILE . 60.7 mt -95.63 80.28 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.33 -0.857 . . . . 0.0 109.504 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.421 ' O ' ' HG3' ' A' ' 5' ' ' LYS . 0.2 OUTLIER -100.14 145.94 27.4 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.537 179.971 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.597 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -52.15 162.9 0.77 Allowed Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.227 -0.921 . . . . 0.0 109.451 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.597 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 36.2 Cg_endo -77.95 162.81 28.99 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.642 2.228 . . . . 0.0 110.484 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.547 HG23 ' O ' ' A' ' 8' ' ' THR . 2.5 t -82.95 105.74 14.2 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.186 -0.947 . . . . 0.0 109.436 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.415 ' HB3' ' HB ' ' A' ' 13' ' ' ILE . 10.8 m-85 -72.4 150.72 91.76 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.187 -0.946 . . . . 0.0 109.492 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.612 ' HD2' HD12 ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.07 176.34 10.09 Favored 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.6 2.2 . . . . 0.0 110.42 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.436 ' O ' ' C ' ' A' ' 12' ' ' SER . 2.1 mt-10 -56.64 -50.98 70.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.309 -0.869 . . . . 0.0 109.441 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 11' ' ' GLU . 7.3 t -42.93 -46.65 5.46 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.37 -0.831 . . . . 0.0 109.58 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.738 HG22 ' H ' ' A' ' 15' ' ' ASP . 64.5 mt -92.76 150.34 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.212 -0.93 . . . . 0.0 109.477 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -127.0 17.07 7.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.942 . . . . 0.0 109.471 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.738 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 178.75 -169.08 0.09 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.196 -0.94 . . . . 0.0 109.499 -179.962 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.414 ' O ' HG23 ' A' ' 65' ' ' THR . . . -147.91 -176.17 21.23 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 69.4 m -149.91 115.27 5.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.254 -1.145 . . . . 0.0 109.495 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.585 HG12 ' N ' ' A' ' 19' ' ' ALA . 27.5 t -49.41 169.28 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.264 -0.898 . . . . 0.0 109.391 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.585 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -114.69 -73.97 0.63 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.191 -0.943 . . . . 0.0 109.53 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.0 m -160.07 133.72 7.09 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.198 -0.939 . . . . 0.0 109.523 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.734 ' CH2' HD12 ' A' ' 58' ' ' ILE . 34.5 m95 -89.87 92.9 9.21 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 121.155 -0.965 . . . . 0.0 109.556 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.714 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.6 m80 -54.98 -72.24 0.07 Allowed 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.324 -0.86 . . . . 0.0 109.421 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -84.18 -172.77 4.35 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.238 -0.914 . . . . 0.0 109.609 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -136.35 166.97 23.78 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.388 -0.82 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.496 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.6 Cg_endo -77.03 138.82 18.67 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.683 2.256 . . . . 0.0 110.493 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 106.79 -9.82 40.75 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -102.2 -174.37 2.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.315 -1.109 . . . . 0.0 109.417 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.82 147.77 27.36 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.302 -0.873 . . . . 0.0 109.466 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m -129.95 -169.53 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.212 -0.93 . . . . 0.0 109.467 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.448 ' O ' ' CB ' ' A' ' 33' ' ' GLU . 9.9 tptm -157.06 139.61 14.92 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.224 -0.923 . . . . 0.0 109.479 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.426 ' C ' ' O ' ' A' ' 30' ' ' LYS . 2.3 ttp180 -42.78 154.83 0.06 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.289 -0.882 . . . . 0.0 109.622 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.0 t70 60.24 33.44 20.97 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.244 -0.91 . . . . 0.0 109.47 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.448 ' CB ' ' O ' ' A' ' 30' ' ' LYS . 28.9 tt0 -126.45 113.92 17.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.223 -0.923 . . . . 0.0 109.508 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.714 HD21 ' NE2' ' A' ' 22' ' ' HIS . 56.8 tp -42.86 160.23 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.357 -0.839 . . . . 0.0 109.623 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.813 HD11 ' CA ' ' A' ' 49' ' ' ALA . 4.3 mt -142.77 -43.95 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.229 -0.919 . . . . 0.0 109.56 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.58 HG12 ' HB ' ' A' ' 47' ' ' VAL . 13.6 p -160.87 138.65 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.282 -0.886 . . . . 0.0 109.439 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.521 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 28.3 m-20 -97.76 149.5 22.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.139 -0.976 . . . . 0.0 109.39 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.416 HG22 ' N ' ' A' ' 39' ' ' GLU . 31.5 mt -122.46 156.3 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.196 -0.94 . . . . 0.0 109.42 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.416 ' N ' HG22 ' A' ' 38' ' ' ILE . 2.4 tm-20 -135.62 153.17 51.74 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.433 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.414 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -140.23 -178.98 5.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.195 -0.94 . . . . 0.0 109.509 -179.993 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.435 ' HB2' HG12 ' A' ' 13' ' ' ILE . 6.7 t0 -42.78 -70.02 0.12 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.344 -0.848 . . . . 0.0 109.593 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.2 mttt -129.38 35.05 4.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.255 -0.903 . . . . 0.0 109.392 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 9.7 t -144.09 152.71 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 109.447 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.4 t -130.5 153.88 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.184 -0.948 . . . . 0.0 109.487 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . 0.415 ' C ' ' HG3' ' A' ' 46' ' ' GLU . 4.4 mmt -143.25 167.38 22.28 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.188 -0.945 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.415 ' HG3' ' C ' ' A' ' 45' ' ' MET . 0.7 OUTLIER -128.98 156.22 44.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.285 -0.884 . . . . 0.0 109.478 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.58 ' HB ' HG12 ' A' ' 36' ' ' VAL . 20.9 t -126.88 99.95 6.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.895 . . . . 0.0 109.502 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.768 ' N ' HD23 ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.93 164.96 11.31 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.295 -0.878 . . . . 0.0 109.396 -179.992 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.813 ' CA ' HD11 ' A' ' 35' ' ' ILE . . . -83.34 129.41 34.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.291 -0.881 . . . . 0.0 109.522 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.581 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -91.35 10.84 25.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.197 -0.939 . . . . 0.0 109.443 -179.973 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.581 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 171.58 132.33 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.316 -0.865 . . . . 0.0 109.454 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.506 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -47.42 170.93 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.253 -0.904 . . . . 0.0 109.294 179.973 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.506 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 153.88 -160.95 29.67 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 46.5 t -124.56 123.91 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.272 -1.134 . . . . 0.0 109.494 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.556 HG22 ' N ' ' A' ' 56' ' ' ALA . 4.9 mt -61.52 163.7 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.338 -0.852 . . . . 0.0 109.615 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.556 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -103.22 -65.51 1.0 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -0.922 . . . . 0.0 109.485 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.496 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER 172.66 141.35 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.239 -0.913 . . . . 0.0 109.427 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.734 HD12 ' CH2' ' A' ' 21' ' ' TRP . 9.9 mm -89.97 140.38 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.279 -0.888 . . . . 0.0 109.398 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 98.8 t -89.99 -53.13 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.184 -0.947 . . . . 0.0 109.438 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.522 ' HA ' ' CE ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -94.87 167.17 11.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.251 -0.906 . . . . 0.0 109.391 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 49.3 m-80 -104.65 156.06 18.31 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.422 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.533 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -64.97 155.54 34.15 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.417 -179.933 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 84.08 2.54 89.4 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -105.28 170.96 7.58 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.196 -1.179 . . . . 0.0 109.313 -179.984 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.51 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 95.4 m -98.93 122.91 42.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.553 -0.717 . . . . 0.0 109.489 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.446 ' HB ' ' HG2' ' A' ' 70' ' ' GLU . 5.5 m -104.41 -172.37 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.273 -0.892 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -133.45 176.3 8.65 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.501 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.9 t -63.8 143.54 57.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.414 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 60.17 26.01 63.07 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.446 ' HG2' ' HB ' ' A' ' 66' ' ' VAL . 35.2 tp10 -82.92 110.43 17.9 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.455 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.768 HD11 ' HD2' ' A' ' 74' ' ' LYS . 9.6 tt -69.24 109.97 4.36 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.264 -0.897 . . . . 0.0 109.486 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.575 ' O ' HG23 ' A' ' 58' ' ' ILE . 35.9 mt -94.33 -11.8 29.29 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.521 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.45 ' O ' ' HG2' ' A' ' 74' ' ' LYS . . . 173.04 177.92 42.66 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.768 ' HD2' HD11 ' A' ' 71' ' ' LEU . 20.3 mtpt -147.7 129.2 14.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -1.127 . . . . 0.0 109.466 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.714 HD23 ' O ' ' A' ' 76' ' ' THR . 1.1 tt -96.02 147.66 23.47 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.238 -0.914 . . . . 0.0 109.539 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.714 ' O ' HD23 ' A' ' 75' ' ' LEU . 5.8 m -91.86 169.67 10.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.513 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.504 ' H ' HG22 ' A' ' 76' ' ' THR . 10.4 mt-10 -57.7 -65.51 0.62 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.205 -0.934 . . . . 0.0 109.466 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 114.33 73.7 0.59 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 CA-C-O 117.924 -1.487 . . . . 0.0 109.523 -179.99 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 36.8 pt -139.6 178.13 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.292 -0.88 . . . . 0.0 109.451 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.518 ' OD1' ' CD1' ' A' ' 71' ' ' LEU . 14.4 t0 -113.97 133.57 55.4 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.233 -0.917 . . . . 0.0 109.479 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.8 mt -105.57 98.08 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.193 -0.942 . . . . 0.0 109.48 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.02 168.69 14.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.17 -0.956 . . . . 0.0 109.5 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.2 153.73 92.33 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.307 -0.87 . . . . 0.0 109.47 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.99 140.64 18.23 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.565 2.177 . . . . 0.0 110.418 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.446 HG23 ' O ' ' A' ' 8' ' ' THR . 8.9 t -62.32 129.59 41.41 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -0.962 . . . . 0.0 109.451 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.497 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 23.4 m-85 -96.93 151.88 38.03 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.887 . . . . 0.0 109.472 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.448 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -78.08 171.31 17.33 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.671 2.247 . . . . 0.0 110.376 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.424 ' O ' ' C ' ' A' ' 12' ' ' SER . 4.5 mt-10 -45.67 -54.52 7.66 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.144 -0.973 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.424 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.95 -62.46 1.01 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.282 -0.886 . . . . 0.0 109.601 -179.917 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.573 HG22 ' H ' ' A' ' 15' ' ' ASP . 29.8 mm -92.85 119.13 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.181 -0.949 . . . . 0.0 109.482 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.438 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -96.18 13.21 28.13 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.262 -0.899 . . . . 0.0 109.484 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.573 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER 167.42 -171.82 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.884 . . . . 0.0 109.431 -179.957 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.34 -159.28 8.39 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.525 HG23 ' O ' ' A' ' 64' ' ' ASP . 52.1 m -149.57 123.29 9.23 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.243 -1.151 . . . . 0.0 109.502 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.592 HG12 ' N ' ' A' ' 19' ' ' ALA . 39.6 t -47.98 168.64 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.302 -0.874 . . . . 0.0 109.426 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.592 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -113.13 -75.0 0.61 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.413 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.5 m -160.08 134.7 7.66 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.336 -0.853 . . . . 0.0 109.451 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.673 ' CH2' HD12 ' A' ' 58' ' ' ILE . 34.1 m95 -89.78 84.9 6.3 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.231 -0.918 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.806 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.8 m80 -42.34 -60.46 1.48 Allowed 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.371 -0.831 . . . . 0.0 109.497 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 4.1 mmtt -99.66 -172.11 2.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.593 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.408 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -130.12 168.59 16.12 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.288 -0.882 . . . . 0.0 109.496 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.528 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.51 115.58 4.11 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 122.664 2.243 . . . . 0.0 110.39 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.83 -11.92 5.38 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.431 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 1.2 pp20? -95.6 -172.89 2.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.352 -1.087 . . . . 0.0 109.467 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.431 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -101.04 151.2 22.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.601 HG22 ' O ' ' A' ' 53' ' ' GLY . 20.1 m -114.9 166.63 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.358 -0.839 . . . . 0.0 109.429 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.436 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.3 mttt -121.3 134.5 55.15 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.262 -0.899 . . . . 0.0 109.506 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.51 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.81 113.42 0.47 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.352 -0.843 . . . . 0.0 109.684 -179.898 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.51 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 14.5 t0 75.99 56.37 0.05 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.293 -0.879 . . . . 0.0 109.495 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.479 ' O ' HG13 ' A' ' 35' ' ' ILE . 15.9 tt0 -131.24 124.15 29.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.319 -0.863 . . . . 0.0 109.437 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.806 HD21 ' NE2' ' A' ' 22' ' ' HIS . 51.1 tp -42.8 151.63 0.12 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.377 -0.827 . . . . 0.0 109.596 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.937 HD11 ' HB2' ' A' ' 49' ' ' ALA . 96.9 mt -137.84 -41.21 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.319 -0.863 . . . . 0.0 109.476 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.526 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 13.6 p -158.24 135.0 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.277 -0.89 . . . . 0.0 109.451 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.514 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 10.7 m-20 -93.28 153.83 18.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.287 -0.883 . . . . 0.0 109.438 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.537 HD11 ' CG2' ' A' ' 47' ' ' VAL . 2.8 mt -121.44 155.81 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.271 -0.893 . . . . 0.0 109.507 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.0 145.06 50.85 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.295 -0.878 . . . . 0.0 109.439 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.538 HG22 ' H ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -130.6 -176.98 4.15 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -0.932 . . . . 0.0 109.479 179.962 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.538 ' H ' HG22 ' A' ' 40' ' ' THR . 63.5 t0 -42.78 -55.08 3.8 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.286 -0.883 . . . . 0.0 109.686 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 18.3 mttm -147.45 25.45 1.08 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.246 -0.908 . . . . 0.0 109.396 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 2.1 t -134.05 130.87 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.231 -0.918 . . . . 0.0 109.457 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.0 t -108.57 139.78 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.218 -0.926 . . . . 0.0 109.512 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 18.7 mtp -131.62 175.28 9.31 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.212 -0.93 . . . . 0.0 109.467 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -124.59 159.91 29.62 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.508 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.537 ' CG2' HD11 ' A' ' 38' ' ' ILE . 5.4 t -130.14 89.5 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.286 -0.884 . . . . 0.0 109.45 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.781 ' N ' HD23 ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.92 156.72 17.47 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.239 -0.913 . . . . 0.0 109.372 179.974 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.937 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -77.84 149.13 34.4 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.196 -0.94 . . . . 0.0 109.538 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 1.3 mt-10 -92.27 12.02 23.84 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.229 -0.92 . . . . 0.0 109.449 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.456 ' HA ' ' HG3' ' A' ' 31' ' ' ARG . . . 179.13 150.07 0.28 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.243 -0.911 . . . . 0.0 109.493 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.509 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -55.35 170.93 0.2 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.216 -0.928 . . . . 0.0 109.32 -179.97 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.601 ' O ' HG22 ' A' ' 29' ' ' VAL . . . 154.74 -153.88 25.12 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 52.4 t -138.75 127.0 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.247 -1.149 . . . . 0.0 109.442 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.501 HD13 ' CD1' ' A' ' 75' ' ' LEU . 14.9 mm -62.25 158.15 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.213 -0.929 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.418 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -97.37 -69.56 0.75 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.238 -0.914 . . . . 0.0 109.468 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.528 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 2.9 pt-20 -174.76 142.44 0.7 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.255 -0.903 . . . . 0.0 109.453 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.673 HD12 ' CH2' ' A' ' 21' ' ' TRP . 15.7 mm -93.86 138.05 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.208 -0.933 . . . . 0.0 109.498 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.7 t -90.56 -57.71 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.275 -0.891 . . . . 0.0 109.532 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.524 ' HA ' ' CE ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -89.93 163.22 15.06 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.17 -0.956 . . . . 0.0 109.439 -179.964 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 -102.56 156.49 17.58 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 109.53 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.522 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.2 OUTLIER -66.49 160.1 25.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.245 -0.909 . . . . 0.0 109.432 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 81.75 -7.35 62.55 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.525 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -100.81 171.02 7.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -1.165 . . . . 0.0 109.333 179.997 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.9 t -92.4 153.77 18.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.546 -0.722 . . . . 0.0 109.441 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.453 ' HA ' ' OE1' ' A' ' 70' ' ' GLU . 18.0 m -129.0 -174.66 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.233 -0.917 . . . . 0.0 109.55 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -128.98 170.88 12.91 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.283 -0.886 . . . . 0.0 109.432 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.438 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 3.9 t -72.22 99.7 2.42 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.872 . . . . 0.0 109.474 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 109.51 14.86 13.28 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.584 ' OE2' HD23 ' A' ' 72' ' ' LEU . 3.9 tt0 -75.45 119.29 19.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -1.127 . . . . 0.0 109.448 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.518 ' CD1' ' OD1' ' A' ' 3' ' ' ASP . 68.4 tp -69.72 108.73 4.03 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.266 -0.896 . . . . 0.0 109.47 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.584 HD23 ' OE2' ' A' ' 70' ' ' GLU . 16.6 mt -88.39 -13.92 39.35 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.24 -0.913 . . . . 0.0 109.514 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 161.45 178.46 35.41 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.456 ' HG3' HD11 ' A' ' 71' ' ' LEU . 5.1 mtpt -137.91 144.17 41.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.22 -1.164 . . . . 0.0 109.444 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.501 ' CD1' HD13 ' A' ' 55' ' ' ILE . 17.1 tp -93.32 140.51 29.47 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.2 -0.937 . . . . 0.0 109.506 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.576 HG22 ' H ' ' A' ' 77' ' ' GLU . 14.8 m -112.85 171.94 7.23 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.576 ' H ' HG22 ' A' ' 76' ' ' THR . 3.0 mt-10 -74.23 -72.33 0.28 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.901 . . . . 0.0 109.425 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -139.44 -152.89 5.96 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.939 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.587 ' O ' HD13 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.587 HD13 ' O ' ' A' ' 1' ' ' ALA . 35.0 mm -145.9 99.11 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.29 -0.882 . . . . 0.0 109.517 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.56 ' OD2' HD12 ' A' ' 71' ' ' LEU . 62.8 t0 -80.71 132.12 35.52 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.214 -0.929 . . . . 0.0 109.495 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 40.9 mt -104.23 99.1 7.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.327 -0.858 . . . . 0.0 109.481 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.43 ' HA ' ' HA ' ' A' ' 71' ' ' LEU . 4.2 mttp -106.66 177.03 4.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.244 -0.91 . . . . 0.0 109.508 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.711 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -77.98 165.8 48.06 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.264 -0.897 . . . . 0.0 109.493 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.711 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.3 Cg_endo -77.6 157.11 32.17 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.615 2.21 . . . . 0.0 110.44 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.3 t -62.77 146.63 52.02 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.848 . . . . 0.0 109.495 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.528 ' CZ ' ' HG2' ' A' ' 7' ' ' PRO . 24.0 m-85 -129.99 91.37 39.77 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.224 -0.922 . . . . 0.0 109.477 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.5 Cg_endo -78.03 -162.94 0.19 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.63 2.22 . . . . 0.0 110.445 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.429 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.0 OUTLIER -51.81 -54.83 24.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.293 -0.879 . . . . 0.0 109.446 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.429 ' C ' ' O ' ' A' ' 11' ' ' GLU . 34.4 t -42.94 -60.23 1.69 Allowed 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.324 -0.86 . . . . 0.0 109.626 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.472 HG22 ' O ' ' A' ' 15' ' ' ASP . 27.0 mt -102.47 119.03 50.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.215 -0.928 . . . . 0.0 109.56 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -96.88 -0.25 48.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.922 . . . . 0.0 109.549 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.472 ' O ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -173.53 -173.59 0.9 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.244 -0.91 . . . . 0.0 109.401 -179.976 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.885 ' O ' HG23 ' A' ' 65' ' ' THR . . . -154.6 170.79 32.99 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.684 HG23 ' O ' ' A' ' 64' ' ' ASP . 21.8 m -150.04 118.59 6.51 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.312 -1.111 . . . . 0.0 109.414 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.594 HG12 ' N ' ' A' ' 19' ' ' ALA . 42.8 t -45.25 168.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.204 -0.935 . . . . 0.0 109.506 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.594 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -113.65 -70.68 0.79 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.185 -0.947 . . . . 0.0 109.574 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.437 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 17.1 m -158.56 134.77 9.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.171 -0.955 . . . . 0.0 109.608 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.592 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 31.4 m95 -89.86 84.77 6.26 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.269 -0.894 . . . . 0.0 109.559 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.825 ' CE1' HD21 ' A' ' 34' ' ' LEU . 2.7 m80 -42.69 -70.41 0.11 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.37 -0.831 . . . . 0.0 109.48 -179.763 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -101.11 -172.11 2.11 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.223 -0.923 . . . . 0.0 109.534 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 4.0 mttt -125.92 167.41 16.92 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.264 -0.897 . . . . 0.0 109.441 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.986 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.0 Cg_endo -76.93 131.22 11.95 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.608 2.205 . . . . 0.0 110.49 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.45 -12.48 18.8 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -89.8 -174.33 4.24 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.3 -1.118 . . . . 0.0 109.398 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.7 140.31 42.42 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.288 -0.883 . . . . 0.0 109.456 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 1.039 HG21 HD11 ' A' ' 55' ' ' ILE . 47.3 t -128.21 161.68 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.431 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.496 ' N ' HG12 ' A' ' 29' ' ' VAL . 3.7 tptt -153.28 137.5 16.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.207 -0.933 . . . . 0.0 109.491 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 30' ' ' LYS . 8.3 tmm_? -42.8 139.61 1.59 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.296 -0.877 . . . . 0.0 109.593 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.41 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 20.0 t70 68.05 49.0 0.9 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.349 -0.844 . . . . 0.0 109.469 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.424 ' O ' ' C ' ' A' ' 34' ' ' LEU . 1.6 tt0 -133.95 103.88 6.02 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.921 . . . . 0.0 109.426 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.825 HD21 ' CE1' ' A' ' 22' ' ' HIS . 38.4 tp -42.58 151.54 0.12 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.357 -0.839 . . . . 0.0 109.632 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.98 HD11 ' HB2' ' A' ' 49' ' ' ALA . 5.1 mt -142.04 -40.18 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.166 -0.959 . . . . 0.0 109.542 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.512 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 12.2 p -151.92 128.2 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.489 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 12.9 m-20 -89.89 164.24 14.67 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.403 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.821 ' O ' HG23 ' A' ' 44' ' ' VAL . 80.8 mt -136.69 151.97 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.223 -0.923 . . . . 0.0 109.522 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 17' ' ' THR . 4.6 pt-20 -140.68 135.11 31.3 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.265 -0.897 . . . . 0.0 109.425 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.564 HG22 ' O ' ' A' ' 43' ' ' VAL . 5.3 t -128.31 -162.33 1.17 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.336 -0.853 . . . . 0.0 109.35 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.508 ' N ' HG23 ' A' ' 40' ' ' THR . 11.8 t70 -42.43 -61.85 1.11 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.325 -0.859 . . . . 0.0 109.697 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . 0.454 ' HG3' ' O ' ' A' ' 41' ' ' ASP . 5.9 mtpm? -149.47 45.09 0.96 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.225 -0.922 . . . . 0.0 109.515 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.564 ' O ' HG22 ' A' ' 40' ' ' THR . 54.5 t -154.69 108.25 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.195 -0.94 . . . . 0.0 109.489 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.821 HG23 ' O ' ' A' ' 38' ' ' ILE . 3.8 p -96.43 140.01 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.343 -0.848 . . . . 0.0 109.396 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -131.77 134.23 45.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.261 -0.9 . . . . 0.0 109.499 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.543 ' HB3' HD13 ' A' ' 34' ' ' LEU . 25.2 mt-10 -89.64 151.49 21.86 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.296 -0.878 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.512 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 91.8 t -123.0 103.62 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.173 -0.954 . . . . 0.0 109.507 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.494 ' H ' HD12 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -102.78 171.2 7.55 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.276 -0.89 . . . . 0.0 109.37 179.966 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.98 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.98 134.81 34.22 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.255 -0.903 . . . . 0.0 109.464 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.543 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.9 OUTLIER -84.81 10.95 10.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.156 -0.965 . . . . 0.0 109.426 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.543 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 173.38 154.39 0.1 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 109.42 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.513 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -69.07 171.03 8.83 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.277 -179.939 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.513 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.22 -146.02 15.15 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.9 t -138.68 126.9 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -1.158 . . . . 0.0 109.492 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 1.039 HD11 HG21 ' A' ' 29' ' ' VAL . 1.1 mm -74.6 171.91 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.203 -0.936 . . . . 0.0 109.422 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.448 ' CB ' ' HG3' ' A' ' 74' ' ' LYS . . . -104.33 -63.85 1.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.227 -0.921 . . . . 0.0 109.509 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.528 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -179.29 158.39 0.87 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.246 -0.909 . . . . 0.0 109.5 180.0 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.986 HD11 ' HD3' ' A' ' 25' ' ' PRO . 1.5 mp -93.52 146.2 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.211 -0.93 . . . . 0.0 109.468 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.865 HG23 ' O ' ' A' ' 72' ' ' LEU . 49.5 t -89.9 -52.46 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.226 -0.921 . . . . 0.0 109.479 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.466 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 2.1 tptp -108.29 157.37 18.42 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.274 -0.891 . . . . 0.0 109.397 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 50.2 m-80 -88.82 156.18 19.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.482 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.492 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 2.4 pp20? -61.09 145.91 49.22 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.257 -0.902 . . . . 0.0 109.384 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 94.96 -12.15 68.79 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.684 ' O ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -89.04 170.9 10.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.273 -1.133 . . . . 0.0 109.325 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.885 HG23 ' O ' ' A' ' 16' ' ' GLY . 62.7 m -111.96 146.92 36.96 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.489 -0.757 . . . . 0.0 109.467 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.494 ' HB ' ' CB ' ' A' ' 70' ' ' GLU . 27.3 m -129.62 -176.21 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.8 mp -116.63 173.9 6.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.177 -0.952 . . . . 0.0 109.469 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -63.85 125.74 25.35 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.897 . . . . 0.0 109.384 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 86.85 19.6 55.73 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.494 ' CB ' ' HB ' ' A' ' 66' ' ' VAL . 4.6 tp10 -82.18 112.82 19.56 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -1.134 . . . . 0.0 109.465 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.734 ' C ' HD23 ' A' ' 71' ' ' LEU . 7.5 tt -78.26 128.42 33.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.307 -0.87 . . . . 0.0 109.491 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.865 ' O ' HG23 ' A' ' 59' ' ' VAL . 13.3 mt -97.05 -70.51 0.72 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.421 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -128.14 163.64 21.67 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.448 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 2.2 ptmt -126.33 147.97 49.64 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.27 -1.135 . . . . 0.0 109.493 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.707 HD23 ' O ' ' A' ' 76' ' ' THR . 6.0 tt -90.56 166.45 13.2 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.278 -0.889 . . . . 0.0 109.488 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.707 ' O ' HD23 ' A' ' 75' ' ' LEU . 3.0 t -89.35 -157.74 0.47 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.268 -0.895 . . . . 0.0 109.735 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.671 ' N ' HG23 ' A' ' 76' ' ' THR . 4.4 mm-40 -79.61 163.17 24.82 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 121.804 -0.56 . . . . 0.0 109.544 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -136.62 -110.27 1.01 Allowed Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 CA-C-O 117.967 -1.463 . . . . 0.0 109.523 179.93 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.777 ' HB1' ' O ' ' A' ' 75' ' ' LEU . . . . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.473 HD12 HD22 ' A' ' 75' ' ' LEU . 15.4 mt -141.98 104.8 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.187 -0.946 . . . . 0.0 109.482 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -67.64 125.9 27.65 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.461 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.9 mm -104.61 120.64 55.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.262 -0.899 . . . . 0.0 109.424 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -136.83 176.23 8.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.169 -0.957 . . . . 0.0 109.469 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.428 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -80.44 157.78 72.26 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.282 -0.886 . . . . 0.0 109.439 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.428 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.6 Cg_endo -78.01 156.32 30.33 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.661 2.241 . . . . 0.0 110.48 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 77.0 m -68.53 119.36 12.86 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.301 -0.874 . . . . 0.0 109.478 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -73.85 154.58 89.06 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.294 -0.878 . . . . 0.0 109.539 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.55 ' HG2' HD12 ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.09 -173.93 2.03 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.677 2.252 . . . . 0.0 110.433 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.7 mp0 -73.15 -49.34 28.76 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.461 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.2 OUTLIER -42.82 -29.05 0.29 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.371 -0.831 . . . . 0.0 109.589 -179.87 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.692 HG22 ' H ' ' A' ' 15' ' ' ASP . 4.1 mt -121.17 146.04 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -0.895 . . . . 0.0 109.496 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -114.31 1.76 14.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.247 -0.908 . . . . 0.0 109.611 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.692 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -178.35 -171.41 0.26 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.18 -0.95 . . . . 0.0 109.457 -179.984 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.38 -167.44 17.69 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.852 HG23 ' O ' ' A' ' 64' ' ' ASP . 29.4 m -148.13 130.88 16.01 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -1.122 . . . . 0.0 109.468 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.548 HG12 ' N ' ' A' ' 19' ' ' ALA . 46.6 t -44.56 165.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.248 -0.907 . . . . 0.0 109.49 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.568 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -114.06 -73.12 0.67 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.301 -0.874 . . . . 0.0 109.53 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 38.5 m -160.01 132.19 6.32 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.205 -0.934 . . . . 0.0 109.518 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.667 ' CH2' HD12 ' A' ' 58' ' ' ILE . 36.0 m95 -89.84 81.78 6.3 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.259 -0.901 . . . . 0.0 109.517 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.776 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.1 m80 -42.87 -61.54 1.25 Allowed 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.305 -0.872 . . . . 0.0 109.42 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.478 ' O ' ' HE3' ' A' ' 24' ' ' LYS . 1.2 mtpt -96.89 -177.36 3.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.918 . . . . 0.0 109.584 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.478 ' HE3' ' O ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -120.95 167.72 12.44 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.248 -0.908 . . . . 0.0 109.516 179.989 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.504 ' HA ' ' CG2' ' A' ' 55' ' ' ILE . 35.1 Cg_endo -76.96 90.21 1.25 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.694 2.263 . . . . 0.0 110.395 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 138.59 45.03 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.46 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 2.2 pp20? -139.35 -173.37 3.58 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.317 -1.108 . . . . 0.0 109.462 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.46 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -90.68 128.78 36.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.206 -0.934 . . . . 0.0 109.474 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 12.4 p -127.11 155.15 38.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.215 -0.928 . . . . 0.0 109.528 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.409 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -134.63 133.72 40.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -0.949 . . . . 0.0 109.502 -179.989 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.506 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.78 143.26 0.73 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.288 -0.883 . . . . 0.0 109.658 -179.969 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.506 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 8.2 t70 75.51 41.59 0.26 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.262 -0.898 . . . . 0.0 109.452 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.445 ' O ' HG12 ' A' ' 35' ' ' ILE . 3.5 tt0 -141.83 121.75 13.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.229 -0.919 . . . . 0.0 109.477 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.835 ' O ' HD13 ' A' ' 35' ' ' ILE . 59.6 tp -42.84 156.1 0.05 OUTLIER 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.328 -0.858 . . . . 0.0 109.644 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.835 HD13 ' O ' ' A' ' 34' ' ' LEU . 15.7 mm -146.12 -39.12 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.276 -0.89 . . . . 0.0 109.505 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.516 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -159.79 141.95 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -0.891 . . . . 0.0 109.369 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.568 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 1.2 m-20 -104.93 146.37 29.12 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.251 -0.906 . . . . 0.0 109.465 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.452 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 57.2 mt -107.13 142.46 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.175 -0.953 . . . . 0.0 109.514 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.515 ' CB ' ' O ' ' A' ' 17' ' ' THR . 1.4 tt0 -105.35 129.21 53.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.209 -0.932 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -115.73 171.61 7.65 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.238 -0.914 . . . . 0.0 109.49 -179.948 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 40' ' ' THR . 12.7 t0 -42.87 -51.37 5.53 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.321 -0.862 . . . . 0.0 109.618 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . 0.431 ' HG2' ' O ' ' A' ' 41' ' ' ASP . 7.8 mmtt -148.37 30.66 0.84 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.271 -0.893 . . . . 0.0 109.443 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.412 ' O ' ' OG1' ' A' ' 40' ' ' THR . 2.0 t -139.6 134.49 38.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.939 . . . . 0.0 109.436 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 8.1 p -98.76 136.86 28.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.255 -0.903 . . . . 0.0 109.474 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . 0.452 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 0.9 OUTLIER -125.17 165.83 17.54 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.15 -0.969 . . . . 0.0 109.473 -179.983 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -129.26 161.91 29.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.501 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.516 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 78.7 t -140.73 108.89 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.214 -0.929 . . . . 0.0 109.501 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.49 ' H ' HD12 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -103.14 155.74 18.19 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.339 -0.851 . . . . 0.0 109.362 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -70.58 144.78 51.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.898 . . . . 0.0 109.521 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.422 ' C ' ' HG3' ' A' ' 31' ' ' ARG . 0.6 OUTLIER -101.87 11.23 38.97 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.276 -0.89 . . . . 0.0 109.475 179.988 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -178.57 138.2 0.17 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.305 -0.872 . . . . 0.0 109.428 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.504 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.2 OUTLIER -58.5 170.95 0.67 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.245 -0.91 . . . . 0.0 109.343 -179.977 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.504 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 145.65 -162.39 28.26 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.475 ' O ' HG22 ' A' ' 76' ' ' THR . 48.1 t -128.94 124.97 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.328 -1.101 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.577 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.0 mt -59.41 165.23 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.278 -0.889 . . . . 0.0 109.568 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.577 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -103.43 -66.08 0.97 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.188 -0.945 . . . . 0.0 109.518 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.476 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.1 OUTLIER -167.75 139.11 2.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.206 -0.934 . . . . 0.0 109.55 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.667 HD12 ' CH2' ' A' ' 21' ' ' TRP . 23.9 mm -95.09 121.69 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.326 -0.859 . . . . 0.0 109.508 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.4 t -89.94 -27.99 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.19 -0.944 . . . . 0.0 109.428 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.502 ' HG2' ' CG1' ' A' ' 66' ' ' VAL . 0.0 OUTLIER -91.08 134.21 34.7 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.288 -0.882 . . . . 0.0 109.466 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.473 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 13.7 m120 -98.71 165.76 11.64 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.286 -0.884 . . . . 0.0 109.519 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -68.85 141.12 55.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 80.52 14.92 79.26 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.852 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -101.73 170.88 7.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -1.141 . . . . 0.0 109.277 -179.972 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 23.3 m -97.3 141.76 30.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.493 -0.754 . . . . 0.0 109.416 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.502 ' CG1' ' HG2' ' A' ' 60' ' ' LYS . 2.3 m -126.98 139.04 53.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.469 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.04 167.53 10.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.261 -0.899 . . . . 0.0 109.486 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 36.2 t -57.17 128.82 38.9 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 73.56 23.31 77.22 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -79.19 119.25 22.01 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.247 -1.149 . . . . 0.0 109.491 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.506 ' C ' HD23 ' A' ' 71' ' ' LEU . 10.2 tt -67.37 138.31 56.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.288 -0.882 . . . . 0.0 109.543 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -118.85 -24.86 6.47 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.293 -0.879 . . . . 0.0 109.428 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.64 159.67 26.6 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 8.3 mtpt -122.31 133.39 54.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.204 -1.174 . . . . 0.0 109.446 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.777 ' O ' ' HB1' ' A' ' 1' ' ' ALA . 0.6 OUTLIER -92.1 147.57 22.84 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -0.948 . . . . 0.0 109.512 179.99 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.675 HG23 ' N ' ' A' ' 77' ' ' GLU . 3.0 t -97.72 -157.77 0.62 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.272 -0.893 . . . . 0.0 109.724 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.675 ' N ' HG23 ' A' ' 76' ' ' THR . 64.7 mm-40 -81.57 177.18 9.09 Favored 'General case' 0 C--N 1.295 -1.774 0 O-C-N 121.728 -0.608 . . . . 0.0 109.508 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.405 ' HA2' ' HA2' ' A' ' 53' ' ' GLY . . . -78.61 -51.25 5.64 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.223 0 CA-C-O 117.997 -1.446 . . . . 0.0 109.602 -179.931 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 61.7 mt -133.92 93.2 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.32 -0.863 . . . . 0.0 109.473 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 74' ' ' LYS . 15.9 t70 -76.15 162.73 27.75 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.228 -0.92 . . . . 0.0 109.441 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mt -135.39 125.03 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.269 -0.894 . . . . 0.0 109.452 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.0 pttm -133.04 172.98 11.91 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.243 -0.911 . . . . 0.0 109.462 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.565 ' HB3' ' O ' ' A' ' 67' ' ' LEU . . . -81.46 147.72 60.63 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.144 -0.972 . . . . 0.0 109.447 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.03 155.11 29.79 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.649 2.233 . . . . 0.0 110.455 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.411 ' HA ' ' HB2' ' A' ' 68' ' ' SER . 1.3 m -71.11 132.49 45.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.414 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.404 ' HB3' ' HB ' ' A' ' 13' ' ' ILE . 63.0 m-85 -99.34 153.6 37.7 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.426 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.4 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -77.99 -159.65 0.1 Allowed 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.632 2.221 . . . . 0.0 110.454 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.0 OUTLIER -77.18 -55.6 5.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.464 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 11' ' ' GLU . 18.6 t -42.72 -50.3 5.55 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.278 -0.889 . . . . 0.0 109.617 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.49 HG22 ' H ' ' A' ' 15' ' ' ASP . 14.8 mt -90.11 143.45 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.418 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.517 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -115.1 -1.76 12.94 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.517 ' CB ' ' O ' ' A' ' 14' ' ' ALA . 0.5 OUTLIER 163.89 -169.09 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.212 -0.93 . . . . 0.0 109.464 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.673 ' O ' HG23 ' A' ' 65' ' ' THR . . . -142.97 -163.13 9.6 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.625 HG23 ' O ' ' A' ' 64' ' ' ASP . 17.0 m -150.0 133.07 16.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -1.114 . . . . 0.0 109.426 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.483 ' O ' ' HG3' ' A' ' 39' ' ' GLU . 39.4 t -49.08 159.73 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.216 -0.928 . . . . 0.0 109.419 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.519 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -104.35 -77.0 0.58 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.218 -0.926 . . . . 0.0 109.517 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 17.8 m -159.97 130.48 5.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.555 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.637 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 35.6 m95 -89.95 85.54 6.38 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.207 -0.933 . . . . 0.0 109.509 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.798 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.1 m80 -43.18 -67.28 0.29 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.346 -0.846 . . . . 0.0 109.419 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -93.81 -172.33 2.84 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.216 -0.927 . . . . 0.0 109.468 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.425 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -125.23 168.23 14.14 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.287 -0.883 . . . . 0.0 109.392 -179.894 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.498 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.3 Cg_endo -76.59 127.75 9.81 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.733 2.288 . . . . 0.0 110.373 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.65 18.99 9.01 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 13.8 mm-40 -119.69 -176.98 3.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.306 -1.114 . . . . 0.0 109.486 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -92.85 145.93 24.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.267 -0.896 . . . . 0.0 109.444 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 69.0 t -139.37 151.33 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -0.896 . . . . 0.0 109.532 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 11.0 mptt -126.64 140.11 52.66 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.228 -0.92 . . . . 0.0 109.463 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.434 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.7 OUTLIER -42.71 153.1 0.08 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.383 -0.823 . . . . 0.0 109.704 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.445 ' HA ' HD23 ' A' ' 48' ' ' LEU . 25.2 t0 63.19 41.8 7.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.927 . . . . 0.0 109.468 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.423 ' C ' ' HG ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -135.98 116.05 13.33 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.291 -0.88 . . . . 0.0 109.51 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.798 HD21 ' NE2' ' A' ' 22' ' ' HIS . 37.5 tp -43.1 142.9 0.88 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.275 -0.891 . . . . 0.0 109.556 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.798 HD11 ' HB2' ' A' ' 49' ' ' ALA . 10.9 mt -125.92 -46.08 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.272 -0.893 . . . . 0.0 109.585 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.405 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -162.8 147.5 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.277 -0.889 . . . . 0.0 109.528 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.519 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 1.2 m-20 -105.32 160.25 15.26 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.347 -0.845 . . . . 0.0 109.428 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.531 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 1.8 tt -129.31 148.54 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -0.933 . . . . 0.0 109.449 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.483 ' HG3' ' O ' ' A' ' 18' ' ' VAL . 4.8 mm-40 -106.96 150.33 26.58 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.305 -0.872 . . . . 0.0 109.481 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.404 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -135.47 -175.38 3.92 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 40' ' ' THR . 7.8 t0 -42.78 -68.9 0.16 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.307 -0.871 . . . . 0.0 109.643 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.7 mtmm -135.39 36.73 2.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.172 -0.955 . . . . 0.0 109.493 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 67.9 t -152.0 153.44 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.34 -0.85 . . . . 0.0 109.472 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.462 ' O ' HG13 ' A' ' 44' ' ' VAL . 11.7 p -124.2 131.04 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . 0.531 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 0.0 OUTLIER -107.89 177.2 4.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.181 -0.949 . . . . 0.0 109.502 179.98 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -130.28 151.3 50.94 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.223 -0.923 . . . . 0.0 109.452 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.405 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 44.3 t -122.75 98.11 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.45 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.536 HD12 ' HA ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -90.99 168.72 11.45 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.195 -0.941 . . . . 0.0 109.487 -179.998 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.798 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -85.1 136.91 33.35 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.223 -0.923 . . . . 0.0 109.402 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.533 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 2.2 mm-40 -98.53 14.64 27.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.545 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.533 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 173.54 134.78 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.268 -0.895 . . . . 0.0 109.469 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.502 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.25 171.02 0.12 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -0.894 . . . . 0.0 109.3 179.999 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.502 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 142.77 -154.04 25.02 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.612 ' H ' HG22 ' A' ' 76' ' ' THR . 66.2 t -136.65 134.63 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.274 -1.133 . . . . 0.0 109.412 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.618 HD13 HD12 ' A' ' 75' ' ' LEU . 15.3 mm -61.85 168.84 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.218 -0.926 . . . . 0.0 109.516 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.574 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -101.42 -62.83 1.2 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.914 . . . . 0.0 109.53 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.498 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.7 OUTLIER -177.89 131.47 0.15 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.259 -0.9 . . . . 0.0 109.462 179.95 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.637 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 21.5 mm -90.09 125.63 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.435 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 42.2 t -89.93 -33.13 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.291 -0.88 . . . . 0.0 109.471 -179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.492 ' CG ' ' OD1' ' A' ' 64' ' ' ASP . 1.5 mptt -94.38 143.66 26.22 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.282 -0.886 . . . . 0.0 109.488 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.459 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 65.3 m-80 -111.0 164.74 12.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.248 -0.908 . . . . 0.0 109.526 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -59.06 146.43 38.47 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.493 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 86.75 7.74 77.82 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.625 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -105.35 170.71 7.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.221 -1.164 . . . . 0.0 109.411 -179.98 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.673 HG23 ' O ' ' A' ' 16' ' ' GLY . 11.9 m -107.77 145.69 33.2 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.536 -0.728 . . . . 0.0 109.458 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 4.9 m -114.98 137.37 48.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.471 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.565 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -106.08 174.53 5.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.192 -0.943 . . . . 0.0 109.522 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.411 ' HB2' ' HA ' ' A' ' 8' ' ' THR . 1.5 t -62.03 129.13 39.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.234 -0.917 . . . . 0.0 109.497 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.98 21.63 73.53 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -79.82 104.34 10.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.255 -1.144 . . . . 0.0 109.52 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.478 ' C ' HD23 ' A' ' 71' ' ' LEU . 9.1 tt -78.1 121.9 24.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.243 -0.911 . . . . 0.0 109.458 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.5 mp -92.69 -69.05 0.76 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.352 -0.843 . . . . 0.0 109.38 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -140.74 -175.82 14.87 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.43 ' HA ' ' HA ' ' A' ' 3' ' ' ASP . 0.3 OUTLIER -143.69 142.0 30.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.297 -1.119 . . . . 0.0 109.485 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.618 HD12 HD13 ' A' ' 55' ' ' ILE . 0.6 OUTLIER -90.51 144.52 25.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.886 . . . . 0.0 109.436 -179.96 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.67 HG23 ' N ' ' A' ' 77' ' ' GLU . 3.0 t -81.78 -157.83 0.21 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.74 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.67 ' N ' HG23 ' A' ' 76' ' ' THR . 79.7 mm-40 -57.94 174.09 0.28 Allowed 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -173.78 -62.82 0.05 OUTLIER Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.282 0 CA-C-O 118.02 -1.434 . . . . 0.0 109.565 179.966 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.433 ' C ' HD12 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.777 HD13 ' CD2' ' A' ' 75' ' ' LEU . 3.2 mp -148.13 88.05 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.326 -0.859 . . . . 0.0 109.476 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.997 ' OD1' HD11 ' A' ' 71' ' ' LEU . 22.9 t70 -82.28 154.12 25.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.204 -0.935 . . . . 0.0 109.496 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.2 mt -130.86 122.34 51.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.883 . . . . 0.0 109.432 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.473 ' HD2' ' OD2' ' A' ' 3' ' ' ASP . 0.0 OUTLIER -144.89 164.85 29.82 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.234 -0.916 . . . . 0.0 109.464 179.958 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.404 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -67.34 148.13 98.77 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.291 -0.881 . . . . 0.0 109.495 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 35.9 Cg_endo -78.02 -172.2 1.42 Allowed 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.628 2.219 . . . . 0.0 110.417 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -97.86 96.52 8.26 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.235 -0.915 . . . . 0.0 109.449 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.54 ' CZ ' ' HA3' ' A' ' 16' ' ' GLY . 19.5 m-85 -59.81 149.34 72.98 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.245 -0.909 . . . . 0.0 109.493 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.04 -166.25 0.39 Allowed 'Trans proline' 0 C--N 1.308 -1.556 0 C-N-CA 122.61 2.207 . . . . 0.0 110.494 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.43 ' O ' ' C ' ' A' ' 12' ' ' SER . 4.8 tt0 -72.78 -42.43 63.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.231 -0.918 . . . . 0.0 109.484 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 11' ' ' GLU . 2.5 t -42.88 -64.54 0.61 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.298 -0.876 . . . . 0.0 109.554 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.584 HG22 ' H ' ' A' ' 15' ' ' ASP . 15.1 mm -104.95 145.86 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.216 -0.928 . . . . 0.0 109.445 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -114.36 21.77 14.33 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.294 -0.879 . . . . 0.0 109.485 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.584 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.3 OUTLIER -161.74 -173.11 3.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.135 -0.978 . . . . 0.0 109.572 -179.997 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.54 ' HA3' ' CZ ' ' A' ' 9' ' ' PHE . . . -150.56 -176.56 23.65 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.518 HG23 ' O ' ' A' ' 64' ' ' ASP . 25.8 m -150.06 122.09 8.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.176 -1.19 . . . . 0.0 109.5 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.581 HG12 ' N ' ' A' ' 19' ' ' ALA . 41.4 t -45.83 168.72 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.251 -0.906 . . . . 0.0 109.353 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.581 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -111.13 -74.34 0.65 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.117 -0.989 . . . . 0.0 109.589 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.403 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 16.2 m -160.05 127.78 4.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.254 -0.904 . . . . 0.0 109.605 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.705 ' CH2' HD12 ' A' ' 58' ' ' ILE . 36.7 m95 -89.91 83.4 6.15 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.26 -0.9 . . . . 0.0 109.461 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.604 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.8 m80 -42.95 -70.18 0.11 Allowed 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.322 -0.861 . . . . 0.0 109.424 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -93.67 177.98 5.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.25 -0.906 . . . . 0.0 109.678 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.455 ' HD3' ' HD2' ' A' ' 25' ' ' PRO . 5.4 mttp -121.39 169.48 9.06 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.283 -0.886 . . . . 0.0 109.445 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.529 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.3 Cg_endo -76.15 119.7 5.42 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.657 2.238 . . . . 0.0 110.463 179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 122.68 10.13 6.04 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.444 ' OE2' ' O ' ' A' ' 28' ' ' ALA . 1.1 pp20? -112.4 173.88 6.15 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -1.129 . . . . 0.0 109.507 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.444 ' O ' ' OE2' ' A' ' 27' ' ' GLU . . . -82.5 144.28 30.53 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.922 . . . . 0.0 109.511 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.8 t -112.31 156.85 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.287 -0.883 . . . . 0.0 109.47 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.1 OUTLIER -142.96 135.88 27.96 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.274 -0.892 . . . . 0.0 109.493 179.957 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.466 ' HG2' ' N ' ' A' ' 32' ' ' ASP . 2.7 ttm180 -42.8 141.13 1.14 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.337 -0.852 . . . . 0.0 109.651 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.466 ' N ' ' HG2' ' A' ' 31' ' ' ARG . 20.8 t70 69.71 49.66 0.53 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.289 -0.882 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' A' ' 34' ' ' LEU . 3.0 tt0 -138.5 106.89 5.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 0.0 109.429 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.604 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 40.1 tp -43.46 165.14 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.291 -0.88 . . . . 0.0 109.472 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.791 HD11 ' HB2' ' A' ' 49' ' ' ALA . 91.3 mt -134.26 -47.13 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.15 -0.969 . . . . 0.0 109.637 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.579 ' HB ' ' CE3' ' A' ' 21' ' ' TRP . 2.6 p -171.99 144.01 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.158 -0.964 . . . . 0.0 109.52 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.526 ' C ' ' HB3' ' A' ' 19' ' ' ALA . 1.3 m-20 -100.19 167.03 10.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.247 -0.908 . . . . 0.0 109.458 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.473 HG22 ' O ' ' A' ' 45' ' ' MET . 1.2 tt -142.63 156.33 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.253 -0.904 . . . . 0.0 109.539 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.58 122.14 38.99 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.268 -0.895 . . . . 0.0 109.47 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.418 ' O ' ' C ' ' A' ' 41' ' ' ASP . 44.4 p -101.92 -151.91 0.43 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 109.475 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.478 ' HA ' HG13 ' A' ' 13' ' ' ILE . 43.1 t0 -42.71 -62.82 0.9 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.277 -0.89 . . . . 0.0 109.613 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.7 mttt -149.48 17.78 0.92 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.212 -0.93 . . . . 0.0 109.474 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.469 HG12 ' H ' ' A' ' 44' ' ' VAL . 1.9 t -119.34 172.21 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.895 . . . . 0.0 109.503 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.537 ' O ' HG13 ' A' ' 44' ' ' VAL . 9.6 p -129.62 126.7 63.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.3 -0.875 . . . . 0.0 109.431 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . 0.473 ' O ' HG22 ' A' ' 38' ' ' ILE . 1.3 mtt -113.83 124.43 52.21 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.186 -0.946 . . . . 0.0 109.484 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.6 147.32 26.46 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.334 -0.854 . . . . 0.0 109.443 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.455 ' O ' ' HB ' ' A' ' 35' ' ' ILE . 55.9 t -116.06 103.87 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.184 -0.947 . . . . 0.0 109.504 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.403 HD21 ' N ' ' A' ' 33' ' ' GLU . 0.3 OUTLIER -105.03 163.85 12.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.915 . . . . 0.0 109.396 -179.89 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.791 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.88 164.83 18.16 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.159 -0.963 . . . . 0.0 109.456 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.698 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -105.82 3.67 28.97 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.542 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.698 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 163.94 167.54 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.184 -0.948 . . . . 0.0 109.455 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.502 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -49.96 170.98 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.291 -0.881 . . . . 0.0 109.313 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.502 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.93 -164.01 30.67 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.818 ' O ' HG22 ' A' ' 76' ' ' THR . 48.7 t -136.85 125.35 34.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -1.142 . . . . 0.0 109.427 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.875 HD13 ' CD1' ' A' ' 75' ' ' LEU . 15.3 mm -61.68 160.08 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.294 -0.879 . . . . 0.0 109.448 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.448 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -100.51 -66.31 0.92 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.306 -0.871 . . . . 0.0 109.492 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.529 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 33.4 tt0 177.34 141.68 0.08 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.294 -0.879 . . . . 0.0 109.46 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.705 HD12 ' CH2' ' A' ' 21' ' ' TRP . 15.3 mm -91.42 158.28 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.273 -0.892 . . . . 0.0 109.449 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.823 HG23 ' O ' ' A' ' 72' ' ' LEU . 52.8 t -90.03 -67.52 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.261 -0.899 . . . . 0.0 109.342 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.483 ' HD3' ' CB ' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -101.1 174.99 5.75 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.254 -0.904 . . . . 0.0 109.399 179.926 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -95.87 155.43 16.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.931 . . . . 0.0 109.469 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.537 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -60.1 149.94 31.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.3 -0.875 . . . . 0.0 109.387 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 92.39 -12.62 69.25 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.518 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -87.3 170.94 10.99 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.295 -1.12 . . . . 0.0 109.286 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.499 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 99.0 m -100.73 135.41 42.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.519 -0.738 . . . . 0.0 109.461 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.665 ' O ' HD23 ' A' ' 67' ' ' LEU . 5.2 m -118.58 -176.8 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.448 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.665 HD23 ' O ' ' A' ' 66' ' ' VAL . 13.2 mt -121.45 162.38 20.56 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.248 -0.907 . . . . 0.0 109.441 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 t -64.25 122.54 16.88 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.238 -0.914 . . . . 0.0 109.494 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 91.31 10.16 62.53 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -84.98 112.56 20.7 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.191 -1.182 . . . . 0.0 109.447 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.997 HD11 ' OD1' ' A' ' 3' ' ' ASP . 1.2 tp -72.49 127.11 31.55 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.319 -0.863 . . . . 0.0 109.496 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.823 ' O ' HG23 ' A' ' 59' ' ' VAL . 77.0 mt -93.92 -68.05 0.82 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.302 -0.874 . . . . 0.0 109.435 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -136.39 178.8 18.52 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.53 ' CG ' HD21 ' A' ' 71' ' ' LEU . 1.5 mtmp? -145.94 151.74 38.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -1.162 . . . . 0.0 109.472 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.875 ' CD1' HD13 ' A' ' 55' ' ' ILE . 13.2 tp -99.05 152.37 19.92 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.224 -0.923 . . . . 0.0 109.474 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.818 HG22 ' O ' ' A' ' 54' ' ' VAL . 3.0 t -106.55 -157.75 0.63 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.286 -0.884 . . . . 0.0 109.677 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.674 ' N ' HG23 ' A' ' 76' ' ' THR . 2.5 mt-10 -84.8 -82.0 0.18 Allowed 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 71.71 117.82 0.05 OUTLIER Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 CA-C-O 118.02 -1.433 . . . . 0.0 109.552 -179.996 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 24.3 mm -114.62 102.93 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.231 -0.918 . . . . 0.0 109.483 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.519 ' OD2' ' CD1' ' A' ' 71' ' ' LEU . 43.7 t0 -71.84 142.28 49.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.16 -0.963 . . . . 0.0 109.463 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.414 HD12 HG23 ' A' ' 4' ' ' ILE . 4.9 mm -112.19 103.83 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.225 -0.922 . . . . 0.0 109.415 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.63 166.02 10.67 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.225 -0.922 . . . . 0.0 109.468 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.494 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -72.72 159.69 84.72 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.27 -0.894 . . . . 0.0 109.435 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.494 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.18 165.29 26.03 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.57 2.18 . . . . 0.0 110.368 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -90.28 108.8 19.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.472 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -60.86 149.24 81.23 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.442 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.08 -160.6 0.12 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.626 2.218 . . . . 0.0 110.369 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.3 OUTLIER -77.4 -58.88 3.03 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.247 -0.908 . . . . 0.0 109.497 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.2 t -42.93 -55.97 3.49 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.359 -0.838 . . . . 0.0 109.594 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.464 ' CD1' ' HB2' ' A' ' 41' ' ' ASP . 12.0 mm -95.1 136.55 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.275 -0.891 . . . . 0.0 109.444 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.78 14.48 10.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.216 -0.927 . . . . 0.0 109.436 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.415 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -156.53 -171.34 3.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.244 -0.91 . . . . 0.0 109.419 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.5 178.82 39.59 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.696 HG23 ' O ' ' A' ' 64' ' ' ASP . 17.8 m -150.03 119.25 6.79 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.23 -1.159 . . . . 0.0 109.367 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.503 HG12 ' N ' ' A' ' 19' ' ' ALA . 46.4 t -44.25 162.99 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.438 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.511 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -106.2 -75.47 0.63 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -0.906 . . . . 0.0 109.58 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.474 ' HA ' ' HB3' ' A' ' 62' ' ' GLU . 17.3 m -160.01 136.23 8.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.238 -0.914 . . . . 0.0 109.531 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.636 ' CH2' HD12 ' A' ' 58' ' ' ILE . 35.1 m95 -89.85 84.11 6.22 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.244 -0.91 . . . . 0.0 109.512 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.588 ' CE1' HD21 ' A' ' 34' ' ' LEU . 2.3 m80 -42.59 -55.64 3.44 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.44 -0.788 . . . . 0.0 109.531 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -109.82 158.71 17.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.098 -1.001 . . . . 0.0 109.612 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.426 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 4.9 mttt -97.22 167.99 10.99 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.275 -0.891 . . . . 0.0 109.428 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.485 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.68 101.84 1.55 Allowed 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.625 2.216 . . . . 0.0 110.446 179.869 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.5 -5.08 4.48 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.477 ' N ' ' CD ' ' A' ' 27' ' ' GLU . 1.3 mp0 -90.36 -172.66 3.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.18 -1.188 . . . . 0.0 109.458 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -97.3 149.83 21.63 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.301 -0.874 . . . . 0.0 109.438 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.6 m -135.5 161.55 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.214 -0.929 . . . . 0.0 109.514 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.8 tttt -129.29 135.29 48.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.24 -0.912 . . . . 0.0 109.52 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.433 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 9.2 ttt180 -42.86 140.34 1.39 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.325 -0.86 . . . . 0.0 109.613 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 18.0 t0 70.82 47.0 0.47 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.23 -0.919 . . . . 0.0 109.516 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.434 ' O ' ' O ' ' A' ' 34' ' ' LEU . 29.4 tt0 -140.12 121.99 15.51 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.279 -0.888 . . . . 0.0 109.558 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.588 HD21 ' CE1' ' A' ' 22' ' ' HIS . 47.4 tp -43.14 164.56 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.278 -0.889 . . . . 0.0 109.587 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.607 HG13 ' HB2' ' A' ' 49' ' ' ALA . 25.4 mm -145.27 -42.56 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.185 -0.947 . . . . 0.0 109.535 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.506 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 12.7 p -154.7 134.18 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.234 -0.916 . . . . 0.0 109.551 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.511 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 22.1 m-20 -100.39 159.45 15.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.267 -0.896 . . . . 0.0 109.463 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.519 ' CG2' ' HB2' ' A' ' 45' ' ' MET . 7.3 tt -128.87 156.9 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.463 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.409 ' N ' HG12 ' A' ' 38' ' ' ILE . 1.3 tt0 -129.65 142.78 50.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.208 -0.933 . . . . 0.0 109.423 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.721 HG22 ' O ' ' A' ' 43' ' ' VAL . 5.5 t -132.01 -163.45 1.34 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.256 -0.903 . . . . 0.0 109.362 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.464 ' HB2' ' CD1' ' A' ' 13' ' ' ILE . 2.2 t0 -42.34 -68.0 0.22 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.317 -0.864 . . . . 0.0 109.782 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . 0.512 ' O ' ' CG2' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -142.97 48.76 1.49 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.136 -0.978 . . . . 0.0 109.541 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.721 ' O ' HG22 ' A' ' 40' ' ' THR . 90.0 t -159.04 118.04 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.251 -0.906 . . . . 0.0 109.499 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.6 t -100.57 126.63 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.487 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . 0.519 ' HB2' ' CG2' ' A' ' 38' ' ' ILE . 31.4 mtt -106.44 -179.65 4.0 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.456 ' HA ' ' OD1' ' A' ' 37' ' ' ASP . 3.7 mt-10 -133.52 146.96 51.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.249 -0.907 . . . . 0.0 109.44 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.506 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 36.2 t -117.76 106.68 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.492 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.515 HD12 ' HA ' ' A' ' 34' ' ' LEU . 0.6 OUTLIER -89.99 161.35 15.92 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.294 -0.879 . . . . 0.0 109.377 -179.964 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.607 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -81.03 160.91 24.42 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.44 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.701 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.5 OUTLIER -99.02 2.12 45.99 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.178 -0.951 . . . . 0.0 109.608 179.958 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.18 155.34 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.212 -0.93 . . . . 0.0 109.478 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.503 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -65.12 170.86 4.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.33 -0.856 . . . . 0.0 109.321 -179.995 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.503 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.45 -137.59 6.09 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.47 ' O ' ' CB ' ' A' ' 76' ' ' THR . 44.8 t -139.87 135.25 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.338 -1.095 . . . . 0.0 109.448 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.433 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 9.5 mm -75.74 153.9 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.332 -0.855 . . . . 0.0 109.457 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -87.94 -65.99 0.96 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.208 -0.933 . . . . 0.0 109.397 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.485 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -178.88 139.21 0.16 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -0.907 . . . . 0.0 109.399 179.949 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.636 HD12 ' CH2' ' A' ' 21' ' ' TRP . 23.1 mm -94.84 138.69 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.233 -0.917 . . . . 0.0 109.515 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 96.1 t -110.04 -14.52 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.309 -0.869 . . . . 0.0 109.425 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.711 ' HE2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -91.04 -172.4 3.32 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.286 -0.884 . . . . 0.0 109.39 179.995 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 46.2 m-80 -137.05 155.95 49.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.328 -0.858 . . . . 0.0 109.576 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.474 ' HB3' ' HA ' ' A' ' 20' ' ' THR . 0.5 OUTLIER -72.18 144.14 48.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.265 -0.897 . . . . 0.0 109.518 -179.939 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 57.54 19.56 34.84 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.696 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -99.4 170.95 8.27 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.262 -1.14 . . . . 0.0 109.352 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 11.5 t -88.17 154.25 20.6 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.525 -0.734 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.711 HG12 ' HE2' ' A' ' 60' ' ' LYS . 1.5 m -141.67 173.94 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.233 -0.917 . . . . 0.0 109.42 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.469 ' O ' ' HB2' ' A' ' 70' ' ' GLU . 0.3 OUTLIER -127.99 162.56 26.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.301 -0.875 . . . . 0.0 109.433 -179.956 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 6.6 t -56.53 143.71 34.34 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.19 -0.944 . . . . 0.0 109.478 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 58.99 24.61 58.49 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.469 ' HB2' ' O ' ' A' ' 67' ' ' LEU . 13.9 tp10 -79.21 105.23 10.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -1.184 . . . . 0.0 109.491 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.519 ' CD1' ' OD2' ' A' ' 3' ' ' ASP . 0.4 OUTLIER -61.99 130.39 45.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.275 -0.89 . . . . 0.0 109.392 -179.915 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 7.9 mt -100.84 -71.12 0.72 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.27 -0.894 . . . . 0.0 109.45 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -144.39 -176.9 18.82 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 10.0 mtmt -128.26 151.67 49.01 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.313 -1.11 . . . . 0.0 109.462 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -103.63 152.09 22.17 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.174 -0.954 . . . . 0.0 109.512 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.575 HG22 ' H ' ' A' ' 77' ' ' GLU . 13.0 m -107.39 171.75 7.21 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 109.427 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.575 ' H ' HG22 ' A' ' 76' ' ' THR . 1.3 mm-40 -79.73 167.09 21.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.293 -0.88 . . . . 0.0 109.493 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -148.68 -65.16 0.01 OUTLIER Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 CA-C-O 117.997 -1.446 . . . . 0.0 109.53 179.999 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.448 ' HA ' ' O ' ' A' ' 75' ' ' LEU . . . . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 62.9 mt -137.33 126.1 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.192 -0.942 . . . . 0.0 109.461 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.506 ' OD2' ' CG ' ' A' ' 5' ' ' LYS . 24.9 t0 -61.04 154.54 22.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.2 -0.937 . . . . 0.0 109.496 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 16.4 mt -123.58 98.59 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.286 -0.884 . . . . 0.0 109.429 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.506 ' CG ' ' OD2' ' A' ' 3' ' ' ASP . 3.8 mtmt -122.39 154.76 37.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.914 . . . . 0.0 109.465 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.579 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -78.93 162.5 64.56 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.252 -0.905 . . . . 0.0 109.52 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.579 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.8 Cg_endo -78.04 159.57 30.44 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.555 2.17 . . . . 0.0 110.485 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.1 m -73.74 142.36 46.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.348 -0.845 . . . . 0.0 109.436 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.574 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 25.6 m-85 -89.88 156.95 46.72 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.27 -0.894 . . . . 0.0 109.512 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -77.97 -167.12 0.45 Allowed 'Trans proline' 0 C--N 1.309 -1.516 0 C-N-CA 122.655 2.237 . . . . 0.0 110.48 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.438 ' O ' ' C ' ' A' ' 12' ' ' SER . 39.0 tt0 -75.24 -56.38 4.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.176 -0.953 . . . . 0.0 109.456 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 11' ' ' GLU . 4.9 t -42.72 -52.8 4.8 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.3 -0.875 . . . . 0.0 109.619 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.595 HG22 ' H ' ' A' ' 15' ' ' ASP . 25.2 mt -94.1 147.42 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.236 -0.915 . . . . 0.0 109.494 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -124.33 6.54 8.4 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.183 -0.948 . . . . 0.0 109.615 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.595 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER 178.91 -172.53 0.15 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.236 -0.915 . . . . 0.0 109.488 -179.974 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.413 ' C ' HG22 ' A' ' 66' ' ' VAL . . . -154.78 -157.41 8.18 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.65 HG23 ' O ' ' A' ' 64' ' ' ASP . 36.4 m -150.02 135.4 18.15 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -1.135 . . . . 0.0 109.529 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 19' ' ' ALA . 19.5 t -55.88 158.78 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 109.461 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.625 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -101.94 -76.81 0.56 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.154 -0.967 . . . . 0.0 109.485 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 19.6 m -160.04 136.61 9.0 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.602 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.839 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 32.4 m95 -89.99 83.15 6.09 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.259 -0.9 . . . . 0.0 109.491 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.64 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.7 m80 -43.02 -68.34 0.2 Allowed 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.313 -0.867 . . . . 0.0 109.395 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.11 -172.0 3.17 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.259 -0.9 . . . . 0.0 109.561 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.407 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 7.8 mttp -141.09 168.29 14.66 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.31 -0.869 . . . . 0.0 109.4 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.791 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.0 Cg_endo -76.55 125.96 8.65 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.569 2.179 . . . . 0.0 110.467 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 117.19 10.96 9.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 45.6 mm-40 -128.4 -172.3 2.67 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.207 -1.172 . . . . 0.0 109.472 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -100.91 179.39 4.4 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.266 -0.896 . . . . 0.0 109.468 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.612 HG12 ' N ' ' A' ' 30' ' ' LYS . 64.6 t -147.04 165.95 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.293 -0.879 . . . . 0.0 109.451 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.612 ' N ' HG12 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -112.34 132.38 55.02 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.565 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.477 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -43.01 121.01 1.96 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.291 -0.88 . . . . 0.0 109.604 -179.931 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.477 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 3.0 t70 73.94 55.21 0.1 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.26 -0.9 . . . . 0.0 109.484 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 34' ' ' LEU . 2.3 tp10 -131.74 126.51 34.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.278 -0.888 . . . . 0.0 109.475 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.64 HD21 ' NE2' ' A' ' 22' ' ' HIS . 48.6 tp -42.89 161.68 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.288 -0.882 . . . . 0.0 109.586 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 34' ' ' LEU . 29.8 mm -144.72 -42.56 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.209 -0.932 . . . . 0.0 109.586 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.541 HG12 ' HB ' ' A' ' 47' ' ' VAL . 9.4 p -152.3 137.18 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.224 -0.923 . . . . 0.0 109.514 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.625 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 25.1 m-20 -100.71 163.14 12.47 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -0.871 . . . . 0.0 109.411 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.6 mt -129.86 154.34 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.232 -0.918 . . . . 0.0 109.517 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.483 ' HB3' ' O ' ' A' ' 17' ' ' THR . 27.8 tt0 -116.57 149.66 39.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.46 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.415 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -133.94 174.57 10.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.268 -0.895 . . . . 0.0 109.487 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 40' ' ' THR . 5.6 t0 -42.9 -64.68 0.58 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.334 -0.853 . . . . 0.0 109.624 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . 0.46 ' C ' HG23 ' A' ' 43' ' ' VAL . 11.6 mttp -134.06 39.76 3.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.217 -0.927 . . . . 0.0 109.479 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.46 HG23 ' C ' ' A' ' 42' ' ' LYS . 38.5 t -155.23 143.63 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.222 -0.924 . . . . 0.0 109.474 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 81.9 t -115.76 136.28 53.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.871 . . . . 0.0 109.487 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 84.4 mtp -121.36 178.27 4.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.213 -0.929 . . . . 0.0 109.456 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -137.27 160.03 40.22 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.218 -0.926 . . . . 0.0 109.467 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.541 ' HB ' HG12 ' A' ' 36' ' ' VAL . 21.3 t -127.2 104.78 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.94 . . . . 0.0 109.559 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.522 HD12 ' CD1' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -95.58 158.16 15.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.347 -0.845 . . . . 0.0 109.491 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.464 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -82.56 161.94 22.12 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.271 -0.893 . . . . 0.0 109.45 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.707 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -89.3 -0.49 57.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.229 -0.919 . . . . 0.0 109.618 179.994 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.707 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.12 162.75 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.48 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.507 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -53.64 171.05 0.1 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.257 -0.902 . . . . 0.0 109.367 179.955 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.507 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 154.54 -150.88 22.57 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.8 t -136.2 123.11 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -1.172 . . . . 0.0 109.493 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.552 HG22 ' N ' ' A' ' 56' ' ' ALA . 15.5 mm -61.66 166.29 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -0.915 . . . . 0.0 109.512 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.552 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -105.46 -67.21 0.93 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.252 -0.905 . . . . 0.0 109.464 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.532 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 2.9 tm-20 -174.6 150.13 1.33 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.139 -0.976 . . . . 0.0 109.577 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.839 HG23 ' CZ2' ' A' ' 21' ' ' TRP . 8.1 mt -89.98 151.72 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.279 -0.888 . . . . 0.0 109.514 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.437 HG21 ' O ' ' A' ' 71' ' ' LEU . 56.0 t -97.16 -67.01 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.267 -0.896 . . . . 0.0 109.453 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.421 ' HD2' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -92.62 -170.71 2.54 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.232 -0.917 . . . . 0.0 109.451 179.988 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.468 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 12.6 m-80 -125.24 168.52 13.36 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.209 -0.932 . . . . 0.0 109.512 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.4 ' HA ' ' HB ' ' A' ' 18' ' ' VAL . 0.2 OUTLIER -65.99 149.8 49.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.196 -0.94 . . . . 0.0 109.542 179.931 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 82.07 4.94 90.09 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.65 ' O ' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER -99.93 170.89 8.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.16 -1.2 . . . . 0.0 109.319 179.969 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.509 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 28.3 m -95.46 126.29 40.65 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.522 -0.737 . . . . 0.0 109.504 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.413 HG22 ' C ' ' A' ' 16' ' ' GLY . 18.8 m -89.97 176.38 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.33 -0.856 . . . . 0.0 109.427 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -142.51 164.09 31.06 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.141 -0.974 . . . . 0.0 109.443 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.1 t -58.14 133.17 55.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 109.453 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 62.75 24.58 66.58 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 30.1 tp10 -73.47 119.55 17.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.255 -1.144 . . . . 0.0 109.431 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.45 HD23 ' N ' ' A' ' 73' ' ' GLY . 6.8 tt -75.93 109.08 9.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.199 -0.938 . . . . 0.0 109.444 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -88.81 -10.44 48.12 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.177 -0.952 . . . . 0.0 109.477 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.45 ' N ' HD23 ' A' ' 71' ' ' LEU . . . 157.59 -175.4 34.94 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 1.3 mtmm -138.84 149.08 44.52 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.193 -1.18 . . . . 0.0 109.498 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 1' ' ' ALA . 0.8 OUTLIER -100.3 146.95 26.32 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.264 -0.898 . . . . 0.0 109.448 -179.915 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.569 HG22 ' H ' ' A' ' 77' ' ' GLU . 14.9 m -114.43 171.97 7.3 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.246 -0.909 . . . . 0.0 109.483 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.569 ' H ' HG22 ' A' ' 76' ' ' THR . 0.8 OUTLIER -77.94 -148.81 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 0.0 109.434 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 156.98 147.38 4.76 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 CA-C-O 117.986 -1.452 . . . . 0.0 109.491 179.989 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.43 ' C ' HG13 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.43 HG13 ' C ' ' A' ' 1' ' ' ALA . 3.7 mt -149.14 124.07 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.249 -0.907 . . . . 0.0 109.503 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -71.13 150.91 44.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.318 -0.864 . . . . 0.0 109.486 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.3 mt -127.2 72.6 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.232 -0.918 . . . . 0.0 109.426 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.422 ' HA ' ' HG ' ' A' ' 72' ' ' LEU . 5.0 pttp -101.34 167.99 9.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.194 -0.941 . . . . 0.0 109.472 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.45 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -66.34 158.02 79.52 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.344 -0.848 . . . . 0.0 109.438 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.45 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.2 Cg_endo -78.05 169.26 20.71 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.586 2.191 . . . . 0.0 110.422 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.7 141.35 40.94 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.464 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.53 ' CD2' ' HB2' ' A' ' 68' ' ' SER . 18.6 m-85 -107.91 153.07 41.86 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.23 -0.919 . . . . 0.0 109.462 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.445 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -78.06 167.41 23.49 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.593 2.195 . . . . 0.0 110.373 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.1 mt-10 -49.45 -53.52 22.53 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.2 -0.938 . . . . 0.0 109.54 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 11' ' ' GLU . 19.1 t -42.75 -48.88 5.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.385 -0.822 . . . . 0.0 109.631 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.816 HG21 ' CG2' ' A' ' 40' ' ' THR . 22.5 mt -96.18 122.05 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.223 -0.923 . . . . 0.0 109.402 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -101.13 11.46 39.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.214 -0.929 . . . . 0.0 109.439 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.598 ' O ' HG22 ' A' ' 13' ' ' ILE . 0.9 OUTLIER -176.67 -170.13 0.31 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.247 -0.908 . . . . 0.0 109.403 179.982 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.613 ' O ' HG23 ' A' ' 65' ' ' THR . . . -151.58 -173.33 21.28 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.523 HG23 ' O ' ' A' ' 64' ' ' ASP . 4.2 m -150.04 127.93 11.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -1.147 . . . . 0.0 109.411 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.531 HG12 ' N ' ' A' ' 19' ' ' ALA . 47.9 t -54.31 164.05 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.218 -0.926 . . . . 0.0 109.45 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.558 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -109.7 -73.86 0.67 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.26 -0.9 . . . . 0.0 109.518 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.534 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 18.3 m -158.46 134.67 9.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.211 -0.931 . . . . 0.0 109.489 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.656 ' CH2' HD12 ' A' ' 58' ' ' ILE . 35.1 m95 -89.7 84.7 6.32 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.231 -0.918 . . . . 0.0 109.567 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.799 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.2 m80 -42.76 -60.31 1.62 Allowed 'General case' 0 N--CA 1.499 2.004 0 O-C-N 121.401 -0.812 . . . . 0.0 109.483 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.405 ' HA ' ' HD2' ' A' ' 23' ' ' LYS . 1.1 mmmt -100.28 -171.99 2.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -0.873 . . . . 0.0 109.562 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.439 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -124.54 169.17 11.31 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.254 -0.904 . . . . 0.0 109.483 -179.934 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.514 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.2 Cg_endo -76.48 94.24 1.04 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.67 2.247 . . . . 0.0 110.409 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 151.04 -17.45 0.92 Allowed Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -84.75 170.68 13.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -1.134 . . . . 0.0 109.541 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.11 127.94 42.57 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.886 . . . . 0.0 109.389 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.584 HG22 ' O ' ' A' ' 53' ' ' GLY . 18.3 m -96.63 -172.04 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.464 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.426 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -148.4 136.97 21.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.47 -179.959 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.454 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 10.3 tmm_? -42.79 128.28 4.14 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.319 -0.863 . . . . 0.0 109.624 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 7.7 t70 72.81 54.36 0.14 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.276 -0.89 . . . . 0.0 109.453 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.466 ' N ' HD23 ' A' ' 48' ' ' LEU . 1.4 tp10 -141.91 120.78 12.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.296 -0.877 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.799 HD21 ' NE2' ' A' ' 22' ' ' HIS . 47.9 tp -42.87 142.31 0.92 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.309 -0.87 . . . . 0.0 109.581 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.589 HG13 ' HB2' ' A' ' 49' ' ' ALA . 22.7 mm -129.75 -42.15 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.889 . . . . 0.0 109.443 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.585 HG12 ' HB ' ' A' ' 47' ' ' VAL . 7.3 p -157.53 144.43 9.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.296 -0.878 . . . . 0.0 109.466 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.558 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 19.6 m-20 -102.68 150.3 23.58 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.627 HD11 HG22 ' A' ' 47' ' ' VAL . 21.8 mt -110.47 150.72 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.186 -0.946 . . . . 0.0 109.464 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -141.7 98.73 3.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.486 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.816 ' CG2' HG21 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -90.19 -174.37 4.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.202 -0.936 . . . . 0.0 109.488 -179.996 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.626 ' H ' HG22 ' A' ' 40' ' ' THR . 0.6 OUTLIER -42.87 -45.18 4.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.274 -0.891 . . . . 0.0 109.647 -179.866 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . 0.434 ' HG3' ' O ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -156.28 27.33 0.35 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.199 -0.938 . . . . 0.0 109.446 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 3.5 t -128.36 106.66 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.327 -0.858 . . . . 0.0 109.42 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.5 t -90.31 130.48 39.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.242 -0.911 . . . . 0.0 109.484 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 10.2 mmt -141.86 108.45 5.34 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.181 -0.95 . . . . 0.0 109.476 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.477 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 5.4 mt-10 -63.0 172.08 1.92 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.278 -0.889 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.627 HG22 HD11 ' A' ' 38' ' ' ILE . 15.7 t -135.25 102.32 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.236 -0.915 . . . . 0.0 109.504 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.466 HD23 ' N ' ' A' ' 33' ' ' GLU . 0.0 OUTLIER -94.5 154.85 17.21 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.479 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.589 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -84.94 143.15 29.16 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.227 -0.921 . . . . 0.0 109.525 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.31 13.93 31.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.325 -0.859 . . . . 0.0 109.45 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -179.7 140.83 0.14 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.322 -0.862 . . . . 0.0 109.454 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -59.83 170.89 1.02 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.248 -0.908 . . . . 0.0 109.309 179.999 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.584 ' O ' HG22 ' A' ' 29' ' ' VAL . . . 154.32 175.84 25.97 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.576 ' O ' HG22 ' A' ' 76' ' ' THR . 49.2 t -112.93 124.83 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.206 -1.173 . . . . 0.0 109.498 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.939 HD13 HD12 ' A' ' 75' ' ' LEU . 15.6 mm -61.25 164.82 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.488 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.524 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -106.39 -63.7 1.24 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.314 -0.867 . . . . 0.0 109.462 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.488 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -170.41 136.43 1.33 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.16 -0.962 . . . . 0.0 109.528 -179.915 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.656 HD12 ' CH2' ' A' ' 21' ' ' TRP . 26.6 mm -89.94 141.37 14.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.343 -0.848 . . . . 0.0 109.452 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 89.1 t -90.18 -62.46 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -0.912 . . . . 0.0 109.55 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.474 ' HG2' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -89.95 155.1 19.35 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 109.44 -179.917 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -102.54 158.47 16.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.247 -0.908 . . . . 0.0 109.433 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.534 ' CB ' ' HA ' ' A' ' 20' ' ' THR . 2.1 pp20? -60.81 143.35 54.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.206 -0.934 . . . . 0.0 109.451 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 98.48 -10.32 62.99 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.523 ' O ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -100.16 170.9 8.15 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.239 -1.153 . . . . 0.0 109.274 -179.971 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.613 HG23 ' O ' ' A' ' 16' ' ' GLY . 47.5 m -101.54 146.91 27.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.492 -0.755 . . . . 0.0 109.484 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.41 160.94 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.226 -0.921 . . . . 0.0 109.497 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 15.0 mt -90.42 145.28 25.05 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.246 -0.909 . . . . 0.0 109.476 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.53 ' HB2' ' CD2' ' A' ' 9' ' ' PHE . 1.9 t -49.33 114.32 1.0 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.295 -0.878 . . . . 0.0 109.515 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.45 22.43 24.34 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 38.9 tp10 -84.0 131.9 34.79 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.293 -1.122 . . . . 0.0 109.483 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 4.9 tt -66.09 114.25 5.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.261 -0.899 . . . . 0.0 109.501 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.55 ' O ' HG23 ' A' ' 58' ' ' ILE . 6.1 mt -96.59 -22.17 17.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.266 -0.896 . . . . 0.0 109.456 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.38 159.83 23.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -124.32 133.98 53.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.265 -1.138 . . . . 0.0 109.483 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.939 HD12 HD13 ' A' ' 55' ' ' ILE . 4.5 tp -92.35 152.09 19.94 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.92 . . . . 0.0 109.503 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.667 HG23 ' N ' ' A' ' 77' ' ' GLU . 2.9 t -104.87 -157.8 0.63 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.313 -0.867 . . . . 0.0 109.727 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.667 ' N ' HG23 ' A' ' 76' ' ' THR . 8.5 mm-40 -74.08 -179.25 3.71 Favored 'General case' 0 C--N 1.295 -1.791 0 CA-C-O 121.313 0.578 . . . . 0.0 109.458 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.463 ' HA2' ' HA2' ' A' ' 53' ' ' GLY . . . -78.46 -37.61 27.03 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.286 0 CA-C-O 118.013 -1.437 . . . . 0.0 109.558 -179.971 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 121.287 0.565 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.575 HD12 HD22 ' A' ' 75' ' ' LEU . 25.1 mt -114.58 109.1 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.915 . . . . 0.0 109.494 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -77.67 124.03 27.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.244 -0.91 . . . . 0.0 109.459 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.6 mm -100.32 108.28 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.235 -0.916 . . . . 0.0 109.472 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.5 mtmt -125.15 165.72 17.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.627 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -75.59 163.41 67.53 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.207 -0.933 . . . . 0.0 109.528 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.627 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.09 134.69 13.23 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.637 2.225 . . . . 0.0 110.436 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.1 m -57.64 134.74 56.44 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.194 -0.941 . . . . 0.0 109.503 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.479 ' CE1' ' O ' ' A' ' 7' ' ' PRO . 4.2 m-85 -94.97 149.17 35.88 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.201 -0.937 . . . . 0.0 109.415 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 9' ' ' PHE . 35.8 Cg_endo -78.09 -165.22 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.621 2.214 . . . . 0.0 110.456 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.1 OUTLIER -72.41 -49.19 35.53 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.414 179.995 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 11' ' ' GLU . 30.9 t -42.78 -52.12 5.12 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.308 -0.87 . . . . 0.0 109.635 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.783 HG22 ' H ' ' A' ' 15' ' ' ASP . 3.2 mt -92.95 150.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.206 -0.934 . . . . 0.0 109.439 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.419 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -122.28 12.77 10.25 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.327 -0.858 . . . . 0.0 109.494 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.783 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.3 OUTLIER 170.75 -170.76 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.256 -0.902 . . . . 0.0 109.499 -179.987 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.09 -169.92 18.09 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.471 HG23 ' O ' ' A' ' 64' ' ' ASP . 17.1 m -149.94 128.78 12.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -1.126 . . . . 0.0 109.469 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.44 HG12 ' N ' ' A' ' 19' ' ' ALA . 25.5 t -52.35 160.65 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.336 -0.852 . . . . 0.0 109.489 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.651 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -100.52 -75.63 0.58 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.473 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.7 m -160.11 136.11 8.57 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.564 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.721 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 33.4 m95 -89.76 82.46 6.26 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.256 -0.902 . . . . 0.0 109.64 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.668 ' CE1' HD21 ' A' ' 34' ' ' LEU . 1.8 m80 -43.57 -71.46 0.08 Allowed 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.284 -0.885 . . . . 0.0 109.362 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.404 ' HB2' ' HE3' ' A' ' 23' ' ' LYS . 30.0 mtmt -100.09 -171.93 2.13 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.245 -0.909 . . . . 0.0 109.571 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.62 167.39 19.41 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.328 -0.858 . . . . 0.0 109.465 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.835 ' HD3' HD11 ' A' ' 58' ' ' ILE . 35.5 Cg_endo -76.92 153.18 32.69 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.66 2.24 . . . . 0.0 110.412 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.11 9.49 67.48 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 41.5 mm-40 -113.38 -173.33 2.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.172 -1.193 . . . . 0.0 109.418 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -83.58 132.5 34.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.457 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.6 t -123.28 138.26 53.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.458 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 31' ' ' ARG . 10.1 mttt -119.01 132.95 56.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.437 ' C ' ' O ' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -42.9 143.39 0.74 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.258 -0.901 . . . . 0.0 109.595 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.435 ' N ' ' HD2' ' A' ' 31' ' ' ARG . 17.6 t0 69.56 46.76 0.7 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.224 -0.923 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.452 ' O ' HG12 ' A' ' 35' ' ' ILE . 1.8 tp10 -140.41 110.19 6.41 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.229 -0.92 . . . . 0.0 109.49 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.668 HD21 ' CE1' ' A' ' 22' ' ' HIS . 55.7 tp -42.97 161.51 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.27 -0.894 . . . . 0.0 109.604 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.519 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 22.2 mm -149.9 -40.25 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.213 -0.929 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.522 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 13.5 p -151.03 131.01 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.257 -0.902 . . . . 0.0 109.541 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.651 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 12.9 m-20 -97.96 171.94 7.95 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.247 -0.908 . . . . 0.0 109.485 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 2.5 mt -138.74 164.49 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.288 -0.882 . . . . 0.0 109.44 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.446 ' HB2' ' O ' ' A' ' 17' ' ' THR . 37.4 mt-10 -132.95 141.6 48.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.238 -0.913 . . . . 0.0 109.419 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -126.35 -160.48 0.99 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 -179.992 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 40' ' ' THR . 3.8 t70 -42.87 -63.1 0.85 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.277 -0.889 . . . . 0.0 109.563 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . 0.412 ' HG2' ' O ' ' A' ' 41' ' ' ASP . 6.6 mttt -145.65 22.3 1.46 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 1.9 t -127.42 139.22 52.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.226 -0.921 . . . . 0.0 109.437 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.415 ' O ' HG13 ' A' ' 44' ' ' VAL . 9.1 p -105.98 134.26 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.403 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . 0.427 ' C ' ' HG3' ' A' ' 46' ' ' GLU . 8.8 mtm -113.55 -176.81 2.98 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.264 -0.897 . . . . 0.0 109.463 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.478 ' HB3' HD13 ' A' ' 34' ' ' LEU . 29.1 mt-10 -143.97 161.65 38.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.307 -0.87 . . . . 0.0 109.402 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.522 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 63.5 t -136.72 108.25 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.773 ' N ' HD23 ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.89 148.9 25.07 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.286 -0.883 . . . . 0.0 109.381 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -63.55 147.62 50.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.442 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.699 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 1.1 mt-10 -93.05 10.49 31.28 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.239 -0.913 . . . . 0.0 109.473 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.699 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 164.34 157.23 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.257 -0.902 . . . . 0.0 109.479 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.508 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -65.55 170.96 4.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.336 -0.852 . . . . 0.0 109.348 -179.977 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.508 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.31 -143.79 10.94 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.8 t -138.21 124.46 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.249 -1.147 . . . . 0.0 109.489 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.552 HG22 ' N ' ' A' ' 56' ' ' ALA . 9.6 mm -75.13 171.76 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.3 -0.875 . . . . 0.0 109.523 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.552 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -102.88 -62.45 1.27 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.203 -0.935 . . . . 0.0 109.514 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.534 ' HA ' ' CG ' ' A' ' 25' ' ' PRO . 5.3 pt-20 173.27 161.05 0.14 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 109.533 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.835 HD11 ' HD3' ' A' ' 25' ' ' PRO . 1.6 mp -90.43 143.84 10.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.255 -0.903 . . . . 0.0 109.44 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.927 HG21 HD23 ' A' ' 71' ' ' LEU . 53.5 t -99.42 -21.09 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.214 -0.929 . . . . 0.0 109.47 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.518 ' CG ' ' OD2' ' A' ' 64' ' ' ASP . 9.8 tptt -120.65 -171.87 2.27 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.248 -0.907 . . . . 0.0 109.559 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.478 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 17.1 m120 -123.25 167.9 13.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.896 . . . . 0.0 109.49 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -71.52 143.03 50.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.272 -0.893 . . . . 0.0 109.533 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 72.86 17.06 78.18 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.716 -1.353 . . . . 0.0 109.716 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.518 ' OD2' ' CG ' ' A' ' 60' ' ' LYS . 0.2 OUTLIER -100.65 170.83 8.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.232 -1.157 . . . . 0.0 109.331 179.966 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.513 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.8 t -90.94 153.78 19.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.481 -0.762 . . . . 0.0 109.53 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 16.1 m -133.39 144.49 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.227 -0.921 . . . . 0.0 109.517 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -92.67 160.73 14.86 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.3 -0.875 . . . . 0.0 109.387 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.2 t -52.89 119.3 4.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.129 -0.982 . . . . 0.0 109.493 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 74.53 33.36 56.24 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -76.8 137.73 39.43 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.277 -1.131 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.927 HD23 HG21 ' A' ' 59' ' ' VAL . 0.6 OUTLIER -78.19 128.32 33.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.456 -179.961 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 7.5 mt -105.76 -23.17 12.78 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.313 -0.867 . . . . 0.0 109.459 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 171.87 171.16 36.63 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 4.4 mtmt -127.78 136.81 52.0 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.27 -1.135 . . . . 0.0 109.509 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.575 HD22 HD12 ' A' ' 2' ' ' ILE . 2.7 tt -97.75 151.27 20.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.235 -0.916 . . . . 0.0 109.508 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.574 ' O ' HD23 ' A' ' 75' ' ' LEU . 15.1 m -112.36 171.9 7.24 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.262 -0.899 . . . . 0.0 109.464 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.56 ' H ' HG22 ' A' ' 76' ' ' THR . 19.0 mt-10 -70.26 -68.86 0.39 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.177 -0.952 . . . . 0.0 109.462 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 134.99 -170.81 22.71 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 CA-C-O 118.0 -1.444 . . . . 0.0 109.535 179.983 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.1 pp -143.88 133.97 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.29 -0.881 . . . . 0.0 109.471 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.508 ' OD2' HD11 ' A' ' 71' ' ' LEU . 8.9 t70 -80.41 133.42 35.88 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.178 -0.951 . . . . 0.0 109.449 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 12.2 mt -96.45 107.76 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.1 mttt -121.28 173.36 7.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.909 . . . . 0.0 109.449 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.96 149.19 82.52 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.292 -0.88 . . . . 0.0 109.468 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.02 135.87 14.28 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.661 2.24 . . . . 0.0 110.372 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.519 HG23 ' O ' ' A' ' 8' ' ' THR . 3.0 t -56.73 112.33 1.27 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.202 -0.936 . . . . 0.0 109.474 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -67.24 157.45 85.19 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.867 . . . . 0.0 109.431 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.455 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.07 -159.61 0.1 Allowed 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.557 2.171 . . . . 0.0 110.423 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.416 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.1 tt0 -80.07 -61.94 1.83 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.25 -0.906 . . . . 0.0 109.521 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.416 ' C ' ' O ' ' A' ' 11' ' ' GLU . 1.9 t -42.81 -47.51 5.53 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.296 -0.877 . . . . 0.0 109.633 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.522 HD11 ' HB2' ' A' ' 41' ' ' ASP . 16.6 mt -99.81 130.16 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.234 -0.916 . . . . 0.0 109.418 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -118.79 28.15 8.47 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.274 -0.891 . . . . 0.0 109.383 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.491 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 176.42 -170.44 0.07 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.314 -0.866 . . . . 0.0 109.429 -179.978 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.85 -173.53 33.58 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 18' ' ' VAL . 16.7 m -149.91 122.75 8.71 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.154 -1.204 . . . . 0.0 109.422 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.426 ' C ' ' O ' ' A' ' 17' ' ' THR . 47.1 t -44.24 156.96 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -0.905 . . . . 0.0 109.41 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.412 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -106.12 -74.9 0.64 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -0.906 . . . . 0.0 109.475 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.8 m -158.85 134.81 8.93 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.258 -0.901 . . . . 0.0 109.413 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.632 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 33.1 m95 -89.85 84.4 6.24 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.232 -0.917 . . . . 0.0 109.565 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.763 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.1 m80 -42.93 -63.25 0.83 Allowed 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.364 -0.835 . . . . 0.0 109.372 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -92.39 -172.07 2.98 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.187 -0.946 . . . . 0.0 109.509 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.48 ' HB2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -136.47 164.39 43.06 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.272 -0.893 . . . . 0.0 109.452 -179.95 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.482 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -77.59 90.38 1.26 Allowed 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 122.688 2.259 . . . . 0.0 110.36 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 160.56 -23.28 0.25 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 49.6 mm-40 -94.38 -172.43 2.78 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.35 -1.088 . . . . 0.0 109.472 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -105.0 149.1 26.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.241 -0.912 . . . . 0.0 109.483 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.0 m -120.55 175.66 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.269 -0.894 . . . . 0.0 109.431 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.09 130.6 50.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.425 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 14.1 ttt180 -42.91 141.65 1.07 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.287 -0.883 . . . . 0.0 109.625 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.7 t70 65.55 45.56 2.71 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.434 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.426 ' O ' ' C ' ' A' ' 34' ' ' LEU . 4.9 tt0 -136.52 124.83 23.25 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.334 -0.854 . . . . 0.0 109.502 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.862 HD13 ' HB3' ' A' ' 46' ' ' GLU . 49.8 tp -42.81 150.93 0.14 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.372 -0.83 . . . . 0.0 109.603 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.765 HD11 ' HB2' ' A' ' 49' ' ' ALA . 11.8 mt -139.49 -38.73 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.321 -0.862 . . . . 0.0 109.509 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.518 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 9.7 p -154.51 131.12 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.208 -0.933 . . . . 0.0 109.497 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.46 ' OD1' ' HA ' ' A' ' 46' ' ' GLU . 39.3 m-20 -97.0 152.18 18.98 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.176 -0.952 . . . . 0.0 109.443 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.47 ' O ' ' HA ' ' A' ' 44' ' ' VAL . 5.5 mt -115.91 146.69 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.275 -0.89 . . . . 0.0 109.482 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.68 111.54 21.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.315 -0.866 . . . . 0.0 109.495 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.675 HG23 ' N ' ' A' ' 41' ' ' ASP . 4.8 t -106.64 -153.73 0.5 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.191 -0.943 . . . . 0.0 109.385 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.675 ' N ' HG23 ' A' ' 40' ' ' THR . 0.3 OUTLIER -43.09 -71.53 0.08 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.898 . . . . 0.0 109.627 -179.882 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 17.8 mtmm -143.88 36.9 1.29 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.519 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.587 ' O ' HG22 ' A' ' 40' ' ' THR . 2.1 t -146.82 145.6 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.296 -0.877 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.47 ' HA ' ' O ' ' A' ' 38' ' ' ILE . 10.6 p -109.8 133.51 54.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 0.0 109.438 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 2.7 mtt -105.35 126.95 52.68 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.454 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.862 ' HB3' HD13 ' A' ' 34' ' ' LEU . 6.7 mt-10 -81.4 131.25 35.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.179 -0.951 . . . . 0.0 109.466 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.518 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 92.8 t -116.4 102.03 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.247 -0.908 . . . . 0.0 109.509 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.498 ' H ' HD12 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -102.91 163.24 12.32 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.211 -0.931 . . . . 0.0 109.406 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.765 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -79.45 142.35 35.96 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.207 -0.933 . . . . 0.0 109.48 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -82.5 8.21 12.28 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.281 -0.887 . . . . 0.0 109.535 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -177.08 141.73 0.34 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.889 . . . . 0.0 109.534 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.2 OUTLIER -57.93 170.93 0.56 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.223 -0.923 . . . . 0.0 109.312 -179.953 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.99 -145.09 12.25 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.4 t -138.4 125.21 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.3 -1.118 . . . . 0.0 109.433 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.523 HG22 ' N ' ' A' ' 56' ' ' ALA . 5.0 mt -58.17 161.75 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.316 -0.865 . . . . 0.0 109.529 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.54 ' CB ' ' HG3' ' A' ' 74' ' ' LYS . . . -97.66 -66.84 0.88 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.275 -0.891 . . . . 0.0 109.522 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.482 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 8.2 tt0 -175.05 138.75 0.45 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.207 -0.933 . . . . 0.0 109.456 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.632 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 23.9 mm -101.94 119.92 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.246 -0.909 . . . . 0.0 109.387 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.4 t -90.0 -19.11 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -0.929 . . . . 0.0 109.402 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.442 ' HG3' ' CG ' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -97.81 131.87 43.93 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.466 179.977 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 47.9 m-80 -97.55 156.35 16.55 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -0.867 . . . . 0.0 109.471 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -51.24 148.79 4.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.257 -0.902 . . . . 0.0 109.524 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 75.87 19.7 78.61 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.5 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -100.5 170.91 8.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.267 -1.137 . . . . 0.0 109.274 -179.978 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.5 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 65.1 m -106.67 133.6 51.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.539 -0.725 . . . . 0.0 109.475 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 25.0 m -100.79 163.73 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -0.884 . . . . 0.0 109.451 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.519 HD23 ' H ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -145.68 167.39 23.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.272 -0.893 . . . . 0.0 109.476 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.519 ' H ' HD23 ' A' ' 67' ' ' LEU . 1.5 t -62.29 115.4 4.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.227 -0.921 . . . . 0.0 109.508 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 89.84 18.4 51.25 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 27.2 tp10 -83.19 121.75 27.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.229 -1.159 . . . . 0.0 109.485 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.508 HD11 ' OD2' ' A' ' 3' ' ' ASP . 0.5 OUTLIER -83.98 119.2 24.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.211 -0.931 . . . . 0.0 109.422 -179.973 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 12.0 mt -99.82 -19.09 16.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.268 -0.895 . . . . 0.0 109.44 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 159.5 168.12 21.07 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.54 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -127.21 158.51 36.92 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.16 -1.2 . . . . 0.0 109.487 179.982 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 8.8 tp -96.48 152.84 18.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.436 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.543 HG22 ' H ' ' A' ' 77' ' ' GLU . 9.1 m -105.73 170.91 7.62 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.873 . . . . 0.0 109.523 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.543 ' H ' HG22 ' A' ' 76' ' ' THR . 42.4 mt-10 -64.82 -177.9 0.38 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.209 -0.932 . . . . 0.0 109.41 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -128.75 -150.71 7.25 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.958 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.632 ' C ' HD12 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.632 HD12 ' C ' ' A' ' 1' ' ' ALA . 3.5 mp -133.55 91.25 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.277 -0.89 . . . . 0.0 109.459 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.478 ' OD1' HD11 ' A' ' 71' ' ' LEU . 63.2 t0 -57.85 123.26 15.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.531 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 53.0 mt -98.69 121.3 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.228 -0.92 . . . . 0.0 109.39 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.7 ptpp? -147.1 168.5 21.45 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.242 -0.911 . . . . 0.0 109.53 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.42 150.89 91.78 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.02 127.83 8.75 Favored 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.579 2.186 . . . . 0.0 110.423 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -45.84 143.46 2.12 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.27 -0.894 . . . . 0.0 109.451 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.517 ' CE2' ' C ' ' A' ' 15' ' ' ASP . 22.1 m-85 -102.84 154.5 37.47 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.923 . . . . 0.0 109.443 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.6 Cg_endo -78.0 163.75 28.0 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.671 2.247 . . . . 0.0 110.415 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.0 OUTLIER -45.84 -49.77 14.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.141 -0.974 . . . . 0.0 109.505 179.985 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -43.17 -59.96 1.85 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.293 -0.879 . . . . 0.0 109.68 -179.936 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.704 HG22 ' H ' ' A' ' 15' ' ' ASP . 2.5 mp -90.28 132.94 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.267 -0.895 . . . . 0.0 109.48 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.76 25.98 11.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.906 . . . . 0.0 109.486 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.704 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER 177.09 -171.09 0.09 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.24 -0.913 . . . . 0.0 109.487 -179.94 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.417 ' HA3' ' CZ ' ' A' ' 9' ' ' PHE . . . -159.14 -175.09 29.69 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.849 HG23 ' O ' ' A' ' 64' ' ' ASP . 85.2 m -150.02 122.59 8.55 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.292 -1.122 . . . . 0.0 109.45 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.585 HG12 ' N ' ' A' ' 19' ' ' ALA . 38.2 t -48.14 168.97 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.297 -0.877 . . . . 0.0 109.453 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.585 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -111.1 -73.9 0.66 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.266 -0.897 . . . . 0.0 109.58 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.491 ' HA ' ' HB2' ' A' ' 62' ' ' GLU . 23.9 m -160.08 135.46 8.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.117 -0.989 . . . . 0.0 109.674 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.655 ' CZ2' HG23 ' A' ' 58' ' ' ILE . 34.2 m95 -89.94 83.38 6.13 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 121.161 -0.962 . . . . 0.0 109.494 179.857 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.576 ' NE2' ' CD2' ' A' ' 34' ' ' LEU . 1.5 m80 -43.16 -70.8 0.09 Allowed 'General case' 0 N--CA 1.501 2.109 0 O-C-N 121.315 -0.866 . . . . 0.0 109.425 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.85 -171.75 2.23 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.219 -0.926 . . . . 0.0 109.62 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.443 ' CB ' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.28 169.86 12.72 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.329 -0.857 . . . . 0.0 109.428 -179.903 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.613 ' HD3' HD11 ' A' ' 58' ' ' ILE . 34.9 Cg_endo -76.05 135.98 17.82 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 122.642 2.228 . . . . 0.0 110.377 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.13 10.61 27.59 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.421 ' CD ' ' O ' ' A' ' 28' ' ' ALA . 1.2 pp20? -115.51 173.16 6.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.225 -1.162 . . . . 0.0 109.471 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.421 ' O ' ' CD ' ' A' ' 27' ' ' GLU . . . -78.7 144.96 34.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.288 -0.883 . . . . 0.0 109.481 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.405 HG12 ' N ' ' A' ' 30' ' ' LYS . 5.2 t -127.92 163.95 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.902 . . . . 0.0 109.472 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.422 ' O ' ' C ' ' A' ' 31' ' ' ARG . 4.3 tttp -156.8 141.85 17.17 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.275 -0.891 . . . . 0.0 109.474 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.462 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 1.5 tmm_? -42.78 144.8 0.52 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.337 -0.852 . . . . 0.0 109.718 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.462 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 16.4 t0 72.18 46.91 0.31 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.269 -0.894 . . . . 0.0 109.498 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 34' ' ' LEU . 3.6 tp10 -142.22 100.99 3.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.281 -0.887 . . . . 0.0 109.561 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.576 ' CD2' ' NE2' ' A' ' 22' ' ' HIS . 39.9 tp -43.36 146.9 0.43 Allowed 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.299 -0.875 . . . . 0.0 109.519 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 44.5 mt -121.86 -44.66 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.889 . . . . 0.0 109.652 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.523 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 14.9 p -160.09 139.24 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.2 -0.937 . . . . 0.0 109.566 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.532 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 11.5 m-20 -99.18 168.39 10.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.896 . . . . 0.0 109.478 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.503 ' O ' HG23 ' A' ' 44' ' ' VAL . 12.8 mt -136.02 161.75 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.284 -0.885 . . . . 0.0 109.46 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.438 ' N ' HG22 ' A' ' 38' ' ' ILE . 2.4 tt0 -143.1 167.35 22.29 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.236 -0.915 . . . . 0.0 109.489 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.549 HG22 ' H ' ' A' ' 41' ' ' ASP . 8.5 m -159.18 170.91 20.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.273 -0.892 . . . . 0.0 109.455 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.549 ' H ' HG22 ' A' ' 40' ' ' THR . 8.9 t0 -42.83 -40.61 2.95 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.252 -0.905 . . . . 0.0 109.631 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -156.29 26.0 0.35 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 78.6 t -140.64 105.09 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.33 -0.856 . . . . 0.0 109.46 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 38' ' ' ILE . 3.7 p -95.48 139.32 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.186 -0.946 . . . . 0.0 109.531 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . 0.451 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 13.2 mmt -128.05 -167.88 1.82 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.275 -0.89 . . . . 0.0 109.477 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.5 pt-20 -158.39 167.06 30.7 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.169 -0.957 . . . . 0.0 109.486 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.523 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 71.3 t -138.31 104.02 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.381 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.463 ' HG ' ' HA ' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -95.98 171.02 8.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 -179.994 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.05 139.64 31.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 0.0 109.44 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.659 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 2.9 mm-40 -100.38 8.09 43.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -0.913 . . . . 0.0 109.548 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.659 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 166.57 142.99 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.958 . . . . 0.0 109.491 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.504 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.84 170.98 0.15 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.198 -0.939 . . . . 0.0 109.225 -179.926 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.504 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.95 -146.3 14.88 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.4 t -135.89 124.45 37.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.302 -1.117 . . . . 0.0 109.505 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.526 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 5.0 mt -61.17 158.65 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 109.567 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.462 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -95.56 -69.41 0.76 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.249 -0.907 . . . . 0.0 109.549 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.528 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -178.97 152.9 0.6 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.241 -0.912 . . . . 0.0 109.471 179.992 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.655 HG23 ' CZ2' ' A' ' 21' ' ' TRP . 24.9 mt -89.91 141.28 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.219 -0.926 . . . . 0.0 109.412 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.8 t -90.53 -66.77 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.172 -0.955 . . . . 0.0 109.411 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.641 ' HD2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -92.79 -173.67 3.39 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.25 -0.906 . . . . 0.0 109.448 -179.983 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.461 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 70.7 m-80 -110.6 155.57 22.16 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.296 -0.878 . . . . 0.0 109.44 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.528 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -69.52 153.43 43.51 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.244 -0.91 . . . . 0.0 109.451 -179.984 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 77.49 7.45 87.09 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.849 ' O ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -105.29 170.95 7.59 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.238 -1.154 . . . . 0.0 109.32 -179.966 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.502 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 48.6 m -99.14 128.55 45.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.457 -0.777 . . . . 0.0 109.494 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.641 HG12 ' HD2' ' A' ' 60' ' ' LYS . 6.6 m -121.52 -169.7 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.329 -0.857 . . . . 0.0 109.455 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.472 HD12 ' HA ' ' A' ' 67' ' ' LEU . 1.2 tp -127.15 165.95 18.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -0.903 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.9 t -61.7 138.76 58.34 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.279 -0.888 . . . . 0.0 109.505 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.02 15.4 81.4 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -79.05 116.63 19.47 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.243 -1.151 . . . . 0.0 109.51 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.478 HD11 ' OD1' ' A' ' 3' ' ' ASP . 10.9 tp -66.57 115.92 6.96 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.203 -0.935 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 15.4 mt -98.36 -12.35 21.55 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.245 -0.909 . . . . 0.0 109.404 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 164.1 169.96 28.36 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 26.5 mtmt -132.25 139.09 48.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.188 -1.184 . . . . 0.0 109.504 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.563 HD23 HD13 ' A' ' 2' ' ' ILE . 12.8 tp -98.41 136.86 37.95 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.207 -0.933 . . . . 0.0 109.543 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.558 HG22 ' H ' ' A' ' 77' ' ' GLU . 12.7 m -109.63 171.88 7.18 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.225 -0.922 . . . . 0.0 109.501 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.558 ' H ' HG22 ' A' ' 76' ' ' THR . 1.1 mm-40 -82.67 -170.53 3.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.256 -0.903 . . . . 0.0 109.494 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 171.29 157.4 13.16 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 CA-C-O 118.002 -1.443 . . . . 0.0 109.601 179.965 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.518 ' O ' HD12 ' A' ' 2' ' ' ILE . 2.1 pp -149.07 120.48 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.255 -0.903 . . . . 0.0 109.452 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.464 ' OD2' ' CD1' ' A' ' 71' ' ' LEU . 26.1 t70 -74.53 166.4 23.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.3 -0.875 . . . . 0.0 109.521 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 61.1 mt -129.96 118.45 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 109.475 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 ptpp? -137.25 165.0 27.18 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.272 -0.893 . . . . 0.0 109.425 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -72.45 150.58 91.59 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.485 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.11 166.4 24.78 Favored 'Trans proline' 0 C--N 1.309 -1.524 0 C-N-CA 122.612 2.208 . . . . 0.0 110.409 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.09 94.96 2.98 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.173 -0.954 . . . . 0.0 109.445 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.533 ' CD2' ' HA ' ' A' ' 15' ' ' ASP . 21.5 m-85 -50.1 151.0 3.77 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.298 -0.877 . . . . 0.0 109.457 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.436 ' HG2' HG12 ' A' ' 13' ' ' ILE . 35.2 Cg_endo -78.14 177.31 8.93 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.559 2.173 . . . . 0.0 110.383 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 12' ' ' SER . 43.2 tt0 -66.0 -54.05 31.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.501 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.425 ' C ' ' O ' ' A' ' 11' ' ' GLU . 21.6 t -42.95 -46.41 5.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.34 -0.85 . . . . 0.0 109.628 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.607 HG22 ' H ' ' A' ' 15' ' ' ASP . 11.6 mm -94.5 151.69 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.415 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -121.36 2.64 10.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.618 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.607 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER 167.96 -169.25 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.109 -0.995 . . . . 0.0 109.502 -179.992 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.67 -159.46 9.94 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.691 HG22 ' O ' ' A' ' 64' ' ' ASP . 0.2 OUTLIER -149.06 170.68 17.85 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.277 -1.131 . . . . 0.0 109.048 179.987 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.552 HG12 ' H ' ' A' ' 19' ' ' ALA . 3.8 t -85.66 171.53 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.051 -1.031 . . . . 0.0 109.409 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.578 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -118.91 -74.19 0.62 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.462 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.453 ' HA ' ' HG2' ' A' ' 62' ' ' GLU . 65.2 m -160.21 132.3 6.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.144 -0.972 . . . . 0.0 109.622 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.675 ' CH2' HD12 ' A' ' 58' ' ' ILE . 34.0 m95 -89.85 82.23 6.24 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.256 -0.902 . . . . 0.0 109.397 179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.625 ' CE1' ' CD2' ' A' ' 34' ' ' LEU . 1.4 m80 -42.67 -57.12 2.85 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.401 -0.812 . . . . 0.0 109.484 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.3 163.58 12.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.245 -0.909 . . . . 0.0 109.66 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.498 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 23.6 mttt -114.46 165.8 13.01 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.346 -0.846 . . . . 0.0 109.152 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.533 ' CB ' ' HA ' ' A' ' 57' ' ' GLU . 35.0 Cg_endo -76.76 102.5 1.62 Allowed 'Trans proline' 0 C--N 1.308 -1.582 0 C-N-CA 122.544 2.163 . . . . 0.0 110.419 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 145.01 -13.43 1.91 Allowed Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.8 mm-40 -96.61 -172.13 2.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.234 -1.156 . . . . 0.0 109.512 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.68 161.99 13.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.533 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.462 ' O ' ' OD2' ' A' ' 52' ' ' ASP . 35.5 t -138.36 153.42 26.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.239 -0.913 . . . . 0.0 109.479 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.409 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.6 OUTLIER -126.71 137.6 53.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.929 . . . . 0.0 109.5 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.514 ' HG2' ' N ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -42.98 146.04 0.43 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.302 -0.874 . . . . 0.0 109.639 -179.939 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.514 ' N ' ' HG2' ' A' ' 31' ' ' ARG . 3.1 t70 67.66 38.82 2.9 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.7 ' N ' HD11 ' A' ' 48' ' ' LEU . 8.6 tp10 -127.84 115.94 19.39 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.194 -0.941 . . . . 0.0 109.455 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.625 ' CD2' ' CE1' ' A' ' 22' ' ' HIS . 41.4 tp -43.25 162.37 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.283 -0.886 . . . . 0.0 109.463 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.456 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 29.6 mm -135.49 -48.05 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 109.63 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.506 HG12 ' HB ' ' A' ' 47' ' ' VAL . 14.3 p -160.18 131.55 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.158 -0.964 . . . . 0.0 109.539 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.578 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 3.4 m-20 -90.32 150.82 21.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.5 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 60.9 mt -119.54 155.48 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -0.913 . . . . 0.0 109.501 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.46 ' CG ' ' HB ' ' A' ' 17' ' ' THR . 12.1 pt-20 -128.58 154.51 46.12 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.257 -0.902 . . . . 0.0 109.539 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -141.58 175.5 9.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.258 -0.902 . . . . 0.0 109.425 -179.93 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 4.2 t0 -42.83 -60.67 1.51 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.334 -0.853 . . . . 0.0 109.636 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 15.7 mttt -138.5 36.44 2.25 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.29 -0.881 . . . . 0.0 109.464 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 90.6 t -147.65 127.35 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.28 -0.887 . . . . 0.0 109.436 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.6 t -102.3 152.0 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.277 -0.889 . . . . 0.0 109.463 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.9 176.33 9.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 109.468 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -141.54 149.63 41.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 109.495 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.506 ' HB ' HG12 ' A' ' 36' ' ' VAL . 30.5 t -115.59 96.9 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.285 -0.885 . . . . 0.0 109.431 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.7 HD11 ' N ' ' A' ' 33' ' ' GLU . 29.8 tp -96.04 153.16 17.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.35 -0.843 . . . . 0.0 109.52 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.471 ' N ' ' HG ' ' A' ' 48' ' ' LEU . . . -83.41 148.07 27.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.192 -0.942 . . . . 0.0 109.446 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.562 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -99.77 17.98 19.34 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.936 . . . . 0.0 109.485 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.562 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 171.87 154.01 0.07 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.288 -0.883 . . . . 0.0 109.483 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.501 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -66.09 170.94 5.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.308 -0.87 . . . . 0.0 109.289 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.501 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 151.26 -159.81 28.39 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.0 t -135.62 125.11 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -1.159 . . . . 0.0 109.51 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.59 HG22 ' N ' ' A' ' 56' ' ' ALA . 4.9 mt -59.11 165.5 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.938 . . . . 0.0 109.528 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.59 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -104.45 -67.19 0.91 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.46 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.533 ' HA ' ' CB ' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -169.25 140.63 2.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.227 -0.921 . . . . 0.0 109.565 -179.991 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.675 HD12 ' CH2' ' A' ' 21' ' ' TRP . 23.3 mm -93.77 138.97 19.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.233 -0.917 . . . . 0.0 109.393 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 18.0 t -89.94 -39.42 12.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.237 -0.914 . . . . 0.0 109.435 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.462 ' HD3' ' O ' ' A' ' 60' ' ' LYS . 0.0 OUTLIER -102.39 158.06 16.47 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.222 -0.924 . . . . 0.0 109.411 179.974 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -117.27 163.32 16.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.303 -0.873 . . . . 0.0 109.432 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.453 ' HG2' ' HA ' ' A' ' 20' ' ' THR . 2.3 mp0 -55.28 134.41 49.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.22 -0.925 . . . . 0.0 109.447 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 100.68 -8.29 58.12 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.691 ' O ' HG22 ' A' ' 17' ' ' THR . 0.2 OUTLIER -92.06 170.44 9.84 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.244 -1.151 . . . . 0.0 109.362 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.498 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.6 t -100.36 164.15 12.06 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.565 -0.71 . . . . 0.0 109.511 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.452 ' O ' HG23 ' A' ' 66' ' ' VAL . 22.6 m -130.83 131.08 64.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -0.905 . . . . 0.0 109.44 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -101.59 162.04 13.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -0.885 . . . . 0.0 109.541 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.1 t -59.82 110.03 1.07 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.514 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.79 20.6 16.25 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -83.71 133.91 34.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.264 -1.139 . . . . 0.0 109.499 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.464 ' CD1' ' OD2' ' A' ' 3' ' ' ASP . 9.5 tp -83.26 125.38 31.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.504 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.456 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 4.5 mt -100.0 -22.17 15.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.264 -0.897 . . . . 0.0 109.477 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.67 173.49 27.14 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.466 ' HG3' ' CB ' ' A' ' 56' ' ' ALA . 39.7 pttt -129.46 153.01 48.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -1.122 . . . . 0.0 109.493 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.48 HD12 ' HA ' ' A' ' 55' ' ' ILE . 22.9 tp -96.22 153.02 18.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -0.898 . . . . 0.0 109.464 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.599 HG22 ' H ' ' A' ' 77' ' ' GLU . 8.3 m -95.42 172.95 7.77 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.289 -0.882 . . . . 0.0 109.45 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.599 ' H ' HG22 ' A' ' 76' ' ' THR . 5.0 mt-10 -66.02 -172.73 0.15 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.226 -0.921 . . . . 0.0 109.434 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -119.31 -42.95 0.53 Allowed Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 CA-C-O 117.96 -1.467 . . . . 0.0 109.518 -179.977 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.435 ' C ' HG13 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.435 HG13 ' C ' ' A' ' 1' ' ' ALA . 8.5 mt -142.58 109.74 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.223 -0.923 . . . . 0.0 109.472 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' A' ' 4' ' ' ILE . 10.6 t0 -68.37 152.57 45.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.527 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.502 ' N ' ' OD1' ' A' ' 3' ' ' ASP . 8.2 mm -123.74 136.35 60.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.902 . . . . 0.0 109.524 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.34 172.5 12.67 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.281 -0.887 . . . . 0.0 109.447 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.475 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -69.06 158.82 85.47 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.475 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.5 Cg_endo -78.04 114.86 3.66 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.707 2.271 . . . . 0.0 110.381 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 29.7 m -46.52 126.12 7.81 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.265 -0.897 . . . . 0.0 109.464 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.572 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 1.3 p90 -107.89 151.86 41.4 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.333 -0.854 . . . . 0.0 109.445 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.04 -169.64 0.8 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.68 2.253 . . . . 0.0 110.385 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.438 ' O ' ' C ' ' A' ' 12' ' ' SER . 0.4 OUTLIER -66.61 -45.15 80.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.273 -0.892 . . . . 0.0 109.476 -179.984 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.6 OUTLIER -42.75 -36.85 1.57 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.373 -0.83 . . . . 0.0 109.578 -179.838 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.637 HG22 ' O ' ' A' ' 15' ' ' ASP . 18.5 mm -114.58 108.92 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.249 -0.907 . . . . 0.0 109.411 179.954 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.46 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -74.67 -1.48 21.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.217 -0.927 . . . . 0.0 109.667 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.637 ' O ' HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER 166.92 -174.12 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.917 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.463 ' C ' HG22 ' A' ' 66' ' ' VAL . . . -144.63 -165.96 11.32 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.523 ' CG2' ' O ' ' A' ' 64' ' ' ASP . 0.4 OUTLIER -149.99 128.27 12.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.293 -1.122 . . . . 0.0 109.397 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.476 HG12 ' N ' ' A' ' 19' ' ' ALA . 61.3 t -43.83 159.49 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.217 -0.927 . . . . 0.0 109.529 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.476 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -111.99 -71.02 0.78 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.253 -0.904 . . . . 0.0 109.574 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.6 m -159.28 133.12 7.43 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.264 -0.897 . . . . 0.0 109.594 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.633 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.2 m95 -89.92 85.65 6.41 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.3 -0.875 . . . . 0.0 109.486 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.604 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.4 m80 -42.86 -60.09 1.73 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.325 -0.859 . . . . 0.0 109.352 -179.864 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -105.37 155.0 19.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.231 -0.918 . . . . 0.0 109.495 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.413 ' HG2' ' HD2' ' A' ' 25' ' ' PRO . 9.6 mttt -95.01 167.26 13.29 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.361 -0.837 . . . . 0.0 109.519 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.49 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.5 Cg_endo -76.75 104.56 1.93 Allowed 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.682 2.255 . . . . 0.0 110.494 179.892 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 140.45 -9.72 2.93 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -90.63 -172.17 3.3 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -1.151 . . . . 0.0 109.514 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -101.85 149.19 24.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -0.892 . . . . 0.0 109.421 -179.951 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -130.49 162.65 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.295 -0.878 . . . . 0.0 109.444 179.895 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 31' ' ' ARG . 6.7 tttp -133.22 142.56 48.63 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.224 -0.923 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.46 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 10.5 ttp-105 -42.92 137.45 2.35 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.285 -0.884 . . . . 0.0 109.588 -179.863 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.784 ' HA ' HD21 ' A' ' 48' ' ' LEU . 23.9 t0 72.27 52.04 0.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.256 -0.902 . . . . 0.0 109.524 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.485 ' N ' HD11 ' A' ' 48' ' ' LEU . 0.5 OUTLIER -141.44 114.58 8.67 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.274 -0.891 . . . . 0.0 109.425 -179.978 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.635 ' N ' HD12 ' A' ' 48' ' ' LEU . 54.3 tp -42.74 162.31 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.323 -0.861 . . . . 0.0 109.6 -179.937 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 1.088 HD11 ' HB2' ' A' ' 49' ' ' ALA . 4.2 mt -140.84 -42.03 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.214 -0.929 . . . . 0.0 109.536 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.639 HG12 ' HB ' ' A' ' 47' ' ' VAL . 7.2 p -158.75 139.88 4.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.319 -0.863 . . . . 0.0 109.502 179.925 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -98.62 149.97 22.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.938 . . . . 0.0 109.544 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.448 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 32.8 mm -104.46 140.79 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.288 -0.883 . . . . 0.0 109.424 -179.993 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -126.36 92.51 3.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.503 -179.975 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.44 ' OG1' ' HB ' ' A' ' 43' ' ' VAL . 3.0 p -87.81 -173.49 4.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.296 -0.878 . . . . 0.0 109.515 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 40' ' ' THR . 9.7 t0 -42.8 -61.56 1.23 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.367 -0.833 . . . . 0.0 109.626 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -141.62 33.25 1.63 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.477 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.44 ' HB ' ' OG1' ' A' ' 40' ' ' THR . 9.8 t -132.24 109.86 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.166 -0.959 . . . . 0.0 109.447 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.3 t -93.11 126.45 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.319 -0.863 . . . . 0.0 109.524 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . 0.448 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 0.3 OUTLIER -123.95 -178.27 4.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.321 -0.862 . . . . 0.0 109.477 -180.0 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.424 ' HG3' ' C ' ' A' ' 45' ' ' MET . 0.7 OUTLIER -133.77 155.17 50.27 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.256 -0.902 . . . . 0.0 109.544 179.959 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.639 ' HB ' HG12 ' A' ' 36' ' ' VAL . 35.0 t -126.84 98.19 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.332 -0.855 . . . . 0.0 109.459 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.911 HD23 ' O ' ' A' ' 49' ' ' ALA . 2.6 tt -107.67 151.44 25.65 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.888 . . . . 0.0 109.426 -179.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 1.088 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -83.76 161.12 21.09 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.205 -0.935 . . . . 0.0 109.485 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.86 17.83 23.27 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.194 -0.941 . . . . 0.0 109.396 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -178.58 173.75 1.29 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.298 -0.876 . . . . 0.0 109.494 -179.954 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -77.55 170.92 15.73 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.213 -0.929 . . . . 0.0 109.306 179.953 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.511 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 152.72 175.01 23.77 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.946 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.779 ' O ' HG22 ' A' ' 76' ' ' THR . 47.1 t -121.64 124.9 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.326 -1.102 . . . . 0.0 109.447 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.49 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 16.5 mm -58.22 162.36 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.256 -0.902 . . . . 0.0 109.509 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.476 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -101.67 -67.42 0.87 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.193 -0.942 . . . . 0.0 109.41 -179.965 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.486 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 2.2 mt-10 -162.46 135.09 5.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.445 -179.983 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.633 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 27.3 mm -93.17 122.23 44.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.224 -0.922 . . . . 0.0 109.409 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.5 t -89.95 -15.7 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.508 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.629 ' HB2' HD23 ' A' ' 72' ' ' LEU . 1.5 mptt -110.46 125.47 53.32 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.434 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 -92.99 173.59 7.66 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.905 . . . . 0.0 109.496 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -69.49 147.96 50.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 109.564 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.67 -8.76 76.42 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.523 ' O ' ' CG2' ' A' ' 17' ' ' THR . 0.1 OUTLIER -84.49 170.83 13.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.206 -1.173 . . . . 0.0 109.313 -179.92 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.51 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.8 t -99.9 159.29 15.18 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.511 -0.743 . . . . 0.0 109.48 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.463 HG22 ' C ' ' A' ' 16' ' ' GLY . 29.9 m -122.54 160.51 24.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.222 -0.924 . . . . 0.0 109.452 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.532 HD23 ' N ' ' A' ' 68' ' ' SER . 0.6 OUTLIER -125.36 174.54 8.09 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.179 -0.95 . . . . 0.0 109.492 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.532 ' N ' HD23 ' A' ' 67' ' ' LEU . 35.9 t -72.92 85.97 1.28 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.495 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 108.85 22.51 6.92 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -78.45 118.03 20.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -1.109 . . . . 0.0 109.459 -179.946 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.414 ' C ' HD23 ' A' ' 71' ' ' LEU . 7.6 tt -65.77 131.68 46.88 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.281 -0.887 . . . . 0.0 109.448 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.629 HD23 ' HB2' ' A' ' 60' ' ' LYS . 4.4 mt -115.86 -13.47 11.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.281 -0.887 . . . . 0.0 109.491 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 167.77 163.69 22.12 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.98 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 7.2 mttt -124.54 145.95 49.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.24 -1.153 . . . . 0.0 109.483 179.939 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -91.65 147.85 22.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.289 -0.882 . . . . 0.0 109.463 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.779 HG22 ' O ' ' A' ' 54' ' ' VAL . 2.9 t -107.04 -157.56 0.62 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.911 . . . . 0.0 109.787 179.976 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.675 ' N ' HG23 ' A' ' 76' ' ' THR . 42.2 mt-10 -83.38 175.11 10.09 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.986 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.463 ' HA3' ' HA2' ' A' ' 53' ' ' GLY . . . -171.54 140.1 5.7 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 CA-C-O 118.011 -1.438 . . . . 0.0 109.558 179.988 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.49 ' O ' HD13 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.513 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.49 HD13 ' O ' ' A' ' 1' ' ' ALA . 20.8 mm -117.17 97.9 6.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.273 -0.892 . . . . 0.0 109.439 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -60.5 136.42 58.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.24 -0.912 . . . . 0.0 109.472 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 80.5 mt -114.47 121.3 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.181 -0.949 . . . . 0.0 109.438 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 17.3 mtpt -123.25 178.15 5.25 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.213 -0.93 . . . . 0.0 109.508 179.966 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -84.18 164.58 42.99 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.255 -0.903 . . . . 0.0 109.505 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.9 Cg_endo -77.99 117.76 4.25 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.644 2.229 . . . . 0.0 110.451 179.928 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 8' ' ' THR . 0.0 OUTLIER -53.97 136.47 41.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.241 -0.912 . . . . 0.0 109.474 179.953 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.559 ' CE2' ' HA ' ' A' ' 15' ' ' ASP . 21.8 m-85 -95.33 155.34 38.9 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.469 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.416 ' O ' ' O ' ' A' ' 13' ' ' ILE . 35.1 Cg_endo -77.99 -178.53 4.68 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.71 2.273 . . . . 0.0 110.369 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.5 ' HG3' ' N ' ' A' ' 12' ' ' SER . 16.9 pt-20 -61.64 -43.85 98.08 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.5 ' N ' ' HG3' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.82 -72.93 0.05 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.32 -0.863 . . . . 0.0 109.631 -179.88 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.474 HG22 ' N ' ' A' ' 14' ' ' ALA . 1.8 mp -91.16 167.52 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.243 -0.911 . . . . 0.0 109.446 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.474 ' N ' HG22 ' A' ' 13' ' ' ILE . . . -142.09 44.83 1.67 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.448 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.559 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 0.3 OUTLIER 168.74 -169.91 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.3 -0.875 . . . . 0.0 109.456 179.938 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.485 ' O ' HG23 ' A' ' 65' ' ' THR . . . -168.21 -170.04 32.43 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.996 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.541 HG23 ' O ' ' A' ' 64' ' ' ASP . 29.9 m -150.07 126.69 10.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -1.146 . . . . 0.0 109.514 179.986 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.572 HG12 ' N ' ' A' ' 19' ' ' ALA . 21.8 t -51.89 169.92 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.572 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -113.85 -75.34 0.6 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.229 -0.919 . . . . 0.0 109.534 -179.936 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.524 ' HA ' ' CB ' ' A' ' 62' ' ' GLU . 23.2 m -158.38 133.54 8.58 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.221 -0.924 . . . . 0.0 109.529 -179.918 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.623 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.9 m95 -89.85 84.77 6.26 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.232 -0.917 . . . . 0.0 109.524 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.769 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.9 m80 -43.07 -67.42 0.28 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.298 -0.876 . . . . 0.0 109.35 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -89.26 -171.92 3.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.42 179.911 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.488 ' HB2' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.7 164.76 40.53 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.282 -0.886 . . . . 0.0 109.445 179.974 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.488 ' HD2' ' HB2' ' A' ' 24' ' ' LYS . 34.9 Cg_endo -77.18 101.21 1.48 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.559 2.173 . . . . 0.0 110.4 179.938 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 149.75 -16.8 1.09 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.896 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -93.0 -179.03 4.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -1.152 . . . . 0.0 109.437 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.52 159.62 18.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.21 -0.931 . . . . 0.0 109.519 179.953 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.417 HG12 ' N ' ' A' ' 30' ' ' LYS . 80.5 t -143.57 156.33 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.393 -179.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.417 ' N ' HG12 ' A' ' 29' ' ' VAL . 49.1 tttt -140.79 141.92 34.74 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 30' ' ' LYS . 5.7 ttm180 -42.82 151.34 0.13 Allowed 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.356 -0.84 . . . . 0.0 109.634 -179.848 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.416 ' HA ' HD23 ' A' ' 48' ' ' LEU . 7.9 t70 68.14 40.56 2.15 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.221 -0.924 . . . . 0.0 109.465 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 34' ' ' LEU . 1.6 tt0 -140.14 111.05 6.9 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 0.0 109.467 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.769 HD21 ' NE2' ' A' ' 22' ' ' HIS . 51.2 tp -42.76 163.44 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.381 -0.825 . . . . 0.0 109.611 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.501 ' N ' ' HG ' ' A' ' 34' ' ' LEU . 39.5 mt -147.18 -43.51 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.227 -0.921 . . . . 0.0 109.612 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.435 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 11.4 p -159.81 136.87 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.305 -0.872 . . . . 0.0 109.531 -179.925 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.543 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 3.5 m-20 -94.85 163.17 13.45 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.307 -0.871 . . . . 0.0 109.422 179.84 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.422 HD11 ' CG2' ' A' ' 47' ' ' VAL . 24.3 mt -129.33 156.87 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.119 -0.988 . . . . 0.0 109.527 -179.969 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.17 134.45 50.16 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.288 -0.882 . . . . 0.0 109.503 179.938 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.674 HG22 ' O ' ' A' ' 43' ' ' VAL . 5.6 t -124.24 -163.94 1.2 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.183 -0.948 . . . . 0.0 109.392 180.0 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.471 ' N ' HG23 ' A' ' 40' ' ' THR . 42.3 t0 -42.3 -68.87 0.16 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.247 -0.908 . . . . 0.0 109.741 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . 0.462 ' O ' HG23 ' A' ' 43' ' ' VAL . 1.4 mttp -141.84 48.34 1.61 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.192 -0.942 . . . . 0.0 109.513 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.674 ' O ' HG22 ' A' ' 40' ' ' THR . 76.4 t -156.04 119.92 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.229 -0.92 . . . . 0.0 109.428 -179.956 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.0 t -89.95 118.11 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.216 -0.928 . . . . 0.0 109.523 -179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 1.6 mtp -96.79 -170.8 2.12 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.276 -0.89 . . . . 0.0 109.437 179.945 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 5.2 pt-20 -149.15 159.6 44.1 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.287 -0.883 . . . . 0.0 109.448 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.435 ' HB ' ' O ' ' A' ' 36' ' ' VAL . 68.0 t -130.74 108.28 15.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.263 -0.898 . . . . 0.0 109.459 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.504 ' HG ' ' N ' ' A' ' 34' ' ' LEU . 0.1 OUTLIER -93.85 172.59 8.15 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.294 -0.879 . . . . 0.0 109.537 179.962 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.465 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -76.16 136.01 39.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.278 -0.888 . . . . 0.0 109.419 -179.979 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.676 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -95.67 10.12 37.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.531 179.975 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.676 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 165.54 140.8 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.272 -0.892 . . . . 0.0 109.451 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.508 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -54.31 170.92 0.13 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 109.35 -179.982 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.508 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 140.29 -155.07 24.41 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 55.6 t -134.79 128.62 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.304 -1.116 . . . . 0.0 109.464 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.457 HG22 ' N ' ' A' ' 56' ' ' ALA . 17.0 mm -56.35 159.36 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.28 -0.888 . . . . 0.0 109.511 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.457 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -99.66 -65.55 0.96 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.341 -0.849 . . . . 0.0 109.535 179.975 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.487 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 6.4 tt0 -173.1 132.77 0.51 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.158 -0.963 . . . . 0.0 109.528 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.623 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 28.4 mm -91.64 125.51 44.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.886 . . . . 0.0 109.391 179.953 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 23.2 t -90.08 -39.37 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.219 -0.926 . . . . 0.0 109.449 179.974 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.471 ' HG2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -95.03 128.29 41.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.485 179.951 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 71.2 m-80 -87.91 155.98 19.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.303 -0.873 . . . . 0.0 109.446 -179.95 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.529 ' HA ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -65.02 143.57 57.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.303 -0.873 . . . . 0.0 109.5 -179.937 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 97.11 -13.75 64.48 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.988 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.541 ' O ' HG23 ' A' ' 17' ' ' THR . 0.2 OUTLIER -92.41 170.89 9.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.284 -1.127 . . . . 0.0 109.303 179.955 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.501 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 21.8 m -98.12 139.54 33.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.486 -0.759 . . . . 0.0 109.516 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.471 HG12 ' HG2' ' A' ' 60' ' ' LYS . 6.0 m -114.78 -161.95 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.289 -0.882 . . . . 0.0 109.391 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -146.62 170.84 16.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.278 -0.889 . . . . 0.0 109.49 -179.932 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 5.6 t -69.01 104.81 2.21 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.48 179.988 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 102.56 10.71 37.54 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.984 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 31.2 tp10 -72.3 125.53 27.58 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -1.132 . . . . 0.0 109.404 -179.967 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -74.58 121.42 21.56 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -0.917 . . . . 0.0 109.439 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.447 ' O ' ' HA ' ' A' ' 58' ' ' ILE . 9.1 mt -95.85 -22.53 17.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.222 -0.923 . . . . 0.0 109.489 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 168.38 174.63 37.31 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -127.33 135.82 51.06 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.23 -1.159 . . . . 0.0 109.51 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.4 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 0.6 OUTLIER -90.05 138.23 31.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.392 -179.92 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.537 HG22 ' H ' ' A' ' 77' ' ' GLU . 9.2 m -96.9 171.25 8.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.268 -0.895 . . . . 0.0 109.481 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.537 ' H ' HG22 ' A' ' 76' ' ' THR . 3.0 mp0 -84.98 -65.05 1.05 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.29 -0.881 . . . . 0.0 109.481 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 129.6 117.64 1.98 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 CA-C-O 117.981 -1.455 . . . . 0.0 109.608 -179.959 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.66 HD12 HD13 ' A' ' 75' ' ' LEU . 49.9 mt -133.95 102.52 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.339 -0.85 . . . . 0.0 109.479 179.968 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -75.61 118.47 18.49 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.202 -0.936 . . . . 0.0 109.43 -179.933 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.8 mt -96.04 98.73 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.275 -0.89 . . . . 0.0 109.508 179.935 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.45 ' HG3' ' HA ' ' A' ' 71' ' ' LEU . 7.5 ttpt -118.78 163.93 16.15 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -0.884 . . . . 0.0 109.487 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.539 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -65.5 160.78 57.08 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.897 . . . . 0.0 109.464 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.539 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.1 Cg_endo -78.1 129.76 9.86 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.613 2.209 . . . . 0.0 110.396 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.633 HG23 ' O ' ' A' ' 8' ' ' THR . 6.9 t -56.36 111.92 1.11 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.91 . . . . 0.0 109.445 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -74.24 126.6 88.91 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.329 -0.857 . . . . 0.0 109.345 -179.969 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.464 ' HD2' HD12 ' A' ' 13' ' ' ILE . 36.1 Cg_endo -78.42 -159.44 0.1 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.398 2.065 . . . . 0.0 110.388 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 12' ' ' SER . 1.9 mm-40 -73.36 -55.0 6.98 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.161 -0.962 . . . . 0.0 109.398 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.435 ' C ' ' O ' ' A' ' 11' ' ' GLU . 17.0 t -42.87 -45.42 4.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.358 -0.839 . . . . 0.0 109.585 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.592 HG22 ' H ' ' A' ' 15' ' ' ASP . 16.9 mt -91.3 163.61 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.293 -0.879 . . . . 0.0 109.491 -179.96 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.416 ' N ' HG22 ' A' ' 13' ' ' ILE . . . -143.89 13.37 1.68 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.306 -0.871 . . . . 0.0 109.436 -179.965 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.592 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER 172.23 -172.27 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.454 -179.968 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.42 172.45 40.19 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.497 HG23 ' O ' ' A' ' 64' ' ' ASP . 68.3 m -149.25 125.66 10.9 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.254 -1.145 . . . . 0.0 109.425 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 19' ' ' ALA . 24.9 t -50.01 169.41 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.203 -0.935 . . . . 0.0 109.515 179.946 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.58 ' N ' HG12 ' A' ' 18' ' ' VAL . . . -112.76 -73.27 0.67 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.158 -0.964 . . . . 0.0 109.502 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.552 HG23 ' OE1' ' A' ' 62' ' ' GLU . 52.4 m -159.62 131.21 6.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.483 -179.891 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.633 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 34.4 m95 -89.91 84.16 6.2 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 121.261 -0.899 . . . . 0.0 109.441 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.722 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.5 m80 -42.56 -64.89 0.54 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.373 -0.829 . . . . 0.0 109.454 -179.709 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 5.7 mptt -95.15 -172.19 2.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.244 -0.91 . . . . 0.0 109.532 -179.922 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HB3' ' HD2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -131.67 168.37 17.77 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.312 -0.868 . . . . 0.0 109.452 -179.965 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.494 ' HB2' ' HA ' ' A' ' 57' ' ' GLU . 35.2 Cg_endo -76.64 133.09 13.86 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 C-N-CA 122.648 2.232 . . . . 0.0 110.409 179.878 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.8 -11.47 20.82 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.917 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 53.3 mm-40 -97.13 -174.91 3.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.241 -1.152 . . . . 0.0 109.502 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.03 172.65 8.42 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.222 -0.924 . . . . 0.0 109.51 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 t -141.91 155.08 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.974 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' A' ' 31' ' ' ARG . 0.0 OUTLIER -131.65 128.26 38.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.228 -0.92 . . . . 0.0 109.496 179.969 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 3.2 ttt-85 -42.83 137.27 2.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.394 -0.817 . . . . 0.0 109.601 -179.822 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.497 ' CB ' ' O ' ' A' ' 31' ' ' ARG . 10.7 t0 74.97 33.27 0.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.259 -0.901 . . . . 0.0 109.427 179.955 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.488 ' C ' ' CD1' ' A' ' 48' ' ' LEU . 1.2 tt0 -124.29 115.68 21.42 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.258 -0.902 . . . . 0.0 109.503 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.722 HD21 ' NE2' ' A' ' 22' ' ' HIS . 45.0 tp -43.11 150.94 0.16 Allowed 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.231 -0.918 . . . . 0.0 109.525 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.462 HD11 ' HB2' ' A' ' 49' ' ' ALA . 13.4 mt -129.69 -46.43 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.223 -0.923 . . . . 0.0 109.588 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.515 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 7.7 p -162.83 142.72 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.233 -0.917 . . . . 0.0 109.461 -179.908 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.49 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 33.5 m-20 -100.73 163.03 12.51 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.284 -0.885 . . . . 0.0 109.437 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.548 HG22 ' N ' ' A' ' 39' ' ' GLU . 9.6 mt -129.33 162.86 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.174 -0.954 . . . . 0.0 109.483 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.548 ' N ' HG22 ' A' ' 38' ' ' ILE . 6.1 mm-40 -133.87 151.65 51.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 -179.978 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -140.25 -177.53 5.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.256 -0.903 . . . . 0.0 109.486 179.971 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 40' ' ' THR . 5.4 t70 -42.95 -66.47 0.37 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.326 -0.859 . . . . 0.0 109.629 -179.907 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.2 mttp -135.85 40.69 2.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.286 -0.884 . . . . 0.0 109.461 -179.974 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 52.5 t -151.49 128.18 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.273 -0.892 . . . . 0.0 109.463 -179.994 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.413 ' O ' HG13 ' A' ' 44' ' ' VAL . 9.0 p -98.58 134.41 37.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 0.0 109.442 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . 0.448 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 1.3 mtt -114.59 -172.45 2.11 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 37' ' ' ASP . 6.1 pt-20 -154.73 164.56 38.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.254 -0.904 . . . . 0.0 109.461 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.515 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 58.2 t -134.69 103.55 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 109.442 -179.927 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.632 HD22 HD12 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -93.96 167.04 11.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.2 -0.937 . . . . 0.0 109.52 179.984 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.462 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -84.54 136.1 33.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.405 -179.929 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.645 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -95.87 9.9 39.03 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.162 -0.961 . . . . 0.0 109.466 -179.977 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.645 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 167.06 142.93 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.233 -0.917 . . . . 0.0 109.478 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.505 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -58.63 170.96 0.69 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.317 -0.864 . . . . 0.0 109.375 179.96 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.505 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 148.78 -157.43 27.27 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.928 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.7 t -128.64 127.11 66.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.25 -1.147 . . . . 0.0 109.572 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.462 ' HB ' ' HA ' ' A' ' 25' ' ' PRO . 14.4 mm -64.0 156.79 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.27 -0.894 . . . . 0.0 109.437 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -95.55 -69.57 0.75 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.21 -0.931 . . . . 0.0 109.416 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.494 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 1.2 pt-20 -172.27 142.48 1.35 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.252 -0.905 . . . . 0.0 109.449 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.633 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 24.5 mm -94.8 129.54 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.23 -0.919 . . . . 0.0 109.48 -179.977 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.1 t -90.15 -28.99 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.29 -0.881 . . . . 0.0 109.442 179.987 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.481 ' HD3' ' HG2' ' A' ' 70' ' ' GLU . 0.0 OUTLIER -109.16 131.99 54.54 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.182 -0.949 . . . . 0.0 109.529 179.926 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -85.47 155.93 21.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.165 -0.96 . . . . 0.0 109.461 179.992 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.552 ' OE1' HG23 ' A' ' 20' ' ' THR . 0.0 OUTLIER -68.29 141.51 55.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.914 . . . . 0.0 109.476 179.958 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 96.12 -11.3 67.58 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.505 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.2 OUTLIER -95.95 170.9 8.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.262 -1.14 . . . . 0.0 109.327 -179.986 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.505 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 13.0 t -89.02 157.95 18.18 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.492 -0.755 . . . . 0.0 109.516 -179.992 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.687 HG11 HD21 ' A' ' 72' ' ' LEU . 1.9 m -127.21 -174.82 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.245 -0.909 . . . . 0.0 109.464 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -140.96 177.81 7.79 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.336 -0.853 . . . . 0.0 109.481 -179.957 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.4 t -69.46 124.17 23.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.489 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 75.24 21.89 77.09 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 179.951 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.481 ' HG2' ' HD3' ' A' ' 60' ' ' LYS . 42.6 tp10 -74.58 103.65 4.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.191 -1.182 . . . . 0.0 109.472 179.966 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.813 HD11 ' HG3' ' A' ' 74' ' ' LYS . 0.7 OUTLIER -60.93 105.47 0.47 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.213 -0.929 . . . . 0.0 109.438 180.0 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.687 HD21 HG11 ' A' ' 66' ' ' VAL . 1.4 mt -84.22 -11.46 56.45 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.249 -0.907 . . . . 0.0 109.503 179.94 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.77 165.39 15.82 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.536 -1.425 . . . . 0.0 109.536 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.813 ' HG3' HD11 ' A' ' 71' ' ' LEU . 29.7 mtmt -125.83 151.85 46.27 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.23 -1.159 . . . . 0.0 109.484 179.967 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.667 HD23 ' O ' ' A' ' 76' ' ' THR . 1.9 tt -98.1 152.54 19.21 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.276 -0.89 . . . . 0.0 109.496 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.667 ' O ' HD23 ' A' ' 75' ' ' LEU . 14.2 m -107.24 171.86 7.15 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.243 -0.911 . . . . 0.0 109.438 -179.974 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.565 ' H ' HG22 ' A' ' 76' ' ' THR . 19.0 mt-10 -75.35 172.17 12.94 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.177 -0.952 . . . . 0.0 109.532 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -95.94 -164.63 33.98 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.282 0 CA-C-O 117.982 -1.454 . . . . 0.0 109.602 -179.985 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.43 ' O ' HD13 ' A' ' 2' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.43 HD13 ' O ' ' A' ' 1' ' ' ALA . 25.4 mm -136.09 109.85 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.179 -0.95 . . . . 0.0 109.409 -179.982 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.464 ' HA ' ' HG2' ' A' ' 74' ' ' LYS . 11.7 t70 -89.3 129.93 35.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.192 -0.942 . . . . 0.0 109.562 179.9 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mp -104.81 128.84 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.265 -0.897 . . . . 0.0 109.469 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 48.3 mtpt -130.43 176.25 8.29 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.317 -0.864 . . . . 0.0 109.468 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.94 156.55 60.78 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.479 -179.97 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.97 134.53 13.27 Favored 'Trans proline' 0 C--N 1.308 -1.554 0 C-N-CA 122.664 2.242 . . . . 0.0 110.404 179.959 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.442 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -45.49 115.04 0.85 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.223 -0.923 . . . . 0.0 109.502 179.995 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -64.34 149.27 94.96 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.487 179.969 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.405 ' HD2' ' HB ' ' A' ' 13' ' ' ILE . 35.4 Cg_endo -78.02 174.81 11.95 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.598 2.198 . . . . 0.0 110.402 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 12' ' ' SER . 30.5 tt0 -66.75 -55.31 15.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.313 -0.867 . . . . 0.0 109.463 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 11' ' ' GLU . 35.1 t -42.81 -40.86 3.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.361 -0.837 . . . . 0.0 109.581 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.64 HG22 ' H ' ' A' ' 15' ' ' ASP . 12.3 mm -94.35 152.4 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.266 -0.896 . . . . 0.0 109.452 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -126.43 9.29 7.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.26 -0.9 . . . . 0.0 109.497 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.64 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.2 OUTLIER 173.64 -172.03 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.206 -0.934 . . . . 0.0 109.414 -179.994 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.16 -176.09 27.88 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.988 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.566 HG22 ' O ' ' A' ' 64' ' ' ASP . 0.3 OUTLIER -150.03 128.94 12.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -1.121 . . . . 0.0 109.431 -179.961 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.572 HG12 ' N ' ' A' ' 19' ' ' ALA . 53.0 t -43.96 165.74 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.238 -0.914 . . . . 0.0 109.537 -179.943 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.58 ' HB3' ' O ' ' A' ' 37' ' ' ASP . . . -117.52 -72.8 0.67 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.266 -0.896 . . . . 0.0 109.422 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 34.5 m -160.05 127.48 4.57 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.261 -0.899 . . . . 0.0 109.579 -179.977 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.629 ' CH2' ' CD1' ' A' ' 58' ' ' ILE . 33.1 m95 -89.85 87.37 6.93 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 121.207 -0.933 . . . . 0.0 109.519 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.772 ' NE2' HD21 ' A' ' 34' ' ' LEU . 2.8 m80 -42.46 -57.91 2.45 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.416 -0.803 . . . . 0.0 109.522 -179.76 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 9.3 mttp -106.19 178.94 4.41 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.218 -0.927 . . . . 0.0 109.604 -179.953 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -118.31 167.51 11.32 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.271 -0.893 . . . . 0.0 109.497 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.513 ' HA ' ' HB ' ' A' ' 55' ' ' ILE . 35.3 Cg_endo -76.94 136.31 16.46 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.617 2.211 . . . . 0.0 110.413 179.96 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.34 -8.77 35.51 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.518 ' O ' HG13 ' A' ' 54' ' ' VAL . 4.0 mt-10 -93.5 -175.39 3.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.227 -1.16 . . . . 0.0 109.477 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.61 147.77 27.26 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.93 . . . . 0.0 109.462 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 m -147.56 169.48 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.236 -0.915 . . . . 0.0 109.421 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.427 ' O ' ' C ' ' A' ' 31' ' ' ARG . 16.5 tttp -133.06 143.39 49.32 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.252 -0.905 . . . . 0.0 109.442 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.464 ' O ' ' HB3' ' A' ' 32' ' ' ASP . 0.0 OUTLIER -42.82 152.32 0.11 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.231 -0.918 . . . . 0.0 109.624 -179.89 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.464 ' HB3' ' O ' ' A' ' 31' ' ' ARG . 26.0 t70 69.04 41.78 1.37 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -0.907 . . . . 0.0 109.418 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.437 ' C ' ' HG ' ' A' ' 48' ' ' LEU . 10.8 tt0 -140.97 117.42 10.8 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.325 -0.859 . . . . 0.0 109.456 179.995 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.772 HD21 ' NE2' ' A' ' 22' ' ' HIS . 48.8 tp -42.96 163.34 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.241 -0.912 . . . . 0.0 109.562 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.596 HD11 ' HB2' ' A' ' 49' ' ' ALA . 59.5 mt -149.5 -43.27 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.156 -0.965 . . . . 0.0 109.522 -179.948 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.526 ' CG1' ' HB ' ' A' ' 47' ' ' VAL . 9.3 p -157.75 143.32 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.273 -0.892 . . . . 0.0 109.51 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.58 ' O ' ' HB3' ' A' ' 19' ' ' ALA . 3.7 m-20 -108.54 147.49 31.67 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 109.458 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.484 ' HB ' ' HB2' ' A' ' 45' ' ' MET . 46.7 mt -103.97 150.54 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.316 -0.865 . . . . 0.0 109.434 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.669 ' HG2' HG22 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -131.79 99.46 4.77 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.942 . . . . 0.0 109.468 -179.984 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.529 ' CG2' ' HB ' ' A' ' 43' ' ' VAL . 6.6 t -93.62 -170.14 2.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.237 -0.915 . . . . 0.0 109.476 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 2.6 t0 -42.5 -56.33 3.1 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.294 -0.879 . . . . 0.0 109.767 -179.923 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . 0.473 ' C ' ' CG2' ' A' ' 43' ' ' VAL . 4.1 mtmp? -148.22 49.56 1.04 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -0.884 . . . . 0.0 109.561 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.529 ' HB ' ' CG2' ' A' ' 40' ' ' THR . 1.9 t -154.34 106.44 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.254 -0.904 . . . . 0.0 109.566 179.896 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.669 HG22 ' HG2' ' A' ' 39' ' ' GLU . 94.0 t -89.95 106.63 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.412 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . 0.484 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 27.2 mtp -90.05 177.12 6.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 0.0 109.494 179.941 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -132.76 151.58 51.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.921 . . . . 0.0 109.425 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.526 ' HB ' ' CG1' ' A' ' 36' ' ' VAL . 85.7 t -127.11 107.55 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.246 -0.909 . . . . 0.0 109.456 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.703 HD12 ' HA ' ' A' ' 34' ' ' LEU . 1.1 mp -92.27 176.75 6.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.463 -179.96 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.596 ' HB2' HD11 ' A' ' 35' ' ' ILE . . . -81.9 123.78 29.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.174 -0.954 . . . . 0.0 109.466 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.527 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -92.92 14.5 17.38 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.174 -0.954 . . . . 0.0 109.419 -179.922 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.527 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 174.49 124.96 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.287 -0.883 . . . . 0.0 109.411 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.0 OUTLIER -59.43 170.91 0.9 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.206 -0.934 . . . . 0.0 109.298 -179.969 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.51 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 132.48 -140.56 11.93 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.968 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.65 ' H ' HG22 ' A' ' 76' ' ' THR . 46.4 t -139.12 132.12 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.16 -1.2 . . . . 0.0 109.433 179.979 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.588 HG22 ' N ' ' A' ' 56' ' ' ALA . 14.7 mm -63.69 169.57 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.271 -0.893 . . . . 0.0 109.506 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.588 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -108.52 -65.86 1.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.235 -0.916 . . . . 0.0 109.481 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.479 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 0.0 OUTLIER -165.47 141.53 5.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.212 -0.93 . . . . 0.0 109.474 179.994 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.629 ' CD1' ' CH2' ' A' ' 21' ' ' TRP . 22.7 mm -95.04 125.59 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.192 -0.943 . . . . 0.0 109.425 179.96 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.447 ' C ' ' HE3' ' A' ' 60' ' ' LYS . 23.7 t -89.95 -15.26 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.529 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.585 ' HG2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -110.64 130.04 55.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.27 -0.894 . . . . 0.0 109.453 -179.991 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 57.9 m-80 -105.23 165.37 11.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.227 -0.921 . . . . 0.0 109.44 -179.931 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.402 ' HA ' ' HB ' ' A' ' 18' ' ' VAL . 29.6 mt-10 -67.2 136.6 55.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.538 179.931 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 95.08 2.74 62.21 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.566 ' O ' HG22 ' A' ' 17' ' ' THR . 0.1 OUTLIER -104.92 170.83 7.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.105 -1.233 . . . . 0.0 109.377 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.505 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 10.8 t -98.27 159.59 14.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.497 -0.752 . . . . 0.0 109.51 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.585 HG12 ' HG2' ' A' ' 60' ' ' LYS . 11.9 m -132.7 130.6 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.206 -0.934 . . . . 0.0 109.435 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -94.1 168.64 10.8 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.903 . . . . 0.0 109.509 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.442 ' OG ' ' HA ' ' A' ' 8' ' ' THR . 44.5 t -60.75 130.25 45.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.521 179.989 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 72.74 27.44 69.12 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.999 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.533 ' HG2' ' CD ' ' A' ' 60' ' ' LYS . 0.4 OUTLIER -80.81 132.02 35.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.287 -1.125 . . . . 0.0 109.463 -179.989 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.561 ' C ' HD23 ' A' ' 71' ' ' LEU . 10.4 tt -78.31 122.09 25.28 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.294 -0.879 . . . . 0.0 109.46 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.439 ' O ' HG23 ' A' ' 58' ' ' ILE . 5.7 mt -96.9 -25.53 15.4 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.352 -0.843 . . . . 0.0 109.469 179.936 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 175.07 157.2 15.86 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.978 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.464 ' HG2' ' HA ' ' A' ' 3' ' ' ASP . 0.0 OUTLIER -113.82 159.14 20.13 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.319 -1.106 . . . . 0.0 109.481 179.982 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.456 ' HA ' HD12 ' A' ' 75' ' ' LEU . 19.7 tp -100.83 159.89 14.82 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.225 -0.922 . . . . 0.0 109.429 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.665 HG23 ' N ' ' A' ' 77' ' ' GLU . 2.9 t -86.79 -157.65 0.38 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.278 -0.889 . . . . 0.0 109.703 179.971 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.665 ' N ' HG23 ' A' ' 76' ' ' THR . 55.5 mm-40 -71.36 -90.57 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.757 0 CA-C-O 121.284 0.564 . . . . 0.0 109.487 179.958 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 102.54 -30.13 11.04 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 CA-C-O 117.933 -1.482 . . . . 0.0 109.507 179.945 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.623 HD12 HD22 ' A' ' 75' ' ' LEU . 8.1 mt -106.29 106.12 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.311 -0.868 . . . . 0.0 109.458 179.968 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.745 ' OD1' HD12 ' A' ' 71' ' ' LEU . 11.4 t70 -75.91 127.08 32.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.46 -179.983 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 18.7 mt -103.38 126.18 57.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.271 -0.893 . . . . 0.0 109.432 -179.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -132.96 159.23 40.57 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.303 -0.873 . . . . 0.0 109.481 179.972 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.643 ' HB1' ' HD2' ' A' ' 7' ' ' PRO . . . -74.94 164.45 61.33 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.426 -179.94 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.643 ' HD2' ' HB1' ' A' ' 6' ' ' ALA . 35.3 Cg_endo -78.08 179.78 6.18 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.676 2.25 . . . . 0.0 110.382 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.87 126.55 36.07 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.206 -0.933 . . . . 0.0 109.471 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -81.61 156.08 70.8 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.257 -0.902 . . . . 0.0 109.458 -179.969 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.451 ' HD2' HD12 ' A' ' 13' ' ' ILE . 35.7 Cg_endo -78.05 173.31 14.15 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.682 2.254 . . . . 0.0 110.363 179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 12' ' ' SER . 7.8 pt-20 -65.9 -47.9 73.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.266 -0.896 . . . . 0.0 109.46 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.428 ' C ' ' O ' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -42.74 -49.37 5.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.312 -0.868 . . . . 0.0 109.617 -179.935 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.552 HG22 ' H ' ' A' ' 15' ' ' ASP . 8.7 mt -91.22 166.52 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.284 -0.885 . . . . 0.0 109.475 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.425 ' O ' ' CB ' ' A' ' 15' ' ' ASP . . . -131.9 11.61 4.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.249 -0.907 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.552 ' H ' HG22 ' A' ' 13' ' ' ILE . 0.9 OUTLIER 169.96 -171.45 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.244 -0.91 . . . . 0.0 109.4 -179.966 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.23 -163.71 9.91 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.994 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.458 ' O ' ' HB2' ' A' ' 39' ' ' GLU . 26.5 m -149.95 128.21 12.08 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -1.123 . . . . 0.0 109.424 -179.962 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.5 t -50.74 154.2 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.285 -0.885 . . . . 0.0 109.445 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.532 ' HB3' ' CB ' ' A' ' 37' ' ' ASP . . . -99.84 -76.84 0.54 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.161 -0.962 . . . . 0.0 109.511 179.972 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.2 m -159.89 130.16 5.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.541 -179.998 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.657 ' CH2' HD12 ' A' ' 58' ' ' ILE . 35.1 m95 -89.8 84.94 6.29 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.225 -0.922 . . . . 0.0 109.559 -179.893 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . 0.735 ' NE2' HD21 ' A' ' 34' ' ' LEU . 1.8 m80 -43.26 -61.59 1.29 Allowed 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.313 -0.867 . . . . 0.0 109.335 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -94.67 -172.1 2.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.345 -0.847 . . . . 0.0 109.493 179.986 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.516 ' HD2' ' CD ' ' A' ' 25' ' ' PRO . 2.9 mmmt -130.81 163.87 45.77 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.24 -0.913 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.516 ' CD ' ' HD2' ' A' ' 24' ' ' LYS . 35.5 Cg_endo -77.48 106.43 2.21 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.562 2.175 . . . . 0.0 110.429 179.921 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 137.72 -10.28 3.7 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.939 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.1 -172.33 2.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.249 -1.148 . . . . 0.0 109.416 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -105.7 150.03 25.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.28 -0.888 . . . . 0.0 109.477 179.974 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.3 m -131.93 -170.93 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.244 -0.91 . . . . 0.0 109.459 -179.963 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.448 ' HA ' ' HB2' ' A' ' 52' ' ' ASP . 12.5 mttm -149.91 130.91 14.34 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.217 -0.927 . . . . 0.0 109.52 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.474 ' O ' ' CB ' ' A' ' 32' ' ' ASP . 4.3 ttm105 -42.82 143.61 0.69 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.318 -0.864 . . . . 0.0 109.669 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.53 ' HA ' HD23 ' A' ' 48' ' ' LEU . 6.7 t70 73.84 38.28 0.6 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.316 -0.865 . . . . 0.0 109.476 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.434 ' O ' ' C ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -138.98 122.73 17.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.909 . . . . 0.0 109.436 179.96 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.735 HD21 ' NE2' ' A' ' 22' ' ' HIS . 36.0 tp -43.0 149.14 0.21 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.201 -0.937 . . . . 0.0 109.548 -179.939 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.492 HG13 ' HB2' ' A' ' 49' ' ' ALA . 35.4 mm -132.62 -42.86 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -0.915 . . . . 0.0 109.554 -179.921 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.488 ' O ' HG23 ' A' ' 47' ' ' VAL . 4.4 p -162.1 147.48 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.244 -0.91 . . . . 0.0 109.546 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.532 ' CB ' ' HB3' ' A' ' 19' ' ' ALA . 1.3 m-20 -107.33 154.79 20.77 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.896 . . . . 0.0 109.396 179.966 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.419 ' O ' ' HA ' ' A' ' 44' ' ' VAL . 26.8 mm -122.73 148.09 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.218 -0.926 . . . . 0.0 109.489 -179.937 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.458 ' HB2' ' O ' ' A' ' 17' ' ' THR . 0.3 OUTLIER -107.14 109.69 21.59 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.535 179.941 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 41' ' ' ASP . 35.4 p -97.27 -150.35 0.34 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.202 -0.936 . . . . 0.0 109.434 -179.949 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 40' ' ' THR . 3.0 t0 -42.8 -70.05 0.12 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.318 -0.863 . . . . 0.0 109.668 -179.886 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -145.1 25.19 1.42 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.222 -0.924 . . . . 0.0 109.458 179.963 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.9 t -136.53 130.66 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -0.961 . . . . 0.0 109.466 179.947 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 38' ' ' ILE . 2.1 t -90.96 109.48 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.223 -0.923 . . . . 0.0 109.512 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -79.99 163.79 23.96 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.299 -0.875 . . . . 0.0 109.507 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -108.07 145.17 34.41 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.247 -0.908 . . . . 0.0 109.43 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 36' ' ' VAL . 10.1 t -118.75 100.85 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.312 -0.868 . . . . 0.0 109.426 179.958 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.53 HD23 ' HA ' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -91.91 153.83 19.25 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.193 -0.942 . . . . 0.0 109.49 179.991 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.492 ' HB2' HG13 ' A' ' 35' ' ' ILE . . . -74.17 138.85 44.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.9 . . . . 0.0 109.49 179.983 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.58 ' O ' ' HB2' ' A' ' 51' ' ' ALA . 0.0 OUTLIER -88.51 13.52 11.8 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.294 -0.879 . . . . 0.0 109.505 -179.995 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.58 ' HB2' ' O ' ' A' ' 50' ' ' GLU . . . 170.49 150.37 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.252 -0.905 . . . . 0.0 109.45 -179.981 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.51 ' CG ' ' N ' ' A' ' 53' ' ' GLY . 0.1 OUTLIER -78.6 170.99 15.78 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.317 179.994 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.51 ' N ' ' CG ' ' A' ' 52' ' ' ASP . . . 149.91 -137.69 6.34 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 50.9 t -136.07 125.6 39.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -1.129 . . . . 0.0 109.465 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.464 HG22 ' N ' ' A' ' 56' ' ' ALA . 14.1 mm -64.58 161.78 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.925 . . . . 0.0 109.531 180.0 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.464 ' N ' HG22 ' A' ' 55' ' ' ILE . . . -103.51 -67.02 0.91 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.256 -0.903 . . . . 0.0 109.466 -179.948 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.491 ' HA ' ' HB2' ' A' ' 25' ' ' PRO . 2.5 tt0 -169.83 140.59 2.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.286 -0.884 . . . . 0.0 109.463 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.657 HD12 ' CH2' ' A' ' 21' ' ' TRP . 22.5 mm -93.86 131.63 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.171 -0.956 . . . . 0.0 109.527 -179.965 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 72.0 t -89.96 -38.41 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.274 -0.892 . . . . 0.0 109.497 179.957 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.925 ' HG2' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -94.77 125.21 39.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.343 -0.848 . . . . 0.0 109.424 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.47 ' O ' ' HB3' ' A' ' 64' ' ' ASP . 28.8 m-80 -89.64 176.24 6.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.253 -0.904 . . . . 0.0 109.482 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -74.9 153.33 38.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.246 -0.909 . . . . 0.0 109.502 179.957 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 65.94 15.12 62.13 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.515 ' CG ' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -104.58 170.88 7.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.177 -1.19 . . . . 0.0 109.312 179.993 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.515 ' N ' ' CG ' ' A' ' 64' ' ' ASP . 8.1 m -100.45 138.31 37.69 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.445 -0.784 . . . . 0.0 109.5 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.925 HG12 ' HG2' ' A' ' 60' ' ' LYS . 4.9 m -115.8 172.75 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.207 -0.933 . . . . 0.0 109.461 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -136.06 -173.95 3.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.255 -0.903 . . . . 0.0 109.472 179.936 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.97 149.3 48.98 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.175 -0.953 . . . . 0.0 109.464 -179.965 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 49.69 29.95 13.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.986 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.456 ' OE2' ' HD3' ' A' ' 60' ' ' LYS . 49.6 tp10 -80.55 114.27 19.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.271 -1.135 . . . . 0.0 109.495 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.745 HD12 ' OD1' ' A' ' 3' ' ' ASP . 0.5 OUTLIER -66.31 118.69 10.35 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.191 -0.943 . . . . 0.0 109.47 179.95 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 8.7 mt -87.96 -28.27 21.58 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.483 179.968 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 176.96 170.59 39.6 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -128.44 134.45 48.76 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -1.158 . . . . 0.0 109.445 180.0 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.623 HD22 HD12 ' A' ' 2' ' ' ILE . 0.5 OUTLIER -91.56 147.2 23.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -0.88 . . . . 0.0 109.414 -179.974 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.524 HG22 ' H ' ' A' ' 77' ' ' GLU . 7.3 m -100.54 170.73 8.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.282 -0.886 . . . . 0.0 109.514 179.922 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.524 ' H ' HG22 ' A' ' 76' ' ' THR . 4.5 mm-40 -59.16 -72.91 0.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.238 -0.914 . . . . 0.0 109.454 179.998 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 128.75 150.84 7.28 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 CA-C-O 117.996 -1.447 . . . . 0.0 109.599 179.944 . . . . . . . . 0 0 . 1 stop_ save_